17-spiromethylene	O
steroids	O
The	O
invention	O
relates	O
to	O
a	O
steroid	O
derivative	O
which	O
steroidal	O
skeleton	O
is	O
bound	O
at	O
carbon	O
atom	O
17	O
to	O
a	O
spiromethylene	O
ring	O
of	O
the	O
formula	O
:	O

<	O
See	O
formula	O
I	O
>	O
wherein	O
R	O
a	O
and	O
R	O
b	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
,	O
methyl	O
,	O
and	O
halogen	O
;	O
m	O
is	O
1	O
or	O
2	O
;	O
and	O
the	O
asterisk	O
denotes	O
carbon	O
atom	O
2	O
of	O
the	O
spiromethylene	O
ring	O
which	O
is	O
carbon	O
atom	O
17	O
(	O
or	O
carbon	O
atom	O
17.alpha	O
.	O

of	O
a	O
homosteroid	O
skeleton	O
)	O
of	O
the	O
steroid	O
.	O

The	O
steroids	O
have	O
progestational	O
or	O
antiprogestational	O
activity	O
.	O

Formulations	O
containing	O
coumarins	O
and	O
the	O
use	O
thereof	O
in	O
the	O
pharmaceutical	O
and	O
cosmetic	O
fields	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
coumarins	O
such	O
as	O
esculoside	O
,	O
esculetin	O
,	O
extracts	O
containing	O
them	O
and	O
mixtures	O
thereof	O
,	O
in	O
combination	O
with	O
dimeric	O
and	O
oligomeric	O
proanthocyanidins	O
,	O
in	O
topical	O
formulations	O
for	O
the	O
treatment	O
of	O
peripheral	O
vasculopathies	O
,	O
including	O
the	O
complications	O
of	O
acute	O
venous	O
stasis	O
,	O
or	O
of	O
the	O
unesthetisms	O
related	O
to	O
capillary	O
alterations	O
,	O
or	O
to	O
improve	O
the	O
cicatrization	O
processes	O
.	O

These	O
coumarins	O
,	O
alone	O
or	O
in	O
combination	O
with	O
proanthocyanidins	O
,	O
are	O
also	O
useful	O
in	O
atopical	O
dermatitis	O
and	O
in	O
the	O
treatment	O
of	O
the	O
haematomas	O
.	O

Cosmetic	O
melanins	O
Synthetic	O
melanins	O
suitable	O
for	O
cosmetic	O
uses	O
are	O
produced	O
through	O
oxidative	O
polymerization	O
of	O
monomeric	O
precursors	O
that	O
possess	O
aromatic	O
rings	O
with	O
ionizeable	O
side	O
groups	O
.	O

Agents	O
that	O
enhance	O
adherence	O
of	O
the	O
melanins	O
to	O
skin	O
and	O
hair	O
are	O
co	O
-	O
polymerized	O
with	O
the	O
precursors	O
to	O
become	O
part	O
of	O
the	O
melanin	O
molecules	O
.	O

Potential	O
new	O
precursors	O
and	O
adherence	O
-	O
enhancing	O
agents	O
are	O
screened	O
for	O
efficacy	O
by	O
subjecting	O
them	O
to	O
six	O
separate	O
synthetic	O
procedures	O
,	O
and	O
testing	O
the	O
resulting	O
melanins	O
for	O
color	O
,	O
ultraviolet	O
absorbance	O
charcteristics	O
,	O
and	O
substantivity	O
(	O
adherence	O
)	O
to	O
skin	O
and	O
hair	O
.	O

Melanins	O
of	O
different	O
colors	O
can	O
be	O
blended	O
together	O
in	O
cosmetic	O
creams	O
and	O
lotions	O
to	O
complement	O
the	O
natural	O
skin	O
,	O
eye	O
,	O
and	O
hair	O
colors	O
of	O
an	O
individual	O
.	O

The	O
synthetic	O
procedures	O
are	O
amendable	O
to	O
industrial	O
-	O
scale	O
production	O
of	O
cosmetic	O
melanins	O
.	O

The	O
materials	O
reduce	O
the	O
incidence	O
of	O
solar	O
damage	O
to	O
the	O
skin	O
.	O

Novel	O
silyl	O
compounds	O
and	O
their	O
use	O
The	O
invention	O
describes	O
a	O
process	O
for	O
the	O
epimer	O
enrichment	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
by	O
silylation	O
,	O
fractionated	O
crystallization	O
and	O
acid	O
hydrolysis	O
.	O

Arylalkyl	O
-	O
diazinones	O
Arylalkyl	O
diazinone	O
derivatives	O
of	O
the	O
formula	O

I	O
(	O
see	O
formula	O
I	O
)	O
and	O
their	O
physiologically	O
acceptable	O
salts	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
B	O
,	O
Q	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
exhibit	O
phosphodiesterase	O
IV	O
inhibition	O
and	O
can	O
be	O
employed	O
for	O
the	O
treatment	O
of	O
inflammatory	O
processes	O
and	O
also	O
of	O
allergies	O
,	O
asthma	O
and	O
autoimmune	O
disorders	O
.	O

Novel	O
pharmaceutical	O
combination	O
The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
for	O
topical	O
administration	O
comprising	O
a	O
topically	O
acceptable	O
antiviral	O
substance	O
and	O
an	O
antiiflammatory	O
glucocorticoid	O
in	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
used	O
in	O
the	O
prophylactic	O
and	O
curative	O
treatment	O
of	O
herpesvirus	O
infections	O
in	O
mammals	O
including	O
man	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
combination	O
of	O
a	O
topically	O
acceptable	O
antiviral	O
substance	O
and	O
an	O
antiinflammatory	O
glucocorticoid	O
for	O
the	O
manufacture	O
of	O
a	O
midicament	O
for	O
said	O
prophylactic	O
and	O
curative	O
treatment	O
.	O

Substituted	O
indanylidineacetylguanidines	O
,	O
process	O
for	O
their	O
preparation	O
,	O
their	O
use	O
as	O
medicaments	O
or	O
diagnostic	O
and	O
medicaments	O
containing	O
them	O
Indanylidineacetylguanidines	O
I	O

(	O
see	O
formula	O
I	O
)	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
and	O
X	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
,	O
are	O
effective	O
inhibitors	O
of	O
the	O
cellular	O
sodium	O
/	O
proton	O
antiport	O
(	O
Na	O
+	O
/H	O
+	O
exchanger	O
)	O
,	O
which	O
,	O
in	O
numerous	O
diseases	O
(	O
essential	O
hypertension	O
,	O
atherosclerosis	O
,	O
diabetes	O
and	O
the	O
like	O
)	O
is	O
also	O
increased	O
in	O
those	O
cells	O
which	O
are	O
readily	O
accessible	O
for	O
measurements	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
in	O
erythrocytes	O
,	O
platelets	O
or	O
leukocytes	O
.	O

They	O
are	O
also	O
advantageous	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
disorders	O
of	O
lipid	O
metabolism	O
.	O

Cis-9,10-octadecenoamidase	B
The	O
soporific	O
activity	O
of	O
cis-9,10-octadecenoamide	O
and	O
other	O
soporific	O
fatty	O
acid	O
primary	O
amides	O
is	O
neutralized	O
by	O
hydrolysis	O
in	O
the	O
presence	O
of	O
cis-9,10-octadecenoamidase	O
.	O

Hydrolysis	O
of	O
cis-9,10-octadecenoamide	O
leads	O
to	O
the	O
formation	O
of	O
oleic	O
acid	O
,	O
a	O
compound	O
without	O
soporific	O
activity	O
.	O

Inhibitors	O
of	O
cis-9,10-octadecenoamidase	B
are	O
disclosed	O
to	O
block	O
this	O
activity	O
.	O

Nitroimidazole	O
antibacterial	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O
Methods	O
,	O
compounds	O
and	O
compositions	O
are	O
provided	O
for	O
inhibiting	O
the	O
growth	O
of	O
pathogenic	O
microbes	O
in	O
vitro	O
and	O
of	O
treatment	O
of	O
pathogenic	O
bacterial	O
infections	O
,	O
such	O
as	O
mycobacterial	O
,	O
Clostridium	O
,	O
Cryptosporidium	O
and	O
Helicobacter	O
infections	O
,	O
in	O
vivo	O
using	O
bicyclic	O
nitroimidazole	O
compounds	O
of	O
the	O
formula	O
(	O
II	O
)	O
:	O
(	O
see	O
formula	O
II	O
)	O

The	O
methods	O
,	O
compounds	O
and	O
compositions	O
are	O
particularly	O
useful	O
for	O
inhibiting	O
the	O
growth	O
of	O
Mycobacterium	O
tuberculosis	O
,	O
Clostridium	O
difficile	O
,	O
Cryptosporidium	O
parvum	O
,	O
and	O
Helicobacter	O
pylori	O
,	O
and	O
may	O
be	O
used	O
alone	O
,	O
or	O
in	O
combination	O
with	O
other	O
antimicrobial	O
agents	O
.	O

Administration	O
of	O
ketamine	O
to	O
manage	O
pain	O
and	O
to	O
reduce	O
drug	O
dependency	O
The	O
present	O
invention	O
relates	O
to	O
the	O
management	O
of	O
pain	O
without	O
requiring	O
or	O
allowing	O
for	O
reduction	O
in	O
the	O
level	O
of	O
administration	O
of	O
narcotics	O
,	O
and	O
to	O
self	O
-	O
management	O
of	O
pain	O
on	O
an	O
outpatient	O
basis	O
.	O

Accordingly	O
,	O
the	O
present	O
invention	O
is	O
broadly	O
directed	O
to	O
a	O
method	O
for	O
treating	O
pain	O
in	O
a	O
subject	O
comprising	O
administering	O
via	O
a	O
transmucosal	O
,	O
transdermal	O
,	O
or	O
oral	O
route	O
a	O
dose	O
of	O
ketamine	O
effective	O
to	O
alleviate	O
pain	O
to	O
a	O
subject	O
suffering	O
from	O
pain	O
.	O

The	O
invention	O
is	O
further	O
directed	O
to	O
a	O
method	O
for	O
synergistically	O
treating	O
pain	O
in	O
a	O
subject	O
comprising	O
administering	O
via	O
any	O
route	O
a	O
dose	O
of	O
ketamine	O
effective	O
to	O
allow	O
for	O
reduction	O
in	O
the	O
level	O
of	O
an	O
ongoing	O
pain	O
therapy	O
,	O
or	O
decrease	O
pain	O
(	O
improve	O
the	O
level	O
of	O
pain	O
relief	O
)	O
,	O
or	O
both	O
.	O

Transmucosal	O
,	O
transdermal	O
,	O
and	O
oral	O
administration	O
of	O
ketamine	O
advantageously	O
allows	O
for	O
patient	O
self	O
administration	O
of	O
the	O
drug	O
,	O
which	O
provides	O
for	O
pain	O
management	O
on	O
an	O
outpatient	O
basis	O
.	O

Moreover	O
,	O
ketamine	O
administration	O
in	O
transdermal	O
devices	O
(	O
suppositories	O
,	O
candies	O
,	O
buccal	O
patches	O
)	O
is	O
generally	O
socially	O
acceptable	O
.	O

In	O
a	O
specific	O
example	O
,	O
a	O
patient	O
suffering	O
from	O
intractable	O
bladder	O
pain	O
controlled	O
breakthrough	O
pain	O
by	O
transmucosal	O
(	O
nasal	O
)	O
administration	O
of	O
about	O
16	O
mg	O
to	O
about	O
32	O
mg	O
of	O
ketamine	O
per	O
dose	O
.	O

G	O
-	O
coupled	O
receptor	O
showing	O
selective	O
affinity	O
for	O
atp	O
The	O
present	O
invention	O
concerns	O
a	O
G	B
-	I
coupled	I
receptor	I
which	O
has	O
an	O
amino	O
acid	O
sequence	O
having	O
more	O
than	O
50	O
%	O
homology	O
with	O
the	O
amino	O
acid	O
sequence	O
shown	O
in	O
Figure	O
1	O
.	O

An	O
infectious	O
cdna	O
clone	O
of	O
north	O
american	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
prrs	O
)	O
virus	O
and	O
uses	O
thereof	O
The	O
invention	O
provides	O
isolated	O
polynucleotide	O
molecules	O
,	O
including	O
plasmids	O
;	O
viral	O
vectors	O
;	O
and	O
transfected	O
host	O
cells	O
that	O
comprise	O
a	O
DNA	O
sequence	O
encoding	O
an	O
infectious	O
RNA	O
sequence	O
encoding	O
a	O
North	O
American	O
PRRS	O
virus	O
;	O
and	O
also	O
North	O
American	O
PRRS	O
viruses	O
encoded	O
thereby	O
.	O

The	O
invention	O
further	O
provides	O
isolated	O
infectious	O
RNA	O
molecules	O
encoding	O
a	O
North	O
American	O
PRRS	O
virus	O
.	O

The	O
invention	O
also	O
provides	O
isolated	O
polynucleotide	O
molecules	O
,	O
infectious	O
RNA	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
transfected	O
host	O
cells	O
encoding	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
;	O
and	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
encoded	O
thereby	O
.	O

The	O
invention	O
also	O
provides	O
vaccines	O
comprising	O
such	O
plasmids	O
,	O
RNA	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
North	O
American	O
PRRS	O
viruses	O
,	O
and	O
methods	O
of	O
using	O
these	O
vaccines	O
in	O
swine	O
and	O
in	O
other	O
animals	O
.	O

Also	O
provided	O
are	O
isolated	O
polynucleotide	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
transfected	O
host	O
cells	O
that	O
comprise	O
a	O
nucleotide	O
sequence	O
encoding	O
a	O
peptide	O
of	O
a	O
North	O
American	O
PRRS	O
virus	O
.	O

These	O
viral	O
vectors	O
and	O
transfected	O
host	O
cell	O
lines	O
are	O
useful	O
in	O
providing	O
peptides	O
to	O
compensate	O
for	O
mutated	O
peptide	O
coding	O
sequences	O
of	O
DNA	O
sequences	O
encoding	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
so	O
that	O
functional	O
virions	O
can	O
be	O
generated	O
.	O

Pyridine	O
derivatives	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
and	O
R1	O
to	O
R5	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
are	O
useful	O
for	O
treating	O
disorders	O
mediated	O
full	O
or	O
in	O
part	O
by	O
mGluR5	B
.	O

Therapeutic	O
process	O
for	O
inhibiting	O
nf-.kappa.b	B
A	O
therapeutic	O
process	O
is	O
provided	O
for	O
the	O
inhibition	O
of	O
NF-.kappa	B
.	I

B	B
in	O
mammals	O
in	O
whose	O
cells	O
NF-.kappa	B
.	I

B	B
has	O
been	O
activated	O
by	O
an	O
agency	O
external	O
to	O
said	O
cell	O
.	O

New	O
crystalline	O
form	O
of	O
1-methyl-5-p	O
-	O
toluoylpyrrole-2-acetamidoacetic	O
acid	O
guaiacyl	O
ester	O
A	O
new	O
crystalline	O
form	O
of	O
1-methyl-5-p	O
-	O
toluoylpyrrole-2-acetamidoacetic	O
acid	O
guaiacyl	O
ester	O
,	O
a	O
process	O
for	O
its	O
preparation	O
and	O
pharmaceutical	O
compositions	O
endowed	O
of	O
antiinflammatory	O
,	O
analgesic	O
and	O
antipyretic	O
activity	O
containing	O
same	O
are	O
disclosed	O
.	O

Treatment	O
of	O
neuropathy	O
This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cyclic	B
guanosine	I
3	I
'	I
,	I
5'-monophosphate	I
phosphodiesterase	I
type	I
five	I
(	O
cGMP	B
PDE5	I
)	O
inhibitors	O
,	O
including	O
in	O
particular	O
the	O
compound	O
sildenafil	O
,	O
in	O
combination	O
with	O
gabapentin	O
or	O
pregabalin	O
,	O
which	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
neuropathy	O
,	O
including	O
in	O
particular	O
the	O
treatment	O
of	O
diabetic	O
neuropathy	O
.	O

Improved	O
stable	O
topical	O
ascorbic	O
acid	O
compositions	O
An	O
ascorbic	O
acid	O
(	O
Vitamin	O
C	O
)	O
composition	O
in	O
a	O
nonaqueous	O
or	O
substantially	O
anhydrous	O
silicone	O
vehicle	O
has	O
superior	O
stability	O
.	O

Particulate	O
ascorbic	O
acid	O
is	O
substantially	O
insoluble	O
in	O
the	O
disclosed	O
polyorganosiloxane	O
vehicles	O
,	O
and	O
the	O
vehicle	O
substantially	O
excludes	O
environmental	O
oxygen	O
.	O

The	O
ascorbic	O
acid	O
particles	O
have	O
surprisingly	O
been	O
found	O
to	O
have	O
a	O
high	O
degree	O
of	O
bioavailability	O
and	O
effectiveness	O
,	O
for	O
example	O
in	O
topical	O
applications	O
to	O
reduce	O
wrinkles	O
and	O
increase	O
collagen	O
growth	O
and	O
elasticity	O
.	O

Inhibitors	O
of	O
proteasomal	O
activity	O
for	O
stimulating	O
bone	O
and	O
hair	O
growth	O
Compounds	O
that	O
inhibit	O
the	O
activity	O
of	O
NF	O
-	O
B	O
or	O
inhibit	O
the	O
activity	O
of	O
the	O
proteasome	O
or	O
both	O
promote	O
bone	O
formation	O
and	O
hair	O
growth	O
and	O
are	O
thus	O
useful	O
in	O
treating	O
osteoporosis	O
,	O
bone	O
fracture	O
or	O
deficiency	O
,	O
primary	O
or	O
secondary	O
hyperparathyroidism	O
,	O
periodontal	O
disease	O
or	O
defect	O
,	O
metastatic	O
bone	O
disease	O
,	O
osteolytic	O
bone	O
disease	O
,	O
post	O
-	O
plastic	O
surgery	O
,	O
post	O
-	O
prosthetic	O
joint	O
surgery	O
,	O
and	O
post	O
-	O
dental	O
implantation	O
;	O
they	O
also	O
stimulate	O
the	O
production	O
of	O
hair	O
follicles	O
and	O
are	O
thus	O
useful	O
in	O
stimulating	O
hair	O
growth	O
,	O
including	O
hair	O
density	O
,	O
in	O
subject	O
where	O
this	O
is	O
desirable	O
.	O

Reaction	O
products	O
of	O
hyaluronic	O
acid	O
and	O
natural	O
amino	O
acids	O
and	O
their	O
use	O
in	O
cosmetic	O
and	O
pharmaceutical	O
compositions	O
The	O
present	O
invention	O
relates	O
to	O
new	O
high	O
molecular	O
weight	O
salts	O
of	O
hyaluronic	O
acid	O
.	O

More	O
particularly	O
,	O
these	O
salts	O
are	O
characterized	O
in	O
that	O
they	O
have	O
as	O
a	O
counterion	O
a	O
natural	O
amino	O
acid	O
.	O

The	O
products	O
of	O
the	O
invention	O
can	O
be	O
prepared	O
starting	O
from	O
high	O
molecular	O
weight	O
hyaluronic	O
acid	O
or	O
salts	O
thereof	O
.	O

These	O
new	O
high	O
molecular	O
weights	O
salts	O
of	O
hyaluronic	O
acid	O
may	O
be	O
advantageously	O
employed	O
in	O
the	O
cosmetic	O
of	O
pharmaceutical	O
field	O
.	O

Novel	O
compounds	O
for	O
the	O
management	O
of	O
aging	O
-	O
related	O
and	O
diabetic	O
vascular	O
complications	O
,	O
process	O
for	O
their	O
preparation	O
and	O
therapeutic	O
uses	O
The	O
invention	O
discloses	O
novel	O
compounds	O
of	O
the	O
pyridinium	O
series	O
useful	O
for	O
the	O
management	O
of	O
diabetes	O
and	O
aging	O
-	O
related	O
vascular	O
complications	O
,	O
including	O
kidney	O
disease	O
,	O
nerve	O
damage	O
,	O
atherosclerosis	O
,	O
retinopathy	O
,	O
dermatological	O
disorders	O
and	O
discoloration	O
of	O
teeth	O
,	O
by	O
breaking	O
preformed	O
AGE	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
invention	O
also	O
discloses	O
,	O
method	O
for	O
preparation	O
of	O
the	O
novel	O
compounds	O
of	O
the	O
series	O
and	O
pharmaceutical	O
composition	O
comprising	O
one	O
or	O
more	O
of	O
these	O
compounds	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
method	O
of	O
treatment	O
of	O
a	O
diabetic	O
patient	O
by	O
administering	O
the	O
compounds	O
either	O
singly	O
or	O
in	O
combination	O
with	O
drugs	O
for	O
antidiabetic	O
therapy	O
.	O

Antiparasitic	O
formulations	O
comprising	O
doramectin	O
Long	O
-	O
acting	O
antiparasitic	O
formulations	O
of	O
doramectin	O
,	O
suitable	O
for	O
injection	O
,	O
are	O
described	O
herein	O
.	O

Compounds	O
for	O
the	O
modulation	O
of	O
ppar.gamma	B
.	O

activity	O
Modulators	O
of	O
PPAR.gamma	B
.	O

activity	O
are	O
provided	O
having	O
the	O
following	O
formula	O
,	O
which	O
modulators	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
type	O
II	O
diabetes	O
and	O
obesity	O
.	O

(	O
See	O
above	O
Formula	O
)	O

Arylsulphonamide	O
-	O
substituted	O
benzimidazole	O
derivatives	O
,	O
processes	O
for	O
preparing	O
them	O
and	O
their	O
use	O
as	O
pharmaceutical	O
compositions	O
The	O
invention	O
relates	O
to	O
arylsulphonamide	O
-	O
substituted	O
benzimidazole	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
groups	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
may	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
specification	O
,	O
processes	O
for	O
preparing	O
them	O
as	O
well	O
as	O
the	O
use	O
of	O
arylsulphonamide	O
-	O
substituted	O
benzimidazole	O
derivatives	O
as	O
pharmaceutical	O
compositions	O
,	O
particularly	O
as	O
pharmaceutical	O
compositions	O
with	O
a	O
tryptase	B
-	O
inhibiting	O
activity	O
.	O

Iron	O
chelator	O
delivery	O
system	O
An	O
iron	O
chelator	O
delivery	O
system	O
is	O
disclosed	O
.	O

The	O
system	O
comprises	O
iron	O
chelator	O
and	O
a	O
lipid	O
carrier	O
,	O
e.g.	O
,	O
a	O
liposome	O
.	O

Methods	O
for	O
preparing	O
and	O
administering	O
the	O
iron	O
chelator	O
delivery	O
system	O
are	O
also	O
provided	O
.	O

Method	O
for	O
the	O
antibiotic	O
coating	O
of	O
bodies	O
with	O
interconnecting	O
microcavities	O
as	O
well	O
as	O
coated	O
bodies	O
and	O
their	O
usage	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
antibiotic	O
coating	O
of	O
bodies	O
with	O
interconnecting	O
microcavities	O
as	O
well	O
as	O
bodies	O
coated	O
this	O
way	O
and	O
their	O
usage	O
.	O

The	O
invented	O
method	O
is	O
characterized	O
in	O
that	O
in	O
the	O
microcavities	O
of	O
non	O
-	O
metallic	O
bodies	O
an	O
aqueous	O
solution	O
1	O
,	O
which	O
contains	O
at	O
least	O
one	O
easily	O
water	O
-	O
soluble	O
antibiotic	O
component	O
from	O
the	O
groups	O
of	O
the	O
aminoglycoside	O
antibiotics	O
,	O
the	O
tetracycline	O
antibiotics	O
,	O
the	O
lincosamide	O
antibiotics	O
and	O
the	O
4-quinolone	O
antibiotics	O
,	O
and	O
an	O
aqueous	O
solution	O
2	O
,	O
which	O
contains	O
at	O
least	O
one	O
easily	O
water	O
-	O
soluble	O
amphiphilic	O
component	O
from	O
the	O
groups	O
of	O
the	O
alkyl	O
sulfates	O
,	O
alkyl	O
sulfonates	O
,	O
alkylaryl	O
sulfates	O
,	O
dialkylaryl	O
sulfates	O
,	O
alkylaryl	O
sulfonates	O
,	O
dialkylaryl	O
sulfonates	O
,	O
cycloalkyl	O
sulfates	O
,	O
cycloalkyl	O
sulfonates	O
,	O
alkylcycloalkyl	O
sulfates	O
,	O
are	O
introduced	O
,	O
wherein	O
between	O
the	O
introduction	O
of	O
solutions	O
1	O
and	O
2	O
the	O
water	O
is	O
basically	O
removed	O
through	O
vaporization	O
and/or	O
evaporation	O
,	O
and	O
whereby	O
from	O
the	O
components	O
of	O
solutions	O
1	O
and	O
2	O
in	O
the	O
microcavities	O
a	O
deposit	O
is	O
formed	O
,	O
which	O
is	O
sparingly	O
soluble	O
in	O
water	O
.	O

Ethanol	O
solvate	O
of	O
(	O
-	O
)	O
-cis-2-	O
(	O
2-chlorophenyl	O
)	O
-5,7-dihydroxy-8	O
[	O
4r-	O
(	O
3s	O
-	O
hydroxy-1-methyl	O
)	O
piperidinyl	O
]	O
-4h-1-benzopyran-4-one	O
An	O
ethanol	O
solvate	O
form	O
of	O
(	O
-	O
)	O
-cis-2-	O
(	O
2-chlorophenyl	O
)	O
-5,7-dihydroxy-8	O
[	O
4R-	O
(	O
3S	O
--	O
hydroxy-1-methyl	O
)	O
piperidinyl	O
]	O
-4H-1-benzopyran-4-one	O
(	O
Form	O
II	O
)	O
,	O
a	O
method	O
of	O
making	O
Form	O
II	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
Form	O
II	O
for	O
treating	O
cancer	O
.	O

Myeloid	B
colony	I
stimulating	I
factor	I
and	O
uses	O
thereof	O
The	O
identification	O
of	O
the	O
HYAL1	B
hyaluronidase	I
enzyme	O
as	O
a	O
human	B
plasma	I
-	I
derived	I
myeloid	I
colony	I
-	I
stimulating	I
factor	I
(	O
CSF	B
)	O
,	O
herein	O
designated	O
CSF5-hyaluronidase	B
,	O
its	O
recombinant	O
production	O
and	O
methods	O
of	O
use	O
are	O
described	O
.	O

This	O
protein	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
myelosuppression	O
as	O
may	O
occur	O
after	O
irradiation	O
,	O
chemotherapy	O
or	O
other	O
diseases	O
where	O
an	O
increase	O
in	O
leukocyte	O
levels	O
may	O
be	O
beneficial	O
.	O

For	O
example	O
,	O
CSF5	B
may	O
be	O
used	O
to	O
enhance	O
the	O
immune	O
response	O
to	O
viral	O
infection	O
or	O
other	O
diseases	O
associated	O
with	O
immune	O
suppression	O
.	O

Stable	O
ready	O
-	O
to	O
-	O
use	O
dosage	O
forms	O
containing	O
coloring	O
matter	O
and	O
active	O
chlorine	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
same	O
as	O
disinfectants	O
A	O
method	O
of	O
producing	O
a	O
disinfectant	O
or	O
sterilizing	O
liquid	O
,	O
cream	O
,	O
ointment	O
,	O
paste	O
,	O
or	O
gel	O
by	O
dissolving	O
in	O
a	O
solvent	O
a	O
stable	O
ready	O
-	O
to	O
-	O
use	O
dosage	O
form	O
containing	O
coloring	O
matter	O
and	O
an	O
organic	O
chloroxidizer	O
acting	O
as	O
a	O
chlorine	O
donor	O
releasing	O
active	O
chlorine	O
.	O

The	O
coloring	O
matter	O
is	O
in	O
its	O
maximal	O
level	O
of	O
oxidation	O
.	O

The	O
chloroxidizer	O
with	O
coloring	O
matter	O
has	O
a	O
pH	O
of	O
4	O
-	O
8	O
and	O
is	O
present	O
in	O
a	O
sufficient	O
quantity	O
to	O
disinfect	O
or	O
sterilize	O
the	O
surface	O
,	O
vessel	O
,	O
or	O
tissue	O
as	O
required	O
while	O
the	O
colored	O
appearance	O
of	O
the	O
liquid	O
,	O
cream	O
,	O
ointment	O
,	O
paste	O
,	O
or	O
gel	O
is	O
stably	O
maintained	O
over	O
a	O
period	O
of	O
time	O
which	O
exceeds	O
the	O
period	O
of	O
time	O
that	O
the	O
disinfectant	O
would	O
be	O
normally	O
used	O
for	O
that	O
purpose	O
.	O

Drug	O
formulations	O
for	O
parenteral	O
use	O
This	O
invention	O
relates	O
to	O
parenteral	O
preparations	O
of	O
antiestrogens	O
such	O
as	O
toremifene	O
,	O
desmethyl	O
toremifene	O
,	O
tamoxifen	O
or	O
desmethyltamoxifen	O
.	O

The	O
preparations	O
can	O
be	O
emulsions	O
,	O
liposomes	O
or	O
aqueous	O
solutions	O
of	O
cyclodextrin	O
-	O
drug	O
complexes	O
.	O

Particularly	O
the	O
invention	O
relates	O
to	O
a	O
parenteral	O
drug	O
formulation	O
comprising	O
a	O
complex	O
having	O
a	O
2-hydroxypropyl	O
cyclodextrin	O
component	O
and	O
including	O
an	O
active	O
drug	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
toremifene	O
,	O
desmethyl	O
toremifene	O
,	O
tamoxifen	O
and	O
desmethyltamoxifen	O
or	O
a	O
pharmaceutically	O
acceptable	O
non	O
-	O
toxic	O
salt	O
thereof	O
,	O
said	O
complex	O
being	O
present	O
either	O
in	O
an	O
aqueous	O
solution	O
or	O
emulsion	O
or	O
loaded	O
into	O
a	O
liposome	O
.	O

Pharmaceutical	O
composition	O
for	O
oral	O
use	O
with	O
improved	O
absorption	O
The	O
present	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
inhibiting	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
by	O
a	O
digestive	O
enzyme	O
,	O
which	O
is	O
aminoalkyl	O
methacrylate	O
copolymer	O
E	O
as	O
an	O
effective	O
ingredient	O
,	O
and	O
an	O
agent	O
for	O
reducing	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and	O
mucous	O
layers	O
distributed	O
over	O
this	O
mucosa	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
by	O
a	O
digestive	O
enzyme	O
,	O
or	O
a	O
method	O
for	O
reducing	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
distributed	O
over	O
the	O
mucosa	O
,	O
by	O
administration	O
of	O
aminoalkyl	O
methacrylate	O
copolymer	O
E.	O
Furthermore	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
oral	O
use	O
with	O
improved	O
absorption	O
,	O
which	O
comprises	O
a	O
biologically	O
active	O
peptide	O
and	O
aminoalkyl	O
methacrylate	O
copolymer	O
E.	O
Excellent	O
oral	O
absorption	O
of	O
a	O
biologically	O
active	O
peptide	O
that	O
were	O
considered	O
difficult	O
to	O
absorb	O
by	O
oral	O
administration	O
in	O
the	O
past	O
,	O
can	O
be	O
realized	O
based	O
on	O
the	O
ability	O
to	O
inhibit	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
,	O
the	O
ability	O
to	O
reduce	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
distributed	O
over	O
this	O
mucosa	O
,	O
and	O
the	O
ability	O
to	O
improve	O
permeability	O
of	O
a	O
biologically	O
active	O
peptide	O
in	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
of	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
.	O

Composition	O
and	O
method	O
to	O
prevent	O
or	O
reduce	O
diarrhea	O
and	O
steatorrhea	O
in	O
hiv	O
patients	O
Method	O
of	O
preventing	O
or	O
reducing	O
diarrhea	O
and	O
correcting	O
fat	O
malabsorption	O
(	O
steatorrhea	O
)	O
and	O
loss	O
of	O
body	O
mass	O
in	O
HIV	O
-	O
positive	O
patients	O
being	O
treated	O
with	O
High	O
Activity	O
Antiretroviral	O
drugs	O
(	O
HAART	O
)	O
containing	O
protease	O
inhibitors	O
,	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
or	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
and	O
by	O
co	O
-	O
administering	O
with	O
the	O
HAART	O
a	O
buffered	O
pancrelipase	O
composition	O
.	O

The	O
method	O
includes	O
the	O
steps	O
of	O
:	O
administering	O
to	O
the	O
HIV	O
-	O
positive	O
patient	O
a	O
High	O
Activity	O
Antiretroviral	O
drug	O
containing	O
a	O
protease	O
inhibitor	O
,	O
a	O
nucleoside	O
reverse	B
transcriptase	I
inhibitor	O
or	O
a	O
non	O
-	O
nucleoside	O
reverse	B
transcriptase	I
inhibitor	O
;	O
and	O
co	O
-	O
administering	O
with	O
the	O
HAART	O
drug	O
a	O
gastric	O
acid	O
-	O
resistant	O
polymer	O
-	O
coated	O
and	O
buffered	O
pancrelipase	O
enzyme	O
composition	O
containing	O
pancreatic	B
proteases	I
,	O
lipases	B
,	O
co	O
-	O
lipases	O
,	O
nucleases	B
,	O
amylases	B
and	O
other	O
bio	O
-	O
active	O
substances	O
produced	O
by	O
the	O
pancreatic	O
gland	O
.	O

Dimetalhydroxy	O
malates	O
Dimetalhydroxy	O
malate	O
compositions	O
as	O
well	O
as	O
methods	O
of	O
administering	O
and	O
making	O
such	O
bioavailable	O
compositions	O
are	O
provided	O
.	O

The	O
metal	O
used	O
can	O
be	O
any	O
nutritionally	O
relevant	O
divalent	O
metal	O
such	O
as	O
calcium	O
,	O
magnesium	O
,	O
zinc	O
,	O
copper	O
,	O
manganese	O
,	O
and	O
iron	O
.	O

The	O
composition	O
can	O
be	O
prepared	O
by	O
reacting	O
malic	O
acid	O
with	O
a	O
divalent	O
metal	O
oxide	O
or	O
hydroxide	O
at	O
a	O
1:2	O
molar	O
ratio	O
.	O

The	O
composition	O
can	O
be	O
administered	O
to	O
a	O
warm	O
-	O
blooded	O
animal	O
by	O
any	O
of	O
a	O
number	O
of	O
known	O
delivery	O
routes	O
,	O
including	O
oral	O
delivery	O
.	O

Improved	O
absorption	O
of	O
fat	O
-	O
soluble	O
nutrients	O
Carotenoids	O
are	O
provided	O
as	O
dietary	O
supplements	O
to	O
animal	O
feed	O
.	O

These	O
supplements	O
improve	O
the	O
bioavailability	O
of	O
carotenoids	O
by	O
providing	O
them	O
in	O
combination	O
with	O
phospholipids	O
.	O

The	O
invention	O
provides	O
animal	O
feeds	O
for	O
aquatic	O
and	O
terrestrial	O
animals	O
,	O
and	O
methods	O
for	O
making	O
the	O
feeds	O
.	O

Combinations	O
for	O
the	O
treatment	O
of	O
depression	O
It	O
is	O
intended	O
to	O
provide	O
medicinal	O
compositions	O
and	O
the	O
like	O
useful	O
in	O
treating	O
depression	O
which	O
contain	O
a	O
compound	O
having	O
an	O
antagonism	O
to	O
adenosine	B
A2A	I
receptor	I
(	O
for	O
example	O
,	O
(	O
E	O
)	O
-8-	O
(	O
3,4-dimethoxystyryl	O
)	O
-1,3-diethyl-7-methyl-3,7-dihydro-1H	O
-	O
purin-2,6-dione	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
together	O
with	O
an	O
antidepressant	O
(	O
for	O
example	O
,	O
a	O
tricyclic	O
antidepressant	O
,	O
a	O
tetracyclic	O
antidepressant	O
,	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
,	O
a	O
selective	O
noradrenaline	O
reuptake	O
inhibitor	O
,	O
a	O
dopamine	O
reuptake	O
inhibitor	O
,	O
a	O
serotonin	O
/	O
noradrenaline	O
reuptake	O
inhibitor	O
,	O
a	O
monoamine	B
oxidase	I
inhibitor	O
or	O
a	O
serotonin	B
2	I
antagonist	O
)	O
.	O

Compositions	O
of	O
galactomannan	O
for	O
the	O
treatment	O
of	O
bowel	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
a	O
bowel	O
disease	O
,	O
comprising	O
galactomannan	O
and/or	O
arabinogalactan	O
;	O
a	O
liquid	O
food	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
a	O
bowel	O
disease	O
,	O
characterized	O
in	O
that	O
the	O
liquid	O
food	O
comprises	O
a	O
protein	O
and	O
galactomannan	O
and/or	O
arabinogalactan	O
;	O
and	O
a	O
composition	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
an	O
irritable	O
bowel	O
syndrome	O
,	O
comprising	O
degraded	O
galactomannan	O
.	O

Fluorinated	O
phno	O
and	O
analogs	O
thereof	O
This	O
application	O
describes	O
fluormated	O
(	O
+	O
)	O
PHNO	O
and	O
analogs	O
thereof	O
,	O
including	O
radiolabeled	O
analogs	O
,	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
C1	O
-	O
6	O
alkyl	O
in	O
which	O
one	O
hydrogen	O
atom	O
on	O
the	O
alkyl	O
chain	O
is	O
replaced	O
with	O
fluoro	O
or	O
radioactive	O
fluoro	O
.	O

The	O
application	O
further	O
describes	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
have	O
good	O
affinity	O
and	O
selectivity	O
for	O
the	O
dopamine	B
D2	I
receptors	I
and	O
are	O
therefore	O
useful	O
for	O
the	O
labelling	O
of	O
dopamine	B
D2	I
receptors	I
in	O
vivo	O
and	O
for	O
the	O
identification	O
and	O
quantification	O
of	O
the	O
extent	O
of	O
dopamine	O
supersensitivity	O
in	O
the	O
bram	O
in	O
various	O
stages	O
of	O
a	O
dopamine	O
-	O
related	O
disease	O
.	O

Oral	O
health	O
care	O
drink	O
and	O
method	O
for	O
reducing	O
malodors	O
An	O
oral	O
care	O
composition	O
and	O
method	O
of	O
using	O
.	O

are	O
provided	O
for	O
treating	O
and	O
preventing	O
malodors	O
or	O
disease	O
conditions	O
of	O
the	O
oral	O
cavity	O
in	O
warm	O
-	O
blooded	O
animals	O
,	O
including	O
humans	O
.	O

When	O
applying	O
an	O
oral	O
care	O
effective	O
amount	O
of	O
the	O
oral	O
care	O
composition	O
of	O
the	O
present	O
invention	O
to	O
the	O
mucosal	O
tissue	O
of	O
the	O
oral	O
cavity	O
,	O
the	O
gingival	O
tissues	O
of	O
the	O
oral	O
cavity	O
,	O
and/or	O
surface	O
of	O
the	O
teeth	O
.	O

The	O
application	O
can	O
be	O
as	O
a	O
liquid	O
for	O
bathing	O
,	O
rinsing	O
or	O
gargling	O
,	O
or	O
lather	O
generated	O
by	O
brushing	O
the	O
teeth	O
for	O
a	O
sufficient	O
time	O
.	O

After	O
rinsing	O
,	O
gargling	O
or	O
brushing	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
should	O
be	O
swallowed	O
to	O
achieve	O
effective	O
reduction	O
of	O
various	O
organisms	O
,	O
diseases	O
and	O
malodors	O
.	O

An	O
oral	O
care	O
effective	O
amount	O
can	O
also	O
prevent	O
and	O
heal	O
mouth	O
sores	O
and	O
canker	O
sores	O
.	O

High	O
fructan	O
cereal	O
plants	O
The	O
invention	O
provides	O
cereal	O
plants	O
having	O
a	O
high	O
level	O
of	O
fructan	O
useful	O
for	O
the	O
production	O
of	O
a	O
range	O
of	O
food	O
,	O
beverage	O
,	O
nutraceutical	O
and	O
pharmaceutical	O
products	O
.	O

The	O
invention	O
provides	O
methods	O
of	O
producing	O
high	O
-	O
fructan	O
products	O
from	O
plants	O
modified	O
to	O
comprise	O
a	O
reduced	O
level	O
of	O
an	O
endogenous	O
polypeptide	O
with	O
starch	B
synthase	I
activity	O
,	O
and	O
products	O
so	O
produced	O
.	O

In	O
some	O
embodiments	O
,	O
plants	O
are	O
modified	O
by	O
introduction	O
of	O
an	O
agent	O
such	O
as	O
a	O
nucleic	O
acid	O
molecule	O
which	O
down	O
regulates	O
endogenous	B
starch	I
synthase	I
II	I
gene	O
expression	O
.	O

Adhesive	O
patch	O
containing	O
fentanyl	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
An	O
adhesive	O
preparation	O
comprising	O
a	O
support	O
and	O
a	O
medicine	O
-	O
containing	O
layer	O
laminated	O
on	O
the	O
support	O
,	O
wherein	O
the	O
medicine	O
-	O
containing	O
layer	O
comprises	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
fentanyl	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
an	O
adhesive	O
agent	O
comprising	O
polyisobutylene	O
and	O
a	O
silicon	O
-	O
containing	O
polymer	O
,	O
and	O
wherein	O
the	O
ratio	O
of	O
the	O
polyisobutylene	O
to	O
the	O
silicon	O
-	O
containing	O
polymer	O
in	O
the	O
adhesive	O
agent	O
is	O
20:1	O
to	O
7:3	O
by	O
mass	O
.	O

Induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
cell	O
proliferation	O
through	O
modulation	O
of	O
carnitine	O
palmitoyltransferase	O
1c	O
activity	O
This	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
cancer	O
therapeutics	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
tumors	O
by	O
inhibiting	O
the	O
activity	O
of	O
CPT1C	O
.	O

The	O
methods	O
and	O
compositions	O
can	O
additionally	O
include	O
inhibition	O
of	O
glycolysis	O
.	O

Method	O
for	O
improving	O
storage	O
stability	O
of	O
glutathione	O
Provision	O
of	O
a	O
method	O
of	O
improving	O
preservation	O
stability	O
of	O
glutathione	O
in	O
a	O
solid	O
composition	O
containing	O
glutathione	O
and	O
arginine	O
,	O
or	O
a	O
solid	O
composition	O
containing	O
glutathione	O
and	O
arginine	O
,	O
which	O
shows	O
improved	O
preservation	O
stability	O
of	O
glutathione	O
.	O

In	O
the	O
production	O
of	O
a	O
solid	O
composition	O
containing	O
glutathione	O
and	O
arginine	O
,	O
glutathione	O
and	O
arginine	O
are	O
made	O
to	O
be	O
coexistent	O
with	O
an	O
organic	O
acid	O
.	O

Examples	O
of	O
the	O
organic	O
acid	O
include	O
citric	O
acid	O
,	O
tartaric	O
acid	O
,	O
ascorbic	O
acid	O
,	O
malic	O
acid	O
,	O
malonic	O
acid	O
,	O
succinic	O
acid	O
,	O
fumaric	O
acid	O
,	O
maleic	O
acid	O
and	O
the	O
like	O
.	O

The	O
amount	O
of	O
the	O
organic	O
acid	O
to	O
be	O
coexistent	O
with	O
glutathione	O
and	O
arginine	O
is	O
generally	O
0.1	O
-	O
2	O
parts	O
by	O
weight	O
relative	O
to	O
1	O
part	O
by	O
weight	O
of	O
arginine	O
.	O

Methods	O
for	O
treating	O
bowel	O
diseases	O
The	O
present	O
invention	O
provides	O
new	O
methods	O
of	O
treating	O
bowel	O
disease	O
(	O
BD	O
)	O
by	O
increasing	O
a	O
durability	O
of	O
response	O
;	O
treating	O
BD	O
in	O
males	O
;	O
treating	O
BD	O
in	O
adolescent	O
subjects	O
;	O
treating	O
bloating	O
due	O
to	O
BD	O
in	O
males	O
;	O
and	O
methods	O
of	O
maintaining	O
remission	O
of	O
BD	O
.	O

Novel	O
and	O
potent	O
tapentadol	O
dosage	O
forms	O
The	O
present	O
invention	O
provides	O
a	O
dosage	O
form	O
comprising	O
at	O
least	O
one	O
form	O
of	O
tapentadol	O
,	O
with	O
or	O
without	O
a	O
second	O
analgesic	O
,	O
and	O
at	O
least	O
one	O
opioid	O
antagonist	O
,	O
wherein	O
tapentadol	O
is	O
present	O
in	O
an	O
optimal	O
or	O
suboptimal	O
amount	O
and	O
the	O
said	O
antagonist	O
is	O
present	O
in	O
an	O
amount	O
effective	O
to	O
improve	O
the	O
efficacy	O
and	O
or	O
reduce	O
the	O
side	O
effects	O
of	O
tapentadol	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
pain	O
and	O
pain	O
related	O
conditions	O
by	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
a	O
dosage	O
form	O
comprising	O
at	O
least	O
one	O
form	O
of	O
tapentadol	O
,	O
with	O
or	O
without	O
a	O
second	O
analgesic	O
,	O
and	O
at	O
least	O
one	O
opioid	O
antagonist	O
,	O
wherein	O
tapentadol	O
is	O
present	O
in	O
an	O
optimal	O
or	O
suboptimal	O
amount	O
and	O
the	O
said	O
antagonist	O
is	O
present	O
in	O
an	O
amount	O
effective	O
to	O
improve	O
the	O
efficacy	O
and	O
or	O
reduce	O
the	O
side	O
effects	O
of	O
tapentadol	O
.	O

Compound	O
,	O
certain	O
novel	O
forms	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
for	O
preparation	O
and	O
use	O
Compound	O
of	O
Formula	O
A	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
crystalline	O
Forms	O
I	O
and	O
ll	O
of	O
Compound	O
of	O
Formula	O
A.	O
(	O
see	O
formula	O
A	O
)	O
Also	O
,	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
methods	O
for	O
their	O
uses	O
.	O

Identification	O
of	O
tumor	O
-	O
associated	O
antigens	O
for	O
diagnosis	O
and	O
therapy	O
The	O
invention	O
relates	O
to	O
genetic	O
products	O
the	O
expression	O
of	O
which	O
is	O
associated	O
with	O
cancer	O
diseases	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
therapy	O
and	O
diagnosis	O
of	O
diseases	O
in	O
which	O
the	O
genetic	O
products	O
are	O
expressed	O
or	O
aberrantly	O
expressed	O
,	O
in	O
particular	O
cancer	O
diseases	O
.	O

Novel	O
antibacterial	O
combination	O
therapy	O
An	O
antibacterial	O
composition	O
is	O
provided	O
including	O
a	O
combination	O
of	O
a	O
ß	O
-	O
lactam	O
antibiotic	O
that	O
has	O
a	O
binding	O
affinity	O
for	O
bacterial	O
penicillin	B
-	I
binding	I
protein	I
2	I
;	O
and	O
a	O
non	O
-	O
antibiotic	O
compound	O
which	O
may	O
be	O
a	O
thienopyridine	O
or	O
a	O
non	O
-	O
thienopyridine	O
compound	O
.	O

A	O
method	O
of	O
treatment	O
using	O
the	O
composition	O
is	O
also	O
provided	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
hiv	O
Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
HIV	O
are	O
provided	O
.	O

Method	O
for	O
producing	O
antifungal	O
drug	O
in	O
triazole	O
class	O
This	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
compounds	O
shown	O
in	O
formula	O
I	O
,	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

Phosphates	O
of	O
secondary	O
alcohols	O
According	O
to	O
the	O
invention	O
,	O
there	O
is	O
provided	O
a	O
phosphate	O
derivative	O
of	O
a	O
compound	O
having	O
a	O
secondary	O
hydroxy	O
group	O
.	O

The	O
compound	O
having	O
a	O
secondary	O
hydroxyl	O
group	O
may	O
,	O
for	O
example	O
,	O
be	O
chosen	O
from	O
pravastatin	O
,	O
atorvastatin	O
venlafaxine	O
,	O
their	O
derivatives	O
and	O
mixtures	O
thereof	O
.	O

Salvia	O
minium	O
phenolic	O
acid	O
A	O
and	O
process	O
of	O
preparing	O
preparation	O
and	O
use	O
This	O
invention	O
concerns	O
the	O
method	O
of	O
extracting	O
salvianolic	O
acid	O
A	O
from	O
Chinese	O
crude	O
drug	O
:	O
danshen	O
root	O
,	O
and	O
the	O
quality	O
control	O
methods	O
and	O
drug	O
combinations	O
,	O
and	O
the	O
application	O
of	O
this	O
drug	O
.	O

It	O
can	O
be	O
used	O
in	O
the	O
preparation	O
of	O
the	O
prevention	O
drugs	O
for	O
cardiovascular	O
disease	O
,	O
liver	O
damage	O
,	O
liver	O
fibrosis	O
,	O
pulmonary	O
fibrosis	O
and	O
other	O
.	O

Powder	O
and	O
salve	O
for	O
hyperplasia	O
protrusion	O
rehabilitation	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
hyperplasia	O
and	O
method	O
for	O
preparation	O
,	O
wherein	O
the	O
powdery	O
form	O
medicament	O
is	O
prepared	O
from	O
batryticated	O
silkworm	O
,	O
dahurian	O
angelica	O
root	O
,	O
buthus	O
martensi	O
karsch	O
,	O
centipede	O
,	O
pangolin	O
scales	O
,	O
vomiting	O
nut	O
and	O
musk	O
,	O
and	O
the	O
ointment	O
form	O
medicament	O
is	O
prepared	O
from	O
cibot	O
rhizome	O
,	O
eucommia	O
bark	O
,	O
spatholobus	O
stem	O
,	O
safflower	O
,	O
peach	O
kernels	O
,	O
ledebouriella	O
root	O
,	O
earthworm	O
,	O
agkistrodon	O
acutus	O
,	O
siberian	O
cocklebur	O
fruit	O
,	O
Chinese	O
starjasmine	O
,	O
homalomena	O
rhizoma	O
,	O
frankincense	O
,	O
myrrh	O
,	O
dragon	O
's	O
blood	O
resin	O
and	O
boneol	O
.	O

Organic	O
amine	O
salt	O
of	O
cephalosporin	O
compound	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
the	O
organic	O
amine	O
salt	O
or	O
hydrate	O
for	O
ceph	O
compound	O
used	O
for	O
treating	O
bacteria	O
infection	O
,	O
and	O
the	O
chemical	O
formula	O
is	O
demonstrated	O
in	O
(	O
I	O
)	O
.Said	O
organic	O
amine	O
can	O
be	O
lycine	O
,	O
arginine	O
,	O
tert	O
-	O
butylamine	O
,	O
diethanolamine	O
,	O
triethanolamine	O
,	O
diethylamine	O
or	O
meglumine	O
.	O

It	O
comprises	O
cefuroxime	O
organic	O
amine	O
salt	O
,	O
ceftriaxone	O
organic	O
amine	O
salt	O
,	O
ceftezole	O
organic	O
amine	O
salt	O
,	O
cefoperazone	O
organic	O
amine	O
salt	O
,	O
cephalothin	O
organic	O
amine	O
salt	O
,	O
cefotaxime	O
organic	O
amine	O
salt	O
,	O
cefradine	O
organic	O
amine	O
salt	O
,	O
cefonicid	O
organic	O
amine	O
salt	O
,	O
cefmetazole	O
organic	O
amine	O
salt	O
,	O
cefodizime	O
organic	O
amine	O
salt	O
,	O
cefmenoxime	O
organic	O
amine	O
salt	O
,	O
ceftizoxime	O
organic	O
amine	O
salt	O
,	O
cefpiramide	O
organic	O
amine	O
salt	O
,	O
cefazolin	O
organic	O
amine	O
salt	O
,	O
cefoxitinorganic	O
amine	O
salt	O
and	O
flomoxef	O
organic	O
amine	O
salr	O
.	O

The	O
invention	O
provides	O
the	O
medical	O
compound	O
taking	O
compound	O
in	O
formula	O
(	O
I	O
)	O
as	O
active	O
element	O
and	O
its	O
application	O
to	O
preparation	O
of	O
medicine	O
for	O
treating	O
bacteria	O
infection	O
.	O

1,6-diphospho	O
-	O
D	O
-	O
fructose	O
ester	O
arginine	O
salt	O
and	O
its	O
pharmaceutical	O
uses	O
The	O
invention	O
disclose	O
the	O
arginine	O
salt	O
of	O
1	O
,	O
6-	O
diphosphoric	O
acid-	O
D-	O
fructose	O
esters	O
in	O
hydrate	O
type	O
,	O
and	O
one	O
or	O
more	O
than	O
one	O
of	O
the	O
four	O
function	O
groups	O
is	O
salinized	O
by	O
arginine	O
.	O

The	O
salt	O
precipitation	O
with	O
1	O
,	O
6-	O
diphosphoric	O
acid-	O
D-	O
fructose	O
esters	O
and	O
arginine	O
solves	O
problems	O
of	O
strong	O
side	O
effect	O
of	O
sodium	O
fructose	O
diphosphate	O
,	O
and	O
starting	O
circuit	O
,	O
high	O
natremia	O
risk	O
.	O

It	O
is	O
demonstrated	O
through	O
pharmacological	O
test	O
that	O
arginine	O
salt	O
can	O
cooperate	O
with	O
drug	O
and	O
the	O
toxcity	O
is	O
low	O
.	O

Slow	O
release	O
tablet	O
of	O
amoxicillin	O
The	O
invention	O
discloses	O
slow	O
release	O
tablets	O
of	O
Amoxicillin	O
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
raw	O
materials	O
of	O
the	O
preparation	O
include	O
Amoxicillin	O
of	O
a	O
predetermined	O
proportion	O
,	O
slow	O
release	O
matrix	O
material	O
and	O
medicinal	O
material	O
,	O
the	O
preparation	O
can	O
be	O
prepared	O
into	O
solid	O
dispersing	O
agent	O
,	O
wherein	O
the	O
medicament	O
can	O
be	O
released	O
slowly	O
and	O
continuously	O
after	O
being	O
administrated	O
,	O
the	O
effective	O
concentration	O
in	O
blood	O
can	O
be	O
maintained	O
,	O
and	O
long	O
action	O
can	O
be	O
achieved	O
.	O

The	O
advantages	O
of	O
the	O
invention	O
include	O
decreased	O
frequency	O
of	O
medicinal	O
administration	O
,	O
improved	O
patient	O
's	O
adaptability	O
,	O
lowered	O
blood	O
concentration	O
peak	O
-	O
valley	O
,	O
increased	O
medicinal	O
effect	O
and	O
safety	O
,	O
and	O
reduced	O
total	O
medicinal	O
dose	O
,	O
thereby	O
optimum	O
curative	O
effect	O
can	O
be	O
achieved	O
through	O
minimum	O
dose	O
,	O
thus	O
the	O
preparation	O
is	O
more	O
suitable	O
for	O
patients	O
.	O

Nucleic	O
acid	O
molecule	O
RTN4BSR62	O
and	O
application	O
in	O
preparation	O
of	O
anti	O
-	O
cancer	O
drugs	O
The	O
invention	O
discloses	O
a	O
making	O
method	O
of	O
RTN4BSR32	O
and	O
application	O
to	O
prepare	O
tumour	O
-	O
proof	O
drug	O
,	O
whose	O
sequence	O
contains	O
5'-AATGTCTCTCCAGTACAGG-3	O
'	O
or	O
5'-AAUGUCUCUCCAGUACAGG-3	O
'	O
.	O

The	O
molecular	O
can	O
inhibit	O
tumour	O
from	O
growing	O
obviously	O
,	O
which	O
provides	O
a	O
new	O
path	O
and	O
method	O
to	O
treat	O
and	O
release	O
tumour	O
.	O

Application	O
of	O
ferricitras	O
in	O
preparation	O
of	O
medicine	O
to	O
prevent	O
and	O
treat	O
angiosteosis	O
The	O
present	O
invention	O
relates	O
to	O
the	O
application	O
of	O
ferric	O
citrate	O
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
calcification	O
of	O
blood	O
vessel	O
.	O

The	O
present	O
invention	O
has	O
determined	O
curative	O
effect	O
.	O

Experiment	O
proves	O
that	O
ferric	O
citrate	O
can	O
intervene	O
calcification	O
of	O
blood	O
vessel	O
and	O
inhibit	O
calcification	O
effectively	O
,	O
and	O
may	O
reverse	O
calcification	O
of	O
blood	O
vessel	O
.	O

Hydrophilic	O
polyglycol	O
supported	O
ursolic	O
acid	O
medicines	O
and	O
their	O
prepn	O
process	O
The	O
present	O
invention	O
is	O
serial	O
hydrophilic	O
polyglycol	O
supported	O
ursolic	O
acid	O
medicines	O
obtained	O
through	O
organic	O
synthesis	O
and	O
polymerization	O
to	O
grafting	O
hydrophilic	O
polyglycol	O
onto	O
cyclohydroxy	O
group	O
of	O
ursolic	O
acid	O
A.	O
The	O
structure	O
analysis	O
and	O
experiments	O
show	O
that	O
activated	O
polyglycol	O
is	O
grafted	O
successfully	O
onto	O
ursolic	O
acid	O
said	O
water	O
insoluble	O
ursolic	O
acid	O
becomes	O
water	O
soluble	O
polyglycol	O
-	O
ursolic	O
acid	O
.	O

Polyglycol	O
-	O
ursolic	O
acid	O
has	O
excellent	O
blood	O
compatibility	O
and	O
high	O
physiological	O
activity	O
,	O
so	O
that	O
polyglycol	O
supported	O
ursolic	O
acid	O
medicines	O
may	O
be	O
prepared	O
into	O
different	O
forms	O
,	O
including	O
injection	O
,	O
oral	O
liquid	O
,	O
capsule	O
,	O
tablet	O
,	O
etc	O
.	O

The	O
polyglycol	O
has	O
average	O
molecular	O
weight	O
of	O
200	O
-	O
60,000	O
.	O

Ruthenium	O
porphyrin	O
complex	O
and	O
its	O
prepn	O
process	O
and	O
application	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
The	O
present	O
invention	O
discloses	O
ruthenium	O
porphyrin	O
complex	O
and	O
its	O
preparation	O
process	O
and	O
application	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
.	O

The	O
ruthenium	O
porphyrin	O
complex	O
with	O
the	O
structure	O
as	O
shown	O
has	O
ruthenium	O
as	O
the	O
central	O
metal	O
ion	O
,	O
pyridyl	O
radical	O
containing	O
asymmetrical	O
porphyrin	O
and	O
its	O
metal	O
derivative	O
as	O
the	O
ligand	O
,	O
and	O
coordinate	O
bond	O
jointing	O
the	O
ruthenium	O
pyridyl	O
radical	O
and	O
the	O
porphyrin	O
ring	O
.	O

The	O
ruthenium	O
porphyrin	O
complex	O
of	O
the	O
present	O
invention	O
has	O
determined	O
composition	O
,	O
less	O
toxic	O
side	O
effect	O
and	O
good	O
absorption	O
and	O
metabolism	O
in	O
organism	O
,	O
and	O
is	O
suitable	O
for	O
use	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
.	O

Use	O
of	O
dihydro	O
myricotin	O
element	O
for	O
treating	O
cardiac	O
blood	O
diseases	O
The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
dihydromyricetin	O
in	O
preparation	O
of	O
medicine	O
for	O
preventing	O
or	O
curing	O
angiocardiopathy	O
.	O

The	O
animal	O
tests	O
show	O
that	O
the	O
dihydromyricetin	O
has	O
the	O
effect	O
for	O
resisting	O
internal	O
phlebothrombosis	O
,	O
can	O
be	O
used	O
for	O
effectively	O
preventing	O
angiocardiopathy	O
due	O
to	O
thrombosis	O
,	O
for	O
example	O
cardiac	O
disease	O
and	O
apoplexy	O
.	O

Said	O
invention	O
can	O
be	O
made	O
into	O
medicine	O
or	O
health	O
-	O
care	O
product	O
.	O

Novel	O
dihydrochalcone	O
compound	O
separated	O
and	O
purified	O
from	O
drgon	O
blood	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
new	O
dihydrochalcone	O
compound	O
that	O
is	O
separated	O
and	O
purified	O
from	O
Long	O
Xuejie	O
and	O
the	O
manufacture	O
method	O
.	O

It	O
adopts	O
Long	O
Xuejie	O
as	O
raw	O
material	O
,	O
uses	O
light	O
petroleum	O
and	O
chloroform	O
solvent	O
to	O
distill	O
,	O
decreases	O
pressure	O
and	O
concentrating	O
chloroform	O
extractive	O
,	O
takes	O
silica	O
gel	O
column	O
or	O
rapid	O
silica	O
gel	O
chromatography	O
and	O
takes	O
Sephadex	O
LH-20	O
gelcolumn	O
chromatography	O
andseparating	O
,	O
purifies	O
chromatogram	O
,	O
and	O
finally	O
gains	O
dihydrochalcone	O
compound	O
.	O

The	O
chemical	O
name	O
is	O
4'-	O
hydroxyl-2	O
'	O
,	O
4-	O
dimethoxy-	O
dihydrochalcone	O
.	O

The	O
compound	O
has	O
good	O
effect	O
to	O
avoid	O
platelet	O
aggregation	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
of	O
lower	O
urinary	O
tract	O
diseases	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
compound	O
for	O
treating	O
disease	O
of	O
lower	O
urinary	O
tract	O
,	O
which	O
comprises	O
drug	O
active	O
component	O
,	O
drug	O
carrier	O
or	O
shaping	O
agent	O
,	O
wherein	O
the	O
drug	O
active	O
component	O
is	O
terraazoles	O
and	O
amiloripin	O
.	O

The	O
disease	O
of	O
lower	O
urinary	O
tract	O
relates	O
to	O
prostatitis	O
increment	O
,	O
lower	O
urinary	O
tract	O
syndrome	O
and	O
bladder	O
excessive	O
activities	O
,	O
in	O
particular	O
to	O
treat	O
lower	O
urinary	O
tract	O
syndrome	O
and	O
bladder	O
excessive	O
activities	O
induced	O
by	O
prostatitis	O
increment	O
.	O

And	O
the	O
inventive	O
drug	O
can	O
be	O
used	O
treat	O
the	O
high	O
blood	O
pressure	O
concomitant	O
with	O
lower	O
urinary	O
tract	O
,	O
to	O
effectively	O
control	O
blood	O
pressure	O
and	O
resolve	O
the	O
lower	O
urinary	O
tract	O
disease	O
,	O
compared	O
with	O
single	O
terraazoles	O
or	O
amiloripin	O
drug	O
,	O
to	O
improve	O
the	O
health	O
quality	O
of	O
patient	O
.	O

Nanometer	O
elemental	O
selenium	O
coupled	O
with	O
liquid	O
amino	O
acid	O
and	O
the	O
method	O
for	O
preparing	O
and	O
preserving	O
the	O
same	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
nanometer	O
monomer	O
selenium	O
via	O
coupling	O
liquid	O
amino	O
acid	O
,	O
comprising	O
that	O
at	O
normal	O
temperature	O
and	O
normal	O
pressure	O
,	O
adding	O
vitamin	O
C	O
solution	O
into	O
amino	O
acid	O
solution	O
,	O
mixing	O
uniformly	O
and	O
adding	O
selenious	O
anhydride	O
or	O
selenite	O
solution	O
until	O
the	O
product	O
has	O
held	O
red	O
,	O
to	O
obtain	O
the	O
liquid	O
coupled	O
product	O
of	O
amino	O
acid	O
and	O
nanometer	O
selenium	O
.	O

The	O
nanometer	O
monomer	O
selenium	O
can	O
be	O
used	O
as	O
medical	O
health	O
-	O
care	O
product	O
to	O
display	O
the	O
cooperation	O
between	O
amino	O
acid	O
and	O
nanometer	O
selenium	O
,	O
while	O
the	O
nanometer	O
selenium	O
gel	O
has	O
small	O
diameter	O
,	O
narrow	O
distribution	O
and	O
liquid	O
storage	O
,	O
to	O
develop	O
oral	O
,	O
injection	O
or	O
the	O
like	O
.	O

Anticancer	O
compound	O
including	O
neoangiogenesis	O
inhibitors	O
and	O
alkylate	O
agent	O
The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
cancer	O
compound	O
as	O
a	O
slow	O
release	O
injection	O
which	O
contains	O
vessel	O
restrainer	O
and/or	O
alkyl	O
agent	O
,	O
formed	O
by	O
slow	O
release	O
micro	O
ball	O
and	O
solvent	O
.	O

The	O
slow	O
release	O
micro	O
ball	O
comprises	O
the	O
anti	O
-	O
cancer	O
effective	O
components	O
and	O
slow	O
release	O
findings	O
,	O
the	O
solvent	O
is	O
a	O
common	O
solvent	O
or	O
a	O
special	O
solvent	O
with	O
suspending	O
agent	O
,	O
while	O
the	O
viscosity	O
of	O
suspending	O
agent	O
is	O
100cp-3000cp	O
(	O
at	O
20	O
-	O
30Deg	O
.	O

C	O
)	O
,	O
selected	O
from	O
carboxymethyl	O
cellulose	O
,	O
the	O
anti	O
-	O
cancer	O
effective	O
component	O
is	O
the	O
combination	O
of	O
vessel	O
restrainer	O
and/or	O
the	O
alkyl	O
agent	O
selected	O
from	O
nimuxitin	O
,	O
or	O
the	O
like	O
,	O
the	O
slow	O
release	O
finding	O
is	O
selected	O
from	O
phosphate	O
polyester	O
as	O
p	O
(	O
LAEG	O
-	O
EOP	O
)	O
,	O
p	O
(	O
DAPG	O
-	O
EOP	O
)	O
,	O
or	O
the	O
polyester	O
or	O
mixture	O
of	O
phosphate	O
and	O
polylactic	O
acid	O
,	O
polyphenyl	O
,	O
2-aliphatic	O
acid	O
,	O
sebacic	O
acid	O
polyester	O
,	O
poly	O
(	O
erucic	O
acid	O
dimmer	O
-	O
sebacic	O
acid	O
)	O
or	O
poly	O
(	O
fumaric	O
acid	O
-	O
sebacic	O
acid	O
)	O
.	O

The	O
anti	O
-	O
cancer	O
compound	O
can	O
be	O
made	O
as	O
slow	O
release	O
plant	O
agent	O
,	O
to	O
inject	O
into	O
cancer	O
or	O
around	O
cancer	O
to	O
hold	O
the	O
effective	O
drug	O
density	O
for	O
more	O
than	O
40	O
days	O
,	O
while	O
it	O
can	O
significantly	O
reduce	O
the	O
general	O
reaction	O
of	O
drug	O
and	O
selectively	O
strengthen	O
the	O
effect	O
of	O
non	O
-	O
surgery	O
treatments	O
as	O
chemotherapy	O
or	O
the	O
like	O
.	O

Medicine	O
composition	O
and	O
its	O
preparing	O
method	O
A	O
medicinal	O
composition	O
is	O
prepared	O
from	O
gentamycin	O
,	O
amitriptyline	O
,	O
honey	O
,	O
and	O
11	O
Chinese	O
-	O
medicinal	O
materials	O
including	O
notoginseng	O
,	O
peach	O
kernel	O
,	O
fennel	O
,	O
borax	O
,	O
etc	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

An	O
improved	O
process	O
for	O
preparing	O
pure	O
ondansetron	O
hydrochloride	O
dihydrate	O
An	O
improved	O
method	O
for	O
preparing	O
dimethylamino	O
-	O
methyl	O
-	O
carbazolone	O
and	O
ondansetron	O
base	O
.	O

A	O
recrystallization	O
process	O
for	O
preparing	O
pure	O
ondansetron	O
hydrochloride	O
dihydrate	O
with	O
a	O
purity	O
of	O
at	O
least	O
99.0	O
%	O
is	O
also	O
disclosed	O
.	O

Anethol	O
trithione	O
drop	O
pills	O
,	O
and	O
preparation	O
method	O
A	O
dripping	O
pill	O
of	O
anethol	O
trithione	O
for	O
treating	O
cholecystitis	O
,	O
cholelithiasis	O
and	O
acute	O
or	O
chronic	O
hepatitis	O
is	O
prepared	O
from	O
the	O
anethol	O
trithione	O
and	O
the	O
matrix	O
of	O
dripping	O
pill	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Suppository	O
for	O
treating	O
wound	O
caused	O
by	O
cervical	O
erosion	O
treatment	O
Disclosed	O
is	O
a	O
suppository	O
for	O
processing	O
wounds	O
in	O
the	O
treatment	O
of	O
uterine	O
neck	O
erosion	O
,	O
which	O
comprises	O
biologically	O
active	O
glass	O
,	O
collagen	O
and	O
activated	O
charcoal	O
fiber	O
by	O
a	O
weight	O
ratio	O
of	O
30	O
-	O
70:70	O
-	O
30	O
.	O

The	O
preparing	O
process	O
comprises	O
steps	O
of	O
coating	O
the	O
activated	O
charcoal	O
fiber	O
into	O
a	O
circular	O
form	O
,	O
crosslinking	O
the	O
collagen	O
solution	O
or	O
dried	O
powder	O
,	O
proportioning	O
collagen	O
and	O
biologically	O
active	O
glass	O
,	O
dissolving	O
and	O
stirring	O
20	O
-	O
50	O
minutes	O
,	O
freeze	O
drying	O
,	O
pressurizing	O
to	O
obtain	O
composite	O
film	O
,	O
adhering	O
the	O
composite	O
film	O
with	O
one	O
end	O
of	O
the	O
activated	O
charcoal	O
fiber	O
suppository	O
,	O
and	O
fixing	O
the	O
other	O
end	O
of	O
the	O
activated	O
charcoal	O
fiber	O
suppository	O
with	O
soft	O
wires	O
.	O

The	O
collagen	O
can	O
be	O
replaced	O
with	O
chitosan	O
.	O

Medical	O
combination	O
of	O
teniposide	O
,	O
the	O
preparing	O
method	O
and	O
the	O
function	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicinal	O
component	O
of	O
substitute	O
nipa	O
glycosides	O
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
incorporating	O
substitute	O
nipa	O
glycosides	O
,	O
Tuwen	O
surface	O
activator	O
,	O
assisting	O
solvent	O
and	O
inorganic	O
salt	O
;	O
choosing	O
the	O
assisting	O
solvent	O
as	O
mixture	O
of	O
dimethyl	O
ethanolamine	O
and	O
carbowax	O
;	O
choosing	O
the	O
inorganic	O
salt	O
from	O
one	O
or	O
multiple	O
common	O
salt	O
,	O
potassium	O
chloride	O
,	O
sulphate	O
and	O
sulphate	O
;	O
setting	O
this	O
component	O
as	O
injection	O
or	O
freeze	O
dry	O
powder	O
needle	O
;	O
adding	O
into	O
Tuwen	O
and	O
the	O
assisting	O
dissolvent	O
;	O
adding	O
into	O
the	O
inorganic	O
salt	O
at	O
the	O
same	O
time	O
;	O
increasing	O
solubility	O
of	O
substitute	O
nipa	O
glycosides	O
.	O

This	O
invention	O
also	O
relates	O
to	O
the	O
preparing	O
method	O
and	O
usage	O
of	O
this	O
medicinal	O
component	O
.	O

Novel	O
medicine	O
for	O
giving	O
up	O
drug	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
medicament	O
for	O
drug	O
abstinence	O
which	O
comprises	O
the	O
following	O
constituents	O
(	O
by	O
weight	O
ratio	O
)	O
:	O
acanthopanax	O
root	O
18	O
-	O
30	O
%	O
,	O
polygala	O
root	O
6	O
-	O
12	O
%	O
,	O
dendrobium	O
9	O
-	O
16	O
%	O
,	O
notoginseng	O
3	O
-	O
10	O
%	O
,	O
ginseng	O
10	O
-	O
24	O
%	O
,	O
ginkgo	O
leaves	O
24	O
-	O
34	O
%	O
,	O
atropine	O
sulfate	O
0	O
.	O

05	O
-	O
1	O
.	O
5	O
%	O
,	O
ansiolin	O
0	O
.	O
05	O
-	O
1	O
.	O
0	O
%	O
.	O

The	O
medicament	O
can	O
be	O
prepared	O
into	O
capsules	O
,	O
granules	O
and	O
tablets	O
through	O
conventional	O
processes	O
.	O

Method	O
for	O
preparing	O
iron	O
-	O
complementing	O
agent	O
by	O
complex	O
of	O
parafobrown	O
algin	O
and	O
iron	O
The	O
invention	O
is	O
concerned	O
with	O
the	O
method	O
to	O
produce	O
supply	O
of	O
iron	O
using	O
the	O
algin	O
and	O
compound	O
of	O
iron	O
.	O

Put	O
the	O
water	O
solution	O
or	O
degeneration	O
fluid	O
of	O
algin	O
into	O
a	O
container	O
,	O
add	O
assistant	O
stabilizer	O
and	O
inorganic	O
iron	O
salt	O
,	O
and	O
the	O
concentration	O
is	O
0.1	O
to	O
0.50	O
mol	O
/	O
L	O
,	O
adjust	O
the	O
pH	O
of	O
solution	O
is	O
4	O
to	O
8	O
,	O
refluence	O
for	O
2	O
to	O
5	O
hours	O
,	O
dialyse	O
,	O
concentrate	O
,	O
divide	O
with	O
alcohol	O
and	O
taking	O
centrifugal	O
processing	O
.	O

Wash	O
and	O
dry	O
the	O
sedimentation	O
to	O
get	O
algin	O
Fe	O
(	O
III	O
)	O
compound	O
.	O

The	O
method	O
has	O
reasonable	O
prcess	O
and	O
low	O
cost	O
,	O
the	O
produced	O
supply	O
of	O
iron	O
has	O
nice	O
stability	O
with	O
high	O
biology	O
utilization	O
ratio	O
,	O
the	O
revivification	O
and	O
dissolving	O
time	O
is	O
fit	O
to	O
absorb	O
for	O
body	O
.	O

The	O
algin	O
forms	O
into	O
gel	O
with	O
stomach	O
acid	O
and	O
protecting	O
film	O
on	O
the	O
surface	O
of	O
stomach	O
in	O
order	O
to	O
reduce	O
the	O
stimulating	O
to	O
stomach	O
.	O

It	O
is	O
fit	O
for	O
pregnant	O
woman	O
,	O
children	O
and	O
gastricism	O
sufferer	O
.	O

Novel	O
use	O
of	O
medicine	O
The	O
present	O
invention	O
provides	O
new	O
use	O
of	O
arctiin	O
,	O
and	O
is	O
especially	O
the	O
application	O
of	O
arctiin	O
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
chronic	O
renal	O
failure	O
and	O
renal	O
fiberosis	O
.	O

Improved	O
process	O
of	O
preparing	O
Raltitrexed	O
The	O
improvement	O
in	O
the	O
process	O
of	O
preparing	O
Raltitrexed	O
as	O
antitumor	O
medicine	O
includes	O
the	O
reaction	O
between	O
N-	O
(	O
5-aminothienyl-2-formoxyl	O
)	O
-L	O
-	O
diethyl	O
glutarate	O
and	O
methyl	O
iodide	O
at	O
temperature	O
raised	O
to	O
100	O
deg.c	O
in	O
lucifugous	O
condition	O
with	O
yield	O
raised	O
to	O
91	O
%	O
;	O
the	O
replacement	O
of	O
sodium	O
sulfide	O
for	O
iron	O
powder	O
as	O
reductant	O
to	O
facilitate	O
post	O
-	O
treatment	O
and	O
raise	O
yield	O
;	O
the	O
replacement	O
of	O
re	O
-	O
crystallization	O
in	O
mixed	O
solvent	O
of	O
methanol	O
and	O
ether	O
for	O
column	O
separation	O
to	O
expand	O
the	O
production	O
capacity	O
;	O
and	O
oxidizing	O
5-nitrothienyl-2-formaldehyde	O
with	O
chromic	O
acid	O
,	O
rather	O
than	O
bromine	O
,	O
to	O
eliminate	O
toxicity	O
and	O
raise	O
safety	O
.	O

The	O
improved	O
preparation	O
process	O
of	O
Raltitrexed	O
has	O
high	O
yield	O
,	O
great	O
production	O
capacity	O
,	O
low	O
solvent	O
consumption	O
and	O
high	O
safety	O
.	O

Potato	O
red	O
healing	O
liquid	O
and	O
method	O
for	O
preparing	O
the	O
same	O
The	O
invention	O
relates	O
to	O
a	O
kind	O
of	O
medicine	O
and	O
its	O
production	O
method	O
,	O
especially	O
relates	O
to	O
a	O
kind	O
of	O
rehabilitation	O
liquid	O
and	O
the	O
production	O
method	O
.	O

It	O
is	O
specialized	O
for	O
fiber	O
lung	O
treatment	O
.	O

The	O
anti	O
-	O
inflammation	O
effect	O
of	O
potato	O
is	O
strong	O
,	O
and	O
the	O
disinfection	O
effect	O
of	O
chromargyre	O
is	O
good	O
,	O
the	O
invention	O
combines	O
the	O
anti	O
-	O
inflammation	O
and	O
disinfection	O
effect	O
together	O
,	O
and	O
dissolves	O
them	O
in	O
spirit	O
to	O
treat	O
lung	O
disease	O
;	O
the	O
rehabilitation	O
liquid	O
can	O
be	O
discharged	O
through	O
manure	O
and	O
urine	O
,	O
so	O
it	O
can	O
disinfect	O
and	O
eliminate	O
inflammation	O
when	O
passing	O
through	O
other	O
organs	O
with	O
disease	O
.	O

The	O
production	O
method	O
comprises	O
two	O
technique	O
programs	O
:	O
one	O
is	O
immersion	O
and	O
another	O
is	O
blending	O
.	O

Ruthenium	O
-	O
anthraquinone	O
conjugates	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O
for	O
optical	O
power	O
therapeutic	O
photosensitizer	O
The	O
invention	O
discloses	O
a	O
ruthenium	O
-	O
anthraquinone	O
conjugate	O
,	O
the	O
preparation	O
process	O
thereof	O
and	O
the	O
application	O
as	O
a	O
photo	O
-	O
dynamic	O
therapy	O
photosensitizer	O
.	O

The	O
general	O
formula	O
of	O
the	O
ruthenium	O
-	O
anthraquinone	O
conjugate	O
of	O
the	O
invention	O
is	O
[	O
Ru	O
(	O
L	O
)	O
2HAIP	O
]	O
.	O
(	O
PF6	O
)	O
2	O
,	O
the	O
general	O
formula	O
of	O
the	O
HAIP	O
is	O
1,8-	O
dihydroxy	O
-9,10-	O
anthraquinoneimidazole	O
[	O
4,5-f	O
]	O
[	O
1,10	O
]	O
phenanthroline	O
,	O
the	O
general	O
of	O
the	O
L	O
is	O
bpy	O
or	O
phen	O
.	O

The	O
preparation	O
process	O
for	O
the	O
ruthenium	O
-	O
anthraquinone	O
conjugate	O
comprises	O
the	O
following	O
procedures	O
:	O
1	O
.	O
the	O
synthesis	O
of	O
the	O
HAIP	O
:	O
1,8-	O
dihydroxy	O
-9,10-	O
anthraquinone-3-aldehyde	O
is	O
reacted	O
with	O
the	O
phenanthroline5,6-diketone	O
to	O
produce	O
the	O
HAIP	O
;	O
2	O
.	O

Ru	O
(	O
L	O
)	O
2Cl2	O
is	O
reacted	O
with	O
HAIP	O
and	O
NH4PF6	O
to	O
produce	O
the	O
[	O
Ru	O
(	O
L	O
)	O
2HAIP	O
]	O
.	O
(	O
PF6	O
)	O
2	O
.	O

The	O
invention	O
takes	O
the	O
aloe	O
-	O
emodin	O
as	O
the	O
raw	O
material	O
and	O
the	O
ruthenium	O
polypyridyl	O
complex	O
has	O
single	O
chemical	O
composition	O
;	O
the	O
synthesis	O
route	O
is	O
simple	O
and	O
the	O
yields	O
are	O
higher	O
;	O
during	O
the	O
experiment	O
,	O
the	O
compound	O
shows	O
the	O
light	O
suppression	O
to	O
the	O
growth	O
of	O
cancer	O
cells	O
.	O

Pistachio	O
galls	O
pressure	O
ulcer	O
powder	O
The	O
invention	O
relates	O
to	O
a	O
medicinal	O
and	O
dietary	O
composition	O
for	O
treating	O
bedsore	O
and	O
its	O
preparing	O
process	O
,	O
wherein	O
the	O
composition	O
is	O
prepared	O
mainly	O
from	O
frankincense	O
,	O
Chinese	O
angelica	O
root	O
,	O
dahurian	O
angelica	O
root	O
,	O
dried	O
rehmannia	O
root	O
,	O
goldthread	O
root	O
and	O
boneol	O
,	O
the	O
medicament	O
can	O
also	O
be	O
used	O
as	O
a	O
conventional	O
health	O
dietary	O
preparation	O
having	O
no	O
side	O
effects	O
easy	O
administering	O
.	O

Anticancer	O
diaminocyclohexane	O
metallic	O
complex	O
The	O
invention	O
discloses	O
a	O
medicinal	O
molecule	O
with	O
selective	O
anticancer	O
activity	O
with	O
structure	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
uses	O
chiral	O
cyclohexamethylene	O
diamine	O
derivative	O
and	O
metal	O
ion	O
to	O
form	O
metal	O
complex	O
after	O
coordinating	O
and	O
provides	O
the	O
making	O
method	O
of	O
the	O
typical	O
compound	O
and	O
inhibition	O
and	O
mechanism	O
of	O
the	O
growth	O
of	O
human	O
breast	O
cancer	O
and	O
lung	O
cancer	O
,	O
wherein	O
R1	O
and	O
R2	O
contains	O
random	O
one	O
meaning	O
organic	O
group	O
or	O
hydrogen	O
atom	O
;	O
A1	O
and	O
A2	O
can	O
be	O
individually	O
selected	O
from	O
random	O
organic	O
group	O
;	O
M	O
is	O
random	O
one	O
transition	O
system	O
,	O
expensive	O
metal	O
or	O
rare	O
earth	O
metal	O
ion	O
or	O
radioactive	O
isotope	O
;	O
B1,B2,C1	O
and	O
C2	O
represent	O
random	O
one	O
complex	O
ion	O
,	O
molecular	O
or	O
vacant	O
site	O
individually	O
;	O
B1	O
and	O
B2	O
can	O
represent	O
a	O
couple	O
of	O
tooth	O
complex	O
together	O
;	O
R1,R2	O
,	O
A1,A2,B1,B2,C1	O
and	O
C2	O
can	O
link	O
biological	O
molecule	O
.	O

Application	O
of	O
alkaloids	O
compounds	O
in	O
the	O
preparation	O
of	O
antineoplastic	O
medicament	O
The	O
present	O
invention	O
pertains	O
to	O
the	O
art	O
of	O
medical	O
technology	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
an	O
alkaloid	O
compound	O
in	O
the	O
preparation	O
of	O
antitumor	O
drugs	O
.	O

The	O
alkaloid	O
compound	O
consists	O
of	O
a	O
Lycoris	O
lactone	O
,	O
a	O
narciprimine	O
and	O
a	O
7-dehydroxyl	O
narciprimine	O
and	O
the	O
molecular	O
formula	O
of	O
the	O
alkaloid	O
compound	O
is	O
C17H19NO5	O
,	O
C14H9NO5	O
,	O
C14H9NO4	O
.	O

Animal	O
experiments	O
prove	O
that	O
the	O
compounds	O
have	O
better	O
inhibited	O
activity	O
on	O
a	O
variety	O
of	O
tumors	O
.	O

The	O
invention	O
also	O
includes	O
one	O
or	O
more	O
than	O
one	O
types	O
of	O
three	O
compounds	O
with	O
effective	O
treatment	O
,	O
or	O
includes	O
medicine	O
combinations	O
of	O
the	O
pharmaceutical	O
acceptable	O
carrier	O
.	O

2-dihydro	O
indolone	O
derivant	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
2-dihydroindolone	O
compound	O
as	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
relative	O
application	O
of	O
the	O
compound	O
or	O
the	O
medical	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O

Pharmacological	O
experiment	O
proves	O
that	O
the	O
compound	O
or	O
relative	O
medical	O
acceptable	O
salt	O
can	O
restrain	O
various	O
cancer	O
cell	O
proliferations	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
an	O
intermediate	O
formula	O
(	O
II	O
)	O
of	O
the	O
compound	O
.	O

Pain	O
-	O
relieving	O
plaster	O
and	O
preparing	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pain	O
ointmentl	O
,	O
which	O
is	O
characterized	O
in	O
that	O
:	O
the	O
major	O
components	O
of	O
the	O
drug	O
comprise	O
radix	O
saposhnikoviae	O
and	O
ginseng	O
,	O
the	O
mixture	O
ratio	O
is	O
55	O
-	O
65	O
precent:35	O
-	O
45	O
percent	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
:	O
the	O
radix	O
saposhnikoviae	O
is	O
in	O
wild	O
nature	O
with	O
sweet	O
and	O
pungent	O
taste	O
,	O
which	O
has	O
the	O
efficacy	O
of	O
inducing	O
diaphoresis	O
to	O
dispel	O
wind	O
,	O
clearing	O
wind	O
-	O
damp	O
and	O
anti	O
-	O
spasticity	O
,	O
and	O
has	O
obvious	O
significant	O
efficacy	O
for	O
muscular	O
constricture	O
,	O
rheumatism	O
and	O
pruritus	O
;	O
the	O
ginseng	O
has	O
the	O
efficacy	O
of	O
expanding	O
coronary	O
artery	O
and	O
blood	O
vessels	O
;	O
the	O
product	O
has	O
no	O
additives	O
or	O
stroma	O
for	O
affecting	O
the	O
body	O
skin	O
;	O
the	O
use	O
is	O
convenient	O
and	O
the	O
effect	O
is	O
good	O
;	O
furthermore	O
,	O
the	O
preparation	O
method	O
is	O
simple	O
,	O
economical	O
and	O
practical	O
.	O

Telomerase	B
inhibitor	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
a	O
thiazole	O
[	O
5	O
,	O
4-b	O
]	O
pyrimidine	O
compounds	O
(	O
I	O
)	O
,	O
preparation	O
methods	O
thereof	O
and	O
also	O
to	O
pharmaceutical	O
composites	O
containing	O
the	O
compounds	O
and	O
medical	O
purposes	O
thereof	O
,	O
in	O
particular	O
to	O
telomerase	B
inhibitors	O
.	O

Skeleton	O
type	O
roxithromycin	O
sustained	O
release	O
pellet	O
capsule	O
The	O
invention	O
provides	O
a	O
matrix	O
-	O
typed	O
roxithromycin	O
sustained	O
release	O
micropill	O
capsule	O
which	O
is	O
prepared	O
by	O
60	O
-	O
75wt	O
percent	O
of	O
roxithromycin	O
,	O
2	O
-	O
5wt	O
percent	O
of	O
waxy	O
matrix	O
material	O
,	O
10	O
-	O
25wt	O
percent	O
of	O
microcrystalline	O
cellulose	O
,	O
lactose	O
,	O
cane	O
sugar	O
or	O
xylose	O
,	O
2	O
-	O
5wt	O
percent	O
of	O
hydrophilic	O
matrix	O
material	O
,	O
1	O
-	O
4wt	O
percent	O
of	O
anhydrous	O
sodium	O
carbonate	O
and	O
4	O
-	O
10wt	O
percent	O
of	O
mannite	O
according	O
to	O
the	O
normal	O
preparation	O
method	O
.	O

The	O
waxy	O
matrix	O
material	O
is	O
octodecyl	O
alcohol	O
,	O
cetyl	O
alcohol	O
,	O
octadecanoic	O
acid	O
,	O
glycerin	O
monostearate	O
or	O
hydrogenated	O
castor	O
oil	O
.	O

The	O
hydrophilic	O
matrix	O
material	O
is	O
xanthan	O
gum	O
,	O
alginic	O
acid	O
or	O
carbomer	O
974P	O
.	O

The	O
matrix	O
material	O
adopted	O
in	O
the	O
invention	O
delays	O
the	O
release	O
of	O
the	O
drug	O
,	O
reduces	O
the	O
density	O
of	O
sustained	O
release	O
micropill	O
,	O
prolongs	O
the	O
staying	O
time	O
of	O
the	O
sustained	O
release	O
micropill	O
in	O
the	O
stomach	O
and	O
intestinal	O
tract	O
and	O
improves	O
the	O
bioavailability	O
of	O
the	O
medicine	O
.	O

A	O
comparison	O
test	O
between	O
the	O
medicine	O
of	O
the	O
invention	O
and	O
the	O
roxithromycin	O
sustained	O
release	O
pill	O
is	O
carried	O
out	O
in	O
eighteen	O
testers	O
and	O
the	O
test	O
shows	O
that	O
the	O
matrix	O
-	O
typed	O
roxithromycin	O
slow	O
-	O
release	O
micropill	O
capsule	O
of	O
the	O
invention	O
and	O
the	O
roxithromycin	O
slow	O
-	O
release	O
pill	O
have	O
bioequiavailability	O
.	O

Tinidazole	O
compound	O
nano	O
silver	O
microemulsion	O
antibacterial	O
medicine	O
The	O
invention	O
discloses	O
a	O
tinidazole	O
nano	O
-	O
composite	O
silver	O
micro	O
-	O
emulsified	O
antibiotics	O
,	O
0.10	O
to	O
1.50	O
units	O
of	O
tinidazole	O
and	O
0.008	O
to	O
0.020	O
units	O
of	O
nano	O
-	O
silver	O
being	O
regarded	O
as	O
medical	O
components	O
,	O
and	O
96.92	O
to	O
99.67	O
units	O
of	O
micro	O
-	O
emulsified	O
substrate	O
and	O
0.30	O
to	O
3.00	O
units	O
of	O
auxiliary	O
materials	O
are	O
evenly	O
mixed	O
together	O
with	O
a	O
certain	O
percentage	O
,	O
then	O
the	O
tinidazole	O
complex	O
nano	O
-	O
silver	O
micro	O
-	O
emulsified	O
antibiotics	O
can	O
be	O
got	O
which	O
has	O
a	O
yellow	O
outlook	O
,	O
the	O
diameter	O
of	O
grains	O
is	O
1	O
nm	O
to	O
100	O
nm	O
,	O
the	O
invention	O
is	O
stable	O
,	O
which	O
can	O
not	O
only	O
disturb	O
the	O
synthesis	O
of	O
DNA	O
,	O
but	O
also	O
be	O
able	O
to	O
combine	O
with	O
oxygen	O
metabolic	O
enzyme	O
(	O
-SH	O
)	O
to	O
interrupt	O
the	O
respiration	O
metabolism	O
process	O
,	O
so	O
as	O
to	O
kill	O
the	O
aerobic	O
and	O
anaerobic	O
pathogens	O
and	O
improve	O
the	O
recovery	O
of	O
wounds	O
,	O
and	O
diseases	O
such	O
as	O
vaginitis	O
,	O
endometritis	O
can	O
be	O
quickly	O
and	O
effectively	O
cured	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
simple	O
and	O
safe	O
.	O

Application	O
of	O
asiaticoside	O
in	O
pulmonary	O
fibrosis	O
resistant	O
delayed	O
period	O
The	O
invention	O
discloses	O
a	O
new	O
application	O
in	O
a	O
preparation	O
using	O
asiaticoside	O
in	O
a	O
drug	O
against	O
delayed	O
lung	O
fibrosis	O
.	O

At	O
the	O
end	O
of	O
the	O
delayed	O
lung	O
fibrosis	O
,	O
the	O
asiaticoside	O
has	O
an	O
effect	O
against	O
the	O
lung	O
fibrosis	O
under	O
an	O
action	O
of	O
a	O
promoting	O
fibrosis	O
cytokine	B
in	O
vivo	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
drug	O
composition	O
against	O
delayed	O
lung	O
fibrosis	O
,	O
which	O
active	O
component	O
comprises	O
the	O
asiaticoside	O
and	O
the	O
exogenous	O
promoting	O
fibrosis	O
cytokine	B
.	O

Iron	O
supplement	O
composition	O
,	O
its	O
preparing	O
method	O
and	O
application	O
of	O
the	O
same	O
The	O
invention	O
discloses	O
a	O
drug	O
combination	O
as	O
iron	O
supplementary	O
agent	O
which	O
is	O
characterized	O
in	O
that	O
the	O
drug	O
combination	O
has	O
carbonyl	O
iron	O
and	O
natural	O
anti	O
-	O
oxidant	O
components	O
which	O
have	O
the	O
drug	O
activity	O
;	O
the	O
drug	O
combination	O
can	O
also	O
have	O
pharmaceutical	O
carrier	O
.	O

The	O
invention	O
also	O
disclosed	O
the	O
preparation	O
,	O
comprising	O
the	O
drug	O
combination	O
,	O
the	O
preparation	O
method	O
of	O
the	O
combination	O
and	O
the	O
preparation	O
,	O
and	O
the	O
function	O
of	O
preventing	O
and	O
curing	O
iron	O
deficiency	O
of	O
the	O
drug	O
combination	O
.	O

The	O
drug	O
combination	O
has	O
the	O
advantages	O
that	O
the	O
iron	O
deficiency	O
anemia	O
is	O
treated	O
effectively	O
;	O
the	O
production	O
of	O
free	O
radical	O
in	O
human	O
body	O
is	O
inhibited	O
;	O
the	O
oxygen	O
metabolism	O
balance	O
in	O
human	O
body	O
is	O
maintained	O
;	O
the	O
physical	O
quality	O
of	O
the	O
patient	O
is	O
enhanced	O
;	O
and	O
the	O
immunity	O
of	O
body	O
is	O
improved	O
.	O

Sheep	O
insect	O
powder	O
for	O
treating	O
epilepsy	O
The	O
invention	O
relates	O
to	O
a	O
powder	O
for	O
treating	O
epilepsy	O
,	O
comprising	O
sheep	O
parasite	O
,	O
tussah	O
pupa	O
,	O
fennel	O
,	O
muscardine	O
cadaver	O
,	O
finch	O
brain	O
,	O
hawksbill	O
,	O
oryzanol	O
,	O
and	O
cow	O
-	O
bezoar	O
,	O
which	O
are	O
prepared	O
in	O
proportion	O
and	O
in	O
order	O
under	O
normal	O
temperature	O
.	O

The	O
powder	O
has	O
the	O
advantages	O
:	O
the	O
powder	O
has	O
the	O
advantages	O
of	O
easily	O
-	O
purchased	O
raw	O
materials	O
,	O
low	O
cost	O
,	O
simple	O
technology	O
,	O
easy	O
popularization	O
,	O
and	O
convenient	O
use	O
;	O
the	O
powder	O
can	O
make	O
the	O
percentage	O
of	O
epilepsy	O
-	O
treatment	O
reach	O
98.2	O
%	O
,	O
and	O
the	O
cure	O
rate	O
91.8	O
%	O
.	O

Lamb	O
stomach	O
extract	O
vitamin	O
B12	O
preparations	O
composing	O
prescription	O
The	O
present	O
invention	O
provides	O
a	O
formulation	O
of	O
B12	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
.	O

The	O
material	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
is	O
the	O
total	O
extracts	O
from	O
the	O
forth	O
gastric	O
of	O
the	O
lambs	O
;	O
when	O
calculated	O
as	O
the	O
dried	O
material	O
,	O
the	O
rennet	O
activity	O
in	O
each	O
gram	O
is	O
not	O
less	O
than	O
800	O
units	O
,	O
and	O
the	O
stomach	O
enzyme	O
activity	O
is	O
not	O
less	O
than	O
230	O
units	O
;	O
the	O
ratio	O
of	O
rennet	O
activity	O
and	O
the	O
stomach	O
enzyme	O
activity	O
is	O
2.0	O
to	O
4.1	O
.	O

The	O
ratio	O
can	O
clinically	O
avoid	O
side	O
effects	O
caused	O
by	O
too	O
high	O
stomach	O
enzyme	O
activity	O
;	O
the	O
invention	O
can	O
be	O
used	O
for	O
patients	O
of	O
gastritis	O
with	O
erosion	O
,	O
hyperemia	O
and	O
ulcer	O
,	O
and	O
can	O
also	O
treat	O
anorexia	O
,	O
diarrhea	O
and	O
milk	O
vomiting	O
of	O
babies	O
.	O

The	O
formulation	O
of	O
B12	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
has	O
simple	O
manufacturing	O
process	O
and	O
does	O
not	O
use	O
organic	O
solvent	O
.	O

Smell	O
concealing	O
composition	O
of	O
hydrochloric	O
selegiline	O
,	O
and	O
preparation	O
containing	O
the	O
composition	O
The	O
invention	O
provides	O
a	O
Selegiline	O
hydrochloride	O
smell	O
covering	O
compound	O
,	O
which	O
contains	O
sugar	O
alcohol	O
,	O
corrective	O
agent	O
,	O
gelatin	B
,	O
and	O
xanthan	O
gum	O
,	O
and	O
is	O
treated	O
by	O
special	O
process	O
and	O
is	O
evenly	O
dispersed	O
with	O
Selegiline	O
hydrochloride	O
.	O

The	O
compound	O
covers	O
the	O
stimulating	O
taste	O
of	O
Selegiline	O
hydrochloride	O
,	O
is	O
used	O
for	O
preparing	O
the	O
orally	O
disintegrating	O
tablet	O
,	O
and	O
is	O
used	O
for	O
treating	O
Parkinsons	O
disease	O
.	O

Antisense	O
oligonucleotide	O
for	O
tissue	O
-	O
specific	O
regulation	O
of	O
POKEMON	B
gene	O
expression	O
and	O
application	O
thereof	O
The	O
present	O
invention	O
provides	O
an	O
antisense	O
oligonucleotide	O
of	O
tissue	O
-	O
specific	O
regulation	O
POKEMON	B
gene	O
expression	O
and	O
its	O
application	O
.	O

The	O
antisense	O
oligonucleotide	O
is	O
one	O
of	O
the	O
following	O
formulas	O
:	O
CxCxAxCxGyCyCyGyCyCyGyGyCyCyAxTxCxTx	O
;	O
CxGxCxTxGxAyCyGyAyAyGyTyCyGyAxTxCxTx	O
;	O
GxGxCxCxCyGyGyCyCyCyAyTyAyGyAxAxGxTx	O
;	O
TxTxCxAxGxGyTyCyGyTyAyGyTyTyGxTxGxGx	O
;	O
TxTxCxAxGyGyTyCyGyTyAyGyTyTyGxTxGxGx	O
.	O

X	O
is	O
bond	O
between	O
thiophosphate	O
nucleoside	O
.	O

The	O
antisense	O
oligonucleotide	O
of	O
the	O
invention	O
is	O
used	O
for	O
preparing	O
gene	O
therapeutic	O
drug	O
for	O
curing	O
disease	O
caused	O
by	O
POKEMON	B
high	O
expression	O
.	O

Instant	O
type	O
gel	O
preparation	O
for	O
eye	O
and	O
method	O
of	O
producing	O
the	O
same	O
The	O
invention	O
relates	O
to	O
an	O
in	O
-	O
situ	O
forming	O
eye	O
gel	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
in	O
-	O
situ	O
forming	O
eye	O
gel	O
preparation	O
can	O
be	O
prepared	O
by	O
mixing	O
a	O
Gelrite	O
Gellan	O
gum	O
as	O
a	O
matrix	O
base	O
.	O

Sustained	O
-	O
release	O
injection	O
containing	O
kanamycin	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
released	O
injection	O
comprising	O
kanamycin	O
,	O
which	O
comprises	O
a	O
slow	O
-	O
released	O
microsphere	O
and	O
a	O
dissolvent	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
comprises	O
a	O
slow	O
-	O
release	O
adjuvant	O
and	O
the	O
aminoglycoside	O
antibiotic	O
;	O
the	O
dissolvent	O
is	O
the	O
special	O
dissolvent	O
which	O
comprises	O
a	O
suspending	O
agent	O
such	O
as	O
sodium	O
carboxymethylcellulose	O
,	O
etc	O
.	O
,	O
and	O
the	O
viscosity	O
of	O
which	O
is	O
100cp-3000cp	O
(	O
at	O
20	O
DEG	O
C-30	O
DEC	O
C	O
)	O
;	O
the	O
slow	O
-	O
release	O
adjuvant	O
can	O
be	O
selected	O
from	O
EVAc	O
,	O
polifeprosan	O
,	O
PLA	O
,	O
PLGA	O
,	O
sebacic	O
acid	O
copolymer	O
,	O
albumen	O
glue	O
and	O
gelatin	O
,	O
etc	O
.	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
also	O
can	O
be	O
made	O
into	O
a	O
slow	O
-	O
released	O
implant	O
and	O
an	O
ointment	O
.	O

The	O
slow	O
-	O
released	O
implant	O
and	O
the	O
slow	O
-	O
released	O
injection	O
can	O
be	O
partially	O
placed	O
or	O
injected	O
in	O
a	O
bacterial	O
focus	O
to	O
release	O
locally	O
and	O
slowly	O
for	O
more	O
than	O
5	O
-	O
30	O
days	O
,	O
thereby	O
obviously	O
reducing	O
the	O
toxicity	O
of	O
the	O
entire	O
body	O
while	O
getting	O
and	O
maintaining	O
a	O
valid	O
medicine	O
density	O
in	O
the	O
local	O
focus	O
effectively	O
.	O

The	O
slow	O
-	O
released	O
injection	O
comprising	O
the	O
kanamycin	O
of	O
the	O
invention	O
has	O
obvious	O
special	O
treatment	O
effect	O
for	O
focus	O
of	O
local	O
infection	O
such	O
as	O
chronic	O
osteomyelitis	O
,	O
severe	O
bedsore	O
,	O
refractory	O
skin	O
ulcer	O
,	O
diabetic	O
foot	O
,	O
osteonecrosis	O
of	O
femoral	O
head	O
and	O
various	O
abscesses	O
,	O
etc	O
.	O
,	O
caused	O
by	O
staphylococcus	O
,	O
streptococcus	O
,	O
peptostreptococcus	O
,	O
propionibacterium	O
acnes	O
,	O
enterobacter	O
,	O
tubercle	O
bacillus	O
,	O
gonococcus	O
and	O
meningococcus	O
,	O
etc	O
.	O

Pabala	O
selenizing	O
VE	O
health	O
products	O
The	O
invention	O
relates	O
to	O
a	O
health	O
care	O
product	O
which	O
is	O
Parbara	O
selenizing	O
VE	O
health	O
care	O
product	O
.	O

The	O
health	O
product	O
is	O
made	O
of	O
raw	O
materials	O
,	O
including	O
90	O
to	O
100	O
parts	O
of	O
balsam	O
pear	O
extract	O
,	O
0.5	O
to	O
1.0	O
part	O
of	O
selenium	O
,	O
0.1	O
to	O
0.5	O
part	O
of	O
Vitamin	O
E	O
and	O
90	O
to	O
110	O
parts	O
of	O
starch	O
.	O

Composing	O
prescription	O
is	O
simple	O
and	O
supplementary	O
trace	O
elements	O
are	O
reasonable	O
.	O

So	O
the	O
Parbara	O
selenizing	O
VE	O
health	O
care	O
product	O
can	O
serve	O
as	O
accessory	O
food	O
for	O
patients	O
with	O
diabetes	O
mellitus	O
.	O

The	O
Parbara	O
selenizing	O
VE	O
health	O
care	O
product	O
has	O
no	O
adverse	O
effect	O
and	O
is	O
suitable	O
for	O
long	O
-	O
term	O
administration	O
.	O

Oleanolic	O
acid	O
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
oleanolic	O
acid	O
orally	O
disintegrating	O
tablets	O
with	O
high	O
dissolution	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
oleanolic	O
acid	O
orally	O
disintegrating	O
tablets	O
are	O
characterized	O
in	O
that	O
oleanolic	O
acid	O
is	O
prepared	O
into	O
solid	O
dispersion	O
via	O
hydrophilic	O
solid	O
dispersion	O
carrier	O
,	O
so	O
as	O
to	O
remarkably	O
improve	O
the	O
dissolution	O
,	O
promote	O
the	O
absorption	O
and	O
remarkably	O
improve	O
the	O
bioavailability	O
of	O
oleanolic	O
acid	O
.	O

The	O
weight	O
ratio	O
of	O
the	O
solid	O
dispersion	O
carrier	O
and	O
oleanolic	O
acid	O
is	O
0.5	O
-	O
5	O
.	O

Then	O
,	O
the	O
solid	O
dispersion	O
is	O
mixed	O
with	O
adjuvants	O
such	O
as	O
bulking	O
agent	O
,	O
corrective	O
and	O
lubricant	O
and	O
made	O
into	O
orally	O
disintegrating	O
tablets	O
by	O
using	O
conventional	O
tablet	O
production	O
equipment	O
via	O
directly	O
tabletting	O
or	O
wet	O
granulating	O
process	O
.	O

The	O
preparation	O
has	O
disintegrating	O
time	O
of	O
5	O
-	O
50s	O
,	O
and	O
dissolution	O
in	O
0.5	O
sodium	O
lauryl	O
sulfate	O
solution	O
in	O
1	O
hour	O
over	O
80	O
%	O
,	O
even	O
over	O
90	O
%	O
.	O

Benzoxazole	O
ketones	O
derivative	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
series	O
of	O
novel	O
compounds	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
particularly	O
to	O
a	O
series	O
of	O
benzoxazolone	O
derivatives	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
solves	O
the	O
problem	O
that	O
the	O
prior	O
benzoxazolone	O
compounds	O
have	O
no	O
4-substituted	O
derivatives	O
and	O
have	O
anti	O
-	O
HBV	O
activity	O
and	O
anti	O
-	O
HIV	O
activity	O
.	O

The	O
general	O
structural	O
formula	O
of	O
the	O
derivatives	O
is	O
shown	O
in	O
the	O
figure	O
,	O
wherein	O
R	O
is	O
C3-C6	O
fatty	O
acid	O
ester	O
group	O
,	O
benzoate	O
group	O
/	O
substituted	O
benzoate	O
group	O
,	O
benzene	O
sulfonate	O
group	O
/	O
substituted	O
benzene	O
sulfonate	O
group	O
,	O
amino	O
acid	O
ester	O
group	O
,	O
or	O
heterocyclic	O
acid	O
ester	O
group	O
/	O
substituted	O
heterocyclic	O
acid	O
ester	O
group	O
.	O

The	O
invention	O
obtains	O
a	O
series	O
of	O
4-substituted	O
benzoxazolone	O
derivatives	O
with	O
proven	O
anti	O
-	O
HBV	O
activity	O
and	O
anti	O
-	O
HIV	O
activity	O
,	O
opens	O
new	O
preparation	O
paths	O
of	O
the	O
above	O
three	O
drugs	O
,	O
and	O
brings	O
new	O
breakthrough	O
in	O
pharmaceutical	O
and	O
pesticide	O
fields	O
.	O

In	O
addition	O
,	O
the	O
synthetic	O
method	O
has	O
the	O
advantages	O
of	O
easy	O
operation	O
,	O
mild	O
reaction	O
conditions	O
,	O
single	O
reaction	O
product	O
,	O
and	O
applicability	O
to	O
large	O
scale	O
production	O
.	O

Chitosan	O
oral	O
scented	O
pieces	O
and	O
preparation	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
chitosan	O
cachou	O
.	O

The	O
chitosan	O
cachou	O
is	O
prepared	O
by	O
chitosan	O
,	O
corn	O
starch	O
,	O
xylitol	O
,	O
maltodextrin	O
,	O
acesulfame	O
potassium	O
,	O
sodium	O
cyclamate	O
,	O
menthol	O
,	O
and	O
magnesium	O
stearate	O
,	O
and	O
the	O
preparation	O
method	O
includes	O
the	O
following	O
steps	O
:	O
embedding	O
processing	O
of	O
essence	O
,	O
mixing	O
,	O
damp	O
mass	O
making	O
,	O
wet	O
granule	O
making	O
,	O
drying	O
,	O
granule	O
finishing	O
,	O
final	O
mixing	O
,	O
sheeting	O
,	O
sterilization	O
,	O
and	O
packaging	O
,	O
thus	O
obtaining	O
the	O
chitosan	O
cachou	O
.	O

Diaminopyrimidines	O
as	O
P2X3	B
and	O
P2X2	B
/	I
3	I
modulators	O
Compounds	O
and	O
methods	O
for	O
treating	O
diseases	O
mediated	O
by	O
a	O
P2X3	B
and/or	O
a	O
P2X2	B
/	I
3	I
receptor	I
antagonist	O
,	O
the	O
compounds	O
being	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
D	O
,	O
X	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
,	O
R<6	O
>	O
,	O
R<7	O
>	O
and	O
R<8	O
>	O
are	O
as	O
defined	O
herein	O
.	O

Uses	O
of	O
rutin	O
and	O
quercetin-7-rhamnose	O
in	O
preparing	O
anti	O
-	O
hepatitis	O
medicament	O
The	O
invention	O
belongs	O
to	O
the	O
medicine	O
technical	O
field	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
rutin	O
and	O
quercetin-7-rhamnose	O
in	O
preparation	O
of	O
anti	O
-	O
hepatitis	O
virus	O
agents	O
.	O

According	O
to	O
the	O
results	O
of	O
experiments	O
of	O
hepatitis	B
B	I
surface	I
antigen	I
(	O
HBsAg	B
)	O
and	O
hepatitis	B
B	I
e	I
antigen	I
(	O
HBeAg	B
)	O
detection	O
reagents	O
,	O
the	O
rutin	O
and	O
the	O
quercetin-7-rhamnose	O
can	O
suppress	O
HBsAg	B
and	O
HBeAg	B
obviously	O
and	O
can	O
prevent	O
and	O
cure	O
hepatitis	O
B	O
virus	O
.	O

Therefore	O
,	O
the	O
rutin	O
and	O
the	O
quercetin-7-rhamnose	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
hepatitis	O
virus	O
agents	O
or	O
health	O
care	O
products	O
.	O

Flavin	O
adenine	O
dinucleotide	O
disodium	O
salt	O
freeze	O
-	O
dried	O
powder	O
needle	O
preparation	O
and	O
preparation	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
FAD	O
-	O
Na2	O
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
preparation	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
FAD	O
-	O
Na2	O
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
preparation	O
is	O
a	O
drug	O
composition	O
made	O
by	O
mixing	O
FAD	O
-	O
Na2	O
serving	O
as	O
medicinal	O
active	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

The	O
preparation	O
method	O
is	O
as	O
follows	O
:	O
the	O
FAD	O
-	O
Na2	O
is	O
used	O
as	O
raw	O
material	O
and	O
added	O
with	O
certain	O
spices	O
of	O
excipients	O
according	O
to	O
certain	O
proportions	O
;	O
the	O
mixture	O
is	O
prepared	O
and	O
developed	O
by	O
a	O
technical	O
means	O
provided	O
by	O
the	O
invention	O
into	O
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
agent	O
which	O
can	O
be	O
used	O
for	O
subcutaneous	O
injection	O
,	O
intramuscular	O
and	O
intravenous	O
injection	O
and	O
used	O
to	O
cure	O
a	O
variety	O
of	O
diseases	O
caused	O
by	O
lacks	O
of	O
vitamin	O
B2	O
.	O

Detection	O
method	O
of	O
compound	O
preserved	O
snake	O
gall	O
orange	O
peel	O
powder	O
The	O
present	O
invention	O
provides	O
a	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
five	O
drugs	O
of	O
orange	O
peel	O
,	O
earthworm	O
,	O
stiff	O
silkworm	O
,	O
vermilion	O
and	O
amber	O
contained	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
are	O
identified	O
by	O
a	O
microscope	O
;	O
(	O
2	O
)	O
the	O
orange	O
peel	O
contained	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
identified	O
by	O
the	O
thin	O
layer	O
chromatography	O
;	O
(	O
3	O
)	O
the	O
content	O
of	O
hesperidin	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
measured	O
by	O
the	O
high	O
performance	O
liquid	O
chromatography	O
;	O
(	O
4	O
)	O
the	O
content	O
of	O
ethiopsite	O
in	O
the	O
vermilion	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
measured	O
by	O
thiocyanometry	O
.	O

The	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
provided	O
by	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
overcoming	O
a	O
defect	O
of	O
poor	O
specificity	O
existing	O
in	O
the	O
prior	O
chemical	O
identification	O
method	O
and	O
defects	O
of	O
complicated	O
operation	O
and	O
uncontrollable	O
product	O
quality	O
existing	O
in	O
the	O
prior	O
thin	O
layer	O
chromatography	O
,	O
improving	O
the	O
specificity	O
and	O
the	O
quality	O
stability	O
of	O
the	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
and	O
ensuring	O
the	O
safety	O
and	O
effectiveness	O
of	O
medication	O
.	O

Oxazole	O
substituted	O
dihydro	O
pyrazol	O
multi	O
-	O
heterocyclic	O
ring	O
derivates	O
,	O
preparation	O
method	O
and	O
uses	O
thereof	O
The	O
invention	O
discloses	O
an	O
oxazole	O
substituted	O
dihydro	O
-	O
pyrazole	O
miscellaneous	O
polycyclic	O
derivative	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
use	O
of	O
the	O
same	O
.	O

The	O
derivative	O
provided	O
by	O
the	O
invention	O
has	O
a	O
structure	O
as	O
shown	O
in	O
a	O
chemical	O
formula	O
D	O
and	O
is	O
prepared	O
through	O
the	O
following	O
method	O
that	O
:	O
substituted	O
isoquinoline	O
propiophenone	O
is	O
used	O
for	O
leading	O
,	O
expanded	O
and	O
converted	O
into	O
substituted	O
isoquinoline	O
alpha	O
and	O
beta	O
unsaturated	O
ketone	O
;	O
ring	O
closure	O
is	O
carried	O
out	O
to	O
form	O
5-substituted	O
isoquinoline	O
substituted	O
dihydro	O
-	O
pyrazole	O
ketone	O
;	O
by	O
inducing	O
an	O
oxime	O
structure	O
unit	O
and	O
adopting	O
a	O
microwave	O
auxiliary	O
synthesis	O
method	O
,	O
a	O
series	O
of	O
3-methyl	O
oxazole-5-isoquinoline	O
substituted	O
hydrogen	O
pyrazole	O
miscellaneous	O
polycyclic	O
compounds	O
is	O
designed	O
and	O
synthesized	O
.	O

Structure	O
modification	O
is	O
carried	O
out	O
according	O
to	O
the	O
principle	O
of	O
medicinal	O
chemistry	O
,	O
so	O
as	O
to	O
design	O
and	O
synthesize	O
a	O
high	O
-	O
activity	O
compound	O
with	O
the	O
effects	O
of	O
resisting	O
tumor	O
and	O
sterilizing	O
.	O

Novel	O
cephalosporin	O
compounds	O
,	O
preparation	O
method	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
use	O
The	O
invention	O
provides	O
a	O
novel	O
cephalosporin	O
compound	O
which	O
introduces	O
thioureido	O
onto	O
position	O
7	O
of	O
cephem	O
,	O
nontoxic	O
salt	O
of	O
the	O
cephalosporin	O
compound	O
acceptable	O
on	O
pharmacy	O
,	O
physiological	O
hydrolyzable	O
ester	O
of	O
the	O
cephalosporin	O
compound	O
,	O
acid	O
amide	O
of	O
the	O
cephalosporin	O
compound	O
,	O
hydrate	O
of	O
the	O
cephalosporin	O
compound	O
,	O
solvate	O
of	O
the	O
cephalosporin	O
compound	O
or	O
an	O
isomer	O
of	O
the	O
cephalosporin	O
compound	O
,	O
a	O
method	O
for	O
preparing	O
the	O
cephalosporin	O
compound	O
,	O
a	O
drug	O
composition	O
containing	O
the	O
cephalosporin	O
compound	O
and	O
an	O
application	O
of	O
the	O
cephalosporin	O
compound	O
.	O

Rice	O
fermented	O
with	O
red	O
yeast	O
extract	O
,	O
preparation	O
method	O
and	O
quality	O
detection	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
red	O
yeast	O
rice	O
extract	O
and	O
a	O
preparation	O
method	O
and	O
a	O
quality	O
test	O
method	O
thereof	O
.	O

The	O
main	O
active	O
ingredient	O
of	O
the	O
extract	O
is	O
lovastatin	O
,	O
the	O
content	O
of	O
which	O
is	O
more	O
than	O
3	O
percent	O
.	O

The	O
extract	O
is	O
prepared	O
by	O
subjecting	O
a	O
medical	O
material	O
of	O
red	O
yeast	O
rice	O
to	O
extraction	O
with	O
an	O
organic	O
solvent	O
,	O
water	O
decoction	O
after	O
the	O
volatilization	O
of	O
the	O
solvent	O
,	O
precipitation	O
collection	O
by	O
siphonage	O
and	O
configuration	O
,	O
mixing	O
with	O
excipients	O
and	O
drying	O
.	O

The	O
preparation	O
method	O
improves	O
the	O
content	O
of	O
lovastatin	O
.	O

The	O
invention	O
also	O
provides	O
a	O
quality	O
control	O
method	O
for	O
identifying	O
the	O
ingredients	O
and	O
measuring	O
content	O
.	O

Medicament	O
for	O
treating	O
protrusion	O
of	O
lumber	O
intervertebral	O
disc	O
The	O
invention	O
relates	O
to	O
a	O
medicine	O
for	O
treating	O
prolapse	O
of	O
lumbar	O
intervertebral	O
disc	O
.	O

The	O
preparation	O
method	O
for	O
the	O
medicine	O
comprises	O
the	O
following	O
steps	O
that	O
:	O
medicines	O
such	O
as	O
phrymaceae	O
,	O
buck	O
grass	O
,	O
slenderstyle	O
acanthopanax	O
barks	O
,	O
cortex	O
lycii	O
radicis	O
,	O
dittany	O
,	O
heracleum	O
hemsleyanum	O
,	O
common	O
monkshood	O
mother	O
root	O
,	O
kusnezoff	O
monkshood	O
,	O
safflower	O
,	O
Chinese	O
ephedra	O
,	O
dried	O
ginger	O
,	O
pollen	O
,	O
artemisia	O
leaves	O
,	O
cassia	O
barks	O
and	O
so	O
on	O
are	O
mixed	O
and	O
ground	O
into	O
powder	O
,	O
and	O
then	O
packaged	O
into	O
a	O
medicine	O
bag	O
.	O

When	O
the	O
medicine	O
is	O
used	O
,	O
the	O
medicine	O
bag	O
is	O
immersed	O
into	O
water	O
solution	O
of	O
hot	O
peppers	O
and	O
vinegar	O
,	O
placed	O
on	O
a	O
suffered	O
lumbar	O
part	O
of	O
a	O
patient	O
and	O
heated	O
,	O
and	O
then	O
absorbed	O
through	O
hot	O
application	O
.	O

The	O
medicine	O
can	O
disperse	O
stagnancy	O
and	O
dredge	O
channels	O
,	O
relieve	O
rigidity	O
of	O
muscles	O
and	O
promote	O
blood	O
circulation	O
,	O
reduce	O
swelling	O
and	O
alleviate	O
pain	O
,	O
and	O
stimulate	O
circulation	O
to	O
end	O
stasis	O
,	O
can	O
adjust	O
the	O
water	O
filling	O
level	O
of	O
nucleus	O
pulposus	O
and	O
make	O
the	O
protruded	O
nucleus	O
pulposus	O
retracted	O
,	O
eliminate	O
irritation	O
symptoms	O
of	O
edema	O
,	O
and	O
repair	O
damaged	O
anulus	O
fibrosus	O
,	O
is	O
quick	O
to	O
take	O
effect	O
,	O
has	O
no	O
side	O
effect	O
,	O
and	O
can	O
not	O
cause	O
recrudescence	O
after	O
cure	O
.	O

Preparation	O
of	O
docetaxel	O
long	O
-	O
circulating	O
liposome	O
and	O
freeze	O
-	O
dried	O
powder	O
injection	O
thereof	O
The	O
invention	O
discloses	O
a	O
preparation	O
technique	O
of	O
non	O
-	O
pegylation	O
docetaxel	O
long	O
-	O
circulating	O
liposome	O
which	O
meets	O
clinical	O
and	O
large	O
-	O
scale	O
production	O
requirements	O
and	O
a	O
freeze	O
-	O
dried	O
powder	O
-	O
injection	O
;	O
the	O
liposome	O
consists	O
of	O
docetaxel	O
,	O
neutral	O
phospholipid	O
,	O
charged	O
phospholipid	O
,	O
cholesterin	O
,	O
antioxidant	O
,	O
excipient	O
,	O
buffering	O
agent	O
and	O
water	O
for	O
injection	O
;	O
the	O
preparation	O
technique	O
includes	O
the	O
following	O
steps	O
:	O
preparing	O
multivesicular	O
liposome	O
,	O
homogenizing	O
the	O
liposome	O
,	O
fixing	O
volume	O
,	O
sterilizing	O
,	O
split	O
charging	O
,	O
freeze	O
drying	O
,	O
etc	O
.	O

The	O
liposome	O
increases	O
the	O
solubility	O
of	O
drugs	O
,	O
overcomes	O
poor	O
stability	O
of	O
docetaxel	O
injection	O
and	O
toxicity	O
caused	O
by	O
complex	O
solvent	O
and	O
prolongs	O
the	O
in	O
vivo	O
circulating	O
time	O
of	O
drugs	O
;	O
compared	O
with	O
pegylation	O
long	O
-	O
circulating	O
liposome	O
,	O
the	O
toxicity	O
is	O
decreased	O
and	O
the	O
inhibiting	O
effect	O
on	O
tumor	O
cells	O
is	O
strengthened	O
.	O

Medicine	O
composition	O
for	O
injecting	O
triamcinolone	O
acetonide	O
palmitate	O
lipid	O
microsphere	O
and	O
preparation	O
method	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
the	O
medical	O
technical	O
field	O
,	O
in	O
particular	O
to	O
a	O
lipid	O
microsphere	O
injection	O
medical	O
combination	O
containing	O
triamcinolone	O
palmitate	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

'	O
Yizhi	O
'	O
capsule	O
for	O
enhancing	O
willpower	O
The	O
invention	O
relates	O
to	O
a	O
nootropic	O
capsule	O
used	O
for	O
strengthening	O
willpower	O
.	O

The	O
invention	O
is	O
characterized	O
in	O
that	O
the	O
nootropic	O
capsule	O
has	O
a	O
composing	O
prescription	O
which	O
comprises	O
gen	O
-	O
seng	O
,	O
glossy	O
ganoderma	O
,	O
milkwort	O
root	O
,	O
spine	O
date	O
seed	O
,	O
root	O
poria	O
,	O
grassleaf	O
sweetflag	O
rhizome	O
,	O
silktree	O
albizia	O
bark	O
,	O
the	O
tuber	O
of	O
multiflower	O
knot	O
weed	O
,	O
longan	O
aril	O
,	O
seabuckthorn	O
fruit	O
,	O
ginkgo	O
biloba	O
extract	O
,	O
wheat	O
-	O
germ	O
oil	O
,	O
pollen	O
,	O
tortoise	O
carapace	O
and	O
plastron	O
,	O
cape	O
jasmine	O
fruit	O
,	O
liquorice	O
,	O
royal	O
jelly	O
dry	O
-	O
freezing	O
powder	O
,	O
etc	O
.	O

The	O
extract	O
can	O
be	O
made	O
by	O
the	O
preparation	O
and	O
the	O
extract	O
is	O
mixed	O
with	O
the	O
powdery	O
raw	O
materials	O
and	O
the	O
nootropic	O
capsule	O
can	O
be	O
obtained	O
after	O
the	O
processes	O
of	O
drying	O
,	O
sterilizing	O
and	O
encapsulating	O
the	O
extract	O
in	O
a	O
capsule	O
.	O

Rosuvastatin	O
azelnidipine	O
composition	O
A	O
pharmaceutical	O
composition	O
is	O
an	O
organic	O
salt	O
formed	O
by	O
an	O
organic	O
acid	O
rosuvastatin	O
and	O
an	O
organic	O
base	O
azelnidipine	O
with	O
a	O
molar	O
ratio	O
of	O
1:1	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
made	O
into	O
any	O
dosage	O
forms	O
together	O
with	O
a	O
pharmaceutically	O
-	O
acceptable	O
carrier	O
for	O
reducing	O
blood	O
pressure	O
and	O
blood	O
lipid	O
,	O
reducing	O
myocardial	O
infarction	O
and	O
treating	O
cerebral	O
apoplexy	O
.	O

The	O
inventive	O
pharmaceutical	O
composition	O
has	O
the	O
advantages	O
of	O
stable	O
physiochemical	O
indexes	O
,	O
controllable	O
product	O
quality	O
,	O
and	O
convenient	O
administration	O
.	O

Eye	O
in	O
-	O
situ	O
gel	O
of	O
pirenoxine	O
sodium	O
The	O
invention	O
discloses	O
a	O
pirenoxine	O
sodium	O
eye	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pirenoxine	O
sodium	O
eye	O
gel	O
contains	O
(	O
per	O
1,000	O
mL	O
)	O
pirenoxine	O
sodium	O
20	O
-	O
50	O
mg	O
,	O
antiseptic	O
0.05	O
-	O
1	O
g	O
,	O
osmotic	O
pressure	O
regulator	O
1.0	O
-	O
7.5	O
g	O
,	O
gel	O
matrix	O
30	O
-	O
150	O
g	O
,	O
and	O
acid	O
/	O
base	O
buffer	O
and	O
water	O
for	O
injection	O
in	O
balancing	O
amount	O
.	O

The	O
inventive	O
pirenoxine	O
sodium	O
eye	O
gel	O
optimizes	O
adjuvants	O
and	O
improves	O
production	O
process	O
,	O
so	O
as	O
to	O
enrich	O
the	O
compound	O
taurine	O
dosage	O
forms	O
,	O
remarkably	O
prolong	O
the	O
retention	O
time	O
of	O
the	O
compound	O
taurine	O
in	O
eyes	O
,	O
and	O
improve	O
the	O
therapeutic	O
effect	O
;	O
and	O
has	O
no	O
adverse	O
irritant	O
reactions	O
.	O

Six	O
-	O
membered	O
heterocycles	O
useful	O
as	O
serine	B
protease	I
inhibitors	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
stereoisomer	O
,	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
form	O
thereof	O
,	O
wherein	O
the	O
variables	O
A	O
,	O
B	O
,	O
R<3	O
>	O
and	O
R<11	O
>	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
selective	O
inhibitors	O
of	O
serine	B
protease	I
enzymes	O
of	O
the	O
coagulation	O
cascade	O
and/or	O
contact	O
activation	O
system	O
;	O
for	O
example	O
thrombin	B
,	O
factor	B
Xa	I
,	O
factor	B
XIa	I
,	O
factor	B
IXa	I
,	O
factor	B
VIIa	I
and/or	O
plasma	B
kallikrein	I
.	O

In	O
particular	O
,	O
it	O
relates	O
to	O
compounds	O
that	O
are	O
selective	O
factor	B
XIa	I
inhibitors	O
or	O
dual	O
inhibitors	O
of	O
fXIa	B
and	O
plasma	B
kallikrein	I
.	O

This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
treating	O
thromboembolic	O
and/or	O
inflammatory	O
disorders	O
using	O
the	O
same	O
.	O

Lxeris	O
sonchifolia	O
(	O
bunge	O
)	O
hance	O
flavone	O
extract	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
Disclosed	O
is	O
an	O
extract	O
of	O
flavonoid	O
of	O
ixeris	O
sonchifolia	O
hance	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
invention	O
discloses	O
a	O
novel	O
preparation	O
method	O
of	O
an	O
extract	O
of	O
flavonoid	O
of	O
ixeris	O
sonchifolia	O
hance	O
whose	O
content	O
of	O
luteolin-7-O	O
-	O
Beta	O
-	O
D	O
glucopyranose	O
aldehyde	O
acid	O
glycoside	O
is	O
25	O
percent	O
to	O
99.5	O
percent	O
,	O
discloses	O
a	O
novel	O
preparation	O
method	O
of	O
a	O
reference	O
substance	O
of	O
luteolin-7-O	O
-	O
Beta	O
-	O
D	O
glucopyranose	O
aldehyde	O
acid	O
glycoside	O
and	O
an	O
application	O
thereof	O
in	O
controlling	O
the	O
quality	O
of	O
the	O
ixeris	O
sonchifolia	O
hance	O
and	O
pharmaceutical	O
preparations	O
containing	O
the	O
extract	O
of	O
the	O
ixeris	O
sonchifolia	O
hance	O
,	O
and	O
also	O
discloses	O
an	O
application	O
of	O
the	O
extract	O
in	O
preparing	O
drugs	O
for	O
treating	O
the	O
coronary	O
heart	O
disease	O
,	O
the	O
cerebral	O
infarction	O
and	O
the	O
fracture	O
.	O

Ambroxol	O
hydrochloride	O
oral	O
solution	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
ambroxol	O
hydrochloride	O
oral	O
solution	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
western	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
medical	O
production	O
formula	O
used	O
for	O
curing	O
bronchitis	O
and	O
a	O
preparation	O
method	O
thereof	O
;	O
the	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
sucrose	O
,	O
preservatives	O
and	O
purified	O
water	O
are	O
dissolved	O
in	O
a	O
mixing	O
mode	O
so	O
as	O
to	O
prepare	O
simple	O
syrup	O
;	O
the	O
ambroxol	O
hydrochloride	O
,	O
corrigents	O
and	O
preservatives	O
are	O
dissolved	O
by	O
the	O
purified	O
water	O
so	O
as	O
to	O
prepare	O
ambroxol	O
hydrochloride	O
solution	O
;	O
the	O
ambroxol	O
hydrochloride	O
solution	O
and	O
the	O
simple	O
syrup	O
are	O
stirred	O
and	O
mixed	O
evenly	O
,	O
the	O
corrigents	O
and	O
the	O
preservatives	O
are	O
added	O
successively	O
and	O
discontinuously	O
and	O
then	O
the	O
purified	O
water	O
is	O
added	O
to	O
adjust	O
the	O
concentration	O
.	O

The	O
invention	O
has	O
simple	O
and	O
reasonable	O
process	O
,	O
and	O
is	O
easy	O
to	O
operate	O
practically	O
and	O
the	O
produced	O
products	O
have	O
good	O
stability	O
;	O
the	O
products	O
can	O
used	O
as	O
common	O
phlegm	O
-	O
eliminating	O
drugs	O
,	O
has	O
functions	O
of	O
increasing	O
the	O
liquid	O
level	O
of	O
the	O
respiratory	O
tract	O
,	O
reducing	O
mucus	O
secretion	O
,	O
enhancing	O
the	O
secretion	O
of	O
pulmonary	O
surfactant	O
and	O
the	O
movement	O
of	O
cilium	O
and	O
preventing	O
cough	O
to	O
a	O
certain	O
extent	O
,	O
and	O
is	O
applicable	O
to	O
acute	O
respiratory	O
disease	O
and	O
chronic	O
respiratory	O
disease	O
,	O
such	O
as	O
ropy	O
sputum	O
and	O
difficult	O
cough	O
caused	O
by	O
acute	O
bronchitis	O
and	O
chronic	O
bronchitis	O
,	O
bronchial	O
asthma	O
and	O
pulmonary	O
tuberculosis	O
,	O
etc	O
.	O

Composition	O
injection	O
containing	O
tetrandrine	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composite	O
containing	O
tetrandrine	O
,	O
and	O
discloses	O
a	O
composite	O
injection	O
containing	O
the	O
tetrandrine	O
and	O
a	O
preparation	O
method	O
thereof	O
;	O
the	O
composite	O
injection	O
consists	O
of	O
the	O
tetrandrine	O
,	O
latent	O
solvent	O
,	O
stabilizing	O
agent	O
and	O
sodium	O
chloride	O
;	O
wherein	O
,	O
the	O
content	O
of	O
the	O
tetrandrine	O
is	O
2	O
-	O
60	O
%	O
,	O
the	O
content	O
of	O
the	O
latent	O
solvent	O
is	O
2	O
-	O
40	O
%	O
,	O
the	O
content	O
of	O
the	O
stabilizing	O
agent	O
is	O
1	O
-	O
8	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
sodium	O
chloride	O
is	O
9	O
-	O
90	O
%	O
;	O
the	O
proportion	O
among	O
the	O
tetrandrine	O
,	O
the	O
latent	O
solvent	O
and	O
the	O
stabilizing	O
agent	O
is	O
1:0.5:0.01	O
-	O
1:1:1	O
.	O

The	O
method	O
is	O
that	O
:	O
right	O
amount	O
of	O
water	O
used	O
for	O
injecting	O
is	O
added	O
with	O
2	O
-	O
60	O
%	O
of	O
latent	O
solvent	O
,	O
1	O
-	O
8	O
%	O
of	O
stabilizing	O
agent	O
and	O
9	O
-	O
90	O
%	O
of	O
sodium	O
chloride	O
for	O
dissolving	O
;	O
the	O
2	O
-	O
60	O
%	O
of	O
tetrandrine	O
is	O
added	O
to	O
be	O
stirred	O
and	O
dissolved	O
,	O
and	O
then	O
added	O
with	O
water	O
to	O
full	O
dose	O
;	O
after	O
being	O
mixed	O
,	O
the	O
content	O
and	O
pH	O
value	O
of	O
the	O
tetrandrine	O
is	O
measured	O
,	O
and	O
then	O
poured	O
into	O
a	O
bottle	O
after	O
being	O
filtered	O
;	O
after	O
sterilization	O
,	O
lamp	O
check	O
and	O
quality	O
control	O
are	O
carried	O
out	O
,	O
the	O
injection	O
is	O
prepared	O
.	O

The	O
composite	O
injection	O
is	O
easy	O
to	O
store	O
,	O
has	O
little	O
irritation	O
and	O
good	O
stability	O
,	O
can	O
overcome	O
the	O
problems	O
of	O
easy	O
precipitation	O
of	O
the	O
tetrandrine	O
and	O
clinical	O
pain	O
.	O

Benzenesulfonamides	O
Ca-4	O
analogue	O
,	O
synthesis	O
method	O
and	O
application	O
The	O
invention	O
relates	O
to	O
benzo	O
sulfonamide	O
CA-4	O
analogues	O
,	O
a	O
synthetic	O
method	O
and	O
an	O
application	O
thereof	O
,	O
pertaining	O
to	O
the	O
field	O
of	O
chemical	O
drugs	O
.	O

The	O
compound	O
has	O
the	O
structure	O
shown	O
as	O
the	O
general	O
formula	O
(	O
IV	O
)	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
an	O
N	O
-	O
tert	O
butyl	O
-	O
benzene	O
sulfonamide	O
-	O
derivative	O
is	O
taken	O
as	O
raw	O
material	O
to	O
generate	O
corresponding	O
carbanion	O
under	O
the	O
function	O
of	O
a	O
metal	O
reagent	O
,	O
and	O
then	O
respectively	O
reacts	O
with	O
benzaldehydes	O
containing	O
methoxy	O
and	O
other	O
substituted	O
functional	O
groups	O
to	O
generate	O
secondary	O
alcohol	O
;	O
the	O
secondary	O
alcohol	O
is	O
oxidized	O
by	O
an	O
oxidant	O
;	O
a	O
series	O
of	O
conformational	O
restriction	O
CA-4	O
analogues	O
are	O
synthesized	O
by	O
making	O
use	O
of	O
a	O
novel	O
cyclization	O
reaction	O
induced	O
by	O
trimethylsilyl	O
chlorine	O
/	O
NaI	O
/	O
acetonitrile	O
reagent	O
.	O

The	O
result	O
of	O
a	O
vitro	O
cell	O
growth	O
inhibition	O
activity	O
test	O
of	O
the	O
target	O
compound	O
shows	O
that	O
the	O
CA-4	O
analogues	O
can	O
be	O
applied	O
as	O
anti	O
-	O
tumor	O
drugs	O
.	O

2-	O
(	O
4-substituted	O
phenyl-1,2,3-thiadiazole-5sulfhydryl	O
)	O
-N	O
-	O
substituted	O
phenyl	O
acetamides	O
derivates	O
,	O
preparation	O
thereof	O
and	O
application	O
The	O
invention	O
provides	O
a	O
2-	O
(	O
4-substituted	O
phenyl-1	O
,	O
2	O
,	O
3-	O
thiadiazole-5-	O
mercapto	O
)	O
-N	O
-	O
substituted	O
phenyl	O
acetamide	O
derivative	O
with	O
the	O
structure	O
general	O
formula	O
shown	O
as	O
the	O
right	O
formula	O
,	O
wherein	O
,	O
R<1	O
>	O
is	O
H	O
,	O
F	O
or	O
Cl	O
;	O
R<2	O
>	O
is	O
H	O
,	O
F	O
,	O
Cl	O
or	O
OCH3	O
;	O
X	O
is	O
F	O
,	O
Cl	O
,	O
Br	O
or	O
NO2	O
;	O
and	O
Y	O
is	O
H	O
,	O
CH3	O
,	O
COOCH3	O
or	O
COOC2H5	O
.	O

The	O
derivative	O
is	O
a	O
novel	O
structure	O
framework	O
,	O
has	O
relatively	O
high	O
inhibition	O
activity	O
on	O
HIV	O
and	O
can	O
be	O
taken	O
as	O
a	O
lead	O
compound	O
to	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
anti	O
-	O
HIV	O
agents	O
.	O

Penem	O
compound	O
containing	O
sulfhydryl	O
piperidine	O
The	O
invention	O
pertains	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
particularly	O
relates	O
to	O
a	O
penem	O
compound	O
which	O
contains	O
sulfhydryl	O
piperidine	O
and	O
is	O
shown	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
easily	O
hydrolysable	O
ester	O
and	O
isomers	O
of	O
the	O
compound	O
;	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
and	O
R<6	O
>	O
are	O
defined	O
as	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
medicine	O
composition	O
containing	O
the	O
compounds	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
to	O
the	O
preparation	O
of	O
medicines	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

Carbapenem	O
derivates	O
containing	O
sulfhydryl	O
pyrrolidine	O
The	O
invention	O
pertains	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
particularly	O
relates	O
to	O
a	O
carbon	O
penem	O
derivative	O
which	O
contains	O
sulfhydryl	O
pyrrolidine	O
and	O
is	O
shown	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
easily	O
hydrolysable	O
ester	O
and	O
isomers	O
of	O
the	O
derivative	O
;	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
and	O
R<5	O
>	O
are	O
defined	O
as	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
medicine	O
composition	O
containing	O
the	O
compounds	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
to	O
the	O
preparation	O
of	O
medicines	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

Penem	O
derivative	O
The	O
invention	O
belongs	O
to	O
the	O
pharmaceutical	O
technical	O
field	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
penem	O
derivative	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
easily	O
-	O
hydrolyzed	O
esters	O
thereof	O
,	O
isomers	O
thereof	O
,	O
hydrate	O
thereof	O
and	O
hydrates	O
of	O
esters	O
or	O
salts	O
thereof	O
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
defined	O
as	O
in	O
the	O
description	O
,	O
and	O
can	O
be	O
further	O
substituted	O
on	O
a	O
benzene	O
ring	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
the	O
pharmaceutical	O
compound	O
containing	O
the	O
same	O
,	O
and	O
the	O
application	O
thereof	O
on	O
the	O
preparation	O
of	O
pharmaceuticals	O
for	O
treating	O
and/or	O
preventing	O
infection	O
diseases	O
.	O

Pyrrolidone	O
containing	O
hydroxymethyl	O
and	O
carboxyl	O
,	O
preparation	O
method	O
and	O
medicament	O
composition	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
pyrrolidone	O
containing	O
hydroxymethyl	O
and	O
carboxyl	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
,	O
pharmaceutical	O
compositions	O
and	O
applications	O
thereof	O
,	O
in	O
particular	O
to	O
compounds	O
containing	O
sulfonyl	O
pyrrolidone	O
shown	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
,	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
as	O
well	O
as	O
pharmaceutical	O
applications	O
of	O
the	O
compounds	O
.	O

In	O
the	O
general	O
formula	O
,	O
R1	O
is	O
the	O
hydroxymethyl	O
and	O
the	O
carboxyl	O
.	O

Novel	O
nitrogen	O
-	O
containing	O
medicament	O
with	O
anti	O
-	O
inflammatory	O
activity	O
The	O
invention	O
relates	O
to	O
an	O
androstane	O
azotic	O
glucocorticoid	B
receptor	I
stimulant	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
pharmaceutical	O
preparations	O
comprising	O
the	O
compound	O
and	O
the	O
therapeutic	O
use	O
of	O
the	O
compound	O
,	O
in	O
particular	O
to	O
inflammatory	O
disease	O
,	O
allergic	O
disease	O
or	O
anaphylactic	O
disease	O
.	O

Compound	O
alpha	O
-	O
ketoacid	O
chewing	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablet	O
used	O
for	O
curing	O
chronic	O
renal	O
failure	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablet	O
comprises	O
the	O
following	O
components	O
:	O
Alpha	O
-	O
ketophenylalanine	O
calcium	O
,	O
Alpha	O
-	O
hydroxymethionine	O
calcium	O
,	O
Alpha	O
-	O
ketoleucine	O
calcium	O
,	O
Alpha	O
-	O
ketoisoleucine	O
calcium	O
,	O
Alpha	O
-	O
ketovaline	O
calcium	O
,	O
tryptophan	O
,	O
histidine	O
,	O
tyrosine	O
,	O
threonine	O
,	O
lysine	O
,	O
acetate	O
,	O
a	O
filling	O
agent	O
,	O
a	O
bonding	O
agent	O
,	O
a	O
taste	O
-	O
masking	O
agent	O
,	O
a	O
lubricant	O
and	O
a	O
coating	O
agent	O
.	O

The	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablet	O
not	O
only	O
widens	O
the	O
dosage	O
form	O
range	O
of	O
the	O
compound	O
Alpha	O
-	O
ketonic	O
acid	O
chewable	O
tablets	O
,	O
but	O
also	O
has	O
the	O
advantages	O
of	O
having	O
good	O
dispersing	O
state	O
,	O
short	O
disintegration	O
time	O
,	O
fast	O
drug	O
dissolution	O
,	O
rapid	O
absorption	O
,	O
high	O
biological	O
availability	O
and	O
convenient	O
taking	O
,	O
being	O
capable	O
of	O
being	O
swallowed	O
,	O
chewed	O
and	O
sucked	O
and	O
being	O
especially	O
suitable	O
for	O
old	O
people	O
,	O
stroke	O
patients	O
,	O
patients	O
with	O
special	O
diseases	O
and	O
patients	O
having	O
swallowing	O
difficulty	O
.	O

Putrefaction	O
-	O
removing	O
granulation	O
-	O
promoting	O
paste	O
The	O
invention	O
relates	O
to	O
a	O
curing	O
and	O
healing	O
ointment	O
used	O
for	O
curing	O
the	O
damage	O
of	O
big	O
muscle	O
,	O
muscle	O
fracture	O
,	O
pyogenic	O
infection	O
,	O
carbuncle	O
and	O
surgery	O
cut	O
,	O
in	O
particular	O
to	O
a	O
granulation	O
-	O
promoting	O
ointment	O
which	O
can	O
ensures	O
the	O
quick	O
growth	O
of	O
fester	O
soft	O
tissues	O
without	O
leaving	O
remarkable	O
sclerosis	O
and	O
scars	O
.	O

The	O
ointment	O
consists	O
of	O
xanthium	O
worm	O
(	O
1	O
)	O
,	O
rust	O
powder	O
(	O
2	O
)	O
,	O
vermilion	O
(	O
3	O
)	O
,	O
scorpion	O
(	O
4	O
)	O
,	O
calcined	O
alum	O
(	O
5	O
)	O
(	O
dewatered	O
alum	O
)	O
and	O
beeswax	O
(	O
6	O
)	O
.	O

The	O
curing	O
and	O
healing	O
ointment	O
has	O
the	O
main	O
functions	O
of	O
detumescence	O
and	O
toxin	O
drawing	O
-	O
out	O
as	O
well	O
as	O
pus	O
drainage	O
and	O
removal	O
of	O
necrotic	O
tissue	O
.	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
granulation	O
-	O
promoting	O
ointment	O
which	O
consists	O
of	O
20	O
fresh	O
xanthium	O
worms	O
(	O
1	O
)	O
,	O
2.4	O
g	O
of	O
the	O
rust	O
powder	O
(	O
2	O
)	O
,	O
2.4	O
g	O
of	O
the	O
vermilion	O
(	O
3	O
)	O
,	O
3	O
g	O
of	O
the	O
scorpion	O
(	O
4	O
)	O
,	O
6	O
g	O
of	O
the	O
calcined	O
alum	O
(	O
5	O
)	O
(	O
dewatered	O
alum	O
)	O
and	O
20	O
g	O
of	O
the	O
beeswax	O
(	O
6	O
)	O
.	O

In	O
the	O
method	O
,	O
the	O
xanthium	O
worms	O
are	O
dipped	O
in	O
benne	O
oil	O
for	O
7	O
days	O
and	O
the	O
scorpion	O
is	O
fried	O
.	O

The	O
rust	O
powder	O
,	O
the	O
scorpion	O
powder	O
,	O
the	O
calcined	O
alum	O
,	O
the	O
beeswax	O
and	O
the	O
vermilion	O
are	O
heated	O
and	O
mixed	O
uniformly	O
,	O
cooled	O
and	O
then	O
the	O
xanthium	O
worms	O
and	O
proper	O
amount	O
of	O
the	O
benne	O
oil	O
are	O
added	O
and	O
mashed	O
into	O
ointment	O
for	O
standby	O
.	O

The	O
curing	O
and	O
healing	O
ointment	O
has	O
the	O
main	O
functions	O
of	O
detumescence	O
and	O
toxin	O
drawing	O
-	O
out	O
as	O
well	O
as	O
pus	O
drainage	O
and	O
removal	O
of	O
necrotic	O
tissue	O
,	O
and	O
has	O
stronger	O
sterilization	O
and	O
infection	O
-	O
resistance	O
capacities	O
.	O

The	O
invention	O
also	O
has	O
the	O
advantages	O
of	O
easily	O
obtained	O
materials	O
,	O
novel	O
and	O
specific	O
prescription	O
,	O
simple	O
extraction	O
technique	O
and	O
convenient	O
medication	O
.	O

External	O
-	O
use	O
medicament	O
for	O
scald	O
The	O
invention	O
provides	O
an	O
external	O
use	O
scalding	O
drug	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
scalding	O
drug	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
percentage	O
:	O
10	O
to	O
20	O
percent	O
of	O
gypsum	O
,	O
10	O
to	O
20	O
percent	O
of	O
rhubarb	O
,	O
10	O
to	O
20	O
percent	O
of	O
green	O
tea	O
,	O
10	O
to	O
20	O
percent	O
of	O
sesame	O
oil	O
,	O
10	O
to	O
20	O
percent	O
of	O
borneol	O
,	O
10	O
to	O
20	O
percent	O
of	O
soy	O
sauce	O
.	O

The	O
scalding	O
drug	O
has	O
the	O
efficacy	O
of	O
alleviating	O
the	O
pain	O
and	O
cooling	O
the	O
blood	O
,	O
and	O
effectively	O
avoids	O
blistering	O
on	O
the	O
scalded	O
part	O
,	O
thereby	O
preventing	O
the	O
wound	O
infection	O
;	O
moreover	O
,	O
the	O
scalding	O
drug	O
has	O
the	O
advantages	O
of	O
simple	O
and	O
reasonable	O
compatibility	O
of	O
medicaments	O
,	O
quick	O
onset	O
and	O
good	O
effect	O
.	O

Enterobacter	O
cloacae	O
,	O
and	O
use	O
of	O
polysaccharide	O
and	O
polysaccharide	O
thereof	O
The	O
invention	O
discloses	O
Enterobacter	O
cloacae	O
Z0206	O
,	O
which	O
has	O
been	O
preserved	O
in	O
China	O
General	O
Microbiological	O
Culture	O
Collection	O
Center	O
on	O
December	O
3	O
,	O
2007	O
,	O
wherein	O
the	O
preserving	O
number	O
is	O
CGMCC	O
NO	O
:	O
2279	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
and	O
application	O
thereof	O
.	O

The	O
method	O
has	O
the	O
advantages	O
that	O
the	O
production	O
process	O
of	O
extracting	O
the	O
polysaccharide	O
is	O
simple	O
,	O
and	O
the	O
yield	O
and	O
the	O
purity	O
of	O
products	O
are	O
higher	O
;	O
the	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
can	O
remarkably	O
improve	O
the	O
proliferation	O
capacity	O
of	O
lymph	O
cells	O
and	O
the	O
cytokine	O
level	O
of	O
a	O
small	O
mouse	O
with	O
low	O
immunity	O
and	O
has	O
remarkable	O
adjustment	O
effect	O
on	O
the	O
immunologic	O
function	O
of	O
the	O
small	O
mouse	O
with	O
low	O
immunity	O
;	O
and	O
the	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
has	O
apparent	O
antagonism	O
on	O
the	O
oxidative	O
damage	O
caused	O
by	O
cyclophosphamide	O
,	O
can	O
remarkably	O
improve	O
the	O
antioxidase	O
activity	O
of	O
an	O
organism	O
,	O
strengthen	O
the	O
function	O
of	O
an	O
antioxidant	O
defense	O
system	O
of	O
the	O
organism	O
,	O
and	O
prevent	O
harmful	O
free	O
radicals	O
from	O
damaging	O
biological	O
macromolecules	O
in	O
cells	O
.	O

Novel	O
compound	O
separated	O
from	O
immature	O
exocarp	O
of	O
Juglans	O
mandshurica	O
Maxim	O
,	O
and	O
preparation	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
separated	O
form	O
north	O
Juglans	O
regia	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
preparation	O
method	O
adopts	O
a	O
method	O
for	O
combining	O
alcohol	O
extraction	O
,	O
chromatographic	O
separation	O
and	O
purification	O
and	O
cytoactive	O
assay	O
to	O
separate	O
the	O
novel	O
compound	O
,	O
which	O
is	O
not	O
reported	O
before	O
and	O
has	O
anti	O
-	O
tumor	O
function	O
,	O
from	O
the	O
north	O
Juglans	O
regia	O
,	O
and	O
adopts	O
mass	O
spectrum	O
and	O
high	O
-	O
resolution	O
nuclear	O
magnetic	O
resonance	O
technique	O
to	O
determine	O
the	O
structure	O
of	O
the	O
compound	O
.	O

The	O
structural	O
formula	O
of	O
the	O
novel	O
compound	O
is	O
the	O
right	O
formula	O
(	O
I	O
)	O
.	O

The	O
novel	O
compound	O
is	O
applied	O
in	O
the	O
field	O
of	O
medicine	O
.	O

Cefixime	O
sustained	O
-	O
release	O
tablets	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
tablet	O
prepared	O
from	O
cefixime	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
characterized	O
in	O
that	O
:	O
the	O
slow	O
-	O
release	O
tablet	O
consists	O
of	O
the	O
following	O
raw	O
materials	O
and	O
auxiliary	O
materials	O
in	O
portion	O
by	O
weight	O
:	O
200	O
portions	O
of	O
cefixime	O
(	O
counted	O
as	O
an	O
anhydride	O
)	O
,	O
20	O
to	O
200	O
portions	O
of	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
slow	O
-	O
release	O
material	O
which	O
can	O
control	O
the	O
drug	O
to	O
continuously	O
and	O
completely	O
release	O
,	O
20	O
and	O
400	O
portions	O
of	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
and	O
5	O
to	O
100	O
portions	O
of	O
at	O
least	O
one	O
solubilizer	O
which	O
can	O
effectively	O
improve	O
the	O
release	O
rate	O
of	O
the	O
drug	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
easy	O
to	O
prepare	O
and	O
facilitates	O
the	O
industrialized	O
production	O
.	O

Phenyl	O
substituted	O
heteroaryl	O
-	O
derivatives	O
and	O
use	O
thereof	O
as	O
anti	O
-	O
tumor	O
agents	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
radicals	O
Rto	O
R	O
,	O
L	O
,	O
Q	O
and	O
n	O
are	O
defined	O
as	O
indicated	O
in	O
claim	O
1	O
.	O

Said	O
compounds	O
are	O
suitable	O
for	O
treating	O
diseases	O
that	O
are	O
characterised	O
by	O
excessive	O
or	O
anomal	O
cell	O
proliferation	O
.	O

The	O
invention	O
also	O
relates	O
to	O
their	O
use	O
for	O
producing	O
a	O
medicament	O
having	O
the	O
above	O
-	O
mentioned	O
properties	O
.	O

Anti	O
-	O
infective	O
medicament	O
composition	O
and	O
application	O
The	O
invention	O
discloses	O
an	O
anti	O
-	O
infective	O
drug	O
combination	O
and	O
an	O
application	O
thereof	O
.	O

The	O
anti	O
-	O
infective	O
drug	O
combination	O
comprises	O
a	O
dryopteris	O
fragrans	O
extract	O
with	O
the	O
weight	O
percentage	O
being	O
1	O
%	O
to	O
99	O
%	O
of	O
the	O
drug	O
combination	O
,	O
and	O
pharmaceutically	O
conventional	O
auxiliary	O
materials	O
.	O

The	O
dryopteris	O
fragrans	O
extract	O
comprises	O
the	O
following	O
components	O
:	O
dryopteris	O
fragrans	O
essence	O
,	O
aspidin	O
AB	O
,	O
aspidin	O
PB	O
,	O
aspidin	O
BB	O
,	O
aspidinol	O
and	O
albicanol	O
.	O

The	O
anti	O
-	O
infective	O
drug	O
combination	O
is	O
applicable	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
curing	O
bacterial	O
,	O
fungal	O
or	O
viral	O
infection	O
diseases	O
;	O
and	O
the	O
anti	O
-	O
infective	O
drug	O
combination	O
has	O
the	O
advantages	O
that	O
the	O
anti	O
-	O
bacterial	O
spectrum	O
is	O
wide	O
,	O
the	O
anti	O
-	O
multidrug	O
resistance	O
is	O
good	O
and	O
the	O
safety	O
is	O
high	O
because	O
the	O
anti	O
-	O
infective	O
drug	O
combination	O
is	O
derived	O
from	O
the	O
natural	O
plant	O
resources	O
.	O

Polyhydroxyalkanoate	O
(	O
PHA	O
)	O
targeted	O
carrier	O
,	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
and	O
preparation	O
methods	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
polyhydroxyalkanoate	O
(	O
PHA	O
)	O
targeted	O
carrier	O
with	O
the	O
general	O
formula	O
being	O
FA	O
-	O
PEG	O
-	O
P	O
(	O
HBHO	O
)	O
and	O
a	O
targeted	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
prepared	O
by	O
encapsulating	O
anti	O
-	O
tumor	O
drugs	O
on	O
the	O
basis	O
of	O
ultrasonic	O
emulsification	O
method	O
with	O
the	O
carrier	O
being	O
FA	O
-	O
PEG	O
-	O
P	O
(	O
HBHO	O
)	O
.	O

The	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
is	O
characterized	O
in	O
that	O
the	O
particle	O
size	O
thereof	O
is	O
in	O
narrow	O
distribution	O
within	O
the	O
general	O
range	O
of	O
300	O
to	O
500	O
nm	O
and	O
the	O
morphological	O
feature	O
thereof	O
is	O
regular	O
,	O
has	O
the	O
advantages	O
of	O
high	O
biodegradability	O
and	O
biocompatibility	O
,	O
stable	O
structure	O
and	O
less	O
serious	O
toxic	O
andside	O
effects	O
,	O
and	O
has	O
better	O
effect	O
on	O
inhibiting	O
tumor	O
cells	O
according	O
to	O
the	O
in	O
vitro	O
cell	O
experiment	O
.	O

Liquiritin	O
preparation	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
liquiritin	O
preparation	O
with	O
the	O
molecular	O
formula	O
of	O
C26H30O13	O
and	O
the	O
molecular	O
weight	O
of	O
550	O
.	O

The	O
liquiritin	O
is	O
singly	O
prepared	O
or	O
by	O
matching	O
with	O
other	O
active	O
components	O
or	O
auxiliary	O
materials	O
,	O
and	O
the	O
preparation	O
composition	O
is	O
counted	O
in	O
such	O
a	O
way	O
that	O
1000	O
particles	O
contain	O
40	O
g	O
of	O
liquiritin	O
.	O

The	O
liquiritin	O
preparation	O
has	O
stronger	O
effect	O
for	O
relieving	O
cough	O
and	O
eliminating	O
phlegm	O
,	O
therefore	O
,	O
the	O
preparation	O
can	O
be	O
singly	O
prepared	O
by	O
liquiritin	O
or	O
by	O
the	O
liquiritin	O
matching	O
with	O
other	O
active	O
components	O
or	O
auxiliary	O
materials	O
,	O
can	O
be	O
used	O
for	O
improving	O
symptoms	O
of	O
cough	O
and	O
profuse	O
sputum	O
,	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
medicine	O
for	O
curing	O
acute	O
cough	O
,	O
chronic	O
cough	O
and	O
profuse	O
sputum	O
.	O

The	O
liquiritin	O
preparation	O
originates	O
from	O
natural	O
plants	O
,	O
can	O
be	O
made	O
into	O
a	O
health	O
-	O
care	O
product	O
,	O
and	O
provides	O
the	O
natural	O
cough	O
-	O
relieving	O
medicine	O
with	O
less	O
toxic	O
side	O
effect	O
and	O
obvious	O
healing	O
effect	O
for	O
clinical	O
treatment	O
.	O

Compound	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
invention	O
provides	O
the	O
compound	O
expressed	O
as	O
the	O
formula	O
X	O
:	O
shown	O
as	O
the	O
right	O
,	O
wherein	O
R	O
is	O
-OH	O
or	O
R1COO<-	O
>	O
,	O
R1	O
is	O
C2-C20	O
carbon	O
chain	O
.	O

The	O
invention	O
also	O
provides	O
the	O
method	O
for	O
preparing	O
the	O
compound	O
and	O
a	O
drug	O
compound	O
containing	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
X.	O
The	O
invention	O
also	O
provides	O
the	O
application	O
of	O
the	O
compound	O
on	O
preparing	O
medicaments	O
for	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
.	O

Method	O
for	O
extracting	O
amylase	O
from	O
liquorice	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
method	O
from	O
extracting	O
amylase	O
from	O
liquorice	O
and	O
application	O
thereof	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
a.	O
dried	O
liquorice	O
is	O
ground	O
;	O
b.	O
the	O
ground	O
liquorice	O
is	O
put	O
into	O
an	O
extraction	O
tank	O
,	O
petroleum	O
ether	O
is	O
added	O
for	O
reflowing	O
and	O
degreasing	O
,	O
and	O
then	O
filtered	O
out	O
to	O
obtain	O
degreased	O
residue	O
;	O
c.	O
the	O
residue	O
is	O
added	O
with	O
distilled	O
water	O
for	O
extraction	O
in	O
normal	O
termperature	O
,	O
repeatedly	O
poached	O
and	O
extracted	O
for	O
three	O
times	O
,	O
and	O
triple	O
extraction	O
solutions	O
are	O
combined	O
;	O
d.	O
the	O
extraction	O
solution	O
is	O
decompressed	O
and	O
concentrated	O
to	O
cause	O
the	O
volume	O
of	O
the	O
solution	O
to	O
be	O
the	O
liquorice	O
powder	O
in	O
the	O
step	O
a	O
,	O
thus	O
obtaining	O
a	O
concentrated	O
solution	O
;	O
e.	O
a	O
concentrated	O
solution	O
is	O
added	O
into	O
the	O
concentrated	O
solution	O
in	O
the	O
step	O
d	O
,	O
and	O
then	O
the	O
concentrated	O
mixed	O
solution	O
stands	O
overnight	O
and	O
precipitates	O
;	O
f.	O
the	O
concentrated	O
mixed	O
solution	O
is	O
centrifugalized	O
to	O
obtain	O
the	O
precipitation	O
,	O
dried	O
,	O
and	O
then	O
washed	O
with	O
absolute	O
ethyl	O
alcohol	O
,	O
acetone	O
and	O
aether	O
after	O
is	O
extracted	O
by	O
a	O
Sevag	O
method	O
;	O
g.	O
semi	O
-	O
permeable	O
membrane	O
with	O
the	O
interception	O
molecular	O
weight	O
of	O
1000	O
-	O
10000	O
is	O
used	O
for	O
dialyzing	O
in	O
water	O
,	O
the	O
liquorice	O
amylase	O
is	O
obtained	O
by	O
freezing	O
and	O
drying	O
.	O

The	O
liquorice	O
amylase	O
is	O
applied	O
to	O
the	O
preparation	O
of	O
medicine	O
treating	O
or	O
preventing	O
osteoarthritis	O
.	O

The	O
liquorice	O
amylase	O
has	O
definite	O
active	O
ingredient	O
,	O
definite	O
healing	O
effect	O
and	O
no	O
toxic	O
side	O
effect	O
and	O
the	O
extraction	O
method	O
is	O
easy	O
to	O
be	O
implemented	O
.	O

Method	O
for	O
preparing	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
50	O
to	O
60	O
percent	O
of	O
tea	O
seed	O
oil	O
,	O
3	O
to	O
5	O
percent	O
of	O
borneol	O
,	O
3	O
to	O
5	O
percent	O
of	O
rhubarb	O
,	O
8	O
to	O
15	O
percent	O
of	O
dandelion	O
,	O
and	O
the	O
balance	O
of	O
bamboo	O
charcoal	O
powder	O
;	O
and	O
the	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
cleaning	O
,	O
drying	O
and	O
crushing	O
the	O
borneol	O
,	O
the	O
rhubarb	O
and	O
the	O
dandelion	O
;	O
stirring	O
the	O
materials	O
evenly	O
in	O
proportion	O
;	O
pouring	O
the	O
mixture	O
into	O
the	O
tea	O
seed	O
oil	O
and	O
stirring	O
the	O
mixture	O
;	O
and	O
finally	O
adding	O
the	O
bamboo	O
charcoal	O
powder	O
to	O
the	O
mixture	O
and	O
stirring	O
the	O
mixture	O
.	O

The	O
method	O
overcomes	O
the	O
defects	O
that	O
at	O
present	O
,	O
a	O
burn	O
medicine	O
has	O
less	O
medicinal	O
resources	O
and	O
high	O
price	O
so	O
that	O
the	O
economic	O
burden	O
of	O
a	O
patient	O
is	O
increased	O
,	O
and	O
is	O
easy	O
to	O
trickle	O
and	O
contaminate	O
clothes	O
and	O
beddings	O
.	O

The	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
prepared	O
by	O
the	O
method	O
has	O
the	O
advantages	O
of	O
no	O
trickling	O
,	O
low	O
cost	O
,	O
extensive	O
medicinal	O
resources	O
,	O
remarkable	O
curative	O
effect	O
,	O
simple	O
production	O
process	O
,	O
less	O
equipment	O
investment	O
,	O
and	O
the	O
like	O
.	O

Method	O
for	O
preparing	O
andrographolide	O
derivatives	O
and	O
preparation	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
andrographolide	O
derivatives	O
,	O
and	O
a	O
preparation	O
thereof	O
.	O

The	O
preparation	O
is	O
a	O
salt	O
which	O
consists	O
of	O
Kalii	O
Dethydroandrographolidi	O
Succinas	O
and	O
Adamantanes	O
and	O
has	O
the	O
effect	O
of	O
synergistic	O
interaction	O
.	O

The	O
curative	O
effect	O
of	O
the	O
preparation	O
is	O
better	O
than	O
that	O
of	O
the	O
independent	O
use	O
of	O
Kalii	O
Dethydroandrographolidi	O
Succinas	O
and	O
Adamantanes	O
.	O

Application	O
of	O
7,3'-dimethoxy	O
hesperetin	O
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
immune	O
medicaments	O
The	O
pharmaceutical	O
application	O
of	O
a	O
hesperetin	O
derivative	O
relates	O
to	O
the	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
immune	O
medicaments	O
,	O
in	O
particular	O
to	O
the	O
application	O
in	O
treatment	O
of	O
autoimmune	O
diseases	O
such	O
as	O
rheumatic	O
,	O
rheumatoid	O
arthritis	O
and	O
osteoarthritis	O
,	O
and	O
the	O
like	O
.	O

The	O
hesperetin	O
derivative	O
is	O
the	O
derivative	O
which	O
is	O
prepared	O
by	O
a	O
non	O
-	O
carbohydrate	O
compound	O
obtained	O
by	O
hydrolyzing	O
hesperidin	O
and	O
removing	O
glycosyl	O
.	O

The	O
pharmacological	O
effect	O
of	O
the	O
hesperetin	O
derivative	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
parent	O
hesperidin	O
;	O
and	O
compared	O
with	O
traditional	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
medicament	O
naproxen	O
and	O
a	O
medicament	O
tripterygium	O
treating	O
rheumatoid	O
arthritis	O
,	O
the	O
hesperetin	O
derivative	O
has	O
equivalent	O
activeness	O
,	O
is	O
safe	O
and	O
non	O
-	O
toxic	O
,	O
not	O
only	O
treats	O
the	O
symptom	O
,	O
but	O
also	O
treats	O
the	O
root	O
,	O
thus	O
having	O
very	O
good	O
medicinal	O
prospect	O
.	O

Pharmaceutical	O
composition	O
containing	O
prasugrel	O
and	O
carbazochrome	O
sodium	O
sulfonate	O
The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
containing	O
active	O
carbazochrome	O
sodium	O
sulfonate	O
and	O
prasugrel	O
or	O
the	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
invention	O
aims	O
to	O
invent	O
a	O
more	O
effective	O
and	O
low	O
adverse	O
-	O
reaction	O
method	O
for	O
curing	O
thrombotic	O
diseases	O
by	O
using	O
the	O
combined	O
medication	O
of	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
and	O
the	O
prasugrel	O
.	O

After	O
conscientious	O
trail	O
of	O
the	O
patent	O
applicant	O
for	O
many	O
times	O
,	O
the	O
effect	O
of	O
applying	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
to	O
inhibit	O
thrombosis	O
in	O
a	O
combined	O
manner	O
is	O
discovered	O
unexpected	O
in	O
the	O
process	O
of	O
applying	O
the	O
prasugrel	O
to	O
cure	O
the	O
thrombotic	O
diseases	O
,	O
the	O
anticoagulant	O
effect	O
of	O
the	O
prasugrel	O
is	O
not	O
abated	O
but	O
increased	O
,	O
and	O
the	O
very	O
good	O
synergistic	O
effects	O
are	O
achieved	O
after	O
the	O
combination	O
of	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
and	O
the	O
prasugrel	O
,	O
therefore	O
,	O
the	O
risk	O
of	O
bleeding	O
is	O
greatly	O
reduced	O
when	O
the	O
advantages	O
of	O
good	O
anticoagulant	O
activity	O
and	O
fast	O
effect	O
of	O
the	O
prasugrel	O
during	O
the	O
antiplatelet	O
aggregation	O
are	O
fully	O
exerted	O
,	O
the	O
risk	O
of	O
bleeding	O
caused	O
by	O
the	O
prasugrel	O
is	O
effectively	O
reduced	O
and	O
the	O
compliance	O
of	O
patients	O
is	O
enhanced	O
.	O

Method	O
for	O
preparing	O
zinc	O
supplementing	O
agent	O
carboxymethyl	O
chitosan	O
oligosaccharide	O
zinc	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
zinc	O
supplementing	O
agent	O
carboxymethyl	O
chitosan	O
oligosaccharide	O
zinc	O
,	O
which	O
is	O
characterized	O
in	O
that	O
10	O
g	O
of	O
carboxymethyl	O
chitosan	O
is	O
taken	O
and	O
put	O
into	O
a	O
three	O
-	O
neck	O
flask	O
,	O
and	O
is	O
added	O
with	O
90ml	O
of	O
2	O
%	O
H2O2	O
in	O
batches	O
when	O
being	O
stirred	O
for	O
full	O
reaction	O
until	O
the	O
carboxymethyl	O
chitosan	O
is	O
completely	O
dissolved	O
;	O
pH	O
value	O
is	O
adjusted	O
to	O
be	O
7	O
,	O
the	O
precipitation	O
is	O
filtered	O
out	O
,	O
the	O
product	O
is	O
washed	O
,	O
and	O
filtrate	O
and	O
washing	O
liquid	O
are	O
collected	O
;	O
the	O
filtrate	O
and	O
the	O
washing	O
liquid	O
are	O
decompressed	O
and	O
concentrated	O
,	O
and	O
then	O
precipitated	O
,	O
filtered	O
and	O
washed	O
by	O
ethanol	O
;	O
finally	O
,	O
the	O
product	O
is	O
processed	O
by	O
vacuum	O
drying	O
with	O
the	O
drying	O
temperature	O
controlled	O
to	O
be	O
60	O
DEG	O
C.	O
The	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
carboxymethyl	O
chitosan	O
is	O
prepared	O
after	O
chitosan	O
oligosaccharide	O
is	O
modified	O
,	O
so	O
as	O
to	O
have	O
the	O
pharmacological	O
actions	O
of	O
arrhythmia	O
resistance	O
,	O
anticoagulation	O
,	O
infection	O
resistance	O
and	O
the	O
like	O
;	O
the	O
carboxymethyl	O
chitosan	O
oligosaccharide	O
zinc	O
is	O
natural	O
modified	O
product	O
and	O
has	O
better	O
safety	O
and	O
biological	O
activity	O
compared	O
with	O
other	O
zinc	O
supplementing	O
agents	O
.	O

Two	O
sterol	O
derivatives	O
,	O
separation	O
and	O
extraction	O
method	O
thereof	O
and	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
prostatoplasia	O
diseases	O
The	O
invention	O
discloses	O
two	O
sterol	O
derivatives	O
,	O
a	O
separation	O
and	O
extraction	O
method	O
thereof	O
and	O
an	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
prostatoplasia	O
diseases	O
.	O

The	O
two	O
sterol	O
derivatives	O
arecompounds	O
24-methylene	O
cholesterol	O
linoleate	O
and	O
cycloeucalenol	O
linoleate	O
shown	O
as	O
formula	O
1	O
and	O
formula	O
2	O
.	O

The	O
compounds	O
which	O
are	O
not	O
reported	O
have	O
the	O
function	O
of	O
inhibiting	O
the	O
activity	O
of	O
aromatizing	O
enzyme	O
.	O

The	O
invention	O
also	O
discloses	O
an	O
application	O
of	O
the	O
two	O
sterol	O
derivatives	O
in	O
preparing	O
preparations	O
to	O
inhibit	O
the	O
activity	O
of	O
aromatizing	O
enzyme	O
and	O
in	O
preparing	O
pharmaceutical	O
compositions	O
to	O
prevent	O
or	O
treat	O
prostatoplasia	O
diseases	O
.	O

Tibetan	O
medicine	O
aerosol	O
for	O
treating	O
acute	O
and	O
chronic	O
sprains	O
and	O
contusions	O
,	O
rheumatism	O
and	O
rheumatoid	O
disease	O
The	O
invention	O
discloses	O
a	O
Tibetan	O
medicine	O
aerosol	O
for	O
treating	O
acute	O
and	O
chronic	O
sprains	O
and	O
contusions	O
,	O
rheumatism	O
and	O
rheumatoid	O
disease	O
,	O
comprising	O
raw	O
medicines	O
of	O
Lamiophlomis	O
rotate	O
,	O
whin	O
,	O
curcuma	O
,	O
pricklyash	O
peel	O
,	O
comu	O
bubal	O
,	O
Myricaria	O
paniculata	O
,	O
safflower	O
,	O
camphol	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
invention	O
has	O
the	O
functions	O
of	O
activating	O
blood	O
and	O
dissolving	O
stasis	O
,	O
and	O
relieving	O
swelling	O
and	O
pain	O
.	O

The	O
aerosol	O
of	O
the	O
invention	O
is	O
characterized	O
by	O
advanced	O
dosage	O
form	O
,	O
simple	O
process	O
,	O
rapid	O
effect	O
and	O
the	O
like	O
.	O

Stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
The	O
invention	O
discloses	O
a	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
.	O

The	O
health	O
-	O
care	O
product	O
comprises	O
the	O
following	O
compositions	O
in	O
percentage	O
by	O
weight	O
:	O
10	O
to	O
30	O
percent	O
of	O
hericium	O
erinaceum	O
polysaccharide	O
,	O
70	O
to	O
90	O
percent	O
of	O
hericium	O
erinaceum	O
polysaccharide	O
byproduct	O
,	O
1	O
to	O
10	O
percent	O
of	O
glycopeptide	O
,	O
1	O
to	O
10	O
percent	O
of	O
oleanolic	O
acid	O
,	O
1	O
to	O
10	O
percent	O
of	O
ethylamine	O
sulfonic	O
acid	O
,	O
1	O
to	O
10	O
percent	O
of	O
alkaloid	O
and	O
1	O
to	O
10	O
percent	O
of	O
terpenoid	O
.	O

The	O
main	O
composition	O
of	O
the	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
is	O
the	O
hericium	O
erinaceum	O
polysaccharide	O
,	O
can	O
be	O
stored	O
at	O
normal	O
temperature	O
,	O
improve	O
the	O
immunity	O
level	O
of	O
cells	O
,	O
promote	O
the	O
repair	O
of	O
gastrointestinal	O
mucosa	O
,	O
relieve	O
the	O
gastrointestinal	O
spasm	O
,	O
inhibit	O
the	O
tumor	O
growth	O
,	O
promote	O
the	O
digestive	O
absorption	O
,	O
improve	O
the	O
inflammation	O
of	O
a	O
digestive	O
system	O
,	O
regulate	O
the	O
disorder	O
of	O
gastrointestinal	O
flora	O
and	O
has	O
the	O
functions	O
of	O
strengthening	O
spleen	O
,	O
harmonizing	O
stomach	O
,	O
replenishing	O
spleen	O
qi	O
and	O
relieving	O
pain	O
.	O

The	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
is	O
suitable	O
for	O
the	O
conditioning	O
and	O
health	O
care	O
of	O
diseases	O
of	O
the	O
digestive	O
system	O
.	O

Medicament	O
composition	O
for	O
treating	O
climacteric	O
syndrome	O
of	O
women	O
The	O
invention	O
discloses	O
a	O
medicament	O
composition	O
for	O
treating	O
climacteric	O
syndrome	O
of	O
women	O
.	O

The	O
medicament	O
composition	O
is	O
prepared	O
by	O
taking	O
medroxyprogesterone	O
,	O
nadestryl	O
,	O
amino	O
acid	O
chelated	O
calcium	O
,	O
vitamin	O
A	O
,	O
vitamin	O
D	O
and	O
vitamin	O
E	O
as	O
raw	O
materials	O
and	O
processing	O
the	O
raw	O
materials	O
according	O
to	O
a	O
conventional	O
preparation	O
.	O

By	O
complementing	O
estrogen	O
,	O
progestational	O
hormone	O
,	O
calcium	O
and	O
vitamin	O
,	O
the	O
invention	O
is	O
used	O
for	O
treating	O
the	O
climacteric	O
syndrome	O
of	O
women	O
.	O

Anti	O
-	O
inflammatory	O
and	O
antimicrobial	O
uses	O
for	O
bioactive	O
glass	O
compositions	O
Compositions	O
and	O
methods	O
for	O
treating	O
wounds	O
to	O
significantly	O
reduce	O
the	O
healing	O
time	O
,	O
reduce	O
the	O
incidence	O
of	O
scar	O
formation	O
,	O
improve	O
the	O
success	O
of	O
skin	O
grafts	O
,	O
reduce	O
the	O
inflammatory	O
response	O
and	O
providing	O
anti	O
-	O
bacterial	O
treatments	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
that	O
include	O
small	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
or	O
highly	O
porous	O
bioactive	O
glass	O
,	O
are	O
disclosed	O
.	O

Anti	O
-	O
bacterial	O
solutions	O
derived	O
from	O
bioactive	O
glass	O
,	O
and	O
methods	O
of	O
preparation	O
and	O
use	O
thereof	O
,	O
are	O
also	O
disclosed	O
.	O

The	O
compositions	O
include	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
,	O
alone	O
or	O
in	O
combination	O
with	O
anti	O
-	O
bacterial	O
agents	O
and/or	O
anti	O
-	O
inflammatory	O
agents	O
.	O

The	O
compositions	O
can	O
include	O
an	O
appropriate	O
carrier	O
for	O
topical	O
administration	O
.	O

Anti	O
-	O
bacterial	O
properties	O
can	O
be	O
imparted	O
to	O
implanted	O
materials	O
,	O
such	O
as	O
prosthetic	O
implants	O
,	O
sutures	O
,	O
stents	O
,	O
screws	O
,	O
plates	O
,	O
tubes	O
,	O
and	O
the	O
like	O
,	O
by	O
incorporating	O
small	O
bioactive	O
glass	O
particles	O
or	O
porous	O
bioactive	O
glass	O
into	O
or	O
onto	O
the	O
implanted	O
materials	O
.	O

Anti	O
-	O
bacterial	O
properties	O
can	O
also	O
be	O
imparted	O
to	O
devices	O
used	O
for	O
in	O
vitro	O
and	O
ex	O
vivo	O
cell	O
culture	O
by	O
incorporating	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
into	O
the	O
devices	O
.	O

Anti	O
-	O
bacterial	O
compositions	O
derived	O
from	O
aqueous	O
extracts	O
of	O
bioactive	O
glass	O
are	O
also	O
disclosed	O
.	O

These	O
compositions	O
can	O
be	O
used	O
,	O
for	O
example	O
,	O
in	O
food	O
preparation	O
,	O
solutions	O
used	O
for	O
cell	O
culture	O
,	O
and	O
buffer	O
solutions	O
,	O
such	O
as	O
i.v	O
.	O

solutions	O
.	O

Fluticasone	O
propionate	O
lipidosome	O
cream	O
The	O
invention	O
relates	O
to	O
a	O
lipidosome	O
medical	O
composition	O
which	O
uses	O
fluticasone	O
propionate	O
as	O
an	O
active	O
component	O
,	O
and	O
a	O
cyst	O
diameter	O
of	O
lipidosome	O
is	O
smaller	O
than	O
800	O
nm	O
.	O

The	O
composition	O
comprises	O
0.025	O
percent	O
to	O
0.2	O
percent	O
of	O
fluticasone	O
propionate	O
as	O
the	O
active	O
component	O
,	O
0.5	O
percent	O
to	O
6	O
percent	O
of	O
phospholipid	O
,	O
0	O
percent	O
to	O
1	O
percent	O
of	O
lipophilic	O
additive	O
,	O
0.01	O
percent	O
to	O
1	O
percent	O
of	O
antioxidant	O
which	O
is	O
used	O
for	O
preserving	O
the	O
medical	O
composition	O
,	O
a	O
pH	O
buffering	O
agent	O
which	O
is	O
used	O
for	O
retaining	O
the	O
pH	O
value	O
from	O
5	O
to	O
7.5	O
,	O
3	O
percent	O
to	O
15	O
percent	O
of	O
humectant	O
,	O
20	O
percent	O
to	O
30	O
percent	O
of	O
oil	O
phrase	O
component	O
,	O
0.01	O
percent	O
to	O
0.1	O
percent	O
of	O
antimicrobial	O
preservative	O
and	O
the	O
balanced	O
of	O
water	O
.	O

The	O
fluticasone	O
propionate	O
lipidosome	O
cream	O
is	O
used	O
for	O
treating	O
skin	O
diseases	O
of	O
human	O
beings	O
or	O
animals	O
.	O

Solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
ambroxol	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
ambroxol	O
,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutics	O
.	O

The	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
the	O
ambroxol	O
comprises	O
(	O
1	O
)	O
ambroxol	O
or	O
medicinal	O
salt	O
thereof	O
with	O
single	O
medicinal	O
dosage	O
,	O
(	O
2	O
)	O
isotonic	O
agent	O
and	O
solvent	O
,	O
(	O
3	O
)	O
buffer	O
solution	O
and	O
(	O
4	O
)	O
medicinal	O
package	O
with	O
single	O
dosage	O
;	O
and	O
in	O
terms	O
of	O
the	O
ambroxol	O
,	O
the	O
mass	O
ratio	O
of	O
the	O
medicinal	O
components	O
to	O
the	O
isotonic	O
agent	O
is	O
1:1.1	O
-	O
1:3.3.The	O
invention	O
provides	O
the	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
the	O
ambroxol	O
with	O
single	O
dosage	O
and	O
the	O
medicinal	O
package	O
adopting	O
blowing	O
-	O
filling	O
-	O
sealing	O
(	O
BFS	O
)	O
integrative	O
full	O
-	O
automatic	O
production	O
,	O
which	O
have	O
the	O
advantages	O
that	O
the	O
medicinal	O
package	O
is	O
designed	O
and	O
manufactured	O
for	O
patients	O
special	O
for	O
atomizing	O
and	O
inhaling	O
;	O
the	O
solution	O
preparation	O
does	O
not	O
contain	O
preservative	O
,	O
and	O
is	O
used	O
with	O
disposable	O
single	O
dosage	O
;	O
the	O
using	O
process	O
is	O
convenient	O
and	O
does	O
not	O
need	O
dilution	O
and	O
preparation	O
;	O
and	O
the	O
microbe	O
pollution	O
,	O
waste	O
and	O
the	O
like	O
during	O
using	O
can	O
be	O
greatly	O
reduced	O
.	O

The	O
medicinal	O
preparation	O
provides	O
a	O
treatment	O
medicament	O
and	O
a	O
treatment	O
proposal	O
with	O
accurate	O
medicinal	O
dosage	O
,	O
good	O
-	O
quality	O
and	O
stable	O
medicament	O
quality	O
,	O
and	O
safe	O
and	O
simple	O
clinical	O
application	O
lacking	O
in	O
the	O
prior	O
art	O
.	O

Enrofloxacin	O
double	O
emulsion	O
for	O
livestock	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
an	O
enrofloxacin	O
double	O
emulsion	O
for	O
livestock	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
enrofloxacin	O
double	O
emulsion	O
belongs	O
to	O
the	O
field	O
of	O
antibiotic	O
preparations	O
for	O
livestock	O
.	O

The	O
W	O
/	O
O	O
/	O
W	O
type	O
double	O
emulsion	O
is	O
prepared	O
by	O
using	O
enrofloxacin	O
as	O
active	O
ingredients	O
and	O
adding	O
oil	O
phase	O
,	O
emulsifier	O
,	O
stabilizer	O
and	O
the	O
like	O
.	O

The	O
enrofloxacin	O
double	O
emulsion	O
for	O
livestock	O
can	O
better	O
cover	O
the	O
bitter	O
taste	O
of	O
the	O
enrofloxacin	O
,	O
improves	O
the	O
adaptation	O
of	O
oral	O
drugs	O
for	O
livestock	O
,	O
can	O
better	O
control	O
the	O
diffusion	O
rate	O
of	O
the	O
drugs	O
to	O
play	O
a	O
role	O
of	O
slow	O
release	O
,	O
and	O
better	O
adapts	O
different	O
clinical	O
drugs	O
requirements	O
.	O

Clinical	O
tests	O
show	O
that	O
the	O
invention	O
can	O
overcome	O
phenomena	O
of	O
food	O
refusal	O
and	O
poor	O
appetite	O
of	O
taste	O
acuity	O
animals	O
of	O
pigs	O
and	O
the	O
like	O
,	O
therebyensuring	O
the	O
dosage	O
,	O
improving	O
the	O
medicine	O
effect	O
,	O
and	O
achieving	O
the	O
purpose	O
of	O
ideal	O
treatment	O
.	O

Meanwhile	O
,	O
because	O
of	O
a	O
certain	O
slow	O
release	O
function	O
,	O
the	O
frequency	O
for	O
medicine	O
administration	O
can	O
be	O
reduced	O
,	O
and	O
the	O
invention	O
provides	O
an	O
efficient	O
and	O
long	O
-	O
acting	O
enrofloxacin	O
preparation	O
for	O
clinical	O
veterinarian	O
.	O

New	O
use	O
of	O
isosorbide	O
mononitrate	O
in	O
preparing	O
medicine	O
for	O
increasing	O
endometrial	O
thickness	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
particularly	O
relates	O
to	O
a	O
new	O
use	O
of	O
isosorbide	O
5-mononitrate	O
and	O
a	O
corresponding	O
new	O
dosage	O
form	O
suitable	O
for	O
the	O
new	O
use	O
,	O
and	O
concretely	O
relates	O
to	O
a	O
use	O
of	O
isosorbide	O
5-mononitrate	O
in	O
preparing	O
drug	O
for	O
improving	O
the	O
receptive	O
performance	O
of	O
endometrium	O
.	O

The	O
improvement	O
of	O
the	O
receptive	O
performance	O
of	O
endometrium	O
is	O
concretely	O
realized	O
through	O
repairing	O
and	O
improving	O
the	O
endometrium	O
,	O
or	O
through	O
prompting	O
the	O
development	O
of	O
uterus	O
glandular	O
organ	O
,	O
or	O
through	O
prompting	O
the	O
development	O
of	O
uterus	O
mesenchyma	O
.	O

In	O
order	O
to	O
adapt	O
to	O
the	O
four	O
new	O
uses	O
,	O
the	O
prepared	O
drug	O
is	O
vagina	O
local	O
drug	O
feeding	O
preparation	O
,	O
namely	O
,	O
preparation	O
which	O
takes	O
isosorbide	O
5-mononitrate	O
with	O
effective	O
amount	O
as	O
active	O
components	O
and	O
is	O
prepared	O
through	O
adding	O
accessories	O
which	O
are	O
allowable	O
in	O
pharmacy	O
.	O

The	O
isosorbide	O
5-mononitrate	O
not	O
only	O
can	O
exert	O
excellent	O
medical	O
effects	O
of	O
prompting	O
the	O
development	O
of	O
endometrium	O
tissues	O
and	O
improving	O
the	O
receptive	O
performance	O
of	O
endometrium	O
,	O
but	O
also	O
can	O
effectively	O
avoid	O
the	O
side	O
effect	O
that	O
isosorbide	O
5-mononitrate	O
lowers	O
blood	O
pressure	O
after	O
giving	O
drug	O
in	O
vagina	O
,	O
and	O
provides	O
a	O
new	O
choice	O
for	O
clinical	O
application	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
skin	O
(	O
A	O
)	O
disease	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
skin	O
(	O
A	O
)	O
disease	O
,	O
having	O
the	O
strong	O
eliminating	O
function	O
on	O
bacteria	O
,	O
epiphyte	O
and	O
viruses	O
and	O
has	O
the	O
obvious	O
effect	O
on	O
tinea	O
of	O
feet	O
and	O
hands	O
,	O
onychomycosis	O
,	O
tinea	O
cruris	O
,	O
scald	O
head	O
,	O
furuncle	O
,	O
mosquito	O
bite	O
and	O
acrohyperhidrosis	O
.	O

The	O
high	O
-	O
molecule	O
material	O
and	O
recipe	O
composition	O
of	O
the	O
pharmaceutical	O
composition	O
has	O
no	O
poison	O
and	O
little	O
stimulation	O
on	O
skin	O
,	O
has	O
long	O
action	O
time	O
and	O
presents	O
the	O
actions	O
of	O
controlled	O
release	O
and	O
stability	O
.	O

The	O
quality	O
can	O
be	O
kept	O
to	O
be	O
stable	O
when	O
the	O
composition	O
is	O
stored	O
at	O
normal	O
temperature	O
,	O
and	O
thereby	O
,	O
the	O
composition	O
is	O
safe	O
and	O
effective	O
.	O

The	O
composition	O
contains	O
the	O
main	O
constituents	O
of	O
povidone	O
iodine	O
,	O
acetylsalicylic	O
acid	O
,	O
polyethylene	O
glycol	O
,	O
potash	O
iodate	O
,	O
phenol	O
and	O
high	O
-	O
molecule	O
material	O
.	O

Transdermal	O
zinc	O
supplement	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
zinc	O
supplement	O
,	O
in	O
particular	O
to	O
a	O
transdermal	O
zinc	O
supplement	O
which	O
comprises	O
zinc	O
oxide	O
and	O
citric	O
acid	O
and	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
material	O
components	O
by	O
weight	O
percent	O
:	O
10	O
-	O
40	O
%	O
of	O
zinc	O
oxide	O
,	O
30	O
-	O
70	O
%	O
of	O
citric	O
acid	O
and	O
10	O
-	O
50	O
%	O
of	O
sodium	O
hydroxide	O
.	O

A	O
method	O
for	O
manufacturing	O
the	O
transdermal	O
zinc	O
supplement	O
comprises	O
the	O
following	O
steps	O
:	O
weighing	O
the	O
raw	O
material	O
components	O
according	O
to	O
the	O
weight	O
percent	O
,	O
and	O
mixing	O
and	O
grinding	O
the	O
raw	O
material	O
components	O
until	O
being	O
evenly	O
mixed	O
;	O
heating	O
the	O
ground	O
material	O
to	O
the	O
temperature	O
of	O
120	O
-	O
150	O
DEG	O
C	O
and	O
then	O
carrying	O
out	O
heat	O
preservation	O
for	O
1	O
-	O
2h	O
to	O
lead	O
the	O
material	O
to	O
be	O
dried	O
;	O
and	O
finally	O
,	O
crushing	O
the	O
dried	O
material	O
,	O
screening	O
the	O
material	O
by	O
a	O
No.	O
5	O
sieve	O
,	O
obtaining	O
undersized	O
material	O
which	O
is	O
the	O
finished	O
product	O
of	O
the	O
transdermal	O
zinc	O
supplement	O
,	O
and	O
then	O
split	O
packaging	O
the	O
obtained	O
finished	O
product	O
of	O
the	O
transdermal	O
zinc	O
supplement	O
.	O

The	O
transdermal	O
zinc	O
supplement	O
can	O
avoid	O
the	O
interference	O
of	O
gastrointestinal	O
tract	O
as	O
well	O
as	O
the	O
influence	O
of	O
factors	O
such	O
as	O
the	O
pH	O
value	O
of	O
the	O
gastrointestinal	O
tract	O
,	O
food	O
,	O
digestive	O
juice	O
and	O
the	O
like	O
,	O
improves	O
the	O
bioavailability	O
of	O
the	O
zinc	O
supplement	O
,	O
has	O
wide	O
application	O
range	O
including	O
infants	O
children	O
,	O
pregnant	O
women	O
,	O
nursing	O
women	O
and	O
adults	O
,	O
and	O
improves	O
the	O
life	O
quality	O
of	O
the	O
whole	O
life	O
.	O

Cyclopentenyl	O
fatty	O
acid	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
cyclopentenyl	O
fatty	O
acid	O
and	O
ester	O
or	O
a	O
solvate	O
thereof	O
.	O

The	O
cyclopentenyl	O
fatty	O
acid	O
consists	O
of	O
a	O
cyclopentenyl	O
structural	O
unit	O
and	O
a	O
long	O
-	O
chain	O
fatty	O
acid	O
or	O
the	O
ester	O
or	O
the	O
solvate	O
thereof	O
,	O
and	O
compounds	O
with	O
structural	O
formulas	O
A	O
and	O
B	O
are	O
preferable	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
application	O
thereof	O
in	O
preparing	O
anti	O
-	O
tuberculous	O
drugs	O
.	O

Ornidazole	O
medicinal	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
ornidazole	O
medicinal	O
composition	O
.	O

Each	O
100	O
milliliters	O
of	O
ornidazole	O
medicinal	O
composition	O
contains	O
5	O
grams	O
of	O
ornidazole	O
,	O
35	O
to	O
60	O
milliliters	O
of	O
1,2-propylene	O
glycol	O
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
pH	O
value	O
of	O
the	O
ornidazole	O
medicinal	O
composition	O
is	O
2.5	O
to	O
4.5	O
.	O

The	O
composition	O
can	O
be	O
made	O
into	O
a	O
small	O
-	O
volume	O
injection	O
,	O
wherein	O
the	O
injection	O
can	O
be	O
a	O
5-milliliter	O
injection	O
containing	O
0.25	O
gram	O
of	O
the	O
composition	O
or	O
a	O
10-milliliter	O
injection	O
containing	O
0.5	O
gram	O
of	O
the	O
composition	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
ornidazole	O
medicinal	O
composition	O
,	O
which	O
comprises	O
:	O
adding	O
ornidazole	O
into	O
1,2-propylene	O
glycol	O
,	O
keeping	O
the	O
temperature	O
to	O
be	O
45	O
to	O
60	O
DEG	O
C	O
and	O
stirring	O
the	O
mixture	O
till	O
the	O
ornidazole	O
dissolves	O
completely	O
;	O
adding	O
disodium	O
ethylenediamintetraacetate	O
aqueous	O
solution	O
at	O
a	O
concentration	O
of	O
40	O
-	O
70mg	O
/	O
100ml	O
;	O
and	O
using	O
needle	O
active	O
carbon	O
for	O
absorption	O
and	O
microporous	O
filter	O
membrane	O
for	O
filtration	O
decarbonization	O
,	O
supplying	O
water	O
for	O
injection	O
and	O
adjusting	O
the	O
pH	O
value	O
to	O
2.5	O
to	O
4.5	O
to	O
obtain	O
the	O
ornidazole	O
medicinal	O
composition	O
.	O

The	O
method	O
provided	O
by	O
the	O
invention	O
has	O
simple	O
process	O
and	O
the	O
prepared	O
product	O
has	O
high	O
stability	O
.	O

Plaster	O
for	O
treating	O
facial	O
paralysis	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
facial	O
paralysis	O
,	O
which	O
comprises	O
rhizoma	O
typhonii	O
,	O
scorpio	O
,	O
stiff	O
silkworm	O
,	O
uncaria	O
,	O
rhizoma	O
gastrodiae	O
,	O
futokadsura	O
stem	O
,	O
notopterygium	O
root	O
,	O
asarum	O
,	O
herba	O
schizonepetae	O
,	O
radix	O
sileris	O
,	O
cicada	O
slough	O
,	O
angelica	O
root	O
,	O
centipede	O
,	O
zaocys	O
dhumnade	O
,	O
earthworm	O
,	O
mastic	O
,	O
myrrh	O
,	O
radix	O
salviae	O
miltiorrhizae	O
,	O
safflower	O
,	O
artemisia	O
anomala	O
,	O
cinnamon	O
,	O
rhizoma	O
ligustici	O
wallichii	O
,	O
red	O
peony	O
root	O
,	O
Chinese	O
ephedra	O
,	O
equisetum	O
,	O
tetrandra	O
root	O
,	O
rhizoma	O
atractylodis	O
,	O
pawpaw	O
,	O
pangolin	O
scales	O
,	O
speranskia	O
tuberculata	O
,	O
oyster	O
,	O
sea	O
-	O
ear	O
shell	O
,	O
strychnos	O
,	O
white	O
mustard	O
seed	O
,	O
musk	O
,	O
colophony	O
,	O
verdigris	O
,	O
draconis	O
sanguis	O
,	O
catechu	O
and	O
gleditsia	O
sinensis	O
lam	O
.	O

The	O
components	O
are	O
mutually	O
coordinated	O
to	O
achieve	O
the	O
functions	O
of	O
calming	O
the	O
endopathic	O
wind	O
,	O
relieving	O
convulsion	O
and	O
spasm	O
,	O
dispersing	O
pathogenic	O
wind	O
,	O
dispelling	O
cold	O
,	O
promoting	O
blood	O
circulation	O
,	O
relieving	O
the	O
stasis	O
of	O
blood	O
,	O
resolving	O
phlegm	O
,	O
reducing	O
the	O
stagnation	O
,	O
nourishing	O
the	O
blood	O
,	O
smoothing	O
collaterals	O
,	O
promoting	O
the	O
circulation	O
of	O
qi	O
and	O
alleviating	O
pain	O
.	O

Method	O
for	O
preparing	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
,	O
belonging	O
to	O
the	O
field	O
of	O
the	O
pharmaceutical	O
preparation	O
.	O

The	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
is	O
clear	O
and	O
transparent	O
solution	O
which	O
comprises	O
oil	O
phase	O
,	O
surfactant	O
,	O
cosurfactant	O
and	O
water	O
phase	O
by	O
appropriate	O
proportion	O
,	O
wherein	O
the	O
proportion	O
of	O
the	O
oil	O
phase	O
to	O
the	O
surfactant	O
is	O
45:1	O
-	O
1:7	O
,	O
and	O
the	O
proportion	O
of	O
the	O
surfactant	O
to	O
the	O
cosurfactant	O
is	O
4:1	O
-	O
1:4	O
.	O

The	O
oral	O
chondroitin	O
sulfate	O
nanoemulsion	O
can	O
improve	O
the	O
bioavailability	O
of	O
the	O
chondroitin	O
sulfate	O
,	O
reduce	O
the	O
toxic	O
and	O
side	O
effect	O
of	O
the	O
chondroitin	O
sulfate	O
and	O
fully	O
exert	O
the	O
efficacy	O
of	O
the	O
chondroitin	O
sulfate	O
.	O

Raloxifene	O
emplastrum	O
preparation	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
raloxifene	O
emplastrum	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Raloxifene	O
microemulsion	O
is	O
made	O
into	O
a	O
transdermal	O
emplastrum	O
which	O
is	O
divided	O
into	O
an	O
anti	O
-	O
adhesion	O
layer	O
,	O
a	O
viscose	O
layer	O
,	O
a	O
backlining	O
layer	O
and	O
a	O
medicine	O
storage	O
layer	O
.	O

The	O
raloxifene	O
microemulsion	O
taken	O
as	O
a	O
medical	O
ingredient	O
of	O
the	O
raloxifene	O
emplastrum	O
comprises	O
the	O
following	O
ingredients	O
:	O
raloxifene	O
taken	O
as	O
an	O
active	O
ingredient	O
,	O
polysorbate	O
taken	O
as	O
surfactant	O
,	O
propanediol	O
taken	O
as	O
cosurfactant	O
,	O
pure	O
water	O
or	O
distilled	O
water	O
,	O
and	O
the	O
like	O
.	O

Except	O
for	O
the	O
medical	O
ingredient	O
,	O
a	O
plurality	O
of	O
nonpolar	O
polymers	O
,	O
plasticizing	O
agent	O
,	O
caking	O
agent	O
,	O
transdermal	O
enhancing	O
agent	O
and	O
antioxidant	O
are	O
also	O
added	O
in	O
the	O
emplastrum	O
.	O

Compared	O
with	O
the	O
prior	O
dosage	O
forms	O
,	O
such	O
as	O
tablets	O
,	O
the	O
invention	O
has	O
the	O
remarkable	O
advantages	O
of	O
durable	O
medical	O
effect	O
,	O
safety	O
,	O
low	O
toxicity	O
,	O
simple	O
,	O
convenient	O
and	O
sanitary	O
,	O
and	O
accurate	O
medical	O
dosage	O
.	O

Pharmaceutical	O
composite	O
for	O
reducing	O
blood	O
fat	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composite	O
for	O
reducing	O
blood	O
fat	O
,	O
which	O
comprises	O
sea	O
buckthorn	O
,	O
vitamin	O
B	O
complex	O
,	O
vitamin	O
E	O
and	O
trace	O
elements	O
of	O
zinc	O
,	O
selenium	O
,	O
chromium	O
and	O
molybdenum	O
.	O

The	O
pharmaceutical	O
composite	O
is	O
used	O
for	O
people	O
suffering	O
from	O
hyperlipaemia	O
,	O
has	O
very	O
good	O
effect	O
on	O
reducing	O
blood	O
fat	O
,	O
and	O
can	O
be	O
applied	O
to	O
a	O
long	O
time	O
or	O
in	O
course	O
of	O
treatment	O
.	O

Cancer	O
pain	O
elimination	O
pill	O
The	O
invention	O
relates	O
to	O
a	O
cancer	O
pain	O
elimination	O
pill	O
which	O
is	O
a	O
medicament	O
for	O
treating	O
esophageal	O
cancer	O
,	O
esophagus	O
cancer	O
,	O
gastric	O
cancer	O
and	O
postoperation	O
metastasis	O
cancer	O
.	O

The	O
cancer	O
pain	O
elimination	O
pill	O
is	O
prepared	O
from	O
trogopterus	O
dung	O
,	O
akebia	O
trifoliata	O
koidz	O
.	O
,	O
long	O
-	O
noded	O
pit	O
viper	O
,	O
honeysuckle	O
flower	O
,	O
pangolin	O
,	O
fructus	O
amomi	O
,	O
lima	O
beans	O
,	O
borneol	O
,	O
radix	O
pseudostellariae	O
,	O
paris	O
polyphylla	O
,	O
radix	O
curcumae	O
,	O
white	O
paeony	O
roots	O
,	O
angelica	O
sinensis	O
,	O
peach	O
kernels	O
,	O
rabdosia	O
rubescens	O
,	O
curcuma	O
zedoary	O
,	O
rhizoma	O
zedoariae	O
,	O
malts	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
hawthorns	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
medicated	O
leaven	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
agastache	O
rugosus	O
,	O
senecio	O
dianthus	O
franch	O
and	O
caulis	O
perllae	O
.	O

The	O
cancer	O
pain	O
elimination	O
pill	O
is	O
suitable	O
for	O
treating	O
the	O
esophageal	O
cancer	O
,	O
the	O
esophagus	O
cancer	O
,	O
the	O
gastric	O
cancer	O
and	O
the	O
postoperation	O
metastasis	O
cancer	O
,	O
has	O
good	O
curative	O
effect	O
and	O
quick	O
effect	O
,	O
treats	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
and	O
is	O
convenient	O
to	O
take	O
.	O

Proved	O
by	O
years	O
of	O
clinical	O
experiments	O
,	O
the	O
cancer	O
pain	O
elimination	O
pill	O
effectively	O
relieves	O
pains	O
of	O
patients	O
and	O
gets	O
the	O
praises	O
of	O
a	O
lot	O
of	O
patients	O
.	O

Preparation	O
method	O
and	O
products	O
of	O
danofloxacin	O
mesylate	O
liposome	O
The	O
invention	O
provides	O
a	O
preparation	O
method	O
and	O
products	O
of	O
danofloxacin	O
mesylate	O
liposome	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
adopting	O
the	O
ammonium	O
sulfate	O
gradient	O
method	O
to	O
prepare	O
blank	O
liposome	O
;	O
and	O
(	O
2	O
)	O
adding	O
danofloxacin	O
mesylate	O
liquor	O
in	O
the	O
blank	O
liposome	O
,	O
using	O
water	O
bath	O
for	O
incubation	O
,	O
filtrating	O
,	O
and	O
performing	O
repeated	O
freeze	O
thawing	O
to	O
the	O
filtrate	O
by	O
using	O
the	O
freeze	O
and	O
thawing	O
method	O
to	O
obtain	O
the	O
danofloxacin	O
mesylate	O
liposome	O
.	O

The	O
finished	O
liposome	O
prepared	O
by	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
milky	O
semitransparent	O
mixed	O
suspension	O
which	O
appears	O
as	O
spherical	O
or	O
nearly	O
globose	O
small	O
vesicles	O
with	O
regular	O
shape	O
,	O
good	O
dispersity	O
and	O
uniform	O
grain	O
size	O
under	O
an	O
electron	O
microscope	O
;	O
the	O
entrapment	O
rate	O
of	O
the	O
liposome	O
is	O
above	O
90	O
%	O
and	O
the	O
liposome	O
has	O
good	O
stability	O
;	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
properties	O
of	O
the	O
liposome	O
are	O
better	O
than	O
that	O
of	O
conventional	O
dosage	O
forms	O
and	O
the	O
liposome	O
is	O
characterized	O
by	O
slow	O
release	O
,	O
long	O
acting	O
and	O
high	O
lung	O
-	O
targeting	O
.	O

Anti	O
-	O
drug	O
medicine	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
narcotic	O
-	O
abstaining	O
medicine	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
narcotic	O
-	O
abstaining	O
medicine	O
is	O
a	O
narcotic	O
-	O
abstaining	O
oral	O
medicine	O
prepared	O
from	O
the	O
raw	O
material	O
medicines	O
such	O
as	O
American	O
ginseng	O
,	O
astragalus	O
root	O
,	O
angelica	O
,	O
wild	O
or	O
spiny	O
jujuba	O
seed	O
,	O
schisandra	O
fruit	O
,	O
tuckahoe	O
,	O
corydalis	O
tuber	O
,	O
thymeleaf	O
sandwort	O
,	O
licorice	O
and	O
the	O
like	O
according	O
to	O
the	O
methods	O
of	O
grinding	O
,	O
decocting	O
,	O
distilling	O
,	O
concentrating	O
,	O
mixing	O
and	O
the	O
like	O
.	O

Clinical	O
observation	O
shows	O
that	O
the	O
medicine	O
has	O
good	O
functions	O
of	O
detoxication	O
and	O
addiction	O
abstaining	O
and	O
has	O
an	O
obvious	O
functionof	O
resisting	O
freak	O
-	O
out	O
recovery	O
,	O
and	O
the	O
narcotic	O
-	O
abstaining	O
rehabilitation	O
rate	O
of	O
resisting	O
freak	O
-	O
out	O
recovery	O
is	O
more	O
than	O
65	O
%	O
.	O

Compound	O
in	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
and	O
application	O
thereof	O
in	O
curing	O
treating	O
cardiovascular	O
disease	O
The	O
invention	O
discloses	O
a	O
new	O
phenolic	O
acid	O
compound	O
,	O
i.e.	O
danshinolic	O
acid	O
M	O
extracted	O
from	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
roots	O
,	O
the	O
compound	O
also	O
can	O
be	O
extracted	O
from	O
a	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
,	O
and	O
the	O
invention	O
simultaneously	O
also	O
discloses	O
a	O
method	O
for	O
extracting	O
the	O
new	O
compound	O
respectively	O
from	O
the	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
roots	O
and	O
the	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
.	O

Pharmacological	O
studies	O
indicate	O
that	O
the	O
danshinolic	O
acid	O
M	O
has	O
myocardial	O
preservation	O
and	O
oxidation	O
resistant	O
activity	O
,	O
thereby	O
the	O
compound	O
has	O
the	O
prospect	O
of	O
being	O
further	O
developed	O
into	O
an	O
effective	O
medicament	O
for	O
curing	O
treating	O
cardiovascular	O
diseases	O
and	O
can	O
be	O
used	O
in	O
the	O
quality	O
control	O
standard	O
of	O
the	O
salvia	O
miltiorrhiza	O
bunge	O
red	O
sage	O
root	O
injection	O
.	O

Substituted	O
pyridino-	O
[	O
2',1':2,3	O
]	O
imidazo	O
[	O
4,5-c	O
]	O
isoquinolone	O
compounds	O
,	O
method	O
for	O
synthesizing	O
same	O
,	O
use	O
of	O
same	O
and	O
medicinal	O
composition	O
having	O
same	O
The	O
invention	O
relates	O
to	O
substituted	O
pyridino-	O
[	O
2',1':2,3	O
]	O
imidazo	O
[	O
4,5-c	O
]	O
isoquinolone	O
compounds	O
,	O
a	O
method	O
for	O
synthesizing	O
the	O
same	O
,	O
use	O
of	O
the	O
same	O
and	O
a	O
medicinal	O
composition	O
having	O
the	O
same	O
,	O
in	O
particular	O
to	O
compounds	O
of	O
a	O
general	O
formula	O
(	O
I	O
)	O
or	O
stereoisomers	O
thereof	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
promedicaments	O
thereof	O
or	O
solvate	O
thereof	O
and	O
synthesis	O
method	O
thereof	O
.	O

With	O
specific	O
and	O
high	O
-	O
efficiency	O
mitosis	O
retarding	O
effect	O
,	O
the	O
compounds	O
can	O
be	O
used	O
as	O
mitosis	O
inhibitors	O
to	O
induce	O
the	O
apoptosis	O
of	O
cells	O
.	O

And	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
compounds	O
is	O
different	O
from	O
those	O
of	O
known	O
mitosis	O
inhibitors	O
and	O
can	O
be	O
used	O
in	O
treating	O
leukemia	O
,	O
stomach	O
cancer	O
,	O
cervical	O
cancer	O
,	O
melanoma	O
,	O
colon	O
cancer	O
,	O
breast	O
cancer	O
,	O
ovarian	O
cancer	O
,	O
liver	O
cancer	O
and	O
lung	O
cancer	O
.	O

Cefixime	O
oral	O
administration	O
mixed	O
suspension	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
cefixime	O
oral	O
administration	O
mixed	O
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
in	O
order	O
to	O
meet	O
the	O
requirement	O
of	O
special	O
medicament	O
taking	O
crowds	O
on	O
the	O
taking	O
of	O
cefixime	O
.	O

The	O
cefixime	O
oral	O
administration	O
mixed	O
suspension	O
per	O
100ml	O
comprises	O
the	O
following	O
components	O
:	O
0.5	O
-	O
4.0	O
g	O
of	O
cefixime	O
,	O
larger	O
than	O
0	O
-	O
20.0	O
g	O
of	O
thickening	O
suspension	O
assistant	O
agent	O
,	O
a	O
cosolvent	O
,	O
a	O
flavoring	O
agent	O
,	O
a	O
preservative	O
and	O
the	O
balance	O
of	O
non	O
-	O
aqueous	O
liquid	O
medium	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
the	O
preservative	O
into	O
the	O
cosolvent	O
;	O
adding	O
the	O
thickening	O
suspension	O
assistant	O
agent	O
into	O
the	O
non	O
-	O
aqueous	O
liquid	O
medium	O
,	O
stirring	O
and	O
dissolving	O
;	O
adding	O
solutions	O
of	O
the	O
flavoring	O
agent	O
,	O
the	O
preservative	O
and	O
the	O
cosolvent	O
uniformly	O
stirring	O
;	O
and	O
adding	O
cefixime	O
micropowder	O
and	O
uniformly	O
stirring	O
and	O
spreading	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
unstable	O
cefixime	O
in	O
water	O
is	O
made	O
into	O
the	O
oral	O
administration	O
mixed	O
suspension	O
by	O
using	O
non	O
-	O
aqueous	O
liquid	O
as	O
a	O
dispersing	O
medium	O
,	O
and	O
the	O
invention	O
solves	O
the	O
problem	O
of	O
stability	O
,	O
has	O
good	O
taste	O
and	O
simple	O
preparation	O
method	O
,	O
is	O
convenient	O
for	O
children	O
,	O
old	O
people	O
and	O
a	O
dysphagia	O
patient	O
to	O
accept	O
and	O
is	O
suitable	O
for	O
industrialized	O
production	O
.	O

Preparation	O
and	O
application	O
of	O
N-	O
(	O
3-chloropyridine-4-group	O
)	O
-2-hydroxide	O
group-5-chlorbenzamide	O
The	O
invention	O
discloses	O
a	O
compound	O
of	O
N-	O
(	O
3-chloropyridine-4-group	O
)	O
-2-hydroxide	O
group-5-chlorbenzamide	O
,	O
the	O
first	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
dissolving	O
2-	O
acetoxyl	O
group-5-lorobenzoyl	O
chloride	O
with	O
chloroform	O
,	O
adding	O
4-amino	O
group-3-chloropyridine	O
,	O
reacting	O
at	O
room	O
temperature	O
to	O
obtain	O
a	O
target	O
compound	O
,	O
wherein	O
triethylamine	O
is	O
used	O
an	O
acid	O
-	O
binding	O
agent	O
;	O
and	O
the	O
second	O
preparation	O
method	O
comprises	O
the	O
step	O
of	O
carrying	O
out	O
a	O
heating	O
reflow	O
reaction	O
on	O
2-acetoxyl	O
group-5-chlorobenzoic	O
methyl	O
formate	O
and	O
4-amino	O
group-3-chloropyridin	O
to	O
obtain	O
the	O
target	O
compound	O
.	O

The	O
compound	O
has	O
the	O
function	O
of	O
resisting	O
tubercule	O
bacillus	O
.	O

Docetaxel	O
nano	O
-	O
particle	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
docetaxel	O
nano	O
-	O
particle	O
composition	O
for	O
injection	O
administration	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
docetaxel	O
nano	O
-	O
particle	O
composition	O
contains	O
neutral	O
phospholipid	O
and	O
docetaxel	O
,	O
and	O
does	O
not	O
contain	O
negative	O
phospholipid	O
and	O
cholesterol	O
.	O

Method	O
for	O
preparing	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
docetaxel	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
docetaxel	O
,	O
which	O
uses	O
a	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
as	O
a	O
micelle	O
carrier	O
to	O
wrap	O
the	O
docetaxel	O
inside	O
the	O
micelle	O
and	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
dissolving	O
the	O
carrier	O
and	O
the	O
docetaxel	O
into	O
an	O
organic	O
solvent	O
to	O
make	O
the	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
and	O
the	O
docetaxel	O
fully	O
dissolved	O
in	O
the	O
organic	O
solvent	O
,	O
and	O
then	O
preparing	O
aqueous	O
solution	O
of	O
the	O
docetaxel	O
micelle	O
by	O
using	O
the	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
as	O
the	O
carrier	O
;	O
and	O
(	O
2	O
)	O
adding	O
a	O
freeze	O
-	O
drying	O
protective	O
agent	O
into	O
the	O
aqueous	O
solution	O
of	O
the	O
PEO	O
-	O
PPO	O
-	O
PEO	O
block	O
polymer	O
carrying	O
micelle	O
,	O
and	O
filtering	O
,	O
sterilizing	O
and	O
freeze	O
-	O
drying	O
the	O
mixture	O
to	O
obtain	O
freeze	O
-	O
drying	O
preparation	O
of	O
the	O
carrier	O
micelle	O
system	O
.	O

The	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
the	O
docetaxel	O
can	O
increase	O
the	O
dissolubility	O
,	O
metabolic	O
stability	O
and	O
in	O
vivo	O
circulation	O
time	O
of	O
the	O
docetaxel	O
,	O
reduce	O
the	O
toxicity	O
and	O
improve	O
the	O
bioavailability	O
,	O
and	O
is	O
more	O
suitable	O
for	O
clinical	O
application	O
.	O

Novel	O
application	O
of	O
tetrahydrocurcumin	O
The	O
invention	O
provides	O
application	O
of	O
tetrahydrocurcumin	O
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
or	O
/	O
and	O
treating	O
a	O
set	O
of	O
clinical	O
syndromes	O
which	O
are	O
characterized	O
by	O
aggregating	O
a	O
variety	O
of	O
metabolic	O
disturbances	O
in	O
an	O
individual	O
,	O
such	O
as	O
obesity	O
,	O
hypertension	O
,	O
abnormal	O
blood	O
fat	O
,	O
abnormal	O
saccharometabolism	O
,	O
has	O
specific	O
medicinal	O
effect	O
,	O
and	O
is	O
a	O
new	O
treatment	O
medicament	O
which	O
can	O
simultaneously	O
and	O
effectively	O
correct	O
a	O
variety	O
of	O
clinical	O
disturbance	O
factors	O
of	O
MS	O
clinically	O
.	O

External	O
preparation	O
for	O
treating	O
abdominal	O
pain	O
and	O
women	O
's	O
menorrhalgia	O
,	O
preparation	O
method	O
thereof	O
,	O
and	O
quality	O
control	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
compound	O
preparation	O
prepared	O
from	O
lesser	O
galangal	O
rhizome	O
oil	O
,	O
nutgrass	O
galingale	O
rhizome	O
oil	O
and	O
clonidine	O
hydrochloride	O
,	O
which	O
is	O
an	O
external	O
preparation	O
for	O
treating	O
abdominal	O
pain	O
.	O

Clinical	O
tests	O
prove	O
that	O
the	O
prepared	O
emulsifiable	O
paste	O
preparation	O
has	O
good	O
treatment	O
effects	O
on	O
derangement	O
of	O
vitality	O
and	O
blood	O
,	O
and	O
irregular	O
cycles	O
,	O
abdominal	O
pain	O
during	O
menstruation	O
,	O
hypochondriac	O
pain	O
,	O
abdominal	O
distension	O
and	O
the	O
like	O
caused	O
by	O
the	O
derangement	O
of	O
vitality	O
and	O
blood	O
when	O
applied	O
to	O
abdomen	O
.	O

The	O
invention	O
also	O
carries	O
out	O
a	O
series	O
of	O
related	O
experiments	O
such	O
as	O
percutaneous	O
absorption	O
experiments	O
of	O
the	O
clonidine	O
hydrochloride	O
,	O
and	O
determination	O
tests	O
of	O
the	O
clonidine	O
hydrochloride	O
in	O
blood	O
concentration	O
,	O
which	O
further	O
affirms	O
medicinal	O
quality	O
control	O
and	O
clinical	O
effects	O
.	O

Stable	O
fat	O
emulsion	O
containing	O
prostaglandin	O
e1	O
Disclosed	O
is	O
a	O
fat	O
emulsion	O
containing	O
a	O
compound	O
having	O
prostaglandin	O
E1	O
activity	O
,	O
which	O
fat	O
emulsion	O
is	O
hermetically	O
sealed	O
in	O
a	O
glass	O
container	O
and	O
then	O
heat	O
sterilized	O
.	O

The	O
residual	O
amount	O
of	O
prostaglandin	O
E1	O
activity	O
after	O
16-month	O
storage	O
at	O
5	O
DEG	O
C	O
is	O
not	O
less	O
than	O
65	O
%	O
but	O
not	O
more	O
than	O
100	O
%	O
of	O
the	O
prostaglandin	O
E1	O
activity	O
at	O
the	O
beginning	O
of	O
storage	O
.	O

Solid	O
dispersion	O
of	O
dihydropyrimidine	O
compounds	O
and	O
preparation	O
thereof	O
for	O
medical	O
purpose	O
The	O
invention	O
provides	O
solid	O
dispersion	O
of	O
bromophenyl	O
-	O
substituted	O
thiazole	O
dihydropyrimidine	O
,	O
salts	O
thereof	O
or	O
hydrates	O
thereof	O
and	O
a	O
preparation	O
thereof	O
for	O
medical	O
purpose	O
.	O

Dissolutions	O
of	O
the	O
compound	O
of	O
bromophenyl	O
-	O
substituted	O
thiazole	O
dihydropyrimidine	O
,	O
the	O
salts	O
thereof	O
,	O
or	O
the	O
hydrates	O
thereof	O
in	O
various	O
mediums	O
are	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
the	O
preparation	O
is	O
guaranteed	O
.	O

Diaryl	O
pyrimidine	O
derivative	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
diaryl	O
pyrimidine	O
derivative	O
of	O
the	O
general	O
formula	O
I	O
,	O
medicinal	O
salts	O
thereof	O
,	O
hydrates	O
and	O
solvolytes	O
thereof	O
,	O
polycrystal	O
and	O
eutectic	O
thereof	O
,	O
and	O
precursors	O
and	O
derivatives	O
thereof	O
with	O
the	O
same	O
biological	O
functions	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
application	O
of	O
combination	O
containing	O
one	O
or	O
more	O
compounds	O
in	O
relative	O
medicines	O
for	O
treating	O
acquired	O
immune	O
deficiency	O
syndrome	O
and	O
the	O
like	O
,	O
a	O
preparation	O
method	O
and	O
use	O
of	O
the	O
combination	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
compound	O
of	O
the	O
invention	O
not	O
only	O
has	O
excellent	O
biological	O
activity	O
of	O
resisting	O
HIV-1	O
virus	O
and	O
relatively	O
small	O
cytotoxicity	O
,	O
but	O
also	O
shows	O
relatively	O
good	O
inhibitory	O
action	O
to	O
a	O
drug	O
-	O
resistant	O
virus	O
strain	O
L103N+Y181C	O
,	O
can	O
be	O
used	O
as	O
medical	O
candidate	O
resisting	O
the	O
HIV	O
and	O
can	O
be	O
further	O
developed	O
as	O
a	O
medicine	O
resisting	O
AIDS	O
.	O

5-chloro	O
-	O
salicyloyl	O
hydrazine	O
tributyltin	O
chloride	O
coordination	O
compound	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
5-chloro	O
-	O
salicyloyl	O
hydrazine	O
tributyltin	O
chloride	O
coordination	O
compound	O
which	O
has	O
a	O
structural	O
formula	O
as	O
follows	O
.	O

A	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
sequentially	O
adding	O
1.5	O
-	O
2.0	O
mmol	O
of	O
N-1	O
,	O
8-naphthyl	O
diacyl-5-chloro	O
-	O
salicyloyl	O
hydrazine	O
,	O
3.0	O
-	O
4.0	O
mmol	O
of	O
sodium	O
methoxide	O
and	O
50	O
mL	O
of	O
absolute	O
methanol	O
,	O
stirring	O
for	O
0.5	O
hour	O
;	O
then	O
adding	O
2.0	O
-	O
3.0	O
mmol	O
of	O
tributyltin	O
chloride	O
,	O
stirring	O
for	O
6	O
-	O
8	O
hours	O
at	O
normal	O
temperature	O
;	O
filtering	O
,	O
rotationally	O
evaporating	O
filter	O
liquor	O
to	O
obtain	O
a	O
white	O
solid	O
;	O
and	O
then	O
recrystallizing	O
by	O
using	O
methylene	O
dichloride	O
-	O
absolute	O
methanol	O
to	O
obtain	O
a	O
light	O
yellow	O
crystal	O
,	O
i.e.	O
an	O
organotin	O
coordination	O
compound	O
which	O
has	O
higher	O
anticancer	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
raw	O
material	O
for	O
preparing	O
drugs	O
treating	O
liver	O
cancer	O
and	O
cervical	O
cancer	O
.	O

Compared	O
with	O
the	O
traditional	O
commonly	O
-	O
used	O
platinum	O
anticancer	O
drug	O
,	O
the	O
organotin	O
coordination	O
compound	O
has	O
the	O
advantages	O
of	O
higher	O
anticancer	O
activity	O
,	O
good	O
lipid	O
solubility	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
,	O
and	O
the	O
like	O
.	O

Preparation	O
formulations	O
of	O
sodium	O
pyruvate	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
injection	O
and	O
solid	O
agent	O
and	O
production	O
processes	O
thereof	O
The	O
invention	O
relates	O
to	O
preparation	O
formulations	O
of	O
a	O
sodium	O
pyruvate	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
and	O
production	O
processes	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
method	O
and	O
a	O
technology	O
for	O
preparing	O
pyruvate	O
and	O
a	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
made	O
of	O
the	O
pyruvate	O
.	O

The	O
raw	O
materials	O
of	O
sodium	O
pyruvate	O
(	O
containing	O
calcium	O
and	O
potassium	O
)	O
is	O
synthesized	O
by	O
the	O
following	O
steps	O
of	O
:	O
reacting	O
pyruvic	O
acid	O
and	O
sodium	O
carbonate	O
(	O
salts	O
containing	O
organic	O
acid	O
)	O
produced	O
by	O
fermentation	O
and	O
chemical	O
synthesis	O
to	O
generate	O
sodium	O
pyruvate	O
(	O
and	O
corresponding	O
salts	O
)	O
at	O
a	O
reaction	O
temperature	O
of	O
20	O
-	O
90	O
DEG	O
C	O
for	O
60	O
-	O
70	O
min	O
;	O
filtering	O
in	O
vacuum	O
;	O
washing	O
the	O
crystal	O
with	O
ethyl	O
acetate	O
and	O
ethanol	O
for	O
3	O
-	O
5	O
times	O
;	O
drying	O
in	O
vacuum	O
to	O
obtain	O
a	O
product	O
with	O
the	O
purity	O
higher	O
than	O
99	O
percent	O
;	O
and	O
preparing	O
the	O
product	O
into	O
the	O
preparation	O
formulations	O
of	O
a	O
sodium	O
pyruvate	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
.	O

Dendrobii	O
extract	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
substance	O
with	O
a	O
structure	O
as	O
a	O
formula	O
I	O
,	O
wherein	O
R1	O
and	O
R2	O
in	O
the	O
formula	O
I	O
are	O
one	O
material	O
respectively	O
selected	O
from	O
alpha	O
-	O
arabinose	O
(	O
alpha	O
-	O
Ara	O
)	O
,	O
beta	O
-	O
arabinose	O
(	O
beta	O
-	O
Ara	O
)	O
and	O
beta	O
-	O
xylose	O
(	O
beta	O
-	O
Xyl	O
)	O
.	O

New	O
application	O
of	O
cimetidine	O
The	O
invention	O
relates	O
to	O
a	O
new	O
application	O
of	O
cimetidine	O
for	O
trauma	O
hemostasis	O
and	O
for	O
treating	O
periodontitis	O
.	O

The	O
method	O
for	O
trauma	O
hemostasis	O
comprises	O
the	O
following	O
steps	O
:	O
cimetidine	O
is	O
coated	O
on	O
the	O
bleeding	O
wound	O
surface	O
twice	O
each	O
day	O
with	O
dosage	O
thereof	O
being	O
approximately	O
200	O
mg	O
and	O
the	O
wound	O
can	O
be	O
cured	O
two	O
days	O
later	O
;	O
the	O
method	O
for	O
treating	O
periodontitis	O
:	O
one	O
tablet	O
of	O
cimetidine	O
weighing	O
200	O
mg	O
is	O
put	O
into	O
the	O
mouth	O
and	O
the	O
disease	O
can	O
be	O
cured	O
by	O
taking	O
the	O
medicine	O
once	O
a	O
day	O
.	O

The	O
medicine	O
of	O
the	O
invention	O
features	O
rapid	O
treatment	O
speed	O
,	O
good	O
curative	O
effect	O
and	O
radical	O
treatment	O
,	O
thus	O
being	O
widely	O
applied	O
to	O
various	O
groups	O
of	O
people	O
for	O
treating	O
trauma	O
hemostasis	O
and	O
periodontitis	O
.	O

Propofol	O
phosphate	O
for	O
injection	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
propofol	O
phosphate	O
for	O
injection	O
,	O
pharmaceutical	O
salt	O
thereof	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprising	O
the	O
following	O
steps	O
:	O
adding	O
5	O
-	O
98	O
percent	O
of	O
water	O
for	O
injection	O
into	O
a	O
preparation	O
container	O
,	O
adding	O
propofol	O
phosphate	O
and	O
pharmaceutical	O
salt	O
thereof	O
of	O
90	O
-	O
110	O
percent	O
of	O
accurate	O
prescriptions	O
,	O
slowly	O
dropping	O
a	O
pH	O
value	O
regulator	O
while	O
stirring	O
so	O
as	O
to	O
adjust	O
the	O
pH	O
to	O
be	O
6.0	O
-	O
11	O
,	O
adding	O
water	O
to	O
the	O
full	O
volume	O
,	O
then	O
adding	O
medicinal	O
carbon	O
of	O
0.01	O
-	O
1.0	O
percent	O
(	O
W	O
/	O
V	O
)	O
,	O
stirring	O
for	O
15	O
-	O
60	O
minutes	O
,	O
roughly	O
filtering	O
with	O
a	O
sand	O
filter	O
rod	O
to	O
remove	O
the	O
carbon	O
,	O
and	O
finely	O
filtering	O
with	O
a	O
0.22mum	O
microporous	O
membrane	O
until	O
the	O
clarity	O
is	O
qualified	O
;	O
and	O
measuring	O
until	O
the	O
intermediate	O
content	O
is	O
acceptable	O
,	O
fixing	O
the	O
filling	O
amount	O
,	O
sub	O
-	O
packaging	O
into	O
cillin	O
bottles	O
,	O
plugging	O
in	O
plugs	O
by	O
half	O
,	O
freezing	O
and	O
drying	O
samples	O
to	O
control	O
the	O
moisture	O
content	O
being	O
0.1	O
-	O
8	O
percent	O
,	O
pressing	O
the	O
plugs	O
,	O
and	O
capping	O
.	O

Lipoamide	O
series	O
derivates	O
,	O
preparation	O
method	O
and	O
pharmaceutical	O
application	O
thereof	O
The	O
invention	O
provides	O
lipoamide	O
series	O
derivates	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
derivates	O
are	O
characterized	O
in	O
that	O
the	O
molecular	O
structural	O
formula	O
of	O
the	O
compounds	O
are	O
represented	O
as	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
one	O
of	O
substituted	O
phenyl	O
,	O
and	O
substituted	O
pyridyl	O
,	O
naphthyl	O
and	O
biphenyl	O
;	O
and	O
R2	O
is	O
one	O
of	O
hydrogen	O
,	O
C1	O
-	O
5	O
alkanoyl	O
and	O
aroyl	O
.	O

The	O
novel	O
derivates	O
have	O
low	O
toxicity	O
and	O
anti	O
-	O
tumor	O
activity	O
,	O
and	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
functional	O
foods	O
or	O
medicament	O
for	O
preventing	O
or	O
curing	O
tumor	O
diseases	O
.	O

pharmaceutical	O
compounds	O
The	O
invention	O
provides	O
a	O
compound	O
which	O
is	O
a	O
pyrimidine	O
of	O
formula	O
(	O
I	O
)	O
:	O
The	O
compounds	O
are	O
inhibitors	O
of	O
PI3	B
K	I
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth	O
,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	B
kinase	I
such	O
as	O
cancer	O
,	O
immune	O
disorders	O
,	O
cardiovascular	O
disease	O
,	O
viral	O
infection	O
,	O
inflammation	O
,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O

Tolyltriazole	O
derivatives	O
,	O
preparation	O
method	O
thereof	O
and	O
use	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
antifungal	O
medicaments	O
and	O
provides	O
tolyltriazole	O
derivatives	O
having	O
a	O
structure	O
shown	O
as	O
a	O
general	O
formula	O
(	O
1	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

In	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
and	O
also	O
discloses	O
medicinal	O
compositions	O
using	O
thecompounds	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
as	O
active	O
ingredients	O
and	O
the	O
use	O
of	O
the	O
medicinal	O
compositions	O
as	O
antifungal	O
medicaments	O
.	O

Ant	O
and	O
ginseng	O
wine	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
wine	O
,	O
in	O
particular	O
to	O
ant	O
and	O
ginseng	O
wine	O
.	O

The	O
invention	O
has	O
the	O
main	O
technical	O
scheme	O
that	O
1000	O
g	O
of	O
wine	O
comprises	O
1	O
to	O
5	O
g	O
of	O
ginseng	O
,	O
1	O
to	O
5	O
g	O
of	O
lucid	O
ganoderma	O
,	O
1	O
to	O
5	O
g	O
of	O
polyrhachis	O
vicina	O
,	O
0.01	O
to	O
0.1	O
g	O
of	O
stevioside	O
and	O
0.1	O
to	O
1	O
g	O
of	O
flavouring	O
agents	O
.	O

The	O
invention	O
gives	O
full	O
play	O
to	O
the	O
medical	O
value	O
of	O
the	O
ginseng	O
,	O
the	O
lucid	O
ganoderma	O
and	O
the	O
polyrhachis	O
vicina	O
per	O
se	O
,	O
so	O
the	O
ginseng	O
,	O
the	O
lucid	O
ganoderma	O
and	O
the	O
polyrhachis	O
vicina	O
have	O
the	O
pharmacodynamic	O
effects	O
,	O
and	O
in	O
addition	O
,	O
the	O
wine	O
has	O
the	O
effects	O
of	O
clearing	O
and	O
activating	O
the	O
channels	O
and	O
collaterals	O
,	O
nourishing	O
qi	O
,	O
activating	O
blood	O
and	O
regulating	O
the	O
immunity	O
in	O
two	O
ways	O
.	O

Particularly	O
,	O
the	O
wine	O
of	O
the	O
invention	O
is	O
sweet	O
,	O
contains	O
no	O
sugar	O
,	O
does	O
not	O
have	O
medicine	O
flavor	O
,	O
and	O
is	O
applicable	O
to	O
wide	O
range	O
of	O
people	O
.	O

epothilone	O
derivatives	O
The	O
invention	O
relates	O
to	O
Epothilone	O
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
a	O
medicament	O
.	O

Compounds	O
with	O
a	O
combination	O
of	O
cannabinoid	O
-	O
CB1	B
antagonism	O
and	O
serotonin	O
reuptake	O
inhibition	O
This	O
invention	O
relates	O
to	O
compounds	O
with	O
a	O
combination	O
of	O
cannabinoid	O
-	O
CB1antagonism	B
and	O
serotonin	O
reuptake	O
inhibition	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
to	O
methods	O
for	O
preparing	O
the	O
compounds	O
,	O
methods	O
for	O
preparing	O
novel	O
intermediates	O
useful	O
for	O
their	O
synthesis	O
,	O
and	O
methods	O
for	O
preparing	O
compositions	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
uses	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
particularly	O
their	O
use	O
in	O
administering	O
them	O
to	O
patients	O
to	O
achieve	O
a	O
therapeutic	O
effect	O
in	O
psychosis	O
,	O
anxiety	O
,	O
depression	O
,	O
attention	O
deficits	O
,	O
cognitive	O
disorders	O
,	O
obesity	O
,	O
drug	O
dependence	O
,	O
Parkinson	O
's	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
pain	O
disorders	O
,	O
neuropathic	O
pain	O
disorders	O
and	O
sexual	O
disorders	O
.	O

In	O
particular	O
the	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O

Salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Salvianic	O
acid	O
A	O
can	O
be	O
dissolved	O
in	O
water	O
,	O
but	O
the	O
preparation	O
of	O
the	O
salvianic	O
acid	O
A	O
has	O
poor	O
stability	O
,	O
is	O
easy	O
for	O
oxidization	O
,	O
is	O
sensitive	O
to	O
light	O
and	O
heat	O
,	O
and	O
causes	O
content	O
reduction	O
and	O
impurity	O
increase	O
,	O
and	O
the	O
guarantee	O
on	O
the	O
stability	O
is	O
a	O
technical	O
problem	O
.	O

The	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
comprises	O
the	O
salvianic	O
acid	O
A	O
,	O
a	O
pharmacological	O
allowable	O
pH	O
adjusting	O
substance	O
,	O
a	O
stabilizing	O
agent	O
and	O
an	O
excipient	O
.	O

The	O
salvianic	O
acid	O
A	O
in	O
the	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
has	O
the	O
concentration	O
of	O
0.5	O
-	O
2,000	O
mg	O
.	O

The	O
weight	O
part	O
of	O
the	O
pH	O
adjusting	O
substance	O
is	O
the	O
adding	O
dosage	O
when	O
a	O
pH	O
value	O
is	O
adjusted	O
to	O
2.5	O
-	O
7.5	O
,	O
and	O
the	O
stabilizing	O
agent	O
in	O
the	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
has	O
the	O
concentration	O
of	O
1mg-0.5	O
g	O
.	O

The	O
salvianic	O
acid	O
A	O
pharmaceutical	O
composition	O
is	O
used	O
as	O
an	O
injection	O
with	O
the	O
effects	O
of	O
protecting	O
the	O
cardiac	O
muscle	O
,	O
promoting	O
blood	O
circulation	O
,	O
removing	O
blood	O
stasis	O
,	O
resisting	O
bacteria	O
,	O
eliminating	O
inflammation	O
,	O
strengthening	O
body	O
immunity	O
,	O
resisting	O
atherosclerosis	O
,	O
reducing	O
blood	O
fat	O
,	O
resisting	O
platelet	O
aggregation	O
,	O
resisting	O
thrombosis	O
,	O
expanding	O
the	O
coronary	O
artery	O
,	O
treating	O
liver	O
injury	O
,	O
resisting	O
cerebral	O
ischemia	O
injury	O
,	O
resisting	O
tumors	O
,	O
and	O
the	O
like	O
and	O
a	O
therapeutical	O
effect	O
on	O
pulmonary	O
heart	O
disease	O
,	O
psoriasis	O
,	O
altitude	O
disease	O
,	O
and	O
the	O
like	O
.	O

Composition	O
containing	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
The	O
invention	O
discloses	O
a	O
composition	O
containing	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
.	O

The	O
ratio	O
of	O
the	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
to	O
methylmorphine	O
in	O
the	O
mixture	O
is	O
(	O
8	O
-	O
15	O
)	O
:1	O
,	O
based	O
on	O
the	O
weight	O
;	O
the	O
optimal	O
ratio	O
of	O
the	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
to	O
the	O
methylmorphine	O
in	O
the	O
mixture	O
is	O
12:1	O
,	O
based	O
on	O
the	O
weight	O
;	O
and	O
the	O
ratio	O
of	O
the	O
mixture	O
of	O
the	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
and	O
the	O
methylmorphine	O
to	O
poloxamer	O
is	O
25:1	O
,	O
based	O
on	O
the	O
weight	O
.	O

By	O
combining	O
potassium	O
sodium	O
dehydroandroan	O
drographolide	O
succinate	O
and	O
the	O
methylmorphin	O
,	O
the	O
invention	O
greatly	O
improves	O
the	O
antibacterial	O
activity	O
of	O
the	O
medicament	O
and	O
remarkably	O
reduces	O
the	O
side	O
effects	O
.	O

Flavones	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
as	O
alpha1	O
receptor	O
antagonist	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
a	O
preparation	O
method	O
of	O
new	O
flavonoids	O
compounds	O
and	O
application	O
of	O
the	O
new	O
flavonoids	O
compounds	O
as	O
an	O
alpha1	O
receptor	O
antagonist	O
,	O
wherein	O
R1	O
and	O
R2	O
are	O
defined	O
as	O
the	O
specifications	O
.	O

A	O
group	O
with	O
larger	O
polarity	O
is	O
introduced	O
in	O
a	O
flavones	O
structure	O
to	O
enable	O
the	O
polarity	O
of	O
an	O
integral	O
molecule	O
to	O
be	O
increased	O
;	O
meanwhile	O
,	O
the	O
compounds	O
have	O
a	O
certain	O
alkalinity	O
and	O
can	O
be	O
formed	O
into	O
salts	O
with	O
common	O
medicinal	O
acids	O
to	O
ensure	O
that	O
the	O
integral	O
molecule	O
has	O
a	O
certain	O
water	O
-	O
solubility	O
.	O

Preliminary	O
pharmacological	O
tests	O
indicate	O
that	O
the	O
compounds	O
have	O
an	O
alpha1	O
receptor	O
antagonizing	O
function	O
.	O

Preparation	O
method	O
of	O
gossypol	O
acetate	O
intravenous	O
injection	O
fatty	O
emulsion	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
gossypol	O
acetate	O
intravenous	O
injection	O
fatty	O
emulsion	O
.	O

In	O
the	O
method	O
,	O
gossypol	O
acetate	O
is	O
used	O
as	O
an	O
active	O
constituent	O
,	O
ethyl	O
oleate	O
or	O
middle	O
-	O
chain	O
fatty	O
acid	O
triglyceride	O
is	O
used	O
as	O
an	O
oil	O
phase	O
,	O
soya	O
bean	O
lecithin	O
is	O
used	O
as	O
a	O
surface	O
active	O
agent	O
,	O
absolute	O
ethyl	O
alcohol	O
or	O
PEG	O
(	O
Polyethylene	O
Glycol	O
)	O
400	O
is	O
used	O
as	O
a	O
cosurfactant	O
,	O
and	O
sterilized	O
water	O
for	O
injection	O
is	O
used	O
as	O
a	O
water	O
phase	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
dissolving	O
the	O
gossypol	O
acetate	O
in	O
diethyl	O
ether	O
and	O
then	O
mixing	O
with	O
the	O
oil	O
phase	O
,	O
the	O
surface	O
active	O
agent	O
and	O
the	O
cosurfactant	O
;	O
decompressing	O
and	O
evaporating	O
to	O
remove	O
the	O
diethyl	O
ether	O
and	O
preserving	O
at	O
a	O
constant	O
temperature	O
for	O
later	O
use	O
;	O
(	O
2	O
)	O
heating	O
the	O
sterilized	O
water	O
for	O
injection	O
and	O
preserving	O
at	O
a	O
constant	O
temperature	O
for	O
later	O
use	O
;	O
(	O
3	O
)	O
mixing	O
liquids	O
obtained	O
in	O
the	O
steps	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
at	O
a	O
constant	O
temperature	O
of	O
60	O
or	O
70	O
DEG	O
C	O
and	O
stirring	O
until	O
a	O
transparent	O
and	O
homogeneous	O
solution	O
is	O
formed	O
;	O
making	O
the	O
volume	O
constant	O
and	O
then	O
repeatedly	O
homogenizing	O
by	O
using	O
a	O
homogenizer	O
;	O
and	O
filtering	O
by	O
using	O
a	O
millipore	O
filter	O
membrane	O
.	O

Proved	O
by	O
researches	O
,	O
the	O
gossypol	O
acetate	O
intravenousinjection	O
fatty	O
emulsion	O
prepared	O
by	O
using	O
the	O
method	O
has	O
good	O
slow	O
release	O
and	O
targeting	O
effects	O
and	O
good	O
stability	O
.	O

Magnetic	O
lipid	O
nano	O
particle	O
and	O
preparation	O
method	O
The	O
invention	O
provides	O
a	O
magnetic	O
lipid	O
nano	O
particle	O
comprising	O
2.2%-5.9	O
%	O
of	O
ferroferric	O
oxide	O
nano	O
magnetic	O
powder	O
,	O
4.4%-28.6	O
%	O
of	O
oleic	O
acid	O
,	O
66.7%-93.4	O
%	O
of	O
glycerine	O
or	O
stearic	O
acid	O
and	O
0	O
-	O
28.2	O
%	O
of	O
hydrophobic	O
anti	O
-	O
tumor	O
medicaments	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
a	O
stable	O
ferroferric	O
oxide	O
nano	O
dispersing	O
solution	O
by	O
adopting	O
lipid	O
material	O
oleic	O
acid	O
in	O
a	O
liquid	O
state	O
at	O
room	O
temperature	O
as	O
a	O
surfactant	O
,	O
and	O
further	O
injecting	O
an	O
organic	O
solvent	O
dissolved	O
with	O
lipid	O
materials	O
to	O
the	O
ferroferric	O
oxide	O
nano	O
dispersing	O
solution	O
stabilized	O
by	O
the	O
oleic	O
to	O
prepare	O
the	O
magnetic	O
lipid	O
nano	O
particle	O
.	O

The	O
magnetic	O
lipid	O
nano	O
particle	O
containing	O
the	O
medicaments	O
can	O
be	O
prepared	O
by	O
adding	O
the	O
hydrophobic	O
medicament	O
in	O
the	O
organic	O
solvent	O
dissolved	O
with	O
the	O
lipidmaterials	O
.	O

The	O
magnetic	O
lipid	O
nano	O
particle	O
can	O
be	O
further	O
applied	O
to	O
magnetic	O
resonance	O
imaging	O
and	O
targeted	O
therapy	O
of	O
anti	O
-	O
tumor	O
medicaments	O
.	O

Application	O
of	O
baicalein	O
in	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
Parkinson	O
diseases	O
The	O
invention	O
discloses	O
application	O
of	O
baicalein	O
(	O
chemical	O
name	O
:	O
5,6,7-trihydroxyflavone	O
)	O
as	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
in	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
Parkinson	O
diseases	O
.	O

The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
baicalein	O
capable	O
of	O
reducing	O
the	O
trembling	O
frequencies	O
and	O
amplitudes	O
of	O
the	O
Parkinson	O
diseases	O
and	O
improving	O
and	O
treating	O
the	O
symptoms	O
of	O
the	O
Parkinson	O
diseases	O
,	O
in	O
particular	O
to	O
the	O
application	O
of	O
the	O
baicalein	O
capable	O
of	O
protecting	O
dopaminergic	O
neurons	O
from	O
damage	O
so	O
that	O
the	O
pathological	O
changes	O
and	O
the	O
development	O
of	O
the	O
Parkinson	O
diseases	O
can	O
be	O
effectively	O
prevented	O
and	O
treated	O
;	O
and	O
the	O
baicalein	O
exerts	O
the	O
function	O
of	O
protecting	O
the	O
dopaminergic	O
neurons	O
through	O
apoptosis	O
resistance	O
,	O
inflammatory	O
resistance	O
and	O
antioxidation	O
and	O
exerts	O
the	O
function	O
of	O
inhibiting	O
Parkinson	O
symptoms	O
through	O
the	O
function	O
on	O
nervous	O
systems	O
.	O

Anti	O
-	O
aging	O
compound	O
The	O
invention	O
discloses	O
an	O
anti	O
-	O
aging	O
compound	O
which	O
comprises	O
spirulina	O
polysaccharide	O
and	O
folium	O
ginkgo	O
extract	O
,	O
and	O
the	O
mass	O
ratio	O
of	O
the	O
spirulina	O
polysaccharide	O
to	O
the	O
folium	O
ginkgo	O
extract	O
is	O
0.35	O
to	O
1.5:0.35	O
to	O
1.5	O
.	O

The	O
preferred	O
mass	O
ratio	O
of	O
the	O
spirulina	O
polysaccharide	O
to	O
the	O
folium	O
ginkgo	O
extract	O
is	O
2:1	O
.	O

The	O
spirulina	O
polysaccharide	O
is	O
water	O
-	O
soluble	O
heteropolysaccharide	O
,	O
and	O
the	O
content	O
of	O
the	O
polysaccharide	O
thereof	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
93	O
percent	O
.	O

The	O
content	O
of	O
general	O
flavone	O
of	O
the	O
folium	O
ginkgo	O
extract	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
24	O
percent	O
,	O
and	O
the	O
content	O
of	O
terpene	O
lactones	O
thereof	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
6	O
percent	O
.	O

The	O
anti	O
-	O
aging	O
compound	O
comprises	O
the	O
spirulina	O
polysaccharide	O
and	O
the	O
folium	O
ginkgo	O
extract	O
,	O
can	O
play	O
the	O
cooperative	O
and	O
synergistic	O
roles	O
by	O
combination	O
.	O

because	O
both	O
the	O
spirulina	O
polysaccharide	O
and	O
the	O
folium	O
ginkgo	O
extract	O
contain	O
hydroxyl	O
or	O
phenolic	O
hydroxyl	O
structures	O
,	O
thereby	O
significantly	O
improving	O
the	O
anti	O
-	O
aging	O
effect	O
.	O

Medical	O
composition	O
and	O
mixture	O
for	O
treating	O
chicken	O
infectious	O
bursal	O
disease	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
medical	O
composition	O
and	O
a	O
mixture	O
for	O
treating	O
chicken	O
infectious	O
bursal	O
disease	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medical	O
composition	O
(	O
100	O
grams	O
)	O
comprises	O
:	O
1	O
to	O
10	O
grams	O
of	O
astragalus	O
polysaccharides	O
,	O
3	O
to	O
12	O
grams	O
of	O
taurine	O
,	O
4	O
to	O
15	O
grams	O
of	O
aminopyrine	O
,	O
2	O
to	O
10	O
grams	O
of	O
vitamin	O
C	O
,	O
0.04	O
to	O
0.2	O
gram	O
of	O
interferon	O
inducer	O
,	O
5	O
to	O
20	O
grams	O
of	O
alcohol	O
,	O
0.1	O
to	O
0.4	O
gram	O
of	O
sodium	O
benzoate	O
,	O
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
product	O
is	O
characterized	O
by	O
reasonable	O
formula	O
composition	O
,	O
stable	O
physical	O
and	O
chemical	O
properties	O
,	O
accurate	O
dose	O
,	O
quick	O
effect	O
,	O
long	O
-	O
lasting	O
medicament	O
effect	O
,	O
high	O
bioavailability	O
,	O
safe	O
use	O
and	O
exact	O
treatment	O
effect	O
.	O

Aryl	O
ruthenium	O
(	O
11	O
)	O
composition	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
an	O
aryl	O
ruthenium	O
(	O
II	O
)	O
composition	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

In	O
the	O
structural	O
formula	O
(	O
I	O
)	O
of	O
the	O
aryl	O
ruthenium	O
(	O
II	O
)	O
composition	O
,	O
R	O
is	O
chosen	O
from	O
H	O
,	O
C1	O
to	O
C6	O
alkyl	O
or	O
alkyl	O
substituent	O
,	O
phenyl	O
or	O
phenyl	O
substituent	O
,	O
pyridyl	O
or	O
pyridyl	O
substituent	O
,	O
furyl	O
or	O
furyl	O
substituent	O
,	O
pyrrolyl	O
or	O
pyrrolyl	O
substituent	O
and	O
thiazole	O
or	O
thiazole	O
substituent	O
.	O

R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
independently	O
chosen	O
from	O
H	O
,	O
C2	O
to	O
C6	O
alkenyl	O
,	O
C2	O
to	O
C6	O
alkynyl	O
,	O
oxhydryl	O
C1	O
to	O
C6	O
alkyl	O
,	O
amido	O
C1	O
to	O
C6	O
alkyl	O
,	O
halogen	O
,	O
CO2R7	O
,	O
CONR8R9	O
,	O
COR10	O
,	O
SO3H	O
,	O
SO2R11R12	O
,	O
aryloxy	O
,	O
C1	O
to	O
C6	O
alkoxy	O
,	O
C1	O
to	O
C6	O
alkylthio	O
,	O
-N	O
=	O
NR13,NR14R15	O
,	O
aryl	O
or	O
aralkyl	O
.	O

The	O
aryl	O
ruthenium	O
(	O
II	O
)	O
composition	O
can	O
be	O
used	O
to	O
prepare	O
tumor	O
medicine	O
,	O
has	O
good	O
inhibitory	O
action	O
particularly	O
on	O
lung	O
adenocarcinoma	O
and	O
has	O
potential	O
great	O
value	O
in	O
terms	O
of	O
tumor	O
disease	O
clinical	O
treatment	O
application	O
.	O

The	O
formula	O
(	O
I	O
)	O
.	O

Open	O
loop	O
steroid	O
saponin	O
compound	O
with	O
antibacterial	O
activity	O
in	O
sinularia	O
gyrosa	O
The	O
invention	O
relates	O
to	O
two	O
open	O
loop	O
steroid	O
saponin	O
compounds	O
,	O
i.e.	O
Sinularoside	O
A	O
and	O
Sinularoside	O
B	O
with	O
antibacterial	O
activity	O
,	O
separated	O
from	O
sinularia	O
gyrosa	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

The	O
compounds	O
have	O
the	O
chemical	O
structural	O
formulas	O
as	O
the	O
specification	O
,	O
wherein	O
the	O
R	O
group	O
is	O
FORMULA	O
.	O

The	O
in	O
-	O
vitro	O
antibacterial	O
test	O
on	O
the	O
Sinularoside	O
A	O
and	O
the	O
Sinularoside	O
B	O
shows	O
that	O
the	O
compounds	O
have	O
obvious	O
effect	O
for	O
inhibiting	O
fungus	O
,	O
bacteria	O
and	O
algae	O
for	O
test	O
,	O
thereby	O
the	O
two	O
open	O
loop	O
steroid	O
saponin	O
compounds	O
can	O
be	O
used	O
for	O
preparing	O
antibacterial	O
medicaments	O
.	O

The	O
invention	O
provides	O
a	O
new	O
lead	O
compound	O
for	O
developing	O
new	O
antibacterial	O
medicaments	O
and	O
has	O
great	O
significance	O
for	O
developing	O
ocean	O
medicine	O
biological	O
resources	O
in	O
China	O
.	O

American	O
ginseng	O
saponin	O
F6	O
as	O
well	O
as	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
American	O
ginseng	O
saponin	O
F6	O
as	O
well	O
as	O
an	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
,	O
which	O
belong	O
to	O
a	O
new	O
compound	O
as	O
well	O
as	O
an	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
.	O

The	O
extraction	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
taking	O
American	O
ginseng	O
fruit	O
as	O
a	O
raw	O
material	O
,	O
obtaining	O
the	O
new	O
compound	O
through	O
macroporous	O
absorbent	O
resin	O
,	O
normal	O
and	O
reversed	O
-	O
phase	O
silica	O
gel	O
column	O
chromatography	O
and	O
a	O
recrystallization	O
method	O
of	O
fruit	O
juice	O
,	O
wherein	O
the	O
new	O
compound	O
has	O
the	O
chemical	O
name	O
of	O
6-O	O
-	O
beta	O
-	O
D	O
-	O
glucopyranesyl-20-O-	O
[	O
alpha	O
-	O
L	O
-	O
arabinofuranosyl-	O
(	O
1	O
-	O
6	O
)	O
-beta	O
-	O
D	O
-	O
glucopyranosyl	O
]	O
-dammar-24-ene-3beta	O
,	O
6alpha,12beta	O
,	O
20S	O
-	O
tetraol	O
and	O
is	O
abbreviated	O
as	O
the	O
American	O
ginseng	O
saponin	O
F6	O
,	O
and	O
the	O
yield	O
reaches	O
more	O
than	O
0.01	O
%	O
.	O

The	O
American	O
ginseng	O
saponin	O
F6	O
has	O
wide	O
application	O
in	O
preparing	O
antitumor	O
medicaments	O
.	O

8,8-disubstituted-13,13a	O
-	O
dihyrdroberberine	O
derivative	O
as	O
well	O
as	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
8,8-disubstituted-13,13a	O
-	O
dihyrdroberberine	O
derivative	O
with	O
a	O
structure	O
shown	O
as	O
the	O
following	O
general	O
formula	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
and	O
application	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative	O
.	O

The	O
8,8-disubstituted-13,13a	O
-	O
dihyrdroberberine	O
derivative	O
has	O
the	O
effect	O
of	O
promoting	O
the	O
glucose	O
absorption	O
on	O
muscle	O
cells	O
.	O

Proved	O
by	O
in	O
-	O
vivo	O
animal	O
experiments	O
,	O
the	O
compound	O
has	O
the	O
effects	O
on	O
improving	O
the	O
carbohydrate	O
tolerance	O
and	O
the	O
insulin	B
resistance	O
,	O
reducing	O
weight	O
,	O
relieving	O
fatty	O
livers	O
,	O
and	O
the	O
like	O
,	O
has	O
high	O
bioavailability	O
,	O
enhances	O
the	O
in	O
-	O
vivo	O
pesticide	O
effect	O
,	O
and	O
has	O
stable	O
structure	O
under	O
an	O
acidic	O
condition	O
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
type-2	O
diabetes	O
,	O
obesity	O
,	O
fatty	O
livers	O
or	O
complications	O
thereof	O
.	O

Rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
basically	O
contains	O
5	O
to	O
10	O
mg	O
of	O
rosuvastatin	O
calcium	O
,	O
and	O
the	O
balance	O
of	O
sustained	O
-	O
release	O
framework	O
material	O
and	O
other	O
pharmaceutical	O
excipients	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
;	O
and	O
all	O
the	O
materials	O
are	O
proportioned	O
and	O
the	O
preparation	O
is	O
prepared	O
by	O
the	O
preparation	O
method	O
for	O
common	O
tablets	O
,	O
granules	O
or	O
capsules	O
.	O

The	O
rosuvastatin	O
calcium	O
sustained	O
-	O
release	O
preparation	O
prepared	O
by	O
the	O
method	O
avoids	O
adverse	O
reactions	O
such	O
as	O
rhabdomyolysis	O
,	O
proteinuria	O
,	O
nephrosis	O
,	O
kidney	O
failure	O
,	O
hepatotoxicity	O
and	O
the	O
like	O
caused	O
by	O
overdosage	O
of	O
medicaments	O
;	O
meanwhile	O
,	O
due	O
blood	O
concentration	O
and	O
time	O
for	O
treating	O
diseases	O
after	O
the	O
medicaments	O
are	O
taken	O
can	O
be	O
maintained	O
,	O
and	O
the	O
peak	O
valley	O
phenomenon	O
of	O
the	O
blood	O
concentration	O
is	O
effectively	O
avoided	O
.	O

Medicament	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
.	O

The	O
medicament	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
1	O
to	O
20	O
parts	O
of	O
rose	O
,	O
1	O
to	O
20	O
parts	O
of	O
Seville	O
orange	O
flower	O
,	O
1	O
to	O
20	O
parts	O
of	O
Paris	O
polyphylla	O
Sm	O
.	O
,	O
1	O
to	O
20	O
parts	O
of	O
common	O
selfheal	O
fruit	O
-	O
spike	O
,	O
1	O
to	O
20	O
parts	O
of	O
barbed	O
skullcap	O
herb	O
,	O
1	O
to	O
20	O
parts	O
of	O
snakegourd	O
fruit	O
,	O
1	O
to	O
20	O
parts	O
of	O
seaweed	O
,	O
1	O
to	O
20	O
parts	O
of	O
kelp	O
,	O
1	O
to	O
20	O
parts	O
of	O
frankincense	O
,	O
1	O
to	O
20	O
parts	O
of	O
myrrh	O
,	O
1	O
to	O
20	O
parts	O
of	O
tangerine	O
leaves	O
,	O
1	O
to	O
20	O
parts	O
of	O
green	O
tangerine	O
peel	O
,	O
1	O
to	O
20	O
parts	O
of	O
thunberg	O
fritillary	O
bulb	O
,	O
1	O
to	O
20	O
parts	O
of	O
common	O
burreed	O
rhizome	O
,	O
1	O
to	O
20	O
parts	O
of	O
zedoary	O
,	O
1	O
to	O
20	O
parts	O
of	O
Indian	O
iphigenia	O
bulb	O
,	O
1	O
to	O
20	O
parts	O
of	O
India	O
madder	O
root	O
,	O
1	O
to	O
20	O
parts	O
of	O
edible	O
alcohol	O
of	O
which	O
the	O
content	O
is	O
over	O
95	O
percent	O
.	O

The	O
medicament	O
can	O
be	O
absorbed	O
by	O
spleen	O
and	O
stomach	O
through	O
oral	O
administration	O
or	O
absorbed	O
by	O
skin	O
through	O
external	O
application	O
and	O
also	O
can	O
be	O
absorbed	O
through	O
the	O
combination	O
of	O
oral	O
administration	O
and	O
external	O
administration	O
.	O

The	O
medicament	O
of	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
reasonable	O
formula	O
,	O
simple	O
compatibility	O
,	O
clear	O
treatment	O
effect	O
and	O
addressing	O
both	O
symptoms	O
and	O
root	O
causes	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
medicament	O
.	O

Novel	O
formulation	O
of	O
piperazine	O
ferulate	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
injection	O
of	O
piperazine	O
ferulate	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
novel	O
formulation	O
of	O
the	O
piperazine	O
ferulate	O
is	O
prepared	O
by	O
the	O
steps	O
of	O
dissolving	O
piperazine	O
ferulate	O
as	O
a	O
medicine	O
component	O
into	O
a	O
solvent	O
and	O
regulating	O
the	O
pH	O
value	O
to	O
be	O
5.0	O
-	O
8.0	O
with	O
a	O
pH	O
regulating	O
agent	O
so	O
that	O
the	O
piperazine	O
ferulate	O
is	O
fully	O
dissolved	O
to	O
prepare	O
an	O
injection	O
.	O

The	O
content	O
of	O
the	O
piperazine	O
ferulate	O
in	O
the	O
novel	O
formulation	O
is	O
27	O
-	O
200mg	O
/	O
ml	O
,	O
and	O
the	O
agent	O
is	O
the	O
water	O
of	O
injection	O
.	O

The	O
invention	O
broadens	O
the	O
clinical	O
application	O
range	O
of	O
the	O
piperazine	O
ferulate	O
,	O
has	O
the	O
characteristics	O
of	O
high	O
medicine	O
dissolubility	O
,	O
high	O
bioavailability	O
,	O
rapid	O
medicine	O
administration	O
,	O
more	O
quick	O
effect	O
-	O
taking	O
,	O
stronger	O
treatment	O
effect	O
,	O
and	O
the	O
like	O
,	O
is	O
especially	O
suitable	O
for	O
preventing	O
and	O
treating	O
patients	O
suffering	O
from	O
heavy	O
cerebral	O
infarction	O
,	O
nephroma	O
,	O
coronary	O
heart	O
disease	O
,	O
vascular	O
complication	O
in	O
diabetes	O
mellitus	O
and	O
dysphagia	O
,	O
overcomes	O
the	O
problem	O
of	O
low	O
dissolubility	O
of	O
the	O
piperazine	O
ferulate	O
in	O
the	O
prior	O
art	O
,	O
and	O
realizes	O
the	O
solubilization	O
of	O
the	O
piperazine	O
ferulate	O
by	O
regulating	O
the	O
pH	O
value	O
with	O
the	O
pH	O
regulating	O
agent	O
,	O
wherein	O
at	O
least	O
500	O
mg	O
of	O
piperazine	O
ferulate	O
can	O
be	O
dissolved	O
in	O
10mlof	O
water	O
solution	O
with	O
pH	O
value	O
of	O
5.5	O
.	O

High	O
-	O
release	O
erythrocin	O
enteric	O
-	O
coated	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
high	O
-	O
release	O
erythrocin	O
enteric	O
-	O
coated	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
field	O
of	O
antibiotic	O
drugs	O
.	O

The	O
enteric	O
-	O
coated	O
tablet	O
contains	O
two	O
parts	O
:	O
a	O
substrate	O
and	O
an	O
enteric	O
coating	O
,	O
wherein	O
the	O
substrate	O
contains	O
the	O
following	O
components	O
:	O
12.5	O
(	O
BOU	O
)	O
of	O
erythrocin	O
,	O
2.5	O
-	O
3.0	O
kg	O
of	O
starch	O
,	O
0.21	O
-	O
0.25	O
kg	O
of	O
Tween-80	O
,	O
1	O
-	O
1.5	O
kg	O
of	O
hydroxy	O
propyl	O
cellulose	O
,	O
0.3	O
-	O
0.5	O
kg	O
of	O
magnesium	O
stearate	O
and	O
0.8	O
-	O
1.5	O
kg	O
of	O
talcum	O
powder	O
by	O
the	O
dosage	O
of	O
100	O
thousand	O
finished	O
erythrocin	O
enteric	O
-	O
coated	O
tablets	O
;	O
the	O
enteric	O
-	O
coated	O
tablet	O
contains	O
the	O
following	O
components	O
of	O
:	O
0.81	O
-	O
0.84	O
kg	O
of	O
polyacrylic	O
resin	O
(	O
II	O
)	O
,	O
15	O
-	O
16	O
kg	O
of	O
ethanol	O
the	O
concentration	O
of	O
more	O
than	O
90	O
percent	O
,	O
0.16	O
-	O
0.2	O
kg	O
of	O
Tween-80	O
,	O
0.16	O
-	O
0.20	O
kg	O
of	O
diethyl	O
phthalate	O
,	O
0.48	O
-	O
0.60	O
kg	O
of	O
castor	O
oil	O
and	O
0.59	O
-	O
0.70	O
kg	O
of	O
talcum	O
powder	O
by	O
the	O
dosage	O
of	O
100	O
thousand	O
finished	O
erythrocin	O
enteric	O
-	O
coated	O
tablets	O
.	O

The	O
average	O
release	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
prepared	O
by	O
adopting	O
the	O
prescription	O
of	O
the	O
substrate	O
and	O
the	O
enteric	O
coating	O
is	O
not	O
less	O
than	O
90	O
percent	O
in	O
drug	O
effect	O
and	O
is	O
far	O
higher	O
than	O
the	O
national	O
pharmacopeia	O
standard	O
,	O
and	O
the	O
enteric	O
-	O
coated	O
tablet	O
can	O
be	O
stably	O
released	O
;	O
the	O
drug	O
action	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
higher	O
than	O
the	O
national	O
pharmacopeia	O
standard	O
in	O
the	O
period	O
of	O
validity	O
;	O
the	O
surface	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
fine	O
and	O
smooth	O
and	O
glossy	O
in	O
appearance	O
;	O
and	O
the	O
effectiveness	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
not	O
influenced	O
after	O
being	O
stored	O
for	O
a	O
long	O
time	O
.	O

Plaster	O
for	O
treating	O
bone	O
fracture	O
The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
bone	O
fracture	O
,	O
mainly	O
comprising	O
the	O
following	O
drugs	O
in	O
parts	O
by	O
weight	O
:	O
20	O
-	O
40	O
parts	O
of	O
corydalis	O
tuber	O
,	O
20	O
-	O
30	O
parts	O
of	O
safflower	O
,	O
20	O
-	O
40	O
parts	O
of	O
frankincense	O
,	O
20	O
-	O
30	O
parts	O
of	O
myrrh	O
,	O
15	O
-	O
30	O
parts	O
of	O
scaly	O
anteater	O
,	O
20	O
-	O
40	O
parts	O
of	O
scorpio	O
,	O
20	O
-	O
40	O
parts	O
of	O
panax	O
notoginseng	O
,	O
10	O
-	O
20	O
parts	O
of	O
crinis	O
ustus	O
,	O
10	O
-	O
20	O
parts	O
of	O
eupolyphaga	O
,	O
20	O
-	O
40	O
parts	O
of	O
drgonsbone	O
,	O
20	O
-	O
40	O
parts	O
of	O
earthworm	O
,	O
20	O
-	O
40	O
parts	O
of	O
pyrite	O
,	O
20	O
-	O
40	O
parts	O
of	O
sapanwood	O
,	O
20	O
-	O
40	O
parts	O
of	O
rhizoma	O
drynariae	O
,	O
10	O
-	O
30	O
parts	O
of	O
dragon	O
's	O
blood	O
,	O
20	O
-	O
40	O
parts	O
of	O
peach	O
kernel	O
and	O
20	O
-	O
40	O
parts	O
of	O
angelica	O
.	O

The	O
plaster	O
for	O
treating	O
bone	O
fracture	O
has	O
the	O
effects	O
of	O
dredging	O
the	O
channel	O
,	O
stopping	O
bleeding	O
,	O
promoting	O
the	O
circulation	O
of	O
Qi	O
,	O
relieving	O
swelling	O
,	O
stopping	O
pain	O
,	O
removing	O
heat	O
from	O
the	O
heart	O
to	O
restore	O
to	O
consciousness	O
,	O
reuniting	O
bones	O
and	O
muscles	O
,	O
circulating	O
blood	O
and	O
promoting	O
the	O
quick	O
formation	O
of	O
poroma	O
and	O
has	O
obvious	O
treatment	O
effect	O
and	O
little	O
adverse	O
reaction	O
.	O

Substituted	O
benzodihydropyran	O
derivatives	O
and	O
anti	O
-	O
tumor	O
application	O
thereof	O
The	O
invention	O
discloses	O
substituted	O
benzodihydropyran	O
derivatives	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
hydrogen	O
atom	O
or	O
C1-C6	O
straight	O
chain	O
or	O
branched	O
alkane	O
,	O
methoxy	O
acyl	O
isopropyl	O
or	O
methoxy	O
acyl	O
oxy	O
isopropyl	O
,	O
methoxy	O
acyl	O
isobutyl	O
or	O
methoxy	O
acyl	O
oxy	O
isobutyl	O
,	O
methoxy	O
acyl	O
tertiary	O
butyl	O
or	O
methoxy	O
acyl	O
cyclobutyl	O
;	O
and	O
n	O
is	O
1	O
-	O
5	O
,	O
and	O
is	O
represented	O
as	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
,	O
which	O
comprises	O
a	O
step	O
of	O
applying	O
a	O
composition	O
containing	O
the	O
compounds	O
.	O

The	O
compounds	O
designed	O
by	O
the	O
pharmacokinetics	O
have	O
improved	O
therapeutic	O
index	O
,	O
are	O
strong	O
inhibitors	O
for	O
cancer	O
cell	O
growth	O
,	O
and	O
have	O
high	O
anti	O
-	O
cancer	O
activity	O
and	O
extremely	O
small	O
side	O
effect	O
.	O

Antibacterial	O
agent	O
The	O
invention	O
relates	O
to	O
an	O
antibacterial	O
agent	O
,	O
belonging	O
to	O
the	O
field	O
of	O
hygiene	O
,	O
wherein	O
the	O
antibacterial	O
agent	O
comprises	O
the	O
following	O
active	O
components	O
:	O
tetracycline	O
and	O
bacillus	O
subtilis	O
;	O
the	O
ratio	O
of	O
the	O
tetracycline	O
to	O
the	O
bacillus	O
subtilis	O
in	O
the	O
antibacterial	O
agent	O
is	O
(	O
0.18	O
-	O
6.0	O
)	O
mu	O
g:	O
(	O
2.0	O
-	O
6.0	O
)	O
*10	O
to	O
the	O
power	O
of	O
[	O
6	O
]	O
cfu	O
;	O
and	O
the	O
antibacterial	O
agent	O
can	O
be	O
used	O
for	O
inhibiting	O
and	O
killing	O
staphylococcus	O
aurous	O
,	O
vibrio	O
,	O
escherichia	O
coli	O
,	O
salmonella	O
,	O
proteus	O
bacterial	O
and	O
fusarium	O
,	O
etc	O
.	O

The	O
antibacterial	O
agent	O
provided	O
by	O
the	O
invention	O
has	O
the	O
function	O
of	O
inhibiting	O
the	O
quorum	O
sensing	O
molecules	O
by	O
the	O
bacillus	O
subtilis	O
for	O
the	O
first	O
time	O
,	O
has	O
a	O
synergistic	O
effect	O
together	O
with	O
the	O
tetracycline	O
,	O
greatly	O
improves	O
the	O
performance	O
of	O
the	O
antibacterial	O
agent	O
for	O
killing	O
bacteria	O
,	O
obviously	O
lowers	O
the	O
threshold	O
value	O
of	O
the	O
efficient	O
dosage	O
of	O
the	O
tetracycline	O
and	O
prevents	O
the	O
tolerance	O
during	O
the	O
antibacterial	O
process	O
;	O
the	O
antibacterial	O
agent	O
also	O
has	O
effective	O
antibacterial	O
effect	O
,	O
less	O
side	O
effect	O
to	O
the	O
environment	O
and	O
less	O
toxic	O
side	O
effect	O
.	O

RGD	O
peptide	O
-	O
epimedium	O
flavone	O
combination	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
an	O
RGD	O
peptide	O
-	O
epimedium	O
flavone	O
combination	O
synthesized	O
by	O
combining	O
two	O
structural	O
units	O
of	O
RGD	O
peptides	O
and	O
epimedium	O
flavone	O
which	O
have	O
pharmacological	O
activities	O
of	O
different	O
action	O
mechanisms	O
on	O
osseous	O
metabolic	O
diseases	O
,	O
and	O
also	O
provides	O
a	O
synthesis	O
method	O
thereof	O
.	O

The	O
compound	O
of	O
the	O
invention	O
has	O
two	O
receptor	O
combining	O
sites	O
and	O
simultaneously	O
has	O
the	O
capability	O
of	O
combining	O
estrogen	O
receptors	O
of	O
icaritin	O
and	O
the	O
capability	O
of	O
combining	O
integrins	B
alphaVbeta3	I
of	O
RGD	O
,	O
and	O
the	O
capabilities	O
of	O
combining	O
the	O
two	O
different	O
receptors	O
can	O
produce	O
a	O
synergistic	O
effect	O
to	O
greatly	O
improve	O
the	O
curative	O
activity	O
of	O
the	O
medicament	O
on	O
osteoporosis	O
and	O
osseous	O
metabolic	O
diseases	O
.	O

The	O
synthesis	O
method	O
has	O
the	O
advantages	O
of	O
high	O
yield	O
,	O
high	O
synthesis	O
speed	O
and	O
easy	O
purification	O
of	O
products	O
.	O

Inhibitors	O
for	O
matrix	B
metalloproteinases	I
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
Inhibitors	O
for	O
matrix	B
metalloproteinases	I
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
.	O

The	O
inhibitors	O
for	O
matrix	B
metalloproteinases	I
have	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
W	O
,	O
X1	O
,	O
X2	O
,	O
R1	O
,	O
R2	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

They	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
regulated	O
by	O
matrix	B
metalloproteinases	I
,	O
in	O
particular	O
corneal	O
ulceration	O
,	O
pulmonary	O
emphysema	O
or	O
dermal	O
ulceration	O
resulted	O
from	O
chemical	O
injury	O
,	O
or	O
pulmonary	O
emphysema	O
caused	O
by	O
smoking	O
or	O
drowning	O
.	O

Protecting	O
colloid	O
for	O
gastroenteric	O
mucosa	O
The	O
invention	O
relates	O
to	O
protecting	O
colloid	O
for	O
gastroenteric	O
mucosa	O
,	O
belonging	O
to	O
the	O
field	O
of	O
biomedical	O
preparation	O
and	O
comprising	O
a	O
collagenous	O
substance	O
,	O
an	O
acidifying	O
or	O
alkalizing	O
agent	O
,	O
a	O
cross	O
-	O
linking	O
agent	O
and	O
an	O
adhesive	O
based	O
on	O
the	O
weight	O
ratio	O
of	O
1:0.01	O
-	O
0.3:0.1	O
-	O
0.5	O
,	O
wherein	O
the	O
dosage	O
of	O
the	O
acidifying	O
or	O
alkalizing	O
agent	O
is	O
proper	O
when	O
the	O
pH	O
value	O
is	O
regulated	O
to	O
6.5	O
-	O
8.5	O
.	O

Under	O
the	O
action	O
of	O
gastric	O
acid	O
,	O
the	O
cross	O
-	O
linking	O
agent	O
in	O
the	O
protecting	O
colloid	O
can	O
be	O
released	O
so	O
as	O
to	O
form	O
a	O
colloid	O
membrane	O
on	O
the	O
surface	O
of	O
ulcer	O
,	O
avoid	O
the	O
gastroenteric	O
mucosa	O
from	O
being	O
digested	O
by	O
gastric	O
acid	O
and	O
pepsase	O
and	O
promote	O
healing	O
of	O
the	O
ulcer	O
.	O

Animal	O
tests	O
show	O
that	O
the	O
protecting	O
colloid	O
can	O
greatly	O
lower	O
the	O
ulcer	O
formation	O
caused	O
by	O
absolute	O
ethyl	O
alcohol	O
and	O
hydrochloric	O
acid	O
,	O
inhibit	O
ulcer	O
formation	O
and	O
have	O
a	O
protecting	O
effect	O
on	O
injury	O
of	O
the	O
mice	O
gastroenteric	O
mucosa	O
caused	O
by	O
absolute	O
ethyl	O
alcohol	O
and	O
hydrochloric	O
acid	O
.	O

Therefore	O
,	O
the	O
protecting	O
colloid	O
is	O
used	O
for	O
protecting	O
and	O
curing	O
gastroenteric	O
mucosa	O
ulcer	O
for	O
patients	O
.	O

Aloe	O
oculentum	O
and	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
aloe	O
oculentum	O
and	O
a	O
preparation	O
method	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
eyedrops	O
.	O

The	O
aloe	O
oculentum	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
medicaments	O
and	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
80	O
to	O
90	O
parts	O
of	O
aloe	O
gel	O
,	O
1	O
to	O
5	O
parts	O
of	O
aloin	O
,	O
0.1	O
to	O
1	O
part	O
of	O
alomycin	O
,	O
0.1	O
to	O
0.3	O
part	O
of	O
carbomer	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
sodium	O
hyaluronate	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
anthraquinone	O
compounds	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
cinnamate	O
and	O
0.2	O
to	O
0.5	O
part	O
of	O
free	O
amino	O
acid	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
extracting	O
the	O
aloe	O
gel	O
from	O
aloe	O
barbadensis	O
by	O
adopting	O
a	O
freezing	O
stabilization	O
method	O
,	O
and	O
converting	O
the	O
aloe	O
gel	O
into	O
aloe	O
gel	O
powder	O
;	O
and	O
mixing	O
the	O
aloe	O
gel	O
powder	O
and	O
water	O
for	O
injection	O
under	O
the	O
acidic	O
condition	O
or	O
neutral	O
condition	O
,	O
of	O
which	O
the	O
PH	O
is	O
between	O
5.5	O
and	O
7.5	O
,	O
mixing	O
the	O
mixture	O
and	O
the	O
aloin	O
,	O
the	O
alomycin	O
,	O
the	O
carbomer	O
,	O
the	O
sodium	O
hyaluronate	O
,	O
the	O
anthraquinone	O
compounds	O
,	O
the	O
cinnamate	O
and	O
the	O
free	O
amino	O
acid	O
,	O
stirring	O
uniformly	O
,	O
regulating	O
the	O
pH	O
value	O
to	O
be	O
neutral	O
,	O
and	O
subpackaging	O
and	O
disinfecting	O
.	O

The	O
aloe	O
oculentum	O
can	O
treat	O
eye	O
diseases	O
such	O
as	O
pterygium	O
,	O
conjunctivochalasis	O
,	O
corneal	O
nebula	O
,	O
chronic	O
dacryocystitis	O
,	O
eye	O
itching	O
,	O
xerophthalmia	O
and	O
the	O
like	O
.	O

Hydroxyl	O
whole	O
-	O
protection	O
didecyl	O
quaternary	O
ammonium	O
with	O
anti	O
-	O
tumor	O
activity	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
synthesis	O
of	O
an	O
emodin	O
derivant	O
with	O
an	O
anti	O
-	O
tumor	O
function	O
,	O
in	O
particular	O
to	O
a	O
hydroxyl	O
whole	O
-	O
protection	O
didecyl	O
quaternary	O
ammonium	O
with	O
anti	O
-	O
tumor	O
activity	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
didecyl	O
quaternary	O
ammonium	O
is	O
decyldimethylchlorosilane-	O
[	O
2-	O
(	O
4,5,7-trimethoxy-9,10-anthraquinonyl	O
)	O
methyl	O
]	O
.	O

The	O
preparation	O
method	O
is	O
characterized	O
by	O
taking	O
emodin	O
as	O
a	O
raw	O
material	O
to	O
carry	O
out	O
a	O
series	O
of	O
synthetic	O
reaction	O
.	O

The	O
emodin	O
derivant	O
of	O
the	O
invention	O
has	O
proliferation	O
inhibition	O
action	O
of	O
different	O
degrees	O
on	O
liver	O
cancer	O
HepG2	O
,	O
gastric	O
cancer	O
BGC	O
,	O
neuroma	O
SH	O
-	O
SY5Y	O
,	O
gastric	O
cancer	O
AGS	O
,	O
cervical	O
cancer	O
Hela	O
and	O
the	O
like	O
as	O
well	O
as	O
normal	O
human	O
embryonic	O
lung	O
fibroblast	O
HELP	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
treating	O
cancers	O
.	O

Irinotecan	O
nano	O
circulating	O
liposome	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
novel	O
Irinotecan	O
carrier	O
which	O
is	O
circulating	O
nano	O
liposome	O
and	O
a	O
novel	O
preparation	O
method	O
thereof	O
which	O
is	O
an	O
ethanol	O
injection	O
-	O
ammonium	O
sulfate	O
active	O
medicament	O
-	O
loading	O
method	O
.	O

The	O
preparation	O
process	O
comprises	O
:	O
a	O
,	O
dissolving	O
a	O
lipid	O
material	O
for	O
forming	O
the	O
liposome	O
in	O
ethanol	O
to	O
prepare	O
solution	O
;	O
b	O
,	O
dissolving	O
a	O
polyethylene	O
glycol	O
compound	O
in	O
solution	O
of	O
ammonium	O
sulfate	O
to	O
prepare	O
a	O
hydration	O
medium	O
;	O
c	O
,	O
injecting	O
solution	O
obtained	O
by	O
the	O
step	O
a	O
into	O
the	O
hydration	O
medium	O
obtained	O
by	O
the	O
step	O
b	O
with	O
stirring	O
in	O
a	O
water	O
bath	O
,	O
stirring	O
at	O
a	O
constant	O
temperature	O
for	O
a	O
certain	O
period	O
under	O
a	O
condition	O
of	O
introducing	O
N2	O
to	O
form	O
circulating	O
blank	O
liposome	O
;	O
d	O
,	O
dialyzing	O
the	O
blank	O
liposome	O
obtained	O
by	O
the	O
step	O
c	O
in	O
physiological	O
saline	O
;	O
and	O
e	O
,	O
adding	O
solution	O
of	O
Irinotecan	O
into	O
the	O
blank	O
liposome	O
,	O
regulating	O
the	O
pH	O
value	O
of	O
an	O
external	O
phase	O
,	O
and	O
performing	O
incubation	O
and	O
medicament	O
loading	O
at	O
a	O
certain	O
temperature	O
to	O
obtain	O
the	O
Irinotecan	O
circulating	O
nano	O
liposome	O
.	O

The	O
process	O
is	O
simple	O
,	O
the	O
particle	O
size	O
is	O
80	O
to	O
150	O
nanometers	O
,	O
the	O
coating	O
rate	O
is	O
over	O
95	O
percent	O
,	O
the	O
sterile	O
preparation	O
can	O
be	O
obtained	O
easily	O
,	O
and	O
an	O
industrialization	O
requirement	O
is	O
met	O
.	O

Intranasal	O
administration	O
encapsulated	O
based	O
on	O
polyelectrolyte	O
capsule	O
A	O
micron	O
and	O
nanometer	O
encapsulated	O
technology	O
synthesized	O
by	O
step	O
-	O
by	O
-	O
step	O
shells	O
can	O
be	O
applied	O
for	O
intranasal	O
and	O
pulmonary	O
administration	O
.	O

Liquid	O
,	O
gas	O
or	O
solid	O
encapsulation	O
can	O
form	O
an	O
aerosol	O
in	O
spray	O
treatment	O
.	O

Different	O
shell	O
compositions	O
create	O
stability	O
,	O
compatibility	O
,	O
and	O
degradation	O
and	O
releasing	O
attributes	O
.	O

A	O
plurality	O
of	O
substances	O
comprising	O
the	O
compound	O
widely	O
used	O
for	O
intranasal	O
administration	O
can	O
be	O
encapsulated	O
,	O
or	O
are	O
administrated	O
through	O
spray	O
capsules	O
.	O

Medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
and	O
a	O
preparation	O
method	O
thereof	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicaments	O
.	O

The	O
orally	O
taken	O
medicament	O
is	O
prepared	O
from	O
routine	O
auxiliary	O
materials	O
and	O
the	O
following	O
raw	O
medicinal	O
materials	O
in	O
part	O
by	O
weight	O
:	O
80	O
to	O
120	O
parts	O
of	O
scutellaria	O
total	O
flavonoid	O
,	O
60	O
to	O
100	O
parts	O
of	O
paeonia	O
saponins	O
,	O
60	O
to	O
120	O
parts	O
of	O
liquritin	O
and	O
proper	O
amount	O
of	O
auxiliary	O
materials	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
the	O
scutellaria	O
total	O
flavonoid	O
by	O
performing	O
water	O
extraction	O
on	O
scutellaria	O
;	O
preparing	O
the	O
paeonia	O
saponins	O
by	O
performing	O
water	O
extraction	O
on	O
paeonia	O
;	O
preparing	O
the	O
liquritin	O
by	O
performing	O
percolation	O
on	O
liquorice	O
;	O
and	O
preparing	O
the	O
general	O
formulation	O
by	O
blending	O
the	O
extracts	O
and	O
the	O
auxiliary	O
materials	O
,	O
and	O
obtaining	O
the	O
medicament	O
.	O

The	O
medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
active	O
ingredient	O
content	O
,	O
stable	O
quality	O
,	O
safety	O
,	O
clear	O
treatment	O
effect	O
and	O
convenience	O
.	O

Compared	O
with	O
the	O
traditional	O
medicaments	O
,	O
the	O
orally	O
taken	O
medicament	O
greatly	O
reduces	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
medicaments	O
and	O
obviously	O
improves	O
the	O
treatment	O
effect	O
.	O

Method	O
for	O
establishing	O
experimental	O
model	O
for	O
subclinical	O
hepatic	O
encephalopathy	O
(	O
SHE	O
)	O
The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
biomedicine	O
and	O
particularly	O
relates	O
to	O
a	O
method	O
for	O
establishing	O
an	O
experimental	O
model	O
for	O
subclinical	O
hepatic	O
encephalopathy	O
(	O
SHE	O
)	O
.	O

In	O
the	O
method	O
of	O
the	O
invention	O
,	O
an	O
experimental	O
rat	O
liver	O
cirrhosis	O
model	O
caused	O
by	O
composite	O
factors	O
such	O
as	O
high	O
fat	O
and	O
low	O
protein	O
of	O
carbon	O
tetrachloride	O
is	O
subjected	O
to	O
learning	O
,	O
recall	O
test	O
and	O
evoked	O
potential	O
test	O
of	O
a	O
nervous	O
system	O
and	O
a	O
brain	O
function	O
and	O
the	O
learning	O
,	O
memory	O
and	O
spatial	O
cognition	O
impairment	O
and	O
nerve	O
electrophysiology	O
test	O
abnormity	O
of	O
the	O
model	O
are	O
monitored	O
,	O
so	O
that	O
the	O
method	O
achieves	O
statistical	O
significance	O
compared	O
with	O
the	O
normal	O
comparison	O
group	O
and	O
a	O
relatively	O
ideal	O
SHE	O
animal	O
model	O
is	O
established	O
.	O

An	O
established	O
experiment	O
animal	O
model	O
provides	O
a	O
platform	O
for	O
the	O
research	O
,	O
diagnosis	O
and	O
treatment	O
of	O
SHE	O
and	O
has	O
high	O
clinically	O
practical	O
meaning	O
and	O
value	O
.	O

Compound	O
tincture	O
for	O
treating	O
external	O
acoustic	O
meatus	O
fungal	O
infection	O
The	O
invention	O
discloses	O
a	O
compound	O
tincture	O
for	O
treating	O
external	O
acoustic	O
meatus	O
fungal	O
infection	O
.	O

The	O
compound	O
tincture	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
1.5	O
to	O
5.5	O
parts	O
of	O
densefruit	O
pittany	O
root	O
-	O
bark	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
bark	O
of	O
Chinese	O
redbud	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
palemane	O
prunella	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
Chinese	O
honeylocust	O
spine	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
angelica	O
dahurica	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
platycodon	O
root	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
safflower	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
szechuan	O
lovage	O
rhizome	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
natural	O
indigo	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
wild	O
chrysanthemum	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
dandelion	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
borax	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
borneol	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
peppermint	O
oil	O
and	O
100	O
parts	O
of	O
ethanol	O
.	O

The	O
inventor	O
studies	O
assiduously	O
under	O
the	O
condition	O
that	O
the	O
prior	O
art	O
is	O
not	O
perfect	O
.	O

The	O
compound	O
tincture	O
has	O
unique	O
therapeutic	O
effects	O
of	O
dispelling	O
wind	O
and	O
removing	O
dampness	O
,	O
detoxifying	O
and	O
relieving	O
itching	O
,	O
softening	O
and	O
dilating	O
blood	O
vessels	O
,	O
promoting	O
regeneration	O
of	O
necrotic	O
nerve	O
cells	O
and	O
treating	O
external	O
acoustic	O
meatus	O
mycosis	O
,	O
relieves	O
the	O
pain	O
of	O
patients	O
and	O
does	O
not	O
have	O
toxic	O
or	O
side	O
effect	O
.	O

Microbial	O
feed	O
additive	O
for	O
treating	O
piglet	O
yellow	O
and	O
white	O
dysentery	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
microbial	O
feed	O
additive	O
for	O
treating	O
piglet	O
yellow	O
and	O
white	O
dysentery	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
additive	O
is	O
prepared	O
from	O
the	O
main	O
components	O
of	O
bacillus	O
subtilis	O
and	O
saccharomyces	O
cerevisiae	O
which	O
are	O
mixed	O
with	O
baking	O
soda	O
,	O
xylo	O
-	O
oligosaccharides	O
,	O
vitamins	O
,	O
vitamin	O
complex	O
,	O
glucose	O
and	O
the	O
like	O
according	O
to	O
certain	O
proportions	O
.	O

The	O
microbial	O
feed	O
additive	O
has	O
the	O
following	O
advantages	O
that	O
:	O
the	O
active	O
substances	O
such	O
as	O
subtilin	O
,	O
polymyxin	O
,	O
nystatin	O
,	O
gramicidin	O
and	O
the	O
like	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
bacillus	O
subtilis	O
have	O
obvious	O
inhibitionto	O
pathogens	O
or	O
conditioned	O
pathogens	O
of	O
endogenous	O
infection	O
;	O
cell	O
wall	O
polysaccharides	O
of	O
the	O
saccharomyces	O
cerevisiae	O
and	O
a	O
great	O
amount	O
of	O
nucleotides	O
and	O
bioactive	O
peptides	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
saccharomyces	O
cerevisiae	O
can	O
improve	O
the	O
immunity	O
of	O
animals	O
,	O
and	O
a	O
compound	O
taste	O
substance	O
is	O
also	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
saccharomyces	O
cerevisiae	O
to	O
promote	O
animal	O
feeding	O
;	O
the	O
baking	O
soda	O
replenishes	O
electrolyte	O
;	O
the	O
xylo	O
-	O
oligosaccharides	O
selectively	O
proliferate	O
beneficial	O
bacteria	O
such	O
as	O
bifidobacterium	O
and	O
the	O
like	O
;	O
the	O
vitamins	O
have	O
the	O
effects	O
of	O
resisting	O
stress	O
and	O
replenishing	O
nutrition	O
;	O
and	O
the	O
glucose	O
has	O
the	O
effects	O
of	O
supplying	O
energy	O
and	O
promoting	O
healing	O
.	O

Solution	O
with	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
The	O
invention	O
discloses	O
solution	O
with	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
preparation	O
and	O
application	O
of	O
health	O
care	O
products	O
.	O

One	O
liter	O
of	O
solution	O
comprises	O
200	O
to	O
250	O
g	O
of	O
purslane	O
herb	O
extract	O
and	O
50	O
g	O
of	O
brown	O
sugar	O
.	O

The	O
solution	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
of	O
:	O
1	O
,	O
preparing	O
solution	O
matrix	O
:	O
adding	O
500	O
g	O
of	O
brown	O
sugar	O
into	O
one	O
liter	O
of	O
water	O
,	O
quickly	O
stirring	O
uniformly	O
and	O
heating	O
until	O
the	O
brown	O
sugar	O
is	O
completely	O
dissolved	O
to	O
obtain	O
the	O
matrix	O
solution	O
;	O
and	O
2	O
,	O
adding	O
200	O
to	O
250	O
g	O
of	O
purslane	O
herb	O
extract	O
into	O
the	O
one	O
liter	O
of	O
matrix	O
solution	O
,	O
quickly	O
stirring	O
uniformly	O
and	O
heating	O
until	O
the	O
mixture	O
is	O
boiling	O
to	O
ensure	O
that	O
the	O
purslane	O
herb	O
extract	O
is	O
completely	O
dissolved	O
to	O
obtain	O
solution	O
A	O
or	O
solution	O
B	O
,	O
and	O
cooling	O
,	O
filming	O
and	O
packaging	O
.	O

The	O
solution	O
is	O
edible	O
,	O
does	O
not	O
have	O
toxic	O
or	O
side	O
effect	O
,	O
has	O
the	O
effect	O
of	O
chills	O
and	O
fever	O
complementation	O
,	O
and	O
can	O
be	O
taken	O
for	O
a	O
long	O
time	O
.	O

The	O
solution	O
has	O
an	O
extremely	O
simple	O
formula	O
,	O
an	O
extremely	O
simple	O
preparation	O
method	O
,	O
low	O
cost	O
,	O
and	O
good	O
mouthfeel	O
,	O
has	O
the	O
exact	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
and	O
has	O
ideal	O
effect	O
of	O
treating	O
accompanied	O
delayed	O
muscle	O
soreness	O
and	O
wide	O
market	O
application	O
prospect	O
.	O

Method	O
for	O
preparing	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
an	O
antibacterial	O
agent	O
suspension	O
,	O
in	O
particular	O
to	O
a	O
method	O
for	O
preparing	O
a	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
.	O

Taking	O
5000ml	O
of	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
as	O
reference	O
,	O
the	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
contains	O
the	O
following	O
components	O
:	O
1	O
-	O
2.5	O
percent	O
(	O
W	O
/	O
V	O
)	O
of	O
Cefquinome	O
sulfate	O
micro	O
powder	O
,	O
0.15	O
-	O
0.3	O
percent	O
(	O
W	O
/	O
V	O
)	O
of	O
Vitamin	O
E	O
and	O
the	O
balance	O
of	O
esters	O
solvent	O
or	O
injection	O
oil	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
heating	O
the	O
esters	O
solvent	O
or	O
the	O
injection	O
oil	O
to	O
115	O
-	O
125	O
DEG	O
C	O
in	O
a	O
high	O
-	O
shear	O
homogenizer	O
;	O
carrying	O
out	O
heat	O
preservation	O
on	O
the	O
heated	O
esters	O
solvent	O
or	O
injection	O
oil	O
for	O
4	O
-	O
6	O
hours	O
;	O
cooling	O
to	O
below	O
40	O
DEG	O
C	O
;	O
adding	O
sterilized	O
Cefquinome	O
sulfate	O
raw	O
materials	O
;	O
dispersing	O
at	O
the	O
rotating	O
speed	O
of	O
5000	O
-	O
8000rpm	O
(	O
Revolutions	O
Per	O
Minute	O
)	O
;	O
homogenizing	O
by	O
using	O
a	O
high	O
-	O
pressure	O
homogenize	O
at	O
the	O
working	O
pressure	O
of	O
1200bar	O
after	O
the	O
Cefquinome	O
sulfate	O
raw	O
materials	O
are	O
evenly	O
dispersed	O
;	O
encapsuling	O
;	O
and	O
irradiating	O
with	O
cobalt60	O
for	O
sterilization	O
for	O
5	O
-	O
6	O
hours	O
.	O

The	O
Cefquinome	O
sulfate	O
suspension	O
injection	O
prepared	O
by	O
the	O
invention	O
has	O
high	O
safety	O
,	O
good	O
curative	O
effect	O
and	O
small	O
stimulation	O
in	O
intramuscular	O
injection	O
.	O

Flake	O
and	O
pearl	O
nucleus	O
matching	O
treating	O
fluid	O
for	O
culturing	O
Pinctada	O
martensii	O
pearl	O
The	O
invention	O
relates	O
to	O
treating	O
fluid	O
for	O
culturing	O
a	O
Pinctada	O
martensii	O
seawater	O
pearl	O
and	O
a	O
method	O
for	O
culturing	O
the	O
seawater	O
pearl	O
.	O

The	O
treating	O
fluid	O
is	O
obtained	O
by	O
the	O
steps	O
of	O
weighing	O
raw	O
materials	O
including	O
aureomycin	O
,	O
polyvinylpyrrolidone	O
,	O
taurine	O
,	O
vitamin	O
C	O
and	O
the	O
like	O
and	O
then	O
dissolving	O
the	O
raw	O
materials	O
into	O
sodium	O
alga	O
acid	O
of	O
physiological	O
saline	O
solution	O
with	O
the	O
weight	O
contentof	O
0.7	O
-	O
1	O
%	O
.	O

In	O
the	O
process	O
of	O
culturing	O
the	O
seawater	O
pearls	O
,	O
flake	O
shells	O
and	O
shell	O
pearl	O
nuclei	O
are	O
sliced	O
from	O
selected	O
healthy	O
nacres	O
which	O
are	O
not	O
damaged	O
by	O
diseases	O
and	O
insects	O
and	O
are	O
soaked	O
inthe	O
treating	O
fluid	O
and	O
then	O
are	O
implanted	O
into	O
the	O
pearl	O
culturing	O
bags	O
of	O
the	O
nacres	O
.	O

The	O
nucleus	O
implanting	O
operation	O
procedure	O
is	O
carried	O
out	O
according	O
to	O
the	O
traditional	O
conventional	O
means	O
;	O
the	O
flake	O
shells	O
and	O
shell	O
pearl	O
nuclei	O
are	O
transferred	O
to	O
a	O
sea	O
area	O
for	O
hanging	O
culture	O
after	O
20	O
-	O
25	O
days	O
of	O
recreation	O
period	O
.	O

The	O
seawater	O
pearls	O
cultured	O
by	O
the	O
treating	O
fluid	O
have	O
thick	O
pearl	O
layers	O
,	O
high	O
survival	O
rate	O
and	O
high	O
high	O
-	O
quality	O
pearl	O
rate	O
.	O

The	O
invention	O
reduces	O
the	O
death	O
rate	O
and	O
the	O
nucleus	O
splitting	O
rate	O
of	O
the	O
cultured	O
pearl	O
and	O
greatly	O
improves	O
the	O
yield	O
and	O
the	O
nucleus	O
reservation	O
rate	O
of	O
the	O
cultured	O
pearl	O
and	O
the	O
economic	O
benefits	O
of	O
culture	O
production	O
.	O

Compound	O
apramycin	O
sulfate	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
apramycin	O
sulfate	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
apramycin	O
sulfate	O
injection	O
comprises	O
the	O
following	O
components	O
of	O
:	O
5	O
-	O
110kg	O
/	O
L	O
of	O
apramycin	O
sulfate	O
,	O
10	O
-	O
150kg	O
/	O
L	O
of	O
mequindox	O
,	O
10	O
-	O
400kg	O
/	O
L	O
of	O
soldium	O
salicylate	O
,	O
1	O
-	O
20kg	O
/	O
L	O
of	O
atropine	O
sulfate	O
and	O
1	O
-	O
20kg	O
/	O
L	O
of	O
chlortrimeton	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
adding	O
100	O
-	O
400kg	O
/	O
L	O
of	O
soldium	O
salicylate	O
into	O
a	O
part	O
of	O
water	O
for	O
injection	O
,	O
then	O
adding	O
10	O
-	O
150kg	O
/	O
L	O
of	O
mequindox	O
,	O
and	O
stirring	O
for	O
10	O
-	O
20min	O
until	O
a	O
solution	O
is	O
clarified	O
;	O
(	O
2	O
)	O
taking	O
a	O
part	O
of	O
water	O
for	O
injection	O
,	O
sequentially	O
adding	O
5	O
-	O
110kg	O
/	O
L	O
of	O
apramycin	O
sulfate	O
,	O
1	O
-	O
20kg	O
/	O
L	O
of	O
atropine	O
sulfate	O
and	O
1	O
-	O
20kg	O
/	O
L	O
of	O
chlortrimeton	O
,	O
stirring	O
and	O
dissolving	O
;	O
and	O
(	O
3	O
)	O
combining	O
the	O
solution	O
prepared	O
in	O
steps	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
then	O
adding	O
the	O
water	O
for	O
injection	O
to	O
a	O
marked	O
volume	O
,	O
uniformly	O
stirring	O
,	O
keeping	O
for	O
15	O
-	O
20min	O
,	O
and	O
clarifying	O
liquid	O
medicine	O
to	O
obtain	O
the	O
compound	O
apramycin	O
sulfate	O
injection	O
.	O

In	O
the	O
invention	O
,	O
the	O
compound	O
preparation	O
consisting	O
of	O
the	O
apramycin	O
sulfate	O
and	O
the	O
mequindox	O
has	O
very	O
obvious	O
treatment	O
effect	O
on	O
pig	O
bacterial	O
diarrhea	O
and	O
can	O
effectively	O
relieve	O
stress	O
reaction	O
of	O
a	O
suffering	O
animal	O
body	O
;	O
experiments	O
show	O
that	O
the	O
combination	O
use	O
of	O
the	O
apramycin	O
sulfate	O
,	O
the	O
mequindox	O
and	O
the	O
atropine	O
sulfate	O
can	O
remarkably	O
enhance	O
a	O
curative	O
effect	O
;	O
and	O
the	O
compound	O
has	O
wide	O
clinical	O
application	O
range	O
,	O
and	O
can	O
be	O
widely	O
used	O
for	O
treating	O
bacterial	O
diarrhea	O
of	O
livestock	O
,	O
such	O
as	O
pig	O
,	O
cattle	O
,	O
sheep	O
,	O
and	O
the	O
like	O
,	O
enhance	O
the	O
survival	O
rate	O
and	O
increase	O
the	O
body	O
weights	O
of	O
the	O
pig	O
,	O
the	O
cattle	O
and	O
the	O
sheep	O
.	O

Application	O
of	O
antrodia	O
camphorata	O
cyclohexenone	O
compound	O
in	O
preparing	O
medicine	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
The	O
invention	O
relates	O
to	O
a	O
new	O
purpose	O
of	O
a	O
compound	O
.	O

In	O
the	O
invention	O
,	O
antrodia	O
camphorata	O
extract	O
is	O
separated	O
and	O
purified	O
to	O
obtain	O
4-hydroxy-2,3-dimethoxy-6-methy-5	O
(	O
3,7,11-trimethyl	O
-	O
dodeca-2,6,10-trienyl	O
)	O
-cyclohex-2-enone	O
.	O

The	O
cyclohexenone	O
compound	O
can	O
be	O
used	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
and	O
simultaneously	O
can	O
be	O
used	O
for	O
pharmaceutical	O
compositions	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
.	O

2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
as	O
well	O
as	O
preparation	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
,	O
and	O
discloses	O
an	O
application	O
of	O
the	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
in	O
preparing	O
anti	O
-	O
tumor	O
medicaments	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
the	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
in	O
preparing	O
anti	O
-	O
endometrial	O
cancer	O
or	O
anti	O
-	O
lung	O
cancermedicaments	O
.	O

The	O
invention	O
has	O
the	O
main	O
beneficial	O
effects	O
that	O
:	O
(	O
1	O
)	O
the	O
method	O
for	O
preparing	O
the	O
2,6-dichloro-5-fluoronicotinoyl	O
fluorobenzene	O
salicylamide	O
compound	O
is	O
provided	O
;	O
(	O
2	O
)	O
the	O
novel	O
anti	O
-	O
tumor	O
medicament	O
with	O
remarkable	O
anti	O
-	O
tumor	O
activity	O
is	O
provided	O
,	O
a	O
research	O
foundation	O
is	O
laid	O
for	O
novel	O
medicament	O
screening	O
,	O
and	O
the	O
compound	O
has	O
great	O
application	O
prospect	O
;	O
and	O
(	O
3	O
)	O
the	O
preparation	O
process	O
is	O
simple	O
,	O
and	O
is	O
advantageous	O
to	O
industrial	O
production	O
.	O

Postoperative	O
anti	O
-	O
adhesion	O
medicament	O
The	O
invention	O
relates	O
to	O
a	O
postoperative	O
anti	O
-	O
adhesion	O
medicament	O
capable	O
of	O
effectively	O
preventing	O
postoperative	O
adhesion	O
,	O
lubricating	O
tissues	O
and	O
inhibiting	O
inflammation	O
.	O

The	O
technical	O
scheme	O
is	O
that	O
:	O
the	O
postoperative	O
anti	O
-	O
adhesion	O
medicament	O
consists	O
of	O
berberine	O
hydrochloride	O
,	O
dicynone	O
and	O
polyethylene	O
glycol	O
.	O

Tablet	O
capsule	O
with	O
roxithromycin	O
tablets	O
and	O
ambroxol	O
hydrochloride	O
tablets	O

The	O
invention	O
relates	O
to	O
an	O
oral	O
hard	O
capsule	O
,	O
in	O
particular	O
to	O
a	O
tablet	O
capsule	O
with	O
roxithromycin	O
tablets	O
and	O
ambroxol	O
hydrochloride	O
tablets	O
.	O

The	O
tablet	O
capsule	O
consists	O
of	O
a	O
capsule	O
and	O
tablets	O
in	O
the	O
capsule	O
,	O
wherein	O
the	O
capsule	O
comprises	O
an	O
upper	O
capsule	O
body	O
and	O
a	O
lower	O
capsule	O
body	O
,	O
and	O
at	O
least	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
roxithromycin	O
and	O
at	O
least	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
ambroxol	O
hydrochloride	O
are	O
filled	O
in	O
the	O
capsule	O
.	O

Because	O
the	O
active	O
ingredients	O
in	O
the	O
capsule	O
do	O
not	O
contact	O
,	O
chemical	O
changes	O
can	O
not	O
be	O
generated	O
between	O
the	O
ingredients	O
,	O
side	O
products	O
can	O
not	O
be	O
generated	O
,	O
and	O
the	O
stability	O
of	O
the	O
product	O
is	O
improved	O
,	O
degradation	O
products	O
generated	O
after	O
the	O
roxithromycin	O
and	O
the	O
ambroxol	O
hydrochloride	O
contact	O
are	O
reduced	O
particularly	O
.	O

In	O
addition	O
,	O
the	O
designs	O
of	O
cylindrical	O
tablets	O
and	O
different	O
colors	O
and	O
the	O
application	O
of	O
transparent	O
capsule	O
shells	O
are	O
adopted	O
,	O
and	O
the	O
product	O
of	O
the	O
invention	O
is	O
particularly	O
suitable	O
for	O
industrial	O
production	O
,	O
thereby	O
the	O
compliance	O
of	O
patients	O
is	O
enhanced	O
.	O

Meanwhile	O
,	O
the	O
active	O
ingredients	O
are	O
respectively	O
tabletted	O
,	O
thus	O
the	O
drug	O
assay	O
and	O
the	O
quality	O
control	O
are	O
easier	O
.	O

Chewable	O
tablet	O
of	O
calcium	O
carbonate	O
dimeticone	O
and	O
preparation	O
process	O
The	O
invention	O
discloses	O
a	O
chewable	O
tablet	O
of	O
calcium	O
carbonate	O
dimeticone	O
and	O
a	O
preparation	O
process	O
,	O
belonging	O
to	O
four	O
new	O
national	O
chemical	O
medicines	O
.	O

The	O
preparation	O
of	O
the	O
invention	O
is	O
prepared	O
from	O
the	O
following	O
main	O
components	O
:	O
calcium	O
carbonate	O
,	O
simethicone	O
,	O
siliciidoxydum	O
,	O
aspartame	O
,	O
essence	O
powder	O
,	O
mannite	O
,	O
corn	O
starch	O
,	O
low	O
-	O
substituted	O
hydroxypropyl	O
cellulose	O
and	O
magnesium	O
stearate	O
,	O
wherein	O
the	O
calcium	O
carbonate	O
as	O
the	O
main	O
content	O
has	O
stronger	O
acid	O
-	O
resisting	O
action	O
and	O
rapid	O
and	O
lasting	O
effects	O
,	O
and	O
the	O
simethicone	O
is	O
a	O
foam	O
suppressor	O
for	O
eliminating	O
gastrointestinal	O
tract	O
pneumatosis	O
.	O

The	O
preparation	O
is	O
used	O
for	O
treating	O
peptic	O
ulcers	O
including	O
stomach	O
and	O
duodenal	O
ulcer	O
and	O
easing	O
various	O
uncomfortable	O
symptoms	O
caused	O
by	O
hyperacidity	O
.	O

Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
for	O
treating	O
chronic	O
urticaria	O
The	O
invention	O
relates	O
to	O
a	O
Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
,	O
in	O
particular	O
to	O
the	O
Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
for	O
treating	O
chronic	O
urticaria	O
.	O

The	O
preparation	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
10	O
mg	O
of	O
antihistaminics	O
Loratadine	O
,	O
5	O
g	O
of	O
divaricate	O
saposhnikovia	O
root	O
,	O
8	O
g	O
of	O
belvedere	O
fruit	O
,	O
10	O
g	O
of	O
astragalus	O
mongholicus	O
,	O
5	O
g	O
of	O
Chinese	O
angelica	O
,	O
10	O
g	O
of	O
cocklebur	O
fruit	O
,	O
3	O
g	O
of	O
cassia	O
twig	O
,	O
and	O
1	O
part	O
of	O
musk	O
;	O
the	O
antihistaminics	O
Loratadine	O
,	O
the	O
musk	O
,	O
the	O
divaricate	O
saposhnikovia	O
root	O
,	O
the	O
belvedere	O
fruit	O
,	O
the	O
astragalus	O
mongholicus	O
,	O
the	O
Chinese	O
angelica	O
,	O
the	O
cocklebur	O
fruit	O
and	O
the	O
cassia	O
twig	O
are	O
ground	O
into	O
powder	O
and	O
mixed	O
uniformly	O
,	O
and	O
the	O
powder	O
in	O
which	O
musk	O
is	O
added	O
is	O
then	O
regulated	O
into	O
paste	O
with	O
yellow	O
wine	O
.	O

The	O
preparation	O
for	O
treating	O
the	O
chronic	O
urticaria	O
is	O
simple	O
and	O
practicable	O
in	O
method	O
,	O
has	O
small	O
toxic	O
or	O
side	O
effect	O
,	O
and	O
has	O
good	O
auxiliary	O
treatment	O
effect	O
on	O
the	O
chronic	O
urticaria	O
.	O

Medicine	O
for	O
treating	O
rheumatic	O
fever	O
The	O
invention	O
discloses	O
a	O
Chinese	O
materia	O
medica	O
preparation	O
for	O
treating	O
intense	O
heat	O
evil	O
rheumatic	O
fever	O
,	O
comprising	O
the	O
following	O
medicines	O
by	O
fixed	O
weight	O
ratio	O
:	O
gypsum	O
,	O
rhizoma	O
anemarrhenae	O
,	O
golden	O
cypress	O
,	O
polished	O
round	O
-	O
grained	O
rice	O
,	O
Cape	O
Jasmine	O
Fruit	O
and	O
the	O
like	O
.	O

The	O
raw	O
materials	O
of	O
the	O
medicine	O
are	O
easy	O
to	O
obtain	O
and	O
low	O
in	O
cost	O
;	O
and	O
the	O
medicine	O
has	O
the	O
advantages	O
of	O
short	O
course	O
of	O
treatment	O
,	O
excellent	O
curative	O
effect	O
and	O
no	O
side	O
effect	O
.	O

Nimesulide	O
temperature	O
sensitive	O
hydrogel	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
comprises	O
Nimesulide	O
,	O
a	O
temperature	O
sensitive	O
gel	O
material	O
,	O
a	O
pH	O
regulator	O
,	O
a	O
preservative	O
and	O
the	O
like	O
and	O
is	O
characterized	O
in	O
that	O
:	O
the	O
temperature	O
sensitive	O
gel	O
material	O
is	O
poloxamer	O
,	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
poloxamer	O
to	O
the	O
Nimesulide	O
is	O
9:1	O
;	O
and	O
the	O
optimized	O
temperature	O
sensitive	O
gel	O
material	O
is	O
poloxamer	O
407	O
.	O

The	O
temperature	O
sensitive	O
gel	O
is	O
sensitive	O
to	O
temperature	O
changes	O
,	O
and	O
rabbit	O
rectum	O
experimental	O
results	O
show	O
that	O
the	O
temperature	O
sensitive	O
gel	O
has	O
higher	O
medicament	O
release	O
rate	O
and	O
higher	O
bioavailability	O
which	O
are	O
obviously	O
better	O
than	O
those	O
of	O
the	O
conventional	O
Nimesulide	O
common	O
suppositories	O
.	O

The	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
reserves	O
the	O
advantages	O
of	O
the	O
conventional	O
suppositories	O
,	O
overcomes	O
the	O
defects	O
of	O
the	O
conventional	O
suppositories	O
to	O
a	O
certain	O
extent	O
and	O
has	O
a	O
wide	O
clinical	O
application	O
prospect	O
.	O

The	O
Nimesulide	O
temperature	O
sensitive	O
gel	O
uses	O
common	O
safe	O
pharmaceutical	O
excipients	O
,	O
has	O
a	O
simple	O
production	O
process	O
,	O
stable	O
and	O
easily	O
-	O
controlled	O
quality	O
and	O
high	O
process	O
reproducibility	O
,	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Perfusate	O
and	O
preparation	O
method	O
thereof	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
The	O
invention	O
relates	O
to	O
perfusate	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
,	O
which	O
mainly	O
comprises	O
the	O
raw	O
materials	O
with	O
the	O
following	O
ratios	O
:	O
4000	O
-	O
5000	O
g	O
of	O
radix	O
astragali	O
,	O
4000	O
-	O
5000	O
g	O
of	O
herba	O
epimedii	O
,	O
300	O
-	O
500	O
g	O
of	O
levamisole	O
hydrochloride	O
,	O
300	O
-	O
400	O
g	O
of	O
antibacterial	O
pepetide	O
,	O
2000	O
-	O
3000ml	O
of	O
glycerol	O
,	O
400	O
-	O
500	O
g	O
of	O
gelatine	O
,	O
and	O
50	O
-	O
100	O
g	O
of	O
sodium	O
benzoate	O
,	O
wherein	O
pH	O
of	O
the	O
perfusate	O
is	O
5.5	O
-	O
7.5	O
.	O

The	O
perfusate	O
is	O
used	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
with	O
determine	O
curative	O
effect	O
,	O
drug	O
concentration	O
for	O
local	O
application	O
is	O
high	O
,	O
absorption	O
ratio	O
is	O
high	O
,	O
the	O
direction	O
is	O
high	O
,	O
drug	O
application	O
is	O
convenient	O
and	O
safe	O
,	O
thereby	O
the	O
goal	O
of	O
fast	O
treating	O
cow	O
recessive	O
mastitis	O
is	O
achieved	O
,	O
and	O
the	O
perfusate	O
is	O
compound	O
perfusion	O
preparation	O
combining	O
antibiosis	O
,	O
antiphlogosis	O
and	O
improving	O
immunity	O
of	O
the	O
organism	O
.	O

Nano	O
selenium	O
-	O
germanium	O
snake	O
anion	O
far	O
infrared	O
body	O
-	O
building	O
life	O
-	O
prolonging	O
health	O
-	O
care	O
drink	O
The	O
invention	O
relates	O
to	O
a	O
nano	O
selenium	O
-	O
germanium	O
snake	O
anion	O
far	O
infrared	O
body	O
-	O
building	O
life	O
-	O
prolonging	O
health	O
-	O
care	O
drink	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drink	O
production	O
and	O
preparation	O
.	O

Snake	O
medicinal	O
material	O
has	O
rich	O
nutrients	O
.	O

The	O
snake	O
medicinal	O
material	O
not	O
only	O
contain	O
protein	O
,	O
fat	O
,	O
sugar	O
,	O
macro	O
and	O
trace	O
elements	O
and	O
vitamins	O
,	O
but	O
also	O
contains	O
eight	O
necessary	O
amino	O
acids	O
which	O
can	O
not	O
be	O
synthesized	O
in	O
human	O
bodies	O
or	O
are	O
synthesized	O
slowly	O
in	O
human	O
bodies	O
.	O

The	O
snake	O
medicinal	O
material	O
can	O
purify	O
water	O
source	O
.	O

The	O
snake	O
material	O
can	O
activate	O
,	O
purify	O
and	O
mineralize	O
65	O
percent	O
or	O
100	O
percent	O
of	O
water	O
in	O
human	O
bodies	O
and	O
therefore	O
can	O
promote	O
metabolism	O
element	O
balance	O
and	O
acid	O
-	O
base	O
balance	O
in	O
human	O
bodies	O
,	O
increase	O
oxygen	O
content	O
in	O
cells	O
of	O
human	O
bodies	O
and	O
strength	O
the	O
circulation	O
of	O
anions	O
in	O
the	O
drink	O
in	O
blood	O
;	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
anions	O
in	O
the	O
drink	O
and	O
the	O
far	O
infrared	O
electromagnetic	O
wave	O
resisting	O
materials	O
can	O
reach	O
a	O
3	O
to	O
5	O
millimeter	O
deep	O
place	O
in	O
skin	O
tissues	O
and	O
automatically	O
heats	O
to	O
improve	O
the	O
vitality	O
of	O
cells	O
,	O
promote	O
tissue	O
regeneration	O
,	O
supply	O
nutrients	O
to	O
cell	O
tissues	O
,	O
so	O
the	O
health	O
of	O
human	O
bodies	O
is	O
kept	O
and	O
life	O
is	O
prolonged	O
.	O

Cold	O
-	O
system	O
preparation	O
method	O
of	O
south	O
calcite	O
as	O
a	O
Tibetan	O
medicine	O
The	O
invention	O
relates	O
to	O
a	O
cold	O
-	O
system	O
preparation	O
method	O
of	O
south	O
calcite	O
as	O
a	O
Tibetan	O
medicine	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
collecting	O
mineral	O
south	O
calcite	O
,	O
cleaning	O
,	O
removing	O
impurities	O
,	O
scrapping	O
into	O
particles	O
with	O
the	O
granularity	O
of	O
10	O
-	O
30	O
mm	O
,	O
adding	O
auxiliaries	O
,	O
i.e.	O
,	O
Radix	O
Aconiti	O
and	O
potassium	O
nitrate	O
,	O
heating	O
and	O
continuously	O
boiling	O
for	O
2	O
-	O
16	O
h	O
to	O
obtain	O
the	O
boiled	O
south	O
calcite	O
;	O
(	O
2	O
)	O
rinsing	O
the	O
boiled	O
south	O
calcite	O
with	O
clear	O
water	O
until	O
the	O
rinsing	O
liquid	O
is	O
clear	O
as	O
crystal	O
,	O
and	O
drying	O
until	O
the	O
weight	O
is	O
consistent	O
to	O
obtain	O
the	O
dry	O
south	O
calcite	O
;	O
and	O
(	O
3	O
)	O
grinding	O
the	O
dry	O
south	O
calcite	O
,	O
sieving	O
with	O
a	O
screen	O
of	O
20	O
-	O
100	O
meshes	O
to	O
obtain	O
south	O
calcite	O
powder	O
,	O
uniformly	O
mixing	O
and	O
stirring	O
the	O
south	O
calcite	O
powder	O
with	O
fresh	O
milk	O
and	O
drying	O
in	O
shade	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

The	O
cold	O
-	O
system	O
preparation	O
method	O
is	O
simple	O
and	O
convenient	O
to	O
operate	O
and	O
easy	O
to	O
implement	O
and	O
can	O
greatly	O
increase	O
the	O
content	O
of	O
effective	O
trace	O
elements	O
in	O
the	O
south	O
calcitewithout	O
remarkably	O
influencing	O
the	O
main	O
contents	O
,	O
thereby	O
the	O
method	O
can	O
be	O
used	O
as	O
a	O
reference	O
for	O
preparing	O
high	O
south	O
calcite	O
and	O
a	O
standard	O
preparation	O
method	O
of	O
the	O
south	O
calcite	O
as	O
the	O
Tibetan	O
medicine	O
.	O

Plaster	O
for	O
treating	O
pain	O
of	O
cervical	O
and	O
lumbar	O
vertebrae	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
pain	O
of	O
cervical	O
and	O
lumbar	O
vertebrae	O
,	O
which	O
is	O
prepared	O
according	O
to	O
the	O
following	O
steps	O
:	O
adding	O
raw	O
medicines	O
such	O
as	O
szechuan	O
aconite	O
,	O
wild	O
aconite	O
,	O
rhizoma	O
arisaematis	O
and	O
the	O
like	O
into	O
water	O
for	O
decocting	O
,	O
filtering	O
the	O
obtained	O
decoction	O
with	O
gauze	O
,	O
and	O
concentrating	O
the	O
decoction	O
into	O
fluid	O
extract	O
for	O
later	O
use	O
;	O
then	O
,	O
preparing	O
raw	O
medicines	O
such	O
as	O
mastic	O
,	O
myrrh	O
,	O
safflower	O
,	O
catechu	O
and	O
the	O
like	O
into	O
fine	O
powder	O
,	O
and	O
sieving	O
the	O
fine	O
powder	O
with	O
a	O
100-mesh	O
sieve	O
for	O
later	O
use	O
;	O
and	O
finally	O
,	O
mixing	O
and	O
heating	O
talcum	O
powder	O
,	O
zinc	O
oxide	O
,	O
sesame	O
oil	O
and	O
medical	O
solid	O
pressure	O
-	O
sensitive	O
hot	O
melt	O
adhesive	O
,	O
adding	O
the	O
fluid	O
extract	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
the	O
fine	O
powder	O
obtained	O
in	O
the	O
step	O
(	O
2	O
)	O
while	O
continuously	O
stirring	O
until	O
the	O
moisture	O
is	O
fully	O
evaporated	O
,	O
cooling	O
,	O
adding	O
certain	O
parts	O
by	O
weight	O
of	O
camphor	O
,	O
borneol	O
and	O
azone	O
,	O
stirring	O
uniformly	O
,	O
and	O
spreading	O
5	O
g	O
of	O
ointment	O
on	O
non	O
-	O
woven	O
fabric	O
to	O
obtain	O
the	O
plaster	O
disclosed	O
by	O
the	O
invention	O
.	O

Geldanamycin	O
derivative	O
,	O
preparation	O
thereof	O
and	O
medicament	O
application	O
thereof	O
The	O
invention	O
discloses	O
geldanamycin	O
derivative	O
,	O
preparation	O
thereof	O
and	O
medicament	O
application	O
thereof	O
.	O

The	O
structural	O
formula	O
as	O
shown	O
in	O
the	O
following	O
formula	O
(	O
I	O
)	O
is	O
a	O
novel	O
structural	O
formula	O
formed	O
by	O
modifying	O
the	O
geldanamycin	O
,	O
and	O
the	O
pair	O
of	O
heat	B
shock	I
protein	I
90	I
is	O
good	O
in	O
activity	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
,	O
or	O
the	O
medical	O
salt	O
of	O
the	O
compound	O
;	O
R1	O
group	O
is	O
phenyl	O
or	O
3-furyl	O
or	O
3-pyrryl	O
or	O
the	O
other	O
hexahydric	O
heteroaromatic	O
group	O
,	O
or	O
the	O
other	O
quinary	O
heteroaromatic	O
group	O
;	O
and	O
R2	O
group	O
is	O
carboxylic	O
acid	O
amide	O
or	O
acetyl	O
or	O
ethyl	O
or	O
the	O
fatty	O
hydrocarbon	O
group	O
of	O
the	O
other	O
C1-C5	O
carbon	O
straight	O
chain	O
or	O
the	O
carbonyl	O
group	O
of	O
the	O
other	O
C1-C5	O
carbon	O
straight	O
chain	O
fatty	O
hydrocarbon	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
has	O
the	O
characteristic	O
of	O
the	O
high	O
-	O
efficiency	O
combined	O
heat	B
shock	I
protein	I
90	I
,	O
so	O
that	O
the	O
geldanamycin	O
derivative	O
can	O
be	O
used	O
for	O
curing	O
or	O
preventing	O
the	O
tumor	O
of	O
the	O
mammal	O
,	O
in	O
particular	O
to	O
the	O
solid	O
tumor	O
.	O

Esculentoside	O
A	O
,	O
EsA	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
an	O
Esculentoside	O
A	O
,	O
EsA	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
general	O
formula	O
of	O
the	O
Esculentoside	O
A	O
,	O
EsA	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R	O
is	O
amino	O
acid	O
,	O
polypeptide	O
,	O
piperazine	O
base	O
,	O
substituted	O
piperazine	O
bases	O
or	O
substituted	O
amido	O
.	O

An	O
active	O
ester	O
intermediate	O
formed	O
by	O
the	O
Esculentoside	O
A	O
,	O
EsA	O
under	O
the	O
action	O
of	O
a	O
condensation	O
agent	O
reacts	O
with	O
amine	O
or	O
piperazine	O
or	O
substituted	O
piperazine	O
or	O
amino	O
acid	O
with	O
the	O
protected	O
carboxyl	O
or	O
polypeptide	O
;	O
and	O
the	O
Esculentoside	O
A	O
,	O
EsA	O
is	O
obtained	O
by	O
separation	O
and	O
purification	O
.	O

The	O
Esculentoside	O
A	O
,	O
EsA	O
,	O
as	O
well	O
as	O
pharmaceutical	O
salt	O
and	O
medical	O
composite	O
thereof	O
can	O
be	O
used	O
for	O
preparing	O
inflammatory	O
medicaments	O
.	O

Imidazopyridine	O
and	O
imidazopyrazine	O
compounds	O
useful	O
as	O
kinase	B
inhibitors	O
A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
and	O
enantiomers	O
,	O
diastereomers	O
and	O
pharmaceutically	O
-	O
acceptable	O
salts	O
thereof	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
,	O
and	O
methods	O
of	O
treating	O
conditions	O
associated	O
with	O
the	O
activity	O
of	O
p38	B
kinase	I
.	O

Application	O
of	O
arachidonic	O
acid	O
as	O
xanthine	B
oxidase	I
inhibitor	O
and	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
hyperuricemia	O
or	O
gout	O
The	O
invention	O
relates	O
to	O
application	O
of	O
arachidonic	O
acid	O
as	O
a	O
xanthine	B
oxidase	I
inhibitor	O
and	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
hyperuricemia	O
or	O
gout	O
.	O

Xanthine	B
oxidase	I
is	O
a	O
key	O
enzyme	O
for	O
the	O
generation	O
and	O
the	O
development	O
of	O
the	O
hyperuricemia	O
or	O
the	O
gout	O
,	O
most	O
substrates	O
of	O
the	O
xanthine	B
oxidase	I
are	O
cyclic	O
small	O
molecules	O
,	O
and	O
the	O
arachidonic	O
acid	O
is	O
long	O
chain	O
polyunsaturated	O
fatty	O
acid	O
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
xanthine	B
oxidase	I
is	O
downloaded	O
from	O
a	O
protein	O
data	O
bank	O
(	O
PDB	O
)	O
of	O
a	O
website	O
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
arachidonic	O
acid	O
is	O
downloaded	O
from	O
a	O
pubchem	O
;	O
molecular	O
docking	O
between	O
the	O
arachidonic	O
acid	O
and	O
the	O
xanthine	B
oxidase	I
is	O
performed	O
by	O
iGEMDOCK	O
software	O
and	O
docking	O
energy	O
is	O
computed	O
;	O
and	O
in	O
-	O
vitro	O
enzyme	O
activity	O
tests	O
prove	O
that	O
the	O
arachidonic	O
acid	O
has	O
an	O
inhibition	O
effect	O
on	O
the	O
xanthine	B
oxidase	I
.	O

By	O
the	O
application	O
,	O
another	O
important	O
physiological	O
function	O
of	O
the	O
arachidonic	O
acid	O
is	O
discovered	O
,	O
and	O
a	O
wider	O
way	O
is	O
provided	O
for	O
screening	O
the	O
xanthine	O
oxidase	O
inhibitor	O
from	O
a	O
natural	O
product	O
to	O
treat	O
the	O
hyperuricemia	O
or	O
the	O
gout	O
simultaneously	O
.	O

Preparation	O
method	O
of	O
pulsatilla	O
saponin	O
matter	O
as	O
well	O
as	O
preparation	O
method	O
of	O
preparation	O
thereof	O
and	O
application	O
of	O
pulsatilla	O
saponin	O
matter	O
in	O
preparing	O
medicaments	O
for	O
treating	O
cancers	O
The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
pulsatilla	O
saponin	O
matter	O
as	O
well	O
as	O
a	O
preparation	O
method	O
of	O
a	O
preparation	O
thereof	O
and	O
application	O
of	O
the	O
pulsatilla	O
saponin	O
matter	O
in	O
preparing	O
medicaments	O
for	O
treating	O
cancers	O
.	O

The	O
invention	O
relates	O
to	O
the	O
pulsatilla	O
saponin	O
matter	O
which	O
is	O
pulsatilla	O
saponin	O
A	O
or	O
pulsatilla	O
saponin	O
A	O
produced	O
by	O
hydrolysis	O
,	O
thereby	O
together	O
having	O
the	O
structural	O
units	O
of	O
23-hydroxy	O
oleanolic	O
acid-3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
-alpha	O
-	O
L	O
-	O
pyran	O
Arabic	O
glucoside	O
,	O
and	O
the	O
like	O
,	O
and	O
because	O
the	O
matter	O
is	O
easy	O
to	O
generate	O
the	O
pulsatilla	O
saponin	O
A	O
after	O
being	O
hydrolyzed	O
,	O
the	O
pulsatilla	O
saponin	O
matter	O
has	O
a	O
similar	O
treating	O
effect	O
in	O
human	O
bodies	O
.	O

Dirithromycin	O
medicinal	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
dirithromycin	O
medicinal	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

By	O
the	O
dirithromycin	O
medicinal	O
composition	O
,	O
the	O
problem	O
of	O
the	O
flowability	O
of	O
granules	O
during	O
preparation	O
is	O
mainly	O
solved	O
,	O
and	O
the	O
stability	O
,	O
bioavailability	O
and	O
the	O
like	O
of	O
medicaments	O
are	O
improved	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
dirithromycin	O
medicinal	O
composition	O
,	O
namely	O
the	O
dirithromycin	O
medicinal	O
composition	O
is	O
filled	O
by	O
a	O
direct	O
method	O
,	O
so	O
by	O
the	O
preparation	O
method	O
,	O
the	O
problem	O
that	O
soft	O
materials	O
have	O
high	O
viscosity	O
and	O
are	O
difficult	O
to	O
pelletize	O
in	O
the	O
process	O
of	O
preparing	O
dirithromycin	O
medicinal	O
capsules	O
in	O
the	O
prior	O
art	O
is	O
solved	O
.	O

Application	O
of	O
feather	O
cockscomb	O
saponins	O
compound	O
in	O
antitumor	O
or	O
anti	O
-	O
inflammatory	O
medicines	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
novel	O
application	O
of	O
a	O
feather	O
cockscomb	O
saponins	O
compound	O
,	O
such	O
as	O
Celosin	O
A	O
,	O
Celosin	O
B	O
,	O
Celosin	O
C1	O
,	O
Celosin	O
D1	O
,	O
Celosin	O
E	O
,	O
Celosin	O
F	O
,	O
Celosin	O
G	O
or	O
Cristatain	O
.	O

Proved	O
by	O
in	O
vitro	O
cell	O
experiments	O
,	O
the	O
feather	O
cockscomb	O
saponins	O
compound	O
,	O
such	O
as	O
the	O
Celosin	O
A	O
,	O
the	O
Celosin	O
B	O
,	O
the	O
Celosin	O
C1	O
,	O
the	O
Celosin	O
D1	O
,	O
the	O
Celosin	O
E	O
,	O
the	O
Celosin	O
F	O
,	O
Celosin	O
G	O
and	O
Cristatain	O
have	O
favorable	O
anti	O
-	O
inflammatory	O
activity	O
,	O
and	O
the	O
Celosin	O
A	O
,	O
the	O
Celosin	O
B	O
and	O
Cristatain	O
have	O
better	O
anti	O
-	O
inflammatory	O
effect	O
,	O
therefore	O
,	O
the	O
feather	O
cockscomb	O
saponins	O
compound	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
inflammatory	O
or	O
antitumor	O
medicines	O
.	O

The	O
invention	O
provides	O
a	O
new	O
medicine	O
source	O
for	O
the	O
anti	O
-	O
inflammatory	O
medicines	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
small	O
cell	O
lung	O
cancer	O
and	O
application	O
,	O
kit	O
and	O
package	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
small	O
cell	O
lung	O
cancer	O
and	O
application	O
,	O
a	O
kit	O
and	O
package	O
thereof	O
.	O

The	O
pharmaceutical	O
composition	O
,	O
kit	O
and	O
package	O
contain	O
a	O
treatment	O
effective	O
dose	O
of	O
lobaplatin	O
and	O
a	O
treatment	O
effective	O
dose	O
of	O
etoposide	O
as	O
a	O
combination	O
for	O
simultaneous	O
,	O
separated	O
or	O
sequential	O
use	O
.	O

When	O
used	O
for	O
treating	O
the	O
small	O
cell	O
lung	O
cancer	O
,	O
the	O
pharmaceutical	O
composition	O
,	O
kit	O
and	O
package	O
provided	O
by	O
the	O
invention	O
can	O
obtain	O
excellent	O
treatment	O
effect	O
and	O
have	O
small	O
toxic	O
side	O
effect	O
.	O

Absorption	O
-	O
promoting	O
pharmaceutical	O
composition	O
ointment	O
for	O
treating	O
skin	O
diseases	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
a	O
pharmaceutical	O
composition	O
ointment	O
for	O
treating	O
skin	O
diseases	O
.	O

The	O
pharmaceutical	O
composition	O
contains	O
the	O
following	O
components	O
in	O
proportion	O
by	O
weight	O
:	O
0.05	O
-	O
0.08	O
%	O
of	O
betamethasone	O
valerate	O
,	O
0.08	O
-	O
0.12	O
%	O
of	O
chlorocresol	O
and	O
0.08	O
-	O
0.12	O
%	O
of	O
gentamicin	O
sulfate	O
.	O

The	O
pharmaceutical	O
composition	O
ointment	O
is	O
mainly	O
used	O
for	O
treating	O
dermatitis	O
,	O
eczema	O
,	O
contact	O
dermatitis	O
,	O
seborrheic	O
dermatitis	O
,	O
photodermatitis	O
,	O
neurodermatitis	O
,	O
intertrigo	O
,	O
exfoliative	O
dermatitis	O
,	O
skin	O
itch	O
,	O
psoriasis	O
,	O
first	O
-	O
degree	O
burn	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
composition	O
ointment	O
has	O
the	O
characteristics	O
of	O
jointly	O
applying	O
pharmaceutical	O
components	O
with	O
anti	O
-	O
inflammatory	O
,	O
antifungal	O
and	O
antibacterial	O
curative	O
effects	O
,	O
playing	O
the	O
curative	O
effects	O
in	O
multiple	O
aspects	O
,	O
overcoming	O
the	O
defect	O
that	O
an	O
individual	O
component	O
can	O
not	O
more	O
effectively	O
treat	O
skin	O
mycotic	O
infection	O
,	O
skin	O
allergy	O
,	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
,	O
or	O
concurrence	O
of	O
mycotic	O
infection	O
,	O
skin	O
allergy	O
,	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
,	O
and	O
relieving	O
the	O
serious	O
side	O
effects	O
caused	O
by	O
singly	O
using	O
a	O
big	O
amount	O
of	O
hormone	O
for	O
treating	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
;	O
and	O
a	O
component	O
for	O
promoting	O
percutaneous	O
absorption	O
is	O
added	O
to	O
auxiliary	O
materials	O
to	O
enhance	O
the	O
pharmaceutical	O
curative	O
effect	O
and	O
promote	O
absorption	O
.	O

The	O
ointment	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
exact	O
efficacy	O
,	O
strong	O
local	O
pertinence	O
,	O
no	O
irritation	O
on	O
skin	O
,	O
and	O
the	O
like	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
ointment	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Hyperosteogeny	O
plaster	O
The	O
invention	O
discloses	O
a	O
hyperosteogeny	O
plaster	O
used	O
for	O
treating	O
hyperosteogeny	O
and	O
functional	O
disorder	O
,	O
soft	O
tissue	O
injury	O
,	O
swell	O
,	O
sore	O
,	O
numbness	O
and	O
pain	O
caused	O
thereby	O
.	O

The	O
hyperosteogeny	O
plaster	O
takes	O
cotton	O
cloth	O
as	O
a	O
mounting	O
material	O
,	O
acrylic	O
ester	O
polymer	O
as	O
a	O
pressure	O
sensitive	O
adhesive	O
,	O
glycerol	O
as	O
a	O
cosolvent	O
and	O
azone	O
as	O
an	O
accelerator	O
,	O
and	O
the	O
main	O
medicines	O
comprise	O
80	O
-	O
97	O
%	O
of	O
micalex	O
in	O
weight	O
,	O
1	O
-	O
7	O
%	O
of	O
coptis	O
in	O
weight	O
and	O
2	O
-	O
13	O
%	O
of	O
dried	O
alum	O
in	O
weight	O
.	O

The	O
plaster	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
0.1	O
-	O
30	O
%	O
of	O
main	O
medicines	O
,	O
50	O
-	O
90	O
%	O
of	O
pressure	O
sensitive	O
adhesive	O
acrylic	O
ester	O
polymer	O
,	O
2	O
-	O
20	O
%	O
of	O
cosolvent	O
glycerol	O
and	O
0.5	O
-	O
10	O
%	O
of	O
accelerator	O
azone	O
.	O

Method	O
for	O
preparing	O
infantile	O
lung	O
clearing	O
and	O
phlegm	O
eliminating	O
preparation	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
an	O
infantile	O
lung	O
clearing	O
and	O
phlegm	O
eliminating	O
preparation	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
a	O
,	O
weighing	O
ephedra	O
,	O
gypsum	O
,	O
bitter	O
almond	O
,	O
whiteflower	O
hogfennel	O
root	O
,	O
baical	O
skullcap	O
root	O
,	O
perilla	O
fruit	O
powder	O
,	O
pepperweed	O
seed	O
and	O
bamboo	O
shavings	O
;	O
b	O
,	O
soaking	O
ephedra	O
coarse	O
powder	O
in	O
acidic	O
aqueous	O
solution	O
,	O
and	O
percolating	O
for	O
extracting	O
;	O
c	O
,	O
crushing	O
bitter	O
almond	O
,	O
inactivating	O
enzyme	O
,	O
and	O
extracting	O
by	O
low	O
-	O
degree	O
alcoholic	O
solution	O
;	O
d	O
,	O
decocting	O
gypsum	O
,	O
adding	O
other	O
components	O
,	O
extracting	O
in	O
water	O
,	O
mixing	O
with	O
ephedra	O
concentrating	O
solution	O
and	O
bitter	O
almond	O
concentrating	O
solution	O
,	O
and	O
concentrating	O
to	O
form	O
extract	O
;	O
and	O
e	O
,	O
adding	O
an	O
excipient	O
and	O
auxiliary	O
materials	O
,	O
and	O
preparing	O
by	O
the	O
conventional	O
method	O
of	O
preparations	O
to	O
obtain	O
a	O
pharmaceutically	O
-	O
acceptable	O
preparation	O
.	O

By	O
the	O
method	O
,	O
the	O
extraction	O
rate	O
of	O
ephedrine	O
and	O
amygdalin	O
can	O
be	O
improved	O
,	O
the	O
curative	O
effect	O
of	O
medicines	O
can	O
be	O
improved	O
,	O
and	O
the	O
quality	O
stability	O
ofproducts	O
can	O
be	O
improved	O
simultaneously	O
.	O

Lansoprazole	O
medicinal	O
composition	O
tablets	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
comprise	O
the	O
following	O
components	O
in	O
part	O
by	O
mass	O
:	O
20	O
to	O
30	O
parts	O
of	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
,	O
400	O
to	O
450	O
parts	O
of	O
sodium	O
bicarbonate	O
,	O
100	O
to	O
150	O
parts	O
of	O
calcium	O
hydrophosphate	O
,	O
600	O
to	O
700	O
parts	O
of	O
magnesium	O
hydroxide	O
,	O
250	O
to	O
500	O
parts	O
of	O
filler	O
,	O
40	O
to	O
50	O
parts	O
of	O
disintegrating	O
agent	O
,	O
50	O
to	O
100	O
parts	O
of	O
flavoring	O
agent	O
,	O
80	O
to	O
100	O
parts	O
of	O
bonding	O
agent	O
and	O
20	O
to	O
25	O
parts	O
of	O
lubricating	O
agent	O
.	O

In	O
the	O
Lansoprazole	O
medicinal	O
composition	O
tablets	O
disclosed	O
by	O
the	O
invention	O
,	O
sodium	O
bicarbonate	O
,	O
calcium	O
hydrophosphate	O
and	O
magnesium	O
hydroxide	O
are	O
used	O
in	O
place	O
of	O
enteric	O
coating	O
,	O
the	O
secretion	O
of	O
gastric	O
acid	O
can	O
be	O
inhibited	O
,	O
the	O
Lansoprazole	O
can	O
be	O
prevented	O
from	O
being	O
decomposed	O
by	O
gastric	O
acid	O
,	O
the	O
medicines	O
can	O
be	O
absorbed	O
quickly	O
,	O
and	O
peak	O
concentration	O
can	O
be	O
reached	O
quickly	O
.	O

Hederasaponin	O
derivative	O
,	O
preparation	O
method	O
of	O
salts	O
thereof	O
and	O
application	O
thereof	O
to	O
resisting	O
tumor	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
provides	O
a	O
3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
[	O
beta	O
-	O
D	O
-	O
glucopyranose-	O
(	O
1	O
-	O
4	O
)	O
]	O
-alpha	O
-	O
L	O
-	O
pyran	O
arabinose	O
hederasaponin	O
derivative	O
,	O
a	O
preparation	O
method	O
of	O
salts	O
thereof	O
and	O
application	O
thereof	O
to	O
resisting	O
tumor	O
.	O

The	O
structures	O
of	O
the	O
hederasaponin	O
3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
[	O
beta	O
-	O
D	O
-	O
glucopyranose-	O
(	O
1->4	O
)	O
]	O
-alpha	O
-	O
L	O
-	O
pyran	O
arabinose	O
hederasaponin	O
derivative	O
and	O
salts	O
thereof	O
are	O
shown	O
as	O
follows	O
.	O

The	O
hederasaponin	O
3-O	O
-	O
alpha	O
-	O
L	O
-	O
pyran	O
rhamnose-	O
(	O
1->2	O
)	O
[	O
beta	O
-	O
D	O
-	O
glucopyranose-	O
(	O
1->4	O
)	O
]	O
-alpha	O
-	O
L	O
-	O
pyran	O
arabinose	O
hederasaponin	O
derivative	O
and	O
the	O
salts	O
thereof	O
are	O
combined	O
with	O
a	O
pharmaceutical	O
acceptable	O
carrier	O
to	O
form	O
a	O
pharmaceutical	O
compound	O
which	O
is	O
used	O
for	O
preparing	O
tumor	O
-	O
resistant	O
medicines	O
.	O

Compared	O
with	O
the	O
prototype	O
medicine	O
,	O
a	O
medicine	O
containing	O
the	O
ingredient	O
derivative	O
and	O
the	O
salts	O
thereof	O
has	O
considerable	O
or	O
stronger	O
tumor	O
-	O
resistant	O
activity	O
;	O
and	O
meanwhile	O
,	O
the	O
activity	O
of	O
other	O
tumor	O
-	O
resistant	O
medicines	O
can	O
be	O
obviously	O
enhanced	O
and	O
the	O
side	O
effects	O
of	O
the	O
medicines	O
are	O
reduced	O
.	O

Slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
containing	O
vinpocetine	O
prepared	O
by	O
supercritical	O
fluid	O
method	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
containing	O
vinpocetine	O
prepared	O
by	O
a	O
supercritical	O
fluid	O
method	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
nanoparticle	O
comprises	O
active	O
ingredients	O
of	O
vinpocetine	O
,	O
glyceryl	O
monooleate	O
and	O
surfactant	O
.	O

The	O
slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
of	O
the	O
invention	O
prepared	O
by	O
vinpocetine	O
has	O
an	O
obvious	O
slow	O
-	O
release	O
function	O
relative	O
to	O
a	O
vinpocetine	O
solution	O
and	O
has	O
a	O
remarkably	O
-	O
increased	O
oral	O
bioavailability	O
.	O

Meropenem	O
sodium	O
/	O
sulbactam	O
sodium	O
medicinal	O
composition	O
The	O
invention	O
provides	O
a	O
combined	O
medicament	O
,	O
in	O
particular	O
a	O
meropenem	O
sodium	O
and	O
sulbactam	O
sodium	O
combined	O
medicine	O
which	O
is	O
used	O
for	O
treating	O
infectious	O
diseases	O
caused	O
by	O
Acinetobacter	O
baumanii	O
.	O

The	O
meropenem	O
sodium	O
and	O
sulbactam	O
sodium	O
combined	O
medicine	O
has	O
synergistic	O
and	O
cumulative	O
antibacterial	O
effects	O
on	O
the	O
infectious	O
diseases	O
caused	O
by	O
the	O
Acinetobacter	O
baumanii	O
,	O
particularly	O
has	O
good	O
synergistic	O
and	O
cumulative	O
antibacterial	O
effects	O
on	O
multiple	O
medicine	O
-	O
resistant	O
Acinetobacter	O
baumanii	O
,	O
and	O
can	O
be	O
used	O
for	O
curing	O
the	O
clinical	O
infection	O
caused	O
by	O
the	O
multiple	O
medicine	O
-	O
resistant	O
Acinetobacter	O
baumanii	O
.	O

New	O
application	O
of	O
epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
The	O
invention	O
relates	O
to	O
applications	O
of	O
epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
in	O
preparing	O
a	O
medicament	O
for	O
inducing	O
glioma	O
cell	O
apoptosis	O
and	O
preparing	O
a	O
medicament	O
for	O
inhibiting	O
glioma	O
cell	O
proliferation	O
.	O

Shown	O
by	O
experimental	O
results	O
,	O
the	O
EGCG	O
can	O
obviously	O
inhibit	O
the	O
glioma	O
cell	O
proliferation	O
(	O
P	O
(	O
0.001	O
)	O
,	O
with	O
the	O
increase	O
of	O
dosage	O
of	O
the	O
EGCG	O
and	O
extension	O
of	O
time	O
,	O
the	O
cyto	O
-	O
inhibition	O
is	O
more	O
obvious	O
;	O
and	O
shown	O
by	O
experimental	O
results	O
of	O
cell	O
apoptosis	O
,	O
48	O
hours	O
later	O
after	O
the	O
EGCG	O
is	O
added	O
,	O
with	O
the	O
increase	O
of	O
concentration	O
,	O
the	O
number	O
of	O
cell	O
apoptosis	O
is	O
markedly	O
increased	O
.	O

Motherwort	O
and	O
astragalus	O
capsule	O
used	O
for	O
treating	O
prostatic	O
hyperplasia	O
The	O
invention	O
relates	O
to	O
a	O
motherwort	O
and	O
astragalus	O
capsule	O
used	O
for	O
treating	O
prostatic	O
hyperplasia	O
and	O
can	O
effectively	O
solve	O
the	O
treatment	O
problem	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O

The	O
technical	O
schemes	O
are	O
as	O
follows	O
:	O
the	O
motherwort	O
and	O
astragalus	O
capsule	O
is	O
prepared	O
from	O
motherwort	O
extract	O
,	O
astragalus	O
extract	O
,	O
starch	O
and	O
talcum	O
powder	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
motherwort	O
extract	O
to	O
the	O
astragalus	O
extract	O
is	O
(	O
4	O
-	O
6	O
)	O
:	O
(	O
6	O
-	O
4	O
)	O
;	O
and	O
the	O
motherwort	O
and	O
astragalus	O
capsule	O
is	O
prepared	O
by	O
crushing	O
the	O
motherwort	O
extract	O
and	O
the	O
astragalus	O
extract	O
,	O
screening	O
with	O
a	O
100-mesh	O
sieve	O
,	O
mixing	O
uniformly	O
,	O
then	O
adding	O
starch	O
and	O
talcum	O
powder	O
,	O
uniformly	O
mixing	O
,	O
wherein	O
the	O
addition	O
amount	O
of	O
starch	O
and	O
talcum	O
powder	O
is	O
not	O
more	O
than	O
10	O
%	O
the	O
total	O
weight	O
of	O
the	O
motherwort	O
extract	O
,	O
astragalus	O
extract	O
,	O
starch	O
and	O
talcum	O
powder	O
and	O
the	O
weight	O
ratio	O
of	O
starch	O
to	O
talcum	O
powder	O
is	O
1:1	O
,	O
granulating	O
and	O
encapsulating	O
.	O

The	O
motherwort	O
and	O
astragalus	O
capsule	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
,	O
proper	O
compatibility	O
,	O
good	O
efficacy	O
,	O
no	O
toxic	O
or	O
side	O
effect	O
and	O
significant	O
treatment	O
effect	O
on	O
benign	O
prostatic	O
hyperplasia	O
,	O
is	O
innovative	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
,	O
and	O
has	O
huge	O
economic	O
and	O
social	O
benefits	O
.	O

Chondrocyte	O
-	O
like	O
cell	O
,	O
and	O
method	O
for	O
producing	O
same	O
Disclosed	O
is	O
a	O
cell	O
which	O
enables	O
the	O
reproduction	O
of	O
a	O
cartilage	O
tissue	O
and	O
has	O
a	O
proliferative	O
ability	O
.	O

Also	O
disclosed	O
is	O
a	O
technique	O
for	O
providing	O
a	O
cell	O
supply	O
source	O
which	O
can	O
be	O
used	O
in	O
a	O
definitive	O
treatment	O
of	O
osteochondrosis	O
deformans	O
.	O

A	O
chondrocyte	O
-	O
like	O
cell	O
which	O
has	O
the	O
same	O
properties	O
as	O
those	O
of	O
a	O
chondrocyte	O
and	O
can	O
proliferate	O
can	O
be	O
produced	O
by	O
selecting	O
a	O
combination	O
of	O
an	O
Myc	B
family	O
gene	O
and/or	O
a	O
Klf	B
family	O
gene	O
and	O
a	O
SOX9	B
gene	I
and	O
introducing	O
the	O
combination	O
into	O
a	O
somatic	O
cell	O
.	O

The	O
chondrocyte	O
-	O
like	O
cell	O
can	O
be	O
used	O
for	O
a	O
medical	O
purpose	O
of	O
cartilage	O
regeneration	O
.	O

Medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
cystitis	O
caused	O
by	O
chemotherapy	O
The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
cystitis	O
caused	O
by	O
chemotherapy	O
.	O

The	O
medicinal	O
composition	O
consists	O
of	O
mesna	O
,	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
or	O
a	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
derivative	O
and	O
a	O
pharmaceutically	O
acceptable	O
medicinal	O
carrier	O
.	O

The	O
combined	O
medication	O
of	O
the	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
as	O
well	O
as	O
the	O
derivative	O
thereof	O
and	O
the	O
mesna	O
has	O
an	O
unexpected	O
therapeutic	O
effect	O
on	O
preventing	O
or	O
treating	O
the	O
cystitis	O
caused	O
by	O
a	O
chemotherapeutic	O
medicament	O
.	O

The	O
medicinal	O
composition	O
contributes	O
to	O
relieving	O
the	O
pain	O
of	O
a	O
chemotherapy	O
patient	O
;	O
and	O
the	O
tolerance	O
dose	O
of	O
the	O
patient	O
to	O
the	O
chemotherapeutic	O
medicament	O
is	O
improved	O
.	O

Compared	O
with	O
the	O
conventional	O
medicamentssuch	O
as	O
the	O
mesna	O
and	O
the	O
like	O
,	O
the	O
medicinal	O
composition	O
has	O
the	O
advantages	O
that	O
:	O
the	O
composition	O
of	O
the	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	O
carbonic	O
acid	O
as	O
well	O
as	O
the	O
derivative	O
thereof	O
and	O
the	O
mesna	O
has	O
a	O
wide	O
therapeutic	O
effect	O
on	O
the	O
cystitis	O
caused	O
by	O
the	O
chemotherapeutic	O
medicament	O
and	O
has	O
a	O
limited	O
prevention	O
effect	O
.	O

Application	O
of	O
lycium	O
barbarum	O
polysaccharides	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and	O
posttraumatic	O
stress	O
disorder	O
The	O
invention	O
discloses	O
application	O
of	O
lycium	O
barbarum	O
polysaccharides	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and	O
posttraumatic	O
stress	O
disorder	O
.	O

The	O
application	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
filling	O
the	O
extracted	O
lycium	O
barbarum	O
polysaccharides	O
with	O
the	O
purity	O
of	O
more	O
than	O
or	O
equal	O
to	O
50	O
%	O
in	O
capsules	O
or	O
preparing	O
the	O
lycium	O
barbarum	O
polysaccharidesinto	O
tablets	O
,	O
wherein	O
each	O
capsule	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
,	O
or	O
each	O
tablet	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
;	O
uniformly	O
mixing	O
the	O
extracted	O
lyciumbarbarum	O
polysaccharides	O
with	O
the	O
purity	O
of	O
more	O
than	O
or	O
equal	O
to	O
50	O
%	O
and	O
corn	O
startch	O
;	O
and	O
filling	O
the	O
mixture	O
into	O
capsules	O
or	O
preparing	O
the	O
mixture	O
into	O
tablets	O
,	O
wherein	O
each	O
capsule	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
and	O
100	O
mg	O
of	O
the	O
corn	O
starch	O
,	O
or	O
each	O
tablet	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
and	O
100	O
mg	O
of	O
the	O
corn	O
starch	O
.	O

The	O
application	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
benefits	O
that	O
:	O
the	O
drugs	O
are	O
prescribed	O
preparations	O
composed	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
;	O
the	O
drugs	O
have	O
anti	O
-	O
stress	O
effect	O
and	O
are	O
capable	O
of	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and/or	O
posttraumatic	O
stress	O
disorder	O
and	O
improving	O
cognitive	O
function	O
;	O
the	O
pharmaceutical	O
effect	O
is	O
clear	O
;	O
the	O
safety	O
is	O
high	O
;	O
and	O
the	O
novel	O
drug	O
application	O
selection	O
is	O
provided	O
in	O
clinical	O
.	O

Cucoline	O
derivative	O
as	O
well	O
as	O
salts	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
cucoline	O
derivative	O
as	O
well	O
as	O
salts	O
,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

According	O
to	O
the	O
invention	O
,	O
1	O
,	O
4	O
,	O
6	O
and	O
17	O
positions	O
in	O
a	O
cucoline	O
structure	O
are	O
modified	O
so	O
as	O
to	O
obtain	O
the	O
cucoline	O
derivative	O
the	O
structural	O
general	O
formula	O
of	O
which	O
is	O
as	O
follows	O
(	O
shown	O
in	O
the	O
specification	O
)	O
;	O
the	O
salts	O
of	O
the	O
cucoline	O
derivative	O
comprise	O
hydrochloride	O
,	O
sulfate	O
,	O
bisulfate	O
,	O
hydrobromide	O
,	O
oxalate	O
,	O
citrate	O
and	O
mesylate	O
;	O
and	O
the	O
inhibition	O
activity	O
of	O
partial	O
compounds	O
of	O
the	O
invention	O
on	O
NF	B
-	I
kappa	I
B	I
are	O
obviously	O
superior	O
to	O
that	O
of	O
cucoline	O
,	O
and	O
the	O
cucoline	O
derivative	O
and	O
salts	O
thereof	O
are	O
used	O
for	O
preparing	O
anti	O
-	O
inflammatory	O
medicaments	O
.	O

Ambroxol	O
hydrochloride	O
oral	O
aqueous	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
an	O
oral	O
aqueous	O
composition	O
,	O
which	O
comprises	O
0.1	O
to	O
1	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
ambroxol	O
hydrochloride	O
,	O
0.05	O
to	O
0.2	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
solution	O
thickener	O
,	O
0.005	O
to	O
0.05	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
freshener	O
,	O
a	O
stabilizer	O
and	O
water	O
,	O
wherein	O
the	O
stabilizer	O
is	O
a	O
substance	O
for	O
forming	O
a	O
medicinal	O
solvent	O
system	O
by	O
combining	O
the	O
water	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
composition	O
.	O

The	O
oral	O
aqueous	O
composition	O
has	O
the	O
advantages	O
of	O
cool	O
and	O
refreshing	O
mouthfeel	O
,	O
wide	O
application	O
range	O
and	O
the	O
like	O
,	O
is	O
clear	O
and	O
stable	O
,	O
does	O
not	O
contain	O
any	O
natural	O
or	O
semi	O
-	O
synthetic	O
sweetener	O
,	O
and	O
is	O
suitable	O
for	O
patients	O
who	O
suffer	O
from	O
diabetes	O
and	O
people	O
who	O
are	O
allergic	O
to	O
the	O
semi	O
-	O
synthetic	O
sweetener	O
.	O

Drug	O
combination	O
containing	O
astragalus	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
combination	O
containing	O
astragalus	O
and	O
a	O
use	O
thereof	O
.	O

The	O
drug	O
combination	O
contains	O
astragalus	O
or	O
an	O
astragalus	O
extractive	O
or	O
a	O
derivative	O
thereof	O
capable	O
of	O
being	O
received	O
chemically	O
.	O

The	O
drug	O
combination	O
comprises	O
the	O
following	O
components	O
:	O
100	O
parts	O
of	O
astragalus	O
and	O
1	O
-	O
50	O
of	O
levamisole	O
hydrochloride	O
.	O

On	O
the	O
basis	O
,	O
the	O
following	O
one	O
or	O
more	O
components	O
can	O
be	O
increased	O
,	O
but	O
not	O
limited	O
:	O
20	O
-	O
150	O
parts	O
of	O
vitamin	O
C.	O
The	O
use	O
method	O
and	O
the	O
dosage	O
of	O
the	O
combination	O
are	O
shown	O
as	O
follows	O
:	O
a	O
solid	O
preparation	O
is	O
used	O
after	O
being	O
mixed	O
by	O
0.1	O
-	O
10.0	O
percent	O
of	O
complete	O
feeds	O
;	O
and	O
a	O
liquid	O
preparation	O
is	O
drunk	O
after	O
the	O
water	O
of	O
250	O
-	O
500	O
kg	O
is	O
added	O
in	O
the	O
liquid	O
preparation	O
of	O
100	O
ml	O
.	O

The	O
combination	O
has	O
the	O
main	O
function	O
of	O
inducing	O
a	O
human	O
body	O
to	O
generate	O
the	O
interferon	O
,	O
promoting	O
the	O
antibody	O
formation	O
and	O
adjusting	O
the	O
immunologic	O
function	O
of	O
the	O
human	O
body	O
.	O

The	O
drug	O
combination	O
is	O
used	O
for	O
simulating	O
an	O
immune	O
system	O
of	O
an	O
animal	O
body	O
,	O
adjusting	O
the	O
immunity	O
,	O
enhancing	O
the	O
disease	O
resistance	O
,	O
reducing	O
the	O
disease	O
incidence	O
and	O
assisting	O
to	O
treat	O
the	O
virus	O
infection	O
.	O

Fenticonazole	O
nitrate	O
medicinal	O
composition	O
The	O
invention	O
provides	O
a	O
fenticonazole	O
nitrate	O
-	O
containing	O
medicinal	O
composition	O
.	O

The	O
fenticonazole	O
nitrate	O
-	O
containing	O
medicinal	O
composition	O
consists	O
of	O
fenticonazole	O
nitrate	O
,	O
36-type	O
mixed	O
fatty	O
acid	O
glyceride	O
and	O
silicon	O
dioxide	O
in	O
a	O
ratio	O
of	O
2:	O
(	O
10	O
-	O
14	O
)	O
:	O
(	O
0.05	O
-	O
0.10	O
)	O
.	O

By	O
the	O
formula	O
,	O
the	O
problem	O
that	O
in	O
the	O
prior	O
art	O
,	O
active	O
ingredients	O
can	O
not	O
be	O
dispersed	O
well	O
is	O
solved	O
.	O

Medicinal	O
composition	O
of	O
amlodipine	O
and	O
atorvastatin	O
calcium	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
by	O
taking	O
amlodipine	O
and	O
atorvastatin	O
calcium	O
as	O
active	O
components	O
,	O
the	O
medicinal	O
composition	O
comprises	O
amlodipine	O
,	O
atorvastatin	O
calcium	O
,	O
a	O
filler	O
,	O
a	O
disintegrant	O
and	O
a	O
lubricant	O
;	O
the	O
active	O
components	O
are	O
composed	O
of	O
2	O
-	O
20	O
parts	O
of	O
amlodipine	O
and	O
5	O
-	O
120	O
parts	O
of	O
atorvastatin	O
calcium	O
;	O
the	O
amlodipine	O
is	O
a	O
maleic	O
acid	O
amlodipine	O
hydrate	O
crystal	O
.	O

The	O
molecular	O
formula	O
of	O
the	O
maleic	O
acid	O
amlodipine	O
hydrate	O
crystal	O
is	O
C24H29C1N2O9.1.5H2O	O
.	O

The	O
amlodipine	O
in	O
the	O
medicinal	O
composition	O
has	O
the	O
advantages	O
of	O
fast	O
effectiveness	O
and	O
stability	O
,	O
and	O
is	O
capable	O
of	O
steadily	O
releasing	O
the	O
drug	O
effect	O
in	O
24	O
hours	O
,	O
the	O
medicinal	O
composition	O
has	O
strong	O
synergy	O
,	O
accumulation	O
and	O
complementary	O
effects	O
,	O
and	O
the	O
bioavailability	O
is	O
high	O
.	O

Application	O
of	O
atractylodin	O
alcohol	O
in	O
medicament	O
preparation	O
The	O
invention	O
provides	O
application	O
of	O
an	O
atractylodin	O
alcohol	O
(	O
CZSC	O
)	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
animal	O
virus	O
diseases	O
,	O
in	O
particular	O
application	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
infection	O
and	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
PRRS	O
)	O
,	O
or	O
in	O
preparation	O
of	O
a	O
virus	O
gene	O
expression	O
inhibitor	O
and	O
an	O
anti	O
-	O
virus	O
medicament	O
and	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
inhibiting	O
blue	O
ear	O
disease	O
viruses	O
.	O

The	O
CZSC	O
has	O
remarkable	O
effects	O
of	O
regulating	O
nucleoprotein	B
gene	O
expression	O
of	O
the	O
PRRSV	O
down	O
and	O
inhibiting	O
virus	O
proliferation	O
;	O
and	O
in	O
vitro	O
cellular	O
pharmacological	O
tests	O
shows	O
that	O
the	O
CZSC	O
has	O
definite	O
anti	O
-	O
virus	O
effect	O
.	O

The	O
CZSC	O
has	O
wide	O
application	O
prospect	O
in	O
treatment	O
and	O
control	O
of	O
PRRSV	O
infection	O
.	O

Wound	O
healing	O
gel	O
and	O
preparation	O
process	O
thereof	O
The	O
invention	O
relates	O
to	O
wound	O
healing	O
gel	O
and	O
a	O
preparation	O
process	O
thereof	O
,	O
which	O
belong	O
to	O
the	O
field	O
of	O
medicine	O
preparations	O
and	O
clinic	O
applications	O
.	O

The	O
wound	O
healing	O
gel	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
2	O
to	O
3	O
percent	O
of	O
paste	O
powder	O
,	O
0.5	O
to	O
2	O
percent	O
of	O
30-percent	O
borneol	O
solution	O
,	O
8	O
to	O
12	O
percent	O
of	O
glycerol	O
,	O
0.8	O
to	O
1.2	O
percent	O
of	O
carbomer	O
,	O
0.1	O
to	O
0.2	O
percent	O
of	O
NaHSO3	O
,	O
0.02	O
to	O
0.04	O
percent	O
of	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
disodium	O
(	O
EDTA-2Na	O
)	O
,	O
8	O
to	O
12	O
percent	O
of	O
propylene	O
glycol	O
,	O
0.5	O
to	O
2	O
percent	O
of	O
10-percent	O
methylparaben	O
solution	O
,	O
1.4	O
to	O
1.8	O
percent	O
of	O
triethanolamine	O
and	O
50	O
to	O
80	O
percent	O
of	O
distilled	O
water	O
.	O

The	O
gel	O
can	O
be	O
used	O
for	O
treating	O
radiation	O
injury	O
,	O
cold	O
injury	O
and	O
burn	O
.	O

The	O
gel	O
can	O
be	O
used	O
for	O
II	O
degree	O
surface	O
of	O
burns	O
and	O
can	O
accelerate	O
the	O
healing	O
of	O
the	O
surface	O
of	O
burns	O
and	O
relieve	O
swelling	O
of	O
surface	O
of	O
burns	O
and	O
dehydration	O
of	O
the	O
wound	O
tissue	O
obviously	O
.	O

And	O
the	O
gel	O
has	O
the	O
characteristics	O
that	O
:	O
the	O
treatment	O
effect	O
is	O
exact	O
;	O
the	O
use	O
is	O
safe	O
;	O
the	O
quality	O
index	O
is	O
easy	O
to	O
control	O
;	O
the	O
price	O
is	O
low	O
;	O
and	O
the	O
like	O
.	O

Mangiferin	O
penta	O
-	O
esterified	O
derivative	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
chemically	O
synthesizing	O
a	O
mangiferin	O
penta	O
-	O
esterified	O
derivative	O
and	O
a	O
pharmacological	O
effect	O
of	O
resisting	O
inflammation	O
and	O
reducing	O
blood	O
sugar	O
of	O
the	O
derivative	O
.	O

The	O
chemical	O
structural	O
formula	O
of	O
the	O
derivative	O
is	O
shown	O
in	O
the	O
specifications	O
.	O

The	O
derivative	O
has	O
a	O
remarkable	O
effect	O
of	O
inhibiting	O
mouse	O
auricle	O
tumefaction	O
caused	O
by	O
dimethylbenzene	O
;	O
and	O
the	O
derivative	O
has	O
a	O
remarkable	O
effect	O
of	O
treating	O
diabetic	O
mice	O
induced	O
by	O
alloxan	O
.	O

New	O
aromatic	O
polyketones	O
,	O
extraction	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
microbial	O
engineering	O
,	O
and	O
specifically	O
relates	O
to	O
new	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
,	O
an	O
extraction	O
method	O
and	O
an	O
application	O
thereof	O
,	O
wherein	O
the	O
aromatic	O
polyketones	O
are	O
extracted	O
from	O
a	O
liquid	O
fermented	O
material	O
of	O
the	O
intestinal	O
bacteria	O
of	O
Tenoderaaridifolia	O
,	O
and	O
the	O
intestinal	O
bacteria	O
of	O
the	O
Tenoderaaridifolia	O
is	O
the	O
daldiniaeschscholzii	O
.	O

The	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
the	O
present	O
invention	O
have	O
the	O
following	O
structural	O
formula	O
.	O

The	O
daldiniaeschscholzii	O
aromatic	O
polyketone	O
1	O
has	O
strong	O
antioxidant	O
activity	O
,	O
and	O
the	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
2	O
-	O
5	O
have	O
strong	O
immunosuppression	O
activities	O
,	O
such	O
that	O
the	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
1	O
-	O
5	O
can	O
be	O
adopted	O
for	O
preparing	O
the	O
relevant	O
novel	O
drugs	O
,	O
wherein	O
the	O
daldiniaeschscholzii	O
aromatic	O
polyketones	O
of	O
1	O
-	O
5	O
are	O
adopted	O
as	O
the	O
compounds	O
with	O
the	O
antioxidant	O
effects	O
or	O
the	O
immunosuppression	O
effects	O
.	O

Freeze	O
-	O
dried	O
powder	O
injection	O
with	O
omeprazole	O
sodium	O
as	O
active	O
component	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
freeze	O
-	O
dried	O
powder	O
injection	O
with	O
omeprazole	O
sodium	O
as	O
its	O
active	O
component	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
prepared	O
from	O
omeprazole	O
sodium	O
,	O
edetate	O
disodium	O
,	O
a	O
pH	O
value	O
conditioning	O
agent	O
and	O
injection	O
water	O
,	O
wherein	O
the	O
omeprazole	O
sodium	O
is	O
a	O
novel	O
omeprazole	O
sodium	O
crystalline	O
compound	O
with	O
a	O
molecular	O
formula	O
of	O
C17H18N3NaO3S.2H2O	O
.	O

The	O
omeprazole	O
sodium	O
in	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
the	O
novel	O
omeprazole	O
sodium	O
crystalline	O
compound	O
,	O
and	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
prepared	O
from	O
the	O
novel	O
omeprazole	O
sodium	O
crystalline	O
compound	O
has	O
excellent	O
stability	O
.	O

Novel	O
pyrimidine	O
derivatives	O
as	O
well	O
as	O
preparation	O
method	O
and	O
applications	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pyrimidine	O
compounds	O
and	O
preparation	O
methods	O
thereof	O
.	O

The	O
novel	O
pyrimidine	O
derivatives	O
and	O
salts	O
thereof	O
are	O
compounds	O
shown	O
in	O
the	O
formula	O
(	O
1	O
)	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
represents	O
-CH2NHR4	O
or	O
cyano	O
group	O
;	O
R2	O
and	O
R3	O
independently	O
represent	O
aryl	O
and	O
substituted	O
aryl	O
;	O
X	O
represents	O
methylene	O
,	O
carbonyl	O
or	O
hydroxymethylene	O
;	O
R4	O
represents	O
H	O
,	O
acetyl	O
or	O
tosyl	O
;	O
and	O
n	O
is	O
an	O
integer	O
of	O
0	O
-	O
5	O
.	O

A	O
series	O
of	O
new	O
compounds	O
are	O
prepared	O
by	O
the	O
inventor	O
of	O
the	O
invention	O
;	O
pharmacological	O
results	O
show	O
that	O
the	O
dipeptidyl	B
peptidase	I
IV	I
(	O
DPPIV	B
)	O
inhibition	O
rate	O
is	O
close	O
to	O
or	O
superior	O
to	O
that	O
of	O
the	O
reference	O
substance	O
R-1579	O
;	O
and	O
some	O
pyrimidine	O
compounds	O
with	O
new	O
structures	O
have	O
excellent	O
DPP	B
-	I
IV	I
inhibitory	O
activity	O
and	O
wide	O
application	O
prospects	O
.	O

Macrocyclic	O
4-amino	O
-	O
quinazoline	O
derivatives	O
and	O
their	O
use	O
as	O
MTKI	O
Disclosed	O
are	O
a	O
kinase	B
inhibitor	O
and	O
N	O
-	O
oxide	O
form	O
and	O
pharmaceutically	O
acceptable	O
isomerous	O
form	O
thereof	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Z	O
is	O
NH	O
,	O
and	O
the	O
other	O
substituents	O
are	O
as	O
defined	O
herein	O
.	O

Hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
,	O
which	O
comprises	O
the	O
following	O
preparing	O
steps	O
:	O
step	O
(	O
1	O
)	O
,	O
dissolving	O
the	O
hypericin	O
albumin	O
nanoparticle	O
and	O
the	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
into	O
phosphate	O
buffer	O
solution	O
(	O
PBF	O
)	O
,	O
step	O
(	O
2	O
)	O
,	O
adding	O
glutaraldehyde	O
into	O
the	O
solution	O
obtained	O
by	O
the	O
step	O
(	O
1	O
)	O
,	O
and	O
obtaining	O
the	O
hypericin	O
albumin	O
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
.	O

The	O
hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
high	O
effective	O
utilization	O
;	O
simultaneously	O
,	O
the	O
preparation	O
method	O
of	O
the	O
hypericin	O
albumin	B
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
being	O
simple	O
in	O
process	O
,	O
easy	O
to	O
operate	O
and	O
specially	O
suitable	O
for	O
industrial	O
production	O
.	O

Composition	O
for	O
protecting	O
lever	O
and	O
achieving	O
sobering	O
function	O
The	O
invention	O
discloses	O
a	O
composition	O
for	O
protecting	O
lever	O
and	O
achieving	O
a	O
sobering	O
function	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
composition	O
.	O

The	O
composition	O
contains	O
30	O
-	O
180	O
parts	O
by	O
weight	O
of	O
sesamin	O
,	O
1	O
-	O
6	O
parts	O
by	O
weight	O
of	O
schisandrin	O
B	O
,	O
150	O
-	O
900	O
parts	O
by	O
weight	O
of	O
semen	O
hoveniae	O
extract	O
,	O
150	O
-	O
900	O
parts	O
by	O
weight	O
of	O
pueraria	O
lobata	O
extract	O
,	O
0.0012	O
-	O
0.0072	O
parts	O
by	O
weight	O
of	O
vitamin	O
B12	O
and	O
14	O
-	O
84	O
parts	O
by	O
weight	O
of	O
vitamin	O
E.	O

Bisabolane	O
sesquiterpenoid	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
as	O
selective	O
antibacterial	O
agent	O
The	O
invention	O
discloses	O
a	O
bisabolane	O
sesquiterpenoid	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
as	O
a	O
selective	O
antibacterial	O
agent	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
performing	O
strain	O
culturing	O
on	O
a	O
sponge	O
endophytic	O
fungi	O
,	O
i.e.	O
Asergillus	O
sp.	O
(	O
HM565949	O
)	O
in	O
a	O
strain	O
medium	O
;	O
cultivating	O
the	O
fungi	O
by	O
fermenting	O
in	O
a	O
fermentation	O
medium	O
;	O
filtering	O
the	O
obtained	O
fermentation	O
broth	O
to	O
remove	O
thallus	O
,	O
concentrating	O
the	O
filtrate	O
,	O
and	O
extracting	O
the	O
filtrate	O
with	O
ethyl	O
acetate	O
;	O
and	O
performing	O
chromatographic	O
separation	O
on	O
the	O
concentrate	O
and	O
respectively	O
concentrating	O
the	O
obtained	O
eluent	O
to	O
obtain	O
white	O
powder	O
,	O
i.e.	O
the	O
aspergterpeinoid	O
A	O
,	O
aspergiterpenoid	O
C	O
and	O
aspergiterpenoid	O
D.	O
The	O
bisabolane	O
sesquiterpenoid	O
obtained	O
from	O
a	O
marine	O
fungi	O
can	O
selectively	O
inhibit	O
the	O
activities	O
of	O
Staphylococcus	O
albus	O
,	O
Bacillus	O
subtilis	O
,	O
Bacillus	O
cereus	O
,	O
Sarcina	O
lutea	O
,	O
Escherichia	O
coli	O
,	O
Micrococcus	O
tetrgenus	O
,	O
marine	O
bacterial	O
Vibrio	O
parahaemolyticus	O
and	O
marine	O
bacterial	O
Vibrio	O
anguillarum	O
,	O
and	O
can	O
be	O
used	O
for	O
developing	O
the	O
selective	O
antibacterial	O
agent	O
.	O

In	O
addition	O
,	O
the	O
raw	O
materials	O
can	O
be	O
massively	O
produced	O
and	O
are	O
free	O
of	O
the	O
limitation	O
of	O
resources	O
.	O

Therefore	O
,	O
the	O
bisabolane	O
sesquiterpenoid	O
has	O
wide	O
application	O
prospect	O
.	O

Injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relating	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

The	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
is	O
a	O
powder	O
injection	O
and	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
carbazochrome	O
sodium	O
sulfonate	O
,	O
1.5	O
-	O
8.5	O
parts	O
of	O
pharmaceutically	O
acceptable	O
biological	O
carrier	O
,	O
0.1	O
-	O
1.8	O
parts	O
of	O
stabilizing	O
agent	O
and	O
2	O
-	O
5	O
parts	O
of	O
freezing	O
protective	O
agent	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
stability	O
and	O
the	O
dissolvability	O
of	O
the	O
carbazochrome	O
sodium	O
sulfonate	O
are	O
improved	O
,	O
the	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
has	O
no	O
remarkable	O
change	O
of	O
various	O
indexes	O
through	O
detection	O
after	O
being	O
placed	O
for	O
a	O
long	O
time	O
,	O
the	O
quality	O
of	O
the	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
within	O
a	O
valid	O
period	O
is	O
ensured	O
to	O
be	O
qualified	O
;	O
and	O
the	O
injection	O
carbazochrome	O
sodium	O
sulfonate	O
suspension	O
can	O
be	O
slowly	O
administrated	O
for	O
a	O
long	O
time	O
,	O
thus	O
bioavailability	O
is	O
greatly	O
improved	O
.	O

The	O
pharmaceutically	O
acceptable	O
biological	O
carrier	O
,	O
i.e.	O
protein	O
,	O
is	O
degraded	O
in	O
vivo	O
without	O
toxicity	O
and	O
immunogenicity	O
;	O
and	O
meanwhile	O
,	O
medicine	O
therapeutic	O
indexes	O
can	O
be	O
effectively	O
increased	O
,	O
and	O
medicine	O
toxicity	O
is	O
lowered	O
and	O
medicine	O
side	O
effects	O
are	O
reduced	O
.	O

Adriamycin	O
lipid	O
pharmaceutical	O
composition	O
The	O
invention	O
relates	O
to	O
an	O
adriamycin	O
lipid	O
pharmaceutical	O
composition	O
comprising	O
the	O
following	O
components	O
:	O
(	O
1	O
)	O
adriamycin	O
,	O
(	O
2	O
)	O
phospholipids	O
,	O
(	O
3	O
)	O
cholesterol	O
and	O
(	O
4	O
)	O
a	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
or	O
the	O
formula	O
9	O
(	O
described	O
in	O
the	O
specification	O
)	O
or	O
physiologically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
n	O
is	O
an	O
integral	O
number	O
of	O
5	O
-	O
500	O
,	O
m	O
is	O
an	O
integral	O
number	O
of	O
2	O
-	O
12	O
,	O
and	O
p	O
is	O
an	O
integral	O
number	O
of	O
1	O
-	O
8	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
and	O
application	O
of	O
the	O
lipid	O
pharmaceutical	O
composition	O
,	O
a	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
or	O
the	O
formula	O
9	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
compound	O
.	O

The	O
lipid	O
pharmaceutical	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
good	O
pH	O
sensitivity	O
and	O
optional	O
targeting	O
property	O
,	O
and	O
can	O
be	O
used	O
for	O
increasing	O
the	O
concentration	O
of	O
an	O
antitumour	O
medicament	O
at	O
a	O
target	O
part	O
and	O
also	O
reducing	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
antitumour	O
medicament	O
at	O
a	O
non	O
-	O
target	O
part	O
when	O
being	O
taken	O
as	O
a	O
liposome	O
,	O
thus	O
improving	O
therapeutic	O
index	O
of	O
the	O
antitumour	O
medicament	O
.	O

Combined	O
treatment	O
of	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
and	O
pharmaceutical	O
composition	O
The	O
invention	O
discloses	O
a	O
new	O
pharmaceutical	O
composition	O
for	O
treating	O
osteoporosis	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
greatly	O
improve	O
the	O
efficacy	O
of	O
osteoporosis	O
treatment	O
,	O
and	O
reduce	O
the	O
health	O
risks	O
and	O
side	O
effects	O
associated	O
with	O
taking	O
of	O
commonly	O
used	O
drugs	O
(	O
parathyroid	B
hormone	I
,	O
thyroid	O
hormone	O
,	O
estrogen	O
,	O
and	O
calcium	O
supplements	O
)	O
for	O
treating	O
osteoporosis	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
combined	O
treatment	O
method	O
of	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
.	O

The	O
method	O
includes	O
a	O
step	O
of	O
applying	O
an	O
effective	O
dose	O
of	O
to	O
the	O
new	O
pharmaceutical	O
composition	O
treating	O
osteoporosis	O
to	O
an	O
object	O
so	O
as	O
to	O
treat	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
of	O
the	O
object	O
.	O

Acer	O
truncatum	O
health	O
-	O
care	O
lozenge	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
health	O
-	O
care	O
lozenge	O
prepared	O
by	O
taking	O
an	O
acer	O
truncatum	O
extract	O
as	O
a	O
major	O
raw	O
material	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
health	O
-	O
care	O
lozenge	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
percentage	O
by	O
weight	O
:	O
20	O
-	O
40	O
percent	O
of	O
an	O
acer	O
truncatum	O
extract	O
,	O
15	O
-	O
25	O
percent	O
of	O
an	O
acer	O
truncatum	O
seed	O
extract	O
,	O
30	O
-	O
64	O
percent	O
of	O
a	O
seasoning	O
agent	O
and	O
1	O
-	O
5	O
percent	O
of	O
a	O
nutrition	O
fortifier	O
.	O

A	O
tablet	O
is	O
prepared	O
by	O
performing	O
deep	O
processing	O
on	O
terrestrial	O
plant	O
acer	O
truncatum	O
seeds	O
which	O
are	O
rich	O
in	O
nervonic	O
acid	O
and	O
terrestrial	O
plant	O
acer	O
truncatum	O
leaves	O
which	O
are	O
rich	O
in	O
flavone	O
,	O
and	O
has	O
the	O
effects	O
of	O
preventing	O
nerve	O
fiber	O
atrophy	O
,	O
promoting	O
brain	O
development	O
,	O
delaying	O
ageing	O
and	O
enhancing	O
the	O
immunity	O
and	O
digestive	O
function	O
of	O
a	O
human	O
body	O
;	O
and	O
over	O
-	O
high	O
blood	O
fat	O
concentration	O
in	O
blood	O
can	O
be	O
lowered	O
remarkably	O
,	O
and	O
the	O
occurrence	O
probability	O
of	O
diseases	O
such	O
as	O
certain	O
hypertension	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
blood	O
circulation	O
disorder	O
,	O
and	O
the	O
like	O
is	O
lowered	O
.	O

Sinomenine	O
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
sinomenine	O
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
,	O
relating	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
.	O

Specifically	O
,	O
the	O
invention	O
relates	O
to	O
sinomenine	O
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
sinomenine	O
4-OH	O
etherification	O
and	O
esterification	O
derivatives	O
.	O

An	O
ICR	O
(	O
Institute	O
of	O
Cancer	O
Research	O
)	O
mouse	O
model	O
and	O
an	O
SD	O
(	O
sprague	O
dawley	O
)	O
rat	O
model	O
are	O
applied	O
to	O
test	O
the	O
anti	O
-	O
inflammatory	O
and	O
immune	O
activity	O
293	O
cells	O
of	O
pNF	O
-	O
kB	O
-	O
luc	O
are	O
transfected	O
to	O
test	O
the	O
inhibition	O
of	O
the	O
compounds	O
to	O
an	O
NF	O
-	O
kB	O
signaling	O
channel	O
,	O
and	O
results	O
show	O
that	O
part	O
of	O
the	O
compounds	O
have	O
significant	O
anti	O
-	O
inflammatory	O
and	O
immune	O
activity	O
and	O
effects	O
on	O
inhibition	O
of	O
NF	O
-	O
kB.	O
The	O
derivatives	O
can	O
be	O
applied	O
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
and	O
immune	O
medicine	O
.	O

Active	O
bacteriostasis	O
capsule	O
The	O
invention	O
relates	O
to	O
an	O
active	O
bacteriostasis	O
capsule	O
,	O
comprising	O
the	O
following	O
ingredients	O
,	O
by	O
weight	O
,	O
lactobacillus	O
20	O
-	O
50	O
%	O
,	O
bifidobacterium	O
20	O
-	O
30	O
%	O
,	O
lactococcus	O
15	O
-	O
30	O
%	O
and	O
oliho	O
chitosan	O
15	O
-	O
30	O
%	O
.	O

The	O
Active	O
bacteriostasis	O
capsule	O
provided	O
in	O
the	O
invention	O
adopts	O
a	O
micro	O
ecological	O
theory	O
of	O
using	O
bacterium	O
to	O
kill	O
bacterium	O
and	O
inter	O
-	O
restriction	O
between	O
organisms	O
.	O

Large	O
amount	O
of	O
beneficial	O
bacterium	O
to	O
restrain	O
harmful	O
bacterium	O
is	O
supplied	O
and	O
the	O
beneficial	O
bacterium	O
is	O
planted	O
on	O
the	O
inner	O
wall	O
of	O
reproductive	O
tract	O
,	O
forming	O
a	O
beneficial	O
bacteria	O
barrier	O
.	O

The	O
capsule	O
can	O
repair	O
and	O
activate	O
a	O
self	O
clean	O
function	O
of	O
female	O
,	O
thereby	O
a	O
healthy	O
reproduction	O
tract	O
environment	O
is	O
formed	O
.	O

The	O
capsule	O
can	O
be	O
used	O
to	O
treat	O
various	O
vaginal	O
disease	O
caused	O
by	O
flora	O
disturbance	O
and	O
dysbacteriosis	O
.	O

Antipyrotic	O
powder	O
for	O
external	O
use	O
The	O
invention	O
relates	O
to	O
an	O
antipyrotic	O
powder	O
for	O
external	O
use	O
.	O

The	O
antipyrotic	O
powder	O
is	O
characterized	O
by	O
comprising	O
phellodendron	O
,	O
radix	O
sophorae	O
flavescentis	O
,	O
borneol	O
,	O
scorpio	O
,	O
alum	O
and	O
Senecio	O
scandens	O
with	O
auxiliary	O
materials	O
including	O
tea	O
oil	O
and	O
pig	O
bile	O
.	O

A	O
preparation	O
method	O
of	O
the	O
antipyrotic	O
powder	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
weighing	O
the	O
above	O
various	O
raw	O
materials	O
according	O
to	O
a	O
weight	O
ratio	O
,	O
placing	O
into	O
a	O
pulverizer	O
,	O
stirring	O
and	O
crushing	O
,	O
sieving	O
through	O
a	O
sieve	O
of	O
6	O
meshes	O
to	O
obtain	O
a	O
yellow	O
powder	O
,	O
and	O
packing	O
by	O
the	O
use	O
of	O
aluminium	O
foil	O
with	O
5	O
g	O
per	O
pack	O
.	O

The	O
invention	O
has	O
the	O
following	O
significant	O
effects	O
:	O
drug	O
properties	O
are	O
mild	O
;	O
there	O
is	O
no	O
side	O
effect	O
;	O
the	O
treatment	O
cost	O
is	O
low	O
;	O
the	O
curative	O
effect	O
is	O
fast	O
with	O
no	O
ache	O
;	O
and	O
the	O
total	O
efficiency	O
is	O
about	O
more	O
than	O
90	O
%	O
.	O

Tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
The	O
invention	O
provides	O
a	O
novel	O
tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
.	O

Ethyl	O
cellulose	O
and	O
povidone	O
are	O
used	O
as	O
membrane	O
forming	O
materials	O
of	O
a	O
semipermeable	O
membrane	O
,	O
and	O
the	O
asymmetric	O
tablet	O
form	O
is	O
preferably	O
selected	O
,	O
so	O
that	O
the	O
ageing	O
of	O
the	O
semipermeable	O
membrane	O
can	O
be	O
avoided	O
,	O
and	O
the	O
drug	O
residues	O
can	O
be	O
reduced	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
improving	O
the	O
ageing	O
resistance	O
of	O
the	O
tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
,	O
wherein	O
the	O
method	O
is	O
characterized	O
in	O
that	O
the	O
ethyl	O
cellulose	O
-	O
povidone	O
are	O
used	O
as	O
the	O
membrane	O
forming	O
materials	O
of	O
the	O
semipermeable	O
membrane	O
.	O

In	O
addition	O
,	O
the	O
invention	O
also	O
provides	O
applications	O
of	O
the	O
ethyl	O
cellulose	O
-	O
povidone	O
composition	O
in	O
preparing	O
the	O
anti	O
-	O
ageing	O
tamsulosin	O
hydrochloride	O
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
.	O

Ester	O
derivative	O
of	O
high	O
veratryl	O
alcohol	O
and	O
medical	O
treatment	O
application	O
The	O
invention	O
discloses	O
an	O
ester	O
derivative	O
of	O
high	O
veratryl	O
alcohol	O
and	O
medical	O
treatment	O
application	O
,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicines	O
.	O

A	O
compound	O
with	O
biological	O
activity	O
is	O
a	O
compound	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
shown	O
in	O
the	O
specification	O
,	O
and	O
salt	O
,	O
a	O
solvate	O
or	O
a	O
hydrate	O
of	O
the	O
compound	O
,	O
wherein	O
X1	O
is	O
H	O
or	O
COR1	O
,	O
X2	O
is	O
H	O
or	O
COR2	O
,	O
X3	O
is	O
H	O
or	O
COR3	O
,	O
but	O
X1	O
,	O
X2	O
and	O
X3	O
are	O
not	O
H	O
and	O
3-pyridyl	O
simultaneously	O
;	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
the	O
same	O
as	O
one	O
another	O
or	O
different	O
from	O
one	O
another	O
and	O
are	O
C1-C6	O
alkyl	O
substituted	O
by	O
R4	O
or	O
can	O
be	O
substituted	O
by	O
R9	O
at	O
random	O
and	O
can	O
contain	O
one	O
or	O
more	O
4	O
-	O
7-membered	O
rings	O
of	O
additional	O
heteroatom	O
of	O
O	O
,	O
S	O
(	O
O	O
)	O
n	O
and	O
NR9	O
;	O
R4	O
is	O
F	O
,	O
CF3	O
,	O
OR5	O
,	O
NR6R7	O
or	O
S	O
(	O
O	O
)	O
nR8	O
;	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
the	O
same	O
as	O
one	O
another	O
or	O
different	O
from	O
one	O
another	O
and	O
are	O
H	O
or	O
C1-C6	O
alkyl	O
substituted	O
by	O
R4	O
at	O
random	O
,	O
or	O
NR6R7	O
is	O
one	O
or	O
more	O
C4-C6	O
heterocycle	O
alkyl	O
rings	O
of	O
the	O
heteroatom	O
of	O
O	O
,	O
NR9	O
and	O
S	O
(	O
O	O
)	O
n	O
;	O
each	O
n	O
is	O
0	O
to	O
2	O
;	O
R8	O
is	O
C1-C6	O
alkyl	O
;	O
R9	O
is	O
C1-C4	O
alkyl	O
which	O
is	O
defined	O
by	O
R4	O
or	O
substituted	O
by	O
R4	O
or	O
halogens	O
at	O
random	O
;	O
and	O
R9	O
is	O
H	O
or	O
C1-C6	O
alkyl	O
.	O

The	O
ester	O
derivative	O
has	O
the	O
effect	O
of	O
treating	O
liver	O
diseases	O
,	O
T	O
-	O
cell	O
proliferation	O
related	O
diseases	O
or	O
proinflammatory	O
cytokine	O
mediated	O
diseases	O
.	O

Gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
for	O
injection	O
.	O

The	O
gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
consists	O
of	O
the	O
following	O
components	O
in	O
parts	O
by	O
mass	O
:	O
100	O
parts	O
of	O
gemcitabine	O
hydrochloride	O
,	O
160	O
-	O
180	O
parts	O
of	O
lactose	O
and	O
3	O
-	O
6	O
parts	O
of	O
sodium	O
citrate	O
.	O

As	O
proved	O
by	O
influencing	O
factor	O
testing	O
investigation	O
,	O
each	O
detection	O
index	O
the	O
gemcitabine	O
hydrochloride	O
lyophilized	O
powder	O
for	O
injection	O
prepared	O
by	O
adopting	O
a	O
formula	O
and	O
a	O
process	O
provided	O
by	O
the	O
invention	O
does	O
not	O
change	O
remarkably	O
in	O
a	O
high	O
-	O
temperature	O
,	O
high	O
-	O
humidity	O
and	O
strong	O
-	O
light	O
-	O
irradiation	O
environment	O
,	O
and	O
high	O
stability	O
is	O
achieved	O
.	O

New	O
application	O
of	O
alpinetin	O
The	O
invention	O
discloses	O
new	O
application	O
of	O
alpinetin	O
.	O

The	O
new	O
application	O
means	O
that	O
the	O
alpinetin	O
serving	O
as	O
an	O
active	O
ingredient	O
is	O
used	O
for	O
preparing	O
medicaments	O
or	O
health	O
-	O
care	O
food	O
for	O
treating	O
ulcerative	O
colitis	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
alpinetin	O
can	O
obviously	O
improve	O
the	O
symptoms	O
such	O
as	O
weight	O
loss	O
,	O
bloody	O
stool	O
,	O
colon	O
shortening	O
,	O
inflammatory	O
cell	O
infiltration	O
and	O
pathological	O
tissue	O
damage	O
of	O
ulcerative	O
colitis	O
mice	O
,	O
and	O
can	O
inhibit	O
the	O
expression	O
of	O
proinflammatory	O
factors	O
TNF	O
-	O
alpha	O
and	O
IL-6	O
.	O

Therefore	O
,	O
the	O
alpinetin	O
serving	O
as	O
the	O
active	O
ingredient	O
is	O
expected	O
to	O
be	O
developed	O
into	O
a	O
medicament	O
or	O
health	O
-	O
care	O
food	O
for	O
treating	O
the	O
ulcerative	O
colitis	O
.	O

The	O
medicinal	O
value	O
of	O
the	O
alpinetin	O
can	O
be	O
fully	O
exerted	O
,	O
and	O
the	O
invention	O
has	O
significance	O
for	O
research	O
and	O
application	O
of	O
the	O
alpinetin	O
.	O

Mecobalamin	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
mecobalamin	O
tablet	O
which	O
has	O
very	O
low	O
content	O
of	O
related	O
substances	O
and	O
can	O
simultaneously	O
realize	O
rapid	O
disintegration	O
.	O

The	O
mecobalamin	O
tablet	O
is	O
prepared	O
by	O
mixing	O
mecobalamin	O
powder	O
with	O
a	O
coating	O
filling	O
agent	O
,	O
then	O
using	O
an	O
Opadry	O
coating	O
to	O
prepare	O
mecobalamin	O
coated	O
particles	O
under	O
the	O
conditions	O
of	O
protecting	O
from	O
light	O
,	O
further	O
adding	O
pharmaceutically	O
acceptable	O
tablet	O
excipients	O
,	O
and	O
tabletting	O
.	O

According	O
to	O
the	O
mecobalamin	O
tablet	O
provided	O
by	O
the	O
invention	O
,	O
the	O
process	O
flow	O
of	O
mecobalamin	O
which	O
is	O
very	O
sensitive	O
to	O
light	O
is	O
improved	O
from	O
the	O
way	O
of	O
firstly	O
tabletting	O
and	O
then	O
coating	O
to	O
the	O
way	O
of	O
firstly	O
coating	O
and	O
then	O
tabletting	O
..	O

Through	O
an	O
advanced	O
powder	O
coating	O
technology	O
,	O
the	O
treatment	O
of	O
protecting	O
from	O
the	O
light	O
is	O
performed	O
on	O
the	O
mecobalamin	O
in	O
the	O
first	O
process	O
step	O
to	O
complete	O
the	O
protection	O
of	O
the	O
mecobalamin	O
so	O
as	O
to	O
enable	O
the	O
follow	O
-	O
up	O
process	O
steps	O
to	O
get	O
rid	O
of	O
the	O
influence	O
of	O
a	O
light	O
source	O
on	O
the	O
mecobalamin	O
,	O
the	O
means	O
of	O
controlling	O
the	O
related	O
substances	O
is	O
better	O
than	O
the	O
traditional	O
full	O
-	O
process	O
operation	O
of	O
protecting	O
from	O
the	O
light	O
,	O
the	O
coating	O
time	O
is	O
saved	O
,	O
and	O
the	O
efficiency	O
is	O
improved	O
.	O

Application	O
of	O
baicalin	O
to	O
preparation	O
of	O
medicament	O
for	O
treating	O
pneumonia	O
The	O
present	O
invention	O
relates	O
to	O
application	O
of	O
baicalin	O
to	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
pneumonia	O
.	O

A	O
rabbit	O
erythrocyte	O
hemolysis	O
test	O
,	O
a	O
human	O
pulmonary	O
epithelial	O
cell	O
(	O
A549	O
)	O
injury	O
protection	O
test	O
and	O
a	O
mouse	O
Staphylococcus	O
aureus	O
pneumonia	O
model	O
are	O
employed	O
to	O
confirm	O
the	O
treatment	O
effect	O
of	O
the	O
baicalin	O
.	O

Compared	O
with	O
an	O
antibiotic	O
therapy	O
,	O
the	O
use	O
of	O
baicalin	O
has	O
characteristics	O
of	O
no	O
drug	O
resistance	O
and	O
high	O
cure	O
rate	O
.	O

1-substituted-1H-1,2,4-triazole	O
-	O
formamide	O
derivatives	O
,	O
preparation	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
1-substituted-1H-1,2,4-triazole	O
-	O
formamide	O
derivatives	O
.	O

The	O
substitution	O
position	O
of	O
formamido	O
is	O
in	O
5-	O
or	O
3-	O
position	O
of	O
1H-1,2,4-triazole	O
,	O
rufinamide	O
is	O
a	O
lead	O
compound	O
,	O
the	O
parent	O
nucleus	O
1,2,3-triazole	O
is	O
replaced	O
by	O
1,2,4-triazole	O
,	O
the	O
structure	O
of	O
the	O
side	O
chain	O
formamide	O
is	O
maintained	O
,	O
different	O
substituted	O
aromatic	O
(	O
heterocyclic	O
)	O
rings	O
replace	O
2,6-difluorobenzene	O
structure	O
,	O
the	O
type	O
,	O
number	O
or	O
position	O
of	O
the	O
substituent	O
group	O
on	O
a	O
benzene	O
ring	O
is	O
changed	O
to	O
obtain	O
a	O
series	O
of	O
1-substituted-1H-1,2,4-triazole-5-formamide	O
/	O
1-substituted-1H-1,2,4-triazole-3-formamide	O
derivatives	O
.	O

Pharmaceutical	O
activity	O
screening	O
experiments	O
prove	O
that	O
the	O
compounds	O
have	O
good	O
anticonvulsant	O
activity	O
,	O
and	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
anticonvulsant	O
medicaments	O
.	O

The	O
preparation	O
method	O
has	O
reasonable	O
design	O
,	O
simple	O
steps	O
and	O
practicality	O
;	O
and	O
the	O
derivatives	O
have	O
the	O
structural	O
general	O
formula	O
in	O
the	O
specification	O
.	O

Use	O
of	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
prevention	O
and	O
treatment	O
on	O
senile	O
dementia	O
The	O
invention	O
discloses	O
a	O
use	O
of	O
a	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
prevention	O
and	O
treatment	O
on	O
senile	O
dementia	O
.	O

The	O
compound	O
is	O
N'-	O
{	O
5-	O
[	O
acetyl	O
(	O
hydroxyl	O
)	O
amido	O
]	O
pentyl	O
}	O
-N-	O
[	O
5-	O
(	O
{	O
4-	O
[	O
(	O
5-aminopentyl	O
)	O
(	O
hydroxyl	O
)	O
amido	O
]	O
-4-keto	O
-	O
butyryl	O
}	O
amido	O
)	O
pentyl	O
]	O
-N	O
-	O
hydroxysuccinic	O
acid	O
amide	O
.	O

The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
be	O
used	O
as	O
a	O
drug	O
for	O
preventing	O
and	O
treating	O
senile	O
dementia	O
.	O

The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
penetrate	O
a	O
blood	O
brain	O
barrier	O
and	O
then	O
bind	O
with	O
a	O
heavy	O
metal	O
to	O
form	O
a	O
chelate	O
thereby	O
inhibiting	O
production	O
of	O
amyloid	B
in	O
the	O
brain	O
,	O
preventing	O
polymerization	O
and	O
accumulation	O
of	O
amyloid	B
,	O
dissolving	O
produced	O
amyloid	B
plaques	O
and	O
promoting	O
amyloid	B
degradation	O
.	O

Novel	O
pyridine	O
alkaloids	O
,	O
preparation	O
process	O
thereof	O
,	O
and	O
the	O
uses	O
of	O
the	O
pyridine	O
alkaloids	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
pyridine	O
alkaloid	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
as	O
described	O
in	O
the	O
specification	O
,	O
the	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O
,	O
and	O
the	O
composition	O
comprising	O
the	O
same	O
.	O

The	O
uses	O
of	O
a	O
pyridine	O
compound	O
for	O
increasing	O
the	O
activity	O
of	O
PPAR	B
[	I
gamma	I
]	I
,	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	B
resistance	O
,	O
and	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
metabolic	O
syndrome	O
or	O
its	O
complication	O
are	O
also	O
provided	O
.	O

The	O
invention	O
also	O
provides	O
extracts	O
of	O
red	O
yeast	O
-	O
fermented	O
products	O
and	O
their	O
uses	O
for	O
prevention	O
and/or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	B
resistance	O
,	O
such	O
as	O
metabolic	O
syndrome	O
.	O

Granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
.	O

The	O
granulation	O
promoting	O
powder	O
comprises	O
the	O
following	O
components	O
:	O
125	O
g	O
of	O
realgar	O
,	O
60	O
g	O
of	O
amber	O
,	O
15	O
g	O
of	O
borax	O
,	O
15	O
g	O
of	O
borneol	O
,	O
15	O
g	O
of	O
compound	O
of	O
glauber	O
-	O
salt	O
and	O
liquorice	O
and	O
250	O
g	O
of	O
talcum	O
powder	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
grinding	O
the	O
125	O
g	O
of	O
realgar	O
,	O
60	O
g	O
of	O
amber	O
,	O
15	O
g	O
of	O
borax	O
,	O
15	O
g	O
of	O
borneol	O
,	O
15	O
g	O
of	O
compound	O
of	O
glauber	O
-	O
salt	O
and	O
liquorice	O
and	O
250	O
g	O
of	O
talcum	O
powder	O
into	O
powder	O
;	O
uniformly	O
mixing	O
;	O
and	O
sub	O
-	O
packing	O
the	O
mixed	O
powder	O
.	O

Through	O
the	O
invention	O
,	O
the	O
medicine	O
can	O
be	O
directly	O
applied	O
to	O
the	O
lesion	O
to	O
completely	O
exert	O
the	O
efficacy	O
,	O
the	O
local	O
symptoms	O
of	O
red	O
,	O
swelling	O
,	O
itch	O
,	O
pain	O
and	O
the	O
like	O
can	O
be	O
relieved	O
,	O
the	O
exudation	O
and	O
incrustation	O
are	O
reduced	O
,	O
and	O
infection	O
is	O
eliminated	O
to	O
prompt	O
the	O
inflammation	O
absorption	O
and	O
quick	O
healing	O
of	O
wound	O
.	O

Dual	O
component	O
oral	O
care	O
product	O
A	O
pull	O
-	O
apart	O
fragrance	O
sampler	O
laminate	O
is	O
constructed	O
by	O
dispersing	O
microcapsules	O
containing	O
fragrance	O
oil	O
into	O
a	O
quick	O
setting	O
adhesive	O
.	O

The	O
resulting	O
dispersion	O
is	O
applied	O
to	O
a	O
surface	O
of	O
a	O
substrate	O
and	O
then	O
covered	O
with	O
an	O
overlayer	O
.	O

The	O
substrate	O
and	O
overlayer	O
adhere	O
to	O
the	O
dispersion	O
until	O
they	O
are	O
pulled	O
apart	O
whereby	O
the	O
microcapsules	O
are	O
fractured	O
,	O
releasing	O
the	O
fragrance	O
.	O

The	O
substrate	O
may	O
be	O
a	O
continuous	O
web	O
of	O
two	O
-	O
layer	O
stock	O
having	O
a	O
silicone	O
coated	O
liner	O
and	O
a	O
release	O
layer	O
on	O
which	O
the	O
dispersion	O
is	O
coated	O
for	O
making	O
fragrance	O
samplers	O
in	O
the	O
form	O
of	O
die	O
cut	O
labels	O
.	O

The	O
dispersion	O
may	O
be	O
applied	O
to	O
the	O
substrate	O
by	O
a	O
relief	O
printing	O
plate	O
at	O
a	O
station	O
of	O
a	O
printing	O
press	O
through	O
which	O
the	O
substrate	O
and	O
cover	O
layer	O
are	O
transported	O
.	O

Suction	O
therapy	O
for	O
repairing	O
brain	O
cells	O
,	O
containing	O
cerebral	O
hemorrhage	O
and	O
enhancing	O
immune	O
system	O
The	O
invention	O
aims	O
to	O
provide	O
a	O
suction	O
therapy	O
for	O
repairing	O
brain	O
cells	O
,	O
containing	O
cerebral	O
hemorrhage	O
and	O
enhancing	O
an	O
immune	O
system	O
.	O

The	O
therapy	O
is	O
composed	O
of	O
curcumin	O
,	O
CNB-001	O
and	O
ornithine	O
and	O
is	O
characterized	O
by	O
the	O
utilization	O
of	O
a	O
suction	O
method	O
.	O

Active	O
ingredients	O
in	O
the	O
therapy	O
pass	O
through	O
a	O
respiratory	O
system	O
and	O
directly	O
penetrate	O
through	O
blood	O
cerebral	O
barrier	O
so	O
as	O
to	O
rapidly	O
reach	O
curative	O
effects	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
ecdysone	O
-	O
rich	O
plant	O
standardized	O
extract	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
an	O
ecdysone	O
-	O
rich	O
plant	O
standardized	O
extract	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
extracting	O
ecdysone	O
-	O
rich	O
plant	O
materials	O
using	O
ethanol	O
under	O
reflux	O
,	O
filtering	O
,	O
concentrating	O
and	O
centrifuing	O
;	O
decolorizing	O
the	O
centrifuged	O
supernatant	O
,	O
purifying	O
by	O
macroporous	O
resin	O
column	O
chromatography	O
,	O
concentrating	O
and	O
drying	O
to	O
obtain	O
the	O
standardized	O
extract	O
.	O

The	O
method	O
is	O
simple	O
and	O
feasible	O
,	O
short	O
in	O
production	O
period	O
,	O
and	O
stable	O
and	O
controllable	O
in	O
quality	O
,	O
and	O
is	O
easy	O
for	O
preparation	O
and	O
industrial	O
production	O
in	O
a	O
standardized	O
and	O
batch	O
manner	O
;	O
and	O
the	O
similarity	O
of	O
the	O
extract	O
obtained	O
by	O
the	O
method	O
is	O
more	O
than	O
99	O
%	O
by	O
HPLC	O
(	O
high	O
performance	O
liquid	O
chromatography	O
)	O
fingerprint	O
spectrum	O
detection	O
.	O

The	O
extract	O
can	O
be	O
applied	O
in	O
preparing	O
fixed	O
preparations	O
serving	O
as	O
drugs	O
for	O
reducing	O
blood	O
sugar	O
and	O
resisting	O
rheumatoid	O
arthritis	O
,	O
can	O
be	O
used	O
as	O
a	O
raw	O
material	O
for	O
natural	O
cosmetics	O
and	O
can	O
be	O
applied	O
in	O
animal	O
breeding	O
industry	O
.	O

Application	O
of	O
isobavachalcone	O
in	O
treating	O
nerve	O
inflammatory	O
diseases	O
The	O
invention	O
relates	O
to	O
application	O
of	O
isobavachalcone	O
displayed	O
in	O
formula	O
I	O
in	O
treating	O
microglial	O
cell	O
mediated	O
diseases	O
,	O
in	O
particular	O
to	O
application	O
of	O
isobavachalcone	O
in	O
preparing	O
medicines	O
for	O
treating	O
and/or	O
preventing	O
microglial	O
cell	O
mediated	O
diseases	O
especially	O
microglial	O
cell	O
mediated	O
neural	O
immune	O
inflammatory	O
diseases	O
caused	O
by	O
neurotoxic	O
effect	O
.	O

The	O
isobavachalcone	O
has	O
new	O
functions	O
of	O
being	O
capable	O
of	O
obviously	O
restraining	O
microglial	O
cellsfrom	O
activating	O
or	O
inducing	O
cells	O
to	O
die	O
,	O
restraining	O
generation	O
and	O
expression	O
of	O
inflammatory	O
media	O
NO	O
of	O
activated	O
microglial	O
cells	O
and	O
obviously	O
relieving	O
cytotoxicity	O
of	O
activated	O
microglial	O
cells	O
to	O
neurons	O
.	O

Therefore	O
,	O
isobavachalcone	O
can	O
be	O
applied	O
to	O
preventive	O
treatment	O
of	O
diseases	O
related	O
to	O
brain	O
immune	O
inflammatory	O
diseases	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Application	O
of	O
NSC23766	O
on	O
preparing	O
medicines	O
for	O
treating	O
mental	O
excitation	O
drug	O
addiction	O
The	O
invention	O
discloses	O
application	O
of	O
NSC23766	O
on	O
preparing	O
medicines	O
for	O
treating	O
mental	O
excitation	O
drug	O
addiction	O
.	O

The	O
NSC23766	O
is	O
used	O
for	O
treating	O
cocaine	O
induction	O
behaviouristics	O
plasticity	O
changes	O
,	O
and	O
the	O
NSC23766	O
is	O
proved	O
to	O
be	O
capable	O
of	O
effectively	O
restraining	O
behaviouristics	O
sensitization	O
action	O
and	O
conditioned	O
place	O
preference	O
induced	O
by	O
cocaine	O
,	O
the	O
NSC23766	O
is	O
basically	O
free	O
of	O
toxic	O
and	O
side	O
effects	O
,	O
and	O
the	O
medicine	O
has	O
developing	O
prospects	O
and	O
can	O
treat	O
the	O
mental	O
excitation	O
drug	O
addiction	O
,	O
in	O
particular	O
to	O
cocaine	O
addiction	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
and	O
preparation	O
method	O
The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
and	O
a	O
preparation	O
method	O
,	O
and	O
an	O
application	O
of	O
the	O
medicines	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
.	O

The	O
pharmaceutical	O
composition	O
takes	O
a	O
mixture	O
of	O
at	O
least	O
one	O
or	O
more	O
of	O
Praeruptorin	O
A	O
,	O
Pb	O
-	O
Ia	O
and	O
its	O
isomeride	O
and	O
a	O
racemate	O
,	O
Praeruptorin	O
B	O
,	O
Pb	O
-	O
Ia	O
II	O
and	O
its	O
isomeride	O
and	O
a	O
racemate	O
,	O
and	O
Praeruptorin	O
C	O
according	O
to	O
certain	O
proportion	O
as	O
an	O
active	O
component	O
,	O
and	O
is	O
composed	O
of	O
the	O
mixture	O
and	O
a	O
conventional	O
drug	O
carrier	O
.	O

The	O
weight	O
percentage	O
content	O
of	O
the	O
active	O
component	O
is	O
0.1	O
-	O
99.5	O
%	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
used	O
for	O
preparing	O
and	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
the	O
advantages	O
that	O
the	O
source	O
of	O
the	O
raw	O
materials	O
is	O
abundant	O
,	O
the	O
pharmaceutical	O
composition	O
has	O
substantial	O
prevention	O
and	O
treatment	O
effects	O
for	O
diabetes	O
associated	O
with	O
hyperlipemia	O
,	O
the	O
usage	O
is	O
convenient	O
,	O
and	O
provides	O
a	O
novel	O
treatment	O
candidate	O
medicine	O
for	O
patients	O
.	O

Veterinary	O
compound	O
florfenicol	O
injection	O
The	O
invention	O
aims	O
to	O
provide	O
a	O
veterinary	O
compound	O
florfenicol	O
injection	O
,	O
which	O
is	O
used	O
for	O
efficiently	O
treating	O
porcine	O
respiratory	O
disease	O
complex	O
and	O
porcine	O
digestive	O
tract	O
disease	O
.	O

Each	O
100ml	O
of	O
veterinary	O
compound	O
florfenicol	O
injection	O
contains	O
10	O
-	O
30	O
g	O
of	O
florfenicol	O
,	O
1	O
-	O
5	O
g	O
of	O
andrographolide	O
,	O
1	O
-	O
3	O
g	O
of	O
TMP	O
(	O
Trimethoprim	O
)	O
,	O
0.1	O
-	O
0.2	O
g	O
of	O
antioxygen	O
,	O
0.01	O
-	O
0.02	O
g	O
of	O
ethylenediaminetetraacetic	O
acid	O
disodium	O
,	O
and	O
the	O
balance	O
of	O
solvent	O
for	O
injection	O
.	O

The	O
veterinary	O
compound	O
florfenicol	O
injection	O
is	O
a	O
composition	O
of	O
the	O
florfenicol	O
,	O
the	O
andrographolide	O
and	O
the	O
TMP	O
which	O
have	O
significant	O
effects	O
on	O
the	O
porcine	O
respiratory	O
disease	O
complex	O
,	O
and	O
is	O
administrated	O
through	O
an	O
injection	O
way	O
,	O
the	O
dosage	O
is	O
accurate	O
,	O
the	O
absorption	O
is	O
quick	O
,	O
the	O
blood	O
concentration	O
is	O
high	O
,	O
the	O
distribution	O
is	O
wide	O
,	O
the	O
half	O
-	O
life	O
period	O
is	O
long	O
,	O
the	O
effective	O
concentration	O
maintenance	O
time	O
is	O
long	O
,	O
and	O
compared	O
with	O
the	O
pesticide	O
effect	O
of	O
the	O
existing	O
florfenicol	O
injection	O
and	O
the	O
herba	O
andrographitis	O
injection	O
,	O
the	O
pesticide	O
effect	O
of	O
the	O
veterinary	O
compound	O
florfenicol	O
injection	O
is	O
obviously	O
enhanced	O
.	O

Application	O
of	O
polysaccharide	O
sulphate	O
to	O
preparation	O
of	O
tumor	O
treatment	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
The	O
invention	O
provides	O
application	O
of	O
polysaccharide	O
sulphate	O
to	O
preparation	O
of	O
tumor	O
treatment	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
.	O

Experiments	O
prove	O
that	O
the	O
neovascularization	O
inhibiting	O
rate	O
,	O
the	O
maturation	O
blood	O
vessel	O
disrupting	O
rate	O
and	O
the	O
concentration	O
of	O
the	O
polysaccharide	O
sulphate	O
are	O
in	O
dosage	O
relying	O
relationship	O
in	O
a	O
certain	O
range	O
,	O
and	O
the	O
maturation	O
blood	O
vessel	O
disrupting	O
rate	O
and	O
the	O
polysaccharide	O
sulphate	O
acting	O
time	O
are	O
in	O
dosage	O
relying	O
relationship	O
.	O

The	O
application	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
effect	O
of	O
the	O
polysaccharide	O
sulphate	O
in	O
the	O
aspects	O
of	O
tumor	O
neovascularization	O
inhibiting	O
and	O
tumor	O
blood	O
vessel	O
generation	O
disrupting	O
can	O
be	O
proved	O
,	O
and	O
the	O
polysaccharide	O
sulphate	O
can	O
be	O
used	O
for	O
tumor	O
blood	O
vessel	O
generation	O
and	O
other	O
blood	O
vessel	O
generation	O
disease	O
treatment	O
,	O
and	O
can	O
also	O
be	O
used	O
in	O
aspects	O
of	O
tumor	O
chemotherapy	O
and/or	O
auxiliary	O
chemotherapy	O
.	O

Many	O
diseases	O
of	O
people	O
are	O
relevant	O
to	O
the	O
blood	O
vessel	O
generation	O
,	O
and	O
the	O
polysaccharide	O
sulphate	O
as	O
the	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
can	O
be	O
widely	O
applied	O
to	O
the	O
treatment	O
of	O
diseases	O
of	O
tumor	O
and	O
the	O
like	O
.	O

The	O
application	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
application	O
range	O
of	O
the	O
polysaccharide	O
sulphate	O
is	O
widened	O
,	O
and	O
the	O
scientific	O
basis	O
is	O
provided	O
for	O
the	O
purpose	O
development	O
of	O
the	O
polysaccharide	O
sulphate	O
in	O
the	O
anti	O
-	O
tumor	O
aspect	O
and	O
the	O
like	O
.	O

Vinflunine	O
liposome	O
preparation	O
and	O
preparation	O
method	O
of	O
vinflunine	O
liposome	O
preparation	O
The	O
invention	O
relates	O
to	O
a	O
vinflunine	O
liposome	O
preparation	O
and	O
the	O
preparation	O
method	O
thereof	O
.	O

The	O
vinflunine	O
liposome	O
preparation	O
mainly	O
comprises	O
vinflunine	O
or	O
salt	O
,	O
phospholipid	O
,	O
cholesterin	O
and	O
polyethylene	O
glycol	O
-	O
distearoyl	O
phosphatidyl	O
ethanolamine	O
of	O
the	O
vinflunine	O
,	O
wherein	O
salt	O
,	O
phospholipid	O
,	O
cholesterin	O
and	O
polyethylene	O
glycol	O
-	O
distearoyl	O
phosphatidyl	O
ethanolamine	O
are	O
pharmaceutically	O
acceptable	O
,	O
and	O
the	O
vinflunine	O
liposome	O
preparation	O
can	O
be	O
prepared	O
into	O
an	O
injection	O
or	O
a	O
lyophilized	O
preparation	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
in	O
technology	O
,	O
easy	O
to	O
operate	O
and	O
suitable	O
for	O
industrial	O
production	O
,	O
and	O
long	O
-	O
circulating	O
vinflunine	O
liposomes	O
prepared	O
by	O
using	O
the	O
method	O
are	O
high	O
in	O
encapsulation	O
rate	O
and	O
good	O
in	O
stability	O
.	O

Iloperidone	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
an	O
iloperidone	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
the	O
iloperidone	O
composition	O
,	O
iloperidone	O
which	O
is	O
taken	O
as	O
an	O
active	O
ingredient	O
is	O
pretreated	O
,	O
so	O
that	O
the	O
particle	O
size	O
of	O
the	O
iloperidone	O
is	O
minimized	O
;	O
and	O
therefore	O
,	O
the	O
dissolution	O
rate	O
of	O
the	O
iloperidone	O
is	O
effectively	O
increased	O
.	O

Stable	O
Formulations	O
For	O
Lyophilizing	O
Therapeutic	O
Particles	O
The	O
present	O
disclosure	O
generally	O
relates	O
to	O
lyophilized	O
pharmaceutical	O
compositions	O
comprising	O
polymeric	O
nanoparticles	O
which	O
,	O
upon	O
reconstitution	O
,	O
have	O
low	O
levels	O
of	O
greater	O
than	O
10	O
micron	O
size	O
particles	O
.	O

Other	O
aspects	O
of	O
the	O
invention	O
include	O
methods	O
of	O
making	O
such	O
nanoparticles	O
.	O

Compound	O
neomycin	O
sulfate	O
composition	O
for	O
treating	O
pet	O
abscess	O
and	O
preparation	O
method	O
of	O
compound	O
neomycin	O
sulfate	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
neomycin	O
sulfate	O
composition	O
for	O
treating	O
pet	O
abscess	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
neomycin	O
sulfate	O
composition	O
.	O

The	O
composition	O
is	O
prepared	O
by	O
uniformly	O
mixing	O
the	O
following	O
components	O
by	O
weight	O
:	O
1	O
-	O
3	O
parts	O
of	O
neomycin	O
sulfate	O
,	O
3	O
-	O
5	O
parts	O
of	O
erythromycin	O
thiocyanate	O
,	O
1	O
-	O
2	O
parts	O
of	O
trimethoprim	O
lactate	O
,	O
1	O
-	O
3	O
parts	O
of	O
cetrimonium	O
bromide	O
,	O
3	O
-	O
5	O
parts	O
of	O
piperitol	O
,	O
50	O
-	O
70	O
parts	O
of	O
liquid	O
paraffin	O
,	O
7	O
-	O
9	O
parts	O
of	O
glycerol	O
,	O
0.4	O
part	O
of	O
ethylparaben	O
,	O
1	O
-	O
3	O
parts	O
of	O
essence	O
,	O
80	O
-	O
113	O
parts	O
of	O
distilled	O
water	O
and	O
the	O
like	O
.	O

The	O
compound	O
neomycin	O
sulfate	O
composition	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
formula	O
is	O
reasonable	O
,	O
preparation	O
is	O
simple	O
,	O
curative	O
effects	O
are	O
very	O
remarkable	O
,	O
and	O
furthermore	O
,	O
clinical	O
application	O
show	O
that	O
the	O
compound	O
neomycin	O
sulfate	O
composition	O
has	O
special	O
effect	O
for	O
treating	O
pet	O
abscess	O
.	O

Application	O
of	O
dimethyldiguanide	O
in	O
drugs	O
taking	O
protective	O
effect	O
on	O
chemoradiotherapy	O
injury	O
The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
dimethyldiguanide	O
in	O
drugs	O
taking	O
protective	O
effect	O
on	O
chemoradiotherapy	O
injury	O
.	O

As	O
an	O
optimal	O
implementation	O
scheme	O
,	O
the	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
dimethyldiguanide	O
in	O
preparing	O
drugs	O
taking	O
protective	O
effect	O
on	O
long	O
-	O
term	O
bone	O
marrow	O
suppression	O
caused	O
by	O
radiotherapy	O
.	O

As	O
an	O
optimal	O
implementation	O
scheme	O
,	O
the	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
dimethyldiguanide	O
in	O
preparing	O
drugs	O
taking	O
protective	O
effect	O
on	O
the	O
long	O
-	O
term	O
bone	O
marrow	O
suppression	O
caused	O
by	O
chemotherapeutics	O
.	O

Proved	O
by	O
the	O
invention	O
,	O
the	O
dimethyldiguanide	O
has	O
a	O
certain	O
protective	O
effect	O
on	O
hematopoietic	O
immune	O
cell	O
injury	O
caused	O
by	O
irradiation	O
and/or	O
the	O
chemotherapeutics	O
.	O

Application	O
of	O
Houttuynoid	O
B	O
in	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	O
B	O
in	O
preparing	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

Houttuynoid	O
B	O
can	O
inhibit	O
tumor	O
cell	O
mobility	O
and	O
migration	O
ability	O
.	O

The	O
application	O
of	O
Houttuynoid	O
B	O
in	O
preparing	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
has	O
extremely	O
high	O
migration	O
inhibitory	O
activity	O
to	O
pulmonary	O
cells	O
.	O

Application	O
of	O
Houttuynoid	O
D	O
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	O
D	O
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

In	O
vitro	O
MTT	O
(	O
Methyl	O
Thiazolyl	O
Tetrazolium	O
)	O
antineoplastic	O
activity	O
evaluation	O
finds	O
that	O
Houttuynoid	O
D	O
has	O
remarkable	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
nasopharyngeal	O
carcinoma	O
cell	O
lines	O
HNE1	O
,	O
HNE1	O
,	O
HONE	O
and	O
CNE1	O
,	O
so	O
that	O
Houttuynoid	O
A	O
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
inhibiting	O
nasopharyngeal	O
carcinoma	O
and	O
has	O
good	O
development	O
application	O
prospect	O
.	O

The	O
application	O
of	O
Houttuynoid	O
D	O
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
has	O
extremely	O
high	O
inhibitory	O
activity	O
to	O
breast	O
caner	O
cells	O
as	O
the	O
skeleton	O
type	O
belongs	O
to	O
a	O
completely	O
novel	O
skeleton	O
type	O
.	O

Prulifloxacin	O
oral	O
solid	O
composition	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
prulifloxacin	O
oral	O
solid	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
prulifloxacin	O
oral	O
solid	O
composition	O
is	O
prepared	O
from	O
130	O
to	O
135	O
parts	O
by	O
weight	O
of	O
prulifloxacin	O
,	O
10	O
to	O
30	O
parts	O
by	O
weight	O
of	O
starch	O
,	O
30	O
to	O
50	O
parts	O
by	O
weight	O
of	O
microcrystalline	O
cellulose	O
,	O
20	O
to	O
40	O
parts	O
by	O
weight	O
of	O
lactose	O
,	O
0.05	O
to	O
10	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
binders	O
,	O
2	O
to	O
15	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
disintegrants	O
and	O
0.5	O
to	O
10	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
lubricants	O
.	O

The	O
one	O
or	O
more	O
binders	O
are	O
selected	O
from	O
polyvinylpyrrolidone	O
,	O
lauryl	O
sodium	O
sulfate	O
and	O
polyethylene	O
glycol	O
mixed	O
aqueous	O
solutions	O
or	O
alcoholic	O
solutions	O
.	O

The	O
one	O
or	O
more	O
disintegrants	O
are	O
selected	O
from	O
carboxymethyl	O
starch	O
sodium	O
,	O
polyvinylpolypyrrolidone	O
and	O
hydroxy	O
propyl	O
cellulose	O
.	O

The	O
one	O
or	O
more	O
lubricants	O
are	O
selected	O
from	O
magnesium	O
stearate	O
,	O
calcium	O
stearate	O
and	O
aerosil	O
.	O

The	O
prulifloxacin	O
oral	O
solid	O
composition	O
can	O
be	O
processed	O
into	O
tablets	O
,	O
capsules	O
or	O
granules	O
,	O
has	O
good	O
stability	O
,	O
can	O
effectively	O
improve	O
a	O
dissolution	O
rate	O
,	O
solves	O
the	O
problem	O
that	O
the	O
existing	O
prulifloxacin	O
oral	O
solid	O
preparation	O
has	O
a	O
slow	O
dissolution	O
speed	O
,	O
and	O
improves	O
bioavailability	O
.	O

Cis	O
-	O
platinum	O
complex	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
cis	O
-	O
platinum	O
complex	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Cis	O
-	O
platinum	O
and	O
a	O
polymer	O
with	O
the	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
used	O
as	O
raw	O
materials	O
for	O
preparing	O
the	O
cis	O
-	O
platinum	O
complex	O
,	O
wherein	O
a	O
polymer	O
molecule	O
with	O
the	O
structure	O
of	O
formula	O
(	O
I	O
)	O
contains	O
a	O
poly	O
(	O
L	O
-	O
glutamic	O
acid	O
-	O
co	O
-	O
L	O
-	O
lysine	O
)	O
segment	O
,	O
so	O
that	O
the	O
prepared	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
biocompatibility	O
and	O
is	O
degradable	O
;	O
meanwhile	O
,	O
the	O
poly	O
(	O
L	O
-	O
glutamic	O
acid	O
-	O
co	O
-	O
L	O
-	O
lysine	O
)	O
segment	O
can	O
further	O
prevent	O
the	O
cis	O
-	O
platinum	O
complex	O
from	O
being	O
influenced	O
by	O
a	O
blood	O
circulation	O
system	O
in	O
an	O
aqueous	O
medium	O
,	O
so	O
that	O
the	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
stability	O
;	O
and	O
the	O
terminal	O
of	O
the	O
branched	O
chain	O
of	O
the	O
cis	O
-	O
platinum	O
complex	O
provided	O
by	O
the	O
invention	O
contains	O
an	O
amino	O
group	O
,	O
so	O
that	O
the	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
solubility	O
.	O

In	O
addition	O
,	O
the	O
prepared	O
cis	O
-	O
platinum	O
complex	O
contains	O
a	O
carboxy	O
group	O
,	O
so	O
that	O
the	O
cis	O
-	O
platinum	O
complex	O
has	O
excellent	O
pH	O
value	O
sensitivity	O
,	O
the	O
carboxy	O
group	O
tends	O
to	O
deprotonation	O
in	O
the	O
environment	O
with	O
a	O
lower	O
pH	O
value	O
so	O
as	O
to	O
be	O
beneficial	O
to	O
promoting	O
the	O
drug	O
release	O
and	O
improve	O
the	O
efficacy	O
of	O
drugs	O
.	O

Meloxicam	O
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
The	O
invention	O
discloses	O
a	O
meloxicam	O
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
.	O

The	O
meloxicam	O
injection	O
is	O
a	O
meloxicam	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
and	O
the	O
administration	O
route	O
is	O
intramuscular	O
injection	O
.	O

The	O
meloxicam	O
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
has	O
the	O
effect	O
of	O
dispelling	O
wind	O
and	O
eliminating	O
dampness	O
,	O
tonifying	O
kidney	O
and	O
repelling	O
cold	O
,	O
promoting	O
blood	O
circulation	O
to	O
remove	O
meridian	O
obstruction	O
and	O
strengthening	O
tendons	O
and	O
bones	O
,	O
and	O
achieves	O
remarkable	O
effect	O
in	O
treating	O
chronic	O
infectious	O
arthritis	O
.	O

L	O
-	O
carnitine	O
calcium	O
citrate	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
new	O
pharmaceutically	O
acceptable	O
salt	O
of	O
L	O
-	O
carnitine	O
,	O
namely	O
L	O
-	O
carnitine	O
calcium	O
citrate	O
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
salt	O
.	O

L	O
-	O
carnitine	O
calcium	O
citrate	O
not	O
only	O
has	O
the	O
characteristics	O
of	O
high	O
stability	O
and	O
difficult	O
moisture	O
absorption	O
as	O
compared	O
with	O
L	O
-	O
carnitine	O
inner	O
salt	O
,	O
but	O
also	O
is	O
easier	O
to	O
accept	O
by	O
human	O
bodies	O
and	O
easier	O
to	O
participate	O
in	O
physiologic	O
metabolism	O
of	O
the	O
human	O
bodies	O
as	O
compared	O
with	O
the	O
existing	O
pharmaceutically	O
acceptable	O
salts	O
of	O
L	O
-	O
carnitine	O
,	O
and	O
has	O
stronger	O
nutrition	O
and	O
treatment	O
effects	O
.	O

The	O
invention	O
also	O
provides	O
application	O
of	O
L	O
-	O
carnitine	O
calcium	O
citrate	O
to	O
preparing	O
a	O
slimming	O
medicament	O
or	O
health	O
food	O
,	O
application	O
to	O
preparing	O
a	O
diet	O
/	O
nutritional	O
supplement	O
,	O
and	O
application	O
to	O
preparing	O
veterinarian	O
products	O
or	O
feed	O
.	O

Venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
comprises	O
a	O
blank	O
pellet	O
core	O
,	O
a	O
venlafaxine	O
hydrochloride	O
-	O
containing	O
layer	O
and	O
a	O
controlled	O
-	O
release	O
film	O
,	O
wherein	O
the	O
venlafaxine	O
hydrochloride	O
-	O
containing	O
layer	O
comprises	O
active	O
components	O
including	O
venlafaxine	O
hydrochloride	O
and	O
talcum	O
powder	O
which	O
are	O
in	O
a	O
weight	O
ratio	O
of	O
12:1	O
-	O
8:1	O
,	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
venlafaxine	O
hydrochloride	O
to	O
the	O
blank	O
pellet	O
core	O
is	O
4:10	O
-	O
8:10	O
.	O

The	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
is	O
prepared	O
by	O
adopting	O
a	O
fluidized	O
bed	O
bottom	O
-	O
spraying	O
venlafaxine	O
hydrochloride	O
applying	O
mode	O
;	O
by	O
using	O
75	O
percent	O
alcohol	O
as	O
a	O
solvent	O
,	O
the	O
viscosity	O
of	O
the	O
venlafaxine	O
hydrochloride	O
in	O
a	O
water	O
solution	O
is	O
remarkably	O
lowered	O
,	O
the	O
venlafaxine	O
hydrochloride	O
applying	O
speed	O
is	O
increased	O
;	O
and	O
the	O
prepared	O
venlafaxine	O
hydrochloride	O
containing	O
pellet	O
adopts	O
a	O
bottom	O
-	O
spraying	O
coating	O
process	O
,	O
thus	O
the	O
problem	O
of	O
static	O
electricity	O
generated	O
because	O
of	O
the	O
adoption	O
of	O
the	O
pure	O
organic	O
solvent	O
is	O
overcome	O
;	O
the	O
application	O
process	O
and	O
the	O
wrapping	O
process	O
can	O
be	O
continuously	O
operated	O
in	O
the	O
same	O
device	O
,	O
thus	O
the	O
production	O
efficiency	O
is	O
increased	O
and	O
the	O
production	O
cost	O
is	O
lowered	O
;	O
and	O
no	O
toxic	O
organic	O
solvent	O
is	O
adopted	O
in	O
the	O
whole	O
process	O
,	O
thus	O
the	O
venlafaxine	O
hydrochloride	O
controlled	O
-	O
release	O
pellet	O
is	O
environmental	O
-	O
friendly	O
and	O
is	O
good	O
in	O
stability	O
,	O
and	O
almost	O
no	O
broken	O
pellets	O
or	O
dust	O
is	O
produced	O
.	O

Preparation	O
of	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
and	O
application	O
of	O
antidiabetic	O
medicines	O
of	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
The	O
invention	O
provides	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
which	O
is	O
a	O
new	O
compound	O
with	O
a	O
molecular	O
formula	O
of	O
C40H69O9	O
.	O

The	O
molecular	O
weight	O
of	O
the	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
is	O
692	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
application	O
of	O
antidiabetic	O
medicines	O
of	O
the	O
compound	O
.	O

The	O
ginsenoside	O
M1	O
n	O
-	O
butyrate	O
can	O
resist	O
to	O
physiological	O
activity	O
of	O
diabetes	O
mellitus	O
and	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
diabetes	O
mellitus	O
and	O
conducting	O
assistant	O
treating	O
the	O
diabetes	O
mellitus	O
.	O

Compound	O
elvucitabine	O
medicine	O
composition	O
as	O
well	O
as	O
preparation	O
method	O
and	O
use	O
for	O
same	O
The	O
invention	O
provides	O
a	O
compound	O
elvucitabine	O
medicine	O
composition	O
.	O

The	O
medicine	O
composition	O
comprises	O
elvucitabine	O
or	O
the	O
medicinal	O
salts	O
thereof	O
,	O
entecavir	O
or	O
the	O
medicinal	O
salts	O
thereof	O
and	O
an	O
anti	O
-	O
acid	O
stabilizer	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
medicine	O
composition	O
,	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
mixing	O
elvucitabine	O
or	O
the	O
medicinal	O
salts	O
thereof	O
with	O
the	O
anti	O
-	O
acid	O
stabilizer	O
,	O
then	O
mixing	O
elvucitabine	O
or	O
the	O
medicinal	O
salts	O
thereof	O
with	O
one	O
or	O
more	O
adhesives	O
,	O
and	O
attaching	O
the	O
obtained	O
mixture	O
on	O
an	O
empty	O
carrier	O
to	O
prepare	O
a	O
medicated	O
carrier	O
;	O
and	O
(	O
2	O
)	O
mixing	O
the	O
medicated	O
carrier	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
with	O
entecavir	O
or	O
the	O
medicinal	O
salts	O
thereof	O
and	O
one	O
or	O
more	O
pharmaceutical	O
excipients	O
.	O

The	O
invention	O
further	O
provides	O
a	O
use	O
of	O
the	O
compound	O
elvucitabine	O
medicine	O
composition	O
for	O
preparing	O
a	O
medicine	O
for	O
treating	O
hepatitis	O
B	O
virus	O
.	O

Cough	O
-	O
treating	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
and	O
loquat	O
sustained	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
cough	O
-	O
treating	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
and	O
loquat	O
sustained	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighting	O
raw	O
materials	O
;	O
(	O
2	O
)	O
adding	O
water	O
to	O
loquat	O
leaves	O
,	O
decocting	O
,	O
filtering	O
,	O
concentrating	O
to	O
obtain	O
clear	O
paste	O
,	O
adding	O
ethanol	O
,	O
stirring	O
sufficiently	O
,	O
standing	O
and	O
taking	O
supernate	O
for	O
later	O
use	O
;	O
(	O
3	O
)	O
crushing	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
,	O
carrying	O
out	O
hot	O
reflux	O
extraction	O
on	O
the	O
crushed	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
together	O
with	O
platycodon	O
root	O
and	O
perilla	O
fruit	O
by	O
using	O
ethanol	O
,	O
filtering	O
,	O
mixing	O
the	O
obtained	O
filtrate	O
with	O
the	O
supernate	O
obtained	O
in	O
(	O
2	O
)	O
,	O
recovering	O
the	O
ethanol	O
,	O
concentrating	O
to	O
obtain	O
clear	O
paste	O
,	O
cooling	O
to	O
room	O
temperature	O
,	O
adding	O
butanone	O
for	O
extraction	O
,	O
recovering	O
the	O
butanone	O
,	O
concentrating	O
to	O
obtain	O
thick	O
paste	O
,	O
and	O
drying	O
,	O
crushing	O
and	O
sieving	O
the	O
thick	O
paste	O
to	O
obtain	O
extractive	O
powder	O
;	O
and	O
(	O
4	O
)	O
adding	O
a	O
proper	O
amount	O
of	O
binding	O
agent	O
into	O
the	O
extractive	O
powder	O
,	O
a	O
filling	O
agent	O
,	O
hydroxypropyl	O
methylcellulose	O
and	O
a	O
release	O
rate	O
regulator	O
to	O
prepare	O
a	O
soft	O
material	O
,	O
granulating	O
,	O
drying	O
and	O
tabletting	O
.	O

The	O
sustained	O
release	O
tablet	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
effects	O
of	O
relieving	O
cough	O
,	O
eliminating	O
phlegm	O
and	O
relieving	O
asthma	O
,	O
and	O
the	O
sustained	O
release	O
tablet	O
prepared	O
from	O
the	O
raw	O
materials	O
extracted	O
by	O
using	O
an	O
extraction	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
low	O
in	O
drug	O
dose	O
,	O
high	O
in	O
content	O
,	O
convenient	O
to	O
take	O
and	O
carry	O
,	O
good	O
in	O
curative	O
effect	O
,	O
favorable	O
for	O
fixed	O
-	O
quantity	O
taking	O
,	O
and	O
beneficial	O
to	O
storage	O
and	O
transportation	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
and	O
supramolecular	O
inclusion	O
complex	O
thereof	O
with	O
adriamycin	O
The	O
invention	O
discloses	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
prepared	O
by	O
connecting	O
harmine	O
onto	O
cyclodextrin	O
with	O
ethylenediamine	O
as	O
a	O
connection	O
arm	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
supramolecular	O
inclusion	O
complex	O
of	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
and	O
adriamycin	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
invention	O
further	O
discloses	O
the	O
evaluation	O
of	O
anti	O
-	O
tumor	O
activity	O
and	O
survival	O
rate	O
of	O
the	O
supramolecular	O
inclusion	O
complex	O
provided	O
by	O
the	O
invention	O
on	O
a	O
S180	O
mouse	O
model	O
.	O

As	O
a	O
result	O
of	O
in	O
-	O
vivo	O
experiment	O
,	O
with	O
the	O
supramolecular	O
inclusion	O
complex	O
provided	O
by	O
the	O
invention	O
,	O
adriamycin	O
toxicity	O
is	O
reduced	O
.	O

Especially	O
,	O
under	O
high	O
dosage	O
,	O
on	O
a	O
basis	O
that	O
anti	O
-	O
tumor	O
activity	O
equivalent	O
with	O
that	O
of	O
adriamycin	O
is	O
maintained	O
,	O
mouse	O
survival	O
rate	O
is	O
improved	O
.	O

The	O
invention	O
assists	O
in	O
providing	O
a	O
novel	O
approach	O
for	O
clinical	O
applications	O
of	O
the	O
anticancer	O
medicine	O
adriamycin	O
.	O

Health	O
-	O
care	O
foot	O
solution	O
The	O
invention	O
discloses	O
a	O
health	O
-	O
care	O
foot	O
solution	O
.	O

The	O
health	O
-	O
care	O
foot	O
solution	O
consists	O
of	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
2	O
parts	O
of	O
ginger	O
,	O
6	O
-	O
8	O
parts	O
of	O
red	O
flower	O
,	O
2	O
-	O
5	O
parts	O
of	O
semen	O
armeniacae	O
amarae	O
,	O
3	O
-	O
8	O
parts	O
of	O
green	O
tea	O
,	O
2	O
-	O
3	O
parts	O
of	O
salt	O
and	O
the	O
balance	O
of	O
water	O
.	O

The	O
health	O
-	O
care	O
foot	O
solution	O
can	O
accelerate	O
leg	O
blood	O
circulation	O
,	O
so	O
that	O
venous	O
blood	O
in	O
the	O
legs	O
can	O
timely	O
flow	O
back	O
to	O
the	O
right	O
side	O
of	O
the	O
heart	O
,	O
and	O
the	O
health	O
-	O
care	O
foot	O
solution	O
contributes	O
to	O
lightening	O
venous	O
congestion	O
of	O
the	O
legs	O
and	O
preventing	O
varicose	O
vein	O
of	O
lower	O
limbs	O
and	O
contributes	O
to	O
soothing	O
the	O
nerves	O
and	O
removing	O
troubles	O
,	O
performing	O
hypnosis	O
and	O
falling	O
asleep	O
,	O
so	O
that	O
the	O
sleep	O
is	O
deep	O
and	O
sweet	O
.	O

Tumor	O
cavity	O
filler	O
for	O
treating	O
giant	O
cell	O
tumor	O
of	O
bone	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medical	O
engineering	O
and	O
provides	O
a	O
tumor	O
cavity	O
filler	O
for	O
treating	O
giant	O
cell	O
tumor	O
of	O
bone	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
mixture	O
is	O
formed	O
by	O
mixing	O
a	O
diphosphate	O
medicine	O
and	O
bone	O
cement	O
according	O
to	O
a	O
ratio	O
,	O
wherein	O
the	O
bone	O
cement	O
serves	O
as	O
a	O
controlled	O
release	O
carrier	O
of	O
the	O
diphosphate	O
medicine	O
,	O
so	O
that	O
a	O
topical	O
administration	O
system	O
is	O
formed	O
.	O

The	O
principle	O
is	O
that	O
the	O
bone	O
cement	O
serves	O
as	O
the	O
release	O
carrier	O
of	O
the	O
medicine	O
and	O
the	O
diphosphate	O
medicine	O
is	O
released	O
at	O
a	O
focus	O
,	O
so	O
that	O
the	O
aim	O
that	O
the	O
focus	O
is	O
positioned	O
in	O
a	O
long	O
-	O
term	O
high	O
-	O
concentration	O
medicine	O
environment	O
is	O
fulfilled	O
;	O
and	O
therefore	O
,	O
the	O
effects	O
of	O
suppressing	O
bone	O
destruction	O
and	O
preventing	O
bone	O
resorption	O
through	O
the	O
diphosphate	O
medicine	O
are	O
improved	O
,	O
and	O
the	O
function	O
of	O
repairing	O
the	O
bone	O
destruction	O
through	O
the	O
bone	O
cement	O
is	O
not	O
influenced	O
.	O

Bath	O
powder	O
for	O
treating	O
neurasthenia	O
The	O
invention	O
relates	O
to	O
bath	O
powder	O
for	O
treating	O
neurasthenia	O
.	O

The	O
bath	O
powder	O
is	O
prepared	O
by	O
the	O
steps	O
of	O
mixing	O
50	O
parts	O
of	O
zizyphus	O
jujube	O
tree	O
roots	O
,	O
35	O
parts	O
of	O
salviae	O
miltiorrhizae	O
,	O
30	O
parts	O
of	O
longspur	O
epimedium	O
,	O
30	O
parts	O
of	O
lily	O
,	O
30	O
parts	O
of	O
tuber	O
fleeceflower	O
stem	O
,	O
20	O
parts	O
of	O
coptidis	O
rhizome	O
,	O
30	O
parts	O
of	O
rhizoma	O
sparganii	O
,	O
30	O
parts	O
of	O
earthworm	O
,	O
50	O
parts	O
of	O
agilawood	O
,	O
25	O
parts	O
of	O
mint	O
,	O
30	O
parts	O
of	O
cortex	O
albiziae	O
,	O
20	O
parts	O
of	O
radix	O
curcumae	O
,	O
45	O
parts	O
of	O
mirabilite	O
,	O
20	O
parts	O
of	O
liquorice	O
and	O
20	O
parts	O
of	O
polygala	O
tenuifolia	O
together	O
;	O
performing	O
heating	O
drying	O
the	O
above	O
drugs	O
with	O
an	O
intake	O
air	O
temperature	O
of	O
180	O
-	O
290	O
DEG	O
C	O
and	O
outlet	O
air	O
temperature	O
of	O
80	O
-	O
90	O
DEG	O
C	O
;	O
grinding	O
the	O
above	O
drugs	O
into	O
powder	O
;	O
and	O
subpackaging	O
quantitatively	O
.	O

In	O
the	O
above	O
composition	O
,	O
the	O
composition	O
can	O
be	O
made	O
into	O
80	O
-	O
100	O
g	O
per	O
bag	O
if	O
being	O
weighed	O
in	O
grams	O
.	O

When	O
the	O
bath	O
powder	O
is	O
in	O
use	O
,	O
the	O
drug	O
formula	O
is	O
put	O
in	O
bath	O
water	O
with	O
stirring	O
.	O

The	O
water	O
consumption	O
of	O
the	O
bath	O
is	O
between	O
80	O
L	O
and	O
100	O
L	O
;	O
an	O
immersing	O
time	O
is	O
1	O
-	O
2	O
hours	O
every	O
day	O
;	O
and	O
10	O
days	O
is	O
a	O
course	O
of	O
treatment	O
.	O

Usually	O
,	O
neurasthenia	O
is	O
healed	O
after	O
three	O
to	O
five	O
courses	O
.	O

The	O
effective	O
rate	O
is	O
97	O
%	O
.	O

The	O
usage	O
amount	O
can	O
be	O
adjusted	O
according	O
to	O
conditions	O
of	O
patients	O
.	O

The	O
bath	O
powder	O
has	O
the	O
main	O
functions	O
for	O
treating	O
neurasthenia	O
,	O
intractable	O
insomnia	O
,	O
disturbed	O
consciousness	O
and	O
dysphoria	O
and	O
impatience	O
.	O

Expectorant	O
The	O
invention	O
discloses	O
an	O
expectorant	O
.	O

The	O
expectorant	O
comprises	O
the	O
following	O
active	O
pharmaceutical	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
2	O
-	O
4	O
parts	O
of	O
sapium	O
sebiferum	O
,	O
1	O
-	O
3	O
parts	O
of	O
rhizoma	O
curcumae	O
longae	O
,	O
3	O
-	O
8	O
parts	O
of	O
realgar	O
,	O
1	O
-	O
3	O
parts	O
of	O
agkistrodon	O
,	O
2	O
-	O
5	O
parts	O
of	O
bulbus	O
allii	O
macrostemonis	O
,	O
3	O
-	O
6	O
parts	O
of	O
common	O
achyranthes	O
herb	O
,	O
1	O
-	O
2	O
parts	O
of	O
squama	O
manis	O
,	O
4	O
-	O
9	O
parts	O
of	O
plantago	O
asiatica	O
L.	O
and	O
1	O
-	O
4	O
parts	O
of	O
fructus	O
rosae	O
laevigatae	O
.	O

The	O
expectorant	O
not	O
only	O
has	O
the	O
effects	O
of	O
drying	O
dampness	O
,	O
eliminating	O
phlegm	O
,	O
clearing	O
heat	O
,	O
relieving	O
exterior	O
syndrome	O
,	O
alleviating	O
water	O
retention	O
,	O
activating	O
blood	O
,	O
relieving	O
cough	O
and	O
preventing	O
asthma	O
,	O
but	O
also	O
can	O
activate	O
blood	O
to	O
remove	O
stasis	O
,	O
break	O
blood	O
to	O
promote	O
qi	O
circulation	O
,	O
induce	O
menstruation	O
to	O
relieve	O
menalgia	O
,	O
draw	O
out	O
poison	O
to	O
astringe	O
and	O
dispel	O
wind	O
and	O
dampness	O
.	O

Long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
for	O
treating	O
female	O
animal	O
postpartum	O
infection	O
and	O
preparation	O
process	O
The	O
invention	O
discloses	O
a	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
for	O
treating	O
female	O
animal	O
postpartum	O
infection	O
and	O
a	O
preparation	O
process	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
comprises	O
,	O
by	O
weight	O
,	O
1.5	O
-	O
3.5	O
kg	O
of	O
ofloxacin	O
,	O
0.125	O
-	O
1	O
kg	O
of	O
flunixin	O
meglumine	O
,	O
0.125	O
-	O
0.75	O
kg	O
of	O
metronidazole	O
,	O
0.125	O
-	O
1	O
kg	O
of	O
leonurus	O
extract	O
(	O
injection	O
level	O
)	O
,	O
0.125	O
-	O
1	O
kg	O
of	O
angelica	O
sinensis	O
extract	O
(	O
injection	O
level	O
)	O
,	O
0.25	O
-	O
1.25	O
kg	O
of	O
polyvinyl	O
pyrrolidone	O
(	O
PVP	O
)	O
-K30	O
,	O
2	O
-	O
15	O
kg	O
of	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
-400	O
,	O
0.03	O
kg	O
of	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
(	O
EDTA	O
)	O
-2Na	O
and	O
appropriate	O
water	O
for	O
injection	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
is	O
suitable	O
for	O
postpartum	O
health	O
care	O
,	O
is	O
used	O
for	O
postpartum	O
female	O
animal	O
preventive	O
perfusion	O
,	O
effectively	O
reduces	O
morbidity	O
of	O
endometritism	O
,	O
remarkably	O
shortens	O
female	O
animal	O
estrus	O
interval	O
,	O
and	O
improves	O
breeding	O
success	O
rate	O
and	O
farrowing	O
rate	O
of	O
female	O
animals	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
is	O
injected	O
in	O
uterus	O
by	O
using	O
an	O
irrigator	O
.	O

Folium	O
mori	O
tablets	O
for	O
moistening	O
dryness	O
and	O
lungs	O
The	O
invention	O
discloses	O
a	O
folium	O
mori	O
tablet	O
for	O
moistening	O
dryness	O
and	O
lungs	O
.	O

The	O
folium	O
mori	O
tablet	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
:	O
folium	O
mori	O
,	O
gypsum	O
fibrosum	O
,	O
unibract	O
fritillary	O
bulb	O
,	O
fructus	O
trichosanthis	O
,	O
liquorice	O
,	O
sang	O
,	O
linseed	O
,	O
donkey	O
-	O
hide	O
gelatin	O
,	O
radix	O
ophiopogonis	O
,	O
roasted	O
almond	O
and	O
folium	O
eriobotryae	O
.	O

Urease	B
inhibitor	O
genistein	O
hydroxamic	O
acid	O
compound	O
and	O
synthesis	O
and	O
application	O
thereof	O
A	O
genistein	O
hydroxamic	O
acid	O
compound	O
has	O
the	O
following	O
structural	O
general	O
formula	O
.	O

The	O
genistein	O
hydroxamic	O
acid	O
compound	O
has	O
good	O
inhibitional	O
effect	O
on	O
urease	B
and	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
treating	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
lithangiuria	O
and	O
the	O
like	O
.	O

A	O
manufacturing	O
method	O
of	O
the	O
genistein	O
hydroxamic	O
acid	O
compound	O
is	O
disclosed	O
.	O

Antitussive	O
and	O
expectorant	O
compound	O
chemical	O
drug	O
The	O
invention	O
provides	O
an	O
antitussive	O
and	O
expectorant	O
compound	O
chemical	O
drug	O
,	O
and	O
especially	O
relates	O
to	O
a	O
drug	O
composed	O
of	O
dimemorfan	O
and	O
carbocisteine	O
which	O
are	O
effective	O
components	O
,	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
accessories	O
,	O
and	O
a	O
preparation	O
technology	O
.	O

The	O
dimemorfan	O
used	O
in	O
the	O
invention	O
is	O
a	O
non	O
-	O
narcotic	O
central	O
antitussive	O
drug	O
;	O
and	O
compared	O
with	O
central	O
antitussive	O
drugs	O
present	O
on	O
the	O
market	O
,	O
the	O
dimemorfan	O
is	O
equivalent	O
in	O
antitussive	O
effects	O
but	O
low	O
in	O
adverse	O
reaction	O
.	O

Compared	O
with	O
commercially	O
available	O
compound	O
antitussive	O
and	O
expectorant	O
drugs	O
,	O
the	O
compound	O
chemical	O
drug	O
provided	O
by	O
the	O
invention	O
has	O
advantages	O
of	O
relatively	O
good	O
efficacies	O
and	O
low	O
adverse	O
reaction	O
rate	O
,	O
and	O
has	O
quite	O
good	O
social	O
and	O
economic	O
benefits	O
.	O

Compound	O
chemical	O
medicament	O
containing	O
guaiacol	O
The	O
invention	O
provides	O
a	O
compound	O
chemical	O
medicament	O
containing	O
guaiacol	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
medicament	O
consisting	O
of	O
dimemorfan	O
and	O
guaifenesin	O
serving	O
as	O
effective	O
components	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
,	O
and	O
a	O
preparation	O
process	O
of	O
the	O
medicament	O
.	O

According	O
to	O
the	O
compound	O
chemical	O
medicament	O
,	O
guaiacol	O
serving	O
as	O
a	O
non	O
-	O
narcotic	O
central	O
antitussive	O
drug	O
has	O
equivalent	O
antitussive	O
effect	O
but	O
lower	O
adverse	O
reaction	O
compared	O
with	O
a	O
conventional	O
central	O
antitussive	O
drug	O
in	O
current	O
market	O
.	O

Compared	O
with	O
currently	O
commercial	O
compound	O
antitussive	O
expectorant	O
drug	O
,	O
the	O
composition	O
has	O
advantages	O
of	O
better	O
curative	O
effect	O
and	O
low	O
adverse	O
reaction	O
,	O
and	O
has	O
good	O
social	O
benefit	O
and	O
economic	O
benefit	O
.	O

Application	O
of	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
in	O
preparation	O
of	O
medicament	O
for	O
treating	O
or	O
inhibiting	O
mucus	O
in	O
wind	O
pipe	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
in	O
preparation	O
of	O
medicament	O
for	O
treating	O
or	O
inhibiting	O
mucus	O
in	O
a	O
wind	O
pipe	O
.	O

The	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
can	O
obviously	O
inhibit	O
the	O
hypersecretion	O
of	O
mucoprotein	O
in	O
the	O
wind	O
pipe	O
of	O
the	O
lung	O
tissue	O
.	O

Compared	O
with	O
the	O
commonly	O
used	O
mucolytic	O
agents	O
,	O
the	O
tanshinone	O
IIA	O
or	O
pharmaceutically	O
acceptable	O
salt	O
can	O
obviously	O
inhibit	O
the	O
expression	O
and	O
the	O
secretion	O
of	O
mucoprotein	O
,	O
and	O
the	O
obvious	O
side	O
and	O
toxic	O
effects	O
can	O
not	O
be	O
found	O
.	O

Application	O
of	O
doxycycline	O
in	O
preparing	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
novel	O
application	O
of	O
doxycycline	O
in	O
preparing	O
a	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

Animal	O
experiments	O
and	O
in	O
-	O
vitro	O
cell	O
experiments	O
prove	O
that	O
doxycycline	O
can	O
inhibit	O
multiplication	O
and	O
invasion	O
of	O
ovarian	O
cancer	O
cells	O
,	O
can	O
prevent	O
epithelial	O
ovarian	O
cancer	O
cells	O
from	O
transferring	O
,	O
can	O
promote	O
apoptosis	O
of	O
epithelial	O
ovarian	O
cancer	O
cells	O
,	O
has	O
a	O
remarkable	O
inhibition	O
effect	O
to	O
ovarian	O
cancer	O
cells	O
,	O
in	O
particular	O
platinum	O
-	O
based	O
drug	O
-	O
resistance	O
ovarian	O
cancer	O
cells	O
,	O
and	O
can	O
inhibit	O
growth	O
of	O
ovarian	O
cancer	O
tissues	O
and	O
formation	O
of	O
ascites	O
,	O
so	O
that	O
doxycycline	O
can	O
be	O
used	O
for	O
preparing	O
a	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
application	O
to	O
doxycycline	O
,	O
and	O
compared	O
with	O
other	O
chemotherapeutic	O
drugs	O
,	O
doxycycline	O
has	O
the	O
advantages	O
of	O
convenient	O
administration	O
and	O
small	O
side	O
effect	O
in	O
the	O
field	O
of	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

Application	O
of	O
active	O
component	O
baicalin	O
of	O
Qingkailing	O
compound	O
in	O
preparation	O
of	O
medicines	O
resisting	O
multiple	O
drug	O
-	O
resistance	O
bacteria	O
The	O
invention	O
relates	O
to	O
an	O
active	O
component	O
baicalin	O
of	O
a	O
Qingkailing	O
compound	O
,	O
which	O
has	O
an	O
inhibiting	O
effect	O
on	O
acinetobacter	O
calcoaceticus	O
,	O
acinetobacter	O
baumannii	O
,	O
A.baumannii	O
,	O
stenotrophomonas	O
maltophilia	O
and	O
escherichia	B
coli	I
containing	I
NDM-1	I
drug	O
resistance	O
gene	O
,	O
so	O
that	O
the	O
active	O
component	O
baicalin	O
can	O
be	O
used	O
for	O
inhibiting	O
these	O
bacterial	O
diseases	O
and	O
treating	O
and/or	O
preventing	O
diseases	O
caused	O
by	O
these	O
bacteria	O
.	O

Novel	O
amoxicillin	O
sodium	O
compound	O
and	O
composition	O
of	O
amoxicillin	O
sodium	O
compound	O
and	O
sulbactam	O
sodium	O
compound	O
The	O
invention	O
discloses	O
a	O
novel	O
amoxicillin	O
sodium	O
compound	O
.	O

The	O
purity	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
is	O
more	O
than	O
99	O
%	O
,	O
the	O
specific	O
rotation	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
is	O
between	O
+	O
260	O
degrees	O
and	O
+	O
280	O
degrees	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
composition	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
and	O
the	O
sulbactam	O
sodium	O
compound	O
,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
50	O
-	O
100	O
parts	O
of	O
amoxicillin	O
sodium	O
,	O
25	O
-	O
50	O
parts	O
of	O
sulbactam	O
sodium	O
,	O
3	O
-	O
9	O
parts	O
of	O
vitamin	O
C	O
,	O
1	O
-	O
6	O
parts	O
of	O
proline	O
,	O
and	O
2	O
-	O
8	O
parts	O
of	O
nicotinamide	O
.	O

According	O
to	O
the	O
composition	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
and	O
the	O
sulbactam	O
sodium	O
compound	O
,	O
the	O
vitamin	O
C	O
,	O
the	O
proline	O
and	O
the	O
nicotinamide	O
are	O
taken	O
as	O
stabilizers	O
and	O
play	O
synergistic	O
effect	O
so	O
as	O
to	O
improve	O
the	O
stability	O
of	O
the	O
composition	O
of	O
the	O
amoxicillin	O
sodium	O
compound	O
and	O
the	O
sulbactam	O
sodium	O
compound	O
effectively	O
,	O
the	O
composition	O
can	O
be	O
prepared	O
into	O
stable	O
injection	O
which	O
is	O
not	O
easy	O
to	O
deteriorate	O
due	O
to	O
oxygenolysis	O
after	O
being	O
laid	O
for	O
a	O
period	O
,	O
and	O
the	O
injection	O
does	O
not	O
need	O
to	O
be	O
prepared	O
when	O
being	O
used	O
,	O
thus	O
being	O
convenient	O
to	O
use	O
.	O

Resveratrol	O
nano	O
-	O
liposome	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
resveratrol	O
nano	O
-	O
liposome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
mixing	O
and	O
dissolving	O
resveratrol	O
,	O
a	O
film	O
material	O
,	O
an	O
antioxidant	O
and	O
an	O
organic	O
solvent	O
,	O
forming	O
a	O
film	O
and	O
removing	O
the	O
organic	O
solvent	O
at	O
the	O
same	O
time	O
,	O
and	O
then	O
adding	O
a	O
buffer	O
solution	O
to	O
hydrate	O
to	O
obtain	O
a	O
coarse	O
suspension	O
liquid	O
of	O
the	O
resveratrol	O
nano	O
-	O
liposome	O
,	O
and	O
carrying	O
out	O
high	O
-	O
pressure	O
microjet	O
treatment	O
on	O
the	O
coarse	O
suspension	O
liquid	O
to	O
obtain	O
the	O
resveratrol	O
nano	O
-	O
liposome	O
.	O

The	O
resveratrol	O
nano	O
-	O
liposome	O
is	O
prepared	O
through	O
the	O
steps	O
of	O
dissolving	O
,	O
lipid	O
forming	O
,	O
sufficient	O
hydrating	O
,	O
microjet	O
dispersing	O
and	O
other	O
steps	O
by	O
adopting	O
a	O
high	O
-	O
pressure	O
microjet	O
method	O
.	O

The	O
resveratrol	O
nano	O
-	O
liposome	O
is	O
uniform	O
and	O
consistent	O
,	O
small	O
in	O
grain	O
size	O
,	O
high	O
in	O
encapsulation	O
efficiency	O
,	O
and	O
good	O
in	O
stability	O
.	O

Pharmaceutical	O
composition	O
containing	O
granisetron	O
hydrochloride	O
compound	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
granisetron	O
hydrochloride	O
compound	O
,	O
and	O
in	O
particular	O
to	O
a	O
freeze	O
-	O
dried	O
injection	O
preparation	O
of	O
granisetron	O
hydrochloride	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

For	O
every	O
1000	O
injections	O
,	O
the	O
pharmaceutical	O
composition	O
comprises	O
the	O
following	O
components	O
:	O
3	O
g	O
of	O
granisetron	O
hydrochloride	O
,	O
100	O
-	O
200	O
g	O
of	O
mannitol	O
,	O
1	O
-	O
3	O
g	O
of	O
sodium	O
hydroxide	O
,	O
1	O
-	O
2	O
g	O
of	O
vitamin	O
C	O
,	O
and	O
2000ml	O
of	O
sodium	O
hydrogencitrate	O
and	O
trisodium	O
citrate	O
buffer	O
liquor	O
with	O
molar	O
ratio	O
of	O
1:4	O
.	O

Liver	O
benefiting	O
powder	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
Chinese	O
patent	O
drug	O
for	O
treating	O
a	O
primary	O
liver	O
cancer	O
,	O
and	O
an	O
administration	O
method	O
of	O
the	O
compound	O
Chinese	O
patent	O
drug	O
.	O

The	O
primary	O
liver	O
cancer	O
is	O
one	O
of	O
the	O
common	O
malignant	O
tumors	O
in	O
China	O
.	O

The	O
compound	O
Chinese	O
patent	O
drug	O
adopts	O
13	O
medicinal	O
materials	O
for	O
compounding	O
,	O
can	O
eliminate	O
pathogens	O
,	O
strengthen	O
body	O
resistance	O
,	O
promote	O
blood	O
circulation	O
,	O
stop	O
bleeding	O
and	O
treat	O
a	O
liver	O
and	O
a	O
spleen	O
,	O
and	O
treats	O
the	O
primary	O
liver	O
cancer	O
by	O
integrating	O
external	O
treatment	O
and	O
internal	O
treatment	O
.	O

The	O
compound	O
Chinese	O
patent	O
drug	O
adopts	O
the	O
technical	O
scheme	O
that	O
the	O
following	O
medicinal	O
materials	O
and	O
matching	O
ratio	O
are	O
adopted	O
,	O
and	O
the	O
13	O
medicinal	O
materials	O
are	O
porphyrized	O
and	O
uniformly	O
mixed	O
into	O
powder	O
according	O
to	O
the	O
matching	O
ratio	O
.	O

The	O
1.5	O
-	O
2	O
g	O
liver	O
benefiting	O
powder	O
is	O
taken	O
directly	O
with	O
warm	O
water	O
at	O
each	O
time	O
for	O
2	O
-	O
3	O
times	O
per	O
day	O
.	O

External	O
application	O
treatment	O
is	O
conducted	O
as	O
follows	O
:	O
realgar	O
is	O
placed	O
in	O
an	O
abdomen	O
of	O
a	O
live	O
toad	O
(	O
with	O
viscera	O
being	O
removed	O
)	O
,	O
warm	O
water	O
is	O
added	O
to	O
prepare	O
paste	O
,	O
and	O
then	O
the	O
toad	O
is	O
externally	O
applied	O
at	O
a	O
hepatic	O
region	O
for	O
twice	O
per	O
day	O
.	O

Compound	O
solid	O
preparation	O
containing	O
tranexamic	O
acid	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
solid	O
preparation	O
containing	O
tranexamic	O
acid	O
.	O

The	O
compound	O
oral	O
solid	O
preparation	O
containing	O
the	O
tranexamic	O
acid	O
is	O
prepared	O
from	O
the	O
tranexamic	O
acid	O
serving	O
as	O
a	O
main	O
active	O
ingredient	O
,	O
other	O
active	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
by	O
a	O
preparation	O
technology	O
.	O

The	O
compound	O
solid	O
preparation	O
containing	O
the	O
tranexamic	O
acid	O
is	O
stable	O
and	O
controllable	O
in	O
quality	O
,	O
safe	O
and	O
effective	O
.	O

Bifendate	O
derivative	O
,	O
preparation	O
method	O
and	O
application	O
of	O
bifendate	O
derivative	O
for	O
treating	O
autoimmune	O
disease	O
The	O
invention	O
belongs	O
to	O
the	O
chemical	O
medicine	O
technical	O
field	O
,	O
and	O
especially	O
relates	O
to	O
a	O
bifendate	O
derivative	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
the	O
bifendate	O
derivative	O
for	O
treating	O
autoimmune	O
disease	O
.	O

A	O
structure	O
of	O
the	O
bifendate	O
derivative	O
is	O
shown	O
as	O
a	O
formula	O
I	O
,	O
and	O
has	O
good	O
effects	O
for	O
inhibiting	O
autoimmune	O
diseases	O
such	O
as	O
acute	O
hepatitis	O
,	O
chronic	O
hepatic	O
fibrosis	O
and	O
pulmonary	O
fibrosis	O
,	O
and	O
the	O
bifendate	O
derivative	O
provides	O
a	O
new	O
choice	O
for	O
medicines	O
exploitation	O
for	O
treating	O
the	O
diseases	O
.	O

Imidazole	O
[	O
4,5-c	O
]	O
pyridine-7-methanamide	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicinal	O
chemistry	O
and	O
in	O
particular	O
relates	O
to	O
an	O
imidazole	O
[	O
4,5-c	O
]	O
pyridine-7-methanamide	O
derivative	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
defined	O
in	O
the	O
specification	O
.	O

Pharmacodynamic	O
tests	O
proof	O
that	O
the	O
derivative	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
serve	O
as	O
a	O
tumour	O
therapeutic	O
agent	O
and	O
especially	O
the	O
derivative	O
compound	O
has	O
extremely	O
strong	O
anti	O
-	O
tumour	O
effect	O
when	O
being	O
combined	O
with	O
cis	O
-	O
platinum	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
compound	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative	O
compound	O
.	O

Thiophene	O
derivative	O
and	O
application	O
thereof	O
to	O
medicine	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
an	O
inhibitor	O
for	O
hepatitis	O
C	O
virus	O
.	O

In	O
addition	O
,	O
the	O
invention	O
describes	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
and	O
application	O
of	O
the	O
inhibitor	O
to	O
the	O
treatment	O
of	O
hepatitis	O
C	O
virus	O
infection	O
.	O

Repaglinide	O
and	O
metformin	O
hydrochloride	O
medicinal	O
composition	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
provides	O
a	O
medicinal	O
composition	O
including	O
active	O
components	O
of	O
repaglinide	O
and	O
metformin	O
hydrochloride	O
,	O
and	O
its	O
preparation	O
method	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
carrying	O
out	O
hot	O
melting	O
granulation	O
of	O
metformin	O
hydrochloride	O
to	O
prepare	O
particles	O
,	O
directly	O
spraying	O
a	O
repaglinide	O
solution	O
on	O
the	O
metformin	O
hydrochloride	O
particles	O
through	O
a	O
one	O
-	O
step	O
granulation	O
technology	O
,	O
and	O
adding	O
parts	O
of	O
auxiliary	O
materials	O
to	O
prepare	O
a	O
tablet	O
.	O

Medicine	O
composition	O
for	O
treating	O
mental	O
disorder	O
A	O
medicine	O
composition	O
for	O
treating	O
mental	O
disorder	O
is	O
formed	O
by	O
combining	O
active	O
components	O
with	O
pharmaceutical	O
acceptable	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
active	O
components	O
adopt	O
ecitalopram	O
(	O
salt	O
)	O
and	O
olanzapine	O
(	O
salt	O
)	O
.	O

Oral	O
preparations	O
,	O
such	O
as	O
tablets	O
,	O
capsules	O
,	O
soft	O
capsules	O
,	O
chewable	O
tablets	O
,	O
orally	O
disintegration	O
tablets	O
,	O
buccal	O
tablets	O
,	O
pill	O
and	O
the	O
like	O
,	O
can	O
be	O
produced	O
through	O
certain	O
preparation	O
techniques	O
.	O

The	O
composition	O
is	O
used	O
for	O
treating	O
the	O
mental	O
disorder	O
,	O
such	O
as	O
depression	O
,	O
insomnia	O
,	O
anxiety	O
,	O
schizophrenia	O
and	O
the	O
like	O
.	O

Anti	O
-	O
Japanese	O
-	O
encephalitis	O
-	O
virus	O
-	O
infection	O
compositions	O
and	O
applications	O
thereof	O
The	O
invention	O
discloses	O
compositions	O
with	O
anti	O
-	O
Japanese	O
-	O
encephalitis	O
-	O
virus	O
functions	O
,	O
and	O
applications	O
thereof	O
in	O
preparing	O
medicine	O
used	O
for	O
preventing	O
and/or	O
treating	O
Japanese	O
encephalitis	O
virus	O
infections	O
.	O

The	O
compositions	O
comprise	O
a	O
N-	O
(	O
2-thiazolyl	O
)	O
benzamide	O
compound	O
represented	O
by	O
the	O
formula	O
A	O
,	O
and	O
trehalose	O
or	O
Huangqi	O
Shengmai	O
Yin	O
.	O

R1	O
is	O
OH	O
,	O
OCOCH3	O
,	O
OCOC2H5	O
,	O
OCOCH2CH2CH3	O
or	O
OCOCH	O
(	O
CH3	O
)	O
2	O
;	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
independently	O
H	O
or	O
C1-C3	O
alkyl	O
;	O
R5	O
is	O
halogen	O
,	O
nitro	O
,	O
or	O
C1-C3	O
of	O
the	O
alkylsulfonyl	O
;	O
and	O
R6	O
is	O
H	O
or	O
C1-C3	O
alkylsulfonyl	O
.	O

The	O
composition	O
provided	O
by	O
the	O
invention	O
can	O
effectively	O
inhibit	O
Japanese	O
encephalitis	O
virus	O
proliferation	O
.	O

Compound	O
Caulis	O
Sinomenii	O
tablet	O
The	O
invention	O
discloses	O
a	O
compound	O
preparation	O
for	O
reducing	O
the	O
concentration	O
of	O
uric	O
acid	O
in	O
the	O
blood	O
to	O
treat	O
gout	O
,	O
and	O
concretely	O
discloses	O
a	O
compound	O
Caulis	O
Sinomenii	O
tablet	O
.	O

The	O
tablet	O
is	O
characterized	O
in	O
that	O
the	O
components	O
of	O
the	O
tablet	O
and	O
the	O
proportions	O
of	O
the	O
components	O
are	O
shown	O
in	O
the	O
specification	O
,	O
and	O
eight	O
medicines	O
which	O
are	O
the	O
components	O
are	O
mixed	O
according	O
to	O
the	O
proportions	O
to	O
prepare	O
the	O
tablet	O
or	O
a	O
pill	O
.	O

0.5	O
-	O
1.0	O
g	O
of	O
the	O
tablet	O
or	O
the	O
pill	O
is	O
orally	O
taken	O
each	O
time	O
,	O
and	O
is	O
continuously	O
taken	O
three	O
times	O
a	O
day	O
after	O
each	O
meal	O
for	O
2	O
-	O
3	O
weeks	O
.	O

Medicinal	O
composite	O
for	O
treating	O
Alzheimer	O
's	O
disease	O
The	O
invention	O
discloses	O
a	O
medicinal	O
composite	O
for	O
treating	O
Alzheimer	O
's	O
disease	O
.	O

The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
comprises	O
procyanidine	O
and	O
cysteine	O
,	O
wherein	O
the	O
mass	O
ratio	O
of	O
the	O
procyanidine	O
to	O
the	O
cysteine	O
is	O
(	O
0.1	O
-	O
10	O
)	O
:1	O
,	O
preferably	O
(	O
1	O
-	O
3	O
)	O
:1	O
;	O
and	O
the	O
procyanidine	O
is	O
preferably	O
lotus	O
procyanidine	O
.	O

The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
can	O
improve	O
the	O
oxidation	O
resistance	O
of	O
brain	O
tissue	O
,	O
avoid	O
free	O
radical	O
injury	O
to	O
the	O
brain	O
tissue	O
,	O
inhibit	O
MAO	B
-	I
B	I
and	O
AchE	B
activity	O
and	O
enhance	O
the	O
oxidation	O
resistance	O
of	O
brain	O
and	O
hippocampal	O
anti	O
-	O
oxidation	O
system	O
and	O
serum	O
so	O
as	O
to	O
improve	O
the	O
learning	O
and	O
memory	O
function	O
.	O

According	O
to	O
animal	O
tests	O
,	O
the	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
can	O
effectively	O
improve	O
mouse	O
learning	O
and	O
memory	O
injury	O
induced	O
by	O
ethanol	O
and	O
scopolamine	O
,	O
and	O
the	O
curative	O
effect	O
is	O
more	O
excellent	O
than	O
that	O
of	O
piracetam	O
and	O
procyanidine	O
.	O

Slow	O
-	O
release	O
composition	O
containing	O
L	O
-	O
milnacipran	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
composition	O
containing	O
L	O
-	O
milnacipran	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
composition	O
contains	O
the	O
L	O
-	O
milnacipran	O
serving	O
as	O
an	O
active	O
ingredient	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
also	O
comprising	O
high	O
-	O
viscosity	O
hydroxypropyl	O
methylcellulose	O
serving	O
as	O
a	O
hydrophilic	O
gel	O
slow	O
-	O
release	O
skeleton	O
material	O
and	O
acrylic	O
resin	O
serving	O
as	O
a	O
pH	O
adjustor	O
,	O
wherein	O
the	O
composition	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
10	O
to	O
70	O
parts	O
of	O
L	O
-	O
milnacipran	O
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
5	O
to	O
30	O
parts	O
of	O
hydroxypropyl	O
methylcellulose	O
,	O
and	O
3.5	O
to	O
7.5	O
parts	O
of	O
acrylic	O
resin	O
;	O
and	O
during	O
preparation	O
,	O
the	O
L	O
-	O
milnacipran	O
,	O
the	O
hydroxypropyl	O
methylcellulose	O
and	O
the	O
acrylic	O
resin	O
are	O
bound	O
to	O
be	O
mixed	O
uniformly	O
.	O

The	O
composition	O
can	O
realize	O
consistency	O
of	O
release	O
behaviors	O
in	O
artificial	O
gastric	O
juice	O
and	O
artificial	O
intestinal	O
juice	O
and	O
keep	O
12-hour	O
continuous	O
release	O
effect	O
,	O
and	O
is	O
low	O
in	O
preparation	O
loss	O
,	O
high	O
in	O
efficiency	O
,	O
high	O
in	O
stability	O
,	O
easy	O
to	O
operate	O
and	O
easy	O
to	O
popularize	O
.	O

Carboxylic	O
acid	O
derivative	O
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
provides	O
a	O
carboxylic	O
acid	O
derivative	O
compound	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
provided	O
by	O
the	O
invention	O
not	O
only	O
can	O
reduce	O
the	O
level	O
of	O
triglyceride	O
in	O
high	O
fat	O
model	O
animal	O
blood	O
,	O
but	O
also	O
has	O
the	O
good	O
function	O
of	O
reducing	O
cholesterol	O
and	O
low	O
-	O
density	O
lipoprotein	O
and	O
the	O
effects	O
of	O
promoting	O
biliation	O
,	O
reducing	O
content	O
of	O
cholesterol	O
in	O
bile	O
and	O
increasing	O
the	O
content	O
of	O
bile	O
acid	O
,	O
and	O
also	O
has	O
the	O
effect	O
of	O
preventing	O
and	O
treating	O
gallstone	O
when	O
being	O
applied	O
to	O
a	O
golden	O
gopher	O
gallstone	O
model	O
.	O

The	O
particular	O
importance	O
is	O
that	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
provided	O
by	O
the	O
invention	O
is	O
low	O
in	O
toxicity	O
.	O

Application	O
of	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
The	O
invention	O
belongs	O
to	O
the	O
fields	O
of	O
chemical	O
industry	O
and	O
medicine	O
,	O
and	O
relates	O
to	O
application	O
of	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
.	O

In	O
the	O
application	O
of	O
the	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
,	O
tumor	O
cells	O
include	O
liver	O
cancer	O
cells	O
,	O
leukemia	O
cells	O
and	O
pancreatic	O
cancer	O
cells	O
.	O

The	O
isosteviol	O
lactone	O
belongs	O
to	O
a	O
natural	O
product	O
,	O
is	O
low	O
in	O
toxic	O
and	O
side	O
effect	O
,	O
high	O
in	O
bioavailability	O
and	O
stable	O
in	O
property	O
,	O
and	O
has	O
clinical	O
use	O
value	O
.	O

The	O
small	O
-	O
molecule	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
be	O
developed	O
as	O
a	O
new	O
antitumor	O
medicament	O
or	O
an	O
auxiliary	O
component	O
thereof	O
,	O
has	O
remarkable	O
tumor	O
inhibition	O
effect	O
,	O
and	O
is	O
green	O
and	O
environment	O
-	O
friendly	O
,	O
thereby	O
providing	O
a	O
new	O
way	O
and	O
means	O
for	O
treating	O
and	O
curing	O
tumors	O
.	O

Method	O
for	O
preparing	O
farrerol	O
solid	O
dispersion	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
farrerol	O
solid	O
dispersion	O
,	O
and	O
the	O
method	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
preparations	O
and	O
is	O
used	O
for	O
solving	O
the	O
problems	O
of	O
low	O
dissolution	O
rate	O
,	O
incomplete	O
dissolution	O
and	O
low	O
bioavailability	O
of	O
farrerol	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
the	O
farrerol	O
and	O
a	O
carrier	O
material	O
into	O
a	O
medicinal	O
organic	O
solvent	O
according	O
to	O
a	O
mass	O
ratio	O
of	O
(	O
1:1	O
)	O
-	O
(	O
1:12	O
)	O
so	O
as	O
to	O
form	O
a	O
transparent	O
solution	O
;	O
heating	O
the	O
organic	O
solvent	O
in	O
a	O
water	O
bath	O
of	O
50	O
-	O
80	O
DEG	O
C	O
,	O
vaporizing	O
the	O
organic	O
solvent	O
to	O
be	O
sticky	O
and	O
then	O
quickly	O
putting	O
the	O
organic	O
solvent	O
in	O
a	O
refrigerator	O
of	O
-20	O
DEG	O
C	O
to	O
be	O
solidified	O
for	O
3	O
-	O
5	O
hours	O
;	O
taking	O
the	O
solidified	O
organic	O
solvent	O
out	O
,	O
and	O
grinding	O
the	O
solidified	O
organic	O
solvent	O
into	O
small	O
particles	O
of	O
20	O
meshes	O
;	O
putting	O
the	O
small	O
particles	O
in	O
a	O
vacuum	O
drying	O
oven	O
for	O
12	O
-	O
24	O
hours	O
so	O
as	O
to	O
thoroughly	O
remove	O
the	O
residual	O
organic	O
solvent	O
;	O
taking	O
the	O
small	O
particles	O
out	O
,	O
finely	O
grinding	O
and	O
screening	O
the	O
small	O
particles	O
through	O
a	O
screen	O
of	O
80	O
meshes	O
and	O
putting	O
the	O
small	O
particles	O
in	O
a	O
drying	O
device	O
to	O
be	O
kept	O
in	O
dark	O
places	O
.	O

In	O
a	O
process	O
of	O
preparing	O
the	O
solid	O
dispersion	O
,	O
the	O
farrerol	O
is	O
uniformly	O
dispersed	O
into	O
the	O
water	O
-	O
soluble	O
carrier	O
,	O
so	O
that	O
the	O
water	O
solubility	O
,	O
dissolution	O
rate	O
,	O
bioavailability	O
and	O
therapeutic	O
effect	O
of	O
the	O
farrerol	O
are	O
improved	O
.	O

Application	O
of	O
Aphanamixoid	O
A	O
in	O
medicine	O
for	O
treating	O
liver	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Aphanamixoid	O
A	O
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
liver	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
the	O
medicine	O
.	O

The	O
Aphanamixoid	O
A	O
has	O
outstanding	O
inhibiting	O
effect	O
on	O
the	O
growth	O
of	O
human	O
liver	O
cancer	O
cell	O
strains	O
HepG2	O
,	O
MHCC	O
-	O
LM3	O
,	O
Bel-7402	O
and	O
HuH-7	O
through	O
in	O
-	O
vitro	O
MTT	O
(	O
Methyl	O
Thiazolyl	O
Tetrazolium	O
)	O
antineoplastic	O
activity	O
evaluation	O
.	O

Thus	O
,	O
the	O
Aphanamixoid	O
A	O
can	O
be	O
used	O
for	O
preparing	O
the	O
medicine	O
for	O
resisting	O
the	O
liver	O
cancer	O
and	O
has	O
good	O
development	O
and	O
application	O
prospect	O
;	O
and	O
the	O
application	O
of	O
the	O
Aphanamixoid	O
A	O
in	O
preparing	O
the	O
medicine	O
for	O
treating	O
the	O
liver	O
cancer	O
is	O
firstly	O
disclosed	O
because	O
a	O
skeleton	O
type	O
belongs	O
to	O
a	O
fire	O
-	O
new	O
skeleton	O
type	O
and	O
the	O
inhibitory	O
activity	O
of	O
the	O
Aphanamixoid	O
A	O
on	O
liver	O
cancer	O
cells	O
is	O
inconceivably	O
high	O
.	O

Composition	O
containing	O
high	O
purity	O
bilobalide	O
B	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
high	O
purity	O
bilobalide	O
B.	O
The	O
composition	O
is	O
a	O
bilobalide	O
B	O
injection	O
which	O
comprises	O
the	O
following	O
medical	O
active	O
components	O
in	O
parts	O
by	O
weight	O
:	O
20	O
parts	O
of	O
bilobalide	O
B	O
extract	O
,	O
580	O
-	O
630	O
parts	O
of	O
polyethylene	O
glycol-400	O
,	O
770	O
-	O
830	O
parts	O
of	O
glycerol	O
and	O
640	O
-	O
700	O
parts	O
of	O
ethanol	O
.	O

The	O
bilobalide	O
B	O
extract	O
is	O
extracted	O
from	O
ginkgo	O
leaves	O
and	O
contains	O
bilobalide	O
B	O
and	O
bilobalide	O
A	O
'	O
.	O

The	O
content	O
of	O
bilobalide	O
B	O
is	O
greater	O
than	O
99	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
bilobalide	O
A	O
'	O
is	O
less	O
than	O
0.4	O
%	O
.	O

In	O
the	O
bilobalide	O
B	O
composition	O
provided	O
by	O
the	O
invention	O
,	O
purity	O
of	O
bilobalide	O
B	O
in	O
the	O
bilobalide	O
B	O
extract	O
as	O
a	O
raw	O
material	O
medicine	O
is	O
high	O
,	O
and	O
the	O
content	O
of	O
the	O
bilobalide	O
A'is	O
extremely	O
low	O
,	O
so	O
that	O
the	O
demand	O
of	O
injection	O
to	O
the	O
raw	O
material	O
medicine	O
is	O
met	O
,	O
and	O
the	O
bioavailability	O
of	O
the	O
raw	O
material	O
medicine	O
and	O
the	O
medication	O
safety	O
of	O
patients	O
are	O
improved	O
.	O

Composition	O
taking	O
high	O
-	O
purity	O
ginkgolide	O
B	O
as	O
active	O
ingredient	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
taking	O
high	O
-	O
purity	O
ginkgolide	O
B	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
composition	O
is	O
a	O
ginkgolide	O
B	O
injection	O
.	O

The	O
ginkgolide	O
B	O
injection	O
comprises	O
the	O
following	O
pharmaceutical	O
active	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
20	O
parts	O
of	O
ginkgolide	O
B	O
extract	O
,	O
580	O
-	O
630	O
parts	O
of	O
polyethylene	O
glycol-400	O
,	O
770	O
-	O
830	O
parts	O
of	O
glycerol	O
and	O
640	O
-	O
700	O
parts	O
of	O
ethanol	O
,	O
wherein	O
the	O
ginkgolide	O
B	O
extract	O
is	O
extracted	O
from	O
ginkgo	O
leaves	O
,	O
and	O
comprises	O
ginkgolide	O
B	O
and	O
ginkgolide	O
K	O
,	O
the	O
content	O
of	O
the	O
ginkgolide	O
B	O
is	O
more	O
than	O
99	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
ginkgolide	O
K	O
is	O
less	O
than	O
0.6	O
%	O
.	O

In	O
a	O
ginkgolide	O
B	O
composition	O
provided	O
by	O
the	O
invention	O
,	O
the	O
ginkgolide	O
B	O
in	O
the	O
ginkgolide	O
B	O
extract	O
as	O
a	O
raw	O
medicine	O
has	O
a	O
high	O
purity	O
,	O
and	O
the	O
content	O
of	O
the	O
ginkgolide	O
K	O
is	O
extremely	O
low	O
,	O
so	O
that	O
requirement	O
of	O
the	O
injection	O
on	O
the	O
raw	O
medicine	O
is	O
met	O
and	O
the	O
bioavailability	O
of	O
the	O
raw	O
medicine	O
and	O
the	O
medication	O
safety	O
of	O
patients	O
are	O
improved	O
.	O

Calcitriol	O
powder	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
calcitriol	O
powder	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
powder	O
is	O
prepared	O
from	O
the	O
following	O
ingredients	O
in	O
percentage	O
by	O
weight	O
:	O
0.0005	O
%	O
of	O
calcitriol	O
,	O
2.0	O
-	O
7.0	O
%	O
of	O
meglumine	O
,	O
2	O
-	O
4	O
%	O
of	O
polyethylene	O
glycol	O
400	O
,	O
20	O
-	O
30	O
%	O
of	O
polyethylene	O
glycol	O
6000	O
,	O
50.0	O
-	O
70.0	O
%	O
of	O
filler	O
and	O
an	O
appropriate	O
amount	O
of	O
lubricant	O
.	O

According	O
to	O
the	O
powder	O
,	O
the	O
content	O
of	O
calcitriol	O
is	O
remarkably	O
increased	O
,	O
so	O
that	O
the	O
drug	O
dosage	O
is	O
reduced	O
;	O
and	O
the	O
stability	O
of	O
calcitriol	O
to	O
light	O
and	O
air	O
is	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
calcitriol	O
is	O
also	O
remarkably	O
improved	O
.	O

Application	O
of	O
barbaloin	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
barbaloin	O
in	O
preparing	O
medicines	O
or	O
cosmetics	O
for	O
preventing	O
or	O
treating	O
acne	O
caused	O
by	O
propionibacterium	O
acne	O
breeding	O
.	O

The	O
invention	O
discloses	O
the	O
medicines	O
or	O
cosmetics	O
which	O
contain	O
the	O
barbaloin	O
which	O
can	O
effectively	O
treat	O
the	O
acne	O
generation	O
caused	O
by	O
propionibacterium	O
acne	O
breeding	O
.	O

Ipecacuanha	O
effective	O
component	O
composition	O
,	O
its	O
preparation	O
method	O
and	O
application	O
The	O
invention	O
discloses	O
an	O
ipecacuanha	O
effective	O
component	O
composition	O
,	O
its	O
preparation	O
method	O
and	O
application	O
.	O

The	O
composition	O
contains	O
cephaeline	O
and	O
emetine	O
that	O
are	O
in	O
a	O
weight	O
ratio	O
of	O
1	O
-	O
2:1	O
.	O

The	O
preparation	O
method	O
of	O
the	O
ipecacuanha	O
effective	O
component	O
composition	O
comprises	O
:	O
taking	O
ipecacuanha	O
medicinal	O
materials	O
with	O
different	O
producing	O
areas	O
and/or	O
different	O
batches	O
,	O
mixing	O
them	O
in	O
proportion	O
to	O
prepare	O
an	O
extract	O
,	O
a	O
fluid	O
extract	O
or	O
a	O
tincture	O
,	O
or	O
conducting	O
extraction	O
on	O
the	O
ipecacuanha	O
medicinal	O
materials	O
with	O
different	O
producing	O
areas	O
and/or	O
different	O
batches	O
to	O
prepare	O
extracts	O
,	O
performing	O
mixing	O
in	O
proportion	O
,	O
and	O
then	O
making	O
the	O
mixture	O
into	O
an	O
extract	O
,	O
a	O
fluid	O
extract	O
or	O
a	O
tincture	O
.	O

Based	O
on	O
the	O
pharmacological	O
and	O
pharmacokinetic	O
differences	O
of	O
emetine	O
and	O
cephaeline	O
,	O
screening	O
research	O
on	O
cough	O
relieving	O
and	O
sputum	O
reducing	O
effect	O
differences	O
caused	O
by	O
different	O
proportions	O
of	O
emetine	O
and	O
cephaeline	O
is	O
carried	O
out	O
,	O
and	O
a	O
good	O
emetine	O
and	O
cephaeline	O
combination	O
region	O
for	O
ideal	O
cough	O
relieving	O
and	O
sputum	O
reducing	O
effects	O
can	O
be	O
determined	O
.	O

Bicyclic	O
heteroaryl	O
kinase	B
inhibitors	O
and	O
methods	O
of	O
use	O
Provided	O
are	O
compounds	O
having	O
an	O
inhibitory	O
effect	O
on	O
kinases	B
including	O
Mixed	B
Lineage	I
Kinases	I
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
preparing	O
the	O
compounds	O
,	O
synthetic	O
intermediates	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
,	O
independently	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
,	O
for	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
affected	O
by	O
Mixed	B
Lineage	I
Kinase	I
inhibition	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
that	O
comprise	O
the	O
inhibition	O
of	O
Mixed	B
Lineage	I
Kinases	I
.	O

Kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
human	O
drugs	O
and	O
drug	O
composition	O
thereof	O
The	O
invention	O
discloses	O
kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
human	O
drugs	O
and	O
a	O
drug	O
composition	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drugs	O
.	O

Kidney	O
bean	O
phytolectins	O
are	O
used	O
as	O
active	O
components	O
for	O
preparing	O
drugs	O
used	O
for	O
adding	O
lactobacillus	O
amounts	O
in	O
woman	O
vaginas	O
.	O

The	O
drug	O
composition	O
adopts	O
the	O
kidney	O
bean	O
phytolectins	O
,	O
tremella	O
polysaccharide	O
,	O
stachyose	O
or	O
/	O
and	O
raffinose	O
and	O
bletilla	O
gum	O
,	O
or	O
added	O
scutellaria	O
,	O
Hollygreen	O
Barberry	O
and	O
matrine	O
extraction	O
as	O
the	O
active	O
components	O
.	O

The	O
drug	O
composition	O
comprises	O
relative	O
weight	O
parts	O
of	O
that	O
0.5	O
-	O
1.0	O
part	O
of	O
the	O
kidney	O
bean	O
phytolectins	O
,	O
1.5	O
-	O
3.0	O
parts	O
of	O
the	O
tremella	O
polysaccharide	O
,	O
0.2	O
-	O
2.0	O
parts	O
of	O
the	O
stachyose	O
or	O
/	O
and	O
raffinose	O
,	O
0.2	O
-	O
0.5	O
part	O
of	O
the	O
bletilla	O
gum	O
and	O
1.0	O
-	O
3.0	O
parts	O
of	O
the	O
extraction	O
of	O
one	O
kind	O
or	O
more	O
than	O
one	O
kind	O
of	O
scutellaria	O
dry	O
powder	O
,	O
Hollygreen	O
Barberry	O
dry	O
powder	O
and	O
matrine	O
dry	O
powder	O
.	O

The	O
kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
people	O
use	O
drugs	O
and	O
the	O
drug	O
composition	O
can	O
be	O
water	O
-	O
soluble	O
complex	O
liquid	O
and	O
is	O
best	O
to	O
be	O
gel	O
,	O
and	O
also	O
can	O
be	O
solid	O
dosage	O
forms	O
such	O
as	O
suppository	O
,	O
disintegrating	O
tablets	O
and	O
the	O
like	O
which	O
are	O
drug	O
dosage	O
forms	O
suitable	O
for	O
external	O
uses	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
obtained	O
products	O
do	O
not	O
need	O
to	O
be	O
preserved	O
in	O
a	O
low	O
temperature	O
and	O
is	O
long	O
in	O
storage	O
time	O
and	O
convenient	O
to	O
use	O
.	O

Vidarabine	O
monophosphate	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
vidarabine	O
monophosphate	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
injection	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
:	O
50	O
-	O
200	O
parts	O
of	O
vidarabine	O
monophosphate	O
,	O
0.015	O
-	O
0.05	O
part	O
of	O
a	O
pH	O
regulator	O
and	O
2000	O
parts	O
of	O
water	O
for	O
injection	O
.	O

A	O
finished	O
product	O
prepared	O
by	O
the	O
method	O
provided	O
by	O
the	O
invention	O
has	O
low	O
impurity	O
content	O
,	O
good	O
homogeneity	O
and	O
good	O
stability	O
.	O

A	O
water	O
injection	O
is	O
subjected	O
to	O
terminal	O
sterilization	O
to	O
ensure	O
the	O
safety	O
of	O
the	O
product	O
.	O

The	O
water	O
injection	O
is	O
convenient	O
to	O
use	O
,	O
and	O
does	O
not	O
need	O
to	O
be	O
prepared	O
before	O
clinical	O
application	O
,	O
so	O
as	O
to	O
reduce	O
the	O
potential	O
safety	O
hazard	O
caused	O
by	O
operation	O
and	O
provide	O
a	O
new	O
choice	O
of	O
medication	O
for	O
clinical	O
use	O
.	O

Application	O
of	O
terpenoid	O
The	O
invention	O
provides	O
an	O
application	O
of	O
a	O
terpenoid	O
to	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
.	O

The	O
terpenoid	O
has	O
a	O
structural	O
formula	O
I	O
which	O
is	O
as	O
shown	O
in	O
the	O
description	O
,	O
wherein	O
R1	O
represents	O
H	O
,	O
C1-C5	O
linear	O
alkyl	O
,	O
glycosyl	O
or	O
a	O
formula	O
which	O
is	O
as	O
shown	O
in	O
the	O
description	O
,	O
and	O
R2	O
is	O
selected	O
from	O
C1-C4	O
linear	O
alkyl	O
.	O

According	O
to	O
the	O
application	O
of	O
the	O
terpenoid	O
,	O
an	O
ionane	O
type	O
sesquiterpene	O
compound	O
separated	O
and	O
obtained	O
from	O
leonurus	O
for	O
the	O
first	O
time	O
can	O
obviously	O
inhibit	O
the	O
platelet	O
aggregation	O
in	O
vitro	O
and	O
has	O
extension	O
tendencies	O
to	O
prothrombin	B
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	B
time	O
(	O
APTT	O
)	O
and	O
thrombin	B
time	O
(	O
TT	O
)	O
and	O
has	O
a	O
certain	O
anticoagulation	O
activity	O
,	O
so	O
that	O
a	O
new	O
choice	O
is	O
provided	O
for	O
the	O
development	O
of	O
natural	O
anti	O
-	O
thrombus	O
drugs	O
.	O

Imatinib	O
mesylate	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
imatinib	O
mesylate	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
imatinib	O
mesylate	O
tablet	O
comprises	O
8	O
-	O
30	O
%	O
of	O
crospovidone	O
and	O
8	O
to	O
40	O
%	O
of	O
silica	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
carrying	O
out	O
granulation	O
of	O
imatinib	O
mesylate	O
and	O
a	O
waterless	O
organic	O
solvent	O
,	O
drying	O
the	O
granules	O
,	O
uniformly	O
mixing	O
the	O
granules	O
,	O
crospovidone	O
,	O
silica	O
,	O
a	O
filler	O
and	O
a	O
lubricant	O
,	O
and	O
carrying	O
out	O
tabletting	O
.	O

The	O
preparation	O
method	O
solves	O
the	O
problem	O
of	O
a	O
slow	O
dissolution	O
rate	O
of	O
a	O
preparation	O
obtained	O
by	O
the	O
prior	O
art	O
.	O

Ezetimibe	O
,	O
simvastatin	O
and	O
nicotinic	O
acid	O
compound	O
preparation	O
and	O
preparation	O
method	O
of	O
ezetimibe	O
,	O
simvastatin	O
and	O
nicotinic	O
acid	O
compound	O
preparation	O
The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
preparations	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
preparation	O
which	O
takes	O
ezetimibe	O
,	O
simvastatin	O
and	O
nicotinic	O
acid	O
as	O
effective	O
components	O
and	O
has	O
the	O
effects	O
of	O
reducing	O
blood	O
pressure	O
and	O
blood	O
lipid	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
preparation	O
.	O

The	O
compound	O
preparation	O
is	O
a	O
sustained	O
release	O
tablet	O
.	O

Aiming	O
at	O
the	O
problems	O
of	O
poor	O
water	O
solubility	O
of	O
the	O
ezetimibe	O
,	O
unstability	O
of	O
the	O
simvastatin	O
to	O
acid	O
and	O
oxygen	O
,	O
and	O
the	O
like	O
,	O
the	O
preparation	O
method	O
of	O
the	O
compound	O
preparation	O
adopts	O
a	O
melt	O
extrusion	O
technology	O
for	O
improving	O
the	O
dissolution	O
rate	O
of	O
the	O
ezetimibe	O
,	O
and	O
adopts	O
a	O
cladding	O
membrane	O
technology	O
for	O
enhancing	O
the	O
stability	O
of	O
the	O
simvastatin	O
in	O
a	O
body	O
so	O
as	O
to	O
give	O
full	O
play	O
to	O
the	O
efficacy	O
of	O
all	O
components	O
of	O
the	O
compound	O
preparation	O
and	O
have	O
the	O
best	O
synergy	O
effect	O
.	O

The	O
specific	O
process	O
comprises	O
the	O
steps	O
of	O
preparing	O
the	O
nicotinic	O
acid	O
into	O
a	O
tablet	O
core	O
as	O
a	O
sustained	O
release	O
part	O
,	O
spraying	O
an	O
isolating	O
layer	O
on	O
the	O
tablet	O
core	O
,	O
then	O
spraying	O
the	O
simvastatin	O
and	O
the	O
ezetimibe	O
on	O
an	O
outer	O
layer	O
of	O
the	O
sustained	O
release	O
part	O
as	O
a	O
quick	O
release	O
layer	O
,	O
and	O
then	O
carrying	O
out	O
film	O
coating	O
on	O
the	O
quick	O
release	O
layer	O
.	O

The	O
compound	O
preparation	O
provided	O
by	O
the	O
invention	O
is	O
mainly	O
applied	O
to	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
and	O
indications	O
associated	O
with	O
heart	O
and	O
cerebral	O
vessels	O
.	O

Enrofloxacin	O
clathrate	O
compound	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
enrofloxacin	O
clathrate	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
enrofloxacin	O
clathrate	O
compound	O
is	O
prepared	O
by	O
taking	O
enrofloxacin	O
and	O
fenugreek	O
as	O
raw	O
materials	O
,	O
performing	O
clathration	O
treatment	O
on	O
auxiliary	O
materials	O
such	O
as	O
a	O
slow	O
release	O
formulation	O
,	O
a	O
flavoring	O
agent	O
,	O
a	O
plasticizer	O
,	O
a	O
curing	O
agent	O
and	O
a	O
flocculant	O
,	O
and	O
drying	O
the	O
materials	O
.	O

The	O
enrofloxacin	O
clathrate	O
compound	O
has	O
the	O
advantages	O
that	O
the	O
delay	O
medicines	O
are	O
released	O
,	O
the	O
clinical	O
administration	O
frequency	O
is	O
reduced	O
,	O
the	O
product	O
stability	O
is	O
improved	O
and	O
the	O
palatability	O
of	O
the	O
medicines	O
is	O
improved	O
.	O

2,6-diketone	O
-	O
piperazine	O
(	O
piperidine	O
)	O
type	O
derivative	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
a	O
2,6-diketone	O
-	O
piperazine	O
(	O
piperidine	O
)	O
type	O
derivative	O
and	O
an	O
application	O
thereof	O
.	O

The	O
derivative	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
medicines	O
for	O
preventing	O
or	O
treating	O
central	O
nervous	O
system	O
diseases	O
.	O

Animal	O
experiment	O
results	O
show	O
that	O
the	O
derivative	O
has	O
smaller	O
ED50	O
and	O
stronger	O
action	O
in	O
MK-801-induced	O
high	O
activity	O
and	O
apomorphine	O
-	O
induced	O
climbing	O
animal	O
models	O
as	O
well	O
as	O
has	O
larger	O
ED50	O
and	O
larger	O
therapeutic	O
indexes	O
in	O
an	O
animal	O
catalepsy	O
model	O
.	O

The	O
derivative	O
is	O
a	O
compound	O
or	O
salt	O
thereof	O
with	O
a	O
general	O
formula	O
(	O
I	O
)	O
.	O

Application	O
of	O
ampelopsin	O
in	O
mutation	O
resistance	O
composition	O
preparation	O
The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
ampelopsin	O
in	O
preparation	O
of	O
mutation	O
resistance	O
health	O
food	O
or	O
drugs	O
,	O
wherein	O
purified	O
ampelopsin	O
or	O
an	O
unpurified	O
extract	O
containing	O
ampelopsin	O
can	O
be	O
adopted	O
to	O
prepare	O
into	O
a	O
pharmaceutically	O
acceptable	O
oral	O
formulation	O
,	O
a	O
pharmaceutically	O
acceptable	O
injection	O
formulation	O
or	O
a	O
pharmaceutically	O
acceptable	O
external	O
application	O
formulation	O
.	O

Application	O
of	O
5,7,3',4',5'-pentamethoxyl	O
flavone	O
in	O
preparing	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
drugs	O
The	O
invention	O
relates	O
to	O
drug	O
application	O
of	O
an	O
organic	O
compound	O
and	O
in	O
particular	O
relates	O
to	O
application	O
of	O
5,7,3',4',5'-pentamethoxyl	O
flavone	O
in	O
preparing	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

According	O
to	O
the	O
pharmacological	O
experiment	O
results	O
,	O
the	O
compound	O
has	O
better	O
inbibitional	O
effect	O
for	O
pains	O
and	O
inflammations	O
,	O
and	O
can	O
be	O
used	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
and	O
treating	O
diseases	O
including	O
rheumatic	O
arthritis	O
,	O
rheumatoid	O
arthritis	O
and	O
the	O
like	O
.	O

Pleuromutilin	O
expansion	O
ring	O
derivative	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pleuromutilin	O
expansion	O
ring	O
derivative	O
shown	O
in	O
a	O
structural	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

A	O
novel	O
expansion	O
ring	O
pleuromutilin	O
compound	O
is	O
synthetized	O
by	O
rearrangement	O
reaction	O
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
synthesizing	O
a	O
new	O
pleuromutilin	O
derivative	O
and	O
preparing	O
an	O
antibacterial	O
agent	O
.	O

Topical	O
ointment	O
for	O
treating	O
furunculosis	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
topical	O
ointment	O
for	O
treating	O
furunculosis	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
topical	O
ointment	O
is	O
characterized	O
in	O
that	O
the	O
topical	O
ointment	O
is	O
made	O
from	O
the	O
following	O
raw	O
medicines	O
,	O
by	O
weight	O
,	O
17	O
-	O
23	O
parts	O
of	O
honeysuckles	O
,	O
8	O
-	O
12	O
parts	O
of	O
chrysanthemums	O
,	O
8	O
-	O
12	O
parts	O
of	O
scutellaria	O
baicalensis	O
,	O
8	O
-	O
12	O
parts	O
of	O
rheum	O
officinale	O
,	O
8	O
-	O
12	O
parts	O
of	O
fructus	O
forsythia	O
,	O
6	O
-	O
8	O
parts	O
of	O
Chinese	O
violets	O
,	O
6	O
-	O
8	O
parts	O
of	O
moutan	O
bark	O
,	O
6	O
-	O
8	O
parts	O
of	O
golden	O
cypress	O
,	O
6	O
-	O
8	O
parts	O
of	O
coptis	O
,	O
6	O
-	O
8	O
parts	O
of	O
radix	O
rehmanniae	O
,	O
6	O
-	O
8	O
parts	O
of	O
hematoxylon	O
,	O
6	O
-	O
8	O
parts	O
of	O
Chinese	O
angelica	O
,	O
4	O
-	O
6	O
parts	O
of	O
cape	O
jasmine	O
,	O
4	O
-	O
6	O
parts	O
of	O
notopterygium	O
roots	O
,	O
4	O
-	O
6	O
parts	O
of	O
flos	O
sophorae	O
,	O
4	O
-	O
6	O
parts	O
of	O
platycodon	O
grandiflorum	O
,	O
4	O
-	O
6	O
parts	O
of	O
Chinese	O
parsnip	O
roots	O
,	O
2	O
-	O
4	O
parts	O
of	O
smoked	O
plums	O
,	O
2	O
-	O
4	O
parts	O
of	O
plant	O
soot	O
and	O
0.8	O
-	O
1.2	O
parts	O
of	O
calomel	O
.	O

The	O
topical	O
ointment	O
is	O
advantaged	O
by	O
rapid	O
effects	O
,	O
significant	O
effects	O
and	O
simple	O
preparation	O
method	O
.	O

Through	O
clinical	O
verifications	O
,	O
the	O
cure	O
rate	O
of	O
the	O
topical	O
ointment	O
for	O
treating	O
furunculosis	O
is	O
100	O
%	O
.	O

[	O
0	O
]	O

High	O
-	O
permeability	O
emulsifiable	O
paste	O
for	O
diminishing	O
inflammation	O
and	O
easing	O
pain	O
The	O
invention	O
relates	O
to	O
an	O
emulsifiable	O
paste	O
for	O
diminishing	O
inflammation	O
and	O
easing	O
pain	O
.	O

The	O
emulsifiable	O
paste	O
comprises	O
geniposide	O
,	O
isopropyl	O
myristate	O
,	O
caprylic	O
/	O
capric	O
triglyceride	O
and	O
polyoxyethylene	O
ether	O
40	O
hydrogenated	O
castor	O
oil	O
.	O

In	O
the	O
emulsifiable	O
paste	O
disclosed	O
by	O
the	O
invention	O
,	O
isopropyl	O
myristate	O
is	O
used	O
as	O
a	O
novel	O
percutaneous	O
permeation	O
agent	O
for	O
geniposide	O
,	O
thus	O
greatly	O
increasing	O
the	O
permeation	O
amount	O
for	O
geniposide	O
.	O

The	O
emulsifiable	O
paste	O
disclosed	O
by	O
the	O
invention	O
is	O
excellent	O
in	O
performance	O
,	O
low	O
in	O
greasy	O
feeling	O
,	O
easy	O
to	O
coat	O
and	O
clean	O
,	O
and	O
good	O
in	O
heat	O
stability	O
.	O

Method	O
for	O
preparing	O
long	O
-	O
acting	O
terramycin	O
injection	O
by	O
utilizing	O
carbamide	O
and	O
sodium	O
bisulfite	O
in	O
combined	O
way	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
long	O
-	O
acting	O
terramycin	O
injection	O
by	O
utilizing	O
carbamide	O
and	O
sodium	O
bisulfite	O
in	O
a	O
combined	O
way	O
.	O

The	O
long	O
-	O
acting	O
terramycin	O
injection	O
comprises	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
15	O
parts	O
of	O
tetramycin	O
hydrochloride	O
,	O
4	O
-	O
5	O
parts	O
of	O
magnesium	O
chloride	O
,	O
2	O
-	O
3	O
parts	O
of	O
carbamide	O
,	O
0.5	O
-	O
0.8	O
part	O
of	O
sodium	O
thiosulfate	O
,	O
4	O
-	O
6	O
parts	O
of	O
ethanolamine	O
,	O
1	O
-	O
1.5	O
parts	O
of	O
sodium	O
bisulfite	O
,	O
50	O
-	O
60	O
parts	O
of	O
alpha	O
-	O
pyrrolidone	O
,	O
0.01	O
-	O
0.03	O
part	O
of	O
disodium	O
EDTA	O
and	O
100	O
-	O
150	O
parts	O
of	O
water	O
for	O
injection	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
long	O
-	O
acting	O
terramycin	O
injection	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
bioavailability	O
,	O
good	O
curative	O
effect	O
,	O
quick	O
effect	O
,	O
definite	O
curative	O
effect	O
and	O
stability	O
in	O
quality	O
and	O
can	O
keep	O
higher	O
biological	O
activity	O
for	O
a	O
longer	O
time	O
and	O
sufficiently	O
keep	O
the	O
stability	O
of	O
a	O
product	O
;	O
the	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
easiness	O
for	O
operation	O
of	O
product	O
preparation	O
,	O
low	O
cost	O
and	O
industrialized	O
large	O
-	O
scale	O
production	O
.	O

Application	O
of	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
.	O

According	O
to	O
the	O
application	O
disclosed	O
by	O
the	O
invention	O
,	O
pharmacological	O
research	O
performed	O
on	O
Polyflavanostilbene	O
A	O
,	O
Polyflavanostilbene	O
A	O
is	O
found	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
acute	O
liver	O
injury	O
induced	O
by	O
D	O
-	O
galactosamine	O
(	O
D	O
-	O
GalN	O
)	O
,	O
of	O
mice	O
,	O
and	O
a	O
protective	O
effect	O
on	O
the	O
acute	O
liver	O
injury	O
induced	O
by	O
CC14	O
,	O
of	O
mice	O
.	O

Therefore	O
,	O
the	O
Polyflavanostilbene	O
A	O
can	O
be	O
used	O
for	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
or	O
hepatitis	O
.	O

The	O
application	O
of	O
the	O
Polyflavanostilbene	O
A	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
Polyflavanostilbene	O
A	O
has	O
a	O
new	O
framework	O
type	O
,	O
and	O
an	O
unexpectedly	O
high	O
activity	O
for	O
the	O
treatment	O
effect	O
on	O
liver	O
injury	O
,	O
so	O
that	O
the	O
possibility	O
of	O
giving	O
any	O
revelation	O
by	O
other	O
compounds	O
is	O
avoided	O
;	O
and	O
the	O
Polyflavanostilbene	O
A	O
has	O
prominent	O
substantive	O
features	O
and	O
has	O
an	O
obviously	O
remarkable	O
improvement	O
in	O
case	O
of	O
being	O
used	O
for	O
resisting	O
liver	O
injury	O
.	O

Cinnamic	O
amide	O
derivatives	O
,	O
their	O
preparation	O
methods	O
and	O
their	O
application	O
in	O
preparation	O
of	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
The	O
invention	O
discloses	O
cinnamic	O
amide	O
derivatives	O
,	O
their	O
preparation	O
methods	O
and	O
their	O
application	O
in	O
the	O
preparation	O
of	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
.	O

The	O
preparation	O
methods	O
adopting	O
hydroxycinnamic	O
acid	O
and	O
sulfanilamide	O
medicines	O
as	O
raw	O
materials	O
comprise	O
the	O
following	O
steps	O
:	O
dissolving	O
hydroxycinnamic	O
acid	O
in	O
acetic	O
anhydride	O
,	O
sequentially	O
adding	O
pyridine	O
and	O
tetrahydrofuran	O
for	O
reacting	O
with	O
the	O
sulfanilamide	O
medicines	O
to	O
obtain	O
crude	O
amide	O
compounds	O
,	O
filtering	O
,	O
washing	O
,	O
and	O
recrystallizing	O
to	O
obtain	O
the	O
novel	O
cinnamic	O
amide	O
derivatives	O
.	O

Researches	O
find	O
that	O
the	O
derivatives	O
can	O
activate	O
the	O
blood	O
coagulation	O
factor	O
in	O
an	O
endogenous	O
and	O
exogenous	O
blood	O
coagulation	O
way	O
,	O
reinforces	O
the	O
uterine	O
action	O
,	O
can	O
be	O
well	O
combined	O
with	O
the	O
human	O
serum	O
,	O
has	O
a	O
coagulation	O
promoting	O
activity	O
and	O
a	O
pain	O
easing	O
effect	O
,	O
and	O
also	O
has	O
a	O
two	O
-	O
way	O
regulation	O
effect	O
on	O
the	O
stasis	O
dissolving	O
.	O

Experiments	O
on	O
the	O
four	O
blood	O
coagulation	O
indexes	O
,	O
the	O
calcium	O
recovering	O
time	O
of	O
the	O
blood	O
plasma	O
and	O
the	O
mouse	O
in	O
-	O
vitro	O
uterus	O
confirm	O
that	O
the	O
derivatives	O
have	O
the	O
coagulation	O
promoting	O
,	O
coagulation	O
preventing	O
and	O
two	O
-	O
way	O
regulating	O
activities	O
,	O
have	O
a	O
use	O
in	O
the	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
blood	O
disease	O
medicines	O
.	O

Oxiracetam	O
medicinal	O
composition	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
an	O
oxiracetam	O
medicinal	O
composition	O
having	O
a	O
high	O
safety	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
medicinal	O
composition	O
contains	O
oxiracetam	O
and	O
below	O
0.5	O
%	O
of	O
a	O
compound	O
having	O
a	O
structure	O
represented	O
by	O
formula	O
II	O
.	O

A	O
case	O
that	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	O
is	O
the	O
largest	O
-	O
content	O
impurity	O
in	O
the	O
oxiracetam	O
compound	O
is	O
proved	O
for	O
the	O
first	O
time	O
,	O
purifying	O
characterization	O
and	O
relevant	O
researches	O
on	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	O
are	O
carried	O
out	O
,	O
and	O
the	O
researches	O
find	O
that	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	O
is	O
related	O
with	O
the	O
side	O
effects	O
of	O
the	O
oxiracetam	O
medicine	O
and	O
can	O
cause	O
a	O
series	O
of	O
untoward	O
effects	O
.	O

The	O
oxiracetam	O
medicinal	O
composition	O
has	O
a	O
high	O
safety	O
.	O

The	O
invention	O
further	O
provides	O
the	O
preparation	O
method	O
of	O
the	O
oxiracetam	O
medicinal	O
composition	O
.	O

Natural	O
pharmaceutical	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
natural	O
pharmaceutical	O
composition	O
.	O

The	O
natural	O
pharmaceutical	O
composition	O
comprises	O
a	O
katsumade	O
galangal	O
seed	O
and	O
baical	O
skullcap	O
root	O
water	O
decoction	O
concentrated	O
extract	O
,	O
a	O
katsumade	O
galangal	O
seed	O
ethyl	O
acetate	O
extract	O
,	O
total	O
flavonoids	O
of	O
baical	O
skullcap	O
root	O
and	O
baicalin	O
according	O
to	O
the	O
proportion	O
of	O
(	O
2	O
-	O
4	O
)	O
:	O
(	O
3	O
-	O
8	O
)	O
:	O
(	O
3	O
-	O
9	O
)	O
:	O
(	O
1	O
-	O
4	O
)	O
,	O
and	O
the	O
composition	O
has	O
an	O
excellent	O
curative	O
effect	O
against	O
diarrhea	O
which	O
is	O
related	O
to	O
cancer	O
chemotherapy	O
and	O
can	O
simultaneously	O
realize	O
a	O
synergistic	O
action	O
against	O
the	O
cancer	O
chemotherapy	O
.	O

N-3-arylamine-5-cyclopropane	O
spirohydantoin	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
discloses	O
N-3-arylamine-5-cyclopropane	O
spirohydantoin	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
N-3-arylamine	O
substituent-5-cyclopropane	O
spirohydantoin	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
is	O
phenyl	O
,	O
substituted	O
phenyl	O
and	O
heterocyclic	O
arene	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
performing	O
a	O
reaction	O
between	O
1-carboxyl-2,2-dimethylcyclopropane	O
ethyl	O
carboxylate	O
and	O
ethyl	O
chloroformate	O
to	O
generate	O
1-acyl	O
azide-2,2-dimethylcyclopropane	O
ethyl	O
carboxylate	O
under	O
the	O
effect	O
of	O
NaN3	O
;	O
performing	O
Curtius	O
rearrangement	O
on	O
the	O
1-acyl	O
azide-2,2-dimethylcyclopropane	O
ethyl	O
carboxylate	O
to	O
generate	O
corresponding	O
isocyanate	O
;	O
performing	O
a	O
reaction	O
between	O
the	O
isocyanate	O
and	O
hydrazine	O
to	O
obtain	O
N'-arylamine	O
substituent	O
ureidocyclopropane	O
;	O
and	O
generating	O
N-3-arylamine	O
substituent-5-cyclopropane	O
spirohydantoin	O
from	O
the	O
N'-arylamine	O
substituent	O
ureidocyclopropane	O
.	O

The	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
simple	O
,	O
has	O
higher	O
yield	O
,	O
and	O
can	O
be	O
used	O
for	O
easily	O
preparing	O
the	O
N-3-arylamine	O
substituent-5-cyclopropane	O
spirohydantoin	O
.	O

6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
,	O
which	O
has	O
a	O
chemical	O
structure	O
formula	O
shown	O
in	O
formula	O
(	O
I	O
)	O
.	O

The	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
reacting	O
phenylpiperazine	O
pyridazinone	O
and	O
1-	O
(	O
2-bromoethoxyl	O
)	O
-2-chlorobenzene	O
.	O

The	O
6-	O
(	O
4-arylpiperazine-1-yl	O
)	O
pyridazine-3	O
(	O
2H	O
)	O
-ketone	O
disclosed	O
by	O
the	O
invention	O
is	O
remarkable	O
in	O
effect	O
of	O
suppressing	O
an	O
alpha	B
1-adrenergic	I
receptor	I
.	O

Feed	O
additive	O
for	O
preventing	O
dairy	O
cow	O
mastitis	O
The	O
invention	O
relates	O
to	O
a	O
feed	O
additive	O
for	O
preventing	O
dairy	O
cow	O
mastitis	O
.	O

The	O
feed	O
additive	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
10	O
parts	O
of	O
medlar	O
,	O
15	O
-	O
20	O
parts	O
of	O
Chinese	O
dates	O
,	O
5	O
-	O
8	O
parts	O
of	O
flowers	O
carthami	O
,	O
5	O
-	O
8	O
parts	O
of	O
chrysanthemum	O
,	O
2	O
-	O
4	O
parts	O
of	O
radix	O
paeoniae	O
alba	O
,	O
8	O
-	O
12	O
parts	O
of	O
polygonum	O
multiflorum	O
,	O
2	O
-	O
4	O
parts	O
of	O
smoked	O
plum	O
,	O
1	O
-	O
3	O
parts	O
of	O
yeast	O
culture	O
,	O
2	O
-	O
4	O
parts	O
of	O
medicinal	O
stones	O
and	O
3	O
-	O
5	O
parts	O
of	O
bentonite	O
.	O

The	O
feed	O
additive	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
used	O
for	O
preventing	O
the	O
dairy	O
cow	O
mastitis	O
effectively	O
,	O
so	O
that	O
the	O
health	O
condition	O
of	O
dairy	O
cow	O
is	O
improved	O
,	O
and	O
the	O
effects	O
on	O
the	O
milk	O
yield	O
and	O
the	O
quality	O
of	O
a	O
dairy	O
product	O
due	O
to	O
diseases	O
such	O
as	O
mastitis	O
are	O
avoided	O
.	O

By	O
virtue	O
of	O
the	O
feed	O
additive	O
disclosed	O
by	O
the	O
invention	O
,	O
the	O
economic	O
benefits	O
of	O
cow	O
cultivation	O
are	O
greatly	O
improved	O
,	O
and	O
the	O
adverse	O
effects	O
on	O
the	O
quality	O
of	O
the	O
dairy	O
product	O
and	O
the	O
health	O
of	O
the	O
dairy	O
cow	O
caused	O
by	O
antibiotics	O
can	O
be	O
avoided	O
.	O

Natural	O
pharmaceutical	O
extractive	O
The	O
invention	O
relates	O
to	O
a	O
natural	O
pharmaceutical	O
extractive	O
which	O
comprises	O
concentrated	O
extractive	O
of	O
water	O
decocted	O
shizandra	O
berry	O
-	O
long	O
pepper	O
,	O
shizandra	O
berry	O
polyose	O
,	O
long	O
pepper	O
-	O
ethanol	O
extractive	O
,	O
and	O
piperine	O
according	O
to	O
the	O
proportion	O
of	O
(	O
3	O
-	O
6	O
)	O
:	O
(	O
3	O
-	O
7	O
)	O
:	O
(	O
1	O
-	O
3	O
)	O
:	O
(	O
4	O
-	O
9	O
)	O
.	O

The	O
natural	O
pharmaceutical	O
extractive	O
has	O
an	O
excellent	O
curative	O
effect	O
on	O
diarrhea	O
related	O
to	O
cancer	O
chemo	O
-	O
treatment	O
and	O
a	O
synergistic	O
effect	O
on	O
cancer	O
chemo	O
-	O
treatment	O
.	O

Composition	O
with	O
alimentary	O
anemia	O
improving	O
function	O
and	O
preparation	O
method	O
of	O
composition	O
The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
with	O
an	O
alimentary	O
anemia	O
improving	O
function	O
and	O
a	O
preparation	O
method	O
of	O
the	O
composition	O
.	O

The	O
composition	O
is	O
prepared	O
from	O
astragalus	O
membranaceus	O
,	O
codonopsis	O
pilosula	O
,	O
angelica	O
,	O
jujube	O
and	O
prepared	O
rehmannia	O
root	O
according	O
to	O
a	O
certain	O
weight	O
percentage	O
,	O
and	O
the	O
composition	O
can	O
be	O
prepared	O
into	O
any	O
commonly	O
used	O
preparation	O
,	O
preferably	O
an	O
oral	O
preparation	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
a	O
function	O
of	O
improving	O
alimentary	O
anemia	O
.	O

Application	O
of	O
Sarcaboside	O
B	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
alzheimer	O
disease	O
The	O
invention	O
discloses	O
a	O
new	O
application	O
of	O
Sarcaboside	O
B.	O
The	O
Sarcaboside	O
B	O
has	O
inhibitory	O
activity	O
on	O
acetylcholin	B
esterase	I
and	O
a	O
nerve	O
cell	O
protection	O
effect	O
.	O

As	O
a	O
multi	O
-	O
target	O
directed	O
compound	O
,	O
the	O
Sarcaboside	O
B	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
resisting	O
the	O
alzheimer	O
disease	O
.	O

The	O
application	O
of	O
the	O
Sarcaboside	O
B	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
the	O
alzheimer	O
disease	O
is	O
disclosed	O
by	O
the	O
invention	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Sarcaboside	O
B	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Sarcaboside	O
B	O
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
the	O
acetylcholin	B
esterase	I
,	O
and	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O

The	O
Sarcaboside	O
B	O
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
alzheimer	O
disease	O
.	O

Application	O
of	O
Chukrasone	O
A	O
in	O
preparing	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Chukrasone	O
A	O
in	O
preparing	O
medicines	O
for	O
treating	O
or	O
preventing	O
yellow	O
fever	O
virus	O
infection	O
.	O

The	O
Chukrasone	O
A	O
can	O
effectively	O
inhibit	O
proliferation	O
of	O
yellow	O
fever	O
virus	O
but	O
is	O
small	O
in	O
cytotoxicity	O
,	O
so	O
that	O
the	O
Chukrasone	O
A	O
can	O
be	O
further	O
developed	O
to	O
medicines	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
virus	O
infection	O
,	O
and	O
has	O
a	O
wide	O
application	O
prospect	O
.	O

The	O
use	O
of	O
the	O
Chukrasone	O
A	O
for	O
preparing	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
framework	O
type	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
framework	O
type	O
,	O
and	O
the	O
inhibitory	O
activity	O
of	O
the	O
Chukrasone	O
A	O
to	O
yellow	O
fever	O
virus	O
infection	O
is	O
unimaginably	O
strong	O
,	O
the	O
probability	O
of	O
giving	O
any	O
enlightenment	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

The	O
Chukrasone	O
A	O
has	O
remarkable	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkable	O
progress	O
for	O
preventing	O
and	O
treating	O
yellow	O
fever	O
virus	O
infection	O
.	O

Crystal	O
form	O
,	O
preparation	O
method	O
and	O
application	O
of	O
agomelatine	O
,	O
as	O
well	O
as	O
medicine	O
composition	O
The	O
invention	O
provides	O
a	O
crystal	O
form	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
agomelatine	O
,	O
as	O
well	O
as	O
a	O
medicine	O
composition	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
crystal	O
form	O
provided	O
by	O
the	O
invention	O
has	O
the	O
following	O
advantages	O
and	O
positive	O
effects	O
that	O
the	O
new	O
crystal	O
form	O
of	O
the	O
agomelatine	O
obtained	O
by	O
the	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
is	O
high	O
in	O
purity	O
,	O
stable	O
,	O
good	O
in	O
repeatability	O
,	O
better	O
than	O
a	O
plurality	O
of	O
existing	O
crystal	O
forms	O
in	O
purity	O
and	O
stability	O
,	O
and	O
suitable	O
for	O
preparing	O
medicament	O
preparations	O
.	O

The	O
preparation	O
method	O
of	O
the	O
new	O
crystal	O
form	O
of	O
the	O
agomelatine	O
provided	O
by	O
the	O
invention	O
is	O
simpler	O
and	O
more	O
convenient	O
than	O
the	O
existing	O
crystal	O
form	O
,	O
is	O
also	O
moderate	O
in	O
condition	O
,	O
easy	O
to	O
be	O
applied	O
in	O
actual	O
production	O
and	O
low	O
in	O
cost	O
,	O
and	O
satisfies	O
the	O
requirements	O
of	O
industrial	O
production	O
.	O

Salt	O
of	O
chelidonine	O
derivative	O
The	O
invention	O
relates	O
to	O
chelidonine	O
,	O
fumarate	O
of	O
a	O
derivative	O
of	O
the	O
chelidonine	O
or	O
a	O
pharmaceutically	O
acceptable	O
solvate	O
of	O
the	O
chelidonine	O
and	O
applications	O
of	O
the	O
chelidonine	O
,	O
the	O
fumarate	O
and	O
the	O
solvate	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
hepatitis	O
B.	O

Ursodeoxycholic	O
acid	O
vitamin	O
composition	O
,	O
preparation	O
method	O
and	O
applications	O
thereof	O
The	O
invention	O
discloses	O
an	O
ursodeoxycholic	O
acid	O
vitamin	O
composition	O
,	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O

The	O
composite	O
comprises	O
following	O
raw	O
materials	O
in	O
percentage	O
by	O
weight	O
:	O
1	O
to	O
30	O
%	O
of	O
ursodesoxycholic	O
acid	O
,	O
0.1	O
to	O
5	O
%	O
of	O
thiamine	O
mononitrate	O
,	O
0.05	O
to	O
2.5	O
%	O
of	O
riboflavin	O
and	O
the	O
balance	O
of	O
dispersion	O
supporter	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
capsule	O
preparation	O
of	O
the	O
composition	O
,	O
and	O
the	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
simple	O
operation	O
and	O
good	O
capsule	O
luster	O
and	O
homogeneity	O
.	O

The	O
ursodesoxycholic	O
acid	O
,	O
thiamine	O
mononitrate	O
and	O
riboflavin	O
are	O
used	O
together	O
to	O
have	O
the	O
functions	O
of	O
antagonizing	O
liver	O
hydrophobic	O
toxic	O
bile	O
acid	O
,	O
protecting	O
liver	O
cells	O
,	O
providing	O
enough	O
energy	O
to	O
liver	O
cells	O
,	O
and	O
helping	O
damaged	O
liver	O
cells	O
to	O
recover	O
,	O
the	O
ursodesoxycholic	O
acid	O
vitamin	O
composition	O
has	O
the	O
function	O
of	O
protecting	O
liver	O
and	O
gallbladder	O
,	O
and	O
is	O
capable	O
of	O
being	O
used	O
for	O
preparing	O
drugs	O
for	O
curing	O
liver	O
and	O
gallbladder	O
.	O

Application	O
of	O
ginseng	O
oligosaccharide	O
composition	O
in	O
preparation	O
of	O
anti	O
-	O
oxidation	O
medicine	O
or	O
health	O
-	O
care	O
food	O
The	O
invention	O
discloses	O
a	O
novel	O
application	O
of	O
a	O
ginseng	O
oligosaccharide	O
composition	O
in	O
preparation	O
of	O
an	O
anti	O
-	O
oxidation	O
medicine	O
and	O
a	O
health	O
-	O
care	O
food	O
.	O

The	O
ginseng	O
oligosaccharide	O
composition	O
is	O
extracted	O
from	O
ginseng	O
.	O

According	O
to	O
an	O
in	O
-	O
vitro	O
experiment	O
,	O
the	O
ginseng	O
oligosaccharide	O
composition	O
has	O
a	O
good	O
effect	O
of	O
clearing	O
away	O
hydroxyl	O
free	O
radicals	O
and	O
DPPH	O
(	O
1,1-Diphenyl-2-picrylhydrazyl	O
radical	O
2,2-Diphenyl-1-	O
(	O
2,4,6-trinitrophenyl	O
)	O
hydrazyl	O
)	O
,	O
and	O
also	O
has	O
the	O
good	O
effect	O
of	O
chelating	O
Fe<2+>.	O
According	O
to	O
an	O
animal	O
experiment	O
,	O
the	O
ginseng	O
oligosaccharide	O
composition	O
has	O
the	O
good	O
effect	O
of	O
enhancing	O
the	O
enzyme	O
activities	O
of	O
SOD	B
(	O
Superoxide	B
Dismutase	I
)	O
,	O
CAT	B
(	O
Catalase	B
)	O
,	O
GSH	B
-	I
Px	I
(	O
Glutathione	B
Peroxidase	I
)	O
and	O
T	O
-	O
AOC	O
(	O
Total	O
Antioxidative	O
Capacity	O
)	O
in	O
the	O
serum	O
and	O
the	O
liver	O
of	O
an	O
oxidative	O
stress	O
-	O
injured	O
mice	O
induced	O
by	O
D	O
-	O
Gal	O
(	O
Galactosamine	O
)	O
,	O
and	O
can	O
be	O
used	O
for	O
obviously	O
decreasing	O
the	O
MDA	O
(	O
Methane	O
Dicarboxylic	O
Aldehyde	O
)	O
level	O
of	O
the	O
oxidative	O
stress	O
-	O
injured	O
mice	O
.	O

Medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
The	O
invention	O
provides	O
a	O
medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
.	O

The	O
medicament	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
6	O
-	O
12	O
parts	O
of	O
spina	O
date	O
seed	O
,	O
8	O
-	O
16	O
parts	O
of	O
tuber	O
fleeceflower	O
stem	O
,	O
8	O
-	O
12	O
parts	O
of	O
rhizoma	O
acori	O
graminei	O
,	O
8	O
-	O
12	O
parts	O
of	O
platycladi	O
seed	O
,	O
7	O
-	O
15	O
parts	O
of	O
polygala	O
tenuifolia	O
,	O
8	O
-	O
12	O
parts	O
of	O
nacre	O
mother	O
of	O
pearl	O
,	O
8	O
-	O
16	O
parts	O
of	O
amber	O
,	O
8	O
-	O
16	O
parts	O
of	O
magnet	O
,	O
9	O
-	O
15	O
parts	O
of	O
lily	O
,	O
7	O
-	O
14	O
parts	O
of	O
stamen	O
nelumbinis	O
,	O
and	O
8	O
-	O
15	O
parts	O
of	O
red	O
-	O
rooted	O
salvia	O
root	O
.	O

The	O
medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
has	O
the	O
advantages	O
and	O
positive	O
effects	O
of	O
good	O
treatment	O
effect	O
,	O
no	O
independence	O
and	O
small	O
toxic	O
and	O
side	O
effects	O
.	O

Amide	O
arylpiperazine	O
derivatives	O
,	O
their	O
preparation	O
method	O
,	O
and	O
their	O
application	O
in	O
benign	O
prostatic	O
hyperplasia	O
resistance	O
The	O
invention	O
relates	O
to	O
ten	O
amide	O
arylpiperazine	O
derivatives	O
,	O
their	O
preparation	O
method	O
,	O
and	O
their	O
use	O
in	O
the	O
preparation	O
of	O
benign	O
prostatic	O
hyperplasia	O
treatment	O
medicines	O
.	O

The	O
preparation	O
method	O
of	O
the	O
amide	O
arylpiperazine	O
derivatives	O
comprises	O
the	O
following	O
steps	O
:	O
reacting	O
free	O
alkali	O
of	O
3-bromopropylamine	O
hydrobromide	O
with	O
di	O
-	O
tert	O
-	O
butyl	O
dicarbonate	O
to	O
obtain	O
a	O
colorless	O
oily	O
liquid	O
,	O
reacting	O
the	O
colorless	O
oily	O
liquid	O
with	O
o	O
-	O
methoxyphenylpiperazine	O
to	O
obtain	O
a	O
light	O
yellow	O
oily	O
material	O
,	O
reacting	O
the	O
light	O
yellow	O
oily	O
material	O
with	O
trifluoroacetic	O
acid	O
to	O
obtain	O
a	O
product	O
,	O
and	O
reacting	O
the	O
product	O
with	O
N	O
,	O
N	O
-	O
diisopropylethylaine	O
,	O
2-	O
(	O
7-azobenzotriazol	O
)	O
-N	O
,	O
N	O
,	O
N',N'-tetramethylformamidinium	O
hexafluorophosphate	O
,	O
and	O
5-indoleacetic	O
acid	O
or	O
3-indoleacetic	O
acid	O
or	O
3-indolepropionic	O
acid	O
or	O
3-indolebutyric	O
acid	O
or	O
5-hydroxy-2-indoleacetic	O
acid	O
or	O
5-methoxy-2-indoleacetic	O
acid	O
or	O
1-methyl-3-indoleacetic	O
acid	O
or	O
6-bromo-2-indoleacetic	O
acid	O
or	O
5-chloro-2-indoleacetic	O
acid	O
or	O
7-nitro-2-indoleacetic	O
acid	O
to	O
obtain	O
final	O
products	O
.	O

Experiments	O
prove	O
that	O
the	O
benign	O
prostatic	O
hyperplasia	O
resistance	O
activities	O
of	O
eight	O
compounds	O
in	O
the	O
amide	O
arylpiperazine	O
derivatives	O
are	O
stronger	O
than	O
a	O
contrast	O
drug	O
prazosin	O
.	O

Vagina	O
mold	O
containing	O
estriol	O
The	O
invention	O
relates	O
to	O
a	O
vagina	O
mold	O
containing	O
estriol	O
.	O

The	O
vagina	O
mold	O
is	O
composed	O
of	O
silicone	O
rubber	O
and	O
the	O
estriol	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
silicone	O
rubber	O
and	O
the	O
estriol	O
is	O
20	O
:	O
(	O
5	O
-	O
8	O
)	O
.	O

The	O
vagina	O
mold	O
containing	O
the	O
estriol	O
has	O
the	O
advantages	O
that	O
the	O
vagina	O
mold	O
containing	O
estrogen	O
greatly	O
lowers	O
the	O
contracture	O
rate	O
of	O
a	O
man	O
-	O
made	O
vagina	O
.	O

The	O
silicone	O
rubber	O
and	O
the	O
estrogen	O
are	O
combined	O
to	O
manufacture	O
the	O
vagina	O
mold	O
with	O
the	O
estrogen	O
slow	O
releasing	O
ability	O
,	O
and	O
therefore	O
vagina	O
mold	O
treatment	O
and	O
estrogen	O
treatment	O
are	O
effectively	O
combined	O
,	O
and	O
the	O
vagina	O
mold	O
with	O
the	O
slow	O
releasing	O
function	O
has	O
great	O
potential	O
in	O
future	O
clinical	O
application	O
.	O

Application	O
of	O
berberine	O
in	O
medicine	O
for	O
treating	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
preparation	O
and	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
berberine	O
in	O
a	O
medicine	O
for	O
treating	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
.	O

According	O
to	O
the	O
invention	O
,	O
db	O
/	O
db	O
mouse	O
with	O
diabetic	O
obesity	O
and	O
NAFLD	O
(	O
Non	O
-	O
Alcoholic	O
Fatty	O
Liver	O
Disease	O
)	O
is	O
employed	O
to	O
simulate	O
a	O
fat	O
NAFLD	O
patient	O
,	O
and	O
a	O
mouse	O
with	O
non	O
-	O
obese	O
fatty	O
liver	O
caused	O
by	O
methionine	O
-	O
choline	O
deficient	O
(	O
MCD	O
)	O
is	O
used	O
as	O
a	O
model	O
to	O
simulate	O
a	O
non	O
-	O
fat	O
NAFLD	O
patient	O
so	O
as	O
to	O
observe	O
the	O
effect	O
of	O
BBR	O
.	O

Shown	O
by	O
all	O
test	O
results	O
,	O
the	O
BBR	O
not	O
only	O
can	O
reduce	O
the	O
weight	O
of	O
the	O
obese	O
mouse	O
and	O
improve	O
the	O
glycometabolism	O
and	O
lipid	O
metabolism	O
,	O
but	O
also	O
can	O
treat	O
the	O
concurrent	O
fatty	O
liver	O
of	O
the	O
obese	O
mouse	O
,	O
and	O
also	O
has	O
obvious	O
treatment	O
effect	O
on	O
the	O
fatty	O
liver	O
of	O
the	O
non	O
-	O
obese	O
mouse	O
,	O
and	O
the	O
results	O
are	O
verified	O
in	O
a	O
cell	O
model	O
simulated	O
in	O
vitro	O
,	O
so	O
that	O
the	O
BBR	O
has	O
obvious	O
treatment	O
effect	O
on	O
the	O
obesity	O
and	O
the	O
non	O
-	O
obese	O
NAFLD	O
surely	O
and	O
can	O
be	O
used	O
in	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
the	O
NAFLD	O
.	O

Imidazolyl	O
-	O
substituted	O
thiazocyclohexane	O
compounds	O
and	O
antitumor	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
anticancer	O
related	O
drugs	O
,	O
particularly	O
imidazolyl	O
-	O
substituted	O
thiazocyclohexane	O
derivatives	O
with	O
antitumor	O
activity	O
disclosed	O
as	O
Formula	O
I	O
,	O
and	O
a	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O
.	O

Substituted	O
-	O
pyrrolidinyl	O
-	O
contained	O
thiomorpholine	O
compounds	O
The	O
invention	O
discloses	O
substituted	O
-	O
pyrrolidinyl	O
-	O
contained	O
thiomorpholine	O
compounds	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
applications	O
thereof	O
.	O

In	O
concrete	O
,	O
the	O
invention	O
relates	O
to	O
compounds	O
having	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
stereoisomers	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
acceptable	O
salts	O
of	O
the	O
compounds	O
,	O
wherein	O
R	O
is	O
shown	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
the	O
applications	O
of	O
the	O
compounds	O
in	O
preparing	O
medicines	O
used	O
for	O
treating	O
and/or	O
preventing	O
a	O
disease	O
or	O
a	O
symptom	O
which	O
are	O
related	O
to	O
over	O
-	O
high	O
activity	O
of	O
DPP	B
-	I
IV	I
or	O
over	O
-	O
expression	O
of	O
the	O
DPP	B
-	I
IV	I
,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
using	O
the	O
compounds	O
for	O
treating	O
related	O
diseases	O
.	O

The	O
compounds	O
have	O
activity	O
for	O
effectively	O
inhibiting	O
the	O
DPP	B
-	I
IV	I
.	O

Meclozine	O
oral	O
film	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
meclozine	O
oral	O
film	O
comprising	O
a	O
pharmaceutical	O
ingredient	O
meclozine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
flavoring	O
agent	O
,	O
a	O
filling	O
agent	O
,	O
a	O
wetting	O
agent	O
,	O
a	O
coloring	O
agent	O
,	O
a	O
film	O
-	O
forming	O
material	O
and	O
an	O
essence	O
.	O

The	O
meclozine	O
oral	O
film	O
is	O
uniform	O
in	O
appearance	O
,	O
pleasant	O
in	O
mouth	O
feel	O
and	O
capable	O
of	O
reducing	O
medication	O
compliance	O
of	O
children	O
,	O
is	O
directly	O
swallowed	O
after	O
dissolution	O
in	O
the	O
mouth	O
without	O
drinking	O
water	O
,	O
is	O
quick	O
in	O
drug	O
release	O
and	O
especially	O
suitable	O
for	O
children	O
,	O
old	O
people	O
and	O
critical	O
patients	O
who	O
are	O
difficult	O
in	O
swallowing	O
.	O

The	O
meclozine	O
oral	O
film	O
also	O
has	O
the	O
advantages	O
of	O
few	O
auxiliary	O
materials	O
,	O
low	O
production	O
cost	O
and	O
simple	O
preparation	O
process	O
and	O
is	O
liable	O
to	O
industrial	O
production	O
.	O

Pharmaceutical	O
composition	O
of	O
paclitaxel	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
discloses	O
a	O
pharmaceutical	O
composition	O
of	O
paclitaxel	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
of	O
paclitaxel	O
,	O
polyoxyethylated	O
castor	O
oil	O
,	O
sodium	O
dihydrogen	O
phosphate	O
,	O
hexanedioic	O
acid	O
and	O
ethanol	O
.	O

The	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
is	O
prepared	O
into	O
an	O
injection	O
;	O
the	O
single	O
impurity	O
and	O
total	O
impurities	O
accord	O
with	O
the	O
quality	O
requirements	O
by	O
virtue	O
of	O
a	O
high	O
-	O
temperature	O
and	O
highlight	O
test	O
.	O

The	O
preparation	O
prepared	O
from	O
the	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
stability	O
and	O
low	O
impurity	O
content	O
.	O

Composition	O
containing	O
resveratrol	O
and	O
pterostilbene	O
and	O
preparation	O
containing	O
composition	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
resveratrol	O
and	O
pterostilbene	O
,	O
which	O
contains	O
resveratrol	O
and	O
pterostilbene	O
.	O

As	O
shown	O
in	O
an	O
experimental	O
result	O
,	O
the	O
composition	O
containing	O
the	O
resveratrol	O
and	O
the	O
pterostilbene	O
has	O
a	O
synergistic	O
effect	O
of	O
inhibiting	O
the	O
growth	O
of	O
malignant	O
melanoma	O
grafts	O
.	O

Application	O
of	O
Incarviatone	O
A	O
in	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
a	O
new	O
application	O
of	O
medicaments	O
.	O

In	O
-	O
vitro	O
methyl	O
thiazolyl	O
tetrazolium	O
(	O
MTT	O
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
discovers	O
that	O
the	O
Incarviatone	O
A	O
has	O
a	O
prominent	O
inhibiting	O
effect	O
on	O
growth	O
of	O
human	O
bladder	O
cancer	O
cell	O
strains	O
T-24	O
.	O

Therefore	O
,	O
the	O
Incarviatone	O
A	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
bladder	O
cancer	O
medicaments	O
,	O
and	O
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
the	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
the	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
is	O
made	O
public	O
for	O
the	O
first	O
time	O
,	O
the	O
skeleton	O
type	O
is	O
completely	O
novel	O
,	O
and	O
the	O
Incarviatone	O
A	O
has	O
an	O
unexpectedly	O
strong	O
bladder	O
cancer	O
cell	O
inhibiting	O
activity	O
.	O

Application	O
of	O
Incarviatone	O
A	O
in	O
medicaments	O
for	O
treating	O
bile	O
duct	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
human	O
bile	O
duct	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
a	O
new	O
application	O
of	O
medicaments	O
.	O

In	O
-	O
vitro	O
methyl	O
thiazolyl	O
tetrazolium	O
(	O
MTT	O
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
discovers	O
that	O
the	O
Incarviatone	O
A	O
has	O
a	O
prominent	O
inhibiting	O
effect	O
on	O
growth	O
of	O
human	O
bile	O
duct	O
cancer	O
cell	O
strains	O
RBE	O
.	O

Therefore	O
,	O
the	O
Incarviatone	O
A	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
bile	O
duct	O
cancer	O
medicaments	O
,	O
and	O
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
the	O
Incarviatone	O
A	O
in	O
preparation	O
of	O
the	O
medicaments	O
for	O
treating	O
human	O
bile	O
duct	O
cancer	O
is	O
made	O
public	O
for	O
the	O
first	O
time	O
,	O
the	O
skeleton	O
type	O
is	O
completely	O
novel	O
,	O
and	O
the	O
Incarviatone	O
A	O
has	O
an	O
unexpectedly	O
strong	O
human	O
bile	O
duct	O
cancer	O
cell	O
inhibiting	O
activity	O
.	O

Application	O
of	O
Lycojaponicumin	O
A	O
in	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
The	O
invention	O
discloses	O
application	O
of	O
Lycojaponicumin	O
A	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
drugs	O
.	O

In	O
vitro	O
MTT	O
anticancer	O
activity	O
evaluation	O
discovers	O
that	O
Lycojaponicumin	O
A	O
shows	O
remarkable	O
inhibitory	O
effects	O
on	O
growth	O
of	O
human	O
tongue	O
cancer	O
cell	O
lines	O
Tca8113	O
and	O
T6	O
.	O

Therefore	O
,	O
the	O
Lycojaponicumin	O
A	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
tongue	O
cancer	O
drugs	O
,	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

Application	O
of	O
the	O
Lycojaponicumin	O
A	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
and	O
because	O
skeleton	O
type	O
is	O
completely	O
new	O
,	O
inhibitory	O
activity	O
on	O
tongue	O
cancer	O
cells	O
is	O
extraordinary	O
strong	O
.	O

Application	O
of	O
Lycojaponicumin	O
C	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
ovarian	O
cancer	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
ovarian	O
cancer	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

The	O
evaluation	O
on	O
an	O
in	O
vitro	O
MTT	O
(	O
3-	O
(	O
4,5-Dimethylthiazol-2-yl	O
)	O
-2,5-diphenyltetrazolium	O
bromide	O
)	O
anti	O
-	O
tumor	O
activity	O
shows	O
that	O
the	O
Lycojaponicumin	O
C	O
also	O
has	O
an	O
obvious	O
inhibiting	O
effect	O
on	O
the	O
growth	O
of	O
human	O
ovarian	O
cancer	O
cell	O
lines	O
HO-8910	O
,	O
HOC1	O
and	O
OVAC	O
.	O

Therefore	O
,	O
the	O
Lycojaponicumin	O
C	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
resisting	O
the	O
ovarian	O
cancer	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

The	O
application	O
of	O
the	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
treating	O
the	O
human	O
ovarian	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Lycojaponicumin	O
C	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Lycojaponicumin	O
C	O
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
human	O
ovarian	O
cancer	O
cells	O
.	O

Application	O
of	O
Lycojaponicumin	O
C	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
or	O
preventing	O
yellow	O
fever	O
virus	O
infection	O
.	O

The	O
Lycojaponicumin	O
C	O
can	O
be	O
used	O
for	O
effectively	O
inhibiting	O
the	O
proliferation	O
of	O
yellow	O
fever	O
virus	O
,	O
has	O
very	O
low	O
toxicity	O
on	O
cells	O
,	O
can	O
be	O
further	O
developed	O
into	O
the	O
medicines	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
virus	O
infection	O
and	O
has	O
wide	O
application	O
prospects	O
.	O

The	O
application	O
of	O
the	O
Lycojaponicumin	O
C	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
the	O
yellow	O
fever	O
virus	O
infection	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Lycojaponicumin	O
C	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Lycojaponicumin	O
C	O
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
yellow	O
fever	O
virus	O
,	O
and	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O

The	O
Lycojaponicumin	O
C	O
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
or	O
treating	O
the	O
yellow	O
fever	O
virus	O
infection	O
.	O

CBP	B
/	O
catenin	B
antagonists	O
for	O
enhancing	O
asymmetric	O
division	O
of	O
somatic	O
stem	O
cells	O
Provided	O
are	O
:	O
methods	O
for	O
treating	O
aging	O
or	O
an	O
age	O
-	O
related	O
condition	O
,	O
symptom	O
or	O
disease	O
;	O
methods	O
for	O
stimulating	O
hair	O
growth	O
,	O
regrowth	O
or	O
pigmentation	O
(	O
or	O
preventing	O
hair	O
loss	O
)	O
;	O
methods	O
for	O
increasing	O
the	O
expression	O
of	O
an	O
adenosine	O
receptor	O
in	O
dermal	O
cells	O
(	O
in	O
combination	O
with	O
hair	O
growth	O
)	O
;	O
methods	O
for	O
treating	O
a	O
condition	O
or	O
disease	O
of	O
the	O
skin	O
or	O
at	O
least	O
one	O
symptom	O
thereof	O
,	O
including	O
cosmetic	O
treatment	O
(	O
e.g.	O
,	O
wrinkles	O
,	O
hyperpigmentation	O
,	O
redness	O
,	O
rosacea	O
,	O
dryness	O
,	O
cracking	O
,	O
loss	O
of	O
firmness	O
,	O
loss	O
of	O
elasticity	O
,	O
thinning	O
,	O
and	O
loss	O
of	O
vibrance	O
)	O
.	O

The	O
methods	O
comprise	O
administering	O
a	O
sufficient	O
amount	O
of	O
a	O
CBP	B
/	O
catenin	B
(	O
e.g.	O
,	O
CBP	B
/	O
ss	O
-	O
catenin	O
)	O
antagonist	O
as	O
disclosed	O
,	O
and	O
particularly	O
wherein	O
administration	O
is	O
in	O
an	O
amount	O
and	O
manner	O
sufficient	O
to	O
provide	O
for	O
increasing	O
the	O
number	O
of	O
asymmetric	O
renewing	O
divisions	O
relative	O
to	O
,	O
or	O
at	O
the	O
expense	O
of	O
symmetric	O
divisions	O
in	O
relevant	O
somatic	O
stem	O
cell	O
population	O
.	O

In	O
particular	O
aspects	O
,	O
the	O
CBP	B
/	O
catenin	B
(	O
e.g.	O
,	O
CBP	B
/	O
ss	O
-	O
catenin	O
)	O
antagonist	O
comprises	O
an	O
alkyl	O
and/or	O
fatty	O
acid	O
ester	O
derivative	O
thereof	O
as	O
disclosed	O
herein	O
.	O

Method	O
for	O
preparing	O
levofloxacin	O
hydrochloride	O
sodium	O
chloride	O
injection	O
The	O
invention	O
provides	O
a	O
method	O
for	O
preparing	O
levofloxacin	O
hydrochloride	O
sodium	O
chloride	O
injection	O
.	O

By	O
researching	O
a	O
liquid	O
medicine	O
preparation	O
method	O
,	O
medicinal	O
charcoal	O
pretreatment	O
and	O
a	O
terminal	O
sterilization	O
process	O
,	O
product	O
quality	O
is	O
ensured	O
by	O
the	O
aid	O
of	O
technologies	O
of	O
a	O
concentrated	O
solution	O
and	O
diluted	O
solution	O
method	O
,	O
charcoal	O
slurry	O
preparation	O
from	O
medicinal	O
charcoal	O
,	O
water	O
bath	O
sterilization	O
and	O
the	O
like	O
,	O
production	O
is	O
facilitated	O
,	O
obtained	O
finished	O
products	O
have	O
higher	O
stability	O
,	O
so	O
that	O
the	O
storage	O
life	O
of	O
the	O
finished	O
products	O
can	O
be	O
prolonged	O
,	O
and	O
clinical	O
use	O
effects	O
are	O
better	O
.	O

Compound	O
norfloxacin	O
nicotinate	O
soluble	O
powder	O
for	O
animals	O
,	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
norfloxacin	O
nicotinate	O
soluble	O
powder	O
for	O
animals	O
.	O

A	O
formula	O
of	O
100	O
g	O
of	O
the	O
powder	O
comprises	O
5	O
-	O
10	O
g	O
of	O
norfloxacin	O
nicotinate	O
,	O
5	O
-	O
10	O
g	O
of	O
apramyein	O
sulfate	O
,	O
2	O
-	O
4	O
g	O
of	O
trimethoprim	O
lactate	O
,	O
and	O
the	O
balance	O
anhydrous	O
glucose	O
.	O

The	O
above	O
medicine	O
can	O
rapidly	O
kill	O
intestinal	O
pathogenic	O
microorganisms	O
to	O
timely	O
effectively	O
control	O
intestinal	O
bacterial	O
diseases	O
of	O
the	O
animals	O
,	O
and	O
alleviates	O
the	O
bacterial	O
drug	O
resistance	O
.	O

Burn	O
ointment	O
for	O
treating	O
burn	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
burn	O
ointment	O
for	O
treating	O
burn	O
.	O

The	O
ointment	O
comprises	O
the	O
following	O
active	O
components	O
by	O
weight	O
:	O
60	O
-	O
80	O
g	O
of	O
indigo	O
naturalis	O
,	O
40	O
-	O
60	O
g	O
of	O
mint	O
,	O
40	O
-	O
60	O
g	O
of	O
astragalus	O
,	O
20	O
-	O
30	O
g	O
of	O
talcum	O
,	O
40	O
-	O
60	O
g	O
of	O
fresh	O
sunflower	O
,	O
50	O
-	O
70	O
g	O
of	O
polygonum	O
cuspidatum	O
,	O
40	O
-	O
60	O
g	O
of	O
ligusticum	O
wallichii	O
,	O
50	O
-	O
70	O
g	O
of	O
bamboo	O
leaves	O
,	O
50	O
-	O
70	O
g	O
of	O
common	O
jujube	O
bark	O
,	O
40	O
-	O
60	O
g	O
of	O
bile	O
arisaema	O
,	O
10	O
-	O
20	O
g	O
of	O
fructus	O
evodiae	O
,	O
40	O
-	O
60	O
g	O
of	O
beewax	O
,	O
40	O
-	O
60	O
g	O
of	O
borneol	O
,	O
and	O
30	O
-	O
50	O
g	O
of	O
angelica	O
root	O
.	O

The	O
ointment	O
can	O
be	O
used	O
for	O
solving	O
the	O
problems	O
of	O
local	O
blood	O
stasis	O
and	O
obstruction	O
,	O
meridian	O
stagnation	O
and	O
toxic	O
heat	O
flourishing	O
,	O
and	O
has	O
good	O
effects	O
in	O
activating	O
blood	O
circulation	O
,	O
removing	O
stasis	O
and	O
dredging	O
collaterals	O
,	O
clearing	O
heat	O
and	O
toxicity	O
and	O
cooling	O
blood	O
,	O
and	O
treating	O
burns	O
,	O
wherein	O
the	O
effective	O
rate	O
is	O
93.6	O
percent	O
,	O
and	O
the	O
rate	O
of	O
favorable	O
curative	O
effect	O
is	O
90.7	O
percent	O
.	O

Resorcarenes	O
-	O
polysubstitution	O
pyrimidine	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
of	O
derivative	O
The	O
invention	O
relates	O
to	O
a	O
resorcarenes	O
-	O
polysubstitution	O
pyrimidine	O
derivative	O
shown	O
in	O
a	O
general	O
formula	O
I	O
and	O
a	O
salt	O
,	O
ester	O
or	O
prodrug	O
acceptable	O
in	O
pharmacy	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
and	O
an	O
application	O
of	O
a	O
composition	O
containing	O
one	O
or	O
a	O
plurality	O
of	O
such	O
type	O
of	O
compounds	O
during	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
and	O
preventing	O
infection	O
of	O
an	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
.	O

Combined	O
medicine	O
for	O
treating	O
diarrhea	O
disease	O
in	O
livestock	O
The	O
invention	O
discloses	O
a	O
combined	O
medicine	O
for	O
treating	O
the	O
diarrhea	O
disease	O
in	O
livestock	O
.	O

The	O
combined	O
medicine	O
comprises	O
the	O
following	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
8	O
-	O
12	O
parts	O
of	O
streptomycin	O
sulphate	O
or	O
derivative	O
,	O
4	O
-	O
8	O
parts	O
of	O
sulfamethoxazole	O
or	O
derivative	O
,	O
1	O
-	O
2	O
parts	O
of	O
trimethoprim	O
or	O
derivative	O
,	O
and	O
2	O
-	O
3	O
parts	O
of	O
Tranexamic	O
acid	O
or	O
derivative	O
.	O

The	O
combined	O
medicine	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
following	O
beneficial	O
effects	O
:	O
a	O
specific	O
antibiotic	O
,	O
a	O
specific	O
bacteriophage	O
and	O
a	O
specific	O
hemostatic	O
agent	O
are	O
used	O
in	O
combination	O
,	O
so	O
that	O
the	O
antibacterial	O
activity	O
and	O
antivirus	O
capacity	O
of	O
the	O
medicine	O
are	O
obviously	O
improved	O
and	O
the	O
curative	O
effect	O
is	O
improved	O
.	O

Composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
and	O
applications	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
and	O
applications	O
thereof	O
.	O

The	O
composition	O
comprises	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
60	O
%	O
to	O
80	O
%	O
of	O
mushroom	O
mycelium	O
polysaccharides	O
,	O
10	O
%	O
to	O
20	O
%	O
of	O
black	O
rice	O
polypeptide	O
,	O
and	O
10	O
%	O
to	O
20	O
%	O
of	O
bird	O
cherry	O
anthocyanin	O
.	O

The	O
composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
can	O
be	O
used	O
to	O
produce	O
anti	O
-	O
fatigue	O
drugs	O
,	O
anti	O
-	O
fatigue	O
health	O
food	O
and	O
feed	O
.	O

Vitamin	O
A	O
nano	O
-	O
emulsion	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
comprises	O
vitamin	O
A	O
and	O
tween-80	O
in	O
a	O
mass	O
ratio	O
of	O
1:	O
(	O
1.5	O
-	O
5	O
)	O
,	O
and	O
water	O
of	O
which	O
the	O
mass	O
is	O
0.5	O
-	O
3	O
times	O
of	O
the	O
total	O
mass	O
of	O
vitamin	O
A	O
and	O
tween-80	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
adding	O
vitamin	O
A	O
and	O
tween-80	O
into	O
a	O
container	O
,	O
uniformly	O
mixing	O
,	O
and	O
adding	O
water	O
to	O
obtain	O
a	O
mixed	O
solution	O
;	O
performing	O
ultrasonic	O
treatment	O
on	O
the	O
mixed	O
solution	O
until	O
the	O
mixed	O
solution	O
is	O
clear	O
and	O
transparent	O
,	O
thus	O
obtaining	O
the	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
.	O

The	O
method	O
is	O
used	O
for	O
preparing	O
the	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
by	O
adopting	O
an	O
ultrasonic	O
emulsification	O
method	O
,	O
is	O
simple	O
in	O
production	O
process	O
,	O
mild	O
in	O
condition	O
,	O
short	O
in	O
preparation	O
time	O
and	O
low	O
in	O
equipment	O
requirement	O
.	O

The	O
prepared	O
vitamin	O
A	O
nano	O
-	O
emulsion	O
is	O
of	O
an	O
oil	O
-	O
in	O
-	O
water	O
mode	O
,	O
is	O
clear	O
and	O
transparent	O
,	O
excellent	O
in	O
water	O
solution	O
and	O
good	O
in	O
stability	O
,	O
has	O
a	O
grain	O
distribution	O
range	O
of	O
23	O
-	O
62	O
nm	O
and	O
average	O
grain	O
diameter	O
of	O
38	O
nm	O
,	O
and	O
accords	O
with	O
the	O
basic	O
characteristics	O
of	O
a	O
nano	O
-	O
grade	O
material	O
.	O

Compound	O
alpha	O
-	O
ketoacid	O
tablet	O
free	O
of	O
talcum	O
powder	O
and	O
preparation	O
process	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
alpha	O
-	O
ketoacid	O
tablet	O
free	O
of	O
talcum	O
powder	O
and	O
a	O
preparation	O
process	O
thereof	O
.	O

The	O
conventional	O
preparation	O
process	O
is	O
changed	O
without	O
adding	O
the	O
talcum	O
powder	O
;	O
the	O
tablet	O
prepared	O
by	O
the	O
method	O
has	O
good	O
compressibility	O
,	O
attractive	O
appearance	O
,	O
high	O
disintegrating	O
speed	O
,	O
high	O
dissolution	O
rate	O
,	O
high	O
stability	O
in	O
long	O
-	O
term	O
placement	O
and	O
high	O
medicinal	O
safety	O
.	O

Wet	O
granulation	O
is	O
performed	O
separately	O
according	O
to	O
the	O
acidic	O
and	O
alkaline	O
ingredients	O
and	O
the	O
mass	O
balance	O
ratio	O
of	O
main	O
medicines	O
,	O
i.e.	O
,	O
a	O
meta	O
-	O
alkaline	O
ingredient	O
,	O
a	O
meta	O
-	O
acidic	O
ingredient	O
and	O
a	O
nearly	O
neutral	O
ingredient	O
are	O
subjected	O
to	O
wet	O
granulation	O
separately	O
,	O
and	O
then	O
mixing	O
,	O
tabletting	O
and	O
coating	O
are	O
performed	O
,	O
so	O
that	O
the	O
direct	O
contact	O
among	O
the	O
ingredients	O
is	O
avoided	O
,	O
long	O
-	O
term	O
stable	O
placement	O
can	O
be	O
realized	O
and	O
the	O
contents	O
of	O
the	O
active	O
ingredients	O
are	O
guaranteed	O
.	O

A	O
disintegrating	O
agent	O
internal	O
and	O
external	O
addition	O
method	O
is	O
adopted	O
in	O
the	O
formula	O
,	O
the	O
content	O
of	O
polyethylene	O
glycol	O
is	O
optimized	O
,	O
and	O
no	O
talcum	O
powder	O
or	O
analogs	O
with	O
ingredients	O
similar	O
to	O
the	O
talcum	O
powder	O
are	O
included	O
in	O
the	O
formula	O
,	O
so	O
that	O
the	O
problems	O
of	O
agglomeration	O
phenomenon	O
and	O
larger	O
viscosity	O
in	O
the	O
granulation	O
process	O
are	O
solved	O
,	O
and	O
the	O
safety	O
in	O
medication	O
is	O
guaranteed	O
.	O

Application	O
of	O
tumor	O
inhibitor	O
MLN4924	O
to	O
preparation	O
of	O
antiviral	O
drug	O
The	O
invention	O
discloses	O
application	O
of	O
a	O
tumor	O
inhibitor	O
MLN4924	O
to	O
preparation	O
of	O
an	O
antiviral	O
drug	O
.	O

Experiments	O
prove	O
that	O
the	O
small	O
-	O
molecule	O
inhibitor	O
MLN4924	O
with	O
good	O
performance	O
in	O
human	O
anti	O
-	O
tumor	O
clinical	O
trials	O
is	O
strong	O
in	O
antiviral	O
activity	O
and	O
can	O
inhibit	O
virus	O
replication	O
by	O
more	O
than	O
80	O
%	O
due	O
to	O
the	O
virus	O
inhibition	O
accessory	O
protein	O
function	O
.	O

With	O
long	O
preliminary	O
experimental	O
clinical	O
experience	O
and	O
a	O
strong	O
drug	O
action	O
effect	O
,	O
the	O
drug	O
can	O
be	O
produced	O
in	O
a	O
large	O
scale	O
and	O
has	O
great	O
potential	O
of	O
becoming	O
an	O
efficient	O
antiviral	O
drug	O
.	O

Through	O
an	O
ubiquitin	B
system	O
for	O
inhibiting	O
Neddylation	O
activation	O
dominated	O
by	O
virus	O
protein	O
by	O
small	O
molecule	O
drugs	O
,	O
the	O
application	O
value	O
of	O
the	O
tumor	O
inhibitor	O
MLN4924	O
for	O
preparing	O
the	O
antiviral	O
drug	O
is	O
detected	O
.	O

Preparation	O
method	O
for	O
gel	O
The	O
invention	O
discloses	O
a	O
preparation	O
method	O
for	O
a	O
gel	O
,	O
belonging	O
to	O
the	O
field	O
of	O
preparation	O
of	O
medicines	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
extracting	O
common	O
cnidium	O
fruit	O
to	O
obtain	O
an	O
extract	O
containing	O
osthole	O
and	O
carrying	O
out	O
clathration	O
on	O
the	O
extract	O
by	O
using	O
beta	O
-	O
cyclodextrin	O
or	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
so	O
as	O
to	O
obtain	O
a	O
clathrate	O
of	O
the	O
extract	O
of	O
common	O
cnidium	O
fruit	O
;	O
treating	O
clindamycin	O
hydrochloride	O
and	O
adding	O
a	O
saturated	O
aqueous	O
solution	O
prepared	O
from	O
beta	O
-	O
cyclodextrin	O
so	O
as	O
to	O
obtain	O
a	O
clindamycin	O
hydrochloride	O
clathrate	O
;	O
and	O
mixing	O
the	O
clathrate	O
of	O
the	O
extract	O
of	O
common	O
cnidium	O
fruit	O
with	O
the	O
clindamycin	O
hydrochloride	O
clathrate	O
,	O
adding	O
hydroxypropyl	O
methylcellulose	O
,	O
water	O
,	O
glycerin	O
,	O
chitosan	O
,	O
a	O
10	O
%	O
ethylparaben	O
ethanol	O
solution	O
,	O
a	O
10	O
%	O
aqueous	O
sodium	O
hydrosulphite	O
solution	O
and	O
Tween-80	O
and	O
carrying	O
out	O
mixing	O
with	O
stirring	O
so	O
as	O
to	O
obtain	O
the	O
gel	O
.	O

With	O
the	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
,	O
the	O
gel	O
can	O
safely	O
and	O
effectively	O
perform	O
curative	O
effects	O
and	O
has	O
reduced	O
irritation	O
,	O
improved	O
solubility	O
,	O
an	O
accelerated	O
dissolution	O
speed	O
and	O
enhanced	O
bioavailability	O
.	O

Preparation	O
method	O
for	O
Sanhuang	O
tablet	O
The	O
invention	O
provides	O
a	O
preparation	O
method	O
for	O
a	O
Sanhuang	O
tablet	O
.	O

The	O
Sanhuang	O
tablet	O
is	O
prepared	O
from	O
the	O
bulk	O
drugs	O
consisting	O
of	O
300	O
g	O
of	O
rhubarb	O
root	O
and	O
rhizome	O
,	O
5	O
g	O
of	O
berberine	O
hydrochloride	O
and	O
80	O
g	O
of	O
baical	O
skullcap	O
root	O
extract	O
through	O
supercritical	O
extraction	O
,	O
so	O
the	O
content	O
of	O
Sanhuang	O
tablet	O
is	O
greatly	O
increased	O
,	O
and	O
the	O
dose	O
of	O
the	O
Sanhuang	O
tablet	O
is	O
reduced	O
.	O

The	O
invention	O
further	O
provides	O
application	O
of	O
the	O
Sanhuang	O
tablet	O
in	O
preparation	O
of	O
drugs	O
used	O
for	O
inhibiting	O
cell	O
proliferation	O
of	O
human	O
large	O
cell	O
carcinoma	O
NCI	O
-	O
H460	O
.	O

Dextromethorphan	O
hydrobromide	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
dextromethorphan	O
hydrobromide	O
injection	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
:	O
15	O
g	O
of	O
dextromethorphan	O
hydrobromide	O
,	O
13	O
g	O
of	O
lactic	O
acid	O
,	O
7	O
g	O
of	O
sorbic	O
acid	O
,	O
42	O
g	O
of	O
polyethylene	O
glycol	O
2000	O
and	O
2000ml	O
of	O
water	O
for	O
injection	O
through	O
adjusting	O
the	O
pH	O
value	O
to	O
3.4	O
-	O
3.5	O
.	O

Proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
,	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
.	O

The	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
comprise	O
1	O
-	O
5	O
parts	O
of	O
proanthocyanidin	O
,	O
1	O
-	O
12	O
parts	O
of	O
chitosan	O
or	O
derivatives	O
thereof	O
,	O
1	O
-	O
12	O
parts	O
of	O
phospholipid	O
or	O
derivatives	O
thereof	O
and	O
1	O
-	O
10	O
parts	O
of	O
excipients	O
,	O
wherein	O
the	O
chitosan	O
and	O
the	O
derivatives	O
thereof	O
are	O
one	O
or	O
more	O
of	O
high	O
,	O
medium	O
and	O
low	O
-	O
molecular	O
weight	O
chitosan	O
,	O
chitosan	O
oligosaccharide	O
,	O
chitosan	O
quaternary	O
ammonium	O
salt	O
and	O
carboxymethyl	O
chitosan	O
.	O

The	O
particle	O
size	O
of	O
the	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
is	O
10nm-0.3	O
mu	O
m	O
;	O
the	O
proanthocyanidin	O
is	O
prepared	O
into	O
the	O
powder	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
,	O
and	O
the	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
can	O
directly	O
play	O
a	O
role	O
in	O
the	O
lung	O
as	O
a	O
pulmonary	O
inhalation	O
medicine	O
-	O
carrying	O
formulation	O
,	O
improve	O
the	O
bioavailability	O
of	O
the	O
proanthocyanidin	O
and	O
reduce	O
the	O
dosage	O
by	O
sustained	O
release	O
;	O
the	O
proanthocyanidin	O
nano	O
-	O
micro	O
spheres	O
can	O
also	O
be	O
applied	O
as	O
an	O
oral	O
sustained	O
release	O
formulation	O
;	O
the	O
proanthocyanidin	O
nano	O
-	O
micro	O
spheres	O
have	O
appropriate	O
particle	O
size	O
and	O
morphology	O
and	O
other	O
powder	O
properties	O
,	O
as	O
well	O
as	O
sustained	O
release	O
;	O
furthermore	O
,	O
the	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
simplicity	O
and	O
convenience	O
in	O
operation	O
,	O
stable	O
process	O
and	O
easiness	O
in	O
industrial	O
production	O
.	O

Application	O
of	O
fisetin	O
in	O
preparation	O
of	O
drug	O
with	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
The	O
invention	O
relates	O
to	O
application	O
of	O
fisetin	O
in	O
preparation	O
of	O
a	O
drug	O
with	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
.	O

The	O
drug	O
can	O
reduce	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response	O
,	O
and	O
has	O
the	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
.	O

According	O
to	O
the	O
technical	O
scheme	O
provided	O
by	O
the	O
invention	O
,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
for	O
generating	O
anticoagulation	O
effects	O
is	O
for	O
inhibiting	O
ADP	O
-	O
induced	O
platelet	O
aggregation	O
,	O
inhibiting	O
thrombocyte	O
release	O
,	O
and	O
reducing	O
serum	O
Fg	O
and	O
vWF	B
content	O
to	O
achieve	O
anticoagulation	O
function	O
;	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anti	O
-	O
thrombosis	O
drug	O
is	O
also	O
for	O
significantly	O
prolonging	O
CT	O
,	O
PT	O
,	O
TT	O
and	O
APTT	O
to	O
indirectly	O
achieve	O
an	O
anti	O
-	O
thrombosis	O
effect	O
;	O
moreover	O
,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
a	O
drug	O
with	O
the	O
cardioprotective	O
effects	O
on	O
ischemia	O
/	O
reperfusion	O
myocardial	O
cells	O
is	O
for	O
reducing	O
the	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response	O
,	O
decreasing	O
the	O
infarct	O
area	O
of	O
injured	O
cardiac	O
muscle	O
and	O
achieving	O
a	O
protection	O
effect	O
on	O
the	O
ischemic	O
myocardial	O
cell	O
by	O
means	O
of	O
inhibiting	O
inflammatory	O
cells	O
invasion	O
,	O
MMP-9	B
and	O
NF	B
-	I
kB	I
expression	O
and	O
NF	B
-	I
kB	I
nuclear	O
migration	O
,	O
myocardial	O
apoptosis	O
and	O
the	O
like	O
.	O

Haemorrhoid	O
treatment	O
lotion	O
The	O
invention	O
discloses	O
a	O
haemorrhoid	O
treatment	O
lotion	O
,	O
which	O
is	O
used	O
for	O
positively	O
preventing	O
,	O
treating	O
and	O
performing	O
health	O
-	O
care	O
to	O
patients	O
with	O
three	O
human	O
common	O
diseases	O
,	O
namely	O
haemorrhoid	O
,	O
acnes	O
and	O
male	O
and	O
female	O
sexual	O
dysfunctions	O
,	O
as	O
well	O
as	O
frequently	O
-	O
occurring	O
diseases	O
radically	O
by	O
a	O
mode	O
of	O
self	O
-	O
healthcare	O
or	O
simple	O
self	O
-	O
therapy	O
in	O
daily	O
lives	O
.	O

The	O
lotion	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
15	O
elementary	O
components	O
according	O
to	O
a	O
scientific	O
proportional	O
prescription	O
and	O
compatibility	O
.	O

The	O
lotion	O
has	O
the	O
characteristics	O
of	O
wide	O
adaptability	O
,	O
high	O
popularization	O
and	O
application	O
values	O
,	O
safety	O
and	O
efficiency	O
,	O
and	O
no	O
toxic	O
or	O
side	O
effect	O
,	O
the	O
aim	O
that	O
the	O
three	O
diseases	O
severely	O
disturbing	O
human	O
beings	O
by	O
an	O
economical	O
and	O
simple	O
method	O
can	O
be	O
achieved	O
,	O
and	O
the	O
novel	O
product	O
has	O
three	O
dramatic	O
efficacies	O
and	O
applications	O
.	O

Antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
The	O
invention	O
discloses	O
an	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
.	O

The	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
following	O
raw	O
materials	O
according	O
to	O
percentage	O
by	O
weight	O
:	O
5	O
-	O
15	O
%	O
of	O
folium	O
ginkgo	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
dandelion	O
extract	O
,	O
8	O
-	O
10	O
%	O
of	O
borneol	O
,	O
10	O
-	O
20	O
%	O
of	O
folium	O
artemisiae	O
argyi	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
honey	O
,	O
5	O
-	O
10	O
%	O
of	O
felwort	O
extract	O
,	O
5	O
-	O
15	O
%	O
of	O
seven	O
-	O
leaf	O
ginseng	O
extract	O
,	O
5	O
-	O
15	O
%	O
of	O
pueraria	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
pseudo	O
-	O
ginseng	O
extract	O
and	O
15	O
-	O
30	O
%	O
of	O
medical	O
ethanol	O
.	O

The	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
has	O
the	O
advantages	O
that	O
the	O
prepared	O
medicament	O
has	O
a	O
quick	O
anti	O
-	O
inflammation	O
effect	O
and	O
a	O
high	O
curative	O
effect	O
,	O
generates	O
no	O
resistance	O
to	O
medicaments	O
on	O
bacteria	O
and	O
has	O
a	O
remarkable	O
effect	O
on	O
such	O
diseases	O
caused	O
by	O
fungus	O
as	O
tinea	O
pedis	O
,	O
tinea	O
manuum	O
,	O
neurodermatitis	O
,	O
contact	O
dermatitis	O
and	O
onychomycosis	O
.	O

Capsule	O
and	O
preparation	O
containing	O
rich	O
hydroxytyrosol	O
,	O
lycium	O
barbarum	O
polysaccharide	O
and	O
apple	O
polyphenol	O
and	O
used	O
for	O
protecting	O
liver	O
The	O
invention	O
discloses	O
a	O
capsule	O
and	O
a	O
tablet	O
containing	O
rich	O
hydroxytyrosol	O
,	O
lycium	O
barbarum	O
polysaccharide	O
and	O
apple	O
polyphenol	O
and	O
particularly	O
discloses	O
a	O
preparation	O
product	O
used	O
for	O
protecting	O
liver	O
.	O

The	O
preparation	O
product	O
,	O
namely	O
the	O
capsule	O
or	O
tablet	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
0	O
-	O
60	O
%	O
of	O
hydroxytyrosol	O
,	O
0	O
-	O
30	O
%	O
of	O
lycium	O
barbarum	O
polysaccharide	O
,	O
0	O
-	O
50	O
%	O
of	O
apple	O
polyphenol	O
,	O
20	O
-	O
98	O
%	O
of	O
starch	O
,	O
0	O
-	O
20	O
%	O
of	O
xylitol	O
,	O
0	O
-	O
10	O
%	O
of	O
aspartame	O
and	O
0	O
-	O
2	O
%	O
of	O
magnesium	O
stearate	O
.	O

On	O
the	O
condition	O
of	O
satisfying	O
the	O
preparation	O
processing	O
and	O
producing	O
conditions	O
,	O
the	O
components	O
are	O
respectively	O
filtered	O
through	O
a	O
sieve	O
of	O
10	O
-	O
100	O
meshes	O
and	O
are	O
weighed	O
and	O
uniformly	O
mixed	O
according	O
to	O
prescriptions	O
,	O
the	O
mixed	O
components	O
are	O
pelletized	O
and	O
dried	O
,	O
and	O
products	O
with	O
proper	O
particle	O
sizes	O
are	O
selected	O
and	O
are	O
filled	O
to	O
capsules	O
or	O
tabletted	O
.	O

The	O
preparation	O
product	O
disclosed	O
by	O
the	O
invention	O
has	O
strong	O
oxidation	O
resistance	O
and	O
radiation	O
resistance	O
and	O
has	O
a	O
strong	O
effect	O
of	O
recovering	O
health	O
of	O
human	O
body	O
internal	O
organs	O
and	O
especially	O
protecting	O
the	O
liver	O
,	O
and	O
the	O
efficacy	O
is	O
better	O
than	O
the	O
single	O
component	O
effect	O
in	O
the	O
formulation	O
.	O

Since	O
the	O
dosage	O
of	O
a	O
single	O
component	O
in	O
the	O
composition	O
disclosed	O
by	O
the	O
invention	O
is	O
relatively	O
decreased	O
,	O
adverse	O
reactions	O
caused	O
by	O
single	O
use	O
of	O
the	O
single	O
component	O
is	O
alleviated	O
or	O
reduced	O
.	O

The	O
composition	O
disclosed	O
by	O
invention	O
has	O
the	O
advantages	O
of	O
being	O
clear	O
in	O
curative	O
effect	O
,	O
free	O
of	O
toxic	O
side	O
effect	O
,	O
convenient	O
to	O
take	O
and	O
low	O
in	O
price	O
.	O

Compound	O
vitamin	O
lyophilized	O
preparation	O
for	O
injection	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
a	O
compound	O
vitamin	O
lyophilized	O
preparation	O
for	O
injection	O
and	O
its	O
preparation	O
method	O
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
scientific	O
prescription	O
and	O
preparation	O
process	O
are	O
utilized	O
to	O
make	O
the	O
prepared	O
compound	O
vitamin	O
lyophilized	O
preparation	O
for	O
injection	O
have	O
the	O
advantages	O
of	O
high	O
stability	O
,	O
low	O
impurity	O
content	O
and	O
the	O
like	O
.	O

Damp	O
clearing	O
decoction	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
damp	O
clearing	O
decoction	O
which	O
is	O
a	O
medicament	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
7	O
parts	O
of	O
rhizoma	O
alismatis	O
,	O
8	O
-	O
12	O
parts	O
of	O
plantain	O
seed	O
,	O
8	O
-	O
12	O
parts	O
of	O
talc	O
,	O
5	O
-	O
7	O
parts	O
of	O
cortex	O
phellodendri	O
,	O
5	O
-	O
7	O
parts	O
of	O
white	O
poria	O
,	O
5	O
-	O
7	O
parts	O
of	O
caulis	O
akebiae	O
,	O
8	O
-	O
12	O
parts	O
of	O
christina	O
loosestrife	O
herb	O
,	O
8	O
-	O
12	O
parts	O
of	O
japanese	O
climbing	O
fern	O
spore	O
,	O
15	O
-	O
18	O
parts	O
of	O
herba	O
pyrrosiae	O
stephania	O
,	O
15	O
-	O
18	O
parts	O
of	O
rhizoma	O
atractylodis	O
sinensis	O
,	O
15	O
-	O
18	O
parts	O
of	O
cortex	O
eucommiae	O
,	O
15	O
-	O
18	O
parts	O
of	O
psoralea	O
corylifolia	O
,	O
5	O
-	O
7	O
parts	O
of	O
phaseolus	O
calcaratus	O
and	O
5	O
-	O
7	O
parts	O
of	O
euphorbia	O
helioscopia	O
.	O

By	O
taking	O
the	O
decoction	O
provided	O
by	O
the	O
invention	O
,	O
the	O
damp	O
in	O
a	O
body	O
can	O
be	O
effectively	O
cleared	O
,	O
and	O
the	O
immunity	O
of	O
the	O
body	O
is	O
enhanced	O
.	O

Bufalin	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
bufalin	O
derivative	O
having	O
a	O
structure	O
represented	O
as	O
a	O
general	O
formula	O
I	O
,	O
wherein	O
R	O
is	O
selected	O
from	O
one	O
of	O
the	O
following	O
structure	O
groups	O
as	O
shown	O
in	O
the	O
specification	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
,	O
a	O
pharmaceutical	O
composition	O
and	O
application	O
of	O
the	O
derivative	O
.	O

The	O
bufalin	O
derivative	O
has	O
an	O
activity	O
on	O
inhibiting	O
tumor	O
cell	O
lines	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
medicine	O
for	O
treating	O
malignant	O
tumors	O
.	O

Preparation	O
capable	O
of	O
increasing	O
bone	O
mineral	O
density	O
The	O
invention	O
discloses	O
a	O
preparation	O
capable	O
of	O
increasing	O
bone	O
mineral	O
density	O
.	O

The	O
preparation	O
is	O
prepared	O
with	O
the	O
main	O
raw	O
materials	O
including	O
American	O
ginseng	O
powder	O
,	O
walnut	O
powder	O
,	O
soy	O
isoflavone	O
and	O
calcium	O
phosphate	O
.	O

The	O
product	O
is	O
prepared	O
according	O
to	O
the	O
appropriate	O
ratio	O
,	O
so	O
as	O
to	O
generate	O
synergistic	O
effects	O
,	O
and	O
is	O
in	O
particular	O
suitable	O
for	O
having	O
by	O
the	O
middle	O
aged	O
and	O
elderly	O
people	O
.	O

Medical	O
application	O
of	O
2	O
,	O
2-dimethyl	O
thiochromanone	O
compounds	O
containing	O
piperazine	O
structures	O
and	O
analogues	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
medical	O
application	O
of	O
2	O
,	O
2-dimethyl	O
thiochromanone	O
compounds	O
containing	O
piperazine	O
structures	O
and	O
analogues	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
2	O
,	O
2-dimethyl	O
thiochromanone	O
compounds	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
in	O
the	O
general	O
formula	O
,	O
X	O
is	O
independently	O
selected	O
from	O
CH2	O
or	O
C	O
=	O
O	O
;	O
when	O
Y	O
is	O
selected	O
from	O
CH2	O
,	O
Ar	O
is	O
independently	O
selected	O
from	O
methyl	O
,	O
hydroxy	O
,	O
methoxy	O
,	O
ethoxy	O
,	O
nitryl	O
,	O
fluorine	O
,	O
chlorine	O
,	O
bromine	O
substituted	O
or	O
unsubstituted	O
phenyl	O
;	O
n	O
is	O
defined	O
as	O
an	O
integer	O
from	O
0	O
to	O
3	O
;	O
and	O
X	O
is	O
independently	O
selected	O
from	O
CH2	O
or	O
C	O
=	O
O	O
;	O
when	O
Y	O
is	O
selected	O
from	O
C	O
=	O
O	O
,	O
Ar	O
is	O
independently	O
selected	O
from	O
methyl	O
,	O
hydroxy	O
,	O
methoxy	O
,	O
ethoxy	O
,	O
nitryl	O
,	O
fluorine	O
,	O
chlorine	O
,	O
bromine	O
substituted	O
or	O
unsubstituted	O
phenyl	O
;	O
and	O
n	O
is	O
defined	O
as	O
an	O
integer	O
from	O
1	O
to	O
3	O
.	O

The	O
novel	O
compounds	O
provided	O
by	O
the	O
invention	O
are	O
used	O
as	O
effective	O
antiplatelet	O
drugs	O
and	O
are	O
especially	O
used	O
for	O
preparing	O
drugs	O
for	O
preventing	O
or	O
treating	O
platelet	O
aggregation	O
caused	O
coronary	O
syndrome	O
,	O
myocardial	O
infarction	O
,	O
myocardial	O
ischemia	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
for	O
clinical	O
use	O
.	O

Pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
a	O
freeze	O
-	O
drying	O
method	O
for	O
the	O
pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
,	O
every	O
1000	O
bottles	O
of	O
the	O
pantoprazole	O
sodium	O
freeze	O
-	O
dried	O
powder	O
injection	O
are	O
prepared	O
by	O
dissolving	O
the	O
components	O
consisting	O
of	O
pantoprazole	O
sodium	O
,	O
mannitol	O
,	O
calcium	O
edentate	O
/	O
sodium	O
edentate	O
/	O
sodium	O
calcium	O
edentate	O
and	O
citric	O
acid	O
in	O
injection	O
water	O
to	O
obtain	O
drug	O
liquid	O
and	O
freeze	O
-	O
drying	O
the	O
drug	O
liquid	O
,	O
wherein	O
before	O
freeze	O
-	O
drying	O
of	O
the	O
drug	O
liquid	O
,	O
a	O
proper	O
amount	O
of	O
sodium	O
hydroxide	O
is	O
used	O
to	O
adjust	O
a	O
pH	O
value	O
to	O
9.5	O
to	O
10.5	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
1	O
)	O
weighing	O
;	O
2	O
)	O
preparation	O
;	O
3	O
)	O
degerming	O
and	O
filtering	O
;	O
4	O
)	O
bottle	O
washing	O
,	O
drying	O
and	O
disinfection	O
;	O
5	O
)	O
rubber	O
plug	O
cleaning	O
,	O
disinfection	O
and	O
drying	O
;	O
6	O
)	O
filling	O
;	O
7	O
)	O
freeze	O
-	O
drying	O
and	O
plug	O
pressing	O
;	O
and	O
8)	O
cover	O
rolling	O
.	O

With	O
such	O
a	O
technical	O
scheme	O
,	O
the	O
preparation	O
method	O
enables	O
sublimation	O
and	O
drying	O
time	O
to	O
be	O
saved	O
,	O
energy	O
consumption	O
to	O
be	O
reduced	O
and	O
product	O
quality	O
to	O
be	O
guaranteed	O
.	O

Drug	O
delivery	O
system	O
for	O
16-dehydropregnenolone	O
lipidosome	O
for	O
injection	O
and	O
preparation	O
method	O
of	O
same	O
The	O
invention	O
provides	O
a	O
drug	O
delivery	O
system	O
for	O
16-dehydropregnenolone	O
(	O
DHP	O
)	O
lipidosome	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
.	O

The	O
drug	O
delivery	O
system	O
comprises	O
effective	O
amount	O
of	O
16-dehydropregnenolone	O
,	O
a	O
phospholipid	O
membrane	O
,	O
a	O
membrane	O
stabilization	O
material	O
and	O
pharmaceutically	O
-	O
acceptable	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
16-dehydropregnenolone	O
to	O
the	O
phospholipid	O
membrane	O
to	O
the	O
membrane	O
stabilization	O
material	O
is	O
1:5:0.2	O
-	O
1:50:50	O
.	O

The	O
preparation	O
technology	O
comprises	O
the	O
steps	O
of	O
preparing	O
multi	O
-	O
chamber	O
lipidosome	O
,	O
homogenizing	O
the	O
lipidosome	O
,	O
metering	O
volume	O
,	O
sterilizing	O
,	O
subpackaging	O
,	O
freeze	O
-	O
drying	O
and	O
the	O
like	O
.	O

The	O
lipidosome	O
prepared	O
by	O
the	O
method	O
is	O
small	O
in	O
average	O
grain	O
diameter	O
,	O
narrow	O
in	O
distribution	O
,	O
high	O
in	O
encapsulation	O
efficiency	O
,	O
high	O
in	O
drug	O
loading	O
capacity	O
,	O
good	O
in	O
repeatability	O
and	O
good	O
in	O
stability	O
,	O
and	O
can	O
satisfy	O
the	O
requirements	O
on	O
intravenous	O
injection	O
.	O

The	O
results	O
of	O
anti	O
-	O
tumor	O
in	O
vivo	O
experiments	O
show	O
that	O
16-DHP	O
lipidosome	O
prepared	O
by	O
the	O
invention	O
can	O
remarkably	O
inhibit	O
growth	O
of	O
a	O
transplantation	O
tumor	O
of	O
a	O
nude	O
mouse	O
bearing	O
the	O
tumor	O
and	O
has	O
a	O
relatively	O
good	O
anti	O
-	O
tumor	O
effect	O
.	O

An	O
experiment	O
result	O
of	O
rat	O
pharmacokinetics	O
shows	O
that	O
the	O
16-DHP	O
lipidosome	O
prepared	O
by	O
the	O
invention	O
can	O
prolong	O
the	O
time	O
that	O
a	O
medicine	O
stays	O
in	O
the	O
body	O
and	O
improve	O
the	O
amount	O
of	O
the	O
medicine	O
that	O
enters	O
systemic	O
circulation	O
of	O
a	O
rat	O
.	O

Formula	O
and	O
preparation	O
method	O
for	O
externally	O
-	O
applied	O
medicine	O
capable	O
of	O
rapidly	O
diminishing	O
inflammation	O
and	O
relieving	O
pain	O
The	O
invention	O
discloses	O
a	O
formula	O
and	O
a	O
preparation	O
method	O
for	O
an	O
externally	O
-	O
applied	O
medicine	O
capable	O
of	O
rapidly	O
diminishing	O
inflammation	O
and	O
relieving	O
pain	O
.	O

The	O
formula	O
comprises	O
,	O
by	O
mass	O
,	O
3.5	O
%	O
of	O
sorbitan	O
olivate	O
,	O
3	O
%	O
of	O
cetearyl	O
alcohol	O
,	O
2	O
%	O
of	O
squalane	O
,	O
2	O
%	O
of	O
iso	O
-	O
octyl	O
palmitate	O
,	O
2	O
%	O
of	O
caprylic	O
/	O
capric	O
triglyceride	O
,	O
0.5	O
%	O
of	O
xanthan	O
gum	O
,	O
4	O
%	O
of	O
glycerin	O
,	O
0.5	O
%	O
of	O
azelaic	O
acid	O
,	O
2	O
%	O
of	O
aloe	O
,	O
1	O
%	O
of	O
a	O
honeysuckle	O
flower	O
extract	O
,	O
1	O
%	O
of	O
a	O
chrysanthemum	O
extract	O
,	O
0.05	O
%	O
of	O
a	O
freshener	O
(	O
menthol	O
)	O
,	O
0.1	O
%	O
of	O
methyl	O
hydroxybenzoate	O
,	O
0.1	O
%	O
of	O
propyl	O
hydroxybenzoate	O
,	O
0.15	O
%	O
of	O
imidazolidinyl	O
urea	O
and	O
79.1	O
%	O
of	O
water	O
.	O

The	O
medicine	O
is	O
prepared	O
by	O
processing	O
the	O
above	O
-	O
mentioned	O
components	O
.	O

The	O
medicine	O
provided	O
by	O
the	O
invention	O
uses	O
herbaceous	O
plants	O
as	O
raw	O
materials	O
and	O
has	O
small	O
toxic	O
and	O
side	O
effects	O
;	O
the	O
medicine	O
can	O
be	O
directly	O
applied	O
on	O
the	O
surface	O
layer	O
of	O
the	O
skin	O
,	O
targetedly	O
reaches	O
a	O
desired	O
site	O
through	O
rapid	O
absorption	O
by	O
the	O
skin	O
,	O
exerts	O
good	O
anti	O
-	O
inflammation	O
and	O
sterilization	O
effects	O
and	O
has	O
fast	O
action	O
.	O

Efficient	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
for	O
livestock	O
The	O
invention	O
relates	O
to	O
veterinary	O
drugs	O
,	O
in	O
particular	O
to	O
a	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
,	O
and	O
aims	O
to	O
provide	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
which	O
has	O
small	O
side	O
effects	O
.	O

The	O
formula	O
of	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
comprises	O
the	O
following	O
components	O
:	O
60	O
g	O
of	O
plaster	O
,	O
30	O
-	O
45	O
g	O
of	O
radix	O
rehmanniae	O
,	O
60	O
g	O
of	O
cornu	O
bubali	O
,	O
20	O
g	O
of	O
coptis	O
chinensis	O
,	O
35	O
-	O
45	O
g	O
of	O
cape	O
jasmine	O
,	O
20	O
g	O
of	O
cortex	O
moutan	O
,	O
25	O
g	O
of	O
scutellaria	O
baicalensis	O
,	O
30	O
g	O
of	O
radix	O
paeoniae	O
rubra	O
,	O
30	O
g	O
of	O
rhizoma	O
anemarrhenae	O
,	O
30	O
g	O
of	O
fructus	O
forsythia	O
,	O
25	O
g	O
of	O
platycodon	O
grandiflorum	O
,	O
15	O
g	O
of	O
liquorice	O
,	O
and	O
25	O
g	O
of	O
lophatherum	O
gracile	O
,	O
and	O
the	O
raw	O
materials	O
of	O
the	O
drug	O
are	O
smashed	O
and	O
further	O
smashed	O
superfinely	O
to	O
obtain	O
superfine	O
powder	O
.	O

According	O
to	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
,	O
the	O
use	O
amount	O
of	O
plaster	O
is	O
remarkably	O
reduced	O
,	O
the	O
cold	O
property	O
of	O
the	O
drug	O
is	O
lowered	O
,	O
and	O
harm	O
and	O
side	O
effects	O
on	O
animal	O
bodies	O
are	O
alleviated	O
;	O
the	O
effects	O
of	O
an	O
original	O
drug	O
is	O
maintained	O
through	O
the	O
appropriate	O
adjustment	O
on	O
the	O
use	O
amount	O
of	O
other	O
components	O
;	O
the	O
curative	O
effect	O
is	O
exact	O
,	O
remarkable	O
,	O
and	O
the	O
drug	O
is	O
mild	O
in	O
property	O
;	O
radix	O
scrophulariae	O
is	O
eliminated	O
,	O
so	O
that	O
the	O
drug	O
formula	O
is	O
simplified	O
;	O
the	O
drug	O
raw	O
materials	O
and	O
processing	O
cost	O
are	O
reduced	O
.	O

Medicine	O
for	O
treating	O
cough	O
and	O
preparation	O
method	O
of	O
medicine	O
The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
cough	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
atractylodes	O
macrocephala	O
koidz	O
,	O
radix	O
polygonati	O
officinalis	O
,	O
herba	O
houttuyniae	O
,	O
spreading	O
hedyotis	O
herb	O
,	O
edible	O
tulip	O
,	O
honeysuckle	O
,	O
rhizoma	O
belamcandae	O
,	O
adenophora	O
tetraphylla	O
,	O
common	O
hogfenneI	O
root	O
,	O
flos	O
farfarae	O
,	O
radix	O
ophiopogonis	O
and	O
other	O
medicines	O
in	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
dispelling	O
cold	O
and	O
warming	O
lung	O
,	O
eliminating	O
phlegm	O
and	O
stopping	O
cough	O
,	O
clearing	O
lung	O
and	O
harmonizing	O
stomach	O
,	O
and	O
is	O
quick	O
in	O
response	O
and	O
short	O
in	O
course	O
of	O
treatment	O
after	O
healing	O
when	O
used	O
for	O
treating	O
cough	O
,	O
and	O
prevents	O
relapse	O
.	O

Medicine	O
for	O
treating	O
male	O
infertility	O
and	O
preparation	O
method	O
of	O
medicine	O
The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
male	O
infertility	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
dendrobe	O
,	O
nidus	O
vespae	O
,	O
epimedium	O
,	O
tribulus	O
terrestris	O
,	O
bamboo	O
leaf	O
,	O
actinolite	O
,	O
raspberry	O
and	O
other	O
medicines	O
in	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
invigorating	O
the	O
kidney	O
and	O
strengthening	O
Yang	O
,	O
activating	O
the	O
channels	O
and	O
strengthening	O
spleen	O
,	O
nourishing	O
blood	O
and	O
arresting	O
emission	O
,	O
and	O
is	O
quick	O
in	O
response	O
and	O
good	O
in	O
curative	O
effect	O
when	O
used	O
for	O
treating	O
male	O
infertility	O
,	O
and	O
prevents	O
relapse	O
.	O

Drug	O
for	O
treating	O
infantile	O
cough	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
treating	O
infantile	O
cough	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
drug	O
contains	O
5	O
-	O
15	O
parts	O
of	O
honeysuckle	O
,	O
10	O
-	O
15	O
parts	O
of	O
platycodon	O
grandiflorum	O
,	O
10	O
-	O
15	O
parts	O
of	O
licorice	O
,	O
5	O
-	O
10	O
parts	O
of	O
white	O
radish	O
,	O
5	O
-	O
12	O
parts	O
of	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
,	O
2	O
-	O
8	O
parts	O
of	O
towel	O
gourd	O
and	O
15	O
-	O
25	O
parts	O
of	O
brown	O
sugar	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighing	O
honeysuckle	O
,	O
platycodon	O
grandiflorum	O
,	O
licorice	O
and	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
according	O
to	O
a	O
proportion	O
,	O
adding	O
water	O
to	O
decoct	O
the	O
components	O
,	O
filtering	O
to	O
obtain	O
filtrate	O
I	O
after	O
the	O
decocting	O
treatment	O
;	O
(	O
2	O
)	O
weighing	O
white	O
radish	O
and	O
towel	O
gourd	O
according	O
to	O
a	O
proportion	O
,	O
adding	O
water	O
to	O
decoct	O
the	O
components	O
,	O
and	O
then	O
,	O
filtering	O
to	O
obtain	O
filtrate	O
II	O
;	O
(	O
3	O
)	O
mixing	O
the	O
filtrate	O
I	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
the	O
filtrate	O
II	O
obtained	O
in	O
the	O
step	O
(	O
2	O
)	O
,	O
and	O
decocting	O
the	O
mixture	O
to	O
obtain	O
a	O
mixed	O
concentrated	O
solution	O
III	O
;	O
and	O
(	O
4	O
)	O
adding	O
brown	O
sugar	O
in	O
the	O
mixed	O
concentrated	O
solution	O
III	O
,	O
and	O
slightly	O
heating	O
the	O
mixture	O
to	O
obtain	O
the	O
drug	O
.	O

The	O
drug	O
is	O
good	O
in	O
curative	O
effect	O
,	O
free	O
of	O
side	O
effect	O
and	O
capable	O
of	O
both	O
treating	O
infantile	O
cough	O
fundamentally	O
and	O
reinforcing	O
body	O
and	O
enhancing	O
immunity	O
of	O
children	O
on	O
chills	O
and	O
fever	O
and	O
the	O
like	O
.	O

Antibacterial	O
finishing	O
agent	O
for	O
medical	O
dressing	O
The	O
invention	O
relates	O
to	O
an	O
antibacterial	O
finishing	O
agent	O
for	O
a	O
medical	O
dressing	O
.	O

The	O
antibacterial	O
finishing	O
agent	O
is	O
prepared	O
through	O
an	O
antibacterial	O
agent	O
,	O
a	O
hemostatic	O
,	O
and	O
an	O
astringent	O
capable	O
of	O
promoting	O
wound	O
healing	O
by	O
virtue	O
of	O
a	O
special	O
process	O
.	O

The	O
antibacterial	O
finishing	O
agent	O
is	O
used	O
for	O
finishing	O
gauze	O
,	O
a	O
bandage	O
,	O
sponge	O
and	O
other	O
medical	O
dressings	O
,	O
and	O
has	O
the	O
characteristics	O
of	O
broad	O
-	O
spectrum	O
antibacterial	O
property	O
,	O
blood	O
stopping	O
,	O
healing	O
promoting	O
,	O
safety	O
and	O
non	O
-	O
irritation	O
,	O
and	O
simple	O
preparation	O
process	O
.	O

The	O
finished	O
medical	O
dressing	O
has	O
the	O
effects	O
of	O
resisting	O
bacteria	O
,	O
stopping	O
blooding	O
,	O
diminishing	O
inflammation	O
,	O
and	O
promoting	O
wound	O
healing	O
.	O

Mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
The	O
invention	O
discloses	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
,	O
and	O
is	O
applicable	O
to	O
diagnosis	O
and	O
treatment	O
in	O
dental	O
clinic	O
.	O

A	O
formula	O
of	O
the	O
mouth	O
wash	O
consists	O
of	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
3	O
-	O
6	O
%	O
of	O
carboxymethyl	O
chitosan	O
,	O
2	O
-	O
6	O
%	O
of	O
marine	O
organism	O
lysozyme	B
and	O
reverse	O
osmosis	O
pure	O
water	O
to	O
100	O
%	O
.	O

The	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
containing	O
a	O
marine	O
organism	O
antibacterial	O
component	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
(	O
1	O
)	O
being	O
remarkable	O
in	O
antibacterial	O
effect	O
;	O
(	O
2	O
)	O
being	O
free	O
from	O
irritation	O
to	O
mucous	O
membrane	O
of	O
mouth	O
;	O
and	O
(	O
3	O
)	O
being	O
environmentally	O
friendly	O
and	O
non	O
-	O
toxic	O
due	O
to	O
the	O
marine	O
organism	O
component	O
.	O

Pharmaceutical	O
use	O
of	O
2	O
,	O
2-dimethyl	O
chromanone	O
type	O
compound	O
and	O
analogs	O
thereof	O
The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
pharmaceutical	O
use	O
of	O
a	O
2	O
,	O
2-dimethyl	O
chromanone	O
type	O
compound	O
and	O
analogs	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
is	O
as	O
follows	O
,	O
wherein	O
X	O
can	O
be	O
selected	O
from	O
CH2	O
or	O
C	O
=	O
O	O
;	O
and	O
R	O
and	O
R	O
'	O
are	O
as	O
described	O
in	O
the	O
description	O
.	O

The	O
new	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
be	O
used	O
as	O
an	O
effective	O
anti	O
-	O
platelet	O
medicament	O
,	O
can	O
be	O
particularly	O
applied	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
or	O
treating	O
coronary	O
syndrome	O
,	O
myocardial	O
infarction	O
,	O
myocardial	O
ischemia	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
caused	O
by	O
platelet	O
aggregation	O
and	O
can	O
further	O
treat	O
thrombus	O
formation	O
,	O
ischemia	O
,	O
stroke	O
,	O
restenosis	O
or	O
inflammation	O
.	O

Oxazole	O
and	O
thiazole	O
derivatives	O
as	O
selective	O
protein	B
kinase	I
inhibitors	O
(	O
c	B
-	I
kit	I
)	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
,	O
Q	O
,	O
W	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

These	O
compounds	O
selectively	O
modulate	O
,	O
regulate	O
,	O
and/or	O
inhibit	O
signal	O
transduction	O
mediated	O
by	O
certain	O
native	O
and/or	O
mutant	O
proteine	O
kinases	O
implicated	O
in	O
a	O
variety	O
of	O
human	O
and	O
animal	O
diseases	O
such	O
as	O
cell	O
proliferative	O
,	O
metabolic	O
,	O
allergic	O
,	O
and	O
degenerative	O
disorders	O
.	O

More	O
particularly	O
,	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
native	O
and/or	O
mutant	O
c	B
-	I
kit	I
inhibitors	O
.	O

Teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
The	O
invention	O
relates	O
to	O
teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
.	O

25	O
parts	O
of	O
teasel	O
roots	O
,	O
14	O
parts	O
of	O
sappan	O
wood	O
,	O
12	O
parts	O
of	O
peach	O
seeds	O
and	O
16	O
parts	O
of	O
borneol	O
are	O
washed	O
,	O
chopped	O
and	O
dried	O
;	O
16	O
parts	O
of	O
catechu	O
,	O
17	O
parts	O
of	O
green	O
tea	O
and	O
filiform	O
medicinal	O
material	O
are	O
uniformly	O
mixed	O
and	O
dried	O
,	O
and	O
are	O
packaged	O
into	O
packed	O
dipsacus	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
.	O

The	O
teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
and	O
convenient	O
carriage	O
with	O
good	O
effect	O
;	O
the	O
invention	O
has	O
the	O
blood	O
circulation	O
invigorating	O
,	O
stasis	O
dispersing	O
,	O
pain	O
relieving	O
and	O
hemostasis	O
efficacies	O
,	O
and	O
the	O
product	O
can	O
help	O
people	O
to	O
invigorate	O
blood	O
circulation	O
,	O
disperse	O
stasis	O
,	O
prevent	O
and	O
control	O
stasis	O
ache	O
symptoms	O
.	O

Fluoroquinolonesilver	O
compound	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
fluoroquinolonesilver	O
,	O
and	O
a	O
preparation	O
method	O
and	O
medical	O
application	O
of	O
the	O
fluoroquinolonesilver	O
.	O

The	O
fluoroquinolonesilver	O
has	O
a	O
structure	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
(	O
refer	O
to	O
the	O
Specification	O
)	O
.	O

Silver	O
ions	O
and	O
fluoroquinolone	O
are	O
combined	O
together	O
,	O
and	O
through	O
the	O
synergistic	O
effect	O
of	O
the	O
silver	O
ions	O
and	O
fluoroquinolone	O
,	O
the	O
antibacterial	O
effect	O
is	O
further	O
enhanced	O
,	O
and	O
the	O
problem	O
of	O
the	O
drug	O
resistance	O
of	O
the	O
existing	O
fluoroquinolone	O
drugs	O
can	O
be	O
solved	O
to	O
a	O
certain	O
degree	O
.	O

The	O
fluoroquinolonesilver	O
is	O
simple	O
in	O
preparation	O
process	O
,	O
and	O
stable	O
in	O
productivity	O
(	O
refer	O
to	O
the	O
Specification	O
for	O
the	O
formula	O
I	O
)	O
.	O

Substituted	O
imidazole-1-ethylene	O
compound	O
and	O
application	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
substituted	O
imidazole-1-ethylene	O
compound	O
as	O
well	O
as	O
a	O
preparation	O
and	O
an	O
application	O
thereof	O
.	O

The	O
substituted	O
imidazole-1-ethylene	O
compound	O
is	O
a	O
compound	O
shown	O
as	O
a	O
formula	O
I	O
,	O
or	O
salts	O
thereof	O
formed	O
with	O
medicinal	O
acids	O
or	O
bases	O
.	O

According	O
to	O
the	O
antifungal	O
activity	O
test	O
performed	O
on	O
eight	O
clinical	O
fungi	O
by	O
the	O
compound	O
provided	O
in	O
the	O
invention	O
,	O
a	O
good	O
fungus	O
killing	O
effect	O
is	O
achieved	O
.	O

The	O
compound	O
can	O
serve	O
as	O
a	O
novel	O
broad	O
-	O
spectrum	O
antifungal	O
activity	O
compound	O
and	O
is	O
developed	O
into	O
antifungal	O
medicines	O
,	O
disinfectants	O
or	O
feed	O
additives	O
.	O

Application	O
of	O
natural	O
medicinal	O
composition	O
in	O
preparing	O
anti	O
-	O
hypoxia	O
medicines	O
and	O
health	O
-	O
care	O
products	O
The	O
invention	O
provides	O
a	O
natural	O
medicinal	O
composition	O
beneficial	O
to	O
hypoxia	O
tolerance	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
asiaticoside	O
and	O
paeoniflorin	O
with	O
effects	O
of	O
anti	O
-	O
inflammation	O
anti	O
-	O
exudation	O
,	O
and	O
ginseng	O
saponin	O
and	O
total	O
saponins	O
of	O
dried	O
tangerine	O
peel	O
with	O
anti	O
-	O
ischemia	O
and	O
anti	O
-	O
hypoxia	O
effects	O
.	O

The	O
natural	O
medicinal	O
composition	O
is	O
clear	O
in	O
substances	O
and	O
controllable	O
in	O
quality	O
,	O
and	O
sufficiently	O
utilizes	O
the	O
synergetic	O
effect	O
of	O
each	O
component	O
.	O

Besides	O
consideration	O
on	O
anti	O
-	O
ischemia	O
and	O
anti	O
-	O
hypoxia	O
substances	O
,	O
the	O
prescription	O
of	O
the	O
natural	O
medicinal	O
composition	O
is	O
contributed	O
to	O
prevention	O
and	O
treatment	O
of	O
emergent	O
inflammatory	O
exudation	O
caused	O
by	O
ischemia	O
and	O
hypoxia	O
to	O
tissues	O
of	O
heart	O
and	O
cerebral	O
vessels	O
.	O

The	O
composition	O
can	O
be	O
used	O
for	O
preparing	O
oral	O
preparations	O
,	O
such	O
as	O
hard	O
capsules	O
,	O
tablets	O
,	O
granules	O
,	O
powder	O
,	O
pills	O
,	O
teabags	O
and	O
oral	O
solutions	O
,	O
and	O
can	O
be	O
used	O
in	O
Chinese	O
patent	O
medicines	O
or	O
health	O
-	O
care	O
foods	O
for	O
improving	O
hypoxia	O
tolerance	O
.	O

Ornidazole	O
paster	O
for	O
transluminal	O
administration	O
The	O
invention	O
provides	O
an	O
oidazole	O
paster	O
for	O
transluminal	O
administration	O
,	O
and	O
the	O
oidazole	O
paster	O
comprises	O
ornidazole	O
and	O
a	O
solid	O
water	O
-	O
soluble	O
matrix	O
.	O

The	O
solid	O
water	O
-	O
soluble	O
matrix	O
includes	O
carbopol	O
,	O
lactose	O
,	O
low	O
-	O
substituted	O
hydroxy	O
propyl	O
cellulose	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
.	O

A	O
preparation	O
method	O
of	O
the	O
oidazole	O
patch	O
comprises	O
the	O
following	O
steps	O
:	O
respectively	O
sieving	O
secnidazole	O
,	O
lactose	O
,	O
low	O
-	O
substituted	O
hydroxy	O
propyl	O
cellulose	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
in	O
the	O
prescription	O
dose	O
through	O
a	O
screen	O
of	O
80	O
mesh	O
,	O
mixing	O
well	O
,	O
adding	O
70	O
%	O
ethanol	O
for	O
granulation	O
,	O
drying	O
,	O
finishing	O
by	O
a	O
screen	O
of	O
30	O
mesh	O
,	O
adding	O
carbopol	O
,	O
magnesium	O
stearate	O
and	O
talcum	O
powder	O
,	O
which	O
are	O
sieved	O
through	O
a	O
screen	O
of	O
100	O
mesh	O
,	O
fully	O
mixing	O
and	O
tabletting	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
of	O
rapid	O
,	O
durable	O
and	O
reliable	O
effect	O
,	O
and	O
high	O
safety	O
;	O
at	O
the	O
same	O
time	O
,	O
the	O
local	O
administration	O
can	O
avoid	O
or	O
reduce	O
adverse	O
effects	O
of	O
systemic	O
administration	O
.	O

Application	O
of	O
3'-methoxy	O
benzyl-4-hydroxy-3,5-dimethoxy	O
-	O
benzoate	O
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
or	O
preventing	O
rheumatoid	O
arthritis	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
drugs	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
capable	O
of	O
inhibiting	O
proteasomes	O
and	O
preventing	O
and	O
treating	O
rheumatoid	O
arthritis	O
.	O

The	O
compound	O
has	O
the	O
molecular	O
structure	O
of	O
3'-methoxy	O
benzyl-4-hydroxy-3,5-dimethoxy	O
-	O
benzoate	O
.	O

The	O
compound	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
compound	O
can	O
be	O
used	O
for	O
treating	O
rheumatoid	O
arthritis	O
,	O
and	O
has	O
potential	O
new	O
drug	O
development	O
value	O
.	O

Preparation	O
containing	O
methimazole	O
and	O
its	O
preparing	O
method	O
A	O
slowly	O
-	O
releasing	O
thiazmazole	O
tablet	O
for	O
treating	O
thyroidism	O
is	O
disclosed	O
.	O

It	O
is	O
prepared	O
by	O
unique	O
slow	O
-	O
releasing	O
technique	O
,	O
that	O
is	O
using	O
high	O
molecular	O
material	O
to	O
wrap	O
the	O
medicine	O
.	O

Use	O
of	O
gossypol	O
and	O
its	O
derivative	O
in	O
preparation	O
of	O
drug	O
for	O
leukemia	O
/	O
bone	O
marrow	O
cancer	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
gossypol	O
and	O
its	O
derivative	O
in	O
preparation	O
of	O
drug	O
for	O
leukemia	O
/	O
bone	O
marrow	O
cancer	O
,	O
wherein	O
the	O
gossypol	O
has	O
the	O
constitutional	O
formula	O
disclosed	O
in	O
the	O
specification	O
,	O
the	O
gossypol	O
derivative	O
is	O
gossypol	O
acetate	O
or	O
formic	O
acid	O
gossypol	O
.	O

Freeze	O
-	O
drying	O
fluconazole	O
injection	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
discloses	O
a	O
freeze	O
-	O
drying	O
fluconazole	O
injection	O
and	O
its	O
preparation	O
method	O
which	O
comprises	O
,	O
charging	O
a	O
definite	O
quantity	O
of	O
supporting	O
agent	O
into	O
reactive	O
medicinal	O
Fluconazole	O
(	O
50	O
-	O
200	O
mg	O
per	O
bottle	O
)	O
,	O
adding	O
pH	O
modifier	O
,	O
solubilizing	O
agent	O
so	O
as	O
to	O
prepare	O
solution	O
of	O
a	O
finite	O
concentration	O
,	O
and	O
loading	O
for	O
freeze	O
drying	O
.	O

Antiviral	O
activity	O
possessed	O
compound	O
The	O
invention	O
provides	O
an	O
antiviral	O
activity	O
possessed	O
compound	O
,	O
in	O
particular	O
organic	O
ionic	O
compounds	O
with	O
antiviral	O
reactivity	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
,	O
and	O
the	O
external	O
antiviral	O
method	O
.	O

Dripping	O
pills	O
of	O
nefopam	O
hydrochloride	O
and	O
its	O
preparation	O
method	O
The	O
invention	O
relates	O
to	O
a	O
Nefopam	O
Hydrochloride	O
drop	O
pill	O
prepared	O
by	O
utilizing	O
ultramicro	O
disintegration	O
and	O
drop	O
pill	O
manufacturing	O
process	O
,	O
which	O
has	O
the	O
advantages	O
of	O
improving	O
collapse	O
and	O
dissolving	O
speed	O
,	O
quick	O
effect	O
,	O
increased	O
medicament	O
stability	O
,	O
reduced	O
adjuvant	O
consumption	O
,	O
lowered	O
production	O
costs	O
,	O
and	O
easiness	O
in	O
carrying	O
and	O
use	O
.	O

It	O
has	O
good	O
compliance	O
,	O
thus	O
is	O
especially	O
suitable	O
for	O
children	O
,	O
the	O
elderly	O
,	O
bedridden	O
patients	O
and	O
dysphagia	O
patients	O
.	O

Method	O
for	O
preparing	O
astragaloside	O
and	O
its	O
use	O
in	O
preparation	O
of	O
drug	O
for	O
preventing	O
and	O
treating	O
diabetic	O
nephropathy	O
The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
astragaloside	O
and	O
its	O
use	O
in	O
pharmacy	O
,	O
wherein	O
the	O
preparing	O
process	O
comprises	O
subjecting	O
the	O
astragalus	O
root	O
powder	O
to	O
ethanol	O
backflow	O
,	O
decompression	O
concentrating	O
with	O
the	O
inverse	O
flow	O
,	O
charging	O
NaOH	O
into	O
the	O
concentration	O
liquid	O
,	O
compressionalcohol	O
liquid	O
backflow	O
,	O
steaming	O
the	O
ethyl	O
alcohol	O
to	O
obtain	O
ethanol	O
hydrolysate	O
,	O
extracting	O
with	O
acetic	O
ester	O
,	O
washing	O
to	O
neutral	O
,	O
evaporating	O
to	O
dryness	O
,	O
obtaining	O
crude	O
saponin	O
,	O
charging	O
acetic	O
ester	O
,	O
stirring	O
in	O
water	O
-	O
bath	O
,	O
cooling	O
down	O
,	O
filtering	O
,	O
deposition	O
,	O
and	O
recrystallizing	O
with	O
methanol	O
.	O

Hydroxymethyl	O
coumarine	O
soft	O
capsule	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
relates	O
to	O
soft	O
hydroxymethyl	O
coumarine	O
capsule	O
and	O
its	O
preparation	O
process	O
.	O

The	O
soft	O
hydroxymethyl	O
coumarine	O
capsule	O
is	O
prepared	O
with	O
hydroxymethyl	O
coumarine	O
as	O
active	O
component	O
in	O
20	O
-	O
75	O
wt%	O
,	O
preferably	O
35	O
-	O
55	O
wt%	O
;	O
solvent	O
and	O
diluent	O
in	O
20	O
-	O
75	O
wt%	O
,	O
preferably	O
40	O
-	O
55	O
wt%	O
;	O
emulsifier	O
in	O
2	O
-	O
12	O
wt%	O
,	O
preferably	O
5	O
-	O
8	O
wt%	O
to	O
increase	O
the	O
solubility	O
of	O
hydroxymethyl	O
coumarine	O
in	O
animal	O
and	O
vegetable	O
oil	O
and	O
raise	O
its	O
stability	O
;	O
and	O
antioxidant	O
in	O
0.2	O
-	O
5	O
wt%	O
,	O
preferably	O
0.5	O
-	O
3	O
wt%	O
,	O
to	O
raise	O
the	O
antioxidant	O
performance	O
.	O

The	O
soft	O
capsule	O
shell	O
is	O
prepared	O
with	O
gelatin	O
,	O
glycerin	O
,	O
sorbic	O
alcohol	O
,	O
etc	O
.	O
and	O
contains	O
titania	O
in	O
0.2	O
-	O
1.2	O
wt%	O
,	O
preferably	O
0.5	O
-	O
0.7	O
wt%	O
,	O
as	O
light	O
screening	O
agent	O
.	O

Application	O
of	O
ursolic	O
acid	O
in	O
prepartation	O
of	O
anticancer	O
medicine	O
An	O
application	O
of	O
ursolic	O
acid	O
in	O
preparing	O
the	O
anticancer	O
medicine	O
for	O
treating	O
liver	O
cancer	O
,	O
breast	O
cancer	O
,	O
lymphomatosis	O
,	O
leukemia	O
,	O
etc	O
is	O
disclosed	O
.	O

Glycosyl	O
phthalic	O
imidine	O
compounds	O
with	O
anti	O
-	O
inflammatory	O
activity	O
The	O
invention	O
relates	O
to	O
N	O
-	O
glycosyl	O
(	O
substituted	O
)	O
phthalimide	O
compounds	O
having	O
the	O
structural	O
formula	O
disclosed	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
separate	O
halogen	O
,	O
hydroxy	O
,	O
substituted	O
C1-C10	O
alkyl	O
,	O
C1-C10	O
aryl	O
,	O
C2-C8	O
alkene	O
,	O
C1-C10	O
alkoxy	O
,	O
C1-C10	O
acyl	O
,	O
C1-C10	O
ester	O
,	O
C1-C10	O
carboxyl	O
,	O
nitro	O
,	O
amido	O
,	O
monoalkyl	O
amino	O
,	O
dialkyl	O
amido	O
,	O
cyano	O
,	O
sulfonyl	O
,	O
alkyl	O
sulfonyl	O
,	O
alkyl	O
,	O
sulfhydryl	O
,	O
A	O
is	O
various	O
substituted	O
or	O
nonsubstituted	O
glycosyl	O
residue	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
and	O
method	O
for	O
preparation	O
and	O
use	O
in	O
preparing	O
anti	O
-	O
inflammatory	O
medicament	O
.	O

Application	O
of	O
dihydromyricetrin	O
An	O
application	O
of	O
dihydromyricetin	O
in	O
preparing	O
the	O
antalgic	O
and	O
apophlegmatic	O
medicine	O
or	O
health	O
-	O
care	O
food	O
is	O
disclosed	O
.	O

Usage	O
of	O
glanthidine	O
,	O
total	O
alkali	O
extract	O
and	O
preparation	O
method	O
and	O
usage	O
thereof	O
The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
lycoramine	O
in	O
preparing	O
medicine	O
for	O
resisting	O
SARS	O
virus	O
,	O
total	O
lycoramine	O
extract	O
containing	O
lycoramine	O
and	O
its	O
preparation	O
process	O
,	O
use	O
in	O
preparing	O
medicine	O
for	O
resisting	O
SARS	O
virus	O
and	O
the	O
composition	O
therewith	O
.	O

Antiadhesion	O
protective	O
preparation	O
and	O
its	O
application	O
An	O
anti	O
-	O
adhesion	O
protector	O
used	O
for	O
preparing	O
the	O
anti	O
-	O
adhesion	O
medicine	O
for	O
the	O
veterinary	O
operation	O
is	O
prepared	O
from	O
dihydrated	O
terramycin	O
,	O
acenocoumarol	O
,	O
erucic	O
acid	O
,	O
adrenine	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
.	O

Powder	O
and	O
injection	O
preparation	O
of	O
new	O
houttuynine	O
sodium	O
bisulfite	O
and	O
preparation	O
method	O
A	O
powder	O
injection	O
of	O
sodium	O
neohouttuyfonate	O
is	O
prepared	O
from	O
the	O
sodium	O
neohouttuyfnoate	O
or	O
its	O
physiologically	O
acceptable	O
salt	O
and	O
the	O
phamacological	O
acceptable	O
auxiliary	O
for	O
injection	O
.	O

Paracetamol	O
Pseudoephedrine	O
desintegration	O
piece	O
and	O
preparation	O
method	O

An	O
oral	O
disintegrating	O
tablet	O
of	O
Shuangpuweima	O
is	O
prepared	O
from	O
acetylaminophenol	O
,	O
pseudoephedrine	O
hydrochloride	O
,	O
chlorpheniramine	O
,	O
disintegrant	O
,	O
filler	O
and	O
flavouring	O
.	O

Angelica	O
polysaccharide	O
and	O
its	O
preparation	O
and	O
use	O
The	O
invention	O
relates	O
to	O
a	O
Chinese	O
angelica	O
polysaccharide	O
,	O
which	O
is	O
made	O
in	O
the	O
following	O
way	O
:	O
dissolve	O
alcohol	O
deposit	O
of	O
Chinese	O
angelica	O
into	O
distilled	O
water	O
,	O
use	O
savage	O
method	O
to	O
more	O
the	O
protein	O
away	O
until	O
there	O
is	O
no	O
protein	O
absorption	O
peak	O
of	O
280	O
nm	O
by	O
ultraviolet	O
test	O
,	O
centrifugation	O
to	O
clear	O
the	O
deposit	O
;	O
keep	O
the	O
water	O
-	O
phase	O
and	O
add	O
into	O
alcohol	O
for	O
depositing	O
polysaccharide	O
,	O
abandon	O
the	O
supernatant	O
liquid	O
,	O
wash	O
the	O
deposit	O
by	O
alcohol	O
,	O
then	O
freeze	O
and	O
dry	O
it	O
,	O
through	O
gel	O
molecular	O
chromatography	O
,	O
accumulate	O
the	O
separated	O
product	O
with	O
the	O
relative	O
molecule	O
mass	O
between	O
10,000	O
-	O
110,000	O
,	O
then	O
freeze	O
and	O
dry	O
it	O
again	O
to	O
acquire	O
the	O
Chinese	O
angelica	O
polysaccharide	O
.	O

The	O
invention	O
has	O
remarkable	O
analgesia	O
for	O
ache	O
caused	O
by	O
chemicals	O
and	O
hot	O
simulation	O
;	O
as	O
well	O
as	O
dysmenorrheal	O
caused	O
by	O
female	O
hormone	O
;	O
and	O
it	O
can	O
be	O
made	O
into	O
drug	O
for	O
analgesia	O
especially	O
that	O
for	O
curing	O
dysmenorrheal	O
.	O

Use	O
of	O
rapamycin	O
in	O
preparation	O
of	O
intraocularly	O
embedded	O
drug	O
The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
rapamycin	O
(	O
RAPA	O
)	O
and	O
medicament	O
capable	O
of	O
self	O
-	O
degrading	O
in	O
preparing	O
eye	O
implantation	O
slow	O
release	O
medicament	O
,	O
the	O
medicament	O
can	O
keep	O
certain	O
reinforcement	O
and	O
shape	O
after	O
complete	O
release	O
,	O
and	O
can	O
be	O
naturally	O
degraded	O
under	O
internal	O
physiological	O
conditions	O
,	O
thus	O
can	O
be	O
absorbed	O
and	O
discharged	O
externally	O
through	O
metabolizing	O
,	O
and	O
no	O
secondary	O
surgery	O
is	O
needed	O
to	O
be	O
taken	O
out	O
.	O

The	O
invention	O
can	O
be	O
applied	O
to	O
the	O
repulsion	O
reaction	O
in	O
cornea	O
transplantation	O
for	O
treating	O
ophthalmology	O
diseases	O
.	O

Anti	O
cancer	O
gene	O
medicinal	O
composition	O
,	O
micromolecule	O
interfere	O
RNA	O
and	O
its	O
screening	O
method	O
The	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
composition	O
includes	O
antisense	O
fup1	O
gene	O
and/or	O
small	O
molecular	O
interfering	O
RNA	O
and	O
pharmaceutically	O
acceptable	O
supplementary	O
material	O
.	O

The	O
antisense	O
fup1	B
gene	O
has	O
the	O
DNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
2	O
in	O
the	O
sequence	O
list	O
,	O
while	O
the	O
small	O
molecular	O
interfering	O
RNA	O
includes	O
the	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
3	O
in	O
the	O
sequence	O
list	O
.	O

The	O
present	O
invention	O
also	O
provides	O
the	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
screening	O
method	O
to	O
design	O
small	O
molecular	O
interfering	O
RNA	O
based	O
on	O
fup1	O
encoding	O
area	O
via	O
adopting	O
ambion	O
web	O
site	O
provided	O
RNAi	O
design	O
software	O
.	O

The	O
present	O
invention	O
further	O
provides	O
liver	O
cancer	O
resisting	O
small	O
molecule	O
include	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
3	O
in	O
the	O
sequence	O
list	O
.	O

The	O
present	O
invention	O
adopts	O
gene	O
fup1	O
high	O
expressed	O
in	O
liver	O
cancer	O
cell	O
as	O
medicine	O
target	O
to	O
design	O
the	O
antagonistic	O
molecule	O
to	O
provide	O
powerful	O
measure	O
for	O
the	O
gene	O
treatment	O
of	O
liver	O
cancer	O
and	O
excellent	O
platform	O
for	O
further	O
screening	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
.	O

Ethylamine	O
thiourea	O
injection	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
an	O
ethylamine	O
thiourea	O
injection	O
and	O
preparation	O
method	O
,	O
wherein	O
the	O
main	O
medicinal	O
constituent	O
is	O
diaminoethylisothiuramium	O
hydrobromate	O
.	O

By	O
employing	O
the	O
two	O
methods	O
of	O
cushioning	O
liquid	O
and	O
anti	O
-	O
oxidant	O
,	O
the	O
problem	O
of	O
unstable	O
ethylamine	O
thiocarbamide	O
can	O
be	O
solved	O
effectively	O
.	O

The	O
injection	O
has	O
the	O
advantages	O
of	O
simple	O
process	O
for	O
manufacturing	O
and	O
stabilized	O
product	O
quality	O
.	O

New	O
action	O
and	O
application	O
of	O
methylene	O
blue	O
in	O
preventing	O
dental	O
caries	O
The	O
present	O
invention	O
relates	O
to	O
the	O
new	O
action	O
application	O
of	O
methylene	O
blue	O
in	O
preventing	O
dental	O
caries	O
.	O

Methylene	O
blue	O
is	O
used	O
as	O
effective	O
component	O
in	O
preparing	O
dental	O
caries	O
preventing	O
preparation	O
.	O

Method	O
for	O
preparing	O
hard	O
-	O
soluble	O
gel	O
formulation	O
The	O
present	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
insoluble	O
medicine	O
gel	O
preparation	O
.	O

The	O
physiological	O
active	O
substance	O
of	O
said	O
gel	O
preparation	O
is	O
insoluble	O
medicine	O
.	O

Its	O
preparation	O
method	O
is	O
characterized	O
by	O
that	O
the	O
ink	O
course	O
of	O
preparation	O
of	O
gel	O
a	O
hydrophilic	O
substance	O
is	O
added	O
so	O
as	O
to	O
raise	O
the	O
solubility	O
of	O
main	O
medicine	O
in	O
water	O
,	O
and	O
can	O
make	O
the	O
main	O
medicine	O
be	O
uniformly	O
diffused	O
in	O
the	O
gel	O
,	O
and	O
the	O
gel	O
stability	O
is	O
good	O
.	O

Use	O
of	O
chitin	O
,	O
chitinous	O
glycan	O
and	O
its	O
derivative	O
biomembrane	O
in	O
medicinal	O
preparation	O
for	O
treaing	O
colpitis	O
and	O
cervicitis	O
An	O
application	O
of	O
the	O
membrane	O
made	O
of	O
chitin	O
,	O
chitosan	O
,	O
or	O
their	O
derivatives	O
in	O
treating	O
vaginitis	O
and	O
cervicitis	O
is	O
disclosed	O
.	O

Said	O
membrane	O
may	O
be	O
replaced	O
by	O
fibrous	O
net	O
or	O
composite	O
material	O
.	O

Anti	O
-	O
cancer	O
analgetic	O
preparation	O
The	O
anticancer	O
analgetic	O
preparation	O
has	O
lappaconitine	O
and	O
vincristine	O
as	O
main	O
active	O
anticancer	O
components	O
.	O

Lappaconitine	O
has	O
the	O
effect	O
of	O
increasing	O
the	O
sensitivity	O
of	O
vincristine	O
in	O
killing	O
cancer	O
cell	O
,	O
so	O
that	O
the	O
preparation	O
of	O
the	O
present	O
invention	O
can	O
reverse	O
the	O
drug	O
resistance	O
of	O
tumor	O
.	O

The	O
present	O
invention	O
has	O
obvious	O
functions	O
of	O
resisting	O
liver	O
cancer	O
,	O
lung	O
cancer	O
,	O
cancer	O
of	O
uterus	O
and	O
breast	O
cancer	O
,	O
stopping	O
pain	O
,	O
etc	O
.	O
and	O
has	O
the	O
feature	O
of	O
less	O
recovery	O
of	O
the	O
blood	O
supply	O
to	O
embolized	O
tumor	O
artery	O
.	O

Compared	O
with	O
similar	O
medicines	O
,	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
less	O
side	O
effect	O
,	O
high	O
tumor	O
cell	O
killing	O
effect	O
,	O
high	O
stability	O
,	O
low	O
cost	O
,	O
etc	O
.	O

Use	O
of	O
pentacylic	O
triterpene	O
compounds	O
in	O
preparing	O
glycogenic	B
phosphorylase	I
inhibitor	O
The	O
present	O
invention	O
relates	O
to	O
application	O
of	O
pentacyclic	O
triterpene	O
compounds	O
in	O
preparing	O
glycogenic	B
phosphorylase	I
inhibitor	O
,	O
and	O
includes	O
the	O
application	O
of	O
medicine	O
composition	O
of	O
crataegolic	O
acid	O
,	O
Corosolic	O
acid	O
,	O
oleanolic	O
acid	O
,	O
ursolic	O
acid	O
,	O
betulin	O
,	O
betulic	O
acid	O
,	O
lupeol	O
or	O
their	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
in	O
preparing	O
medicine	O
for	O
treating	O
diabetes	O
.	O

Oral	O
emulsion	O
combination	O
of	O
'	O
Chuanhuning	O
'	O
An	O
orally	O
-	O
taken	O
composite	O
emulsion	O
of	O
Chuanhuning	O
is	O
prepared	O
from	O
Chuanhuning	O
,	O
surfactant	O
as	O
emulsifier	O
,	O
organic	O
solvent	O
as	O
coemulsifier	O
and	O
oil	O
.	O

It	O
has	O
higher	O
biologic	O
utilization	O
rate	O
.	O

Nanometer	O
preparation	O
of	O
silybin	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
provides	O
a	O
silybin	O
nano	O
medicinal	O
preparation	O
,	O
which	O
comprises	O
liposome	O
nano	O
particles	O
of	O
silybin	O
,	O
the	O
liposome	O
material	O
is	O
the	O
mixture	O
of	O
soya	O
bean	O
lecithin	O
,	O
vitamin	O
E	O
and	O
soyabean	O
oil	O
by	O
the	O
mass	O
ratio	O
of	O
1:2.5:12.5	O
-	O
1:15:24	O
,	O
the	O
mass	O
ratio	O
of	O
silybin	O
and	O
lipsome	O
material	O
is	O
1:32	O
-	O
1:400	O
,	O
the	O
grain	O
diameter	O
of	O
the	O
liposome	O
nano	O
particles	O
is	O
less	O
than	O
500	O
nanometer	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
preparing	O
process	O
of	O
the	O
preparation	O
.	O

Vaginal	O
tablet	O
with	O
clindamycin	O
and	O
metronidazole	O
The	O
invention	O
relates	O
to	O
a	O
vaginal	O
tablet	O
of	O
clindamycinum	O
and	O
metronidazole	O
,	O
which	O
uses	O
the	O
salts	O
or	O
esters	O
of	O
clindamycinum	O
and	O
metronidazole	O
as	O
the	O
active	O
constituents	O
,	O
and	O
the	O
conventional	O
tablets	O
as	O
the	O
auxiliary	O
material	O
.	O

Purple	O
bergenia	O
element	O
pentaacetylate	O
and	O
its	O
uses	O
The	O
invention	O
provides	O
a	O
Bergenini	O
penta	O
-	O
acetyl	O
,	O
whose	O
chemical	O
name	O
is	O
(	O
2R,3R,4R,4aS,10bS	O
)	O
-2-	O
(	O
acetoxymethyl	O
)	O
-9-methoxy-6-oxo-2,3,4,4a,6,10b	O
-	O
hexahydr	O
o	O
pyrano	O
[	O
3,2-c	O
]	O
isochromene-3,4,8,10-tetrayl	O
tetraacetate	O
,	O
and	O
is	O
prepared	O
from	O
Bergenini	O
as	O
lead	O
compound	O
through	O
butanoylation	O
reaction	O
,	O
the	O
hydroxyl	O
on	O
the	O
precursor	O
is	O
blocked	O
so	O
as	O
to	O
enhance	O
the	O
lipophilicity	O
.	O

The	O
Bergenini	O
penta	O
-	O
acetyl	O
can	O
be	O
used	O
for	O
preparing	O
medicine	O
for	O
relieving	O
cough	O
.	O

The	O
invention	O
further	O
provides	O
a	O
compound	O
preparation	O
containing	O
the	O
Bergenini	O
penta	O
-	O
acetyl	O
.	O

Azithromycin	O
gel	O
The	O
present	O
invention	O
relates	O
to	O
an	O
azithromycin	O
gel	O
.	O

Its	O
composition	O
includes	O
(	O
weight	O
portion	O
)	O
1	O
-	O
5	O
portions	O
of	O
azithromycin	O
,	O
0.5	O
-	O
10	O
portions	O
of	O
skeleton	O
materials	O
,	O
suchas	O
agar	O
and	O
arabic	O
gum	O
,	O
etc	O
.	O

capable	O
of	O
forming	O
gel	O
,	O
25	O
-	O
35	O
portions	O
of	O
sweetening	O
agent	O
and	O
80	O
-	O
120	O
portions	O
of	O
water	O
.	O

Ointment	O
medicine	O
for	O
treating	O
bedsore	O
The	O
present	O
invention	O
discloses	O
an	O
ointment	O
medicine	O
preparation	O
for	O
curing	O
bed	O
sore	O
with	O
obvious	O
therapeutic	O
effect	O
.	O

Its	O
raw	O
material	O
composition	O
includes	O
(	O
by	O
weight	O
portion	O
)	O
0.1	O
-	O
5	O
portions	O
of	O
berberine	O
,	O
20	O
-	O
40	O
portions	O
of	O
fluocinonide	O
ointment	O
,	O
0.1	O
-	O
5	O
portions	O
of	O
Yunnan	O
white	O
medicine	O
and	O
0.1	O
-	O
5	O
portions	O
of	O
sulfonamides	O
anti	O
-	O
inflammatory	O
powder	O
.	O

Soybean	O
isoflavone	O
soft	O
capsule	O
and	O
its	O
preparation	O
process	O
The	O
invention	O
discloses	O
a	O
soybean	O
isoflavone	O
soft	O
capsule	O
and	O
the	O
preparing	O
method	O
,	O
belonging	O
to	O
medical	O
field	O
,	O
with	O
the	O
technique	O
feature	O
being	O
:	O
the	O
material	O
in	O
the	O
capsule	O
comprising	O
soybean	O
isoflavone	O
,	O
phospholipid	O
,	O
calcium	O
salt	O
,	O
vitamin	O
,	O
anti	O
-	O
oxidant	O
,	O
capsule	O
stabilizing	O
agent	O
and	O
deflocculating	O
agent	O
,	O
the	O
capsule	O
shell	O
comprising	O
gelatine	O
,	O
plasticity	O
agent	O
,	O
conservative	O
,	O
hiding	O
agent	O
,	O
coloring	O
matter	O
,	O
corrective	O
and	O
water	O
.	O

The	O
soft	O
capsule	O
prepared	O
by	O
using	O
method	O
in	O
this	O
invention	O
is	O
characterized	O
by	O
the	O
stale	O
quality	O
,	O
safety	O
,	O
convenient	O
usage	O
,	O
ease	O
for	O
body	O
adsorption	O
,	O
and	O
high	O
bioavailability	O
,	O
and	O
particularly	O
be	O
used	O
for	O
regulating	O
the	O
estrogenic	O
hormones	O
for	O
menopausal	O
woman	O
,	O
and	O
for	O
preventing	O
and	O
treating	O
disease	O
relevant	O
with	O
estrogenic	O
hormones	O
.	O

Breviscapine	O
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O
The	O
invention	O
discloses	O
a	O
Breviscapine	O
oral	O
disintegrating	O
tablet	O
,	O
which	O
comprises	O
21.0	O
-	O
35.0	O
wt%	O
of	O
Breviscapine	O
,	O
11.0	O
-	O
15.0.0wt%	O
of	O
sodium	O
carboxymethylstarch	O
,	O
45.0	O
-	O
60.0	O
wt%	O
of	O
crystalline	O
cellulose	O
,	O
1.0	O
-	O
2.0	O
wt%	O
of	O
magnesium	O
stearate	O
,	O
5.0	O
-	O
10.0	O
wt%	O
of	O
miropowdered	O
silica	O
gel	O
,	O
and	O
0.1	O
-	O
0.5wt%	O
of	O
Aspartame	O
.	O

the	O
relative	O
weight	O
ratio	O
of	O
Breviscapine	O
and	O
sodium	O
carboxymethylstarch	O
is	O
1:0.3	O
-	O
1:0.7	O
.	O

Non	O
-	O
metal	O
salt	O
of	O
Glicididazole	O
and	O
its	O
prepn	O
The	O
present	O
invention	O
relates	O
to	O
non	O
-	O
metal	O
salt	O
compounds	O
of	O
glycididazole	O
,	O
including	O
ammonium	O
salt	O
of	O
glycididazole	O
,	O
diethylamine	O
double	O
salt	O
of	O
glycididazole	O
and	O
ethylene	O
diamine	O
double	O
salt	O
of	O
glycididazole	O
,	O
and	O
their	O
preparation	O
process	O
.	O

The	O
present	O
invention	O
provides	O
new	O
glycididazole	O
compounds	O
with	O
improved	O
water	O
solubility	O
and	O
stability	O
for	O
convenient	O
medicinal	O
application	O
.	O

In	O
addition	O
,	O
the	O
non	O
-	O
metal	O
salt	O
compounds	O
of	O
glycididazole	O
are	O
non	O
-	O
sodium	O
ion	O
salt	O
and	O
can	O
avoid	O
sodium	O
accumulation	O
and	O
other	O
bad	O
reaction	O
causing	O
electrolyte	O
metabolism	O
disorder	O
.	O

Stepronin	O
injection	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
is	O
new	O
preparation	O
form	O
of	O
Stepronin	O
,	O
especially	O
great	O
capacity	O
Stepronin	O
injection	O
,	O
and	O
its	O
preparation	O
process	O
.	O

The	O
injection	O
consists	O
of	O
Stepronin	O
or	O
its	O
metal	O
salt	O
or	O
amino	O
salt	O
as	O
active	O
component	O
and	O
medicinal	O
carrier	O
.	O

Compared	O
with	O
available	O
orally	O
taken	O
Stepronin	O
preparation	O
,	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
bioavailability	O
,	O
good	O
medicine	O
absorption	O
,	O
fast	O
medicine	O
dispersion	O
,	O
fast	O
acting	O
,	O
etc	O
.	O

The	O
present	O
invention	O
expands	O
the	O
administration	O
range	O
of	O
Stepronin	O
and	O
raises	O
the	O
clinical	O
administration	O
level	O
of	O
Stepronin	O
.	O

(	O
3R,4R	O
)	O
-trans-3,4-diarylchroman	O
derivatives	O
with	O
estrogenic	O
activity	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
substituents	O
R<2	O
>	O
and	O
R<3	O
>	O
are	O
arranged	O
in	O
trans	O
-	O
configuration	O
,	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
R<1	O
>	O
is	O
H	O
or	O
C1-C6	O
alkyl	O
;	O
C3-C7	O
cycloalkyl	O
;	O
R<2	O
>	O
is	O
phenyl	O
,	O
optionally	O
substituted	O
with	O
1	O
to	O
5	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
comprising	O
OH	O
,	O
C1-C6	O
-alkyl	O
,	O
halogen	O
,	O
nitro	O
,	O
cyano	O
,	O
SH	O
,	O
SR<4	O
>	O
,	O
trihalo	O
-	O
C1-C6-alkyl	O
,	O
C1-C6	O
-alkoxy	O
and	O
phenyl	O
,	O
wherein	O
R<4	O
>	O
is	O
C1-C6	O
alkyl;R<3	O
>	O
is	O
phenyl	O
substituted	O
with	O
OR<5	O
>	O
wherein	O
R<5	O
>	O
has	O
the	O
Formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
or	O
(	O
IV	O
)	O
,	O
wherein	O
Y	O
is	O
chosen	O
from	O
NHR<4	O
>	O
,	O
NR<4>2	O
,	O
NHCOR<4	O
>	O
,	O
NHSO2R<4	O
>	O
,	O
CONHR<4	O
>	O
,	O
CONR<4	O
>	O
,	O
CONR<4>2	O
,	O
COOH	O
,	O
COOR<4	O
>	O
,	O
SO2R<4	O
>	O
,	O
SOR<4	O
>	O
,	O
SONHR<4	O
>	O
,	O
SONR<4>2	O
,	O
a	O
C3-C7	O
heterocyclic	O
ring	O
,	O
saturated	O
or	O
unsaturated	O
,	O
containing	O
one	O
or	O
two	O
heteroatoms	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
O	O
,	O
S	O
and	O
N	O
,	O
optionally	O
being	O
substituted	O
with	O
1	O
to	O
3	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
comprising	O
H	O
,	O
OH	O
,	O
halogen	O
,	O
nitro	O
,	O
cyano	O
,	O
SH	O
,	O
SR<4	O
>	O
,	O
trihalo	O
-	O
C1-C6-	O
alkyl	O
,	O
C1-C6-alkyl	O
and	O
C1-C6	O
-alkoxy	O
,	O
preferably	O
NHR<4	O
>	O
,	O
NR2<4	O
>	O
,	O
or	O
a	O
nitrogen	O
heterocycle	O
,	O
wherein	O
R<4	O
>	O
is	O
as	O
defined	O
above	O
,	O
and	O
the	O
esters	O
,	O
ethers	O
,	O
and	O
salts	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
optionally	O
along	O
pharmaceutically	O
acceptable	O
excipients	O
,	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O
,	O
and	O
a	O
method	O
of	O
preventing	O
and/or	O
treating	O
estrogen	O
-	O
related	O
disease	O
conditions	O
in	O
a	O
subject	O
using	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
its	O
salts	O
,	O
optionally	O
along	O
with	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Tape	O
preparation	O
The	O
present	O
invention	O
provides	O
a	O
tape	O
preparation	O
including	O
a	O
support	O
and	O
an	O
adhesive	O
layer	O
directly	O
or	O
indirectly	O
formed	O
on	O
at	O
least	O
one	O
surface	O
of	O
the	O
support	O
,	O
wherein	O
the	O
adhesive	O
layer	O
contains	O
a	O
rubber	O
adhesive	O
containing	O
at	O
least	O
one	O
kind	O
of	O
rubber	O
polymer	O
and	O
capsaicin	O
as	O
an	O
active	O
ingredient	O
.	O

Since	O
the	O
adhesive	O
layer	O
shows	O
extremely	O
fine	O
adhesive	O
property	O
and	O
superior	O
capsaicin	O
releaseability	O
,	O
a	O
rapid	O
pharmacological	O
effect	O
can	O
be	O
afforded	O
with	O
a	O
small	O
capsaicin	O
content	O
.	O

Micro	O
-	O
powder	O
dom	O
peridone	O
maleate	O
medicinal	O
composition	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
relates	O
to	O
a	O
medicine	O
composition	O
with	O
domperidone	O
maleate	O
.	O

It	O
is	O
characterized	O
by	O
that	O
said	O
medicine	O
composition	O
is	O
micropowdered	O
,	O
and	O
can	O
be	O
used	O
for	O
invigorating	O
function	O
of	O
gastrointestinal	O
tract	O
and	O
curing	O
the	O
diseases	O
of	O
dyspepsia	O
and	O
nausea	O
-	O
vomiting	O
,	O
etc	O
.	O

Said	O
micropowdered	O
domperidone	O
maleate	O
preparation	O
can	O
raise	O
its	O
bioavailability	O
.	O

Besides	O
,	O
said	O
invention	O
also	O
provides	O
its	O
preparation	O
method	O
.	O

Compound	O
Silybum	O
drip	O
balls	O
and	O
preparation	O
thereof	O
A	O
dripping	O
pill	O
of	O
compound	O
silymarinum	O
is	O
prepared	O
from	O
the	O
silymarinum	O
and	O
the	O
alcohol	O
extract	O
of	O
5	O
kernels	O
through	O
proportionally	O
mixing	O
it	O
with	O
matrix	O
(	O
polyoxyvinyl	O
monostearate	O
)	O
,	O
heating	O
until	O
the	O
mixture	O
is	O
fused	O
,	O
stirring	O
,	O
and	O
dripping	O
in	O
condensing	O
liquid	O
.	O

Ganciclovir	O
ophthalmic	O
gel	O
and	O
its	O
prepn	O
.	O

method	O
An	O
eye	O
gel	O
of	O
Ganciclovir	O
for	O
treating	O
viral	O
keratitis	O
is	O
proportionally	O
prepared	O
from	O
ganciclovir	O
and	O
eye	O
gel	O
matrix	O
through	O
mixing	O
Ganciclovir	O
,	O
eye	O
gel	O
matrix	O
and	O
water	O
,	O
stirring	O
,	O
regulating	O
pH	O
value	O
,	O
adding	O
water	O
,	O
stirring	O
and	O
sterilizing	O
.	O

Soft	O
capsule	O
of	O
medication	O
composition	O
,	O
and	O
preparation	O
method	O
A	O
composite	O
medicine	O
in	O
the	O
form	O
of	O
softgel	O
is	O
prepared	O
from	O
domperidone	O
and	O
the	O
auxiliary	O
chosen	O
from	O
diluent	O
,	O
cosolvent	O
,	O
solubilizer	O
and	O
surfactant	O
.	O

It	O
has	O
high	O
stability	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Application	O
of	O
medication	O
composition	O
of	O
containing	O
acetamino	O
phenol	O
in	O
treating	O
insufficiency	O
of	O
blood	O
supply	O
for	O
brain	O
An	O
application	O
of	O
the	O
medicinal	O
composition	O
containing	O
paracetamol	O
,	O
propylphenazone	O
and	O
caffeine	O
in	O
treating	O
cerebral	O
ischemia	O
is	O
disclosed	O
.	O

Method	O
for	O
preparing	O
rhubarb	O
sulfur	O
gel	O
agent	O
The	O
invention	O
relates	O
to	O
the	O
process	O
for	O
preparing	O
gelling	O
agent	O
of	O
rhubarb	O
horsetails	O
and	O
sulfur	O
by	O
using	O
free	O
anthraquinone	O
of	O
rhubarb	O
horsetails	O
extract	O
and	O
sulfur	O
as	O
the	O
main	O
constituents	O
,	O
using	O
carbomer	O
as	O
the	O
gel	O
matrix	O
,	O
and	O
using	O
methyl	O
ethylene	O
glycol	O
and	O
urea	O
as	O
the	O
mixed	O
transdermal	O
accelerating	O
agent	O
.	O

The	O
preparation	O
can	O
be	O
used	O
for	O
treating	O
acne	O
.	O

An	O
externally	O
applied	O
medicine	O
for	O
treating	O
hicismus	O
by	O
use	O
of	O
steatite	O
Disclosed	O
is	O
an	O
externally	O
used	O
medicament	O
for	O
treating	O
tragomaschalia	O
,	O
which	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
:	O
talcum	O
powder	O
,	O
goldthread	O
root	O
,	O
dandelion	O
,	O
gypsum	O
,	O
camphor	O
,	O
perfume	O
compound	O
and	O
ethanol	O
.	O

Compound	O
medicine	O
composition	O
and	O
its	O
prepn	O
and	O
use	O
The	O
present	O
invention	O
relates	O
to	O
one	O
kind	O
of	O
veterinary	O
medicine	O
composition	O
for	O
eliminating	O
fever	O
,	O
relieving	O
pain	O
and	O
diminishing	O
inflammation	O
and	O
its	O
preparation	O
process	O
and	O
use	O
.	O

The	O
veterinary	O
medicine	O
composition	O
consists	O
of	O
diclofenac	O
sodium	O
and	O
naproxen	O
in	O
the	O
weight	O
ratio	O
of	O
0.1	O
-	O
10	O
,	O
preferably	O
0.2	O
-	O
5	O
;	O
or	O
consists	O
of	O
diclofenac	O
sodium	O
and	O
barbitone	O
in	O
the	O
weight	O
ratio	O
of	O
0.2	O
-	O
10	O
,	O
preferably1	O
-	O
7.5	O
.	O

The	O
veterinary	O
medicine	O
composition	O
is	O
used	O
in	O
preventing	O
and	O
treating	O
feverish	O
animal	O
diseases	O
and	O
has	O
synergistic	O
fever	O
eliminating	O
effect	O
,	O
fast	O
acting	O
and	O
less	O
recurrence	O
.	O

Sobering	O
-	O
up	O
beverage	O
A	O
sobering	O
-	O
up	O
beverage	O
is	O
proportionally	O
prepared	O
from	O
8	O
raw	O
materials	O
including	O
purified	O
water	O
,	O
pear	O
juice	O
,	O
pueraria	O
root	O
(	O
or	O
flower	O
)	O
,	O
ginsenoside	O
Rg3	O
,	O
rebescensine	O
A	O
,	O
isoliquiritigenin	O
,	O
etc	O
.	O

Chlorhydric	O
acid	O
tranditerol	O
aerosol	O
The	O
invention	O
provides	O
a	O
Tranditerol	O
Hydrochloride	O
aerosol	O
,	O
which	O
comprises	O
(	O
by	O
weight	O
ratio	O
)	O

Tranditerol	O
Hydrochloride	O
0.005	O
-	O
0.01	O
part	O
,	O
double	O
solvent	O
5	O
-	O
10	O
parts	O
,	O
and	O
propellant	O
90	O
-	O
95	O
parts	O
.	O

Preparation	O
method	O
of	O
dexibuprofen	O
amino	O
acid	O
salt	O
and	O
application	O
The	O
invention	O
discloses	O
a	O
nalorphine	O
amino	O
compound	O
and	O
preparing	O
method	O
with	O
structural	O
formula	O
as	O
(	O
I	O
)	O
,	O
wherein	O
the	O
amino	O
can	O
be	O
Arg	O
,	O
Lys	O
or	O
His	O
;	O
the	O
molecular	O
rate	O
of	O
nalorphine	O
and	O
amino	O
is	O
1:1	O
-	O
1	O
:	O
5	O
or	O
5:1	O
-	O
1:1	O
.	O

Nifuratel	O
-	O
nystatin	O
vaginal	O
effervescent	O
-	O
tablets	O
The	O
invention	O
relates	O
to	O
a	O
nifungin	O
-	O
canstat	O
vagina	O
effervescent	O
tablet	O
.	O

Wherein	O
,	O
it	O
uses	O
nifungin	O
and	O
canstat	O
,	O
with	O
acid	O
-	O
alkali	O
adding	O
system	O
,	O
and	O
stuff	O
or	O
directly	O
being	O
compressed	O
into	O
tablet	O
or	O
particles	O
then	O
to	O
be	O
compressed	O
into	O
tablet	O
,	O
or	O
uses	O
macrogol	O
to	O
cover	O
the	O
alkali	O
,	O
then	O
to	O
be	O
compressed	O
into	O
tablet	O
.	O

The	O
invention	O
uses	O
the	O
acid	O
alkali	O
system	O
which	O
will	O
generate	O
carbon	O
dioxide	O
gas	O
when	O
meeting	O
water	O
as	O
slaking	O
agent	O
;	O
therefore	O
,	O
the	O
tablet	O
will	O
foam	O
and	O
slake	O
when	O
adsorbs	O
water	O
in	O
vagina	O
,	O
to	O
disperse	O
the	O
elements	O
into	O
vagina	O
completely	O
,	O
as	O
uterine	O
cervix	O
,	O
etc	O
.	O

Aromatic	O
reductive	O
derivative	O
of	O
geldanamycin	O
benzoquinone	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
geldanamycin	O
type	O
aromatic	O
reduced	O
benzoquinone	O
derivative	O
and	O
its	O
preparation	O
process	O
as	O
well	O
as	O
the	O
medicine	O
composition	O
with	O
the	O
compound	O
as	O
active	O
component	O
and	O
its	O
use	O
.	O

The	O
compound	O
is	O
prepared	O
through	O
fermentation	O
with	O
,	O
say	O
,	O
pseudostreptoverticillium	O
,	O
and	O
it	O
is	O
proved	O
experimentally	O
that	O
the	O
compound	O
may	O
be	O
used	O
in	O
preparing	O
cell	O
period	O
inhibitor	O
and	O
antitumor	O
preparation	O
.	O

Stomatocase	O
treating	O
medicine	O
The	O
stomatocase	O
treating	O
medicine	O
is	O
prepared	O
with	O
five	O
kinds	O
of	O
main	O
materials	O
,	O
including	O
gypsum	O
,	O
cape	O
jasmine	O
,	O
reed	O
rhizome	O
,	O
mint	O
and	O
anemarrhena	O
rhizome	O
,	O
and	O
six	O
kinds	O
of	O
supplementary	O
medicine	O
materials	O
,	O
including	O
rehmannia	O
root	O
,	O
skullcap	O
root	O
,	O
etc	O
.	O

The	O
present	O
invention	O
has	O
unique	O
recipe	O
,	O
obvious	O
treating	O
effect	O
and	O
fast	O
acting	O
.	O

Pediatric	O
paracetamol	O
artifical	O
low	O
-	O
bezoar	O
and	O
chlorphenzmine	O
maleategel	O
preparation	O
and	O
its	O
preparing	O
method	O
The	O
present	O
invention	O
relates	O
to	O
a	O
Xiaoer	O
anfenhuangnamin	O
gel	O
preparation	O
for	O
children	O
and	O
its	O
preparation	O
method	O
.	O

Said	O
gel	O
preparation	O
composition	O
contains	O
(	O
by	O
wt%	O
)	O
0.05	O
-	O
30	O
%	O
of	O
acetaminophen	O
,	O
0.005	O
-	O
1	O
%	O
of	O
artificial	O
cow	O
-	O
bezoare	O
,	O
0.0005	O
-	O
0.08	O
%	O
of	O
chlorpheamine	O
maleate	O
,	O
0.2	O
-	O
10	O
%	O
of	O
agar	O
,	O
1	O
-	O
20	O
%	O
of	O
cane	O
sugar	O
,	O
1	O
-	O
10	O
%	O
of	O
cyclodextrin	O
and	O
45	O
-	O
90	O
%	O
of	O
water	O
.	O

Pharmaceutical	O
use	O
of	O
ent	O
-	O
eudesmane	O
alcohol	O
type	O
sesquiterpene	O
for	O
inhibiting	O
hepatitis	O
virus	O
The	O
invention	O
relates	O
to	O
an	O
enantiomorphic	O
amine	O
alkyl	O
sesquiterpene	O
alcohol	O
and	O
glucoside	O
and	O
the	O
medicated	O
salt	O
or	O
solvent	O
thereof	O
,	O
as	O
well	O
as	O
the	O
effect	O
and	O
activity	O
of	O
the	O
composed	O
medicine	O
combination	O
,	O
mainly	O
relating	O
to	O
the	O
medical	O
use	O
in	O
reducing	O
HBV	O
-	O
DNA	O
replication	O
activity	O
.	O

And	O
it	O
has	O
considerably	O
strong	O
inhibiting	O
effect	O
on	O
HBsAG	O
screted	O
by	O
HepG2.2.15	O
and	O
HBV	O
-	O
DNA	O
replication	O
as	O
compared	O
with	O
positive	O
contrast	O
Lamivudine	O
;	O
and	O
it	O
has	O
obvious	O
inhibition	O
activity	O
to	O
HBV	O
-	O
DNA	O
replication	O
at	O
large	O
dosage	O
(	O
100	O
mug	O
/	O
mL	O
)	O
and	O
medium	O
dosage	O
(	O
20	O
mug	O
/	O
mL	O
)	O
as	O
contrasted	O
with	O
Lamivudine	O
,	O
and	O
can	O
be	O
expected	O
to	O
apply	O
to	O
preparing	O
medicines	O
for	O
curing	O
HB	O
virus	O
infection	O
disease	O
.	O

Medical	O
usage	O
of	O
milkvetch	O
-	O
root	O
methcoside	O
An	O
application	O
of	O
astragaloside	O
A	O
in	O
preventing	O
and	O
treating	O
acute	O
or	O
chronic	O
nephritis	O
and	O
acute	O
or	O
chronic	O
renal	O
failure	O
,	O
its	O
preparing	O
process	O
,	O
and	O
its	O
medical	O
composition	O
are	O
disclosed	O
.	O

Fat	O
emulsion	O
injection	O
liquid	O
containing	O
soybean	O
oil	O
,	O
medium	O
chain	O
triglyceride	O
,	O
olive	O
oil	O
and	O
fish	O
oil	O
and	O
method	O
for	O
preparing	O
the	O
same	O
The	O
invention	O
relates	O
to	O
an	O
intralipid	O
injection	O
which	O
contains	O
soya	O
oil	O
,	O
middle	O
chain	O
triglyceride	O
,	O
olive	O
oil	O
,	O
and	O
fish	O
oil	O
,	O
wherein	O
it	O
comprises	O
48	O
-	O
72	O
g	O
.	O

L	O
soya	O
oil	O
,	O
48	O
-	O
72g	O
/	O
L	O
middle	O
chain	O
triglyceride	O
,	O
40	O
-	O
60g	O
/	O
L	O
olive	O
oil	O
,	O
and	O
24	O
-	O
36g	O
/	O
L	O
fish	O
oil	O
,	O
108	O
-	O
162	O
mg	O
/	O
L	O
dl	O
-	O
alpha	O
-	O
tocofecol	O
,	O
9.6	O
-	O
14.4g	O
/	O
L	O
lipovitellin	O
,	O
22.5	O
-	O
27.5g	O
/	O
L	O
pure	O
glycerin	O
,	O
240	O
-	O
360mg	O
/	O
L	O
sodium	O
oleate	O
,	O
18	O
-	O
22mg	O
/	O
L	O
caustic	O
soda	O
,	O
and	O
1L	O
injection	O
water	O
.	O

The	O
ratio	O
between	O
w-6	O
and	O
w-3	O
aliphatic	O
acid	O
is	O
3.0	O
-	O
2.2:1	O
.	O

The	O
invention	O
optimizes	O
and	O
balances	O
the	O
aliphatic	O
acid	O
mode	O
.	O

Medicament	O
for	O
harmonizing	O
middle	O
energizer	O
,	O
invigorating	O
spleen	O
and	O
regulating	O
stomach	O
function	O
The	O
invention	O
relates	O
to	O
a	O
medicament	O
for	O
spleen	O
-	O
reinforcing	O
and	O
digestion	O
-	O
promoting	O
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
medicament	O
comprises	O
(	O
by	O
weight	O
ratio	O
)	O
wrinkled	O
giant	O
hyssop	O
3	O
-	O
8	O
,	O
cape	O
jasmine	O
2	O
-	O
5	O
,	O
calcium	O
sulphate	O
3	O
-	O
8	O
,	O
licorice	O
root	O
5	O
-	O
10	O
,	O
ledebouriella	O
root	O
10	O
-	O
20	O
,	O
ginseng	O
3	O
-	O
8	O
,	O
poria	O
cocos	O
wolf	O
2	O
-	O
5	O
,	O
white	O
atractylodes	O
rhizome	O
2	O
-	O
5	O
,	O
dried	O
orange	O
peel	O
2	O
-	O
5	O
,	O
cardamorn	O
0.1	O
-	O
0.2	O
,	O
clove	O
0.1	O
-	O
0.2	O
,	O
sulfur	O
flour	O
0.1	O
-	O
0.2	O
and	O
talcum	O
powder	O
0.3	O
-	O
0.8	O
.	O

Largngopharyngitis	O
treating	O
medicine	O
composition	O
and	O
its	O
preparation	O
The	O
medicine	O
composition	O
for	O
treating	O
laryngopharyngitis	O
is	O
prepared	O
with	O
rehmannia	O
root	O
5	O
-	O
100	O
weight	O
portions	O
,	O
date	O
coating	O
3	O
-	O
100	O
weight	O
portions	O
,	O
and	O
tortoise	O
plastron	O
5	O
-	O
200	O
weight	O
portions	O
.	O

The	O
preparation	O
process	O
includes	O
the	O
steps	O
of	O
decoction	O
,	O
filtering	O
,	O
concentrating	O
the	O
filtrate	O
to	O
obtain	O
paste	O
of	O
density	O
1.00	O
-	O
1.15	O
,	O
dissolving	O
the	O
paste	O
in	O
alcohol	O
,	O
filtering	O
,	O
concentrating	O
the	O
filtrate	O
toobtain	O
dense	O
paste	O
of	O
density	O
1.20	O
-	O
1.50	O
while	O
recovering	O
alcohol	O
,	O
and	O
drying	O
to	O
obtain	O
the	O
medicine	O
composition	O
.	O

The	O
medicine	O
composition	O
is	O
used	O
in	O
treating	O
laryngopharyngitis	O
,	O
and	O
has	O
high	O
safety	O
,	O
low	O
cost	O
,	O
high	O
effective	O
component	O
content	O
and	O
high	O
stability	O
.	O

Medicament	O
composition	O
of	O
cefpodoxime	O
proxetil	O
and	O
cyclodextrin	O
and	O
preparation	O
method	O
thereof	O
A	O
medication	O
compound	O
,	O
which	O
include	O
cyclodextrin	O
and	O
cephalosporin	O
ester	O
's	O
clathrate	O
;	O
this	O
invention	O
alao	O
related	O
to	O
the	O
method	O
to	O
produce	O
it	O
.	O

Cerumen	O
softening	O
agent	O
The	O
invention	O
relates	O
to	O
a	O
solvent	O
for	O
softening	O
ear	O
wax	O
,	O
which	O
is	O
prepared	O
from	O
compositions	O
of	O
sodium	O
hydrogen	O
carbonate	O
,	O
water	O
and	O
glycerine	O
through	O
specific	O
processes	O
.	O

The	O
medicament	O
provided	O
by	O
the	O
invention	O
has	O
good	O
effect	O
in	O
softening	O
ear	O
wax	O
,	O
and	O
easy	O
accessibility	O
of	O
raw	O
material	O
.	O

4-methyl	O
cyclopentadecanone	O
and	O
its	O
uses	O
The	O
invention	O
discloses	O
an	O
application	O
of	O
4-methyl	O
cyclopentadecanone	O
in	O
the	O
drug	O
of	O
ischemic	O
cerebrovascular	O
disease	O
,	O
which	O
also	O
treats	O
antirheumatic	O
,	O
rheumatoid	O
disease	O
as	O
well	O
as	O
prevent	O
tumour	O
.	O

Bra	O
technical	O
structure	O
The	O
utility	O
model	O
relates	O
to	O
a	O
bra	O
technical	O
structure	O
simple	O
in	O
structure	O
and	O
convenient	O
for	O
the	O
use	O
of	O
a	O
bra	O
or	O
bra	O
pads	O
filled	O
with	O
medicine	O
,	O
wherein	O
hollow	O
protection	O
layers	O
in	O
contact	O
with	O
the	O
breasts	O
are	O
arranged	O
on	O
the	O
bra	O
or	O
the	O
bra	O
pads	O
,	O
and	O
openings	O
corresponding	O
to	O
the	O
breasts	O
are	O
formed	O
on	O
the	O
two	O
protection	O
layers	O
;	O
medicine	O
materials	O
are	O
arranged	O
in	O
the	O
protective	O
layers	O
after	O
being	O
wrapped	O
by	O
soft	O
and	O
air	O
permeable	O
cloths	O
,	O
so	O
as	O
to	O
permeate	O
through	O
the	O
breasts	O
through	O
the	O
contact	O
between	O
the	O
openings	O
on	O
the	O
protective	O
layers	O
and	O
the	O
breast	O
skins	O
;	O
by	O
wearing	O
the	O
bra	O
,	O
the	O
skin	O
-	O
permeation	O
of	O
the	O
medicine	O
can	O
stimulate	O
the	O
hormone	O
to	O
secrete	O
,	O
and	O
can	O
preserve	O
the	O
excellent	O
shapes	O
of	O
the	O
breasts	O
;	O
in	O
addition	O
,	O
as	O
the	O
medicine	O
has	O
the	O
functions	O
of	O
anti	O
-	O
inflammatory	O
detumescence	O
and	O
blood	O
circulation	O
improvement	O
,	O
the	O
translucency	O
of	O
the	O
breasts	O
can	O
be	O
enhanced	O
,	O
the	O
lump	O
shadow	O
is	O
lessened	O
,	O
and	O
the	O
vascularity	O
gradually	O
becomes	O
normal	O
,	O
and	O
therefore	O
the	O
purposes	O
of	O
health	O
care	O
,	O
breast	O
enlarging	O
and	O
breast	O
rounding	O
and	O
firming	O
are	O
achieved	O
.	O

Drug	O
delivery	O
plaster	O
for	O
reduction	O
of	O
bleeding	O
amount	O
in	O
operation	O
In	O
order	O
to	O
solve	O
the	O
technical	O
problem	O
existing	O
in	O
the	O
process	O
of	O
delivering	O
the	O
drug	O
to	O
the	O
skin	O
for	O
reduction	O
of	O
bleeding	O
amount	O
when	O
an	O
operation	O
is	O
performed	O
at	O
present	O
,	O
the	O
utility	O
model	O
relates	O
to	O
medical	O
supplies	O
,	O
and	O
provides	O
a	O
drug	O
delivery	O
plaster	O
for	O
reduction	O
of	O
the	O
bleeding	O
amount	O
in	O
an	O
operation	O
.	O

The	O
drug	O
delivery	O
plaster	O
comprises	O
a	O
plaster	O
body	O
,	O
and	O
is	O
characterized	O
in	O
that	O
the	O
plaster	O
body	O
is	O
formed	O
by	O
three	O
layers	O
,	O
wherein	O
the	O
surface	O
layer	O
is	O
a	O
bonding	O
layer	O
with	O
viscosity	O
,	O
and	O
a	O
plurality	O
of	O
drug	O
delivery	O
holes	O
are	O
formed	O
in	O
the	O
bonding	O
layer	O
,	O
the	O
intermediate	O
layer	O
is	O
a	O
drug	O
layer	O
,	O
the	O
bottom	O
layer	O
is	O
a	O
heating	O
layer	O
,	O
and	O
heater	O
strips	O
are	O
arranged	O
in	O
the	O
heating	O
layer	O
;	O
a	O
power	O
interface	O
connected	O
with	O
an	O
external	O
power	O
supply	O
is	O
arranged	O
in	O
the	O
bottom	O
surface	O
of	O
the	O
bottom	O
layer	O
.	O

The	O
drug	O
delivery	O
plaster	O
is	O
reasonable	O
in	O
structure	O
,	O
convenient	O
to	O
use	O
and	O
high	O
in	O
drug	O
delivery	O
efficiency	O
,	O
and	O
can	O
be	O
widely	O
applied	O
to	O
surgical	O
operations	O
.	O

New	O
piperazine	O
salt	O
of	O
omeprazol	O
is	O
proton	B
pump	I
inhibitor	O
useful	O
to	O
prevent	O
/	O
treat	O
e.g.	O
peptic	O
ulcer	O
,	O
gastritis	O
,	O
gastroesophageal	O
reflux	O
,	O
acute	O
stress	O
ulcer	O
or	O
dyspepsia	O
Piperazine	O
salt	O
(	O
I	O
)	O
of	O
omeprazole	O
or	O
its	O
enantiomer	O
is	O
new	O
.	O

An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
the	O
preparation	O
of	O
(	O
I	O
)	O
.	O

-	O
ACTIVITY	O
:	O
Gastrointestinal	O
-	O
Gen	O
.	O
;	O
Antiulcer	O
;	O
Antiinflammatory	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Proton	O
pump	O
inhibitor	O
.	O

No	O
biological	O
data	O
given	O
.	O

Composition	O
for	O
topical	O
application	O
,	O
useful	O
as	O
a	O
cosmetic	O
or	O
dermatological	O
product	O
,	O
contains	O
finely	O
divided	O
barium	O
sulfate	O
Composition	O
for	O
topical	O
application	O
contains	O
barium	O
sulfate	O
with	O
a	O
particle	O
size	O
of	O
1	O
-	O
30	O
mu	O
m.	O
An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
preparing	O
a	O
composition	O
as	O
above	O
by	O
adding	O
barium	O
sulfate	O
to	O
known	O
ingredients	O
of	O
conventional	O
cosmetic	O
products	O
.	O

Cosmetic	O
or	O
dermatological	O
preparations	O
for	O
skin	O
care	O
and	O
cleaning	O
,	O
containing	O
apiogalacturonan	O
compounds	O
or	O
extracts	O
thereof	O
from	O
seaweed	O
,	O
together	O
with	O
emulsifiers	O
Preparations	O
containing	O
one	O
or	O
more	O
apiogalacturonans	O
(	O
I	O
)	O
or	O
extract	O
(	O
s	O
)	O
of	O
(	O
I	O
)	O
from	O
Zostera	O
marina	O
and	O
also	O
one	O
or	O
more	O
emulsifiers	O
.	O

Cosmetic	O
or	O
dermatological	O
preparations	O
for	O
skin	O
care	O
,	O
protection	O
and	O
cleaning	O
,	O
containing	O
apiogalacturonan	O
compounds	O
or	O
extracts	O
thereof	O
from	O
seaweed	O
,	O
together	O
with	O
UV	O
light	O
absorbers	O
Preparations	O
containing	O
one	O
or	O
more	O
apiogalacturonans	O
(	O
I	O
)	O
or	O
extract	O
(	O
s	O
)	O
of	O
(	O
I	O
)	O
from	O
Zostera	O
marina	O
and	O
also	O
one	O
or	O
more	O
UV	O
light	O
absorbers	O
.	O

Veterinary	O
rehydration	O
product	O
A	O
composition	O
for	O
the	O
treatment	O
of	O
livestock	O
suffering	O
from	O
disorders	O
such	O
as	O
fluid	O
depletion	O
,	O
acidosis	O
,	O
and	O
imbalances	O
or	O
loss	O
of	O
essential	O
electrolytes	O
,	O
same	O
to	O
be	O
made	O
up	O
in	O
water	O
at	O
point	O
of	O
use	O
as	O
an	O
oral	O
rehydration	O
formulation	O
,	O
comprises	O
an	O
intimate	O
mixture	O
of	O
an	O
energy	O
source	O
,	O
electrolytes	O
,	O
and	O
bicarbonate	O
precursors	O
,	O
which	O
precursors	O
are	O
provided	O
as	O
physiologically	O
acceptable	O
carboxylic	O
acid	O
anions	O
with	O
corresponding	O
physiologically	O
acceptable	O
cations	O
including	O
sodium	O
,	O
the	O
yield	O
of	O
bicarbonate	O
being	O
in	O
excess	O
of	O
30	O
millimole	O
/	O
litre	O
(	O
mmol	O
/	O
1	O
)	O
of	O
final	O
formulation	O
,	O
and	O
the	O
concentration	O
of	O
sodium	O
being	O
in	O
excess	O
of	O
80	O
mmol	O
/	O
1	O
of	O
final	O
formulation	O
.	O

[	O
a	O
]	O
-ANNELATED	O
PYRROLE	O
DERIVATIVES	O
AND	O
PHARMACEUTICAL	O
USES	O

THEREOF	O
The	O
present	O
invention	O
concerns	O
heterocyclic	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1-R7	O
,	O
B	O
,	O
a	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
.	O

These	O
compounds	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
rheumatic	O
ailments	O
and	O
for	O
the	O
prevention	O
of	O
allergic	O
illnesses	O
.	O

Method	O
for	O
inhibiting	O
adenylosuccinate	B
synthetase	I
activity	O
methylthioadenosine	B
phosphorylase	I
deficient	O
cells	O
An	O
in	O
vivo	O
method	O
for	O
depleting	O
mammalian	O
cells	O
of	O
adenosine	O
5'-monophosphate	O
(	O
AMP	O
)	O
useful	O
in	O
the	O
treatment	O
of	O
certain	O
cancers	O
is	O
provided	O
.	O

According	O
to	O
the	O
method	O
,	O
a	O
population	O
of	O
cells	O
is	O
obtained	O
from	O
a	O
host	O
and	O
assayed	O
for	O
loss	O
of	O
methylthioadenosine	B
phosphorylase	I
(	O
MTAse	B
)	O
activity	O
.	O

MTAse	B
catabolizes	O
methylthioadenosine	O
to	O
adenine	O
for	O
endogenous	O
salvage	O
incorporation	O
into	O
the	O
intracellular	O
AMP	O
pool	O
.	O

The	O
preferred	O
method	O
for	O
assaying	O
loss	O
of	O
MTAse	B
activity	O
is	O
a	O
hybridization	O
technique	O
for	O
detection	O
of	O
a	O
homozygous	O
loss	O
of	O
the	O
gene	O
which	O
encodes	O
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
which	O
inhibits	O
the	O
activity	O
of	O
adenylsuccinate	B
synthetase	I
,	O
which	O
converts	O
inosine	O
5'-monophosphate	O
to	O
AMP	O
,	O
thus	O
depleting	O
the	O
tumor	O
cells	O
of	O
substrates	O
for	O
de	O
novo	O
AMP	O
production	O
.	O

L	O
-	O
alanosine	O
is	O
the	O
preferred	O
ASS	B
inhibitory	O
agent	O
for	O
use	O
in	O
the	O
method	O
of	O
the	O
invention	O
.	O

The	O
figure	O
is	O
a	O
nucleotide	O
sequence	O
for	O
genomic	O
MTAse	O
(	O
SEQ	O
.	O
ID	O
.	O

No.	O
1	O
)	O
wherein	O
the	O
exons	O
are	O
underlined	O
.	O

Use	O
of	O
nk-1	B
receptor	I
antagonists	O
for	O
treating	O
major	O
depressive	O
disorders	O
with	O
anxiety	O
The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
an	O
orally	O
active	O
,	O
long	O
acting	O
,	O
CNS	O
-	O
penetrant	O
NK-1	B
receptor	I
antagonist	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
adapted	O
for	O
oral	O
administration	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
major	O
depressive	O
disorder	O
with	O
anxiety	O
without	O
concomitant	O
therapy	O
with	O
other	O
anti	O
-	O
depressant	O
or	O
anti	O
-	O
anxiety	O
agents	O
,	O
methods	O
of	O
treatment	O
using	O
such	O
a	O
NK-1	B
receptor	I
antagonist	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
.	O

Method	O
for	O
antagonizing	O
HEREGUlin	O
or	O
its	O
receptor	O
and	O
use	O
for	O
the	O
inhibition	O
of	O
cancer	O
cells	O
The	O
invention	O
provides	O
a	O
method	O
of	O
inhibiting	O
cancer	O
cell	O
growth	O
,	O
and	O
thereby	O
of	O
treating	O
cancer	O
comprising	O
administering	O
to	O
a	O
mammal	O
afflicted	O
with	O
cancer	O
an	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
variables	O
of	O
R1+and	O
R2	O
have	O
the	O
meanings	O
defined	O
in	O
the	O
specification	O
.	O

The	O
present	O
invention	O
also	O
provides	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
novel	O
pharmaceutical	O
compositions	O
and	O
intermediates	O
useful	O
for	O
preparing	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
figure	O
illustrates	O
the	O
structure	O
and	O
binding	O
activity	O
of	O
compounds	O
of	O
the	O
invention	O
and	O
some	O
of	O
the	O
rifamycin	O
analogs	O
.	O

Compositions	O
and	O
methods	O
for	O
stimulating	O
bone	O
growth	O
Compounds	O
of	O
formulas	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
wherein	O
the	O
variables	O
of	O
X	O
,	O
Y	O
and	O
R	O
'	O
are	O
herein	O
defined	O
in	O
the	O
specification	O
,	O
promote	O
bone	O
information	O
and	O
are	O
thus	O
useful	O
in	O
treating	O
osteoporosis	O
,	O
bone	O
fracture	O
or	O
deficiency	O
,	O
primary	O
or	O
secondary	O
hyperparathyroidism	O
,	O
periodontal	O
disease	O
or	O
defect	O
,	O
metastatic	O
bone	O
disease	O
,	O
osteolytic	O
bone	O
disease	O
,	O
post	O
-	O
plastic	O
surgery	O
,	O
post	O
-	O
prosthetic	O
joint	O
surgery	O
,	O
and	O
post	O
-	O
dental	O
implantation	O
.	O

The	O
figure	O
shows	O
the	O
structure	O
and	O
activity	O
of	O
several	O
compounds	O
of	O
the	O
invention	O
namely	O
,	O
nevastatin	O
,	O
lovastatin	O
and	O
pravastatin	O
,	O
as	O
tested	O
in	O
the	O
in	O
vitro	O
BMP	O
-	O
promoter	O
based	O
assay	O
.	O

Controlled	O
release	O
compositions	O
for	O
the	O
treatment	O
of	O
hyperlipidemia	O
Lipid	O
lowering	O
dosage	O
units	O
,	O
to	O
be	O
used	O
once	O
a	O
day	O
,	O
produce	O
minimal	O
side	O
effects	O
.	O

They	O
contain	O
a	O
combination	O
of	O
microspheres	O
formulated	O
to	O
co	O
-	O
deliver	O
a	O
HMG	B
-	I
CoA	I
reductase	I
inhibitor	O
component	O
and	O
a	O
niacin	O
component	O
.	O

Beta	B
-	I
catenin	I
,	O
tcf-4	B
,	O
and	O
apc	O
interact	O
to	O
prevent	O
cancer	O
The	O
APC	B
tumor	O
suppressor	O
protein	O
binds	O
to	O
beta	B
-catenin	I
,	O
a	O
protein	O
recently	O
shown	O
to	O
interact	O
with	O
Tcf	O
/	O
Lef	O
transcription	O
factors	O
.	O

Here	O
,	O
the	O
gene	O
encoding	O
a	O
Tcf	B
family	O
member	O
that	O
is	O
expressed	O
in	O
colonic	O
epithelium	O
(	O
hTcf-4	B
)	O
was	O
cloned	O
and	O
characterized	O
.	O

hTcf-4	B
transactivates	O
transcription	O
only	O
when	O
associated	O
with	O
beta	O
-catenin	O
.	O

Nuclei	O
of	O
APC<-	B
/	O
-	O
>	O
colon	O
carcinoma	O
cells	O
were	O
found	O
to	O
contain	O
a	O
stable	O
beta	B
-catenin	I
-	O
hTCF-4	B
complex	O
that	O
was	O
constitutively	O
active	O
,	O
as	O
measured	O
by	O
transcription	O
of	O
a	O
Tcf	B
reporter	O
gene	O
.	O

Reintroduction	O
of	O
APC	B
removed	O
beta	O
-catenin	O
from	O
hTcf4	B
and	O
abrogated	O
the	O
transcriptional	O
transactivation	O
.	O

Constitutive	O
transcription	O
of	O
TCF	B
target	O
genes	O
,	O
caused	O
by	O
loss	O
of	O
APC	B
function	O
,	O
may	O
be	O
a	O
crucial	O
event	O
in	O
the	O
early	O
transformation	O
of	O
colonic	O
epithelium	O
.	O

It	O
is	O
also	O
shown	O
here	O
that	O
the	O
products	O
of	O
mutant	O
APC	B
genes	O
found	O
in	O
colorectal	O
tumors	O
are	O
defective	O
in	O
regulating	O
beta	B
-catenin	I
/	O
Tcf-4	B
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
colorectal	O
tumors	O
with	O
intact	O
APC	B
genes	O
were	O
shown	O
to	O
contain	O
subtle	O
activating	O
mutations	O
of	O
beta	B
-catenin	I
that	O
altered	O
functionally	O
significant	O
phosphorylation	O
sites	O
.	O

These	O
results	O
indicate	O
that	O
regulation	O
of	O
beta	B
-catenin	I
is	O
critical	O
to	O
APC	O
's	O
tumor	O
suppressive	O
effect	O
and	O
that	O
this	O
regulation	O
can	O
be	O
circumvented	O
by	O
mutations	O
in	O
either	O
APC	B
or	O
beta	B
-catenin	I
.	O

A	O
method	O
of	O
modulating	O
an	O
immune	O
response	O
in	O
an	O
infected	O
mammal	O
by	O
transmucosal	O
administration	O
of	O
modulating	O
agent	O
Methods	O
and	O
compositions	O
for	O
modulating	O
an	O
immune	O
response	O
in	O
a	O
mammal	O
infected	O
with	O
a	O
bacterium	O
,	O
a	O
virus	O
,	O
or	O
a	O
parasite	O
are	O
provided	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
useful	O
in	O
mammals	O
experiencing	O
an	O
acute	O
infection	O
and	O
in	O
mammals	O
experiencing	O
a	O
chronic	O
infection	O
.	O

The	O
methods	O
and	O
compositions	O
may	O
be	O
used	O
in	O
conjunction	O
with	O
a	O
known	O
treatment	O
for	O
infection	O
of	O
a	O
mammal	O
by	O
an	O
infectious	O
agent	O
.	O

Methods	O
and	O
compositions	O
for	O
transmucosal	O
delivery	O
of	O
a	O
molecule	O
comprising	O
an	O
epitope	O
located	O
in	O
close	O
proximity	O
to	O
the	O
immune	O
response	O
are	O
provided	O
.	O

C-4''-substituted	O
macrolide	O
derivatives	O
This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
are	O
potent	O
antibacterial	O
agents	O
that	O
may	O
be	O
used	O
to	O
treat	O
various	O
bacterial	O
infections	O
and	O
disorders	O
related	O
to	O
such	O
infections	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
methods	O
of	O
treating	O
bacterial	O
infections	O
by	O
administering	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
intermediates	O
useful	O
in	O
such	O
preparation	O
.	O

Crystalline	O
macrolides	O
and	O
process	O
for	O
their	O
preparation	O
33-Epichloro-33-desoxyascomycin	O
of	O
formula	O
(	O
I	O
)	O
and	O
various	O
tautomeric	O
or	O
solvated	O
forms	O
thereof	O
,	O
in	O
crystalline	O
form	O
,	O
such	O
as	O
Form	O
A	O
and	O
Form	O
B.	O
Their	O
preparation	O
involves	O
appropriately	O
converting	O
amorphous	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
other	O
than	O
Form	O
A	O
,	O
or	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
other	O
than	O
Form	O
B	O
,	O
respectively	O
,	O
from	O
a	O
solution	O
thereof	O
under	O
crystallization	O
-	O
inducing	O
conditions	O
or	O
conditions	O
inducing	O
preferential	O
crystallization	O
of	O
Form	O
A	O
or	O
B	O
,	O
respectively	O
.	O

Such	O
crystals	O
are	O
particularly	O
indicated	O
for	O
use	O
in	O
the	O
preparation	O
of	O
topical	O
galenical	O
forms	O
of	O
the	O
compound	O
for	O
pharmaceutical	O
use	O
,	O
e.g.	O
creams	O
,	O
emulsions	O
and	O
ointments	O
.	O

Use	O
of	O
taurolidine	O
or	O
taurultam	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
of	O
metastases	O
The	O
invention	O
provides	O
the	O
use	O
of	O
taurolidine	O
or	O
taurultam	O
solutions	O
to	O
prevent	O
or	O
reduce	O
metastatic	O
growth	O
.	O

This	O
is	O
of	O
particular	O
application	O
in	O
preventing	O
or	O
reducing	O
the	O
incidence	O
of	O
metastatic	O
growth	O
following	O
surgery	O
,	O
particularly	O
following	O
the	O
use	O
of	O
trocars	O
during	O
minimal	O
invasive	O
laparoscopic	O
surgery	O
.	O

metal	O
complexes	O
with	O
antibacterian	O
and	O
fungicidal	O
effects	O
Invented	O
are	O
zinc	O
chelated	O
G	B
-	I
CSF	I
receptor	I
ligands	O
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
as	O
agonist	O
of	O
the	O
G	B
-	I
CSF	I
receptor	I
.	O

Also	O
invented	O
are	O
novel	O
processes	O
used	O
in	O
preparing	O
these	O
compounds	O
.	O

Also	O
invented	O
are	O
novel	O
G	B
-	I
CSF	I
receptor	I
binding	O
moieties	O
of	O
the	O
invented	O
zinc	O
chelated	O
G	B
-	I
CSF	I
receptor	I
ligands	O
.	O

Novel	O
optically	O
active	O
aminopentane	O
derivative	O
Novel	O
compounds	O
involving	O
optically	O
pure	O
(	O
-	O
)	O
-1-	O
(	O
benzofuran-2-yl	O
)	O
-2-propylaminopentane	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
which	O
is	O
substantially	O
free	O
from	O
the	O
(	O
+	O
)	O
-isomer	O
and	O
pharmacologically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O

Because	O
of	O
being	O
excellent	O
in	O
the	O
effect	O
of	O
regulatively	O
enhancing	O
neurotransmitters	O
catecholamines	O
(	O
i.e.	O
,	O
CAE	O
(	O
Catecholaminergic	O
Activity	O
Enhancer	O
)	O
effect	O
)	O
,	O
these	O
compounds	O
are	O
useful	O
as	O
psychotropic	O
drugs	O
and	O
remedies	O
for	O
Parkinson	O
's	O
disease	O
,	O
depression	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Thyroid	O
hormone	O
analogues	O
and	O
methods	O
for	O
their	O
preparation	O
Thyroid	O
hormone	O
analogues	O
are	O
disclosed	O
.	O

Methods	O
of	O
using	O
such	O
analogues	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
disclosed	O
,	O
as	O
are	O
novel	O
procedures	O
for	O
their	O
preparation	O
.	O

Use	O
of	O
citrate	O
in	O
a	O
catheter	O
lock	O
solution	O
This	O
invention	O
relates	O
to	O
an	O
infusion	O
device	O
for	O
a	O
catheter	O
lock	O
solution	O
,	O
to	O
a	O
method	O
of	O
enhancing	O
the	O
patency	O
of	O
catheters	O
in	O
animals	O
and	O
to	O
a	O
catheter	O
lock	O
solution	O
.	O

The	O
device	O
includes	O
a	O
syringe	O
(	O
34	O
)	O
containing	O
a	O
lock	O
solution	O
comprising	O
a	O
citrate	O
salt	O
.	O

The	O
method	O
for	O
enhancing	O
the	O
patency	O
of	O
catheters	O
includes	O
infusing	O
a	O
lumen	O
(	O
14	O
,	O
16	O
)	O
of	O
an	O
indwelling	O
catheter	O
(	O
10	O
)	O
with	O
a	O
lock	O
solution	O
comprising	O
a	O
citrate	O
salt	O
.	O

In	O
one	O
aspect	O
of	O
the	O
invention	O
,	O
the	O
catheter	O
lock	O
solution	O
includes	O
a	O
citrate	O
salt	O
and	O
a	O
viscosifying	O
agent	O
.	O

The	O
lock	O
solution	O
is	O
prepared	O
to	O
have	O
sufficient	O
viscosity	O
and	O
density	O
to	O
remain	O
in	O
the	O
lumen	O
for	O
a	O
desired	O
amount	O
of	O
time	O
.	O

Nucleic	O
acid	O
constructs	O
for	O
genetic	O
immunisation	O
Recombinant	O
nucleic	O
acid	O
molecules	O
are	O
described	O
.	O

The	O
molecules	O
have	O
a	O
first	O
sequence	O
encoding	O
a	O
Hepatitis	B
B	I
virus	I
core	I
antigen	I
and	O
a	O
second	O
sequence	O
encoding	O
at	O
least	O
one	O
T	O
cell	O
epitope	O
inserted	O
within	O
the	O
first	O
sequence	O
.	O

Vectors	O
and	O
compositions	O
containing	O
these	O
molecules	O
are	O
also	O
described	O
.	O

Methods	O
of	O
eliciting	O
an	O
immune	O
response	O
using	O
these	O
molecules	O
are	O
also	O
described	O
.	O

Chlamydia	O
antigen	O
and	O
corresponding	O
dna	O
fragments	O
and	O
uses	O
thereof	O
In	O
summary	O
of	O
this	O
disclosure	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
nucleic	O
acid	O
,	O
including	O
DNA	O
,	O
immunization	O
of	O
a	O
host	O
,	O
including	O
humans	O
,	O
against	O
disease	O
caused	O
by	O
infection	O
by	O
a	O
strain	O
of	O
Chlamydia	O
,	O
specifically	O
DOLLAR	O
I	O
(	O
C.	O
pneumoniae	O
)	O
,	O
employing	O
a	O
vector	O
,	O
containing	O
a	O
nucleotide	O
sequence	O
encoding	O
an	O
POMP91B	O
precursor	O
protein	O
of	O
a	O
strain	O
of	O
DOLLAR	O
I	O
(	O
Chlamydia	O
pneumoniae	O
)	O
and	O
a	O
promoter	O
to	O
effect	O
expression	O
of	O
the	O
POMP91B	O
precursor	O
gene	O
in	O
the	O
host	O
.	O

Modifications	O
are	O
possible	O
within	O
the	O
scope	O
of	O
this	O
invention	O
.	O

Inhibitors	O
of	O
c	B
-	I
jun	I
n	I
-	I
terminal	I
kinases	I
(	O
jnk	B
)	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
or	O
prodrug	O
thereof	O
;	O
wherein	O
Y	O
is	O
selected	O
from	O
-	O
(	O
CH2	O
)	O
-Q1	O
;	O
-	O
(	O
CO	O
)	O
-Q1	O
;	O
-	O
(	O
CO	O
)	O
NH	O
-	O
Q1	O
;	O
-	O
(	O
CO	O
)	O
-O	O
-	O
Q1	O
;	O
-	O
(	O
SO2	O
)	O
-Q1	O
or	O
-	O
(	O
SO2	O
)	O
NH	O
-	O
Q1	O
;	O
Q1	O
is	O
a	O
C1-C6	O
straight	O
chain	O
or	O
branched	O
alkyl	O
or	O
alkenyl	O
group	O
;	O
a	O
5	O
-	O
7	O
membered	O
aromatic	O
or	O
non	O
-	O
aromatic	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
;	O
or	O
a	O
9	O
-	O
14	O
membered	O
bicyclic	O
or	O
tricyclic	O
aromatic	O
or	O
non	O
-	O
aromatic	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
system	O
,	O
W	O
is	O
N	O
or	O
C	O
;	O
Z	O
is	O
CH	O
or	O
N	O
,	O
which	O
are	O
inhibitors	O
of	O
JNK	B
,	O
a	O
mammalian	O
protein	O
kinase	B
involved	O
cell	O
proliferation	O
,	O
cell	O
death	O
and	O
response	O
to	O
extracellular	O
stimuli	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
producing	O
these	O
inhibitors	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O

Screening	O
methods	O
for	O
compounds	O
which	O
affect	O
melanogenesis	O
Methods	O
of	O
screening	O
for	O
compounds	O
that	O
affect	O
melanogenesis	O
and	O
the	O
function	O
of	O
P	B
protein	I
in	O
organisms	O
,	O
cells	O
,	O
or	O
cell	O
-	O
free	O
systems	O
are	O
provided	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
pharmacologic	O
and	O
cosmetic	O
uses	O
of	O
such	O
compounds	O
to	O
reduce	O
or	O
increase	O
the	O
synthesis	O
of	O
melanin	O
in	O
animal	O
and	O
human	O
melanocytes	O
and	O
melanocyte	O
-	O
derived	O
cells	O
.	O

AMINO	O
SUBSTITUTED	O
PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES	O
AND	O
PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES	O
Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
:	O
(	O
I	O
)	O
,	O
where	O
R?1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
¿	O
,	O
and	O
X	O
are	O
defined	O
herein	O
.	O

These	O
compounds	O
are	O
selective	O
modulators	O
of	O
NPY1	B
receptors	I
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
number	O
of	O
CNS	O
disorders	O
,	O
metabolic	O
disorders	O
,	O
and	O
peripheral	O
disorders	O
,	O
particularly	O
eating	O
disorders	O
and	O
hypertension	O
.	O

Methods	O
of	O
treatment	O
of	O
such	O
disorders	O
as	O
well	O
as	O
packaged	O
pharmaceutical	O
compositions	O
are	O
also	O
provided	O
.	O

Compounds	O
of	O
the	O
invention	O
are	O
also	O
useful	O
as	O
probes	O
for	O
the	O
localization	O
of	O
NPY1	B
receptors	I
and	O
as	O
standards	O
in	O
assays	O
for	O
NPY1	B
receptor	I
binding	O
.	O

Methods	O
of	O
using	O
the	O
compounds	O
in	O
receptor	O
localization	O
studies	O
are	O
given	O
.	O

Use	O
of	O
the	O
residues	O
from	O
wine	O
production	O
The	O
use	O
of	O
the	O
residues	O
from	O
wine	O
production	O
as	O
active	O
substance	O
preparations	O
in	O
the	O
production	O
of	O
cosmetic	O
and/or	O
pharmaceutical	O
preparations	O
is	O
disclosed	O
.	O

Pharmaceutical	O
preparation	O
containing	O
cytostatic	O
agents	O
and	O
electron	O
acceptors	O
for	O
treating	O
tumor	O
diseases	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
preparation	O
containing	O
at	O
least	O
one	O
active	O
substance	O
that	O
is	O
cytostatically	O
active	O
,	O
at	O
least	O
one	O
biological	O
electron	O
acceptor	O
,	O
and	O
the	O
customary	O
pharmaceutical	O
additives	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
preparation	O
for	O
treating	O
tumor	O
diseases	O
,	O
in	O
particular	O
,	O
for	O
treating	O
cancer	O
.	O

Novel	O
stromelysin	B
inhibitors	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
diseases	O
,	O
in	O
which	O
an	O
increased	O
activity	O
of	O
matrix	B
-	I
degrading	I
enzymes	I
,	O
in	O
particular	O
,	O
stromelysin	B
,	O
are	O
implicated	O
.	O

New	O
gamma	O
selective	O
retinoids	O
New	O
RAR	O
selective	O
retinoid	O
agonists	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
symbols	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
active	O
salts	O
of	O
carboxylic	O
acids	O
of	O
formula	O
(	O
I	O
)	O
,	O
further	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
such	O
retinoic	B
acid	I
receptor	I
agonists	O
,	O
particularly	O
retinoic	B
acid	I
receptor	I
η	I
(	O
RARη	B
)	O
selective	O
agonists	O
for	O
the	O
treatment	O
of	O
emphysema	O
and	O
associated	O
pulmonary	O
diseases	O
,	O
as	O
well	O
as	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
dermatological	O
disorders	O
,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
malignant	O
and	O
premalignant	O
epithelial	O
lesions	O
,	O
tumours	O
and	O
precancerous	O
changes	O
of	O
the	O
mucous	O
membrane	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
larynx	O
,	O
oesophagus	O
,	O
bladder	O
,	O
cervix	O
and	O
colon	O
.	O

Method	O
for	O
preparing	O
a	O
fatty	O
substance	O
ester	O
and	O
use	O
thereof	O
in	O
pharmaceutics	O
,	O
cosmetics	O
or	O
food	O
industry	O

The	O
invention	O
concerns	O
a	O
method	O
for	O
preparing	O
a	O
fatty	O
substance	O
ester	O
,	O
characterised	O
in	O
that	O
it	O
consists	O
in	O
subjecting	O
to	O
an	O
esterification	O
reaction	O
at	O
least	O
a	O
fatty	O
substance	O
with	O
at	O
least	O
an	O
alcohol	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
sterols	O
,	O
stanols	O
,	O
4-methylsterols	O
and	O
their	O
hydrogenated	O
homologues	O
,	O
triterpene	O
alcohols	O
and	O
their	O
hydrogenated	O
homologues	O
,	O
and	O
mixtures	O
thereof	O
,	O
in	O
the	O
presence	O
of	O
at	O
least	O
a	O
solid	O
catalyst	O
selected	O
in	O
the	O
group	O
consisting	O
of	O
lanthanide	O
oxides	O
and	O
the	O
mixtures	O
of	O
said	O
oxides	O
.	O

Said	O
method	O
enables	O
to	O
obtain	O
products	O
particularly	O
suited	O
for	O
use	O
in	O
the	O
field	O
of	O
pharmaceutics	O
,	O
in	O
particular	O
dermatology	O
,	O
cosmetics	O
and	O
special	O
food	O
production	O
(	O
functional	O
food	O
products	O
,	O
medicinal	O
food	O
products	O
and	O
dietetic	O
food	O
products	O
)	O

Tetrazole	O
derivatives	O
The	O
present	O
invention	O
is	O
concerned	O
with	O
2H	O
-	O
tetrazole-5-yl	O
-	O
amide	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
signifies	O
hydrogen	O
,	O
lower	O
alkyl	O
,	O
-	O
(	O
CH¿2?	O
)	O
n	O
-	O
CF3	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
CHF2	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
CN	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
cycloalkyl	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
O	O
-	O
lower	O
alkyl	O
,	O
-	O
(	O
CH2	O
)	O
n	O
-	O
O	O
-	O
cycloalkyl	O
or	O
-	O
(	O
CH2	O
)	O
n	O
-	O
C	O
(	O
O	O
)	O
O	O
-	O
lower	O
alkyl	O
;	O
R?2	O
¿	O
signifies	O
hydrogen	O
,	O
lower	O
alkyl	O
,	O
lower	O
alkoxy	O
,	O
halogen	O
,	O
-C	O
(	O
O	O
)	O
-lower	O
alkyl	O
,	O
-C	O
(	O
O	O
)	O
OH	O
,	O
-C	O
(	O
O	O
)	O
O	O
-	O
lower	O
alkyl	O
,	O
-NR3R4	O
or	O
-C	O
(	O
O	O
)	O
-NR3R4	O
and	O
wherein	O
R?3	O
and	O
R4	O
¿	O
may	O
be	O
independently	O
from	O
each	O
other	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
X	O
signifies	O
-O-	O
,	O
-S-	O
,	O
-CH¿2	O
?	O
,	O
-OCH2-	O
or	O
two	O
hydrogen	O
atoms	O
not	O
forming	O
a	O
bridge	O
;	O
and	O
n	O
signifies	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
as	O
well	O
as	O
with	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
are	O
group	B
1	I
metabotropic	I
glutamate	I
receptor	I
agonists	O
(	O
mGluR	B
)	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
corresponding	O
CNS	O
-	O
disorders	O
.	O

Masp-2	B
,	O
a	O
complement	O
-	O
fixing	O
enzyme	O
,	O
and	O
uses	O
for	O
it	O
The	O
present	O
invention	O
relates	O
to	O
substantially	O
pure	O
mannin	B
-	I
binding	I
lectin	I
associated	I
serine	I
protease-2	I
(	O
MASP-2	B
)	O
polypeptides	O
and	O
fragments	O
thereof	O
as	O
well	O
as	O
nucleic	O
acids	O
encoding	O
such	O
polpeptides	O
.	O

Futhermone	O
,	O
the	O
present	O
invention	O
realates	O
to	O
uses	O
of	O
a	O
substantially	O
pure	O
polypeptide	O
comprising	O
amino	O
acid	O
sequences	O
derived	O
from	O
mannan	B
-	I
binding	I
lectin	I
associated	I
serine	I
protease-2	I
(	O
MASP2	B
)	O
or	O
a	O
functional	O
homologue	O
thereof	O
for	O
the	O
production	O
of	O
a	O
pharmaceutical	O
composition	O
as	O
well	O
as	O
pharmaceutical	O
compositons	O
comprising	O
MASP-2	B
and/or	O
MASP-2	B
fragments	O
.	O

In	O
addition	O
the	O
present	O
invetion	O
relates	O
to	O
inhibitors	O
of	O
MASP-2	B
and	O
pharmaceutical	O
compositiosn	O
compring	O
such	O
inhibitors	O
.	O

Methods	O
for	O
detecting	O
MASP-2	B
nucleic	O
acid	O
expression	O
are	O
included	O
in	O
the	O
invention	O
.	O

Antisense	O
modulation	O
of	O
clusterin	O
expression	O
Antisense	O
compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
clusterin	O
.	O

The	O
compositions	O
comprise	O
antisense	O
compounds	O
,	O
particularly	O
antisense	O
oligonucleotides	O
,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
clusterin	O
.	O

Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
clusterin	O
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
clusterin	O
are	O
provided	O
.	O

Macrolide	O
antibiotics	O
The	O
present	O
invention	O
relates	O
to	O
11,12	O
gamma	O
lactone	O
ketolides	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
and	O
R<3	O
>	O
are	O
as	O
defined	O
herein	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
,	O
to	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
therapy	O
or	O
prophylaxis	O
of	O
systemic	O
or	O
topical	O
bacterial	O
infections	O
in	O
a	O
human	O
or	O
animal	O
body	O
.	O

Promoting	O
cell	O
regeneration	O
and/or	O
cell	O
differentiation	O
with	O
non	O
-	O
metabolizable	O
sugar	O
and	O
a	O
polymeric	O
absorbent	O
The	O
invention	O
concerns	O
the	O
use	O
of	O
a	O
combination	O
comprising	O
at	O
least	O
an	O
absorbent	O
and	O
at	O
least	O
a	O
compound	O
selected	O
among	O
the	O
group	O
consisting	O
of	O
non	O
-	O
metabolizable	O
sugars	O
and	O
polyols	O
for	O
preparing	O
a	O
composition	O
,	O
in	O
particular	O
medicinal	O
,	O
for	O
promoting	O
cell	O
regeneration	O
and/or	O
cell	O
differentiation	O
.	O

Use	O
of	O
er	B
-	I
beta	I
selective	O
antagonists	O
as	O
contraceptives	O
The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
ERSS	O
-	O
selective	O
ligands	O
for	O
production	O
of	O
medicaments	O
for	O
regulating	O
fertility	O
without	O
additional	O
use	O
of	O
a	O
progestin	O
.	O

ERSS	O
-	O
agonists	O
are	O
used	O
for	O
treatment	O
of	O
infertility	O
and	O
ERSS	O
-	O
antagonists	O
for	O
contraception	O
.	O

Sapogenin	O
derivatives	O
,	O
their	O
synthesis	O
and	O
use	O
The	O
invention	O
discloses	O
certain	O
steroidal	O
sapogenins	O
and	O
derivatives	O
thereof	O
,	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
cognitive	O
dysfunction	O
,	O
non	O
-	O
cognitive	O
neurodegeneration	O
,	O
non	O
-	O
cognitive	O
neuromuscular	O
degeneration	O
,	O
and	O
receptor	O
loss	O
in	O
the	O
absence	O
of	O
cognitive	O
,	O
neural	O
and	O
neuromuscular	O
impairment	O
.	O

Methods	O
of	O
synthesis	O
,	O
treatment	O
and	O
pharmaceutical	O
compositions	O
are	O
also	O
disclosed	O
.	O

PHARMACEUTICAL	O
COMPOSITIONS	O
FOR	O
THE	O
COORDINATED	O
DELIVERY	O
OF	O
NSAIDs	O
The	O
present	O
invention	O
is	O
directed	O
to	O
drug	O
dosage	O
forms	O
that	O
release	O
an	O
agent	O
that	O
raises	O
the	O
pH	O
of	O
a	O
patient	O
's	O
gastrointestinal	O
tract	O
,	O
followed	O
by	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
.	O

The	O
dosage	O
form	O
is	O
designed	O
so	O
that	O
the	O
NSAID	O
is	O
not	O
released	O
until	O
the	O
intragastric	O
pH	O
has	O
been	O
raised	O
to	O
a	O
safe	O
level	O
.	O

The	O
invention	O
also	O
encompasses	O
methods	O
of	O
trating	O
patients	O
by	O
administering	O
this	O
coordinated	O
release	O
,	O
gastroprotective	O
,	O
antiarthitic	O
/	O
analgesic	O
combination	O
unit	O
dosage	O
form	O
to	O
achieve	O
pain	O
and	O
symptom	O
relief	O
with	O
a	O
reduced	O
risk	O
of	O
developing	O
gastrointestinal	O
damage	O
such	O
as	O
ulcers	O
,	O
erosions	O
and	O
hemorrhages	O
.	O

Improved	O
pharmaceutical	O
composition	O
containing	O
a	O
ppar	B
alpha	I
agent	O
and	O
a	O
process	O
for	O
preparing	O
it	O
Oral	O
semi	O
-	O
solid	O
or	O
liquid	O
composition	O
for	O
treating	O
hyperlipidemia	O
or	O
hypercholesterolemia	O
in	O
humans	O
,	O
which	O
comprises	O
at	O
least	O
an	O
effective	O
amount	O
of	O
peroxisome	B
proliferator	I
activated	I
receptor	I
alpha	I
agent	O
(	O
PPARa	B
)	O
,	O
one	O
polyglycolized	O
glyceride	O
and	O
one	O
hydrophilic	O
disintegrating	O
agent	O
.	O

Pharmaceutical	O
formulations	O
for	O
the	O
controlled	O
release	O
of	O
4-amino-6,7-dimethoxy-2-	O
(	O
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	O
)	O
-5-	O
(	O
2-pyridyl	O
)	O
quinazoline	O
The	O
invention	O
provides	O
a	O
controlled	O
-	O
release	O
pharmaceutical	O
formulation	O
for	O
oral	O
administration	O
comprising	O
4-amino-6,7-dimethoxy-2-	O
(	O
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	O
)	O
-5-	O
(	O
2-pyridyl	O
)	O
quinazoline	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
adjuvant	O
,	O
diluent	O
or	O
carrier	O
;	O
characterized	O
in	O
that	O
the	O
formulation	O
is	O
adapted	O
to	O
release	O
at	O
least	O
50	O
%	O
by	O
weight	O
of	O
the	O
4-amino-6,7-dimethoxy-2-	O
(	O
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	O
)	O
-5-	O
(	O
2-pyridyl	O
)	O
-quinazoline	O
,	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
after	O
6	O
hours	O
in	O
Apparatus	O
1	O
described	O
in	O
the	O
United	O
States	O
Pharmacopoeia	O
24	O
(	O
2000	O
)	O
,	O
pp	O
1941	O
-	O
1943	O
,	O
having	O
1	O
litre	O
vessels	O
,	O
baskets	O
of	O
40	O
mesh	O
(	O
0.4	O
mm	O
apertures	O
)	O
,	O
a	O
rotation	O
speed	O
of	O
100	O
rpm	O
,	O
and	O
a	O
dissolution	O
medium	O
consisting	O
of	O
900	O
ml	O
of	O
0.01	O
M	O
hydrochloric	O
acid	O
containing	O
0.7	O
%	O
w	O
/	O
v	O
sodium	O
chloride	O
at	O
37	O
DEG	O
C.	O
Formulations	O
according	O
to	O
the	O
invention	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
BPH	O
.	O

Oxadiazoles	O
having	O
antiproliferative	O
activity	O
Oxadiazole	O
derivatives	O
of	O
general	O
formula	O
(	O
1	O
)	O
in	O
which	O
X	O
,	O
Y	O
,	O
R	O
and	O
R2	O
have	O
the	O
meanings	O
defined	O
in	O
the	O
disclosure	O
.	O

The	O
compounds	O
have	O
antiproliferative	O
activity	O
against	O
a	O
number	O
of	O
human	O
tumors	O
cell	O
lines	O
and	O
can	O
therefore	O
be	O
used	O
for	O
the	O
preparation	O
of	O
antitumor	O
medicaments	O
.	O

Pharmaceutical	O
composition	O
that	O
is	O
used	O
to	O
control	O
blood	O
glucose	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
active	O
glimepiride	O
and	O
metformin	O
substances	O
or	O
the	O
salts	O
thereof	O
,	O
such	O
as	O
hydrochloride	O
,	O
succinate	O
,	O
fumarate	O
,	O
etc	O
.	O
,	O
which	O
are	O
used	O
to	O
control	O
blood	O
glucose	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

Clinical	O
studies	O
,	O
which	O
were	O
carried	O
out	O
in	O
order	O
to	O
demonstrate	O
the	O
effectiveness	O
of	O
said	O
combination	O
,	O
have	O
shown	O
that	O
the	O
effect	O
produced	O
by	O
the	O
two	O
drugs	O
is	O
not	O
only	O
additive	O
but	O
also	O
synergetic	O
in	O
comparison	O
with	O
the	O
monotherapy	O
which	O
uses	O
only	O
one	O
of	O
the	O
drugs	O
from	O
the	O
combination	O
.	O

As	O
a	O
result	O
,	O
the	O
use	O
of	O
said	O
combination	O
is	O
suggested	O
as	O
an	O
effective	O
and	O
safe	O
therapy	O
for	O
the	O
control	O
of	O
blood	O
glucose	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

According	O
to	O
the	O
invention	O
,	O
different	O
proportions	O
of	O
the	O
active	O
substances	O
can	O
be	O
used	O
so	O
that	O
the	O
combination	O
suits	O
the	O
different	O
requirements	O
of	O
each	O
patient	O
.	O

Delivery	O
of	O
solid	O
drug	O
compositions	O
This	O
invention	O
relates	O
to	O
the	O
parenteral	O
administration	O
of	O
solid	O
drug	O
compositions	O
.	O

In	O
particular	O
,	O
this	O
invention	O
relates	O
to	O
a	O
syringe	O
-	O
like	O
device	O
for	O
delivering	O
solid	O
drug	O
cylinders	O
including	O
a	O
syringe	O
barrel	O
,	O
a	O
needle	O
,	O
and	O
a	O
microplunger	O
and	O
piston	O
assembly	O
,	O
wherein	O
said	O
microplunger	O
pushes	O
said	O
solid	O
drug	O
cylinder	O
out	O
of	O
said	O
needle	O
and	O
into	O
a	O
patient	O
and	O
said	O
piston	O
pushes	O
on	O
said	O
microplunger	O
.	O

Cascade	O
esters	O
of	O
camptothecins	O
and	O
methods	O
of	O
treating	O
cancer	O
using	O
these	O
compounds	O
Cascade	O
esters	O
of	O
camptothecin	O
are	O
described	O
.	O

Processes	O
for	O
making	O
these	O
compounds	O
and	O
for	O
using	O
them	O
in	O
cancer	O
treatment	O
are	O
also	O
described	O
.	O

Formulation	O
for	O
inwardly	O
transferring	O
nucleic	O
acids	O
into	O
eucaryotic	O
cells	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
formulation	O
for	O
inwardly	O
transferring	O
nucleic	O
acids	O
into	O
eucaryotic	O
cells	O
,	O
characterized	O
in	O
that	O
the	O
formulation	O
has	O
a	O
pH	O
value	O
of	O
6.0	O
-	O
pH	O
7,4	O
,	O
and/or	O
an	O
anion	O
concentration	O
of	O
5	O
-	O
100	O
mmol	O
/	O
l	O
and/or	O
a	O
concentration	O
of	O
10	O
-	O
500	O
ñmol	O
/	O
l	O
of	O
nonsteroidal	O
antiphlogistics	O
.	O

Compositions	O
for	O
altering	O
mucus	O
secretion	O
A	O
peptide	O
that	O
inhibits	O
mucus	O
secretion	O
in	O
subjects	O
is	O
described	O
,	O
for	O
use	O
in	O
inhibiting	O
mucus	O
secretion	O
by	O
a	O
mucus	O
secreting	O
cell	O
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
myristoylated	O
polypeptide	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
is	O
also	O
described	O
.	O

4-	O
(	O
3,5-dicyanophenoxy	O
)	O
pyrazole	O
derivatives	O
for	O
use	O
as	O
transcriptase	B
modulators	O
in	O
the	O
treatment	O
of	O
i.a	O
.	O

hiv	O
This	O
invention	O
relates	O
to	O
the	O
pyrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
derivatives	O
thereof	O
,	O
to	O
their	O
use	O
in	O
medicine	O
,	O
to	O
compositions	O
containing	O
them	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
and	O
to	O
intermediates	O
used	O
in	O
such	O
processes	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
bind	O
to	O
the	O
enzyme	O
reverse	B
transcriptase	I
and	O
are	O
modulators	O
,	O
especially	O
inhibitors	O
,	O
thereof	O
.	O

Reverse	B
transcriptase	I
is	O
implicated	O
in	O
the	O
infectious	O
lifecycle	O
of	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
.	O

Compounds	O
which	O
interfere	O
with	O
the	O
function	O
of	O
this	O
enzyme	O
have	O
shown	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
caused	O
by	O
HIV	O
and	O
genetically	O
related	O
retroviruses	O
,	O
such	O
as	O
Acquired	O
Immune	O
Deficiency	O
Syndrome	O
(	O
AIDS	O
)	O
.	O

Therapeutic	O
use	O
of	O
fused	O
bicyclic	O
or	O
tricyclic	O
amino	O
acids	O
The	O
compounds	O
of	O
the	O
instant	O
invention	O
are	O
bicyclic	O
or	O
tricyclic	O
amino	O
acids	O
useful	O
in	O
the	O
treatment	O
of	O
fibromylagia	O
.	O

Pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
the	O
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
fibromyalgia	O
are	O
also	O
included	O
.	O

A	O
method	O
of	O
treating	O
vasomotor	O
symptoms	O
comprising	O
a	O
compound	O
having	O
norepinephrine	O
reuptake	O
inhibitor	O
activity	O
and	O
5-ht2a	B
antagonistic	O
activity	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
composition	O
of	O
compounds	O
that	O
modulate	O
norepinephrine	O
levels	O
for	O
the	O
treatment	O
of	O
vasomotor	O
symptoms	O
such	O
as	O
thermoregulatory	O
disorders	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
compositions	O
of	O
compounds	O
having	O
norepinephrine	O
reuptake	O
inhibitor	O
(	O
NRI	O
)	O
activity	O
alone	O
or	O
norepinephrine	O
reuptake	O
inhibitor	O
and	O
serotonin	O
reuptake	O
inhibitor	O
(	O
NRI	O
/	O
SRI	O
)	O
dual	O
activity	O
in	O
combination	O
with	O
5-HT2a	B
receptor	O
antagonist	O
activity	O
.	O

Method	O
for	O
counteracting	O
a	O
pathologic	O
change	O
in	O
the	O
beta	B
-	I
adrenergic	I
pathway	O
The	O
invention	O
concerns	O
methods	O
for	O
modulating	O
the	O
ß	B
-	I
adrenergic	I
pathway	O
.	O

In	O
particular	O
,	O
the	O
invention	O
concerns	O
methods	O
for	O
counteracting	O
a	O
pathologic	O
change	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
a	O
loss	O
in	O
ß	B
-	I
adrenergic	I
sensitivity	O
,	O
in	O
the	O
ß	B
-	I
adrenergic	I
signal	O
transduction	O
pathway	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
capable	O
of	O
inhibiting	O
TGF	B
-	I
ß	I
signaling	O
through	O
a	O
TGF	B
-	I
ß	I
receptor	I
.	O

Compositions	O
and	O
methods	O
for	O
improving	O
the	O
condition	O
of	O
patients	O
suffering	O
from	O
copd	O
and	O
other	O
diseases	O
A	O
food	O
supplement	O
of	O
therapeutic	O
composition	O
is	O
provided	O
suitable	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
COPD	O
and	O
other	O
acute	O
or	O
chronic	O
diseases	O
in	O
a	O
mammal	O
,	O
especially	O
a	O
human	O
being	O
,	O
comprising	O
at	O
least	O
one	O
of	O
glutamate	O
,	O
other	O
than	O
mono	O
sodium	O
glutamate	O
,	O
and	O
a	O
precursor	O
of	O
glutamate	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
leucine	O
,	O
valine	O
,	O
isoleucine	O
,	O
and	O
a	O
keto	O
acid	O
thereof	O
,	O
in	O
a	O
daily	O
dose	O
for	O
said	O
mammal	O
of	O
at	O
least	O
6	O
grams	O
,	O
preferably	O
between	O
9	O
and	O
20	O
grams	O
,	O
of	O
the	O
total	O
of	O
said	O
glutamate	O
and	O
precursor	O
forms	O
thereof	O
.	O

Human	B
CLTA-8	I
and	O
uses	O
of	O
CTLA-8-related	B
proteins	O
An	O
antibody	O
that	O
specifically	O
reacts	O
with	O
a	O
protein	O
comprising	O
an	O
amino	O
acid	O
sequence	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
(	O
a	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
;	O
(	O
b	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	O
acids	O
11	O
to	O
163	O
;	O
(	O
c	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	O
acids	O
29	O
to	O
163	O
;	O
(	O
d	O
)	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	O
acids	O
31	O
to	O
163	O
;	O
and	O
(	O
e	O
)	O
a	O
fragment	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
having	O
a	O
CTLA-8	B
activity	O
chosen	O
from	O
one	O
or	O
more	O
of	O
induction	O
of	O
expression	O
or	O
secretion	O
of	O
γ	B
-	I
IFN	I
,	O
IL-6	B
,	O
or	O
IL-8	B
,	O
or	O
inhibition	O
of	O
angiogenesis	O
.	O

Inhibitors	O
of	O
hepatitis	O
c	O
virus	O
,	O
compositions	O
and	O
treatments	O
using	O
the	O
same	O
The	O
invention	O
relates	O
to	O
methods	O
of	O
inhibiting	O
HCV	O
viral	O
replication	O
activityy	O
comprising	O
contacting	O
an	O
HCV	B
polymerase	I
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
hydroxamate	O
MMP	B
inhibitor	O
,	O
and	O
composition	O
comprising	O
the	O
same	O
.	O

Fused	O
pyrido	O
[	O
3',2':4,5	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidines	O
and	O
pyrido	O
[	O
3',2':4,5	O
]	O
furo	O
[	O
3,2-d	O
]	O
pyrimidines	O
Tricyclic	O
thiophene	O
,	O
furan	O
or	O
pyrrole	O
derivatives	O
(	O
I	O
)	O
are	O
new	O
.	O

Tricyclic	O
thiophene	O
,	O
furan	O
or	O
pyrrole	O
derivatives	O
(	O
I	O
)	O
of	O
formula	O
(	O
Ia	O
)	O
-	O
(	O
Id	O
)	O
and	O
their	O
salts	O
,	O
solvates	O
,	O
metabolites	O
,	O
tautomers	O
and	O
prodrugs	O
are	O
new	O
,	O
other	O
than	O
2-dimethylamino-4,7-diethoxy-8-cyano-9-p	O
henyl	O
-	O
pyrido	O
[	O
3',2':4,5	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidine	O
,	O
1,4-dihydro-2,2-dimethyl-5-morpholino-10-propylthio-2H	O
-	O
pyrano	O
[	O
"4"",3"":4"	O
'	O
,	O
5'	O
]	O
pyrido	O
[	O
3',2':4',5'	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidin-8	O
(	O
9H	O
)	O
-one	O
,	O
1	O
-	O
-butylthio-1,4-dihydro-2,2-dimethyl-5-morpholino-2H	O
-	O
pyrano	O
[	O
"4"",3"":4"	O
'	O
,	O
5'	O
]	O
pyrido	O
[	O
3',2':4',5'	O
]	O
thieno	O
[	O
3,2-d	O
]	O
pyrimidin-8	O
(	O
9H	O
)	O
-one	O
and	O
2-methyl-5-	O
(	O
2thienyl	O
)	O
-1,2,3,4-tetrahydro-11H-7-thia-2,6,9,11-tetraaza	O
-benzo	O
[	O
c	O
]	O
fluorene-8,10-dione	O
.	O

Y	O
'	O
:	O
S	O
,	O
O	O
or	O
N	O
;	O
R1	O
>	O
H	O
;	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkyl	O
,	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkenyl	O
or	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkynyl	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkyl	O
,	O
5-	O
to	O
14-membered	O
mono-	O
or	O
bicyclic	O
heterocyclyl	O
with	O
1	O
-	O
4	O
heteroatoms	O
,	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkoxy	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkoxy	O
,	O
2	O
-	O
12C	O
alkanoyl	O
,	O
benzoyl	O
or	O
1-	O
or	O
2-naphthoyl	O
,	O
alkylthio	O
,	O
alkylsulfinyl	O
,	O
alkoxysulfonyl	O
or	O
alkylsulfonyl	O
,	O
alkoxycarbonyl	O
,	O
alkylcarbamoyl	O
or	O
dialkylcarbamoyl	O
,	O
(	O
hetero	O
)	O
arylthio	O
,	O
(	O
hetero	O
)	O
arylsulfinyl	O
or	O
(	O
hetero	O
)	O
arylsulfonyl	O
,	O
aryloxycarbonyl	O
,	O
arylcarbamoyl	O
,	O
arylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylcarbamoyl	O
,	O
aralkoxycarbonyl	O
or	O
aralkylcarbamoyl	O
with	O
1	O
-	O
5C	O
alkyl	O
or	O
6	O
-	O
10C	O
aryl	O
,	O
heterocyclylcarbonyl	O
,	O
heterocyclylcarbamoyl	O
,	O
heterocyclylamido	O
,	O
N	O
-	O
heterocyclyl	O
-	O
N	O
-	O
alkylamino	O
,	O
heterocyclylalkoxycarbonyl	O
or	O
heterocyclylalkylcarbamoyl	O
,	O
arylhydrazino	O
or	O
phenyl	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
1-	O
or	O
2-naphthyl	O
;	O
OH	O
,	O
SH	O
,	O
CHO	O
,	O
COOH	O
,	O
CONH2	O
,	O
CN	O
,	O
SCN	O
,	O
NO2	O
,	O
SO3H	O
;	O
with	O
heterocyclyl	O
as	O
above	O
and	O
1	O
-	O
5C	O
alkyl	O
;	O
halo	O
;	O
NH2	O
,	O
1	O
-	O
6C	O
alkylamino	O
or	O
di	O
(	O
1	O
-	O
5C	O
alkyl	O
)	O
amino	O
,	O
optionally	O
substituted	O
;	O
heterocyclylamino	O
;	O
or	O
La	O
-	O
A	O
-	O
Lb	O
-	O
B	O
;	O
La	O
:	O
a	O
bond	O
,	O
NR	O
'	O
,	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
;	O
A	O
:	O
phenyl	O
or	O
naphthyl	O
(	O
both	O
optionally	O
substituted	O
)	O
or	O
heterocyclyl	O
;	O
or	O
a	O
tricyclic	O
group	O
;	O
Lb	O
:	O
a	O
bond	O
,	O
NR	O
'	O
,	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
,	O
CHR	O
,	O
CH2O	O
,	O
OCH2	O
,	O
NR'CO	O
,	O
NR'CS	O
,	O
NR'CONR	O
'	O
,	O
NR'CSNR	O
'	O
,	O
NR'C	O
(	O
NH	O
)	O
,	O
NR'SO	O
,	O
NR'SO2	O
,	O
N	O
(	O
R'	O
)	O
=S	O
(	O
O	O
)	O
(	O
R	O
'	O
)	O
,	O
NR'C	O
(	O
NHOH	O
)	O
,	O
NHNR	O
'	O
,	O
N	O
(	O
NHR'	O
)	O
CO	O
,	O
NHN=	O
,	O
N	O
(	O
OH	O
)	O
CS	O
,	O
NR'COO	O
,	O
NR'C	O
(	O
S	O
)	O
O	O
,	O
N	O
(	O
OH	O
)	O
CO	O
;	O
B	O
:	O
H	O
;	O
alkyl	O
(	O
optionally	O
substituted	O
)	O
;	O
CONH2	O
;	O
CONHQ	O
;	O
COOH	O
;	O
COOAlk	O
;	O
COQ	O
;	O
CH2CONH2	O
;	O
CH2CONHQ	O
;	O
CH2COOH	O
;	O
CH2COOAlk	O
;	O
CH2COQ	O
;	O
phenyl	O
or	O
naphthyl	O
or	O
4-	O
to	O
14-membered	O
mono-	O
or	O
bicyclic	O
heterocyclyl	O
with	O
1	O
-	O
5	O
heteroatoms	O
(	O
optionally	O
substituted	O
with	O
oxo	O
)	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
Alk	O
:	O
alkyl	O
(	O
optionally	O
substituted	O
)	O
;	O
Q	O
:	O
alkyl	O
,	O
aryl	O
or	O
heteroaryl	O
(	O
optionally	O
substituted	O
)	O
;	O
R	O
'	O
:	O
H	O
or	O
Alk	O
;	O
R2	O
>	O
H	O
,	O
1	O
-	O
12C	O
alkyl	O
,	O
2	O
-	O
12C	O
alkenyl	O
or	O
alkynyl	O
;	O
phenyl	O
(	O
1	O
-	O
6C	O
)	O
alkyl	O
(	O
optionally	O
substituted	O
)	O
;	O
phenacyl	O
(	O
optionally	O
substituted	O
)	O
;	O
COOH	O
,	O
1	O
-	O
4C	O
alkoxycarbonyl	O
,	O
CONH2	O
or	O
mono-	O
or	O
di	O
(	O
1	O
-	O
6C	O
alkyl	O
)	O
carbamoyl	O
;	O
COR	O
'	O
;	O
CN	O
,	O
NO2	O
,	O
NH2	O
,	O
mono-	O
or	O
di	O
(	O
1	O
-	O
6C	O
alkyl	O
)	O
amino	O
,	O
N	O
=	O
N	O
-	O
Ph	O
,	O
N	O
=	O
N	O
-	O
C6H4-R	O
,	O
1,3-diphenyl-4-pyrazolyl	O
,	O
2-thiazolinyl	O
,	O
2-imidazolinyl	O
or	O
3,4,5,6-tetrahydropyrimidinyl	O
;	O
R3	O
>	O
H	O
;	O
OH	O
,	O
SH	O
,	O
CHO	O
,	O
COOH	O
,	O
CONH2	O
,	O
CN	O
,	O
SCN	O
,	O
NO2	O
,	O
halo	O
;	O
NH2	O
,	O
or	O
SO3H	O
or	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkyl	O
,	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkenyl	O
,	O
2	O
-	O
12C	O
(	O
cyclo	O
)	O
alkynyl	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkyl	O
,	O
phenyl	O
,	O
1-	O
or	O
2-naphthyl	O
,	O
pyridyl	O
N	O
-	O
oxide	O
,	O
1	O
-	O
10C	O
(	O
cyclo	O
)	O
alkoxy	O
,	O
(	O
6	O
-	O
12C	O
)	O
aryl	O
(	O
1	O
-	O
5C	O
)	O
alkoxy	O
,	O
2	O
-	O
12C	O
alkanoyl	O
,	O
benzoyl	O
or	O
1-	O
or	O
2-naphthoyl	O
,	O
alkylthio	O
,	O
alkylsulfinyl	O
,	O
alkoxysulfonyl	O
or	O
alkylsulfonyl	O
,	O
(	O
hetero	O
)	O
arylthio	O
,	O
(	O
hetero	O
)	O
arylsulfinyl	O
or	O
(	O
hetero	O
)	O
arylsulfonyl	O
,	O
alkoxycarbonyl	O
,	O
alkylcarbamoyl	O
or	O
dialkylcarbamoyl	O
,	O
aryloxycarbonyl	O
,	O
arylcarbamoyl	O
,	O
arylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylamido	O
,	O
N	O
-	O
aryl	O
-	O
N	O
-	O
alkylcarbamoyl	O
,	O
aralkoxycarbonyl	O
or	O
aralkylcarbamoyl	O
with	O
1	O
-	O
5C	O
alkyl	O
or	O
6	O
-	O
10C	O
aryl	O
,	O
1	O
-	O
6C	O
alkylamino	O
or	O
di	O
(	O
1	O
-	O
5C	O
alkyl	O
)	O
amino	O
,	O
6	O
-	O
10C	O
arylamino	O
or	O
arylhydrazino	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
R4>2	O
-	O
14C	O
alkyl	O
,	O
3	O
-	O
14C	O
cycloalkyl	O
,	O
2	O
-	O
14C	O
alkenyl	O
,	O
3	O
-	O
14C	O
cycloalkenyl	O
,	O
2	O
-	O
14C	O
alkynyl	O
,	O
phenyl	O
or	O
1-	O
or	O
2-naphthyl	O
,	O
4-	O
to	O
14-membered	O
mono-	O
or	O
bicyclic	O
heterocyclyl	O
with	O
1	O
-	O
5	O
heteroatoms	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
SQ1	O
>	O
,	O
SOQ1	O
>	O
,	O
SO2Q1	O
>	O
;	O
OR6	O
>	O
or	O
NR7	O
>	O
R8	O
>	O
;	O
Q1>1	O
-	O
8C	O
alkyl	O
,	O
2	O
-	O
8C	O
alkenyl	O
or	O
2	O
-	O
8C	O
alkynyl	O
,	O
(	O
optionally	O
substituted	O
)	O
;	O
R6>1	O
-	O
4C	O
n	O
-	O
alkyl	O
,	O
t	O
-	O
Bu	O
,	O
CH2CH2OH	O
,	O
CH2CH2SH	O
,	O
CH2CH2SMe	O
,	O
CH2CF3	O
,	O
CH2CCl3	O
,	O
CH2CHF2	O
,	O
CH2CHCl2	O
,	O
CH2CH2F	O
,	O
CH2CH2Cl	O
,	O
CH2CH2Br	O
;	O
3	O
-	O
7C	O
cycloalkyl	O
,	O
2	O
-	O
5C	O
alkenyl	O
or	O
alkynyl	O
;	O
3	O
-	O
7C	O
cycloalkenyl	O
;	O
aryl	O
or	O
heteroaryl	O
;	O
1-	O
or	O
2-naphthyl	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
pyridyl	O
,	O
isoquinolinyl	O

Medicament	O
for	O
local	O
use	O
Pharmaceutical	O
compositions	O
(	O
A	O
)	O
for	O
local	O
application	O
to	O
stop	O
bleeding	O
,	O
close	O
wounds	O
and/or	O
stimulate	O
wound	O
healing	O
,	O
contain	O
fibrinogen	B
(	O
I	B
)	O
or	O
fibrin	B
(	O
Ia	B
)	O
,	O
thrombin	B
(	O
II	B
)	O
and	O
one	O
or	O
more	O
transglutaminases	B
(	O
III	B
)	O
,	O
also	O
at	O
least	O
one	O
serpin	B
-	I
type	I
protease	I
inhibitor	O
(	O
IV	O
)	O
that	O
has	O
no	O
inhibitory	O
action	O
on	O
collagenases	B
or	O
elastases	B
,	O
are	O
new	O
.	O

All	O
active	O
ingredients	O
are	O
of	O
allogenic	O
origin	O
(	O
isolated	O
from	O
plasma	O
or	O
tissue	O
,	O
or	O
recombinant	O
)	O
and	O
have	O
been	O
subjected	O
to	O
a	O
virus	O
removal	O
and/or	O
inactivation	O
step	O
,	O
provided	O
that	O
virus	O
inactivation	O
of	O
(	O
IV	O
)	O
is	O
not	O
done	O
in	O
presence	O
of	O
other	O
active	O
ingredients	O
.	O

Independent	O
claims	O
are	O
also	O
included	O
for	O
the	O
following	O
:	O
(	O
a	O
)	O
preparation	O
of	O
a	O
(	O
I	O
)	O
-containing	O
solution	O
,	O
as	O
such	O
or	O
as	O
part	O
of	O
(	O
A	O
)	O
,	O
that	O
can	O
be	O
stored	O
at	O
refrigerator	O
or	O
room	O
temperature	O
;	O
(	O
b	O
)	O
pharmaceutical	O
compositions	O
(	O
B	O
)	O
containing	O
a	O
highly	O
purified	O
(	O
I	O
)	O
-	O
or	O
(	O
I	O
)	O
plus	O
fibronectin	O
-	O
containing	O
composition	O
that	O
has	O
activated	O
prothrombin	O
time	O
and	O
Taipan	O
viper	O
venom	O
prothrombin	O
time	O
at	O
37	O
[	O
deg	O
]	O
C	O
of	O
at	O
least	O
200	O
and	O
300	O
sec	O
,	O
respectively	O
;	O
(	O
c	O
)	O
a	O
method	O
for	O
preparing	O
pathogen	O
-	O
free	O
(	O
A	O
)	O
;	O
(	O
d	O
)	O
a	O
method	O
for	O
covalent	O
binding	O
of	O
(	O
A	O
)	O
to	O
a	O
biological	O
matrix	O
;	O
(	O
e	O
)	O
a	O
method	O
for	O
preparing	O
a	O
(	O
Ia	O
)	O
-containing	O
gel	O
of	O
20	O
-	O
90	O
%	O
water	O
content	O
;	O
(	O
f	O
)	O
a	O
method	O
for	O
solidifying	O
a	O
(	O
Ia	O
)	O
-containing	O
gel	O
with	O
or	O
without	O
removal	O
of	O
water	O
;	O
(	O
g	O
)	O
a	O
freeze	O
-	O
dried	O
(	O
Ia	O
)	O
-containing	O
gel	O
to	O
which	O
a	O
plasticizer	O
,	O
particularly	O
glycol	O
,	O
has	O
been	O
added	O
before	O
solidification	O
and	O
freeze	O
-	O
drying	O
;	O
(	O
h	O
)	O
a	O
method	O
for	O
producing	O
a	O
high	O
viscosity	O
(	O
I	O
)	O
-containing	O
solution	O
;	O
and	O
(	O
i	O
)	O
a	O
method	O
for	O
determining	O
the	O
adhesive	O
capacity	O
of	O
a	O
fibrin	O
clot	O
to	O
a	O
wound	O
bed	O
.	O

Use	O
of	O
4,5-dihydro-1h	O
-	O
pyrazole	O
derivatives	O
having	O
cb1-antagonistic	B
activity	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
medical	O
use	O
of	O
4,5-dihydro-1H	O
-	O
pyrazole	O
compounds	O
which	O
are	O
potent	O
antagonists	O
of	O
the	O
cannabis	O
CB1-receptor	B
.	O

Said	O
compounds	O
are	O
particularly	O
suitable	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
CB1	B
receptor	O
related	O
diseases	O
in	O
juvenile	O
patients	O
and/or	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
drug	O
induced	O
obesity	O
in	O
juvenile	O
as	O
well	O
as	O
in	O
adolescent	O
patients	O
.	O

The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
the	O
group	O
Bb	O
represents	O
sulfonyl	O
or	O
carbonyl	O
,	O
and	O
the	O
substituents	O
R	O
,	O
R1	O
,	O
R2and	O
R3	O
,	O
and	O
the	O
group	O
Aa	O
are	O
defined	O
as	O
shown	O
in	O
the	O
description	O
.	O

Benzimidazole	O
derivatives	O
and	O
use	O
thereof	O
as	O
peptide	B
deformylase	I
inhibitors	O
Benzimidazole	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
or	O
esters	O
thereof	O
are	O
peptide	B
deformylase	I
inhibitors	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
infections	O
and	O
other	O
diseases	O
in	O
which	O
peptide	B
deformylases	I
are	O
involved	O
,	O
especially	O
in	O
the	O
treatment	O
of	O
bacterial	O
and	O
parasitic	O
infections	O
,	O
for	O
example	O
infections	O
fully	O
or	O
partly	O
caused	O
by	O
microorganisms	O
belonging	O
to	O
Staphylococcus	O
,	O
Enterococcus	O
,	O
Streptococcus	O
,	O
Haemophilus	O
,	O
Moraxella	O
,	O
Escherichia	O
,	O
Mycobacterium	O
,	O
Mycoplasma	O
,	O
Pseudomonas	O
,	O
Chlamydia	O
,	O
Rickettsia	O
,	O
Klebsiella	O
,	O
Shigella	O
,	O
Salmonella	O
,	O
Bordetella	O
,	O
Clostridium	O
,	O
helicobacter	O
,	O
Campylobacter	O
,	O
Legionella	O
,	O
or	O
Neisseria	O
.	O

Oligo	O
-	O
beta-	O
(	O
1,3	O
)	O
-glucan	O
and	O
monoclonal	O
antibodies	O
against	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
a	O
therapeutical	O
method	O
comprising	O
administration	O
of	O
a	O
composition	O
comprising	O
a	O
monoclonal	O
antibody	O
with	O
an	O
oligo	O
-	O
β-	O
(	O
1,3	O
)	O
-glucan	O
and	O
.	O

a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
to	O
a	O
human	O
being	O
or	O
to	O
a	O
warm	O
-	O
blood	O
animal	O
suffering	O
from	O
cancer	O
in	O
an	O
amount	O
which	O
is	O
effective	O
to	O
treat	O
the	O
cancer	O
.	O

Treatment	O
of	O
a	O
Hemoglobinopathy	O
Disclosed	O
are	O
methods	O
for	O
treating	O
a	O
patient	O
identified	O
as	O
having	O
a	O
hemoglobinopathy	O
that	O
is	O
characterized	O
by	O
a	O
reduced	O
affinity	O
of	O
hemoglobin	B
for	O
oxygen	O
.	O

The	O
methods	O
involve	O
providing	O
gaseous	O
nitric	O
oxide	O
and/or	O
carbon	O
monoxide	O
for	O
(	O
i	O
)	O
inhalation	O
by	O
the	O
patient	O
or	O
(	O
ii	O
)	O
ex	O
vivo	O
treatment	O
of	O
the	O
patient	O
's	O
erythrocytes	O
.	O

Alternatively	O
,	O
a	O
nitric	O
-	O
oxide	O
-	O
releasing	O
compound	O
can	O
be	O
administered	O
to	O
the	O
patient	O
.	O

Method	O
of	O
examining	O
sensitivity	O
of	O
cancer	O
cell	O
to	O
anticancer	O
agent	O
In	O
the	O
case	O
where	O
the	O
sensitivity	O
of	O
a	O
cancer	O
cell	O
to	O
a	O
compound	O
can	O
be	O
understood	O
by	O
examining	O
molecules	O
expressed	O
in	O
the	O
cancer	O
cell	O
collected	O
from	O
a	O
cancer	O
patient	O
by	O
biopsy	O
or	O
the	O
like	O
,	O
it	O
is	O
possible	O
to	O
administer	O
the	O
compound	O
selectively	O
to	O
cancer	O
patients	O
on	O
whom	O
the	O
compound	O
can	O
exert	O
its	O
antitumor	O
effect	O
.	O

Thus	O
,	O
it	O
is	O
expected	O
that	O
the	O
therapeutic	O
effect	O
can	O
be	O
enhanced	O
while	O
relieving	O
unnecessary	O
side	O
effects	O
thereby	O
.	O

More	O
specifically	O
speaking	O
,	O
it	O
is	O
found	O
out	O
that	O
the	O
characteristics	O
""""	O
low	O
pRB	B
-	O
expression	O
""""	O
,	O
""""	O
positive	O
to	O
p16	B
expression	O
""""	O
and	O
""""	O
high	O
cyclin	B
E	I
-	O
expression	O
""""	O
are	O
usable	O
as	O
a	O
marker	O
for	O
the	O
high	O
sensitivity	O
of	O
cancer	O
cells	O
to	O
this	O
compound	O
.	O

Examination	O
of	O
these	O
characteristics	O
of	O
cancer	O
cells	O
,	O
therefore	O
,	O
the	O
sensitivity	O
of	O
the	O
cancer	O
cells	O
to	O
this	O
compound	O
can	O
be	O
preliminarily	O
understood	O
.	O

Pyridylpyrimidine	O
derivatives	O
as	O
effective	O
compounds	O
against	O
prion	O
infections	O
and	O
prion	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
pyridylpyrimidine	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R	O
represents	O
hydrogen	O
or	O
methyl	O
and	O
Z	O
represents	O
nitrogen	O
containing	O
functional	O
groups	O
,	O
the	O
use	O
of	O
the	O
pyridylpyrimidine	O
derivatives	O
as	O
pharmaceutically	O
active	O
agents	O
,	O
especially	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
prion	O
infections	O
and	O
prion	O
diseases	O
,	O
as	O
well	O
as	O
compositions	O
containing	O
at	O
least	O
one	O
pyridylpyrimidine	O
derivative	O
and/or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
preventing	O
and/or	O
treating	O
prion	O
infections	O
and	O
prion	O
diseases	O
using	O
said	O
pyridylpyrimidine	O
derivatives	O
.	O

Human	O
cellular	O
protein	O
kinases	O
,	O
phosphatases	O
and	O
cellular	O
signal	O
transduction	O
molecules	O
are	O
disclosed	O
as	O
targets	O
for	O
detecting	O
,	O
preventing	O
and/or	O
treating	O
prion	O
infections	O
and	O
diseases	O
,	O
especially	O
BSE	O
,	O
vCJD	O
,	O
or	O
CJD	O
which	O
can	O
be	O
inhibited	O
by	O
the	O
inventive	O
pyridylpyrimidine	O
derivatives	O
.	O

2-substituted	O
and	O
4-substituted	O
aryl	O
nitrone	O
compouds	O
The	O
present	O
invention	O
provides	O
aryl	O
nitrones	O
,	O
compositions	O
comprising	O
the	O
same	O
and	O
methods	O
of	O
their	O
use	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
oxidative	O
,	O
ischemic	O
,	O
ischemia	O
/	O
reperfusion	O
-	O
related	O
and	O
chemokine	O
mediated	O
conditions	O
.	O

Formulations	O
comprising	O
a	O
capsaicinoid	O
,	O
a	O
local	O
anesthetic	O
and/or	O
an	O
antipruritic	O
agent	O
for	O
the	O
treatment	O
of	O
pain	O
Formulations	O
and	O
methods	O
are	O
provided	O
for	O
the	O
treatment	O
of	O
pain	O
,	O
and	O
neuropathic	O
pain	O
in	O
particular	O
.	O

The	O
formulations	O
are	O
eutectic	O
mixtures	O
of	O
a	O
capsaicinoid	O
and	O
a	O
local	O
anesthetic	O
agent	O
and/or	O
anti	O
-	O
pruritic	O
agent	O
.	O

Alkyl	O
-	O
and	O
piperidine	O
-	O
substituted	O
benzimidazole	O
-	O
derivates	O
A	O
compound	O
of	O
general	O
formula	O
(	O
1a	O
)	O
wherein	O
R1	O
,	O
R5	O
,	O
R6	O
,	O
A	O
,	O
B	O
,	O
Y	O
,	O
i	O
,	O
j	O
and	O
m	O
are	O
defined	O
as	O
in	O
the	O
description	O
and	O
claims	O
.	O

It	O
is	O
another	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
pharmaceutical	O
compositions	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Oxazole	O
derivatives	O
as	O
histamine	B
h3	I
receptor	I
agents	O
,	O
preparation	O
and	O
therapeutic	O
uses	O
The	O
present	O
invention	O
discloses	O
novel	O
aryl	O
oxazole	O
compounds	O
of	O
Formula	O
I	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
have	O
histamine	B
-	I
H3	I
receptor	I
antagonist	O
or	O
inverse	O
agonist	O
activity	O
,	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
and	O
using	O
such	O
compounds	O
.	O

In	O
another	O
embodiment	O
,	O
the	O
invention	O
discloses	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
I	O
as	O
well	O
as	O
methods	O
of	O
using	O
these	O
compositions	O
to	O
treat	O
obesity	O
,	O
cognitive	O
deficiencies	O
,	O
narcolepsy	O
,	O
and	O
other	O
histamine	B
H3	I
receptor	I
-	O
related	O
diseases	O
.	O

Formula	O
I	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
:	O
m	O
is	O
independenlly	O
at	O
each	O
occurrence	O
1	O
,	O
2	O
,	O
or	O
3	O
,	O
Z	O
independently	O
represents	O
carbon	O
(	O
substituted	O
with	O
hydrogen	O
or	O
the	O
optional	O
substituents	O
indicated	O
herein	O
)	O
or	O
nitrogen	O
,	O
provided	O
that	O
when	O
Z	O
is	O
nitrogen	O
then	O
R6	O
is	O
not	O
attached	O
to	O
Z	O
;	O
R1	O
and	O
R2	O
are	O
independently	O
-	O
(	O
C1-C7	O
)	O
alkyl	O
(	O
optionally	O
substituted	O
with	O
one	O
to	O
three	O
halogens	O
)	O
,	O
or	O
R1	O
and	O
R2	O
and	O
the	O
nitrogen	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
azetidinyl	O
ring	O
,	O
a	O
pyrrolidinyl	O
ring	O
,	O
or	O
a	O
piperidinyl	O
ring	O
,	O
wherein	O
further	O
the	O
azetidinyl	O
,	O
pyrrolidinyl	O
,	O
or	O
piperidinyl	O
ring	O
so	O
formed	O
may	O
be	O
optionally	O
substituted	O
one	O
to	O
three	O
times	O
with	O
R5	O
;	O
R6	O
is	O
independently	O
at	O
each	O
occurrence	O
-H	O
,	O
-halogen	O
,	O
or	O
-CH3	O
.	O

Pyrimidinylimidazoles	O
as	O
tgf	B
-	I
beta	I
inhibitors	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
possess	O
unexpectedly	O
high	O
affinity	O
for	O
Alk	B
5	I
and/or	O
Alk	B
4	I
,	O
and	O
can	O
be	O
useful	O
as	O
antagonists	O
thereof	O
for	O
preventing	O
and/or	O
treating	O
numerous	O
diseases	O
,	O
including	O
fibrotic	O
disorders	O
.	O

The	O
invention	O
features	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
uses	O
thereof	O
.	O

Compositions	O
and	O
methods	O
comprising	O
vitamin	O
b12	O
and	O
an	O
impdh	B
inhibitor	O
for	O
treating	O
viral	O
,	O
inflammatory	O
and	O
proliferative	O
diseases	O
The	O
invention	O
relates	O
generally	O
to	O
novel	O
compositions	O
and	O
methods	O
comprising	O
at	O
least	O
one	O
Vitamin	O
B12	O
compound	O
,	O
at	O
least	O
one	O
IMPDH	B
inhibitor	O
,	O
and	O
optionally	O
an	O
interferon	O
.	O

The	O
compositions	O
and	O
methods	O
provide	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
viral	O
,	O
inflammatory	O
,	O
immunodeficiency	O
,	O
IMPDH	B
-	O
mediated	O
,	O
and	O
proliferative	O
diseases	O
.	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
disease	O
caused	O
by	O
yersinia	O
spp	O
infection	O
The	O
invention	O
generally	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treatment	O
of	O
disease	O
caused	O
by	O
Yersinia	O
spp	O
.	O

infection	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
protein	B
tyrosine	I
phosphatase	I
inhibitors	O
and	O
derivatives	O
and	O
analogs	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
protein	B
tyrosine	I
phosphatase	I
inhibitors	O
and	O
analogs	O
,	O
methods	O
of	O
making	O
the	O
protein	B
tyrosine	I
phosphatase	I
inhibitors	O
and	O
analogs	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Biphenyl	O
integrin	B
antagonists	O
The	O
following	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compounds	O
and	O
compositions	O
of	O
the	O
Formula	O
(	O
I	O
)	O
.	O

useful	O
for	O
treating	O
conditions	O
mediated	O
by	O
αVβ3	B
and/or	O
αVβ5	O
integrin	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
ibandronate	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
multi	O
step	O
synthesis	O
of	O
3-	O
(	O
N	O
-	O
methyl	O
-	O
N	O
-	O
pentyl	O
)	O
amino	O
-	O
l­hydroxypropane-1	O
,	O
1-diphosphonic	O
acid	O
,	O
monosodium	O
salt	O
,	O
monohydrate	O
,	O
of	O
Formula	O
(	O
I	O
)	O
.	O

Cosmetic	O
composition	O
comprising	O
phytosterols	O
,	O
isoflavones	O
and	O
methylricinoleate	O
,	O
use	O
as	O
inhibitor	O
of	O
5-alpha	B
-	I
reductase	I
and	O
hair	O
growth	O
The	O
present	O
invention	O
relates	O
to	O
a	O
cosmetic	O
mixture	O
comprising	O
phytosterols	O
in	O
quantities	O
ranging	O
from	O
1	O
to	O
20	O
%	O
by	O
weight	O
,	O
isoflavones	O
from	O
0.1	O
to	O
4	O
%	O
by	O
weight	O
and	O
methylricinoleate	O
from	O
80	O
to	O
90	O
%	O
by	O
weight	O
.	O

Said	O
cosmetic	O
mixture	O
is	O
formulated	O
with	O
excipients	O
normally	O
used	O
in	O
the	O
cosmetic	O
sector	O
,	O
to	O
give	O
a	O
cosmetic	O
formulation	O
.	O

The	O
cosmetic	O
mixture	O
and	O
formulation	O
are	O
capable	O
of	O
inhibiting	O
the	O
enzyme	O
5-alpha	B
-	I
reductase	I
,	O
and	O
thus	O
have	O
inhibitory	O
or	O
retardatory	O
activity	O
towards	O
the	O
growth	O
of	O
body	O
hair	O
.	O

Iridoid	O
glycoside	O
composition	O
The	O
present	O
invention	O
relates	O
to	O
an	O
adjuvants	O
,	O
particularly	O
to	O
the	O
use	O
of	O
a	O
well	O
-	O
characterized	O
plant	O
based	O
iridoid	O
glycoside	O
adjuvant	O
from	O
plant	O
Picrorhiza	O
kurroa	O
,	O
acting	O
as	O
an	O
adjuvant	O
against	O
T	O
-dependent	O
antigen	O
and	O
specifically	O
against	O
HBsAg	O
and	O
typhoid	O
antigens	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
method	O
of	O
producing	O
the	O
iridoid	O
glycoside	O
adjuvant	O
and	O
the	O
products	O
utilizing	O
such	O
adjuvants	O
for	O
induction	O
of	O
cellular	O
immunity	O
.	O

The	O
adjuvants	O
may	O
be	O
used	O
alone	O
or	O
with	O
specific	O
antigens	O
.	O

The	O
two	O
antigens	O
used	O
in	O
the	O
study	O
represents	O
HBsAg	O
,	O
a	O
recombinant	O
antigen	O
expressed	O
in	O
Pichia	O
pastoris	O
,	O
and	O
typhoid	O
Vi	O
polysaccharide	O
purified	O
from	O
Salmonella	O
typhi	O
broth	O
.	O

These	O
antigens	O
are	O
studied	O
for	O
their	O
immunogenicity	O
with	O
the	O
adjuvant	O
iridoid	O
glycoside	O
adjuvant	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
a	O
taxane	O
derivative	O
The	O
invention	O
relates	O
to	O
an	O
improved	O
process	O
for	O
the	O
synthesis	O
of	O
13-	O
(	O
N	O
-	O
Boc	O
-	O
β	O
-	O
isobutylserinyl	O
)	O
-14-β	O
-	O
hydroxybaccatin	O
III-1,14-carbonate	O
(	O
I	O
)	O
,	O
wherein	O
carbonation	O
of	O
the	O
1,14-hydroxy	O
groups	O
of	O
the	O
baccatin	O
skeleton	O
is	O
carried	O
out	O
with	O
bis	O
(	O
trichloromethylcarbonate	O
and	O
the	O
7-hydroxy	O
group	O
is	O
protected	O
with	O
a	O
trichloroacetyl	O
group	O
.	O

Use	O
of	O
pyridoxal	O
phosphate	O
derivatives	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
related	O
complications	O
Use	O
of	O
a	O
3-acylated	O
pyridoxal	O
analogue	O
,	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof	O
,	O
or	O
a	O
mixture	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
insulin	O
-	O
dependent	O
or	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
,	O
related	O
conditions	O
,	O
symptoms	O
of	O
insulin	O
-	O
dependent	O
or	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
or	O
related	O
conditions	O
,	O
or	O
any	O
combination	O
thereof	O
in	O
a	O
mammal	O
.	O

Alcohol	O
resistant	O
pharmaceutical	O
formulations	O
The	O
present	O
invention	O
provides	O
alcohol	O
resistant	O
oral	O
dosage	O
pharmaceutical	O
forms	O
and	O
methods	O
of	O
using	O
such	O
oral	O
dosage	O
forms	O
to	O
avoid	O
dose	O
dumping	O
if	O
the	O
dosage	O
form	O
is	O
taken	O
together	O
with	O
alcohol	O
.	O

Guanosine	O
-	O
rich	O
oligonucleotides	O
as	O
agents	O
for	O
inducing	O
cell	O
death	O
in	O
eukaryotic	O
cells	O
The	O
present	O
invention	O
relates	O
to	O
guanosine	O
-	O
rich	O
oligonucleotides	O
having	O
the	O
capacity	O
to	O
induce	O
cell	O
death	O
,	O
having	O
characteristics	O
of	O
programmed	O
cell	O
death	O
,	O
in	O
non	O
-	O
quiescent	O
cells	O
of	O
higher	O
eukaryotic	O
organisms	O
.	O

The	O
invention	O
also	O
relates	O
to	O
therapeutic	O
methods	O
involving	O
the	O
administration	O
of	O
these	O
nucleic	O
acid	O
molecules	O
to	O
subjects	O
suffering	O
from	O
,	O
or	O
being	O
predisposed	O
to	O
,	O
disorders	O
involving	O
abnormal	O
cell	O
proliferation	O
and	O
migration	O
.	O

The	O
invention	O
also	O
concerns	O
pharmaceutical	O
compositions	O
comprising	O
the	O
guanosine	O
-	O
rich	O
nucleic	O
acid	O
molecules	O
,	O
in	O
association	O
with	O
suitable	O
carriers	O
.	O

ASSOCIATION	O
OF	O
ß3	B
RECEPTOR	I
AGONIST	O
AND	O
MONOAMINE	O
REUPTAKE	O
INHIBITORS	O
,	O
PHARMACEUTICAL	O
COMPOSITION	O
AND	O
THERAPEUTIC	O
USE	O
THEREOF	O
The	O
invention	O
concerns	O
the	O
association	O
of	O
at	O
least	O
one	O
ß3	B
adrenergic	I
receptor	I
agonist	O
(	O
or	O
ß3	O
agonist	O
)	O
with	O
a	O
monoamine	O
reuptake	O
inhibitor	O
.	O

The	O
invention	O
also	O
concerns	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
inventive	O
association	O
and	O
its	O
therapeutic	O
use	O
.	O

Novel	O
memory	O
ctl	O
induction	O
potentiator	O
The	O
present	O
invention	O
relates	O
to	O
a	O
memory	O
CTL	O
induction	O
enhancer	O
comprising	O
a	O
combination	O
of	O
substance	O
(	O
b	O
)	O
with	O
substance	O
(	O
a	O
)	O
and/or	O
substance	O
(	O
c	O
)	O
,	O
wherein	O
substance	O
(	O
a	O
)	O
is	O
an	O
activator	O
of	O
antigen	O
-	O
presenting	O
cells	O
,	O
substance	O
(	O
b	O
)	O
is	O
an	O
inducer	O
of	O
homeostatic	O
proliferation	O
after	O
induction	O
of	O
lymphopenia	O
,	O
and	O
substance	O
(	O
c	O
)	O
is	O
a	O
suppressor	O
of	O
regulatory	O
T	O
cells	O
.	O

Use	O
of	O
tenatoprazole	O
for	O
the	O
treatment	O
of	O
gastroesophageal	O
reflux	O
disease	O
Use	O
of	O
tenatoprazole	O
is	O
claimed	O
in	O
medicines	O
for	O
the	O
treatment	O
of	O
atypical	O
and	O
esophageal	O
symptoms	O
of	O
gastroesophageal	O
reflux	O
,	O
digestive	O
hemorrhages	O
and	O
dyspepsias	O
.	O

-	O
ACTIVITY	O
:	O
Gastrointestinal	O
-	O
Gen	O
;	O
Antiasthmatic	O
;	O
Antitussive	O
;	O
Respiratory	O
-	O
Gen	O
.	O
;	O
Antianginal	O
;	O
Hemostatic	O
.	O

In	O
a	O
test	O
,	O
fourteen	O
patients	O
suffering	O
from	O
gastroesophageal	O
reflux	O
were	O
given	O
a	O
daily	O
dose	O
of	O
tenatoprazole	O
(	O
20	O
mg	O
)	O
for	O
4	O
-	O
12	O
weeks	O
.	O

In	O
twelve	O
cases	O
,	O
the	O
dosage	O
was	O
tolerated	O
perfectly	O
and	O
in	O
the	O
other	O
two	O
cases	O
it	O
was	O
well	O
-	O
tolerated	O
.	O

The	O
effect	O
on	O
the	O
symptoms	O
was	O
very	O
good	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Proton	B
pump	I
inhibitor	O
.	O

Inhibitors	O
of	O
human	O
immunodeficiency	O
virus	O
replication	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
their	O
derivatives	O
comprising	O
a	O
detectable	O
label	O
,	O
their	O
compositions	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
novel	O
inhibitors	O
of	O
HIV	O
replication	O
,	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
for	O
using	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
HIV	O
infection	O
.	O

Modulation	O
of	O
the	O
P2Y2	B
receptor	I
pathway	O
The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
regulating	O
the	O
activity	O
of	O
the	O
purinergic	B
receptors	I
for	O
the	O
modulation	O
of	O
the	O
vascular	O
tone	O
,	O
particularly	O
for	O
the	O
purpose	O
of	O
treatment	O
of	O
haemodynamic	O
conditions	O
by	O
overriding	O
of	O
vasoconstriction	O
activity	O
,	O
such	O
as	O
increases	O
in	O
sympathic	O
vasoconstriction	O
.	O

Modulators	O
,	O
such	O
as	O
UTP	O
analogues	O
as	O
described	O
herein	O
are	O
preferably	O
specific	O
for	O
P2Y2	O
.	O

Compounds	O
capable	O
of	O
stimulating	O
the	O
P2Y2	B
receptor	I
are	O
suitable	O
for	O
the	O
treatment	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasoconstriction	O
activity	O
is	O
desirable	O
such	O
as	O
hypertension	O
and	O
hypertension	O
relates	O
disorders	O
or	O
diseases	O
,	O
whereas	O
compound	O
capable	O
of	O
counteracting	O
the	O
activity	O
of	O
the	O
P2Y2	B
receptor	I
are	O
suitable	O
for	O
the	O
treatment	O
of	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasodilatation	O
is	O
desirable	O
.	O

Derivatives	O
of	O
1-phenyl-2-pyridynyl	O
alkylene	O
alcohols	O
as	O
phosphodiesterase	B
inhibitors	O
The	O
invention	O
relates	O
to	O
inhibitors	O
of	O
the	O
phosphodiesterase	B
4	I
(	O
PDE4	B
)	O
enzyme	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
derivatives	O
of	O
1-phenyl-2-pyridynyl	O
alkylene	O
alcohols	O
,	O
methods	O
of	O
preparing	O
such	O
compounds	O
,	O
compositions	O
containing	O
them	O
and	O
therapeutic	O
use	O
thereof	O
.	O

Binding	O
interaction	O
of	O
proanthocyanidins	O
with	O
bacteria	O
and	O
bacterial	O
components	O
A	O
composition	O
having	O
:	O
a	O
proanthocyanidin	O
:	O
and	O
a	O
macromolecule	O
,	O
an	O
assembly	O
of	O
macromolecules	O
,	O
a	O
semi	O
-	O
solid	O
,	O
or	O
a	O
solid	O
surface	O
to	O
which	O
the	O
proanthocyanidin	O
is	O
immobilized	O
.	O

A	O
composition	O
having	O
proanthocyanidin	O
compounds	O
having	O
an	O
average	O
degree	O
of	O
polymerization	O
of	O
at	O
least	O
about	O
6	O
.	O

A	O
method	O
of	O
administering	O
to	O
an	O
immunosuppressed	O
patient	O
or	O
a	O
patient	O
diagnosed	O
with	O
sepsis	O
or	O
septic	O
shock	O
a	O
composition	O
having	O
a	O
proanthocyanidin	O
.	O

A	O
method	O
of	O
administering	O
to	O
a	O
patient	O
diagnosed	O
with	O
a	O
gram	O
negative	O
bacterial	O
infection	O
a	O
composition	O
having	O
proanthocyanidin	O
compounds	O
having	O
an	O
average	O
degree	O
of	O
polymerization	O
of	O
at	O
least	O
about	O
6	O
.	O

Pharmaceutical	O
composition	O
using	O
aliskiren	O
and	O
avosentan	O
The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
and	O
method	O
of	O
achieving	O
a	O
therapeutic	O
effect	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
the	O
treatment	O
of	O
hypertension	O
,	O
kidney	O
or	O
heart	O
disease	O
in	O
an	O
animal	O
,	O
preferably	O
a	O
mammal	O
including	O
a	O
human	O
subject	O
,	O
using	O
(	O
i	O
)	O
SPP100	O
/	O
aliskiren	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
combination	O
with	O
(	O
ii	O
)	O
SPP301	O
/	O
avosentan	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
iii	O
)	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

4	O
-	O
1	O
bb	O
ligand	O
in	O
inflammatory	O
diseases	O
The	O
invention	O
provides	O
4-IBBL	O
blocking	O
agents	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
blocking	O
agents	O
as	O
new	O
therapeutic	O
interventions	O
for	O
sustained	O
inflammation	O
.	O

Thus	O
,	O
the	O
invention	O
also	O
provides	O
methods	O
for	O
reducing	O
sustained	O
production	O
of	O
tumor	O
necrosis	O
factor	O
.	O

Glucose	O
metabolism	O
ameliorating	O
agent	O
A	O
compound	O
of	O
the	O
formula	O
I	O
:	O
wherein	O
R1	O
is	O
lower	O
alkyl	O
,	O
R2	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
,	O
Z	O
is	O
optionally	O
substituted	O
lower	O
alkyl	O
,	O
optionally	O
substituted	O
lower	O
alkenyl	O
,	O
optionally	O
substituted	O
amino	O
,	O
optionally	O
substituted	O
lower	O
alkoxy	O
,	O
optionally	O
substituted	O
carbocyclyl	O
or	O
optionally	O
substituted	O
heterocyclyl	O
can	O
stimulate	O
the	O
glucose	O
metabolism	O
independent	O
of	O
change	O
in	O
body	O
weight	O
.	O

The	O
compound	O
can	O
be	O
used	O
as	O
a	O
glucose	O
metabolism	O
stimulating	O
agent	O
.	O

1-aryl-3-aminoalkoxy	O
-	O
pyrazoles	O
as	O
sigma	O
ligands	O
enhancing	O
analgesic	O
effects	O
of	O
opioids	O
and	O
attenuating	O
the	O
dependency	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
potentiation	O
of	O
the	O
analgesic	O
effect	O
of	O
opioids	O
as	O
well	O
as	O
to	O
attenuation	O
of	O
the	O
addiction	O
thereof	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
group	O
of	O
sigma	O
receptor	O
ligands	O
of	O
formula	O
I	O
for	O
the	O
potentiation	O
of	O
the	O
analgesic	O
effect	O
of	O
opioids	O
and	O
at	O
the	O
same	O
time	O
for	O
decreasing	O
of	O
the	O
dependency	O
induced	O
by	O
them	O
.	O

Oxylipins	O
from	O
long	O
chain	O
polyunsaturated	O
fatty	O
acids	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
same	O
Disclosed	O
are	O
novel	O
oxylipins	O
,	O
referred	O
to	O
herein	O
as	O
docosanoids	O
and	O
eicosanoids	O
,	O
that	O
are	O
derived	O
from	O
C22	O
polyunsaturated	O
fatty	O
acids	O
and	O
from	O
C20	O
polyunsaturated	O
fatty	O
acids	O
,	O
respectively	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
such	O
oxylipins	O
.	O

Also	O
disclosed	O
is	O
the	O
use	O
of	O
docosapentaenoic	O
acid	O
(	O
C22:5n-6	O
)	O
(	O
DPAn-6	O
)	O
,	O
docosapentaenoic	O
acid	O
(	O
C22:5n-3	O
)	O
(	O
DPAn-3	O
)	O
,	O
and	O
docosatetraenoic	O
acid	O
(	O
DTAn-6	O
:	O
C22:4n-6	O
)	O
,	O
docosatrienoic	O
acid	O
(	O
C22:3n-3	O
)	O
(	O
DTrAn-3	O
)	O
,	O
docosadienoic	O
acid	O
(	O
C22:2n-6	O
)	O
(	O
DDAn-6	O
)	O
,	O
eicosatrienoic	O
acid	O
(	O
C20:3n-3	O
)	O
(	O
ETrAn-3	O
)	O
eicosapentaenoic	O
acid	O
and	O
arachidonic	O
acid	O
as	O
substrates	O
for	O
the	O
production	O
of	O
novel	O
oxylipins	O
,	O
and	O
to	O
the	O
oxylipins	O
produced	O
thereby	O
.	O

Also	O
disclosed	O
is	O
the	O
use	O
of	O
DPAn-6	O
,	O
DPAn-3	O
,	O
DTAn-6	O
,	O
and/or	O
the	O
oxylipins	O
derived	O
therefrom	O
,	O
and/or	O
novel	O
docosanoids	O
derived	O
from	O
the	O
structures	O
of	O
C22	O
fatty	O
acids	O
in	O
therapeutic	O
and	O
nutritional	O
or	O
cosmetic	O
applications	O
,	O
and	O
particularly	O
as	O
anti	O
-	O
inflammatory	O
or	O
anti	O
-	O
neurodegenerative	O
compounds	O
.	O

The	O
invention	O
also	O
relates	O
to	O
novel	O
ways	O
of	O
producing	O
long	O
chain	O
polyunsaturated	O
acid	O
(	O
LCPUF	O
A	O
)	O
-rich	O
oils	O
and	O
compositions	O
that	O
contain	O
enhanced	O
and	O
effective	O
amounts	O
of	O
LCPUF	O
A	O
-	O
derived	O
oxylipins	O
,	O
and	O
particularly	O
,	O
docosanoids	O
.	O

Method	O
for	O
optimizing	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
with	O
abl	B
tyrosine	O
kinase	O
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
evaluating	O
patients	O
to	O
help	O
optimizing	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
in	O
a	O
human	O
patient	O
population	O
.	O

More	O
specifically	O
,	O
the	O
method	O
comprises	O
the	O
steps	O
of	O
(	O
a	O
)	O
determining	O
the	O
OCT-1	B
Activity	O
in	O
pre	O
-	O
therapy	O
blood	O
of	O
a	O
warm	O
-	O
blooded	O
animal	O
suffering	O
from	O
CML	O
,	O
and	O
(	O
b	O
)	O
administering	O
a	O
daily	O
dose	O
between	O
about	O
500	O
and	O
1200	O
mg	O
of	O
Imatinib	O
mesylate	O
to	O
the	O
warm	O
-	O
blooded	O
animal	O
suffering	O
from	O
CML	O
showing	O
an	O
OCT-1	B
Activity	O
corresponding	O
to	O
Imatinib	O
intracellular	O
concentration	O
below	O
about	O
6.0	O
to	O
10.0	O
ng	O
/	O
200,000	O
cells	O
,	O
especially	O
about	O
8.0	O
to	O
8.5	O
ng	O
/	O
200,000	O
cells	O
.	O

Florfenicol	O
esters	O
for	O
treating	O
bacterial	O
infections	O
The	O
present	O
invention	O
pertains	O
to	O
the	O
use	O
of	O
a	O
composition	O
comprising	O
a	O
florfenicol	O
ester	O
and	O
a	O
pharmaceutically	O
acceptable	O
solvent	O
wherein	O
the	O
florfenicol	O
ester	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
florfenicol	O
acetate	O
,	O
florfenicol	O
propionate	O
,	O
florfenicol	O
butyrate	O
,	O
florfenicol	O
pentanoate	O
,	O
florfenicol	O
heptanoate	O
,	O
florfenicol	O
octanoate	O
,	O
florfenicol	O
nanoate	O
,	O
florfenicol	O
decanoate	O
,	O
florfenicol	O
undecanoate	O
,	O
and	O
florfenicol	O
dodecanoate	O
;	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
a	O
bacterial	O
infection	O
that	O
is	O
susceptible	O
to	O
florfenicol	O
in	O
a	O
bovine	O
that	O
can	O
be	O
administered	O
as	O
a	O
single	O
injection	O
in	O
an	O
amount	O
sufficient	O
to	O
treat	O
the	O
infection	O
without	O
requiring	O
a	O
second	O
injection	O

Anti	O
-	O
glycation	O
properties	O
of	O
asicatic	O
acid	O
and	O
madecassic	O
acid	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
use	O
of	O
compounds	O
from	O
Centella	O
Asiatica	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Asiatic	O
acid	O
and	O
Madecassic	O
acid	O
,	O
and	O
plant	O
extracts	O
containing	O
both	O
acids	O
in	O
cosmetics	O
,	O
pharmaceuticals	O
and	O
food	O
supplements	O
for	O
preventing	O
the	O
glycation	O
phenomenon	O
and	O
the	O
glycation	O
consequences	O
in	O
tissues	O
,	O
more	O
paticularly	O
for	O
preventing	O
skin	O
aging	O
,	O
enhancing	O
wounds	O
treating	O
,	O
venous	O
insufficiency	O
etc	O
.	O

Poly	O
aromatic	O
sodium	B
channel	I
blockers	O
Polyaromatic	O
sodium	B
channel	I
blockers	O
represented	O
by	O
the	O
formula	O
:	O
(	O
I	O
)	O
are	O
provided	O
where	O
the	O
structural	O
variables	O
are	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
includes	O
a	O
variety	O
of	O
compositions	O
,	O
combinations	O
and	O
methods	O
of	O
treatment	O
using	O
these	O
inventive	O
sodium	B
channel	I
blockers	O
.	O

2-aminopyridine	O
kinase	B
inhibitors	O
2-Aminopyridine	O
compounds	O
having	O
the	O
structure	O
of	O
Formula	O
I	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
these	O
compounds	O
.	O

Compounds	O
of	O
Formula	O
I	O
inhibit	O
the	O
activity	O
of	O
tyrosine	B
kinase	I
enzymes	O
in	O
animals	O
,	O
including	O
humans	O
,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
various	O
diseases	O
and	O
conditions	O
.	O

In	O
particular	O
,	O
compounds	O
disclosed	O
herein	O
are	O
inhibitors	O
of	O
kinases	O
,	O
in	O
particular	O
,	O
but	O
not	O
limited	O
to	O
,	O
KDR	B
,	O
Tie-2	B
,	O
F1t3	B
,	O
FGFR3	B
,	O
Ab1	B
,	O
Aurora	B
A	I
,	O
c	B
-	I
Src	I
,	O
IGF-	B
IR	I
,	O
ALK	B
,	O
c	B
-	I
MET	I
,	O
RON	B
,	O
PAK1	B
,	O
PAK2	B
,	O
and	O
TAK1	B
,	O
and	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
,	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
cancer	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
patient	O
having	O
a	O
condition	O
which	O
is	O
mediated	O
by	O
protein	B
kinase	I
activity	O
by	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
above	O
-	O
mentioned	O
pharmaceutical	O
composition	O
.	O

Stabilization	O
of	O
the	O
composition	O
of	O
a	O
mixture	O
Described	O
is	O
a	O
method	O
for	O
slowing	O
the	O
speed	O
of	O
the	O
isomerisation	O
of	O
petasin	O
and	O
neopetasin	O
to	O
isopetasin	O
,	O
and	O
the	O
isomerisation	O
of	O
S	O
-	O
petasin	O
and	O
neo	O
-	O
S	O
-	O
petasin	O
to	O
iso	O
-	O
S	O
-	O
petasin	O
,	O
especially	O
in	O
extracts	O
from	O
plants	O
of	O
the	O
genus	O
Petasites	O
,	O
preferably	O
Petasites	O
hybridus	O
,	O
by	O
the	O
addition	O
of	O
at	O
least	O
one	O
suitable	O
stabilizer	O
and/or	O
the	O
removal	O
of	O
at	O
least	O
one	O
destabilizing	O
substance	O
,	O
e.g.	O
a	O
fatty	O
acid	O
.	O

Enhanced	O
nsaid	O
formulations	O
The	O
application	O
is	O
directed	O
to	O
a	O
composition	O
and	O
its	O
use	O
for	O
treating	O
inflammation	O
comprising	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
active	O
agent	O
,	O
a	O
metasilicate	O
,	O
a	O
first	O
disintegrant	O
and	O
a	O
second	O
disintegrant	O
,	O
resulting	O
in	O
increased	O
absorption	O
of	O
said	O
active	O
in	O
mammals	O
with	O
suppressed	O
vagal	O
systems	O
The	O
preferred	O
composition	O
includes	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
active	O
,	O
sodium	O
bicarbonate	O
,	O
tartaric	O
acid	O
and	O
metasilicate	O
.	O

Tetracyclic	O
compound	O
Provided	O
are	O
a	O
tetracyclic	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
[	O
in	O
the	O
formula	O
(	O
I	O
)	O
,the	O
formula	O
(	O
A	O
)	O
represents	O
a	O
benzene	O
ring	O
or	O
the	O
like	O
,	O
X	O
represents	O
CH	O
or	O
a	O
nitrogen	O
atom	O
,	O
Q	O
represents	O
-O-	O
or	O
the	O
like	O
,	O
R1	O
,	O
R2	O
,	O
and	O
R3	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
,	O
1	O
,	O
m	O
,	O
and	O
n	O
each	O
represent	O
an	O
integer	O
from	O
one	O
to	O
the	O
maximum	O
substitutable	O
number	O
of	O
substituents	O
,	O
and	O
R4	O
and	O
R5	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
the	O
like	O
.	O

Cosmetic	O
composition	O
for	O
sensitive	O
skins	O
Cosmetic	O
composition	O
for	O
sensitive	O
skins	O
comprising	O
hyperoxygenated	O
fatty	O
acids	O
and	O
one	O
or	O
more	O
volatile	O
silicones	O
,	O
together	O
with	O
the	O
use	O
thereof	O
for	O
the	O
prevention	O
of	O
ulcers	O
and	O
the	O
preservation	O
of	O
perilesional	O
skin	O
.	O

Combination	O
of	O
a	O
phosphatidylinositol-3-kinase	B
(	O
pi3k	B
)	O
inhibitor	O
and	O
a	O
mtor	B
inhibitor	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
combination	O
which	O
comprises	O
(	O
a	O
)	O
a	O
phosphoinositide	B
3-kinase	I
inhibitor	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
(	O
b	O
)	O
a	O
mTOR	B
inhibitor	O
for	O
the	O
treatment	O
of	O
a	O
target	B
of	I
raparnycin	I
(	I
mTOR	I
)	I
kinase	I
dependent	O
disease	O
,	O
especially	O
a	O
cancer	O
disease	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
such	O
a	O
combination	O
;	O
the	O
use	O
of	O
such	O
a	O
combination	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease	O
;	O
a	O
commercial	O
package	O
or	O
product	O
comprising	O
such	O
a	O
combination	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
use	O
;	O
and	O
to	O
a	O
method	O
of	O
treatment	O
of	O
a	O
warm¬	O
blooded	O
animal	O
,	O
especially	O
a	O
human	O
.	O

Benzonaphtyridine	O
compounds	O
used	O
as	O
inhibitors	O
of	O
autotaxin	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5,D	O
,	O
Z	O
,	O
X	O
,	O
Y	O
,	O
m	O
and	O
p	O
are	O
defined	O
as	O
cited	O
in	O
claim	O
1	O
.	O

Said	O
compounds	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
tumours	O
.	O

Topical	O
cosmetic	O
or	O
pharmaceutical	O
composition	O
comprising	O
probiotic	O
lactobacillus	O
strains	O
and	O
use	O
of	O
same	O
A	O
topical	O
composition	O
which	O
is	O
suitable	O
for	O
treating	O
or	O
preventing	O
skin	O
or	O
mucosal	O
infectious	O
disorders	O
or	O
troubles	O
in	O
humans	O
,	O
in	O
particular	O
for	O
treating	O
or	O
preventing	O
urinary	O
tract	O
infections	O
and	O
lower	O
vaginal	O
tract	O
infections	O
in	O
females	O
comprises	O
an	O
oily	O
primary	O
phase	O
and	O
a	O
complementary	O
aqueous	O
phase	O
wherein	O
the	O
oily	O
primary	O
phase	O
consists	O
of	O
a	O
non	O
polar	O
mineral	O
or	O
silicone	O
comprising	O
an	O
efficient	O
amount	O
of	O
at	O
least	O
one	O
viable	O
probiotic	O
bacteria	O
strain	O
,	O
in	O
particular	O
a	O
lactobacillus	O
strain	O
.	O

The	O
composition	O
is	O
also	O
useful	O
for	O
suitable	O
for	O
balancing	O
or	O
restoring	O
skin	O
or	O
mucosal	O
indigenous	O
microflora	O
in	O
humans	O
,	O
in	O
particular	O
for	O
balancing	O
or	O
restoring	O
the	O
local	O
urinary	O
tract	O
and	O
lower	O
vaginal	O
tract	O
bacterial	O
flora	O
in	O
females	O
.	O

Pyrazole	O
-	O
amine	O
compounds	O
useful	O
as	O
kinase	O
inhibitors	O
The	O
present	O
invention	O
provides	O
pyrazole	O
derived	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
for	O
treating	O
p38	O
kinase	O
-	O
associated	O
conditions	O
,	O
where	O
W	O
,	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
m	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
further	O
pertains	O
to	O
pharmaceutical	O
compositions	O
containing	O
at	O
least	O
one	O
compound	O
according	O
to	O
the	O
invention	O
useful	O
for	O
treating	O
p38	O
kinase	O
-	O
associated	O
conditions	O
,	O
and	O
methods	O
of	O
inhibiting	O
the	O
activity	O
of	O
p38	O
kinase	O
in	O
a	O
mammal	O
.	O

Methods	O
for	O
making	O
valerenic	O
acid	O
derivatives	O
and	O
their	O
use	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
,	O
intermediates	O
and	O
methods	O
for	O
making	O
valerenic	O
acid	O
and	O
its	O
derivatives	O
as	O
well	O
as	O
the	O
use	O
of	O
such	O
compounds	O
as	O
GABAA	O
receptor	O
ligands	O
.	O

3-	O
(	O
5-Amino-6-oxo-1,6-dihydropyridazin-3-yl	O
)	O
-biphenyl	O
derivatives	O
as	O
PDE4	B
inhibitors	O
New	O
pyridazin-3	O
(	O
2H	O
)	O
-one	O
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
the	O
phosphodiesterase	B
IV	I
(	O
PDE4	B
)	O
.	O

Diazeniumdiolated	O
phosphorylcholine	O
polymers	O
for	O
nitric	O
oxide	O
release	O
The	O
present	O
disclosure	O
in	O
a	O
broad	O
aspect	O
provides	O
for	O
diazeniumdiolated	O
phosphorylcholine	O
polymers	O
and	O
associated	O
methods	O
for	O
achieving	O
nitric	O
oxide	O
release	O
.	O

The	O
present	O
polymers	O
have	O
superior	O
biocompatibility	O
and	O
are	O
useful	O
for	O
coating	O
or	O
fabricating	O
medical	O
devices	O
such	O
as	O
a	O
vascular	O
stent	O
.	O

5,6,7,8-TETRAHYDRO	O
[	O
1,2,4	O
]	O
TRIAZOLO	O
[	O
4,3-a	O
]	O
PYRAZINE	O
DERIVATIVES	O
AS	O
P2X7	O
MODULATORS	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
wherein	O
A	O
is	O
hydrogen	O
,	O
C1	O
-	O
4alkyl	O
,	O
C3	O
-	O
6cycloalkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
C1	O
-	O
3alkoxy	O
C1	O
-	O
4alkyl	O
,	O
C1	O
-	O
2fluoroalkyl	O
,	O
halogen	O
,	O
NR6	O
R7	O
,	O
optionally	O
substituted	O
heteroaryl	O
(	O
Het	O
)	O
,	O
or	O
optionally	O
substituted	O
phenyl	O
,	O
and	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

The	O
compounds	O
or	O
salts	O
are	O
thought	O
to	O
modulate	O
P2X7	O
receptor	O
function	O
and	O
to	O
be	O
capable	O
of	O
antagonizing	O
the	O
effects	O
of	O
ATP	O
at	O
the	O
P2X7	O
receptor	O
.	O

The	O
invention	O
also	O
provides	O
the	O
use	O
of	O
the	O
compound	O
or	O
salt	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
,	O
for	O
example	O
,	O
inflammatory	O
pain	O
,	O
neuropathic	O
pain	O
,	O
visceral	O
pain	O
,	O
rheumatoid	O
arthritis	O
,	O
osteoarthritis	O
or	O
neurodegenerative	O
disorders	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
ophthalmic	O
conditions	O
We	O
describe	O
methods	O
and	O
compositions	O
for	O
treating	O
ophthalmic	O
conditions	O
associated	O
with	O
angiogenesis	O
,	O
vascular	O
leakage	O
,	O
and/or	O
damage	O
to	O
ganglia	O
.	O

Combination	O
of	O
dopamine	O
agonists	O
plus	O
first	O
phase	O
insulin	O
secretagouges	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
metabolic	O
disorder	O
or	O
key	O
elements	O
of	O
a	O
metabolic	O
disorder	O
such	O
method	O
comprising	O
the	O
use	O
of	O
an	O
agent	O
(	O
s	O
)	O
that	O
increases	O
central	O
dopaminergic	O
activity	O
plus	O
a	O
first	O
-	O
phase	O
insulin	B
secretagouge	O
.	O

2-	O
(	O
lh	O
-	O
pyrazol-4	O
-ylamino	O
)	O
-pyrimidine	O
as	O
kinase	B
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts	O
:	O
wherein	O
A1	O
,	O
A2	O
,	O
A3	O
,	O
A4	O
,	O
X	O
and	O
Y	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
present	O
invention	O
relates	O
also	O
to	O
methods	O
of	O
making	O
said	O
compounds	O
,	O
and	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	O
such	O
as	O
aurora	B
and	O
KDR	B
.	O

The	O
use	O
of	O
lpa	O
for	O
encouraging	O
pregnancy	O
,	O
and	O
fertility	O
agent	O
The	O
objective	O
is	O
to	O
find	O
compounds	O
which	O
have	O
an	O
activity	O
to	O
improve	O
the	O
success	O
rate	O
of	O
pregnancy	O
and	O
implantation	O
in	O
blastocyst	O
transfer	O
in	O
mammals	O
,	O
to	O
provide	O
a	O
method	O
of	O
producing	O
and	O
using	O
the	O
compounds	O
,	O
and	O
to	O
provide	O
a	O
pregnancy	O
-	O
promoting	O
agent	O
.	O

Disclosed	O
is	O
a	O
pregnancy	O
-	O
promoting	O
agent	O
containing	O
one	O
or	O
more	O
lysophosphatidic	O
acids	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
LPA	O
-	O
C16:0	O
,	O
LPA	O
-	O
C16:1	O
,	O
LPA	O
-	O
C18:0	O
,	O
LPA	O
-	O
C18:1	O
and	O
LPA	O
-	O
C18:2	O
.	O

Medical	O
use	O
of	O
spla2	O
hydrolysable	O
liposomes	O
The	O
present	O
invention	O
relates	O
to	O
medical	O
use	O
of	O
liposomes	O
,	O
more	O
particular	O
the	O
first	O
medical	O
use	O
of	O
sPLA2	O
hydrolysable	O
liposomes	O
.	O

Such	O
liposomes	O
may	O
be	O
used	O
for	O
targeted	O
delivery	O
of	O
therapeutic	O
agents	O
to	O
cancerous	O
tissue	O
and	O
in	O
such	O
embodiments	O
;	O
the	O
therapeutic	O
agents	O
are	O
typically	O
small	O
molecule	O
antitumor	O
agents	O
.	O

Other	O
aspects	O
of	O
the	O
inventions	O
relates	O
to	O
methods	O
of	O
reducing	O
the	O
side	O
effects	O
of	O
therapeutic	O
agents	O
,	O
e.g.	O
reducing	O
nephrotoxicity	O
,	O
neurotoxicity	O
and	O
gastrointestinal	O
toxicity	O
of	O
a	O
therapeutic	O
agent	O
.	O

Yet	O
another	O
aspect	O
of	O
the	O
present	O
invention	O
relate	O
to	O
methods	O
of	O
prolonging	O
the	O
therapeutic	O
effect	O
of	O
a	O
therapeutic	O
agent	O
.	O

Solid	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
The	O
present	O
invention	O
relates	O
to	O
a	O
solid	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
,	O
containing	O
the	O
following	O
components	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
:	O
(	O
A	O
)	O
2-	O
[	O
4-	O
[	O
2-	O
(	O
benzimidazol-2-ylthio	O
)	O
ethyl	O
]	O
piperazin-1-yl	O
]	O
-N-	O
[	O
2,4	O
-bis	O
(	O
methylthio	O
)	O
-6-methyl-3-pyridyl	O
]	O
acetamide	O
(	O
compound	O
a	O
)	O
or	O
an	O
acid	O
addition	O
salt	O
thereof	O
,	O
and	O
(	O
B	O
)	O
organic	O
acid	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
tartaric	O
acid	O
,	O
malic	O
acid	O
,	O
ascorbic	O
acid	O
and	O
benzoic	O
acid	O
.	O

An	O
improvement	O
is	O
achieved	O
in	O
the	O
dissolubility	O
of	O
the	O
compound	O
a	O
,	O
which	O
is	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
hypercholesterolemia	O
,	O
arteriosclerosis	O
,	O
and	O
the	O
like	O
.	O

Inhibitors	O
of	O
long	O
and	O
very	O
long	O
chain	O
fatty	O
acid	O
metabolism	O
as	O
broad	O
spectrum	O
anti	O
-	O
virals	O
The	O
present	O
invention	O
provides	O
methods	O
and	O
compounds	O
for	O
treating	O
viral	O
infections	O
using	O
modulators	O
of	O
host	O
cell	O
enzymes	O
relating	O
to	O
long	O
chain	O
fatty	O
acid	O
and	O
lipid	O
droplet	O
metabolism	O
.	O

It	O
includes	O
a	O
method	O
of	O
treating	O
viral	O
infections	O
using	O
triacsin	O
C	O
and	O
its	O
relatives	O
,	O
analogues	O
and	O
derivatives	O
as	O
well	O
as	O
other	O
inhibitors	O
of	O
long	O
chain	O
fatty	O
acid	O
metabolism	O
and	O
lipid	O
droplet	O
metabolism	O
.	O

Inhibitors	O
of	O
glucose	O
metabolism	O
for	O
use	O
in	O
the	O
treatment	O
of	O
birt	O
-	O
hogg	O
-	O
dubé	O
syndrome	O
A	O
composition	O
comprising	O
an	O
inhibitor	O
of	O
glucose	O
metabolism	O
for	O
use	O
in	O
the	O
treatment	O
of	O
Birt	O
-	O
Hogg	O
-	O
Dubé	O
syndrome	O
.	O

The	O
inhibitor	O
of	O
glucose	O
metabolism	O
may	O
be	O
a	O
glycolytic	O
inhibitor	O
.	O

The	O
inhibitor	O
of	O
glucose	O
metabolism	O
may	O
be	O
an	O
inhibitor	O
of	O
pyruvate	O
metabolism	O
.	O

Suitable	O
inhibitors	O
of	O
glucose	O
metabolism	O
include	O
2-deoxy	O
-	O
D-	O
glucose	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
or	O
oxamate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
.	O

Treatment	O
of	O
excessive	O
menstrual	O
bleeding	O
associated	O
with	O
uterine	O
fibroids	O
The	O
present	O
invention	O
relates	O
generally	O
to	O
benign	O
gynecological	O
diseases	O
and	O
in	O
particular	O
to	O
a	O
method	O
for	O
reducing	O
heavy	O
menstruation	O
associated	O
with	O
said	O
gynecological	O
diseases	O
following	O
treatment	O
with	O
vascular	O
occlusion	O
methods	O
or	O
thermal	O
related	O
treatment	O
methods	O
.	O

Pharmaceutical	O
composition	O
for	O
the	O
prevention	O
or	O
the	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
and	O
the	O
method	O
for	O
prevention	O
or	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
using	O
the	O
same	O
The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
containing	O
an	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	O
,	O
vildagliptin	O
,	O
linagliptin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Further	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
,	O
including	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	O
,	O
vildagliptin	O
,	O
linagliptin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
a	O
mammal	O
including	O
a	O
human	O
in	O
need	O
thereof	O
.	O

Further	O
,	O
the	O
present	O
invention	O
provides	O
use	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	O
,	O
vildagliptin	O
,	O
linagliptin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
.	O

Therapeutic	O
Agent	O
for	O
Migraine	O
Provided	O
are	O
therapeutic	O
and/or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprise	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	B
A2A	I
receptor	I
antagonistic	O
activity	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
therapeutic	O
and/or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	B
A2A	I
receptor	I
antagonistic	O
activity	O
,	O
which	O
has	O
an	O
affinity	O
for	O
the	O
adenosine	B
A2A	I
receptor	I
10	O
times	O
or	O
higher	O
than	O
that	O
for	O
the	O
adenosine	B
A1	I
receptor	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
the	O
like	O
.	O

Gaseous	O
nitric	O
oxide	O
-	O
sequestering	O
products	O
and	O
processes	O
of	O
preparing	O
same	O
A	O
process	O
of	O
preparing	O
articles	O
having	O
gaseous	O
NO	O
sequestered	O
therein	O
is	O
disclosed	O
,	O
as	O
well	O
as	O
articles	O
prepared	O
thereby	O
.	O

Also	O
disclosed	O
are	O
articles	O
having	O
gaseous	O
NO	O
sequestered	O
therewithin	O
and	O
having	O
reduced	O
amount	O
of	O
oxygen	O
-	O
containing	O
and/or	O
nitrogen	O
-	O
containing	O
reactive	O
species	O
.	O

Also	O
disclosed	O
are	O
processes	O
of	O
preparing	O
packaged	O
articles	O
having	O
a	O
non	O
-	O
gas	O
permeable	O
package	O
that	O
comprises	O
gaseous	O
NO	O
therein	O
and	O
packaged	O
articles	O
made	O
therefrom	O
.	O

Also	O
disclosed	O
are	O
charging	O
devices	O
which	O
can	O
be	O
utilized	O
in	O
the	O
above	O
-	O
described	O
processes	O
.	O

The	O
articles	O
prepared	O
by	O
the	O
above	O
-	O
described	O
processes	O
are	O
preferably	O
medical	O
devices	O
such	O
as	O
indwelling	O
catheters	O
,	O
intubation	O
devices	O
and	O
tampons	O
.	O

Tampons	O
having	O
sequestered	O
therein	O
gaseous	O
NO	O
,	O
uses	O
thereof	O
and	O
processes	O
of	O
preparing	O
same	O
are	O
also	O
disclosed	O
.	O

Pharmaceutical	O
compound	O
for	O
treating	O
status	O
asthmaticus	O
Pharmaceutical	O
composition	O
comprises	O
enoximone	O
,	O
which	O
is	O
administered	O
intravenously	O
in	O
an	O
amount	O
of	O
not	O
>	O
300	O
mg	O
per	O
day	O
,	O
preferably	O
200	O
mg	O
per	O
day	O
.	O

An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
a	O
kit	O
comprising	O
the	O
pharmaceutical	O
composition	O
and	O
a	O
drug	O
including	O
beta	O
-2	O
sympathomimetic	O
agent	O
,	O
catecholamines	O
,	O
aminophylline	O
,	O
corticosteroids	O
,	O
parasympatholytic	O
agent	O
,	O
magnesium	O
sulfate	O
,	O
ketamine	O
and/or	O
S	O
-	O
ketamine	O
for	O
treating	O
status	O
asthmaticus	O
.	O

ACTIVITY	O
:	O
Antiasthmatic	O
.	O

Test	O
details	O
are	O
described	O
but	O
no	O
results	O
given	O
.	O

MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

New	O
cathepsin	O
s	O
protease	O
inhibitors	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
e.g.	O
autoimmune	O
disorders	O
,	O
allergy	O
and	O
chronic	O
pain	O
conditions	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R2a	O
and	O
R2b	O
are	O
independently	O
H	O
,	O
halo	O
,	O
C1-C4alkyl	O
,	O
C1-C4haloalkyl	O
or	O
C1-C4alkoxy	O
,	O
or	O
R2a	O
and	O
R2b	O
together	O
with	O
the	O
carbon	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
C3-C6cycloalkyl	O
;	O
R3	O
is	O
a	O
C5-C10	O
alkyl	O
,	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
independently	O
selected	O
from	O
halo	O
,	O
C1-C4haloalkyl	O
,	O
C1-C4alkoxy	O
,	O
C1-C4haloalkoxy	O
;	O
or	O
R3	O
is	O
a	O
C2-C4alkyl	O
chain	O
with	O
at	O
least	O
2	O
chloro	O
or	O
3	O
fluoro	O
substituents	O
;	O
or	O
R3	O
is	O
C3-C7cycloalkylmethyl	O
,	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
independently	O
selected	O
from	O
C1-C4alkyl	O
,	O
halo	O
,	O
C1-C4haloalkyl	O
,	O
C1-C4alkoxy	O
,	O
C1-C4haloalkoxy	O
;	O
R4	O
is	O
C1-C6alkyl	O
,	O
C1-C6haloalkyl	O
,	O
C1-C6alkoxy	O
,	O
C1-C6haloalkoxy	O
,	O
C1-C6alkylamino	O
,	O
C1-	O
C6dialkylamino	O
or	O
;	O
R4	O
is	O
Het	O
or	O
Carbocyclyl	O
,	O
either	O
of	O
which	O
is	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
;	O
n	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
for	O
the	O
use	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
disorder	O
characterised	O
by	O
inappropriate	O
expression	O
or	O
activation	O
of	O
cathepsin	O
S.	O

Methods	O
of	O
treating	O
or	O
ameliorating	O
diseases	O
and	O
enhancing	O
performance	O
comprising	O
the	O
use	O
of	O
a	O
magnetic	O
dipole	O
stabilized	O
solution	O
The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
treating	O
or	O
ameliorating	O
skin	O
conditions	O
,	O
diabetic	O
conditions	O
,	O
cardiovascular	O
conditions	O
,	O
cancer	O
,	O
infections	O
or	O
metal	O
poisoning	O
,	O
enhancing	O
performance	O
,	O
or	O
providing	O
nutritional	O
support	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
compositions	O
comprising	O
a	O
magnetic	O
dipole	O
stabilized	O
solution	O
(	O
MDSS	O
)	O
.	O

The	O
MDSS	O
solution	O
may	O
include	O
additional	O
components	O
and	O
can	O
be	O
provided	O
in	O
a	O
kit	O
.	O

Stable	O
solid	O
preparations	O
A	O
stable	O
solid	O
dosage	O
form	O
comprising	O
a	O
non	O
-	O
toxic	O
base	O
and	O
an	O
amorphous	O
benzimidazole	O
compound	O
having	O
a	O
proton	B
pump	I
inhibitor	O
(	O
PPI	O
)	O
activity	O
.	O

Hetero	O
ring	O
compound	O
[	O
Problem	O
]	O
A	O
novel	O
and	O
excellent	O
compound	O
which	O
is	O
useful	O
as	O
an	O
agent	O
for	O
preventing	O
and/or	O
treating	O
rejection	O
reactions	O
in	O
various	O
organ	O
transplantations	O
,	O
allergy	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
and	O
hematologic	O
tumor	O
,	O
and	O
based	O
on	O
a	O
PI3Kδ	B
selective	O
inhibitory	O
action	O
and/or	O
an	O
IL-2	B
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

The	O
present	O
inventors	O
have	O
investigated	O
a	O
compound	O
having	O
a	O
PI3Kδ	B
selective	O
inhibitory	O
action	O
and/or	O
an	O
IL-2	B
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
and	O
have	O
found	O
that	O
the	O
heterocyclic	O
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
PI3Kδ	B
selective	O
inhibitory	O
action	O
and/or	O
and	O
IL-2	B
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
thereby	O
completing	O
the	O
present	O
invention	O
.	O

Substituted	O
Thiazoles	O
as	O
VEGFR2	O
kinase	O
Inhibitors	O
This	O
invention	O
relates	O
to	O
substituted	O
thiazoles	O
of	O
formula	O
I	O
:	O
wherein	O
:	O
L	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
-NHC	O
(	O
X	O
)	O
-	O
,	O
-C	O
(	O
X	O
)	O
NH-	O
,	O
-NHC	O
(	O
X	O
)	O
NH-	O
,	O
-C	O
(	O
X	O
)	O
-	O
,	O
-C	O
(	O
X	O
)	O
NH	O
-	O
alkylene-	O
and	O
-NHC	O
(	O
X	O
)	O
-alkylene-	O
,	O
where	O
X	O
is	O
oxygen	O
or	O
sulfur	O
;	O
and	O
Q	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alkyl	O
,	O
substituted	O
alkyl	O
,	O
aryl	O
,	O
substituted	O
aryl	O
,	O
heteroaryl	O
,	O
substituted	O
heteroaryl	O
,	O
cycloalkyl	O
,	O
substituted	O
cycloalkyl	O
,	O
heterocyclic	O
and	O
substituted	O
heterocyclic	O
,	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
use	O
as	O
VEGFR2	O
(	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
)	O
kinase	O
inhibitors	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
capable	O
of	O
treatment	O
by	O
a	O
VEGFR2	O
kinase	O
inhibitor	O
,	O
particularly	O
cancer	O
.	O

Compounds	O
and	O
pharmaceutical	O
compositions	O
for	O
treating	O
disorders	O
associated	O
with	O
the	O
5-ht1a	O
and	O
5-ht2a	O
receptors	O
This	O
invention	O
is	O
related	O
to	O
the	O
alkyl	O
-	O
piperazine	O
-	O
phenyl	O
4	O
(	O
3H	O
)	O
-quinazolinones	O
general	O
formula	O
(	O
I	O
)	O
compounds	O
,	O
pharmacologicaly	O
active	O
and	O
able	O
to	O
act	O
on	O
the	O
5-HT1A	O
and	O
5-HT2A	O
serotonin	O
receptors	O
in	O
a	O
manner	O
that	O
promotes	O
the	O
control	O
,	O
relief	O
or	O
cure	O
of	O
disorders	O
associated	O
with	O
these	O
receptors	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
for	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
these	O
receptors	O
.	O

These	O
compounds	O
and	O
their	O
pharmaceutical	O
compositions	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
depression	O
,	O
anxiety	O
,	O
phobias	O
,	O
addictions	O
,	O
aggressiveness	O
,	O
impulsiveness	O
,	O
panic	O
,	O
psychotic	O
,	O
eating	O
and	O
sleep	O
disorders	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
and	O
female	O
sexual	O
dysfunctions	O
,	O
among	O
other	O
disorders	O
associated	O
with	O
these	O
receptors	O
.	O

Pyrazole	O
compounds	O
acting	O
against	O
allergic	O
,	O
immune	O
and	O
inflammatory	O
conditions	O
The	O
present	O
invention	O
relates	O
to	O
a	O
pyrazole	O
amide	O
derivative	O
,	O
pharmaceutical	O
compositions	O
containing	O
this	O
compound	O
and	O
to	O
its	O
use	O
in	O
therapy	O
.	O

Nitric	O
oxide	O
amino	O
acid	O
esters	O
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
Use	O
of	O
nitric	O
oxide	O
amino	O
acid	O
esters	O
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
,	O
such	O
as	O
peripheral	O
vascular	O
disease	O
.	O

The	O
nitric	O
oxide	O
amino	O
acid	O
esters	O
may	O
be	O
co	O
-	O
administered	O
with	O
an	O
antimicrobial	O
in	O
topical	O
or	O
transdermal	O
compositions	O
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
.	O

Bicyclic	O
ring	O
system	O
substituted	O
amide	O
functionalised	O
phenols	O
as	O
medicaments	O
This	O
invention	O
relates	O
to	O
bicyclic	O
ring	O
system	O
substituted	O
amide	O
functionalized	O
phenols	O
of	O
general	O
formula	O
1	O
,	O
their	O
use	O
as	O
inhibitors	O
of	O
CXCR2	B
activity	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
methods	O
of	O
using	O
the	O
same	O
as	O
agents	O
for	O
treatment	O
and/or	O
prevention	O
of	O
respiratory	O
or	O
gastrointestinal	O
complaints	O
or	O
diseases	O
,	O
inflammatory	O
diseases	O
of	O
the	O
joints	O
,	O
skin	O
,	O
or	O
eyes	O
,	O
diseases	O
of	O
the	O
peripheral	O
or	O
central	O
nervous	O
system	O
or	O
cancers	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
which	O
contain	O
these	O
compounds	O
.	O

Composition	O
for	O
the	O
treatment	O
of	O
skin	O
conditions	O
A	O
topical	O
composition	O
for	O
the	O
treatment	O
of	O
skin	O
conditions	O
.	O

The	O
composition	O
comprises	O
an	O
antifungal	O
agent	O
,	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
an	O
antimicrobial	O
agent	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

The	O
anti	O
-	O
inflammatory	O
is	O
present	O
at	O
a	O
concentration	O
of	O
less	O
than	O
0.01%wt	O
of	O
the	O
composition	O
and	O
the	O
antimicrobial	O
agent	O
has	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
Formula	O
(	O
I	O
)	O
)	O
.	O

Heterocyclic	O
compounds	O
for	O
the	O
inhibition	O
of	O
pask	B
Disclosed	O
herein	O
are	O
new	O
heterocyclic	O
compounds	O
and	O
compositions	O
and	O
their	O
application	O
as	O
pharmaceuticals	O
for	O
the	O
treatment	O
of	O
disease	O
.	O

Methods	O
of	O
inhibiting	O
PAS	B
Kinase	I
(	O
PASK	B
)	O
activity	O
in	O
a	O
human	O
or	O
animal	O
subject	O
are	O
also	O
provided	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
diabetes	O
mellitus	O
.	O

COMPOUNDS	O
FOR	O
THE	O
REDUCTION	O
OF	O
ß	B
-	I
AMYLOID	I
PRODUCTION	O
The	O
present	O
disclosure	O
provides	O
a	O
series	O
of	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
which	O
modulate	O
&	O
bgr	O
;-	O
amyloid	B
peptide	O
(	O
&	O
bgr	O
;-	O
AP	B
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
&	O
bgr	O
;-	O
amyloid	B
peptide	O
(	O
&	O
bgr	O
;-	O
AP	B
)	O
production	O
.	O

Lin28-mediated	B
control	O
of	O
let-7	B
biogenesis	O
The	O
present	O
embodiments	O
provide	O
for	O
compositions	O
and	O
methods	O
that	O
regulate	O
microRNA	O
-	O
binding	O
protein	O
-	O
mediated	O
miRNA	O
biogenesis	O
;	O
for	O
example	O
Lin28-mediated	B
biogenesis	O
of	O
let-7	B
;	O
and	O
in	O
particular	O
Lin28A	B
-	O
recruited	O
3	B
'	I
terminal	I
uridylyl	I
transferase	I
(	O
TUTase	B
)	O
uridylation	O
of	O
pre	O
-	O
let-7	B
.	O

A	O
particular	O
embodiment	O
provides	O
compositions	O
and	O
methods	O
for	O
screening	O
for	O
agents	O
that	O
inhibit	O
TUTase	B
-	O
dependent	O
Lin28A	B
-	O
mediated	O
repression	O
of	O
let-7	B
miRNA	O
.	O

Pyridopyrazine	O
derivatives	O
and	O
their	O
use	O
The	O
present	O
invention	O
provides	O
new	O
pyridopyrazine	O
compounds	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
physiological	O
and/or	O
pathophysiological	O
states	O
mediated	O
and/or	O
modulated	O
by	O
signal	O
transduction	O
pathways	O
and/or	O
enzymes	O
in	O
mammals	O
and	O
in	O
particular	O
in	O
humans	O
.	O

Pyrrolo	O
sulfonamide	O
compounds	O
for	O
modulation	O
of	O
orphan	B
nuclear	I
receptor	I
rar	I
-	I
related	I
orphan	I
receptor	I
-	I
gamma	I
(	O
rorgamma	B
,	O
nr1f3	B
)	O
activity	O
and	O
for	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
and	O
autoimmune	O
diseases	O
The	O
invention	O
provides	O
modulators	O
for	O
the	O
orphan	O
nuclear	O
receptor	O
RORy	B
and	O
methods	O
for	O
treating	O
RORy	B
mediated	O
diseases	O
by	O
administrating	O
these	O
novel	O
RORy	B
modulators	O
to	O
a	O
human	O
or	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
provides	O
pyrrolo	O
sulfonamide	O
compounds	O
of	O
Formula	O
(	O
1	O
)	O
and	O
the	O
enantiomers	O
,	O
diastereomers	O
,	O
tautomers	O
,	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

Methods	O
and	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
hormone	O
-	O
refractory	O
prostate	O
cancers	O
The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
a	O
curcuminoid	O
and	O
a	O
taxane	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

5-	O
or	O
6	O
-	O
substituted	O
3	O
-	O
hydroxy	O
-	O
2	O
(	O
1h	O
)	O
-	O
pyridinones	O
as	O
d	B
-	I
amino	I
acid	I
oxidase	I
(	O
daao	B
)	O
inhibitors	O
in	O
therapy	O
of	O
diseases	O
such	O
as	O
schizophrenia	O
,	O
cognitive	O
disorder	O
and	O
pain	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
R1	O
is	O
hydrogen	O
or	O
fluorine	O
,	O
one	O
of	O
A	O
and	O
B	O
is	O
R2	O
,	O
the	O
other	O
is	O
a	O
group	O
-X	O
-	O
Y	O
-	O
R3	O
.	O

R3	O
represents	O
a	O
carbocyclic	O
or	O
heterocyclic	O
ring	O
.	O

Further	O
variables	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Also	O
claimed	O
are-	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
of	O
diseases	O
such	O
as	O
schizophrenia	O
,	O
cognitive	O
disorders	O
and	O
pain	O
by	O
modulating	O
the	O
D	B
-	I
amino	I
acid	I
oxidase	I
enzyme	O
(	O
DAAO	B
)	O
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
menthane	O
carboxylic	O
acid	O
amide	O
Suggested	O
is	O
a	O
pharmaceutical	O
composition	O
,	O
comprising	O
menthane	O
carboxylic	O
acid	O
-	O
N-	O
(	O
4-methoxy	O
-	O
phenyl	O
)	O
-amide	O
.	O

Anti	O
-	O
obesity	O
agent	O
comprising	O
high	O
-	O
purity	O
epa	O
The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
preventing	O
the	O
increase	O
in	O
a	O
body	O
weight	O
(	O
or	O
for	O
decreasing	O
a	O
body	O
weight	O
)	O
or	O
an	O
anti	O
-	O
obesity	O
agent	O
each	O
comprising	O
at	O
least	O
one	O
component	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
EPA	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
esters	O
and	O
derivatives	O
thereof	O
as	O
an	O
active	O
ingredient	O
for	O
obesity	O
in	O
which	O
the	O
increase	O
in	O
the	O
formation	O
of	O
hepatic	O
lipid	O
or	O
the	O
occurrence	O
of	O
fatty	O
liver	O
is	O
mild	O
,	O
preferably	O
the	O
increase	O
in	O
the	O
formation	O
of	O
hepatic	O
lipid	O
or	O
the	O
occurrence	O
of	O
fatty	O
liver	O
is	O
not	O
observed	O
.	O

Liposome	O
comprising	O
at	O
least	O
a	O
cholesterol	O
derivative	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
galenic	O
form	O
of	O
cholesterol	O
derivative	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
liposomes	O
comprising	O
at	O
least	O
one	O
cholesterol	O
derivative	O
and	O
to	O
compositions	O
comprising	O
said	O
liposomes	O
.	O

Cancer	O
stem	O
cell	O
isolation	O
An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
cancer	O
stem	O
cell	O
isolated	O
using	O
a	O
cell	O
marker	O
;	O
a	O
substantively	O
homogeneous	O
cancer	O
stem	O
cell	O
population	O
including	O
said	O
cancer	O
stem	O
cell	O
;	O
and	O
a	O
method	O
of	O
preparing	O
said	O
cancer	O
stem	O
cell	O
population	O
.	O

Another	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
for	O
separating	O
cancer	O
stem	O
cells	O
with	O
a	O
high	O
proliferative	O
potential	O
and	O
those	O
with	O
a	O
low	O
proliferative	O
potential	O
;	O
a	O
method	O
for	O
inducing	O
cancer	O
stem	O
cells	O
to	O
have	O
a	O
different	O
proliferative	O
potential	O
;	O
and	O
cancer	O
stem	O
cells	O
separated	O
or	O
induced	O
by	O
these	O
separation	O
or	O
induction	O
methods	O
.	O

A	O
further	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
of	O
screening	O
for	O
pharmaceuticals	O
using	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
;	O
a	O
method	O
for	O
detecting	O
the	O
presence	O
of	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
and	O
for	O
identifying	O
or	O
quantifying	O
the	O
same	O
.	O

The	O
present	O
inventors	O
discovered	O
that	O
highly	O
pure	O
colon	O
cancer	O
stem	O
cells	O
(	O
CSC	O
)	O
can	O
be	O
obtained	O
in	O
a	O
large	O
quantity	O
,	O
and	O
identified	O
two	O
types	O
of	O
states	O
of	O
colon	O
CSCs	O
distinguishable	O
through	O
Lgr5	B
expression	O
.	O

Compounds	O
for	O
use	O
in	O
inhibiting	O
HIV	O
capsid	O
assembly	O
The	O
present	O
invention	O
relates	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
for	O
use	O
in	O
inhibiting	O
HIV	O
capsid	O
assembly	O
,	O
wherein	O
the	O
compound	O
is	O
a	O
pyrimidine	O
being	O
at	O
least	O
substituted	O
in	O
two	O
positions	O
,	O
preferably	O
in	O
2	O
and	O
4	O
position	O
or	O
in	O
4	O
and	O
6	O
position	O
,	O
more	O
preferably	O
in	O
2	O
and	O
4	O
position	O
.	O

Method	O
for	O
inhibition	O
of	O
deubiquitinating	O
activity	O
A	O
compound	O
of	O
the	O
general	O
structure	O
(	O
I	O
)	O
is	O
capable	O
of	O
abrogating	O
the	O
deubiquitinating	O
(	O
DUB	O
)	O
activity	O
of	O
the	O
19S	B
RP	I
DUBs	I
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
cancer	O
,	O
in	O
particular	O
of	O
cancer	O
refractory	O
to	O
treatment	O
by	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
chemotherapy	O
.	O

Also	O
disclosed	O
are	O
corresponding	O
methods	O
of	O
treatment	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
.	O

Mannosylated	O
compounds	O
useful	O
for	O
the	O
prevention	O
and	O
the	O
treatment	O
of	O
infectious	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
new	O
anti	O
-	O
infectious	O
compounds	O
consisting	O
of	O
(	O
i	O
)	O
a	O
polar	O
head	O
having	O
from	O
one	O
to	O
three	O
mannose	O
,	O
dimannose	O
or	O
trimannose	O
moieties	O
,	O
which	O
is	O
coupled	O
through	O
an	O
appropriate	O
linker	O
to	O
(	O
ii	O
)	O
a	O
single	O
lipid	O
chain	O
of	O
at	O
least	O
17	O
carbon	O
atoms	O
of	O
length	O
.	O

Pharmaceutical	O
compositions	O
and	O
therapeutic	O
uses	O
thereof	O
are	O
also	O
provided	O
.	O

Inducer	O
of	O
apoptosis	O
This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
E2	O
polypeptide	O
to	O
induce	O
apoptosis	O
(	O
a	O
form	O
of	O
programmed	O
cell	O
death	O
)	O
in	O
cells	O
.	O

The	O
mutant	O
E2	O
derived	O
polypeptide	O
is	O
p53	B
binding	O
deficient	O
.	O

Preferably	O
it	O
is	O
unable	O
to	O
bind	O
p53	B
;	O
or	O
able	O
to	O
bind	O
p53	B
but	O
unable	O
to	O
induce	O
p53-dependent	B
apoptosis	O
.	O

Anticancer	O
agents	O
;	O
controlling	O
apoptosis	O
Use	O
of	O
endothelin	O
receptor	O
antagonists	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
tumour	O
diseases	O
.	O

Substituted	O
isoxazoles	O
and	O
their	O
use	O
as	O
antibiotics	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
is	O
O	O
,	O
S	O
,	O
NH	O
,	O
OCO	O
,	O
NH	O
—	O
CO	O
,	O
NH	O
—	O
COO	O
,	O
NH	O
—	O
CO	O
—	O
NH	O
,	O
NH	O
—	O
CS	O
or	O
NH	O
—	O
CS	O
—	O
NH	O
;	O
R4	O
is	O
H	O
,	O
(	O
C1-C3	O
)	O
-alkyl	O
optionally	O
substituted	O
by	O
halogen	O
,	O
or	O
a	O
C	O
-	O
linked	O
heterocyclic	O
radical	O
selected	O
from	O
several	O
possibilities	O
;	O
R1	O
and	O
R3	O
are	O
H	O
or	O
F	O
;	O
and	O
R2	O
is	O
an	O
N	O
-	O
linked	O
or	O
C	O
-	O
linked	O
heterocyclic	O
radical	O
,	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
microbial	O
infections	O
in	O
human	O
or	O
animal	O
body	O
.	O

Such	O
as	O
4-cyclopentylamino	O
-	O
benzenesulfonic	O
acid	O
2-	O
(	O
3,4-dimethoxy	O
-	O
phenylamino	O
)	O
-1H	O
-	O
benzoimidazol-5-yl	O
ester	O
;	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
that	O
are	O
aimed	O
to	O
be	O
more	O
active	O
than	O
flavopiridol	O
The	O
present	O
invention	O
discloses	O
and	O
claims	O
benzimidazole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
A	O
is	O
aryl	O
or	O
heteroaryl	O
;	O
R1	O
is	O
sleceted	O
from	O
optionally	O
substituted	O
alkyl	O
,	O
alkoxy	O
,	O
aryl	O
or	O
heteroaryl	O
,	O
NH	O
-	O
lower	O
alkyl	O
or	O
NH	O
-	O
cycloalkyl	O
,	O
or	O
halogen	O
,	O
NH2	O
;	O
1-imidazolyl	O
or	O
SO2Me	O
;	O
R2	O
is	O
selected	O
from	O
optionally	O
substituted	O
—CO	O
-	O
alkyl	O
,	O
—CO	O
-	O
cycloalkyl	O
,	O
—CO	O
-	O
aralkyl	O
,	O
—CO	O
-	O
aryl	O
,	O
—CO	O
-	O
alkoxy	O
,	O
aryl	O
or	O
aralkyl	O
,	O
or	O
—O	O
-	O
amino	O
,	O
CO	O
—	O
NHR3	O
or	O
CO	O
—	O
R3R4	O
wherein	O
R3	O
and	O
R4	O
are	O
selecteded	O
independently	O
from	O
hydrogen	O
,	O
alkyl	O
,	O
hydroxyalkyl	O
,	O
alkoxyalkyl	O
,	O
fluoroalkyl	O
,	O
alkynyl	O
,	O
heteroalkyl	O
,	O
alkylheteroalkyl	O
,	O
aryl	O
,	O
aralkyl	O
or	O
together	O
form	O
an	O
alkylene	O
chain	O
optionally	O
containing	O
one	O
to	O
4	O
heteroatoms	O
;	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
a	O
prodrug	O
thereof	O
;	O
the	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
of	O
cancer	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
adjuvants	O
or	O
diluents	O
.	O

Acat	O
inhibitors	O
;	O
cardiovascular	O
disorders	O
;	O
restenosis	O
;	O
Alzheimer	O
's	O
disease	O
Compounds	O
represented	O
by	O
the	O
general	O
formula	O
.	O

[	O
I	O
]	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
each	O
hydrogen	O
,	O
halogen	O
,	O
an	O
optionally	O
substituted	O
linear	O
hydrocarbon	O
group	O
,	O
or	O
hydroxyl	O
which	O
may	O
be	O
substituted	O
with	O
an	O
optionally	O
substituted	O
liner	O
hydrocarbon	O
group	O
,	O
or	O
R1	O
and	O
R2	O
together	O
with	O
the	O
carbon	O
atoms	O
adjacent	O
thereto	O
may	O
form	O
an	O
optionally	O
substituted	O
cyclic	O
hydrocarbon	O
or	O
a	O
dihydrofuran	O
ring	O
which	O
may	O
have	O
an	O
oxo	O
group	O
;	O
ring	O
A	O
is	O
a	O
benzene	O
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
ring	O
B	O
is	O
an	O
aromatic	O
ring	O
which	O
may	O
be	O
substituted	O
;	O
X	O
is	O
a	O
bond	O
or	O
a	O
spacer	O
whose	O
main	O
chain	O
has	O
1	O
to	O
6	O
atoms	O
;	O
Y	O
is	O
carboxyl	O
which	O
may	O
be	O
esterified	O
,	O
carbamoyl	O
which	O
may	O
be	O
substituted	O
,	O
cyano	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclic	O
group	O
bearing	O
a	O
hydrogen	O
atom	O
capable	O
of	O
being	O
deprotonated	O
,	O
or	O
salts	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
lipid	O
-	O
rich	O
plaque	O
regressing	O
agents	O
and/or	O
ACAT	B
inhibitors	O
.	O

administering	O
to	O
humans	O
synergystic	O
mixtures	O
of	O
aromatase	B
inhibitors	O
and	O
epidermal	B
growth	I
factor	I
receptor	I
antagonists	O
as	O
antitumor	O
agents	O
A	O
method	O
of	O
treating	O
a	O
human	O
being	O
suffering	O
from	O
a	O
hormone	O
-	O
dependent	O
disorder	O
characterized	O
by	O
the	O
overexpression	O
of	O
EGFR	B
,	O
comprising	O
administering	O
to	O
said	O
human	O
being	O
an	O
aromatase	O
inhibitor	O
and	O
an	O
EGFR	B
antagonist	O
or	O
EGFR	B
inhibitor	O
,	O
in	O
amounts	O
effective	O
to	O
produce	O
a	O
superadditive	O
or	O
synergistic	O
therapeutic	O
effect	O
.	O

Such	O
as	O
[	O
3-	O
(	O
2-Bromo	O
-	O
ethoxy	O
)	O
-phenyl	O
]	O
-	O
[	O
4-	O
(	O
3-cyclohexyl-5-methyl	O
-	O
isoxazol-4-yl	O
)	O
-pyrimidin-2-yl	O
]	O
-amine	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
wherein	O
A	O
-	O
B	O
is	O
N	O
—	O
O	O
or	O
O	O
—	O
N	O
and	O
G	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
are	O
inhibitors	O
of	O
protein	O
kinase	B
,	O
particularly	O
inhibitors	O
of	O
Src	B
and	O
Lck	B
kinase	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O

Treatment	O
of	O
neovascular	O
opthalmic	O
disease	O
Inhibitors	O
of	O
integrin	O
-	O
linked	O
kinase	O
(	O
ILK	O
)	O
are	O
used	O
in	O
the	O
treatment	O
of	O
various	O
eye	O
diseases	O
with	O
underlining	O
pathology	O
of	O
neovascularization	O
of	O
cornea	O
,	O
iris	O
,	O
retina	O
or	O
choroid	O
.	O

Condom	O
A	O
condom	O
has	O
a	O
vasodilator	O
active	O
compound	O
applied	O
to	O
its	O
external	O
surface	O
,	O
preferably	O
disposed	O
towards	O
the	O
open	O
end	O
of	O
the	O
condom	O
whereby	O
,	O
in	O
use	O
during	O
intercourse	O
,	O
the	O
compound	O
makes	O
contact	O
with	O
the	O
vaginal	O
meatus	O
or	O
proximal	O
region	O
of	O
the	O
vagina	O
,	O
such	O
that	O
the	O
vasodilator	O
is	O
absorbed	O
though	O
the	O
lining	O
of	O
the	O
vagina	O
to	O
stimulate	O
and	O
increase	O
the	O
flow	O
of	O
blood	O
in	O
the	O
labia	O
and	O
through	O
the	O
clitoris	O
to	O
promote	O
engorgement	O
thereof	O
to	O
alleviate	O
symptoms	O
associated	O
with	O
female	O
inorgasmia	O

Combination	O
of	O
an	O
adenosine	B
A2A	I
-	I
receptor	I
agonist	O
and	O
tiotropium	O
or	O
a	O
derivative	O
thereof	O
for	O
treating	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
A	O
combination	O
of	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
(	O
i	O
)	O
an	O
adenosine	B
A2A	I
receptor	I
agonist	O
;	O
and	O
(	O
ii	O
)	O
an	O
anti	O
-	O
cholinergic	O
agent	O
,	O
preferably	O
comprising	O
a	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
tiotropium	O
and	O
derivatives	O
thereof	O
;	O
the	O
combination	O
being	O
therapeutically	O
effective	O
in	O
the	O
treatment	O
of	O
the	O
diseases	O
when	O
administered	O
by	O
inhalation	O
;	O
as	O
well	O
as	O
to	O
a	O
method	O
of	O
treating	O
the	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
administering	O
separately	O
,	O
simultaneously	O
or	O
sequentially	O
to	O
the	O
mammal	O
by	O
inhalation	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
together	O
with	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
product	O
containing	O
the	O
compounds	O
of	O
the	O
combination	O
for	O
separate	O
,	O
simultaneous	O
or	O
sequential	O
administration	O
by	O
inhalation	O
to	O
a	O
mammal	O
for	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
.	O

It	O
is	O
preferred	O
that	O
the	O
anti	O
-	O
cholinergic	O
agent	O
component	O
be	O
tiotropium	O
bromide	O
.	O

3-	O
(	O
Morpholin-4-ylsulfonyl	O
)	O
-5-	O
(	O
1,3-thiazol-2-yl	O
)	O
-1H	O
-	O
indole-2-carboxamide	O
;	O
inhibiting	O
,	O
modulating	O
and/or	O
regulating	O
signal	O
transduction	O
of	O
both	O
receptor	B
and	I
non	I
-	I
receptor	I
tyrosine	I
kinases	I
;	O
anticarcinogenic	O
,	O
-diabetic	O
,	O
-arhtritic	O
,	O
-inflammatory	O
agents	O
;	O
psoriasis	O
;	O
angiogenesisinhibitors	O
;	O
liver	O
cirrhosis	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
capable	O
of	O
inhibiting	O
,	O
modulating	O
and/or	O
regulating	O
signal	O
transduction	O
of	O
both	O
receptor	B
-	I
type	I
and	I
non	I
-	I
receptor	I
type	I
tyrosine	I
kinases	I
.	O

The	O
compounds	O
of	O
the	O
instant	O
invention	O
possess	O
a	O
core	O
structure	O
that	O
comprises	O
a	O
sulfonyl	O
indole	O
moiety	O
.	O

The	O
present	O
invention	O
is	O
also	O
related	O
to	O
the	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
and	O
stereoisomers	O
of	O
these	O
compounds	O
.	O

Sprayable	O
compositions	O
comprising	O
a	O
combination	O
of	O
pharmaceutical	O
actives	O
and	O
an	O
oily	O
phase	O
Sprayable	O
,	O
anhydrous	O
and	O
physically	O
/	O
chemically	O
stable	O
dermatological	O
/	O
pharmaceutical	O
compositions	O
,	O
well	O
suited	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
dermatological	O
disorders	O
,	O
notably	O
psoriasis	O
,	O
contain	O
:	O
a	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
solubilized	O
corticoid	O
,	O
notably	O
dissolved	O
clobetasol	O
propionate	O
;	O
b	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
solubilized	O
vitamin	O
D	O
derivative	O
,	O
notably	O
dissolved	O
calcitriol	O
;	O
and	O
c	O
)	O
an	O
oily	O
phase	O
which	O
comprises	O
one	O
or	O
more	O
oils	O
;	O
formulated	O
into	O
d	O
)	O
,	O
a	O
sprayable	O
and	O
topically	O
applicable	O
,	O
dermatologically	O
/	O
pharmaceutically	O
acceptable	O
vehicle	O
therefor	O
.	O

Marker	O
genes	O
Methods	O
are	O
disclosed	O
for	O
fast	O
and	O
accurate	O
readout	O
of	O
kidney	O
toxicity	O
before	O
it	O
occurs	O
and	O
before	O
it	O
is	O
demonstrated	O
by	O
histopathology	O
examination	O
.	O

Ultimately	O
,	O
this	O
approach	O
shall	O
allow	O
earlier	O
compound	O
selection	O
.	O

The	O
twelve	O
genes	O
identified	O
,	O
namely	O
Calbindin	B
-	I
D28k	I
,	O
KIM-1	B
,	O
OPN	B
,	O
EGF	B
,	O
Clusterin	B
,	O
VEGF	B
,	O
OAT	B
-	I
K1	I
,	O
Aldolase	B
A	I
,	O
Aldolase	B
B	I
,	O
Podocin	B
,	O
Alpha-2u	B
and	I
C4	I
,	O
were	O
grouped	O
and	O
ultimately	O
can	O
be	O
assessed	O
in	O
the	O
form	O
of	O
a	O
kit	O
using	O
PCR	O
,	O
a	O
high	O
throughput	O
technology	O
,	O
in	O
order	O
to	O
characterize	O
and	O
rank	O
new	O
compounds	O
according	O
to	O
their	O
anticipated	O
general	O
kidney	O
toxicity	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
identifying	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
kidney	O
disease	O
,	O
methods	O
for	O
monitoring	O
the	O
efficacy	O
of	O
a	O
treatment	O
for	O
kidney	O
disease	O
and	O
kidney	O
-	O
specific	O
vectors	O
including	O
the	O
sequences	O
of	O
the	O
disclosed	O
genes	O
,	O
and	O
a	O
method	O
for	O
identifying	O
a	O
candidate	O
gene	O
associated	O
with	O
a	O
biological	O
process	O
including	O
kidney	O
function	O
.	O

Composition	O
having	O
antioxidant	O
properties	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
having	O
antioxidant	O
properties	O
comprising	O
at	O
least	O
one	O
compound	O
of	O
the	O
formula	O
I	O
or	O
a	O
cosmetically	O
,	O
dermatologically	O
or	O
pharmacologically	O
tolerated	O
salt	O
or	O
derivative	O
thereof	O
where	O
R1	O
to	O
R4	O
can	O
be	O
identical	O
or	O
different	O
and	O
are	O
selected	O
from	O
H	O
C6	O
-	O
28-alkylcarboxylic	O
acid	O
radicals	O
C6	O
-	O
28-alkenylcarboxylic	O
acid	O
radicals	O
radicals	O
of	O
the	O
formula	O
II	O
where	O
R5-R8	O
,	O
independently	O
of	O
one	O
another	O
,	O
are	O
H	O
,	O
hydroxyl	O
or	O
C1	O
-	O
6-alkoxy	O
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
the	O
radicals	O
R1	O
to	O
R4	O
is	O
a	O
radical	O
of	O
the	O
formula	O
II	O
.	O

Composition	O
for	O
use	O
in	O
prophylaxis	O
and	O
or	O
treatment	O
The	O
present	O
invention	O
relates	O
generally	O
to	O
a	O
composition	O
for	O
use	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
pain	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
use	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
chronic	O
neuromuscular	O
pain	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
is	O
particularly	O
useful	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
chronic	O
neuromuscular	O
pain	O
such	O
as	O
,	O
for	O
example	O
,	O
fibromylagia	O
,	O
myofascial	O
pain	O
,	O
repetitive	O
strain	O
injury	O
or	O
overuse	O
syndromes	O
,	O
and	O
cytokine	O
-	O
mediated	O
cancer	O
and	O
chemotherapy	O
associated	O
pain	O
.	O

Sensitization	O
of	O
cells	O
to	O
cytotoxic	O
agents	O
using	O
oligonucleotides	O
directed	O
to	O
nucleotide	O
excision	O
repair	O
or	O
transcritpion	O
coupled	O
repair	O
genes	O
This	O
invention	O
relates	O
to	O
the	O
fields	O
of	O
molecular	O
biology	O
and	O
oncology	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
relates	O
to	O
the	O
sensitization	O
of	O
cancerous	O
cells	O
to	O
therapeutic	O
agents	O
.	O

The	O
invention	O
provides	O
methods	O
,	O
compositions	O
,	O
and	O
formulations	O
for	O
potentiating	O
or	O
enhancing	O
the	O
toxicity	O
of	O
various	O
cytotoxins	O
and	O
oxidizing	O
agents	O
,	O
and	O
of	O
reducing	O
the	O
resistance	O
and	O
proliferation	O
rate	O
of	O
cancer	O
cells	O
.	O

It	O
also	O
provides	O
various	O
compositions	O
and	O
therapeutic	O
formulations	O
useful	O
as	O
anticancer	O
agents	O
.	O

5-HT4	O
receptor	O
antagonists	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
X	O
—	O
CO	O
—	O
CH2-Z	O
wherein	O
X	O
is	O
a	O
monocyclic	O
or	O
polycyclic	O
aromatic	O
group	O
,	O
Z	O
is	O
of	O
sub	O
-	O
formula	O
(	O
h	O
)	O
,	O
(	O
j	O
)	O
or	O
(	O
k	O
)	O
:	O
wherein	O
n1	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
n2	O
is	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
n3is	O
2	O
,	O
3	O
,	O
4	O
or	O
5	O
;	O
q	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
p	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
m	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
R5	O
is	O
hydrogen	O
,	O
C1	O
-	O
2	O
alkyl	O
,	O
aralkyl	O
or	O
R5	O
is	O
(	O
CH2	O
)	O
z	O
-	O
R10	O
wherein	O
z	O
is	O
2	O
or	O
3	O
and	O
R10	O
is	O
selected	O
from	O
cyano	O
,	O
hydroxyl	O
,	O
C1	O
-	O
6	O
alkoxy	O
,	O
phenoxy	O
,	O
C	O
(	O
O	O
)	O
C1	O
-	O
6	O
alkyl	O
,	O
COC6H5	O
,	O
—CONR11R12	O
,	O
NR11COR12	O
,	O
SO2NR11R12	O
or	O
NR11SO2R12	O
wherein	O
R11	O
and	O
R12	O
are	O
hydrogen	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
or	O
R5	O
is	O
straight	O
or	O
branched	O
chain	O
alkylene	O
of	O
chain	O
length	O
1	O
-	O
6	O
carbon	O
atoms	O
terminally	O
substituted	O
by	O
aryl	O
,	O
3	O
to	O
8	O
membered	O
cycloalkyl	O
,	O
3	O
to	O
8	O
membered	O
heterocyclyl	O
,	O
5	O
or	O
6	O
membered	O
monocyclic	O
heteroaryl	O
or	O
9	O
or	O
10	O
membered	O
fused	O
bicyclic	O
heteroaryl	O
linked	O
through	O
carbon	O
,	O
C2	O
-	O
7	O
alkoxycarbonyl	O
,	O
or	O
secondary	O
or	O
tertiary	O
hydroxy	O
substituted	O
C1	O
-	O
6	O
alkyl	O
;	O
;	O
and	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
independently	O
hydrogen	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
and	O
R9	O
is	O
hydrogen	O
or	O
C1	O
-	O
10alkyl	O
;	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
,	O
cardiovascular	O
disorders	O
and	O
CNS	O
disorders	O
.	O

Method	O
of	O
manufacturing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
A	O
method	O
of	O
manufacturing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
for	O
performing	O
a	O
deposition	O
treatment	O
for	O
causing	O
a	O
treating	O
aqueous	O
solution	O
containing	O
fluorine	O
and	O
iron	O
to	O
contact	O
nucleus	O
particles	O
,	O
to	O
deposit	O
iron	O
hydroxide	O
and	O
form	O
layers	O
around	O
the	O
nucleus	O
particles	O
,	O
and	O
an	O
after	O
-	O
treatment	O
for	O
heating	O
the	O
iron	O
hydroxide	O
layers	O
to	O
change	O
them	O
into	O
ferromagnetic	O
layers	O
,	O
thereby	O
producing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
with	O
outside	O
of	O
the	O
nucleus	O
particles	O
covered	O
by	O
the	O
ferromagnetic	O
layers	O
,	O
wherein	O
,	O
in	O
time	O
of	O
the	O
deposition	O
treatment	O
,	O
a	O
reaction	O
initiator	O
that	O
reacts	O
with	O
hydrogen	O
fluoride	O
is	O
added	O
to	O
said	O
treating	O
aqueous	O
solution	O
.	O

Aryl	O
boronate	O
functionalized	O
polymers	O
for	O
treating	O
obesity	O
Disclosed	O
are	O
polymers	O
comprising	O
one	O
or	O
more	O
phenyl	O
boronate	O
ester	O
,	O
boronamide	O
or	O
boronate	O
thioester	O
groups	O
.	O

The	O
phenyl	O
boronate	O
ester	O
,	O
boronamide	O
and	O
boronate	O
thioester	O
groups	O
are	O
represented	O
by	O
one	O
of	O
the	O
following	O
structural	O
formulas	O
:	O
Ar	O
in	O
Structural	O
Formulas	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
is	O
substituted	O
or	O
unsubstituted	O
;	O
and	O
each	O
Z	O
is	O
—O—	O
,	O
—NH—	O
or	O
—S—	O
and	O
is	O
independently	O
selected	O
.	O

Pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
polymer	O
are	O
also	O
included	O
.	O

The	O
aryl	O
boronate	O
ester	O
,	O
boronamide	O
or	O
boronate	O
thioester	O
can	O
be	O
cleaved	O
to	O
release	O
the	O
corresponding	O
aryl	O
boronic	O
acid	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
polymers	O
of	O
the	O
present	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
diluent	O
;	O
and	O
methods	O
of	O
treating	O
a	O
subject	O
for	O
obesity	O
with	O
the	O
polymers	O
of	O
the	O
present	O
invention	O
.	O

2-Aminobicyclo	O
[	O
3.1.0	O
]	O
hexane-2,6-dicarboxylic	O
acid	O
derivative	O
One	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
drug	O
that	O
is	O
effective	O
in	O
treatments	O
for	O
and	O
prevention	O
of	O
psychiatric	O
disorders	O
and	O
in	O
treatments	O
for	O
and	O
prevention	O
of	O
neurological	O
diseases	O
,	O
inhibiting	O
a	O
Group	O
II	O
metabotropic	O
glutamate	O
receptor	O
.	O

The	O
object	O
is	O
solved	O
by	O
a	O
2-amino	O
-	O
bicyclo	O
[	O
3.1.0	O
]	O
hexane-2,6-dicarboxylic	O
acid	O
derivative	O
represented	O
by	O
formula	O
[	O
I	O
]	O
:	O
(	O
wherein	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
,	O
and	O
each	O
represents	O
a	O
hydrogen	O
atom	O
,	O
C1	O
-	O
10alkyl	O
group	O
,	O
etc	O
;	O
X	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
fluorine	O
atom	O
;	O
and	O
Y	O
represents	O
an	O
amino	O
group	O
,	O
—SR3	O
,	O
—S	O
(	O
O	O
)	O
nR7	O
,	O
—SCHR3R4	O
,	O
—S	O
(	O
O	O
)	O
nCHR3R4	O
,	O
—NHCHR3R4	O
,	O
—N	O
(	O
CHR3R4	O
)	O
(	O
CHR5R6	O
)	O
,	O
—NHCOR3	O
or	O
—OCOR7	O
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
hydrate	O
thereof	O
and	O
so	O
on	O
.	O

Diphosphonate	O
solutions	O
A	O
pharmaceutical	O
product	O
containing	O
pamidronate	O
and	O
other	O
diphosphonate	O
solutions	O
in	O
an	O
appropriate	O
container	O
,	O
a	O
pH	O
of	O
between	O
5	O
and	O
8	O
and	O
without	O
organic	O
acid	O
buffer	O
or	O
polyethylen	O
glycol	O
.	O

The	O
container	O
may	O
be	O
treated	O
glass	O
or	O
made	O
of	O
other	O
appropriate	O
material	O
.	O

Coated	O
elastomeric	O
stoppers	O
are	O
also	O
included	O
.	O

A	O
method	O
of	O
producing	O
a	O
pharmaceutical	O
product	O
comprising	O
steps	O
of	O
making	O
a	O
suspension	O
of	O
pamadronic	O
acid	O
,	O
adding	O
sodium	O
hydroxide	O
,	O
to	O
form	O
a	O
solution	O
adjusting	O
the	O
pH	O
to	O
between	O
5	O
and	O
8	O
and	O
transferring	O
the	O
solution	O
to	O
a	O
container	O
.	O

Method	O
of	O
controlling	O
damage	O
mediated	O
by	O
alpha	O
,	O
beta	O
-	O
unsaturated	O
aldehydes	O
This	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
the	O
reaction	O
of	O
an	O
α	O
,	O
β	O
-	O
unsaturated	O
aldehyde	O
with	O
a	O
biological	O
molecule	O
,	O
the	O
method	O
including	O
the	O
step	O
of	O
administering	O
hydralazine	O
and/or	O
dihydralazine	O
in	O
an	O
amount	O
that	O
is	O
effective	O
to	O
reduce	O
the	O
rate	O
of	O
reaction	O
of	O
the	O
α	O
,	O
β	O
-	O
unsaturated	O
aldehyde	O
with	O
the	O
biological	O
molecule	O
.	O

Phthalazine	O
derivatives	O
as	O
phosphodiesterase	B
4	I
inhibitors	O
Compounds	O
of	O
formula	O
I	O
wherein	O
R	O
and	O
R1	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
PDE	B
4	I
inhibitors	O
.	O

Peptides	O
and	O
nucleic	O
acids	O
of	O
the	O
cathelicidin	O
family	O
,	O
derived	O
from	O
fish	O
,	O
and	O
uses	O
thereof	O
The	O
invention	O
relates	O
to	O
anti	O
-	O
microbial	O
and	O
immunostimulatory	O
molecules	O
of	O
the	O
cathelicidin	O
family	O
derived	O
from	O
fish	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
cathelicidin	O
molecule	O
,	O
fragments	O
,	O
derivatives	O
and	O
uses	O
thereof	O
,	O
and	O
nucleic	O
acids	O
encoding	O
the	O
same	O
.	O

Having	O
antiinflammatory	O
,	O
anti	O
-	O
pyretic	O
and	O
anti	O
-	O
diarrheal	O
properties	O
According	O
to	O
the	O
invention	O
there	O
is	O
provided	O
a	O
compound	O
the	O
formula	O
I	O
;	O
wherein	O
A	O
,	O
X	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

2,3'-bipyridines	O
derivatives	O
as	O
selective	O
cox-2	B
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
2,3′-bipyridines	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
medical	O
uses	O
.	O

Inhibitors	O
of	O
cdc25	B
phosphatases	I
A	O
method	O
of	O
inhibiting	O
cdc25	B
phosphatases	I
in	O
warm	O
-	O
blooded	O
animals	O
comprising	O
administering	O
to	O
warm	O
-	O
blooded	O
animals	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
formula	O
wherein	O
the	O
substituents	O
are	O
defined	O
as	O
in	O
the	O
specification	O
.	O

Therapeutic	O
agent	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
method	O
for	O
treatment	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
with	O
the	O
same	O
This	O
therapeutic	O
agent	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
comprises	O
,	O
an	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
of	O
a	O
7-aminoquinolinone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
alkyl	O
group	O
;	O
R2	O
and	O
R3	O
each	O
represents	O
a	O
group	O
selected	O
from	O
a	O
hydrogen	O
atom	O
,	O
an	O
acyl	O
group	O
,	O
an	O
alkyl	O
group	O
and	O
an	O
alkenyl	O
group	O
;	O
and	O
R4	O
and	O
R5	O
each	O
represents	O
a	O
group	O
selected	O
from	O
a	O
hydrogen	O
atom	O
,	O
an	O
acyl	O
group	O
,	O
an	O
alkyl	O
group	O
,	O
an	O
alkenyl	O
group	O
and	O
an	O
aralkyl	O
group	O
,	O
and	O
its	O
physiologically	O
acceptable	O
salt	O
.	O

Methods	O
of	O
using	O
benzothiophenone	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
Methods	O
of	O
using	O
benzothiophenone	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
in	O
a	O
mammal	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
derivatives	O
are	O
disclosed	O
.	O

Use	O
of	O
chemokines	O
,	O
and	O
pharmaceutical	O
preparations	O
containing	O
the	O
same	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
chemokines	O
and/or	O
nucleic	O
acids	O
encoding	O
a	O
chemokine	O
for	O
recruiting	O
mesenchymal	O
precursor	O
and/or	O
stem	O
cells	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
preparations	O
which	O
comprise	O
these	O
substances	O
and	O
which	O
are	O
preferably	O
intended	O
for	O
recruiting	O
mesenchymal	O
precursor	O
and/or	O
stem	O
cells	O
for	O
tissue	O
synthesis	O
.	O

Amorphous	O
antibiotic	O
composition	O
comprising	O
cefditoren	O
pivoxil	O
According	O
to	O
the	O
present	O
invention	O
,	O
there	O
is	O
provided	O
a	O
solid	O
dispersion	O
composition	O
which	O
can	O
maintain	O
amorphous	O
cefditoren	O
pivoxil	O
in	O
a	O
suspension	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

The	O
present	O
invention	O
is	O
a	O
solid	O
dispersion	O
composition	O
comprising	O
at	O
least	O
0.1	O
mg	O
of	O
a	O
sugar	O
ester	O
fatty	O
acid	O
on	O
the	O
basis	O
of	O
an	O
amount	O
equivalent	O
to	O
100	O
mg	O
efficacy	O
of	O
cefditoren	O
pivoxil	O
.	O

Methods	O
of	O
using	O
isothiazole	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
Methods	O
of	O
using	O
substituted	O
3,5-dithio-	O
,	O
disulfinyl	O
-	O
or	O
disulfonyl	O
-	O
isothiazole	O
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
in	O
a	O
mammal	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
derivatives	O
are	O
disclosed	O
.	O

Sulfotransferase	B
inhibitor	O
The	O
hexuronic	O
acid	O
derivative	O
represented	O
by	O
the	O
following	O
formula	O
1	O
or	O
a	O
salt	O
thereof	O
is	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
heparin	O
/	O
heparan	O
sulfate	O
sulfotransferase	B
inhibitor	O
.	O

In	O
the	O
formula	O
,	O
each	O
of	O
R1	O
,	O
R2	O
,	O
and	O
R3	O
independently	O
represent	O
(	O
s	O
)	O
SO3	O
−	O
or	O
H	O
which	O
may	O
have	O
a	O
substituent	O
,	O
provided	O
that	O
at	O
least	O
one	O
thereof	O
represents	O
SO3	O
−	O
;	O
X	O
represents	O
OR4	O
,	O
SR4	O
,	O
N	O
(	O
R4	O
)	O
2	O
,	O
or	O
C	O
(	O
R4	O
)	O
3	O
,	O
R4	O
independently	O
represents	O
H	O
,	O
alkyl	O
,	O
alkenyl	O
,	O
alkynyl	O
,	O
acyl	O
,	O
aryl	O
,	O
or	O
aralkyl	O
group	O
;	O
one	O
of	O
R5	O
and	O
R6	O
represents	O
COOH	O
while	O
the	O
other	O
represents	O
H	O
;	O
and	O
the	O
wavy	O
line	O
represents	O
α	O
-	O
glycosidic	O
bond	O
or	O
β	O
-	O
glycosidic	O
bond	O
.	O

Angiogenesis	O
inhibitor	O
;	O
anticancer	O
agents	O
;	O
antiarthritic	O
agents	O
;	O
psoriasis	O
The	O
invention	O
concerns	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
ring	O
A	O
is	O
phenyl	O
or	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	O
ring	O
as	O
defined	O
herein	O
;	O
Z	O
is	O
—O—	O
,	O
—NH—	O
or	O
—S—	O
;	O
m	O
is	O
an	O
integer	O
from	O
0	O
to	O
5	O
inclusive	O
;	O
R1	O
is	O
hydrogen	O
,	O
hydroxy	O
,	O
halogeno	O
,	O
nitro	O
,	O
trifluoromethyl	O
,	O
cyano	O
,	O
C1	O
-	O
3alkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
C1	O
-	O
3alkylthio	O
,	O
or	O
—NR5R6	O
(	O
wherein	O
R5	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	O
or	O
C1	O
-	O
3alkyl	O
)	O
;	O
R2	O
is	O
hydrogen	O
,	O
hydroxy	O
,	O
halogeno	O
,	O
C1	O
-	O
3alkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
trifluoromethyl	O
,	O
amino	O
or	O
nitro	O
;	O
R3	O
is	O
hydroxy	O
,	O
halogeno	O
,	O
C1	O
-	O
3alkyl	O
,	O
C1	O
-	O
3alkoxy	O
,	O
C1	O
-	O
3alkanoyloxy	O
,	O
trifluoromethyl	O
,	O
cyano	O
,	O
amino	O
or	O
nitro	O
;	O
provided	O
that	O
when	O
ring	O
A	O
is	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	O
ring	O
,	O
at	O
least	O
one	O
R3	O
is	O
either	O
hydroxy	O
or	O
halogeno	O
;	O
X1	O
is	O
—O—	O
,	O
—CH2—	O
,	O
—S—	O
,	O
—SO—	O
,	O
—SO2—	O
,	O
—NR7—	O
,	O
—NR7CO—	O
,	O
—CONR7—	O
,	O
—SO2NR7—	O
or	O
—NR7SO2—	O
,	O
(	O
wherein	O
R7	O
is	O
hydrogen	O
,	O
C1	O
-	O
3alkyl	O
or	O
C1	O
-	O
3alkoxyC2	O
-	O
3alkyl	O
)	O
;	O
and	O
R4	O
is	O
selected	O
from	O
a	O
number	O
of	O
groups	O
defined	O
herein	O
comprising	O
an	O
C2	O
-	O
5alkylene	O
,	O
C3	O
-	O
5alkenylene	O
or	O
C3	O
-	O
5alkynylene	O
chain	O
wherein	O
each	O
methylene	O
group	O
(	O
other	O
than	O
that	O
of	O
the	O
α	O
-	O
carbon	O
)	O
is	O
optionally	O
substituted	O
by	O
1	O
substituent	O
independently	O
selected	O
from	O
hydroxy	O
,	O
halogeno	O
,	O
amino	O
and	O
C1	O
-	O
4alkanoyloxy	O
;	O
provisos	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
production	O
of	O
an	O
antiangiogenic	O
and/or	O
vascular	O
permeability	O
reducing	O
effect	O
in	O
a	O
warm	O
-	O
blooded	O
animal	O
and	O
to	O
a	O
method	O
for	O
producing	O
an	O
antiangiogenic	O
and/or	O
vascular	O
permeability	O
reducing	O
effect	O
in	O
a	O
warm	O
-	O
blooded	O
animal	O
in	O
need	O
of	O
such	O
treatment	O
.	O

The	O
compounds	O
are	O
useful	O
in	O
disease	O
states	O
such	O
as	O
cancer	O
,	O
rheumatoid	O
arthritis	O
and	O
psoriasis	O
.	O

Preemptive	O
Prophylaxis	O
of	O
Migraine	O
A	O
method	O
of	O
preventing	O
the	O
headache	O
phase	O
of	O
migraine	O
in	O
a	O
human	O
comprises	O
administration	O
of	O
a	O
5HT1	B
receptor	I
agonist	O
or	O
administration	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
or	O
nonprescription	O
drug	O
to	O
said	O
human	O
exhibiting	O
prodrome	O
symptoms	O
of	O
migraine	O
.	O

Suitably	O
,	O
the	O
method	O
comprises	O
administration	O
of	O
a	O
migraine	O
headache	O
phase	O
-	O
preventing	O
effective	O
amount	O
of	O
the	O
5HT1	O
or	O
over	O
-	O
the	O
-	O
counter	O
or	O
nonprescription	O
drug	O
.	O

There	O
is	O
disclosed	O
a	O
preemptive	O
prophylaxis	O
migraine	O
method	O
using	O
the	O
following	O
cognitive	O
tests	O
:	O
Simple	O
Reaction	O
Time	O
;	O
Running	O
Memory	O
Continuous	O
Performance	O
Task	O
;	O
Matching	O
to	O
Sample	O
;	O
Mathematical	O
Processing	O
Task	O
;	O
and	O
interpreting	O
the	O
results	O
as	O
a	O
percent	O
of	O
baseline	O
indicator	O
of	O
need	O
for	O
prophylaxis	O
.	O

Active	O
substance	O
combination	O
comprising	O
a	O
carbinol	O
combined	O
to	O
at	O
least	O
an	O
NSAID	O
The	O
present	O
invention	O
relates	O
to	O
an	O
active	O
substance	O
combination	O
comprising	O
at	O
least	O
one	O
substituted	O
carbinol	O
compound	O
and	O
at	O
least	O
one	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
,	O
a	O
medicament	O
comprising	O
said	O
active	O
substance	O
combination	O
,	O
a	O
pharmaceutical	O
formulation	O
comprising	O
said	O
active	O
substance	O
combination	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
.	O

2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine	O
derivatives	O
as	O
inhibitors	O
of	O
glucosylceramide	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R	O
represents	O
a	O
substituted	O
benzyl	O
group	O
,	O
are	O
useful	O
as	O
inhibitors	O
of	O
glucosylceramide	B
synthase	I
.	O

Amino	O
nicotinate	O
derivatives	O
as	O
glucokinase	B
(	O
GLK	B
)	O
modulators	O
The	O
invention	O
is	O
related	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
n	O
and	O
m	O
are	O
as	O
described	O
in	O
the	O
specification	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
mediated	O
through	O
glucokinase	B
(	O
GLK	B
)	O
,	O
such	O
as	O
type	O
2	O
diabetes	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
medicaments	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
glucokinase	B
.	O

Treating	O
inflammation	O
with	O
ondansetron	O
and	O
pharmaceutical	O
compositions	O
comprised	O
thereof	O
Inflammatory	O
skin	O
disorders	O
such	O
as	O
rosacea	O
,	O
including	O
a	O
variety	O
of	O
skin	O
diseases	O
,	O
whether	O
or	O
not	O
accompanied	O
by	O
dermatosis	O
,	O
are	O
treated	O
by	O
topically	O
applying	O
onto	O
the	O
affected	O
skin	O
area	O
,	O
a	O
thus	O
effective	O
amount	O
of	O
Ondansetron	O
,	O
or	O
salt	O
or	O
base	O
thereof	O
.	O

Combination	O
Comprising	O
Combretastatin	O
and	O
Anticancer	O
Agents	O
An	O
antitumor	O
combination	O
comprising	O
a	O
stilbene	O
derivative	O
and	O
an	O
anticancer	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
taxanes	O
,	O
alkylating	O
agents	O
,	O
antimetabolites	O
,	O
vinca	O
alkaloids	O
,	O
platinum	O
compounds	O
,	O
epidophylloptoxins	O
,	O
and	O
antibiotics	O
as	O
the	O
active	O
ingredients	O
is	O
provided	O
.	O

Methods	O
of	O
using	O
these	O
pharmaceutical	O
preparations	O
for	O
the	O
treatment	O
of	O
solid	O
carcinomas	O
and	O
the	O
like	O
are	O
also	O
provided	O
.	O

Novel	O
ureido	O
-	O
and	O
amido	O
-	O
pyrazolone	O
derivatives	O
The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
;	O
wherein	O
each	O
of	O
R1	O
to	O
R4	O
is	O
independently	O
selected	O
from	O
hydrogen	O
,	O
a	O
halogen	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
cyclic	O
and	O
heterocyclic	O
moiety	O
,	O
substituted	O
or	O
unsubstituted	O
,	O
linear	O
or	O
branched	O
alkyl	O
,	O
alkyloxy	O
,	O
alkylcarbonyl	O
,	O
alkyloxycarbonyl	O
,	O
alkenyl	O
,	O
alkenyloxy	O
,	O
alkenylcarbonyl	O
,	O
alkenyloxycarbonyl	O
,	O
alkynyl	O
,	O
alkynyloxy	O
,	O
alkynylcarbonyl	O
,	O
alkynyloxycarbonyl	O
,	O
aryl	O
,	O
benzyl	O
,	O
arlyoxy	O
,	O
arylcarbonyl	O
,	O
aryloxycarbonyl	O
and	O
sulphur	O
equivalents	O
of	O
said	O
oxy	O
,	O
carbonyl	O
and	O
oxycarbonyl	O
moieties	O
,	O
and	O
A	O
is	O
NH	O
,	O
or	O
(	O
CH2	O
)	O
n	O
,	O
where	O
n	O
is	O
preferably	O
0	O
,	O
1	O
or	O
2	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
the	O
compounds	O
and	O
their	O
uses	O
as	O
CCK	B
receptor	I
ligands	O
and	O
CCK	B
antagonists	O
.	O

Therapy	O
for	O
disease	O
caused	O
by	O
nicotinic	B
receptors	I
;	O
cognition	O
activatrors	O
;	O
central	O
nervous	O
system	O
disorders	O
Compounds	O
complying	O
with	O
the	O
general	O
formula	O
in	O
which	O
R	O
either	O
represents	O
a	O
halogen	O
atom	O
or	O
a	O
phenyl	O
group	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
chosen	O
from	O
halogen	O
atoms	O
and	O
(	O
C1-C6	O
)	O
alkyl	O
,	O
(	O
C1-C6	O
)	O
alkoxy	O
,	O
nitro	O
,	O
amino	O
,	O
trifluoromethyl	O
,	O
cyano	O
,	O
hydroxy	O
,	O
acetyl	O
or	O
methylenedioxy	O
groups	O
,	O
or	O
represents	O
a	O
pyridinyl	O
group	O
,	O
a	O
thienyl	O
group	O
,	O
an	O
indolyl	O
group	O
,	O
or	O
a	O
pyrimidinyl	O
group	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
(	O
C1-C6	O
)	O
alkoxy	O
groups	O
,	O
where	O
,	O
of	O
the	O
two	O
carbon	O
-	O
carbon	O
bonds	O
represented	O
by	O

Prodrugs	O
Of	O
Substituted	O
Amino	O
Heterobicycles	O

Which	O
Modulate	O
The	O
Function	O
Of	O
The	O
Vanilloid-1	B
Receptor	I
(	O
Vr1	B
)	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
useful	O
as	O
therapeutic	O
compounds	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
pain	O
and	O
other	O
conditions	O
ameliorated	O
by	O
the	O
modulation	O
of	O
the	O
function	O
of	O
the	O
vanilloid-1	B
receptor	I
(	O
VR1	B
)	O
.	O

Treating	O
an	O
inflammatory	O
condition	O
in	O
an	O
individual	O
by	O
administering	O
an	O
agent	O
which	O
inhibits	O
the	O
interaction	O
between	O
a	O
Toll	B
-	I
like	I
receptor	I
2	I
and	O
a	O
high	B
mobility	I
group	I
B	I
polypeptide	I
;	O
treating	O
Crohn	O
's	O
disease	O
,	O
sepsis	O
,	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
endotoxic	O
shock	O
,	O
allograft	O
rejection	O
The	O
invention	O
features	O
a	O
method	O
of	O
treating	O
an	O
inflammatory	O
condition	O
in	O
an	O
individual	O
,	O
comprising	O
administering	O
an	O
agent	O
inhibits	O
the	O
interaction	O
between	O
a	O
Toll	B
-	I
like	I
receptor	I
2	I
(	O
TLR2	B
)	O
and	O
a	O
high	B
mobility	I
group	I
B	I
(	O
HMGB	B
)	O
polypeptide	O
to	O
the	O
individual	O
.	O

The	O
invention	O
also	O
features	O
methods	O
for	O
identifying	O
agents	O
that	O
inhibit	O
the	O
interaction	O
between	O
TLR2	B
and	O
HMGB	B
.	O

Growth	B
hormone	I
receptor	I
antagonist	O
cancer	O
treatment	O
The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
tumorigenic	O
cells	O
(	O
e.g.	O
,	O
mammary	O
progenitor	O
cancer	O
cells	O
)	O
,	O
with	O
growth	B
hormone	I
receptor	I
antagonists	O
(	O
e.g.	O
,	O
Pegvisomant	O
)	O
,	O
as	O
well	O
as	O
methods	O
and	O
compositions	O
for	O
screening	O
growth	B
hormone	I
receptor	I
antagonists	O
for	O
their	O
ability	O
serve	O
as	O
anti	O
-	O
neoplastic	O
agents	O
capable	O
of	O
killing	O
tumorigenic	O
cells	O
.	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
identifying	O
tumorigenic	O
cells	O
,	O
methods	O
of	O
obtaining	O
enriched	O
populations	O
of	O
tumorigenic	O
cells	O
,	O
and	O
methods	O
of	O
causing	O
mammary	O
progenitor	O
cells	O
to	O
proliferate	O
and/or	O
differentiate	O
.	O

Chimeric	O
(	O
Double	O
)	O

Decoy	O
The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
,	O
ameliorative	O
or	O
therapeutic	O
medicament	O
for	O
vascular	O
restenosis	O
,	O
ischemic	O
disease	O
,	O
allergic	O
disease	O
,	O
inflammatory	O
disease	O
,	O
autoimmune	O
disease	O
,	O
or	O
cancer	O
metastasis	O
,	O
invasion	O
(	O
cancer	O
metastasis	O
/	O
invasion	O
)	O
or	O
cachexia	O
based	O
on	O
the	O
inhibitory	O
action	O
on	O
a	O
plural	O
of	O
transcriptional	O
regulatory	O
factor	O
.	O

A	O
chimera	O
(	O
double	O
)	O
decoy	O
of	O
the	O
present	O
invention	O
has	O
plural	O
transcriptional	O
regulatory	O
factor	O
binding	O
sequences	O
in	O
a	O
single	O
molecule	O
thereof	O
.	O

Thus	O
,	O
it	O
is	O
able	O
to	O
inhibit	O
the	O
activity	O
of	O
plural	O
transcriptional	O
regulatory	O
factors	O
with	O
a	O
single	O
molecule	O
.	O

For	O
example	O
,	O
stenosis	O
of	O
an	O
anastomosed	O
site	O
of	O
an	O
artificial	O
blood	O
vessel	O
is	O
caused	O
by	O
thickening	O
of	O
the	O
vascular	O
intima	O
,	O
and	O
this	O
is	O
mainly	O
caused	O
by	O
activation	O
of	O
cell	O
proliferation	O
by	O
an	O
inflammatory	O
reaction	O
occurring	O
at	O
the	O
anastomosed	O
site	O
.	O

Thus	O
,	O
thickening	O
of	O
vessel	O
walls	O
can	O
be	O
inhibited	O
by	O
simultaneously	O
inhibiting	O
two	O
transcriptional	O
regulatory	O
factors	O
involved	O
in	O
inflammation	O
and	O
cell	O
proliferation	O
by	O
using	O
the	O
chimera	O
decoy	O
of	O
the	O
present	O
invention	O
.	O

Triazole	O
Derivative	O
or	O
Salt	O
Thereof	O
[	O
Problem	O
]	O
There	O
is	O
provided	O
a	O
compound	O
which	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diseases	O
in	O
which	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11β	B
-	I
HSD1	I
)	O
participates	O
,	O
in	O
particular	O
diabetes	O
,	O
insulin	B
resistance	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

It	O
has	O
been	O
found	O
that	O
a	O
triazole	O
derivative	O
wherein	O
the	O
triazole	O
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	O
methyl	O
group	O
in	O
the	O
2-position	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
has	O
a	O
strong	O
11β	B
-	I
HSD1	I
inhibitory	O
activity	O
.	O

Moreover	O
,	O
the	O
triazole	O
derivative	O
of	O
the	O
invention	O
exhibits	O
an	O
excellent	O
blood	O
-	O
glucose	O
level	O
-	O
lowering	O
action	O
and	O
hence	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diabetes	O
,	O
insulin	O
resistance	O
.	O

Amorphous	O
form	O
of	O
Olanzapine	O
The	O
present	O
invention	O
relates	O
to	O
an	O
amorphous	O
form	O
of	O
olanzapine	O
Formula	O
(	O
I	O
)	O
:	O
and	O
a	O
process	O
for	O
its	O
preparation	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
an	O
amorphous	O
form	O
of	O
olanzapine	O
(	O
I	O
)	O
.	O

The	O
pharmaceutical	O
composition	O
may	O
be	O
used	O
,	O
in	O
particular	O
,	O
for	O
the	O
treatment	O
of	O
psychiatric	O
,	O
psychological	O
or	O
psychotic	O
disorders	O
,	O
anxiety	O
disorders	O
,	O
or	O
gastrointestinal	O
or	O
functional	O
bowel	O
disorders	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treating	O
said	O
disorders	O
.	O

Heterocycle	O
-	O
Substituted	O
Cyclic	O
Urea	O
Derivatives	O
,	O
Preparation	O
Thereof	O
And	O
Pharmaceutical	O
Use	O

Thereof	O
As	O
Kinase	B
Inhibitors	O
The	O
disclosure	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
Y	O
,	O
Y1	O
,	O
Yo	O
,	O
R1	O
,	O
R2	O
,	O
R2′	O
,	O
p	O
,	O
R3	O
,	O
R3′	O
,	O
A	O
,	O
B	O
and	O
Y2	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
,	O
and	O
to	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
and	O
use	O
thereof	O
as	O
protein	B
kinase	I
inhibitors	O
.	O

Delivery	O
of	O
a	O
combination	O
therapy	O
for	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
A	O
method	O
of	O
delivery	O
of	O
a	O
combination	O
therapy	O
to	O
the	O
pulmonary	O
system	O
that	O
includes	O
providing	O
a	O
nebulizer	O
and	O
an	O
aqueous	O
solution	O
comprising	O
a	O
long	O
-	O
acting	O
corticosteroid	O
,	O
a	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
,	O
and	O
a	O
long	O
-	O
acting	O
anticholinergic	O
,	O
and	O
administering	O
the	O
solution	O
to	O
the	O
patient	O
using	O
the	O
nebulizer	O
.	O

The	O
corticosteroid	O
is	O
budesonide	O
,	O
the	O
beta	O
-	O
agonist	O
is	O
formoterol	O
and	O
the	O
anticholinergic	O
is	O
tiotropium	O
.	O

A	O
pharmaceutical	O
composition	O
is	O
also	O
described	O
for	O
the	O
treatment	O
of	O
respiratory	O
conditions	O
and	O
diseases	O
comprising	O
a	O
long	O
-	O
acting	O
corticosteroid	O
,	O
a	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
,	O
and	O
a	O
long	O
-	O
acting	O
anticholinergic	O
,	O
and	O
administering	O
the	O
solution	O
to	O
the	O
patient	O
using	O
the	O
nebulizer	O
.	O

Use	O
of	O
acylaminoalkenylene	O
-	O
amide	O
derivatives	O
in	O
functional	O
motility	O
disorders	O
of	O
the	O
viscera	O
The	O
use	O
of	O
a	O
compound	O
of	O
formula	O

I	O
in	O
free	O
form	O
or	O
in	O
the	O
form	O
of	O
a	O
pharmaceutically	O
acceptable	O
salt	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
functional	O
motility	O
disorder	O
of	O
the	O
viscera	O
.	O

New	O
Expression	O
Tools	O
for	O
Multiprotein	O
Applications	O

The	O
present	O
invention	O
relates	O
to	O
polynucleotides	O
for	O
multigene	O
applications	O
comprising	O
a	O
novel	O
functional	O
arrangement	O
,	O
as	O
well	O
as	O
vectors	O
,	O
host	O
cells	O
,	O
and	O
recombinant	O
animals	O
comprising	O
said	O
polynucleotides	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
generating	O
multigene	O
expression	O
cassettes	O
,	O
methods	O
for	O
producing	O
multiprotein	O
complexes	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
methods	O
for	O
producing	O
a	O
vaccine	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
encompasses	O
methods	O
for	O
screening	O
protein	O
complex	O
interactions	O
or	O
modifications	O
of	O
proteins	O
,	O
and	O
methods	O
for	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
screening	O
of	O
candidate	O
compounds	O
capable	O
of	O
protein	O
complex	O
interactions	O
or	O
modifications	O
of	O
proteins	O
or	O
capable	O
of	O
inhibiting	O
protein	O
complex	O
interactions	O
or	O
inhibiting	O
modifications	O
of	O
proteins	O
.	O

Also	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
polynucleotides	O
,	O
vectors	O
,	O
host	O
cells	O
or	O
recombinant	O
animals	O
of	O
the	O
invention	O
for	O
(	O
i	O
)	O
preparing	O
a	O
medicament	O
for	O
gene	O
therapy	O
,	O
for	O
(	O
ii	O
)	O
the	O
recombinant	O
production	O
of	O
multiprotein	O
complexes	O
,	O
(	O
iii	O
)	O
for	O
producing	O
a	O
vaccine	O
,	O
or	O
(	O
iv	O
)	O
for	O
screening	O
compounds	O
of	O
interest	O
.	O

Last	O
but	O
not	O
least	O
,	O
the	O
invention	O
is	O
directed	O
to	O
a	O
kit	O
of	O
parts	O
comprising	O
at	O
least	O
a	O
polynucleotide	O
,	O
a	O
vector	O
,	O
and/or	O
a	O
host	O
cell	O
according	O
to	O
the	O
invention	O
.	O

Boronated	O
Metal	O
-	O
Phthalocyanines	O
,	O
Process	O
For	O
Their	O
Preparation	O
,	O
Pharmaceutical	O
Compositions	O
Comprising	O
Them	O

And	O
Use	O
Thereof	O
The	O
present	O
invention	O
relates	O
to	O
metal	O
-	O
phthalocyanines	O
bearing	O
at	O
least	O
a	O
group	O
containing	O
boron	O
isotopes	O
11B	O
or	O
10B	O
,	O
covalently	O
bound	O
to	O
the	O
axial	O
positions	O
of	O
metal	O
-	O
phthalocyanine	O
nucleus	O
;	O
moreover	O
it	O
refers	O
to	O
the	O
process	O
for	O
their	O
preparation	O
,	O
the	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
neoplastic	O
and	O
dysplastic	O
pathologies	O
in	O
PDT	O
and/or	O
BNCT	O
.	O

Antimicrobial	O
photoinactivation	O
using	O
chalcogen	O
analogs	O
of	O
benzo	O
(	O
A	O
)	O
phenoxazinium	O
dyes	O
Compositions	O
and	O
methods	O
for	O
the	O
use	O
of	O
photoactivatable	O
antimicrobial	O
chalcogen	O
analogs	O
of	O
benzophenoxazinium	O
dyes	O
in	O
the	O
treatment	O
of	O
infections	O
are	O
provided	O
.	O

Combinations	O
of	O
Serotonin	O
Reuptake	O
Inhibitors	O
and	O
Imidazoline	O
I	O
2	O
Agonists	O
The	O
present	O
invention	O
relates	O
to	O
combinations	O
of	O
serotonin	O
reuptake	O
inhibitors	O
and	O
imidazoline	O
I2	O
agonists	O
as	O
separate	O
chemical	O
units	O
or	O
both	O
properties	O
combined	O
in	O
a	O
single	O
molecule	O
and	O
to	O
the	O
use	O
thereof	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
obsessive	O
-	O
compulsive	O
disorders	O
(	O
OCDs	O
)	O
,	O
obsessive	O
-	O
compulsive	O
spectrum	O
disorders	O
(	O
OCSDs	O
)	O
and	O
other	O
anxiety	O
states	O
.	O

Inhibition	O
Of	O
Superoxide	O
Dismutase	O
By	O
Tetrathiomolybdate	O
:	O
Identification	O
Of	O
New	O
Anti	O
-	O
Angiogenic	O
And	O
Antitumor	O
Agents	O
Though	O
copper	O
is	O
elevated	O
in	O
the	O
tumor	O
tissue	O
and	O
plasma	O
of	O
patients	O
with	O
various	O
malignancies	O
,	O
the	O
molecular	O
targets	O
for	O
copper	O
binding	O
agents	O
in	O
angiogenesis	O
and	O
tumor	O
progression	O
remain	O
poorly	O
understood	O
.	O

It	O
is	O
disclosed	O
that	O
one	O
anti	O
-	O
angiogenic	O
target	O
for	O
the	O
copper	O
binding	O
agent	O
tetrathiomolybdate	O
is	O
intracellular	O
CuZn	O
-	O
superoxide	O
dismutase	O
(	O
SOD1	O
)	O
.	O

A	O
second	O
generation	O
tetrathiomolybdate	O
analog	O
,	O
ATN-224	O
,	O
inhibits	O
endothelial	O
cell	O
(	O
EC	O
)	O
proliferation	O
in	O
vitro	O
,	O
binds	O
to	O
SOD1	O
and	O
inhibits	O
its	O
activity	O
without	O
displacing	O
bound	O
copper	O
ATN-224	O
can	O
accumulate	O
in	O
ECs	O
and	O
inhibit	O
CuZnSOD	O
activity	O
with	O
an	O
IC50	O
similar	O
to	O
the	O
IC50	O
for	O
EC	O
proliferation	O
,	O
resulting	O
in	O
increased	O
generation	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
.	O

Inhibition	O
of	O
EC	O
proliferation	O
by	O
ATN-224	O
in	O
vitro	O
is	O
substantially	O
reversed	O
by	O
a	O
synthetic	O
porphyrin	O
SOD	O
mimetic	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
vivo	O
,	O
where	O
inhibition	O
of	O
angiogenesis	O
by	O
ATN-224	O
in	O
a	O
Matrigel	O
plug	O
model	O
was	O
also	O
reversed	O
by	O
MnTBAP	O
.	O

Thus	O
,	O
a	O
distinct	O
molecular	O
target	O
for	O
copper	O
depletion	O
therapy	O
has	O
been	O
identified	O
and	O
SOD1	O
is	O
now	O
validated	O
as	O
a	O
target	O
for	O
anti	O
-	O
angiogenesis	O
.	O

Methods	O
for	O
screening	O
,	O
or	O
designing	O
,	O
such	O
SOD1	O
inhibitors	O
for	O
use	O
as	O
angiogenesis	O
inhibitors	O
and	O
anti	O
-	O
cancer	O
agents	O
are	O
disclosed	O
.	O

Combinatorial	O
therapy	O
;	O
genetic	O
engineered	O
protein	O
;	O
therapy	O
for	O
autoimmune	O
diaeses	O
;	O
anticancer	O
agents	O
The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
apoptosis	O
.	O

The	O
invention	O
provides	O
novel	O
therapies	O
,	O
for	O
example	O
,	O
novel	O
combinatorial	O
therapies	O
or	O
novel	O
therapeutic	O
compounds	O
that	O
can	O
work	O
alone	O
,	O
sequentially	O
to	O
,	O
or	O
jointly	O
with	O
Apoptin	B
,	O
especially	O
in	O
those	O
cases	O
wherein	O
p53	B
is	O
completely	O
or	O
partially	O
non	O
-	O
functional	O
.	O

Isolated	O
polynucleotides	O
comprising	O
a	O
nucleic	O
acid	O
which	O
operably	O
encodes	O
50	O
contiguous	O
amino	O
acids	O
,	O
nucleic	O
acids	O
are	O
fragments	O
of	O
a	O
codon	O
-	O
optimized	O
coding	O
region	O
;	O
a	O
carrier	O
The	O
invention	O
is	O
related	O
to	O
polynucleotide	O
-	O
based	O
cytomegalovirus	O
vaccines	O
.	O

In	O
particular	O
,	O
the	O
invention	O
is	O
plasmids	O
operably	O
encoding	O
HCMV	O
antigens	O
,	O
in	O
which	O
the	O
naturally	O
-	O
occurring	O
coding	O
regions	O
for	O
the	O
HCMV	O
antigens	O
have	O
been	O
modified	O
for	O
improved	O
translation	O
in	O
human	O
or	O
other	O
mammalian	O
cells	O
through	O
codon	O
optimization	O
.	O

HCMV	O
antigens	O
which	O
are	O
useful	O
in	O
the	O
invention	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
pp65	O
,	O
glycoprotein	O
B	O
(	O
gB	O
)	O
,	O
IE1	O
,	O
and	O
fragments	O
,	O
variants	O
or	O
derivatives	O
of	O
either	O
of	O
these	O
antigens	O
.	O

In	O
certain	O
embodiments	O
,	O
sequences	O
have	O
been	O
deleted	O
,	O
e.g.	O
,	O
the	O
Arg435-Lys438	O
putative	O
kinase	B
in	O
pp65	O
and	O
the	O
membrane	O
anchor	O
and	O
endocellular	O
domains	O
in	O
gB.	O
The	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
to	O
induce	O
an	O
immune	O
response	O
to	O
HCMV	O
in	O
a	O
mammal	O
,	O
for	O
example	O
,	O
a	O
human	O
,	O
comprising	O
delivering	O
a	O
plasmid	O
encoding	O
a	O
codon	O
-	O
optimized	O
HCMV	O
antigen	O
as	O
described	O
above	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
plasmids	O
encoding	O
a	O
codon	O
-	O
optimized	O
HCMV	O
antigen	O
as	O
described	O
above	O
,	O
and	O
further	O
comprising	O
adjuvants	O
,	O
excipients	O
,	O
or	O
immune	O
modulators	O
.	O

N	O
-	O
Hydroxy	O
(	O
2S	O
)	O
-2-hydroxy	O
phenyl	O
or	O
heteroaryl	O
sulfonamide	O
derivatives	O
;	O
for	O
example	O
,	O
N	O
-	O
Hydroxy	O
(	O
2S	O
)	O
-2-hydroxy-3-	O
{	O
N-	O
[	O
4-	O
(	O
4-	O
chlorophenoxy	O
)	O
phenyl	O
]	O
,	O
N-	O
methanesulfonylamino	O
}	O
propionamide	O
;	O
for	O
treating	O
disorders	O
related	O
to	O
matrix	B
metalloproteases	I
,	O
particularly	O
useful	O
for	O
treating	O
strokes	O
;	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
and	O
R7	O
are	O
defined	O
in	O
the	O
specification	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
treating	O
disorders	O
related	O
to	O
matrix	B
metalloproteases	I
.	O

More	O
particularly	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
treating	O
stroke	O
.	O

Polymerizable	O
antimicrobial	O
composition	O
The	O
present	O
invention	O
provides	O
a	O
polymerizable	O
antimicrobial	O
composition	O
and	O
a	O
method	O
for	O
using	O
the	O
same	O
.	O

The	O
polymerizable	O
antimicrobial	O
composition	O
of	O
the	O
invention	O
comprises	O
an	O
antimicrobial	O
compound	O
,	O
a	O
linker	O
,	O
and	O
a	O
polymerizable	O
function	O
group	O
.	O

Topical	O
delivery	O
of	O
codrugs	O
The	O
present	O
invention	O
provides	O
pharmaceutical	O
compositions	O
for	O
topical	O
delivery	O
comprising	O
a	O
suitable	O
carrier	O
and	O
a	O
codrug	O
capable	O
of	O
penetrating	O
,	O
or	O
being	O
transported	O
across	O
,	O
the	O
dermis	O
.	O

The	O
codrug	O
according	O
to	O
the	O
invention	O
comprises	O
a	O
first	O
constituent	O
moiety	O
linked	O
to	O
a	O
second	O
constituent	O
moiety	O
,	O
wherein	O
the	O
second	O
constituent	O
moiety	O
is	O
the	O
same	O
as	O
,	O
or	O
different	O
from	O
,	O
the	O
first	O
constituent	O
moiety	O
.	O

The	O
first	O
and	O
second	O
constituent	O
moieties	O
are	O
so	O
linked	O
that	O
they	O
are	O
easily	O
transported	O
into	O
or	O
across	O
the	O
dermis	O
,	O
into	O
the	O
skin	O
,	O
or	O
into	O
the	O
blood	O
or	O
lymphatic	O
system	O
,	O
and	O
are	O
reconstituted	O
in	O
vivo	O
to	O
form	O
the	O
first	O
and	O
second	O
constituent	O
moieties	O
.	O

Crosslinked	O
Amine	O
Polymers	O
The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
ion	O
imbalances	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
polymeric	O
and	O
pharmaceutical	O
compositions	O
comprising	O
crosslinked	O
amine	O
polymers	O
.	O

Methods	O
of	O
use	O
of	O
the	O
polymeric	O
and	O
pharmaceutical	O
compositions	O
for	O
therapeutic	O
and/or	O
prophylactic	O
benefits	O
are	O
disclosed	O
herein	O
.	O

Examples	O
of	O
these	O
methods	O
include	O
the	O
treatment	O
of	O
renal	O
diseases	O
and	O
hyperphosphatemia	O
.	O

drug	O
delivery	O
devices	O
comprising	O
capsules	O
containing	O
drugs	O
distributed	O
within	O
an	O
aqueous	O
phase	O
in	O
the	O
interior	O
of	O
the	O
capsule	O
The	O
present	O
invention	O
relates	O
to	O
liposomes	O
for	O
drug	O
delivery	O
,	O
wherein	O
a	O
liposome	O
includes	O
molecules	O
of	O
at	O
least	O
one	O
desired	O
drug	O
distributed	O
within	O
an	O
aqueous	O
phase	O
in	O
the	O
interior	O
of	O
the	O
liposome	O
and	O
wherein	O
the	O
liposome	O
further	O
includes	O
molecules	O
of	O
the	O
same	O
or	O
of	O
another	O
drug	O
attached	O
to	O
either	O
or	O
both	O
sides	O
of	O
the	O
liposomal	O
membrane	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
liposomes	O
,	O
wherein	O
at	O
least	O
a	O
part	O
of	O
the	O
molecules	O
of	O
a	O
desired	O
drug	O
bear	O
a	O
functional	O
group	O
that	O
is	O
reactive	O
with	O
a	O
functional	O
group	O
present	O
in	O
at	O
least	O
one	O
lipid	O
fraction	O
,	O
and	O
wherein	O
the	O
drug	O
is	O
covalently	O
linked	O
to	O
the	O
membrane	O
lipids	O
by	O
chemical	O
bonding	O
,	O
e.g.	O
by	O
ester	O
bonding	O
of	O
a	O
hydroxyl	O
group	O
of	O
a	O
lipid	O
molecule	O
and	O
an	O
acidic	O
residue	O
of	O
the	O
drug	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
desired	O
drug	O
is	O
a	O
glycoprotein	B
such	O
as	O
erythropoietin	B
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
manufacture	O
of	O
said	O
liposomes	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Hes6	B
as	O
a	O
marker	O
of	O
pancreatic	O
endocrine	O
cells	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
identifying	O
endocrine	O
stem	O
and	O
progenitor	O
cells	O
.	O

Novel	O
Benzofurans	O
and	O
Indols	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
is	O
a	O
fluorine	O
or	O
a	O
chlorine	O
atom	O
;	O
the	O
methyl	O
groups	O
located	O
at	O
the	O
2-	O
and	O
5-position	O
of	O
the	O
piperazine	O
ring	O
are	O
in	O
trans	O
-	O
configuration	O
to	O
each	O
other	O
;	O
Y	O
is	O
NH	O
or	O
O	O
;	O
R1	O
is	O
selected	O
from	O
hydrogen	O
,	O
chloro	O
,	O
bromo	O
,	O
nitro	O
,	O
methyl	O
or	O
trifluoromethyl	O
;	O
R2	O
is	O
selected	O
from	O
hydrogen	O
,	O
halo	O
,	O
methyl	O
,	O
trifluoromethyl	O
,	O
methoxy	O
or	O
trifluoromethoxy	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
;	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Included	O
are	O
also	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
methods	O
for	O
treating	O
mammals	O
suffering	O
from	O
inflammatory	O
,	O
autoimmune	O
,	O
proliferative	O
or	O
hyperproliferative	O
diseases	O
by	O
administering	O
a	O
compound	O
having	O
the	O
formula	O
(	O
I	O
)	O
to	O
said	O
mammal	O
.	O

Topically	O
administrating	O
an	O
inhibitor	O
of	O
Erbb2	B
or	O
HER2	B
receptor	I
tyrosine	I
kinase	I
activity	O
because	O
of	O
a	O
novel	O
connection	O
between	O
HER2	B
and	O
a	O
DNA	O
damage	O
checkpoint	O
;	O
reducing	O
mutagenesis	O
and	O
apoptosis	O
;	O
antitumor	O
,	O
-carcinogenic	O
,	O
-proliferative	O
agents	O
and	O
-inflammatory	O
agents	O
;	O
sunburn	O
;	O
hyperplasia	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
suppression	O
of	O
ultra	O
violet	O
-	O
induced	O
skin	O
pathologies	O
and	O
skin	O
abnormalities	O
,	O
such	O
as	O
abnormal	O
proliferation	O
and	O
mutagenesis	O
,	O
and	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
having	O
Erbb2	B
or	O
HER2	B
receptors	O
.	O

The	O
method	O
involves	O
administration	O
of	O
Erbb2	B
/	O
HER2	B
inhibitors	O
,	O
either	O
before	O
or	O
after	O
exposure	O
to	O
UV	O
.	O

Endogenous	O
Peptide	O
and	O
Active	O
Subfragments	O
Thereof	O
The	O
present	O
invention	O
relates	O
to	O
a	O
substantially	O
pure	O
biologically	O
active	O
consecutive	O
anti	O
-	O
angiogenic	O
polypeptide	O
comprising	O
the	O
central	O
region	O
of	O
human	B
Histidine	I
Rich	I
Glycoprotein	I
(	O
HRGP	B
)	O
.	O

Said	O
polypeptide	O
is	O
shown	O
to	O
comprise	O
a	O
potential	O
endogenous	O
,	O
naturally	O
occurring	O
subfragment	O
of	O
human	B
HRGP	I
,	O
comprising	O
similar	O
anti	O
-	O
angiogenic	O
activities	O
as	O
the	O
mature	O
protein	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
one	O
or	O
more	O
new	O
biologically	O
active	O
subfragments	O
of	O
human	B
HRGP	I
,	O
derived	O
from	O
said	O
central	O
region	O
.	O

Said	O
subfragments	O
are	O
all	O
characterized	O
by	O
having	O
anti	O
-	O
angiogenic	O
activity	O
.	O

One	O
of	O
the	O
active	O
subfragments	O
is	O
referred	O
to	O
as	O
Pep2	B
.	O

Enscoped	O
by	O
the	O
present	O
invention	O
are	O
also	O
anti	O
-	O
angiogenic	O
subfragments	O
derived	O
from	O
Pep2	B
,	O
one	O
of	O
them	O
comprising	O
a	O
newly	O
identified	O
presently	O
minimal	O
functional	O
entity	O
.	O

Administering	O
vector	O
system	O
that	O
directs	O
regulated	O
erythropoietin	B
(	O
Epo	B
)	O
gene	O
therapy	O
in	O
a	O
manner	O
that	O
physiologically	O
corrects	O
the	O
hematocrit	O
levels	O
in	O
a	O
patient	O
in	O
need	O
of	O
anemia	O
treatment	O
Disclosed	O
is	O
a	O
viral	O
vector	O
containing	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
erythropoietin	B
(	O
Epo	B
)	O
,	O
in	O
operable	O
linkage	O
with	O
an	O
HRE	B
expression	O
control	O
sequence	O
,	O
as	O
well	O
as	O
uses	O
of	O
the	O
vector	O
;	O
for	O
instance	O
,	O
in	O
preparing	O
a	O
medicament	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
treating	O
anemia	O
,	O
can	O
involve	O
administering	O
the	O
vector	O
to	O
a	O
patient	O
,	O
wherein	O
expression	O
of	O
Epo	B
is	O
physiologically	O
regulated	O
such	O
that	O
hematocrit	O
levels	O
of	O
the	O
patient	O
are	O
corrected	O
and	O
maintained	O
.	O

For	O
prophylaxis	O
or	O
treatment	O
of	O
apoptosis	O
or	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
,	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
screening	O
for	O
a	O
prophylactic	O
or	O
therapeutic	O
drug	O
for	O
apoptosis	O
or	O
an	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
and	O
complications	O
thereof	O
or	O
a	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
namely	O
,	O
a	O
method	O
for	O
screening	O
for	O
a	O
prophylactic	O
or	O
therapeutic	O
drug	O
for	O
apoptosis	O
or	O
an	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
and	O
complications	O
thereof	O
or	O
COPD	O
,	O
which	O
includes	O
(	O
1	O
)	O
comparing	O
the	O
activities	O
of	O
a	O
protein	O
having	O
an	O
amino	O
acid	O
sequence	O
the	O
same	O
as	O
or	O
substantially	O
the	O
same	O
as	O
the	O
amino	O
acid	O
sequence	O
shown	O
by	O
SEQ	O
ID	O
NO	O
:	O
2	O
or	O
a	O
partial	O
peptide	O
thereof	O
or	O
a	O
salt	O
thereof	O
,	O
between	O
in	O
the	O
presence	O
of	O
a	O
test	O
substance	O
and	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
,	O
or	O
(	O
2	O
)	O
comparing	O
the	O
expressions	O
of	O
a	O
protein	O
having	O
an	O
amino	O
acid	O
sequence	O
the	O
same	O
as	O
or	O
substantially	O
the	O
same	O
as	O
the	O
amino	O
acid	O
sequence	O
shown	O
by	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
a	O
partial	O
peptide	O
thereof	O
and	O
a	O
salt	O
thereof	O
in	O
the	O
cells	O
having	O
the	O
ability	O
to	O
produce	O
the	O
protein	O
,	O
the	O
partial	O
peptide	O
thereof	O
and	O
the	O
salt	O
thereof	O
,	O
between	O
in	O
the	O
presence	O
of	O
a	O
test	O
substance	O
and	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
.	O

Screening	O
for	O
a	O
compound	O
which	O
inhibits	O
p62	B
/	O
ubiquitin	B
binding	O
;	O
detecting	O
the	O
formation	O
of	O
inclusion	O
bodies	O
in	O
neurodegenerative	O
diseases	O
;	O
screening	O
for	O
therapeutic	O
agents	O
that	O
disperse	O
the	O
inclusions	O
The	O
application	O
discloses	O
a	O
role	O
of	O
p62	B
in	O
aging	O
-	O
related	O
disease	O
,	O
such	O
as	O
development	O
of	O
obesity	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
,	O
various	O
tumors	O
,	O
increased	O
male	O
mortality	O
,	O
intracellular	O
inclusion	O
named	O
sequestosome	O
,	O
and	O
redox	O
regulation	O
.	O

In	O
particular	O
the	O
application	O
discloses	O
a	O
method	O
of	O
detecting	O
the	O
formation	O
of	O
inclusion	O
bodies	O
in	O
neurodegenerative	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
screening	O
for	O
therapeutic	O
agents	O
that	O
disperse	O
the	O
inclusions	O
.	O

Further	O
,	O
transgenic	O
mice	O
containing	O
a	O
mutation	O
in	O
the	O
p62	B
gene	O
and	O
having	O
a	O
functionally	O
disrupted	O
p62	B
gene	O
locus	O
are	O
also	O
disclosed	O
.	O

Administering	O
(	O
3R,5S	O
)	O
-N	O
-	O
propanesulfonyl-7-chloro-5-	O
(	O
2,3-dimethoxyphenyl	O
)	O
-1-	O
(	O
3-hydroxy-2,2-dimethylpropyl	O
)	O
-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide	O
;	O
cerebral	O
infarction	O
The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
functional	O
disorders	O
,	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
dysfunction	O
and	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
obesity	O
and	O
deuteropathy	O
thereof	O
,	O
each	O
of	O
which	O
comprises	O
a	O
compound	O
having	O
an	O
effect	O
of	O
increasing	O
ubiquinone	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
;	O
as	O
well	O
as	O
a	O
ubiquinone	O
increasing	O
agent	O
comprising	O
a	O
compound	O
having	O
a	O
squalene	B
synthase	I
inhibitory	O
effect	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O

Hydrazide	O
Derivatives	O
A	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
hydrate	O
of	O
the	O
foregoing	O
is	O
safe	O
while	O
exhibiting	O
suitable	O
physicochemical	O
stability	O
,	O
and	O
is	O
useful	O
as	O
therapeutic	O
or	O
prophylactic	O
agents	O
for	O
diseases	O
associated	O
with	O
thrombus	O
formation	O
.	O

wherein	O
R1a	O
,	O
R1b	O
,	O
R1c	O
and	O
R1d	O
each	O
independently	O
represent	O
hydrogen	O
,	O
etc	O
.	O
,	O
R2	O
represents	O
optionally	O
substituted	O
phenyl	O
,	O
etc	O
.	O
,	O
R3	O
represents	O
optionally	O
substituted	O
C6	O
-	O
10	O
aryl	O
,	O
etc	O
.	O
,	O
Z1	O
,	O
Z2	O
and	O
Z3	O
each	O
independently	O
represent	O
hydrogen	O
,	O
etc	O
.	O
,	O
Z4	O
represents	O
hydrogen	O
,	O
etc	O
.	O
and	O
X	O
represents	O
a	O
single	O
bond	O
or	O
—CO—	O
,	O
etc	O
.	O

Compositions	O
For	O
Treating	O
Flushing	O
And	O
Lipid	O
-	O
Associated	O
Disorders	O
Comprising	O
Niacin	O
Receptor	O
Partial	O
Agonists	O

The	O
invention	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	O
or	O
a	O
niacin	O
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	O
receptor	O
partial	O
agonist	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	O
or	O
a	O
niacin	O
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	O
receptor	O
partial	O
agonist	O
and	O
an	O
effective	O
lipid	O
altering	O
amount	O
of	O
niacin	O
or	O
a	O
niacin	O
analog	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	O
or	O
a	O
niacin	O
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	O
receptor	O
partial	O
agonist	O
and	O
subsequently	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
lipid	O
altering	O
amount	O
of	O
niacin	O
or	O
a	O
niacin	O
analog	O
.	O

Pharmaceutical	O
Composition	O
Containing	O
Prostaglandin	O
An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
stable	O
aqueous	O
pharmaceutical	O
composition	O
which	O
suppresses	O
degradation	O
of	O
prostaglandin	O
F2α	O
in	O
a	O
preparation	O
containing	O
prostaglandin	O
F2α	O
.	O

The	O
object	O
was	O
attained	O
by	O
formulating	O
a	O
prostaglandin	O
F2α	O
derivative	O
into	O
an	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
together	O
with	O
an	O
oil	O
,	O
for	O
example	O
,	O
medium	O
chain	O
fatty	O
acid	O
triglyceride	O
,	O
a	O
water	O
-	O
soluble	O
polymer	O
and	O
water	O
.	O

Injectable	O
Preparations	O
Of	O
Diclofenac	O
And	O
Its	O
Pharmaceutically	O
Acceptable	O
Salts	O
The	O
present	O
invention	O
provides	O
injectable	O
formulations	O
of	O
water	O
-	O
soluble	O
salts	O
of	O
diclofenac	O
in	O
single	O
doses	O
of	O
less	O
than	O
2	O
ml	O
,	O
which	O
cause	O
significantly	O
less	O
pain	O
at	O
the	O
site	O
of	O
injection	O
and	O
can	O
be	O
administered	O
by	O
intradeltoid	O
route	O
,	O
in	O
addition	O
to	O
intragluteal	O
and	O
slow	O
intravenous	O
route	O
.	O

More	O
specifically	O
the	O
injectable	O
preparations	O
contain	O
75	O
mg	O
to	O
100	O
mg	O
of	O
water	O
-	O
soluble	O
salts	O
of	O
diclofenac	O
,	O
in	O
about	O
1	O
ml	O
injection	O
solution	O
without	O
significantly	O
raising	O
the	O
viscosity	O
of	O
the	O
injection	O
solution	O
without	O
the	O
use	O
surfactants	O
.	O

The	O
formulations	O
are	O
adjusted	O
to	O
pH	O
6	O
to	O
10	O
containing	O
up	O
to	O
100	O
mg	O
of	O
diclofenac	O
salt	O
in	O
a	O
medium	O
comprising	O
of	O
water	O
,	O
along	O
with	O
one	O
or	O
more	O
co	O
-	O
solvent	O
(	O
s	O
)	O
/	O
solubiliser	O
(	O
s	O
)	O
,	O
antioxidants	O
,	O
preservatives	O
,	O
buffers	O
,	O
alkali	O
and	O
stabilizers	O
.	O

Synergistic	O
composition	O
for	O
modulating	O
activity	O
of	O
substrate	O
analogs	O
for	O
NAD+	O
,	O
NADP+	O
,	O
NADH	O
or	O
NADPH	O
dependent	O
enzymes	O
and	O
process	O
thereof	O
The	O
present	O
disclosure	O
provides	O
a	O
composition	O
for	O
enhancing	O
effect	O
of	O
an	O
inhibitor	O
in	O
inhibiting	O
NAD+	O
/	O
NADP+	O
or	O
NADH	O
/	O
NADPH	O
dependent	O
enzymes	O
.	O

The	O
inhibition	O
of	O
the	O
NAD+	O
/	O
NADP+	O
or	O
NADH	O
/	O
NADPH	O
dependent	O
enzymes	O
such	O
as	O
Enoyl	O
-	O
ACP	O
reductase	O
(	O
ENR	O
)	O
by	O
the	O
composition	O
of	O
the	O
present	O
disclosure	O
serves	O
as	O
a	O
target	O
for	O
treating	O
malaria	O
and	O
other	O
infectious	O
diseases	O
.	O

The	O
present	O
disclosure	O
provides	O
composition	O
comprising	O
inhibitor	O
and	O
polyphenol	O
,	O
wherein	O
the	O
polyphenol	O
was	O
found	O
to	O
enhance	O
the	O
inhibitory	O
activity	O
of	O
the	O
inhibitor	O
.	O

The	O
present	O
disclosure	O
provides	O
method	O
for	O
treating	O
an	O
infectious	O
disease	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
the	O
composition	O
of	O
the	O
present	O
disclosure	O
to	O
patients	O
in	O
need	O
thereof	O
.	O

The	O
present	O
disclosure	O
further	O
provides	O
a	O
method	O
for	O
identifying	O
a	O
compound	O
that	O
enhances	O
the	O
effect	O
of	O
the	O
inhibitor	O
,	O
a	O
method	O
of	O
determining	O
the	O
antimalarial	O
activity	O
of	O
a	O
compound	O
and	O
use	O
of	O
polyphenol	O
as	O
a	O
bioenhancer	O
that	O
enhances	O
effect	O
of	O
an	O
inhibitor	O
for	O
inhibiting	O
NAD+	O
/	O
NADP+	O
or	O
NADH	O
/	O
NADPH	O
dependent	O
enzymes	O
.	O

The	O
present	O
disclosure	O
provides	O
a	O
composition	O
comprising	O
inhibitor	O
and	O
a	O
polyphenol	O
wherein	O
the	O
polyphenol	O
enhances	O
effect	O
of	O
the	O
inhibitor	O
for	O
inhibiting	O
aldose	O
reductase	O
for	O
treating	O
complications	O
of	O
diabetes	O
that	O
include	O
diabetic	O
retinopathy	O
,	O
cataract	O
neuropathy	O
and	O
neural	O
complication	O
.	O

e.g.	O
9-Hydroxy-2-	O
(	O
2-methoxy	O
-	O
ethyl	O
)	O
-1,8-dioxo-1,8-dihydro-2H	O
-	O
pyrid	O
[	O
1,2-a	O
]	O
pyrazi	O
ne-7-carboxylic	O
acid	O
4-fluoro	O
-	O
banzylamide	O
;	O
Human	O
T	O
cell	O
leukemia	O
virus	O
,	O
Feline	O
and	O
Simian	O
immunodeficiency	O
virus	O
inhibitor	O
;	O
side	O
effects	O
reduction	O
[	O
Object	O
]	O
Is	O
to	O
provide	O
a	O
novel	O
compound	O
having	O
an	O
anti	O
-	O
viral	O
activity	O
,	O
particularly	O
a	O
HIV	B
integrase	I
inhibitory	O
activity	O
,	O
and	O
an	O
agent	O
,	O
particularly	O
an	O
anti	O
-	O
HIV	O
agent	O
.	O

[	O
Solving	O
means	O
]	O
A	O
compound	O
represented	O
by	O
the	O
formula	O
:	O
(	O
wherein	O
Z1	O
is	O
NR4	O
(	O
R4	O
is	O
hydrogen	O
,	O
optionally	O
substituted	O
lower	O
alkyl	O
etc	O
.	O
)	O
,	O
O	O
or	O
CH2	O
;	O
Z2	O
is	O
optionally	O
substituted	O
lower	O
alkylene	O
or	O
optionally	O
substituted	O
lower	O
alkenylene	O
,	O
each	O
may	O
be	O
intervened	O
by	O
a	O
heteroatom	O
group	O
selected	O
from	O
group	O
consisting	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
,	O
NR5	O
(	O
R5	O
is	O
selected	O
independently	O
from	O
the	O
same	O
substituent	O
group	O
of	O
R4	O
)	O
—N	O
═	O
and	O
═	O
N—	O
;	O
R1	O
is	O
hydrogen	O
or	O
lower	O
alkyl	O
;	O
X	O
is	O
a	O
single	O
bond	O
,	O
a	O
heteroatom	O
group	O
selected	O
from	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
and	O
NH	O
,	O
or	O
lower	O
alkylene	O
or	O
lower	O
alkenylene	O
each	O
may	O
be	O
intervened	O
by	O
the	O
heteroatom	O
group	O
;	O
R2	O
is	O
optionally	O
substituted	O
aryl	O
;	O
R3	O
is	O
hydrogen	O
,	O
halogen	O
,	O
hydroxy	O
,	O
optionally	O
substituted	O
alkyl	O
group	O
etc	O
.	O
)	O

Crystalline	O
,	O
formed	O
by	O
crystallizing	O
from	O
an	O
aqueous	O
solution	O
without	O
agitation	O
;	O
treating	O
cancer	O
Erlotinib	O
hydrochloride	O
hydrate	O
is	O
formed	O
from	O
an	O
aqueous	O
solution	O
and	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
and	O
as	O
a	O
purification	O
intermediate	O
.	O

Compositions	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O
Compositions	O
are	O
provided	O
for	O
the	O
topical	O
treatment	O
of	O
cancer	O
consisting	O
of	O
lotions	O
,	O
creams	O
,	O
sprays	O
,	O
suppositories	O
or	O
slow	O
-	O
release	O
transdermal	O
patches	O
containing	O
lipid	O
-	O
soluble	O
,	O
skin	O
-	O
penetrating	O
organic	O
selenium	O
compounds	O
in	O
combination	O
with	O
inert	O
carriers	O
in	O
therapeutically	O
effective	O
amounts	O
of	O
selenium	O
compound	O
.	O

The	O
selenium	O
compounds	O
are	O
medium	O
linear	O
chain	O
dialkyl	O
diselenides	O
and	O
precursors	O
such	O
as	O
alkyl	O
selenols	O
.	O

Preferred	O
compositions	O
employ	O
R	O
—	O
Se	O
—	O
Se	O
—	O
R	O
compounds	O
where	O
R	O
is	O
from	O
6	O
to	O
8	O
carbon	O
atoms	O
,	O
and	O
most	O
specifically	O
di	O
-	O
n	O
-	O
hexyl	O
diselenide	O
.	O

Commonly	O
used	O
carriers	O
may	O
be	O
purified	O
hydrocarbon	O
fractions	O
,	O
oils	O
,	O
with	O
or	O
without	O
added	O
fat	O
-	O
soluble	O
vitamins	O
,	O
water	O
and	O
emulsifying	O
agents	O
.	O

Allele	O
-	O
specific	O
silencing	O
of	O
disease	O
genes	O
The	O
present	O
invention	O
is	O
directed	O
to	O
small	O
interfering	O
RNA	O
molecules	O
(	O
siRNA	O
)	O
targeted	O
against	O
an	O
allele	O
of	O
interest	O
,	O
and	O
methods	O
of	O
using	O
these	O
siRNA	O
molecules	O
.	O

Sirolimus	O
Formulation	O
The	O
present	O
invention	O
relates	O
to	O
a	O
stable	O
pharmaceutical	O
composition	O
comprising	O
sirolimus	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
sirolimus	O
in	O
the	O
amorphous	O
form	O
,	O
a	O
fatty	O
acid	O
ester	O
and	O
a	O
pharmaceutically	O
acceptable	O
polymer	O
wherein	O
the	O
fatty	O
acid	O
ester	O
is	O
present	O
at	O
a	O
concentration	O
of	O
less	O
than	O
10	O
%	O
w	O
/	O
w	O
compared	O
to	O
the	O
total	O
weight	O
of	O
the	O
composition	O
.	O

N-	O
{	O
2-	O
[	O
(	O
(	O
2S	O
)	O
-3-	O
{	O
[	O
1-	O
(	O
4-chlorobenzyl	O
)	O
piperidin-4-yl	O
]	O
amino	O
}	O
-2-hydroxy-2-methylpropyl	O
)	O
oxy	O
]	O
-4-hydroxyphenyl	O
}	O
acetamide	O
hemifumarate	O
;	O
chemokine	B
receptor	I
1	I
modulation	O
;	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
;	O
chemical	O
stability	O
;	O
easy	O
to	O
handle	O
;	O
inhalant	O
formulations	O
The	O
invention	O
provides	O
N-	O
{	O
2-	O
[	O
(	O
(	O
2S	O
)	O
-3-	O
{	O
[	O
1-	O
(	O
4-chlorobenzyl	O
)	O
piperidin-4-yl	O
]	O
amino	O
}	O
-2-hydroxy-2-methyl	O
-	O
propyl	O
)	O
oxy	O
]	O
-4-hydroxyphenyl	O
}	O
acetamide	O
hemi	O
-	O
fumarate	O
or	O
a	O
solvate	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
salt	O
or	O
solvate	O
and	O
use	O
of	O
the	O
salt	O
or	O
solvate	O
in	O
therapy	O
.	O

Weight	O
control	O
;	O
sexual	O
disorders	O
;	O
stomach	O
blotting	O
;	O
gastrointestinal	O
disorders	O
;	O
anticholesterol	O
agents	O
Disclosed	O
is	O
a	O
composition	O
and	O
method	O
,	O
for	O
various	O
conditions	O
,	O
including	O
body	O
weight	O
control	O
,	O
sexual	O
dysfunction	O
,	O
stomach	O
blotting	O
,	O
heartburn	O
,	O
body	O
pain	O
,	O
and	O
controlling	O
cholesterol	O
,	O
arginine	O
is	O
used	O
as	O
active	O
material	O
.	O

The	O
composition	O
is	O
in	O
the	O
form	O
of	O
lotion	O
/	O
cream	O
applicable	O
to	O
any	O
part	O
of	O
the	O
body	O
and	O
still	O
functional	O
.	O

It	O
does	O
not	O
need	O
to	O
be	O
applied	O
on	O
problematic	O
site	O
.	O

External	O
pharmaceutical	O
composition	O
containing	O
tramadol	O
An	O
analgesic	O
composition	O
for	O
external	O
application	O
for	O
increasing	O
the	O
percutaneous	O
permeability	O
of	O
tramadol	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
for	O
achieving	O
a	O
quick	O
pharmacological	O
effect	O
.	O

The	O
analgesic	O
composition	O
includes	O
tramadol	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
menthol	O
substance	O
and	O
a	O
pyrrolidone	O
compound	O
.	O

Methods	O
for	O
Improving	O
Drug	O
Disposition	O
The	O
invention	O
provides	O
a	O
method	O
for	O
improving	O
the	O
bioavailability	O
,	O
preferably	O
,	O
oral	O
bioavailability	O
and/or	O
drug	O
disposition	O
,	O
e.g.	O
brain	O
penetration	O
,	O
of	O
an	O
iron	O
chelator	O
,	O
which	O
method	O
comprises	O
co	O
-	O
administering	O
to	O
a	O
mammal	O
,	O
especially	O
a	O
human	O
,	O
in	O
need	O
of	O
such	O
treatment	O
,	O
a	O
combination	O
of	O
an	O
iron	O
chelator	O
and	O
an	O
efflux	B
protein	I
inhibitor	O
.	O

Containing	O
phosphodiesterase	B
inhibitor	O
vardensfil	O
;	O
erectile	O
dysfunction	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
dosage	O
forms	O
with	O
controlled	O
release	O
of	O
active	O
ingredient	O
which	O
comprise	O
the	O
PDE	B
5	I
inhibitor	O
vardenafil	O
and/or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
,	O
solvates	O
and/or	O
polymorphic	O
forms	O
thereof	O
as	O
active	O
ingredient	O
,	O
and	O
to	O
the	O
production	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
these	O
novel	O
pharmaceutical	O
dosage	O
forms	O
as	O
medicaments	O
,	O
and	O
to	O
their	O
use	O
for	O
producing	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
disorders	O
in	O
humans	O
and	O
animals	O
.	O

Heterodimers	O
of	O
glutamic	O
acid	O
Compounds	O
of	O
Formula	O
(	O
Ia	O
)	O
wherein	O
R	O
is	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
aryl	O
,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
heteroaryl	O
,	O
a	O
C1-C6	O
substituted	O
or	O
unsubstituted	O
alkyl	O
or	O
—NR′R′	O
,	O
Q	O
is	O
C	O
(	O
O	O
)	O
,	O
O	O
,	O
NR′	O
,	O
S	O
,	O
S	O
(	O
O	O
)	O
2	O
,	O
C	O
(	O
O	O
)	O
2	O
(	O
CH2	O
)	O
p	O
Y	O
is	O
C	O
(	O
O	O
)	O
,	O
O	O
,	O
NR′	O
,	O
S	O
,	O
S	O
(	O
O	O
)	O
2	O
,	O
C	O
(	O
O	O
)	O
2	O
(	O
CH2	O
)	O
p	O
Z	O
is	O
H	O
or	O
C1-C4	O
alkyl	O
,	O
R′	O
is	O
H	O
,	O
C	O
(	O
O	O
)	O
,	O
S	O
(	O
O	O
)	O
2	O
,	O
C	O
(	O
O	O
)	O
2	O
,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
aryl	O
,	O
a	O
C6-C12	O
substituted	O
or	O
unsubstituted	O
heteroaryl	O
or	O
a	O
C1-C6	O
substituted	O
or	O
unsubstituted	O
alkyl	O
,	O
when	O
substituted	O
,	O
aryl	O
,	O
heteroaryl	O
and	O
alkyl	O
are	O
substituted	O
with	O
halogen	O
,	O
C6-C12	O
heteroaryl	O
,	O
—NR′R′	O
or	O
COOZ	O
,	O
which	O
have	O
diagnostic	O
and	O
therapeutic	O
properties	O
,	O
such	O
as	O
the	O
treatment	O
and	O
management	O
of	O
prostate	O
cancer	O
and	O
other	O
diseases	O
related	O
to	O
NAALADase	B
inhibition	O
.	O

Radiolabels	O
can	O
be	O
incorporated	O
into	O
the	O
structure	O
through	O
a	O
variety	O
of	O
prosthetic	O
groups	O
attached	O
at	O
the	O
X	O
amino	O
acid	O
side	O
chain	O
via	O
a	O
carbon	O
or	O
hetero	O
atom	O
linkage	O
.	O

E.g.	O
,	O
[	O
(	O
1-	O
(	O
2-aminoacetyl	O
)	O
-4-	O
{	O
N-	O
[	O
(	O
3-fluoro-2-methylphenyl	O
)	O
methyl	O
]	O
carbamoyl	O
}	O
(	O
4-piperidyl	O
)	O
)	O
methoxy	O
]	O
-N-	O
(	O
4-ethylphenyl	O
)	O
carboxamide	O
;	O
smooth	O
muscle	O
myosin	O
or	O
non	O
-	O
muscle	O
myosin	O
modulator	O
;	O
hypotensive	O
agent	O
;	O
asthma	O
,	O
COPD	O
,	O
bronchoconstrictive	O
disease	O
,	O
glaucoma	O
,	O
pre	O
-	O
menstrual	O
cramps	O
,	O
erectile	O
dysfunction	O
Chemical	O
entities	O
that	O
modulate	O
smooth	O
muscle	O
myosin	O
and/or	O
non	O
-	O
muscle	O
myosin	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
smooth	O
muscle	O
myosin	O
and/or	O
non	O
-	O
muscle	O
myosin	O
are	O
described	O
.	O

glutamate	B
receptors	I
agonists	O
;	O
especially	O
to	O
treat	O
psychotic	O
conditions	O
,	O
including	O
schizophrenia	O
and	O
enhancement	O
of	O
cognition	O
;	O
N-	O
{	O
-2-	O
[	O
4-	O
(	O
6-fluoro-3-pyridinyl	O
)	O
phenyl	O
]	O
cyclopropyl	O
}	O
-2-propanesulfonamide	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
are	O
disclosed	O
:	O
wherein	O
R1	O
is	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C2	O
-	O
6alkenyl	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
R2	O
and	O
R3	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	O
,	O
halogen	O
,	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
,	O
haloC1	O
-	O
4alkoxy	O
,	O
cyano	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
each	O
R4	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
is	O
C1	O
-	O
6alkyl	O
,	O
halogen	O
,	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
,	O
haloC1	O
-	O
4alkoxy	O
,	O
cyano	O
,	O
nitro	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
p	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
n	O
is	O
1	O
or	O
2	O
;	O
R5	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	O
,	O
halogen	O
,	O
C1	O
-	O
6alkyl	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
,	O
haloC1	O
-	O
4alkoxy	O
,	O
cyano	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
or	O
diC1	O
-	O
4alkylamino	O
;	O
and	O
Het	O
is	O
thienyl	O
,	O
pyridyl	O
,	O
pyrimidinyl	O
,	O
pyridazinyl	O
,	O
pyrimidinyl	O
,	O
pyrazinyl	O
,	O
imidazolyl	O
,	O
pyrazolyl	O
,	O
pyrrolyl	O
,	O
quinolyl	O
,	O
thiazolyl	O
or	O
furyl	O
,	O
each	O
of	O
which	O
may	O
be	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
independently	O
selected	O
from	O
the	O
list	O
consisting	O
of	O
C1	O
-	O
6alkyl	O
,	O
C1	O
-	O
6alkoxy	O
,	O
acetyl	O
,	O
halogen	O
,	O
haloC1	O
-	O
6alkyl	O
,	O
cyano	O
,	O
nitro	O
,	O
amino	O
,	O
monoC1	O
-	O
4alkylamino	O
and	O
diC1	O
-	O
4alkylamino	O
.	O

Methods	O
of	O
preparation	O
of	O
the	O
compounds	O
,	O
and	O
uses	O
thereof	O
in	O
medicine	O
,	O
for	O
example	O
treatment	O
of	O
schizophrenia	O
,	O
are	O
also	O
disclosed	O
.	O

Novel	O
sustained	O
release	O
polymer	O
A	O
polymer	O
and	O
a	O
method	O
for	O
its	O
preparation	O
are	O
provided	O
.	O

The	O
polymer	O
comprises	O
poly	O
(	O
lactide	O
)	O
,	O
poly	O
(	O
lactide	O
/	O
glycolide	O
)	O
or	O
poly	O
(	O
lactic	O
acid	O
/	O
glycolic	O
acid	O
)	O
segments	O
bonded	O
by	O
ester	O
linkages	O
to	O
both	O
ends	O
of	O
an	O
alkanediol	O
core	O
unit	O
.	O

The	O
polymer	O
is	O
for	O
use	O
in	O
a	O
controlled	O
release	O
formulation	O
for	O
a	O
medicament	O
,	O
preferably	O
leuprolide	O
acetate	O
.	O

The	O
controlled	O
release	O
formulation	O
is	O
administered	O
to	O
a	O
patient	O
as	O
a	O
subcutaneous	O
depot	O
of	O
a	O
flowable	O
composition	O
comprising	O
the	O
polymer	O
,	O
a	O
biocompatible	O
solvent	O
,	O
and	O
the	O
medicament	O
.	O

Controlled	O
release	O
formulations	O
comprising	O
the	O
polymer	O
release	O
leuprolide	O
for	O
treatment	O
of	O
prostate	O
cancer	O
patients	O
over	O
periods	O
of	O
3	O
-	O
6	O
months	O
.	O

mobilizing	O
triacylglycerol	O
in	O
mammals	O
by	O
feeding	O
the	O
mammal	O
a	O
diet	O
that	O
includes	O
betaine	O
,	O
cysteine	O
and	O
choline	O
bitartrate	O
,	O
while	O
restricting	O
methionine	O
intake	O
;	O
reduction	O
of	O
liver	O
disorders	O
;	O
cirrhosis	O
Methods	O
for	O
use	O
in	O
mobilizing	O
triacylglycerol	O
(	O
TAG	O
)	O
in	O
order	O
to	O
elevate	O
apoliprotein	B
B	I
and	O
Very	O
-	O
Low	O
-	O
Density	O
Lipoprotein	O
(	O
VLDL	O
)	O
are	O
described	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
involves	O
providing	O
betaine	O
in	O
an	O
amount	O
of	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
in	O
order	O
to	O
mobilize	O
TAG	O
.	O

In	O
some	O
embodiments	O
,	O
serum	O
VLDL	O
is	O
elevated	O
as	O
a	O
result	O
of	O
mobilizing	O
hepatic	O
TAG	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
restricting	O
methionine	O
intake	O
to	O
less	O
than	O
about	O
1	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
feeding	O
L	O
-	O
cysteine	O
at	O
a	O
level	O
of	O
at	O
least	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
feeding	O
choline	O
bitartrate	O
at	O
a	O
level	O
of	O
about	O
1.25	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

Mobilizing	O
hepatic	O
TAG	O
is	O
effective	O
to	O
reduce	O
hepatic	O
steatosis	O
.	O

Method	O
For	O
Diagnosing	O
Colorectal	O
Cancers	O
Objective	O
methods	O
for	O
detecting	O
and	O
diagnosing	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
are	O
described	O
herein	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
diagnostic	O
method	O
involves	O
the	O
determining	O
an	O
expression	O
level	O
of	O
C10orf3	B
that	O
discriminate	O
between	O
CRC	O
and	O
normal	O
cell	O
.	O

The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
screening	O
for	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
CRC	O
,	O
methods	O
of	O
treating	O
CRC	O
and	O
method	O
of	O
vaccinating	O
a	O
subject	O
against	O
CRC	O
.	O

Treatment	O
for	O
liver	O
disease	O
The	O
present	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
artificial	O
induction	O
of	O
hepatic	O
stellate	O
cell	O
(	O
HSC	O
)	O
apoptosis	O
in	O
vivo	O
can	O
promote	O
the	O
resolution	O
of	O
liver	O
fibrosis	O
.	O

Thus	O
,	O
the	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
liver	O
disease	O
in	O
a	O
subject	O
involving	O
administration	O
of	O
an	O
inducer	O
of	O
apoptosis	O
which	O
is	O
capable	O
of	O
selectively	O
inducing	O
hepatic	O
stellate	O
cell	O
apoptosis	O
in	O
the	O
liver	O
of	O
the	O
subject	O
or	O
of	O
an	O
agent	O
which	O
is	O
capable	O
of	O
giving	O
rise	O
to	O
such	O
an	O
inducer	O
in	O
the	O
subject	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
treating	O
liver	O
fibrosis	O
in	O
a	O
subject	O
comprising	O
the	O
selective	O
delivery	O
of	O
an	O
inducer	O
of	O
apoptosis	O
specifically	O
to	O
the	O
hepatic	O
stellate	O
cells	O
of	O
the	O
subject	O
or	O
of	O
an	O
agent	O
which	O
is	O
capable	O
of	O
giving	O
rise	O
to	O
an	O
inducer	O
of	O
hepatic	O
stellate	O
cell	O
apoptosis	O
.	O

Early	O
Detection	O
and	O
Prognosis	O
of	O
Colon	O
Cancers	O
We	O
have	O
developed	O
a	O
transcriptome	O
-	O
wide	O
approach	O
to	O
identify	O
genes	O
affected	O
by	O
promoter	O
CpG	O
island	O
hypermethylation	O
and	O
transcriptional	O
silencing	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

By	O
screening	O
cell	O
lines	O
and	O
validating	O
tumor	O
specific	O
hypermethylation	O
in	O
a	O
panel	O
of	O
primary	O
human	O
CRC	O
samples	O
,	O
we	O
estimate	O
that	O
nearly	O
5	O
%	O
of	O
all	O
known	O
genes	O
may	O
be	O
promoter	O
methylated	O
in	O
an	O
individual	O
tumor	O
.	O

When	O
directly	O
compared	O
to	O
gene	O
mutations	O
,	O
we	O
find	O
a	O
much	O
larger	O
number	O
of	O
genes	O
hypermethylated	O
in	O
individual	O
tumors	O
,	O
and	O
much	O
higher	O
frequency	O
of	O
hypermethylation	O
within	O
individual	O
genes	O
harboring	O
either	O
genetic	O
or	O
epigenetic	O
changes	O
.	O

Thus	O
,	O
to	O
enumerate	O
the	O
full	O
spectrum	O
of	O
alterations	O
in	O
the	O
human	O
cancer	O
genome	O
,	O
and	O
facilitate	O
the	O
most	O
efficacious	O
grouping	O
of	O
tumors	O
to	O
identify	O
cancer	O
biomarkers	O
and	O
tailor	O
therapeutic	O
approaches	O
,	O
both	O
genetic	O
and	O
epigenetic	O
screens	O
should	O
be	O
undertaken	O
.	O

The	O
genes	O
we	O
identified	O
can	O
be	O
used	O
inter	O
alia	O
diagnostically	O
to	O
detect	O
cancer	O
,	O
pre	O
-	O
cancer	O
,	O
and	O
likelihood	O
of	O
developing	O
cancer	O
.	O

Use	O
of	O
a	O
CB1	B
Antagonist	O
for	O
Treating	O
Side	O
Effects	O
and	O
Negative	O
Symptoms	O
of	O
Schizophrenia	O
The	O
present	O
invention	O
discloses	O
and	O
claims	O
a	O
method	O
of	O
treating	O
cognition	O
deficits	O
in	O
a	O
patient	O
suffering	O
from	O
schizophrenia	O
by	O
administering	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
CB1	B
receptor	I
antagonist	O
as	O
described	O
herein	O
.	O

In	O
another	O
aspect	O
,	O
this	O
invention	O
also	O
discloses	O
and	O
claims	O
a	O
combination	O
of	O
one	O
or	O
more	O
CB1	B
receptor	I
antagonists	O
and	O
of	O
one	O
or	O
more	O
antipsychotic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
psychiatric	O
disorders	O
.	O

The	O
combination	O
of	O
this	O
invention	O
provides	O
synergistic	O
results	O
in	O
that	O
the	O
combination	O
improves	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
,	O
weight	O
gain	O
and	O
catalepsy	O
.	O

1-	O
[	O
1-	O
(	O
methylsulfonyl	O
)	O
piperidin-4-yl	O
]	O
-3-	O
(	O
adamant-1-yl	O
)	O
urea	O
,	O
1-	O
[	O
1-	O
(	O
acetyl	O
)	O
piperidin-4-yl	O
]	O
-3-	O
(	O
adamant-1-yl	O
)	O
urea	O
;	O
incipient	O
diabetes	O
,	O
glucose	O
intolerance	O
,	O
obesity	O
,	O
hypertension	O
,	O
high	O
blood	O
pressure	O
,	O
elevated	O
serum	O
cholesterol	O
,	O
reduced	O
high	O
-	O
density	O
lipoproteins	O
and	O
elevated	O
triglyceride	O
levels	O
Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
for	O
inhibiting	O
the	O
onset	O
of	O
metabolic	O
syndrome	O
and	O
treating	O
related	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
therapy	O
are	O
disclosed	O
.	O

Controlled	O
Release	O
Formulations	O
The	O
present	O
invention	O
relates	O
to	O
controlled	O
release	O
transmucosal	O
formulations	O
which	O
mediate	O
absorption	O
and	O
methods	O
of	O
use	O
comprising	O
a	O
pharmaceutically	O
active	O
agent	O
,	O
preferably	O
morphine	O
,	O
and	O
a	O
water	O
soluble	O
polymer	O
,	O
chitosan	O
,	O
and	O
preferably	O
one	O
more	O
antioxidants	O
,	O
one	O
or	O
more	O
antimicrobial	O
agents	O
,	O
and	O
water	O
.	O

Method	O
of	O
Treatment	O
by	O
Administration	O
of	O
Rna	O
A	O
method	O
of	O
effecting	O
a	O
treatment	O
response	O
in	O
a	O
target	O
tissue	O
of	O
a	O
subject	O
,	O
comprising	O
:	O
administering	O
to	O
the	O
subject	O
isolated	O
RNA	O
comprising	O
an	O
RNA	O
sequence	O
extractable	O
or	O
extracted	O
from	O
a	O
source	O
tissue	O
such	O
that	O
said	O
treatment	O
response	O
is	O
effected	O
;	O
wherein	O
the	O
RNA	O
is	O
isolated	O
polyA	O
positive	O
RNA	O
in	O
substantially	O
pure	O
form	O
.	O

Two	O
-	O
coat	O
makeup	O
product	O
,	O
its	O
uses	O
,	O
and	O
makeup	O
kit	O
comprising	O
the	O
product	O
A	O
cosmetic	O
makeup	O
product	O
comprising	O
at	O
least	O
two	O
compositions	O
,	O
the	O
first	O
composition	O
comprising	O
a	O
physiologically	O
acceptable	O
medium	O
and	O
the	O
second	O
composition	O
comprising	O
a	O
mixture	O
of	O
at	O
least	O
one	O
high	O
molecular	O
weight	O
polymer	O
having	O
a	O
weight	O
-	O
average	O
molecular	O
mass	O
of	O
greater	O
than	O
or	O
equal	O
to	O
200,000	O
g	O
/	O
mol	O
and	O
at	O
least	O
one	O
low	O
molecular	O
weight	O
non	O
-	O
volatile	O
liquid	O
silicone	O
compound	O
having	O
a	O
weight	O
-	O
average	O
molecular	O
mass	O
of	O
less	O
than	O
200,000	O
g	O
/	O
mol	O
,	O
wherein	O
the	O
at	O
least	O
one	O
high	O
molecular	O
weight	O
polymer	O
and	O
the	O
at	O
least	O
one	O
low	O
molecular	O
weight	O
non	O
-	O
volatile	O
liquid	O
silicone	O
compound	O
are	O
present	O
in	O
a	O
proportion	O
such	O
that	O
the	O
dynamic	O
viscosity	O
of	O
the	O
mixture	O
at	O
25	O
°	O
C.	O
,	O
measured	O
with	O
a	O
Mettler	O
RM	O
180	O
rotational	O
viscometer	O
,	O
ranges	O
from	O
0.1	O
to	O
120	O
Pa·s	O
;	O
a	O
makeup	O
method	O
and	O
a	O
makeup	O
kit	O
comprising	O
the	O
cosmetic	O
makeup	O
product	O
.	O

The	O
cosmetic	O
makeup	O
product	O
may	O
,	O
for	O
example	O
,	O
be	O
a	O
lipstick	O
.	O

Alpha-4	B
Integrin	I
Mediated	O
Cell	O
Adhesion	O
Inhibitors	O
for	O
the	O
Treatment	O
or	O
Prevention	O
of	O
Inflammatory	O
Diseases	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
capable	O
of	O
being	O
modulated	O
by	O
the	O
inhibition	O
of	O
cell	O
adhesion	O
.	O

End	O
-	O
Modified	O
Poly	O
(	O
beta	O
-	O
amino	O
esters	O
)	O
and	O
Uses	O
Thereof	O
Poly	O
(	O
beta	O
-	O
amino	O
esters	O
)	O
are	O
end	O
-	O
modified	O
to	O
form	O
materials	O
useful	O
in	O
the	O
medical	O
as	O
well	O
as	O
non	O
-	O
medical	O
field	O
.	O

An	O
amine	O
-	O
terminated	O
poly	O
(	O
beta	O
-	O
amino	O
ester	O
)	O
is	O
reacted	O
with	O
an	O
electrophile	O
,	O
or	O
an	O
acrylate	O
-	O
terminated	O
poly	O
(	O
beta	O
-	O
amino	O
ester	O
)	O
is	O
reacted	O
with	O
a	O
nucleophile	O
.	O

The	O
inventive	O
end	O
-	O
modified	O
polymers	O
may	O
be	O
used	O
in	O
any	O
field	O
where	O
polymers	O
have	O
been	O
found	O
useful	O
including	O
the	O
drug	O
delivery	O
arts	O
.	O

The	O
end	O
-	O
modified	O
polymers	O
are	O
particularly	O
useful	O
in	O
delivery	O
nucleic	O
acids	O
such	O
as	O
DNA	O
or	O
RNA	O
.	O

The	O
invention	O
also	O
provides	O
compositions	O
including	O
the	O
inventive	O
end	O
-	O
modified	O
polymers	O
,	O
methods	O
of	O
preparing	O
the	O
inventive	O
polymers	O
,	O
and	O
method	O
of	O
using	O
the	O
inventive	O
polymers	O
.	O

Using	O
vector	O
comprising	O
nucleotide	O
sequences	O
coding	O
neublastin	B
as	O
therapeutic	O
treatment	O
for	O
vision	O
defects	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
GFRα3	B
agonists	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
the	O
retina	O
.	O

A	O
preferred	O
GFRα3	B
agonist	O
is	O
Neublastin	B
.	O

Neublastin	B
may	O
be	O
administered	O
to	O
the	O
eye	O
using	O
protein	O
formulations	O
,	O
in	O
vivo	O
or	O
ex	O
vivo	O
gene	O
therapy	O
,	O
or	O
implantation	O
of	O
encapsulated	O
cells	O
delivering	O
Neublastin	B
locally	O
to	O
the	O
retina	O
.	O

Preventive	O
and/or	O
Therapeutic	O
Agent	O
for	O
Cancer	O
As	O
the	O
results	O
of	O
intensive	O
studies	O
aiming	O
at	O
providing	O
a	O
gene	O
targeting	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
,	O
novel	O
nucleotide	O
sequences	O
showing	O
increased	O
expression	O
in	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
compared	O
with	O
normal	O
tissues	O
are	O
identified	O
.	O

As	O
the	O
results	O
of	O
the	O
subsequent	O
studies	O
,	O
genes	O
showing	O
increased	O
expression	O
in	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
which	O
are	O
useful	O
as	O
a	O
drug	O
discovery	O
target	O
are	O
found	O
out	O
.	O

Has	O
acceptable	O
biodegradable	O
polymer	O
;	O
polyglycolic	O
acid	O
,	O
polylactic	O
acid	O
;	O
Parkinson	O
's	O
Disease	O
;	O
injectable	O
microspheres	O
,	O
injectable	O
gels	O
and	O
implants	O
;	O
enhanced	O
bioavailability	O
The	O
present	O
invention	O
relates	O
to	O
a	O
long	O
-	O
acting	O
sustained	O
-	O
release	O
dosage	O
form	O
for	O
treatment	O
of	O
Parkinson	O
Disease	O
,	O
comprising	O
a	O
dopamine	B
receptor	I
agonist	O
and	O
a	O
pharmaceutically	O
acceptable	O
biodegradable	O
polymer	O
accessories	O
,	O
wherein	O
the	O
content	O
of	O
the	O
dopamine	B
receptor	I
agonist	O
in	O
the	O
sustained	O
-	O
release	O
dosage	O
form	O
is	O
5	O
-	O
50	O
%	O
by	O
weight	O
,	O
and	O
the	O
content	O
of	O
the	O
pharmaceutically	O
acceptable	O
polymer	O
accessories	O
is	O
50	O
-	O
95	O
%	O
by	O
weight	O
.	O

Delivery	O
System	O
For	O
Bioactive	O
Agents	O
on	O
the	O
Basis	O
of	O
a	O
Polymeric	O
Drug	O
Carrier	O
Comprising	O
an	O
Amphiphilic	O
Block	O
Polymer	O
and	O
a	O
Polylacticacid	O
Derivative	O
Delivery	O
system	O
for	O
bioactive	O
agents	O
on	O
the	O
basis	O
of	O
a	O
polymeric	O
drug	O
carrier	O
formed	O
from	O
compositions	O
comprising	O
an	O
amphiphilic	O
block	O
copolymer	O
of	O
a	O
hydrophilic	O
block	O
and	O
a	O
hydrophobic	O
block	O
having	O
a	O
terminal	O
hydroxyl	O
group	O
substituted	O
with	O
a	O
tocopherol	O
or	O
cholesterol	O
group	O
,	O
and	O
a	O
polylactic	O
acide	O
derivative	O
wherein	O
one	O
end	O
of	O
the	O
polylactic	O
acid	O
is	O
covalently	O
bound	O
to	O
at	O
least	O
one	O
carboxyl	O
group	O
.	O

The	O
carboxyl	O
group	O
of	O
the	O
polylactic	O
acid	O
derivative	O
may	O
be	O
fixed	O
with	O
a	O
di-	O
or	O
trivalent	O
metal	O
ion	O
,	O
which	O
is	O
obtained	O
by	O
adding	O
the	O
di-	O
or	O
trivalent	O
metal	O
ion	O
to	O
the	O
polymeric	O
composition	O
.	O

Topical	O
;	O
adenosine	O
5'-monophosphates	O
and	O
salts	O
thereof	O
;	O
arbutins	O
,	O
ellagic	O
acid	O
,	O
4-alkylresorcinols	O
,	O
linolic	O
acid	O
,	O
tranexamic	O
acid	O
,	O
chamomile	O
extracts	O
,	O
ubiquinones	O
;	O
chloasma	O
,	O
freckles	O
A	O
composition	O
for	O
the	O
prevention	O
or	O
alleviation	O
of	O
pigmentation	O
which	O
can	O
produce	O
the	O
higher	O
effect	O
of	O
preventing	O
or	O
alleviating	O
pigmentation	O
.	O

The	O
composition	O
for	O
the	O
prevention	O
or	O
alleviation	O
of	O
pigmentation	O
comprises	O
a	O
combination	O
of	O
(	O
A	O
)	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
adenosine	O
5′-monophosphate	O
and	O
salts	O
thereof	O
with	O
(	O
B	O
)	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
arbutin	O
,	O
ellagic	O
acid	O
,	O
4-alkylresorcinols	O
,	O
linoleic	O
acid	O
,	O
tranexamic	O
acid	O
,	O
salts	O
of	O
these	O
,	O
Chamomilla	O
recuita	O
extract	O
,	O
and	O
Ubiquinone	O
.	O

Isolated	O
polynucleotide	O
encoding	O
a	O
Regulated	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
Kinase	O
polypeptide	O
;	O
host	O
cell	O
;	O
hybridization	O
;	O
screening	O
;	O
prediction	O
,	O
diagnosis	O
;	O
prognosis	O
;	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
,	O
cancer	O
,	O
diseases	O
of	O
defective	O
cell	O
signaling	O
Reagents	O
which	O
regulate	O
human	O
RC	O
Kinase	O
activity	O
and	O
reagents	O
which	O
bind	O
to	O
human	O
RC	O
Kinase	O
gene	O
products	O
can	O
be	O
used	O
to	O
regulate	O
this	O
protein	O
for	O
therapeutic	O
effects	O
.	O

Such	O
regulation	O
is	O
particularly	O
useful	O
for	O
treating	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
,	O
cancer	O
,	O
and	O
diseases	O
in	O
which	O
cell	O
signaling	O
is	O
defective	O
.	O

siRNA	O
blocks	O
expression	O
of	O
sphingosine	B
kinase	I
,	O
potentiates	O
effect	O
of	O
radiation	O
in	O
cancer	O
cells	O
of	O
breast	O
,	O
prostate	O
,	O
colorectal	O
,	O
lung	O
,	O
bladder	O
,	O
head	O
and	O
neck	O
,	O
intestine	O
,	O
ovarian	O
,	O
skin	O
;	O
reduces	O
amount	O
of	O
radiation	O
needed	O
to	O
decrease	O
cancer	O
cell	O
viability	O
,	O
tumor	O
size	O
in	O
vivo	O
The	O
present	O
invention	O
relates	O
to	O
Sphingosine	B
kinase	I
inhibitors	O
that	O
are	O
useful	O
for	O
treating	O
various	O
cancers	O
.	O

The	O
invention	O
further	O
relates	O
to	O
compositions	O
and	O
methods	O
of	O
SPK	B
inhibitors	O
,	O
including	O
siRNAs	O
,	O
which	O
specifically	O
block	O
gene	O
expression	O
of	O
SPK	B
and	O
potentiates	O
the	O
effect	O
of	O
radiation	O
in	O
the	O
treatment	O
of	O
various	O
cancers	O
.	O

Inhibitory	O
activity	O
against	O
Pin1	B
;	O
inhibit	O
peptidyl	B
-	I
prolyl	I
isomerase	I
activity	O
of	O
Pin1	B
;	O
inhibits	O
growth	O
of	O
cancer	O
cells	O
;	O
Ac	O
-	O
Phe	O
-	O
Tyr	O
-	O
phosphoSer-	O
pseudo	O
amide	O
-Pro	O
-	O
Arg	O
-	O
NH2	O
;	O
Fmoc	O
-	O
bis	O
(	O
POM	O
)	O
phosphoSer-	O
pseudo	O
amide	O
-Pro-2-aminoethyl-	O
(	O
3-indole	O
)	O
and	O
their	O
Phospho-	O
(	O
D	O
)	O
-serine	O
stereoisomers	O
Ac	O
-	O
Phe	O
-	O
Tyr	O
-	O
phosphoSer	O
-	O
Ψ	O
[	O
CH	O
═	O
C	O
]	O
-Pro	O
-	O
Arg	O
-	O
NH2AND	O
Fmoc	O
-	O
bis	O
(	O
pivaloylmethoxy	O
)	O
phosphoSer	O
-	O
Ψ	O
[	O
CH	O
═	O
C	O
]	O
-Pro-2-aminoethyl-	O
(	O
3-indole	O
)	O
;	O
and	O
their	O
Phospho-	O
(	O
D	O
)	O
-serine	O
stereoisomers	O
are	O
novel	O
compounds	O
.	O

Ψ	O
refers	O
to	O
a	O
pseudo	O
amide	O
.	O

Such	O
novel	O
compounds	O
advantageously	O
may	O
be	O
used	O
as	O
alkene	O
mimics	O
.	O

O	O
-	O
desmethylvenlafaxine	O
succinate	O
;	O
tablet	O
,	O
capsule	O
;	O
sustained	O
release	O
;	O
hydroxypropylmethyl	O
cellulose	O
rate	O
controlling	O
polymer	O
;	O
microcrystalline	O
cellulose	O
binder	O
;	O
depression	O
,	O
bipolar	O
and	O
manic	O
disorders	O
,	O
attention	O
deficit	O
disorder	O
,	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
,	O
Parkinson	O
's	O
disease	O
Methods	O
of	O
preparing	O
,	O
and	O
compositions	O
comprising	O
,	O
derivatives	O
of	O
venlafaxine	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
and	O
preventing	O
diseases	O
and	O
disorders	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
affective	O
disorders	O
such	O
as	O
depression	O
,	O
bipolar	O
and	O
manic	O
disorders	O
,	O
attention	O
deficit	O
disorder	O
,	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
,	O
Parkinson	O
's	O
disease	O
,	O
epilepsy	O
,	O
cerebral	O
function	O
disorders	O
,	O
obesity	O
and	O
weight	O
gain	O
,	O
incontinence	O
,	O
dementia	O
and	O
related	O
disorders	O
.	O

Method	O
for	O
Avoiding	O
Edema	O
in	O
the	O
Treatment	O
or	O
Prevention	O
of	O
Ppary	O
-	O
Responsive	O
Diseases	O
,	O
Including	O
Cancer	O
Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
avoiding	O
edema	O
while	O
treating	O
or	O
preventing	O
PPARγ	B
-	O
mediated	O
diseases	O
,	O
including	O
cancer	O
,	O
using	O
derivatives	O
and	O
prodrugs	O
are	O
provided	O
.	O

Antiserotonine	O
agents	O
;	O
gastrointestinal	O
disorders	O
;	O
irritable	O
bowel	O
syndrome	O
;	O
central	O
nervous	O
system	O
disorders	O
;	O
Alzheimer	O
's	O
disease	O
;	O
cognition	O
activators	O
;	O
analgesics	O
;	O
cardiovascular	O
disorders	O
;	O
antidiabetic	O
agents	O
;	O
sleep	O
disorders	O
This	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
:	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
and	O
m	O
are	O
each	O
as	O
described	O
herein	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
5-HT4	B
agonistic	O
activity	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
gastroesophageal	O
reflux	O
disease	O
,	O
gastrointestinal	O
disease	O
,	O
gastric	O
motility	O
disorder	O
,	O
non	O
-	O
ulcer	O
dyspepsia	O
,	O
functional	O
dyspepsia	O
,	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
constipation	O
,	O
dyspepsia	O
,	O
esophagitis	O
,	O
gastroesophageral	O
disease	O
,	O
nausea	O
,	O
central	O
nervous	O
system	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
cognitive	O
disorder	O
,	O
emesis	O
,	O
migraine	O
,	O
neurological	O
disease	O
,	O
pain	O
,	O
cardiovascular	O
disorders	O
,	O
cardiac	O
failure	O
,	O
heart	O
arrhythmia	O
,	O
diabetes	O
and	O
apnea	O
syndrome	O
.	O

Analgesics	O
;	O
antidepressants	O
;	O
neurodegenerative	O
diseases	O
;	O
antiepileptic	O
agents	O
;	O
cognition	O
activators	O
;	O
antitussive	O
agents	O
;	O
incotinence	O
;	O
irritable	O
bowel	O
syndrome	O
;	O
stroke	O
;	O
vision	O
defects	O
;	O
antiinflammatory	O
agents	O
;	O
skin	O
disorders	O
;	O
diarrhea	O
;	O
eating	O
disorders	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
spiro	O
compounds	O
,	O
to	O
processes	O
for	O
preparing	O
them	O
,	O
to	O
medicaments	O
comprising	O
these	O
compounds	O
and	O
to	O
the	O
use	O
of	O
these	O
compounds	O
for	O
producing	O
medicaments	O
.	O

Antibacterial	O
amide	O
-	O
macrocycles	O
v	O
The	O
invention	O
relates	O
to	O
antibacterial	O
amide	O
-	O
macrocycles	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R26	O
represents	O
hydrogen	O
,	O
halogen	O
,	O
amino	O
or	O
methyl	O
,	O
R7	O
represents	O
a	O
group	O
of	O
formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
or	O
(	O
V	O
)	O
,	O
whereby	O
R1	O
represents	O
hydrogen	O
or	O
hydroxy	O
and	O
*	O
is	O
the	O
linkage	O
site	O
to	O
the	O
carbon	O
atom	O
,	O
R2	O
represents	O
hydrogen	O
or	O
methyl	O
and	O
methods	O
for	O
their	O
production	O
,	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
as	O
well	O
as	O
their	O
use	O
for	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
in	O
particular	O
of	O
bacterial	O
infections	O
.	O

Pharmaceutical	O
Composition	O
for	O
Preventing	O
and	O
Treating	O
Metabolic	O
Bone	O
Diseases	O

Containing	O
Alpha	O
-	O
Arylmethoxyacrylate	O
Derivatives	O

The	O
present	O
invention	O
relates	O
to	O
a	O
use	O
of	O
a	O
specific	O
alpha	O
-	O
arylmethoxyacrylate	O
derivative	O
,	O
or	O
its	O
pharmacologically	O
acceptable	O
salt	O
or	O
solvate	O
for	O
preventing	O
and	O
treating	O
metabolic	O
bone	O
diseases	O
.	O

Plasminogen	B
Activator	I
Inhibitor-1	I
Inhibitors	O
Inhibitors	O
of	O
plasminogen	B
activator	I
inhibitor-1	I
(	O
PAI	B
-	I
I	I
)	O
are	O
provided	O
,	O
which	O
may	O
also	O
act	O
as	O
anti	O
cancer	O
agents	O
,	O
of	O
formulae	O
(	O
I	O
-	O
V	O
)	O
.	O

Method	O
for	O
developing	O
,	O
testing	O
,	O
and	O
using	O
associates	O
of	O
macromolecules	O
and	O
complex	O
aggregates	O
for	O
improved	O
payload	O
and	O
controllable	O
de	O
/	O
association	O
rates	O
This	O
invention	O
describes	O
the	O
principles	O
and	O
procedures	O
suitable	O
for	O
developing	O
,	O
testing	O
,	O
manufacturing	O
,	O
and	O
using	O
combinations	O
of	O
various	O
amphipatic	O
,	O
if	O
necessary	O
modified	O
,	O
macromolecules	O
(	O
such	O
as	O
polypeptides	O
,	O
proteins	O
,	O
etc	O
.	O
)	O
or	O
other	O
chain	O
molecules	O
(	O
such	O
as	O
suitable	O
,	O
e.g.	O
partly	O
hydrophobised	O
,	O
polynucleotides	O
or	O
polysaccharides	O
)	O
with	O
the	O
aggregates	O
which	O
comprise	O
a	O
mixture	O
of	O
polar	O
and/or	O
charged	O
amphipats	O
and	O
form	O
extended	O
surfaces	O
that	O
can	O
be	O
freely	O
suspended	O
or	O
supported	O
.	O

The	O
described	O
methods	O
can	O
be	O
utilised	O
for	O
the	O
optimisation	O
of	O
aggregates	O
that	O
,	O
after	O
association	O
with	O
chain	O
molecules	O
exerting	O
some	O
activity	O
or	O
a	O
useful	O
function	O
,	O
are	O
suitable	O
for	O
the	O
application	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
for	O
example	O
,	O
in	O
the	O
fields	O
of	O
drug	O
delivery	O
,	O
diagnostics	O
or	O
bio	O
/	O
catalysis	O
.	O

As	O
special	O
examples	O
,	O
mixtures	O
of	O
vesicular	O
droplets	O
consisting	O
of	O
lipids	O
loaded	O
(	O
associated	O
)	O
with	O
insulin	B
,	O
interferon	B
,	O
interleukin	B
,	O
nerve	B
growth	I
factor	I
,	O
calcitonin	B
,	O
and	O
an	O
immunoglobulin	B
,	O
etc	O
.	O
,	O
are	O
described	O
.	O

Broad	O
Spectrum	O
Non	O
-	O
Traditional	O
Preservative	O
System	O
Preservative	O
compositions	O
containing	O
emollient	O
solvents	O
such	O
as	O
octanediol	O
or	O
Symdiol	O
™	O
or	O
octoxyglycerine	O
monoesters	O
in	O
combination	O
with	O
organic	O
acids	O
such	O
as	O
alpha	O
hydroxyl	O
acids	O
can	O
be	O
used	O
for	O
preventing	O
microbial	O
growth	O
and	O
spoilage	O
in	O
cosmetic	O
and	O
topical	O
skin	O
formulations	O
with	O
the	O
added	O
benefit	O
of	O
providing	O
silky	O
smooth	O
texture	O
to	O
skin	O
.	O

The	O
compositions	O
may	O
optionally	O
contain	O
an	O
essential	O
oil	O
/	O
component	O
.	O

These	O
preservative	O
compositions	O
are	O
odorless	O
and	O
colorless	O
and	O
small	O
concentrations	O
can	O
be	O
added	O
to	O
cosmetic	O
/	O
topical	O
formulations	O
to	O
prevent	O
bacterial	O
,	O
yeast	O
and	O
fungal	O
growth	O
within	O
24	O
to	O
48	O
hours	O
after	O
contamination	O
.	O

Photochemotherapeutic	O
method	O
using	O
5-aminolevulinic	O
acid	O
and	O
other	O
precursors	O
of	O
endogenous	O
porphyrins	O
Methods	O
of	O
detecting	O
and	O
treating	O
rapidly	O
growing	O
exogenous	O
cells	O
,	O
such	O
as	O
Protista	O
,	O
or	O
parasites	O
,	O
that	O
preferentially	O
accumulate	O
a	O
photoactivatable	O
porphyrin	O
in	O
which	O
5-aminolevulinic	O
acid	O
or	O
precursor	O
thereof	O
is	O
administered	O
to	O
the	O
patient	O
,	O
or	O
contacted	O
to	O
the	O
exogenous	O
cells	O
,	O
in	O
an	O
amount	O
sufficient	O
to	O
induce	O
synthesis	O
fluorescence	O
and/or	O
photosensitizing	O
concentrations	O
of	O
a	O
protoporphyrin	O
IX	O
in	O
the	O
exogenous	O
cells	O
,	O
followed	O
by	O
exposure	O
of	O
the	O
exogenous	O
cells	O
to	O
light	O
of	O
photoactivating	O
wavelengths	O
.	O

Agent	O
for	O
Preventing	O
/	O
Ameliorating	O
Life	O
Style	O
-	O
Related	O
Diseases	O
Containing	O
Turmeric	O
Essential	O
Oil	O
Component	O
The	O
present	O
invention	O
has	O
its	O
object	O
to	O
provide	O
an	O
agent	O
for	O
preventing	O
and/or	O
ameliorating	O
life	O
style	O
-	O
related	O
diseases	O
which	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
substance	O
derived	O
from	O
a	O
safe	O
food	O
material	O
having	O
a	O
long	O
history	O
of	O
being	O
eaten	O
as	O
a	O
food	O
and	O
which	O
is	O
capable	O
of	O
being	O
utilized	O
as	O
functional	O
foods	O
such	O
as	O
health	O
foods	O
or	O
functional	O
health	O
foods	O
(	O
specific	O
health	O
foods	O
,	O
functional	O
nutritive	O
foods	O
)	O
.	O

The	O
agent	O
for	O
preventing	O
and/or	O
ameliorating	O
life	O
style	O
-	O
related	O
diseases	O
according	O
to	O
the	O
invention	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ar	O
-	O
turmerone	O
,	O
α	O
-	O
turmerone	O
,	O
β	O
-	O
turmerone	O
,	O
curlone	O
,	O
bisacumol	O
and	O
β	O
-	O
sesquiphellandrene	O
,	O
or	O
at	O
least	O
one	O
compound	O
selected	O
from	O
among	O
the	O
bisabolane	O
type	O
sesquiterpenoids	O
derived	O
from	O
Curcuma	O
longa	O
L.	O
,	O
and	O
therefore	O
is	O
useful	O
for	O
preventing	O
and/or	O
ameliorating	O
diabetes	O
,	O
visceral	O
fat	O
obesity	O
,	O
metabolic	O
syndrome	O
and	O
obesity	O
,	O
among	O
others	O
.	O

Use	O
of	O
Surfactant	O
Preparations	O
for	O
the	O
Treatment	O
of	O
Surgical	O
Adhesions	O
The	O
invention	O
describes	O
the	O
use	O
of	O
surfactant	O
comprising	O
phospholipids	O
and	O
pulmonary	O
surfactant	O
proteins	O
for	O
the	O
treatment	O
of	O
surgical	O
adhesions	O
.	O

Aldos	B
as	O
modifiers	O
of	O
the	O
igf	B
pathway	O
and	O
methods	O
of	O
use	O
Human	B
ALDO	I
genes	I
are	O
identified	O
as	O
modulators	O
of	O
the	O
IGF	B
pathway	O
,	O
and	O
thus	O
are	O
therapeutic	O
targets	O
for	O
disorders	O
associated	O
with	O
defective	O
IGF	B
function	O
.	O

Methods	O
for	O
identifying	O
modulators	O
of	O
IGF	B
,	O
comprising	O
screening	O
for	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
ALDO	B
are	O
provided	O
.	O

Systems	O
and	O
methods	O
for	O
delivering	O
drugs	O
A	O
patch	O
pump	O
device	O
generally	O
includes	O
at	O
least	O
one	O
fluid	O
source	O
,	O
a	O
fluid	O
communicator	O
,	O
and	O
an	O
electrochemical	O
actuator	O
.	O

The	O
fluid	O
communicator	O
is	O
in	O
fluid	O
communication	O
with	O
the	O
fluid	O
source	O
.	O

The	O
electrochemical	O
actuator	O
is	O
operative	O
to	O
cause	O
fluid	O
to	O
be	O
delivered	O
from	O
the	O
fluid	O
source	O
into	O
the	O
fluid	O
communicator	O
.	O

Human	B
dnase	I
ii	I
This	O
invention	O
relates	O
to	O
a	O
novel	O
human	O
deoxyribonuclease	O
,	O
referred	O
to	O
as	O
human	B
DNase	I
II	I
.	O

The	O
invention	O
provides	O
nucleic	O
acid	O
sequences	O
encoding	O
human	B
DNase	I
II	I
,	O
thereby	O
enabling	O
the	O
production	O
of	O
human	B
DNase	I
II	I
by	O
recombinant	O
DNA	O
methods	O
in	O
quantities	O
sufficient	O
for	O
clinical	O
use	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
and	O
therapeutic	O
uses	O
of	O
human	B
DNase	I
II	I
.	O

Polyglycerol	O
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
Polyglycerol	O
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
are	O
provided	O
.	O

The	O
agents	O
are	O
effective	O
against	O
a	O
variety	O
of	O
pathogens	O
including	O
fungi	O
,	O
Gram	O
positive	O
bacteria	O
and	O
Gram	O
negative	O
bacteria	O
yet	O
are	O
expected	O
to	O
have	O
low	O
human	O
toxicity	O
due	O
in	O
part	O
to	O
their	O
polymeric	O
nature	O
.	O

Applications	O
for	O
the	O
polyglycerol	O
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
include	O
those	O
involving	O
human	O
and	O
plant	O
contact	O
,	O
such	O
as	O
cosmetics	O
,	O
hair	O
care	O
products	O
,	O
textiles	O
and	O
plant	O
protections	O
,	O
as	O
well	O
as	O
in	O
applications	O
with	O
much	O
less	O
human	O
contact	O
,	O
such	O
as	O
plastics	O
,	O
coatings	O
,	O
wood	O
,	O
paper	O
and	O
other	O
materials	O
of	O
construction	O
.	O

Substituted	O
nitrogen	O
-	O
containing	O
heteroaryl	O
derivatives	O
useful	O
as	O
modulators	O
of	O
the	O
histamine	O
H4	O
receptor	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
nitrogen	O
-	O
containing	O
heteroaryl	O
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
methods	O
of	O
using	O
any	O
of	O
these	O
derivatives	O
and	O
compositions	O
for	O
H4	O
receptor	O
activity	O
modulation	O
and	O
the	O
treatment	O
of	O
states	O
mediated	O
by	O
histamine	O
H4	O
receptor	O
activity	O
.	O

Novel	O
Spiro	O
-	O
benzo	O
[	O
c	O
]	O
chromene	O
derivatives	O
useful	O
as	O
modulators	O
of	O
the	O
estrogen	B
receptors	I
The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
spiro	O
-	O
benzo	O
[	O
C	O
]	O
chromene	O
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
mediated	O
by	O
one	O
or	O
more	O
estrogen	B
receptors	I
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
the	O
depletion	O
of	O
estrogen	O
such	O
as	O
hot	O
flashes	O
,	O
vaginal	O
dryness	O
,	O
osteopenia	O
and	O
osteoporosis	O
;	O
hormone	O
sensitive	O
cancers	O
and	O
hyperplasia	O
of	O
the	O
breast	O
,	O
endometrium	O
,	O
cervix	O
and	O
prostate	O
;	O
endometriosis	O
,	O
uterine	O
fibroids	O
,	O
osteoarthritis	O
and	O
as	O
contraceptive	O
agents	O
,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
progestogen	O
or	O
progestogen	O
antagonist	O
.	O

Deuterium	O
-	O
enriched	O
miglustat	O
The	O
present	O
application	O
describes	O
deuterium	O
-	O
enriched	O
miglustat	O
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Substituted	O
N	O
[	O
N-	O
(	O
sulphonylphenyl	O
)	O
sulfonyl	O
-	O
prolyl	O
]	O
-phenylalanine	O
derivatives	O
are	O
antagonists	O
of	O
the	O
very	B
late	I
antigen-4	I
integrin	I
;	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
,	O
asthma	O
,	O
multiple	O
sclerosis	O
,	O
rheumatoid	O
arthritis	O
Substituted	O
N—	O
[	O
N-	O
(	O
sulphonylphenyl	O
)	O
sulfonyl	O
-	O
prolyl	O
]	O
-phenylalanine	O
derivatives	O
of	O
the	O
present	O
invention	O
are	O
antagonists	O
of	O
the	O
VLA-4	B
integrin	I
and	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
VLA-4-binding	B
and	O
cell	O
adhesion	O
and	O
activation	O
.	O

Moreover	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
demonstrate	O
significant	O
receptor	O
occupancy	O
of	O
VLA-4	B
bearing	O
cells	O
after	O
oral	O
administration	O
and	O
are	O
suitable	O
for	O
once-	O
,	O
twice-	O
,	O
or	O
thrice	O
-	O
a	O
-	O
day	O
oral	O
administration	O
.	O

This	O
invention	O
also	O
relates	O
to	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
using	O
such	O
compounds	O
.	O

Dipeptides	O
for	O
Prevention	O
of	O
Muscle	O
Breakdown	O
and	O
Microbial	O
Infection	O
The	O
subject	O
invention	O
provides	O
dipeptides	O
useful	O
in	O
promoting	O
healthy	O
muscle	O
tissues	O
as	O
well	O
as	O
effective	O
immune	O
responses	O
.	O

The	O
dipeptides	O
of	O
the	O
subject	O
invention	O
are	O
particularly	O
advantageous	O
because	O
they	O
are	O
stable	O
,	O
bioavailable	O
,	O
and	O
can	O
be	O
formulated	O
in	O
an	O
aqueous	O
solution	O
.	O

Targeting	O
Prodrugs	O
for	O
the	O
Treatment	O
of	O
Gastrointestinal	O
Diseases	O
Provided	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
decreasing	O
NFκB	B
DNA	O
-	O
binding	O
activity	O
in	O
a	O
patient	O
comprising	O
administering	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
or	O
composition	O
of	O
the	O
application	O
to	O
the	O
patient	O
to	O
reduce	O
,	O
alleviate	O
or	O
treat	O
various	O
gastrointestinal	O
diseases	O
,	O
such	O
as	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Bifunctional	O
Resorcinol	O
,	O
Thioresorcinol	O
,	O
and	O
Dithioresorcinol	O
Derivative	O
Metal	O
Chelating	O
Conjugates	O
The	O
present	O
invention	O
is	O
directed	O
to	O
metal	O
chelating	O
conjugates	O
for	O
use	O
as	O
metallopharmaceutical	O
diagnostic	O
or	O
therapeutic	O
agents	O
.	O

Specifically	O
,	O
conjugates	O
of	O
the	O
present	O
invention	O
include	O
one	O
or	O
more	O
carriers	O
,	O
a	O
linker	O
,	O
and	O
metal	O
coordinating	O
moiety	O
comprising	O
a	O
resorcinol	O
,	O
thioresorcinol	O
,	O
or	O
dithioresorcinol	O
derivative	O
through	O
which	O
the	O
metal	O
coordinating	O
moiety	O
is	O
bonded	O
to	O
the	O
linker	O
.	O

Triazole	O
derivative	O
or	O
a	O
salt	O
thereof	O
[	O
Problem	O
]	O
To	O
provide	O
a	O
compound	O
which	O
may	O
be	O
used	O
in	O
treating	O
diseases	O
in	O
which	O
11β	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11β	B
-	I
HSD1	I
)	O
is	O
concerned	O
,	O
especially	O
diabetes	O
and	O
insulin	B
resistance	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

It	O
was	O
found	O
that	O
a	O
triazole	O
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
which	O
the	O
3-position	O
of	O
triazole	O
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	O
methyl	O
group	O
and	O
the	O
5-position	O
is	O
substituted	O
with	O
a	O
lower	O
alkyl	O
,	O
cycloalkyl	O
or	O
the	O
like	O
,	O
has	O
a	O
strong	O
11β	B
-	I
HSD1-inhibitory	I
activity	O
.	O

In	O
addition	O
,	O
since	O
the	O
triazole	O
derivative	O
of	O
the	O
present	O
invention	O
shows	O
excellent	O
blood	O
glucose	O
-	O
lowering	O
action	O
,	O
it	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diabetes	O
and	O
insulin	B
resistance	O
.	O

Novel	O
Cyclic	O
Urea	O
Derivatives	O
,	O
Preparation	O
Thereof	O
and	O
Pharmaceutical	O
Use	O

Thereof	O
as	O
Kinase	B
Inhibitors	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
Ra	O
,	O
Rb	O
,	O
R	O
,	O
X1	O
and	O
X2	O
are	O
as	O
defined	O
in	O
the	O
disclosure	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
,	O
processes	O
for	O
making	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
provided	O
.	O

Deuterium	O
-	O
enriched	O
pioglitazone	O
The	O
present	O
application	O
describes	O
deuterium	O
-	O
enriched	O
pioglitazone	O
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

withanolide	O
compounds	O
extracted	O
from	O
a	O
Solanaceae	O
plant	O
as	O
anticancer	O
agents	O
;	O
solvent	O
extraction	O
from	O
Tubocapsicum	O
anomalum	O
A	O
composition	O
for	O
treating	O
cancer	O
cells	O
and	O
a	O
preparation	O
method	O
therefore	O
is	O
provided	O
.	O

The	O
composition	O
includes	O
novel	O
withanolide	O
compounds	O
derived	O
from	O
a	O
Solanaceae	O
plant	O
,	O
which	O
the	O
novel	O
withanolide	O
compounds	O
have	O
the	O
cytotoxicity	O
to	O
the	O
cancer	O
cells	O
.	O

Ginkgolides	O
in	O
the	O
Treatment	O
and	O
Prevention	O
of	O
Ovarian	O
Cancer	O
The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
and	O
nutritional	O
supplements	O
that	O
contain	O
large	O
amount	O
of	O
ginkgolides	O
,	O
particularly	O
ginkgolide	O
A	O
or	O
B	O
,	O
and	O
for	O
which	O
,	O
the	O
other	O
components	O
normally	O
found	O
in	O
Ginkgo	O
biloba	O
extracts	O
have	O
been	O
removed	O
.	O

The	O
compositions	O
may	O
be	O
administered	O
to	O
women	O
to	O
prevent	O
or	O
treat	O
ovarian	O
cancer	O
,	O
particularly	O
non	O
-	O
mucinous	O
ovarian	O
cancer	O
.	O

Short	O
interfering	O
rna	O
as	O
an	O
antiviral	O
agent	O
for	O
hepatitis	O
c	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
is	O
a	O
major	O
cause	O
of	O
chronic	O
liver	O
disease	O
and	O
affects	O
over	O
270	O
million	O
individuals	O
worldwide	O
.	O

The	O
HCV	O
genome	O
is	O
a	O
single	O
-	O
stranded	O
RNA	O
that	O
functions	O
as	O
both	O
a	O
messenger	O
RNA	O
and	O
replication	O
template	O
,	O
making	O
it	O
an	O
attractive	O
target	O
for	O
the	O
study	O
of	O
RNA	O
interference	O
.	O

Double	O
-	O
stranded	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
designed	O
to	O
target	O
the	O
HCV	O
genome	O
are	O
disclosed	O
herein	O
.	O

20-Alkyl	O
,	O
Gemini	O
Vitamin	O
D3	O
Compounds	O
and	O
Methods	O
of	O
Use	O
Thereof	O
The	O
invention	O
provides	O
20-alkyl	O
Gemini	O
vitamin	O
D3	O
compounds	O
,	O
methods	O
for	O
using	O
the	O
compounds	O
to	O
treat	O
vitamin	O
D3	O
associated	O
states	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
.	O

Methods	O
of	O
Identifying	O
and	O
Treating	O
Individuals	O
Exhibiting	O
MDR-1	B
Overexpression	O
With	O
Protein	B
Tyrosine	I
Kinase	I
Inhibitors	O
and	O
Combinations	O
Thereof	O
The	O
invention	O
described	O
herein	O
relates	O
to	O
diagnostic	O
and	O
treatment	O
methods	O
and	O
compositions	O
useful	O
in	O
the	O
management	O
of	O
disorders	O
,	O
for	O
example	O
cancers	O
,	O
involving	O
cells	O
that	O
overexpress	O
MDR-1	B
,	O
and	O
methods	O
of	O
decreasing	O
the	O
incidence	O
of	O
CNS	O
complications	O
that	O
are	O
often	O
associated	O
with	O
CML	O
patients	O
that	O
have	O
been	O
administered	O
imatinib	O
or	O
other	O
protein	B
tyrosine	I
kinase	I
inhibitors	O
.	O

Compositions	O
and	O
methods	O
of	O
using	O
capsid	B
protein	O
from	O
flaviviruses	O
and	O
pestiviruses	O
This	O
invention	O
provides	O
methods	O
of	O
inducing	O
cell	O
death	O
with	O
Flavivirus	O
or	O
Pestivirus	O
capsid	B
protein	O
,	O
such	O
as	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
capsid	B
protein	O
,	O
and	O
functional	O
fragments	O
thereof	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
patients	O
suffering	O
from	O
diseases	O
characterized	O
by	O
hyperproliferating	O
cells	O
by	O
administering	O
pharmaceutical	O
compositions	O
comprising	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
capsid	O
or	O
other	O
protein	O
or	O
a	O
nucleic	O
acid	O
molecule	O
encoding	O
the	O
same	O
.	O

Methods	O
of	O
identifying	O
compounds	O
which	O
have	O
anti	O
-	O
viral	O
and/or	O
anti	O
-	O
WNV	O
and/or	O
anti	O
-	O
Flavivirus	O
and/or	O
anti	O
-	O
Pestivirus	O
capsid	O
or	O
other	O
protein	O
activity	O
are	O
disclosed	O
.	O

The	O
invention	O
also	O
provides	O
vaccine	O
compositions	O
comprising	O
capsid	B
or	O
other	O
proteins	O
,	O
or	O
fragments	O
thereof	O
,	O
or	O
nucleic	O
acids	O
encoding	O
same	O
,	O
from	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
invention	O
also	O
provides	O
diagnostic	O
methods	O
and	O
kits	O
for	O
identifying	O
individuals	O
exposed	O
to	O
WNV	O
or	O
other	O
viruses	O
including	O
Flavivirus	O
or	O
Pestivirus	O
.	O

Herbal	O
composition	O
for	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
herbal	O
composition	O
comprising	O
extract	O
of	O
roots	O
of	O
the	O
plant	O
Murraya	O
koenigii	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
,	O
particularly	O
tinea	O
infections	O
,	O
and	O
method	O
of	O
manufacture	O
of	O
said	O
composition	O
.	O

The	O
said	O
herbal	O
composition	O
comprises	O
2-methoxy-3-methyl-9H	O
-	O
carbazole	O
(	O
compound	O
1	O
)	O
as	O
a	O
bioactive	O
ingredient	O
.	O

Invention	O
also	O
discloses	O
methods	O
for	O
topical	O
application	O
of	O
the	O
said	O
herbal	O
composition	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
.	O

VEGF	B
Inhibition	O
The	O
present	O
invention	O
provides	O
methods	O
for	O
inhibiting	O
VEGF	B
production	O
or	O
secretion	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I.	O
The	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
associated	O
with	O
abnormal	O
levels	O
of	O
VEGF	B
production	O
or	O
secretion	O
.	O

Medicated	O
sleeve	O
Embodiments	O
of	O
the	O
invention	O
provide	O
a	O
stretchable	O
sleeve	O
having	O
a	O
medicinal	O
section	O
that	O
can	O
be	O
loaded	O
with	O
a	O
medicinal	O
composition	O
and	O
a	O
perforated	O
section	O
comprising	O
a	O
plurality	O
of	O
openings	O
,	O
wherein	O
the	O
medicinal	O
section	O
and	O
the	O
perforated	O
section	O
overlap	O
,	O
and	O
wherein	O
the	O
sleeve	O
is	O
sized	O
so	O
that	O
the	O
interior	O
surface	O
of	O
the	O
medicinal	O
section	O
comfortably	O
fits	O
a	O
body	O
portion	O
and	O
the	O
medicinal	O
section	O
contacts	O
the	O
body	O
portion	O
at	O
the	O
site	O
of	O
pain	O
.	O

Embodiments	O
of	O
the	O
invention	O
also	O
provide	O
methods	O
for	O
preparing	O
a	O
sleeve	O
by	O
applying	O
a	O
medicinal	O
composition	O
to	O
the	O
inner	O
surface	O
of	O
the	O
medicinal	O
section	O
through	O
the	O
openings	O
at	O
the	O
perforated	O
section	O
.	O

Embodiments	O
of	O
the	O
invention	O
also	O
provide	O
methods	O
for	O
relieving	O
pain	O
in	O
a	O
body	O
portion	O
by	O
pulling	O
the	O
sleeve	O
in	O
an	O
outside	O
-	O
out	O
configuration	O
straight	O
up	O
a	O
body	O
portion	O
without	O
having	O
to	O
roll	O
and	O
flip	O
its	O
exterior	O
surface	O
outside	O
.	O

Non	O
-	O
peptidyl	O
agents	O
with	O
pHSP20-like	O
activity	O
,	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
modulating	O
smooth	O
muscle	O
cells	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
identifying	O
small	O
molecule	O
candidate	O
therapeutic	O
agents	O
for	O
modulating	O
smooth	O
muscle	O
.	O

Methods	O
of	O
treating	O
neurological	O
diseases	O
by	O
regulating	O
migration	O
of	O
neuroblasts	O
in	O
the	O
adult	O
nervous	O
system	O
with	O
tenascin	B
-	I
R	I
This	O
invention	O
provides	O
a	O
method	O
for	O
regulating	O
migration	O
of	O
neuronal	O
progenitor	O
cells	O
in	O
the	O
nervous	O
system	O
of	O
a	O
mammal	O
.	O

The	O
method	O
comprises	O
providing	O
a	O
mammal	O
with	O
TNR	B
,	O
a	O
biologically	O
active	O
fragment	O
of	O
TNR	B
,	O
or	O
a	O
TNR	B
agonist	O
in	O
an	O
amount	O
sufficient	O
to	O
direct	O
migration	O
of	O
the	O
neuronal	O
progenitor	O
cells	O
.	O

The	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
neurological	O
diseases	O
by	O
replenishing	O
diseased	O
,	O
damaged	O
,	O
or	O
destroyed	O
neural	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
or	O
in	O
the	O
peripheral	O
nervous	O
system	O
.	O

Methods	O
for	O
Making	O
and	O
Delivering	O
Rho	B
-	O
Antagonist	O
Tissue	O
Adhesive	O
Formulations	O
to	O
the	O
Injured	O
Mammalian	O
Central	O
and	O
Peripheral	O
Nervous	O
Systems	O
and	O
uses	O
Thereof	O
The	O
present	O
invention	O
provides	O
methods	O
for	O
making	O
,	O
delivering	O
and	O
using	O
formulations	O
that	O
combine	O
a	O
therapeutically	O
active	O
agent	O
(	O
s	O
)	O
(	O
such	O
as	O
for	O
example	O
a	O
Rho	B
antagonist	O
(	O
s	O
)	O
)	O
and	O
a	O
flowable	O
carrier	O
component	O
capable	O
of	O
forming	O
a	O
therapeutically	O
acceptable	O
matrix	O
in	O
vivo	O
(	O
such	O
as	O
for	O
example	O
tissue	O
adhesives	O
)	O
,	O
to	O
injured	O
nerves	O
to	O
promote	O
repair	O
and	O
regeneration	O
and	O
regrowth	O
of	O
injured	O
(	O
mammalian	O
)	O
neuronal	O
cells	O
,	O
e.g.	O
for	O
facilitating	O
axon	O
growth	O
at	O
a	O
desired	O
lesion	O
site	O
.	O

Preferred	O
active	O
agents	O
are	O
known	O
Rho	B
antagonists	O
such	O
as	O
for	O
example	O
C3	O
,	O
chimeric	O
C3	O
proteins	O
,	O
etc	O
.	O
or	O
substances	O
selected	O
from	O
among	O
known	O
trans-4-amino	O
(	O
alkyl	O
)	O
-1-pyridylcarbamoylcyclohexane	O
compounds	O
or	O
Rho	B
kinase	I
inhibitors	O
.	O

The	O
system	O
for	O
example	O
may	O
deliver	O
an	O
antagonist	O
(	O
s	O
)	O
in	O
a	O
tissue	O
adhesive	O
such	O
as	O
,	O
for	O
example	O
,	O
a	O
fibrin	O
glue	O
or	O
a	O
collagen	B
gel	O
to	O
create	O
a	O
delivery	O
matrix	O
in	O
situ	O
.	O

A	O
kit	O
and	O
methods	O
of	O
stimulating	O
neuronal	O
regeneration	O
are	O
also	O
included	O
.	O

Rate	O
-	O
controlled	O
particles	O
Rate	O
-	O
controlled	O
particles	O
,	O
comprising	O
compounds	O
of	O
the	O
formula	O
as	O
a	O
solid	O
dispersion	O
.	O

Substituted	O
nitrogen	O
-	O
containing	O
heterobicycles	O
,	O
the	O
preparation	O
thereof	O
and	O
their	O
use	O
as	O
pharmaceutical	O
compositions	O
The	O
present	O
invention	O
relates	O
to	O
new	O
substituted	O
nitrogen	O
-	O
containing	O
heterobicyclic	O
compounds	O
of	O
general	O
formula	O
wherein	O
B	O
,	O
X1	O
to	O
X3	O
and	O
R1	O
to	O
R5	O
are	O
defined	O
as	O
in	O
claim	O
1	O
,	O
the	O
tautomers	O
,	O
the	O
enantiomers	O
,	O
the	O
diastereomers	O
,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof	O
,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases	O
,	O
which	O
have	O
valuable	O
properties	O
.	O

The	O
compounds	O
of	O
the	O
above	O
general	O
formula	O
I	O
as	O
well	O
as	O
the	O
tautomers	O
,	O
the	O
enantiomers	O
,	O
the	O
diastereomers	O
,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof	O
,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases	O
,	O
and	O
their	O
stereoisomers	O
have	O
valuable	O
pharmacological	O
properties	O
,	O
particularly	O
an	O
antithrombotic	O
activity	O
and	O
a	O
factor	B
Xa	I
-	O
inhibiting	O
activity	O
.	O

Nebivolol	O
in	O
the	O
treatment	O
of	O
sexual	O
dysfunction	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
sexual	O
dysfunction	O
.	O

The	O
methods	O
include	O
administering	O
an	O
effective	O
amount	O
of	O
nebivolol	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
second	O
active	O
agent	O
e.g.	O
a	O
PDE-5	B
inhibitor	O
,	O
such	O
as	O
sildenafil	O
citrate	O
.	O

The	O
methods	O
of	O
the	O
present	O
invention	O
are	O
particularly	O
suited	O
to	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
and	O
female	O
sexual	O
arousal	O
disorder	O
.	O

Nitrosation	O
-	O
Inducible	O
Inhibitors	O
Biological	O
Macromolecules	O
Biomacromolecules	O
such	O
as	O
proteins	O
are	O
inactivated	O
by	O
hydrophobic	O
ANSA	O
derivatives	O
of	O
the	O
formula	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
hydrophobic	O
or	O
affinity	O
groups	O
and	O
R3	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aminoacyl	O
groups	O
and	O
peptidyl	O
groups	O
upon	O
nitrosation	O
.	O

ANSA	O
derivatives	O
can	O
be	O
designed	O
to	O
selectively	O
kill	O
tumor	O
cells	O
and	O
various	O
pathogens	O
,	O
including	O
bacteria	O
,	O
viruses	O
,	O
and	O
fungi	O
.	O

Agents	O
and	O
Methods	O
for	O
Osteogenic	O
Oxysterols	O
Inhibition	O
of	O
Oxidative	O
Stress	O
on	O
Osteogenic	O
Cellular	O
Differentiation	O
The	O
present	O
invention	O
discloses	O
oxygenic	O
oxygenic	O
oxysterols	O
.	O

Also	O
disclosed	O
,	O
agents	O
and	O
methods	O
for	O
protecting	O
,	O
blocking	O
or	O
rescuing	O
marrow	O
stromal	O
cells	O
from	O
the	O
inhibitory	O
effects	O
of	O
oxidative	O
stress	O
on	O
their	O
osteoblastic	O
cellular	O
differentiation	O
.	O

Exemplary	O
agents	O
include	O
oxysterols	O
,	O
rhBMP2	B
,	O
alone	O
or	O
in	O
combination	O
which	O
are	O
demonstrated	O
to	O
specifically	O
combat	O
oxidative	O
stress	O
caused	O
by	O
inflammatory	O
oxidized	O
lipids	O
,	O
such	O
as	O
xanthine	O
/	O
xanthine	O
oxidase	O
and	O
minimally	O
oxidized	O
LDL	O
.	O

The	O
synergistic	O
effects	O
of	O
oxysterols	O
and	O
bone	O
morphogenic	O
proteins	O
are	O
disclosed	O
.	O

Quinoxaline	O
Derivatives	O
as	O
Antitumor	O
Agents	O

The	O
invention	O
relates	O
to	O
methods	O
of	O
screening	O
for	O
binding	O
partners	O
,	O
especially	O
binding	O
partners	O
essential	O
for	O
the	O
biological	O
activity	O
of	O
erastin	O
(	O
e.g.	O
VDACs	O
such	O
as	O
VDAC3	O
)	O
.	O

The	O
invention	O
also	O
provides	O
reagents	O
and	O
methods	O
for	O
effective	O
killing	O
of	O
cancer	O
cells	O
with	O
erastin	O
and	O
related	O
compounds	O
or	O
derivatives	O
.	O

Kinesin	B
inhibitors	O
This	O
invention	O
relates	O
to	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
shown	O
below	O
.	O

Each	O
variable	O
in	O
formula	O
(	O
I	O
)	O
is	O
defined	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
can	O
be	O
used	O
to	O
treat	O
a	O
kinesin	B
Eg5	I
protein	I
-	O
mediated	O
disorder	O
.	O

Cancer	O
Related	O
Genes	O
(	O
PRLR	B
)	O
This	O
invention	O
is	O
in	O
the	O
field	O
of	O
cancer	O
-	O
associated	O
genes	O
.	O

Specifically	O
it	O
relates	O
to	O
methods	O
for	O
detecting	O
cancer	O
or	O
the	O
likelihood	O
of	O
developing	O
cancer	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
expression	O
of	O
a	O
PRLR	B
gene	O
or	O
protein	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
and	O
molecules	O
for	O
upregulating	O
or	O
downregulating	O
PRLR	B
gene	O
expression	O
and	O
PRLR	B
protein	O
activity	O
.	O

Cosmeceutical	O
composition	O
Topical	O
compositions	O
comprising	O
:	O
—a	O
physiologically	O
acceptable	O
alkanediol	O
,	O
ether	O
diol	O
or	O
diether	O
alcohol	O
containing	O
up	O
to	O
(	O
8)	O
carbon	O
atoms	O
;	O
—water	O
;	O
and	O
—	O
optionally	O
an	O
unsaturated	O
fatty	O
alcohol	O
;	O
and	O
optionally	O
further	O
conventional	O
excipients	O
,	O
for	O
use	O
as	O
a	O
cosmeceutical	O
,	O
in	O
particular	O
for	O
use	O
in	O
the	O
repair	O
or	O
maintenance	O
of	O
skin	O
barrier	O
function	O
.	O

They	O
are	O
indicated	O
for	O
use	O
in	O
e.g.	O
moisturizing	O
skin	O
,	O
nail	O
and	O
mucosa	O
and	O
,	O
when	O
an	O
optional	O
pharmaceutically	O
active	O
agent	O
is	O
present	O
,	O
additionally	O
in	O
the	O
treatment	O
of	O
various	O
skin	O
,	O
nail	O
and	O
mucosal	O
diseases	O
.	O

Also	O
disclosed	O
are	O
compositions	O
suitable	O
for	O
topical	O
application	O
to	O
infants	O
and	O
babies	O
for	O
treating	O
dry	O
skin	O
,	O
and	O
soothing	O
skin	O
irritated	O
from	O
diaper	O
rash	O
and	O
scrapes	O
.	O

Drug	O
screening	O
;	O
antagonizing	O
macrophage	B
migration	I
inhibitory	I
factor	I
(	O
MIF	B
)	O
using	O
ibudilast	O
;	O
neuropathic	O
pain	O
;	O
identifying	O
agents	O
useful	O
for	O
opiate	O
withdrawal	O
and	O
for	O
treating	O
other	O
addictions	O
and	O
dependence	O
Methods	O
of	O
antagonizing	O
MIF	B
activity	O
using	O
ibudilast	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
screening	O
for	O
MIF	B
antagonists	O
.	O

These	O
agents	O
can	O
be	O
used	O
for	O
treating	O
addictions	O
,	O
including	O
drug	O
and	O
behavioral	O
addictions	O
,	O
as	O
well	O
as	O
for	O
treating	O
neuropathic	O
pain	O
.	O

High	O
penetration	O
composition	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
uses	O
of	O
novel	O
high	O
penetration	O
compositions	O
or	O
high	O
penetration	O
prodrugs	O
(	O
HPP	O
)	O
,	O
in	O
particular	O
HPPs	O
for	O
4-aminophenol	O
derivatives	O
,	O
which	O
are	O
capable	O
of	O
crossing	O
biological	O
barriers	O
with	O
high	O
penetration	O
efficiency	O
.	O

The	O
HPPs	O
herein	O
are	O
capable	O
of	O
being	O
converted	O
to	O
parent	O
active	O
drugs	O
or	O
drug	O
metabolites	O
after	O
crossing	O
the	O
biological	O
barrier	O
and	O
thus	O
can	O
render	O
treatments	O
for	O
the	O
conditions	O
that	O
the	O
parent	O
drugs	O
or	O
metabolites	O
can	O
.	O

Additionally	O
,	O
due	O
to	O
the	O
ability	O
of	O
penetrating	O
biological	O
barriers	O
,	O
the	O
HPPs	O
herein	O
are	O
capable	O
of	O
reaching	O
areas	O
that	O
parent	O
drugs	O
may	O
not	O
be	O
able	O
to	O
access	O
or	O
to	O
render	O
a	O
sufficient	O
concentration	O
at	O
the	O
target	O
areas	O
and	O
therefore	O
render	O
novel	O
treatments	O
.	O

The	O
HPPs	O
herein	O
can	O
be	O
administered	O
to	O
a	O
subject	O
through	O
various	O
administration	O
routes	O
.	O

For	O
example	O
,	O
the	O
HPPs	O
can	O
be	O
locally	O
delivered	O
to	O
an	O
action	O
site	O
of	O
a	O
condition	O
with	O
a	O
high	O
concentration	O
due	O
to	O
their	O
ability	O
of	O
penetrating	O
biological	O
barriers	O
and	O
thus	O
obviate	O
the	O
need	O
for	O
a	O
systematic	O
administration	O
.	O

For	O
another	O
example	O
,	O
the	O
HPPs	O
herein	O
can	O
be	O
systematically	O
administer	O
to	O
a	O
biological	O
subject	O
and	O
enter	O
the	O
general	O
circulation	O
with	O
a	O
faster	O
rate	O
.	O

Delivery	O
scaffolds	O
and	O
related	O
methods	O
of	O
use	O
The	O
present	O
invention	O
relates	O
to	O
delivery	O
systems	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
microporous	O
scaffolds	O
having	O
thereon	O
agents	O
(	O
e.g.	O
,	O
extracellular	B
matrix	I
proteins	I
,	O
exendin-4	B
)	O
and	O
biological	O
material	O
(	O
e.g.	O
,	O
pancreatic	O
islet	O
cells	O
)	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
scaffolds	O
are	O
used	O
for	O
transplanting	O
biological	O
material	O
into	O
a	O
subject	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
scaffolds	O
are	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
(	O
e.g.	O
,	O
type	O
1	O
diabetes	O
)	O
,	O
and	O
related	O
methods	O
(	O
e.g.	O
,	O
diagnostic	O
methods	O
,	O
research	O
methods	O
,	O
drug	O
screening	O
)	O
.	O

N	O
-	O
Pyrrolidin-3-YL	O
-	O
Amide	O
Derivatives	O
As	O
Serotonin	O
and	O
Noradrenalin	O
Re	O
-	O
Uptake	O
Inhibitors	O
A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
and/or	O
veterinarily	O
acceptable	O
derivatives	O
thereof	O
,	O
wherein	O
:	O
R1	O
is	O
H	O
,	O
C1	O
-	O
6alkyl	O
,	O
—C	O
(	O
A	O
)	O
D	O
,	O
C3	O
-	O
8cycloalkyl	O
,	O
aryl	O
,	O
het	O
,	O
aryl	O
-	O
C1	O
-	O
4alkyl	O
or	O
het	O
-	O
C1	O
-	O
4alkyl	O
,	O
wherein	O
the	O
cycloalkyl	O
,	O
aryl	O
or	O
het	O
groups	O
are	O
optionally	O
substituted	O
;	O
A	O
is	O
S	O
or	O
O	O
;	O
D	O
is	O
H	O
,	O
C1	O
-	O
6alkyl	O
,	O
aryl	O
,	O
het	O
,	O
aryl	O
-	O
C1	O
-	O
4alkyl	O
or	O
het	O
-	O
C1	O
-	O
4alkyl	O
;	O
aryl	O
represents	O
phenyl	O
,	O
naphthyl	O
,	O
anthracyl	O
or	O
phenanthryl	O
;	O
het	O
represents	O
an	O
aromatic	O
or	O
non	O
-	O
aromatic	O
4-	O
,	O
5-	O
or	O
6-membered	O
heterocycle	O
which	O
contains	O
at	O
least	O
one	O
N	O
,	O
O	O
or	O
S	O
heteroatom	O
,	O
optionally	O
fused	O
to	O
a	O
5-	O
or	O
6-membered	O
carbocyclic	O
group	O
or	O
a	O
second	O
4-	O
,	O
5-	O
or	O
6-membered	O
heterocycle	O
which	O
contains	O
at	O
least	O
one	O
N	O
,	O
O	O
or	O
S	O
heteroatom	O
;	O
R2	O
is	O
aryl1	O
or	O
het1	O
,	O
each	O
optionally	O
substituted	O
;	O
n	O
is	O
1	O
or	O
2	O
,	O
provided	O
that	O
when	O
n	O
is	O
1	O
,	O
m	O
is	O
0	O
or	O
1	O
and	O
when	O
n	O
is	O
2	O
,	O
m	O
is	O
0	O
,	O
wherein	O
if	O
m	O
is	O
0	O
,	O
then	O
*	O
represents	O
a	O
chiral	O
centre	O
;	O
R3	O
is	O
(	O
CH2	O
)	O
aE	O
,	O
wherein	O
a	O
is	O
0	O
,	O
1	O
or	O
2	O
and	O
E	O
is	O
a	O
group	O
selected	O
from	O
:	O
Formula	O
(	O
i	O
)	O
wherein	O
:	O
X	O
is	O
O	O
,	O
S	O
,	O
NR12	O
,	O
(	O
CH2	O
)	O
v	O
or	O
a	O
bond	O
;	O
b	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
c	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
v	O
is	O
1	O
or	O
2	O
;	O
R10	O
and	O
11	O
are	O
each	O
independently	O
H	O
or	O
C1	O
-	O
4	O
alkyl	O
;	O
and	O
R12	O
is	O
H	O
,	O
1	O
-	O
6	O
alkyl	O
,	O
C	O
(	O
O	O
)	O
C1	O
-	O
6	O
alkyl	O
,	O
SO2—C1	O
-	O
6alkyl	O
;	O
and	O
wherein	O
one	O
or	O
more	O
pairs	O
of	O
hydrogen	O
atoms	O
on	O
adjacent	O
carbon	O
or	O
nitrogen	O
atoms	O
may	O
be	O
replaced	O
by	O
a	O
corresponding	O
number	O
of	O
double	O
bonds	O
,	O
provided	O
the	O
ring	O
system	O
is	O
not	O
aromatic	O
;	O
Formula	O
(	O
ii	O
)	O
a	O
carbocyclic	O
spiro	O
group	O
containing	O
6	O
to	O
12	O
carbon	O
atoms	O
;	O
Formula	O
(	O
iii	O
)	O
wherein	O
:	O
d	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
a	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
f	O
is	O
1	O
or	O
2	O
;	O
and	O
R30	O
is	O
H	O
or	O
C1	O
-	O
4alkyl	O
;	O
and	O
wherein	O
one	O
or	O
more	O
pairs	O
of	O
hydrogen	O
atoms	O
on	O
adjacent	O
carbon	O
atoms	O
may	O
be	O
replaced	O
by	O
a	O
corresponding	O
number	O
of	O
double	O
bonds	O
,	O
provided	O
the	O
ring	O
system	O
is	O
not	O
aromatic	O
;	O
Formula	O
(	O
iv	O
)	O
wherein	O
:	O
g	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
J	O
is	O
NR40	O
;	O
and	O
R40	O
is	O
C	O
(	O
O	O
)	O
C1	O
-	O
6	O
alkyl	O
,	O
S02-C1	O
-	O
6alkyl	O
;	O
Formula	O
(	O
v	O
)	O
wherein	O
:	O
h	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
and	O
R50	O
is	O
H	O
,	O
C1	O
-	O
8alkyl	O
,	O
C1	O
-	O
8alkoxy	O
,	O
OH	O
,	O
halo	O
,	O
CF3	O
,	O
OCF3	O
,	O
SCF3	O
,	O
hydroxy	O
-	O
C1	O
-	O
6alkyl	O
,	O
C1	O
-	O
4alkoxy	O
-	O
C1	O
-	O
6alkyl	O
and	O
C1	O
-	O
4alkyl	O
-	O
S	O
—	O
C1	O
-	O
4alkyl	O
;	O
Formula	O
(	O
vi	O
)	O
—CH	O
(	O
cyclopropane	O
)	O
2	O
;	O
Formula	O
(	O
vii	O
)	O
C1	O
-	O
6alkyl	O
,	O
substituted	O
by	O
at	O
least	O
one	O
substituent	O
;	O
and	O
Formula	O
(	O
viii	O
)	O
C3	O
-	O
8cycloalkyl	O
-	O
C1	O
-	O
6alkyl	O
;	O
wherein	O
the	O
C1	O
-	O
6alkyl	O
moiety	O
is	O
substituted	O
at	O
any	O
point	O
other	O
than	O
at	O
the	O
junction	O
with	O
the	O
C3	O
-	O
8cycloalkyl	O
moiety	O
,	O
by	O
at	O
least	O
one	O
substituent	O
.	O

The	O
compounds	O
exhibit	O
activity	O
as	O
both	O
serotonin	O
and/or	O
noradrenaline	O
re	O
-	O
uptake	O
inhibitors	O
and	O
therefore	O
have	O
utility	O
in	O
a	O
variety	O
of	O
therapeutic	O
areas	O
,	O
for	O
example	O
urinary	O
incontinence	O
.	O

Method	O
for	O
treating	O
cancer	O
,	O
rheumatoid	O
arthritis	O
and	O
other	O
medical	O
diseases	O
by	O
utilizing	O
modified	O
virus	O
virions	O
to	O
insert	O
medications	O
into	O
targeted	O
cells	O
A	O
safer	O
,	O
more	O
effective	O
treatment	O
of	O
many	O
medical	O
diseases	O
may	O
be	O
approached	O
by	O
a	O
method	O
utilizing	O
modified	O
viruses	O
as	O
vehicles	O
to	O
transport	O
medically	O
therapeutic	O
drug	O
molecules	O
to	O
specific	O
cells	O
in	O
the	O
body	O
with	O
the	O
intent	O
to	O
have	O
the	O
drug	O
exert	O
an	O
effect	O
only	O
on	O
those	O
cells	O
to	O
which	O
the	O
modified	O
virus	O
delivers	O
the	O
drug	O
.	O

The	O
modified	O
virus	O
or	O
virus	O
-	O
like	O
structures	O
make	O
contact	O
with	O
specific	O
target	O
cells	O
by	O
means	O
of	O
the	O
modified	O
virus	O
's	O
exterior	O
probes	O
or	O
virus	O
-	O
like	O
structures	O
'	O
exterior	O
probes	O
.	O

Once	O
the	O
exterior	O
probes	O
engage	O
a	O
target	O
cell	O
's	O
receptors	O
,	O
the	O
modified	O
virus	O
or	O
virus	O
-	O
like	O
structure	O
inserts	O
into	O
the	O
target	O
cell	O
the	O
quantity	O
of	O
medically	O
therapeutic	O
drug	O
molecules	O
it	O
is	O
carrying	O
.	O

By	O
delivering	O
the	O
medically	O
therapeutic	O
drug	O
only	O
to	O
specific	O
cells	O
in	O
the	O
body	O
it	O
is	O
assured	O
the	O
drug	O
reaches	O
the	O
site	O
in	O
the	O
body	O
it	O
will	O
be	O
most	O
beneficial	O
and	O
the	O
occurrence	O
of	O
unwanted	O
side	O
effects	O
due	O
the	O
drug	O
are	O
significantly	O
minimized	O
.	O

2,4-Substituted	O
Quinazolines	O
as	O
Lipid	O
Kinase	B
Inhibitors	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
,	O
which	O
are	O
appropriate	O
for	O
the	O
treatment	O
of	O
kinase	O
,	O
e.g.	O
PI3K	B
-	O
related	O
,	O
diseases	O
,	O
such	O
as	O
proliferative	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
obstructive	O
airways	O
disorders	O
and	O
transplantation	O
related	O
diseases	O
.	O

Concentrated	O
Liquid	O
Thyroid	O
Hormone	O
Composition	O
This	O
invention	O
is	O
directed	O
generally	O
to	O
a	O
liquid	O
pharmaceutical	O
composition	O
comprising	O
at	O
least	O
one	O
thyroid	O
hormone	O
(	O
particularly	O
a	O
composition	O
further	O
comprising	O
at	O
least	O
one	O
cyclodextrin	O
compound	O
)	O
,	O
a	O
process	O
for	O
making	O
such	O
a	O
composition	O
and	O
a	O
method	O
of	O
using	O
such	O
a	O
composition	O
to	O
treat	O
a	O
condition	O
associated	O
with	O
impaired	O
thyroid	O
hormone	O
function	O
.	O

Facial	O
blemish	O
removing	O
device	O
A	O
device	O
and	O
method	O
for	O
removing	O
facial	O
blemishes	O
,	O
including	O
sebum	O
that	O
blocks	O
facial	O
pores	O
.	O

The	O
device	O
includes	O
a	O
substantially	O
flat	O
,	O
elongated	O
and	O
rigid	O
element	O
having	O
a	O
first	O
surface	O
and	O
a	O
second	O
surface	O
,	O
and	O
a	O
distal	O
end	O
and	O
a	O
proximal	O
end	O
.	O

The	O
device	O
also	O
includes	O
a	O
base	O
member	O
to	O
which	O
the	O
rigid	O
element	O
is	O
attached	O
such	O
that	O
a	O
collection	O
area	O
is	O
formed	O
between	O
the	O
second	O
surface	O
of	O
the	O
distal	O
end	O
of	O
the	O
rigid	O
element	O
and	O
a	O
portion	O
of	O
the	O
base	O
member	O
.	O

Use	O
of	O
a	O
lactose	O
-	O
derived	O
c	O
-	O
glycoside	O
compound	O
as	O
an	O
agent	O
for	O
activating	O
and	O
regulating	O
cutaneous	O
immunity	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
lactose	O
-	O
derived	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
to	O
their	O
use	O
as	O
agents	O
for	O
stimulating	O
the	O
immune	O
system	O
of	O
the	O
skin	O
and/or	O
as	O
immunoregulators	O
,	O
and	O
for	O
preparing	O
a	O
composition	O
containing	O
a	O
cosmetically	O
or	O
pharmaceutically	O
acceptable	O
medium	O
,	O
intended	O
in	O
particular	O
to	O
prevent	O
and/or	O
limit	O
the	O
appearance	O
of	O
cutaneous	O
immune	O
imbalances	O
,	O
in	O
particular	O
related	O
to	O
environmental	O
stresses	O
.	O

Substituted	O
heterocycles	O
and	O
their	O
use	O
as	O
chk1	B
,	O
pdk1	B
and	O
pak	B
inhibitors	O
The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
possess	O
CHK1	B
kinase	O
inhibitory	O
activity	O
,	O
PDK1	B
inhibitory	O
activity	O
and	O
Pak	B
kinase	I
inhibitory	O
activity	O
and	O
are	O
accordingly	O
useful	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
cancer	O
.	O

M3	B
Muscarinic	I
Acetylcholine	I
Receptor	I
Antagonists	O
Muscarinic	B
Acetylcholine	I
receptor	I
antagonists	O
and	O
methods	O
of	O
using	O
them	O
are	O
provided	O
.	O

Compositions	O
and	O
Their	O
Uses	O
Directed	O
to	O
IL-4R	O
Alpha	O
Disclosed	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
modulating	O
the	O
expression	O
of	O
IL-4R	O
alpha	O
in	O
a	O
cell	O
,	O
tissue	O
or	O
animal	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
target	O
validation	O
.	O

Also	O
provided	O
are	O
uses	O
of	O
disclosed	O
compounds	O
and	O
compositions	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treatment	O
of	O
diseases	O
and	O
disorders	O
related	O
to	O
expression	O
of	O
IL	O
4R	O
-	O
α	O
,	O
airway	O
hyperresponsiveness	O
,	O
and/or	O
pulmonary	O
inflammation	O
.	O

33	O
Human	O
Secreted	O
Proteins	O
The	O
present	O
invention	O
relates	O
to	O
33	O
novel	O
human	O
secreted	O
proteins	O
and	O
isolated	O
nucleic	O
acids	O
containing	O
the	O
coding	O
regions	O
of	O
the	O
genes	O
encoding	O
such	O
proteins	O
.	O

Also	O
provided	O
are	O
vectors	O
,	O
host	O
cells	O
,	O
antibodies	O
,	O
and	O
recombinant	O
methods	O
for	O
producing	O
human	O
secreted	O
proteins	O
.	O

The	O
invention	O
further	O
relates	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
useful	O
for	O
diagnosing	O
and	O
treating	O
diseases	O
,	O
disorders	O
,	O
and/or	O
conditions	O
related	O
to	O
these	O
novel	O
human	O
secreted	O
proteins	O
.	O

Controlled	O
Release	O
Complex	O
Formulation	O
For	O
Oral	O
Administration	O
of	O
Medicine	O
For	O
Diabetes	O
and	O
Method	O
For	O
The	O
Preparation	O
Thereof	O
A	O
controlled	O
release	O
combination	O
formulation	O
for	O
oral	O
administration	O
comprising	O
a	O
)	O
a	O
controlled	O
release	O
portion	O
containing	O
metformin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
a	O
combination	O
of	O
a	O
polyethylene	O
oxide	O
and	O
a	O
natural	O
gum	O
as	O
a	O
carrier	O
for	O
controlled	O
release	O
;	O
and	O
b	O
)	O
a	O
rapid	O
-	O
release	O
portion	O
containing	O
a	O
sulfonylurea	O
-	O
based	O
medicine	O
for	O
treating	O
diabetes	O
as	O
an	O
active	O
ingredient	O
coated	O
on	O
the	O
controlled	O
release	O
portion	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
for	O
it	O
is	O
capable	O
of	O
maintaining	O
an	O
effective	O
concentration	O
of	O
the	O
medicines	O
in	O
blood	O
at	O
a	O
constant	O
level	O
.	O

Perfluorocarbon	O
conjugate	O
as	O
a	O
blood	O
substitute	O
There	O
are	O
provided	O
disclosures	O
relating	O
to	O
a	O
conjugate	O
of	O
a	O
perfluorocarbon	O
compound	O
and	O
a	O
cationic	O
polymer	O
wherein	O
the	O
conjugate	O
is	O
a	O
blood	O
substitute	O
.	O

Hpv-18-based	O
papillomavirus	O
vaccines	O
Compositions	O
containing	O
one	O
or	O
more	O
early	O
polypeptide	O
(	O
s	O
)	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-18	O
or	O
a	O
nucleic	O
acid	O
encoding	O
one	O
or	O
more	O
early	O
polypeptide	O
(	O
s	O
)	O
of	O
HPV-18	O
are	O
useful	O
for	O
preventing	O
or	O
treating	O
an	O
infection	O
or	O
a	O
pathological	O
condition	O
caused	O
by	O
at	O
least	O
one	O
papillomavirus	O
other	O
than	O
HPV-18	O
;	O
the	O
subject	O
compositions	O
are	O
of	O
very	O
special	O
interest	O
in	O
immunotherapy	O
,	O
in	O
particular	O
for	O
preventing	O
or	O
treating	O
HPV	O
persistent	O
infections	O
that	O
might	O
promote	O
cervical	O
intraepithelial	O
neoplasia	O
(	O
CIN	O
)	O
and	O
ultimately	O
cervical	O
cancer	O
.	O

Drug	O
for	O
treating	O
gastric	O
cancer	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
interleukin-17	B
inhibitor	O
and/or	O
of	O
at	O
least	O
one	O
IL-17	B
receptor	I
inhibitor	O
,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
inhibiting	O
,	O
preventing	O
or	O
treating	O
gastric	O
cancer	O
.	O

Cyclodextrin	O
conjugates	O
It	O
has	O
been	O
discovered	O
that	O
the	O
uptake	O
of	O
anionic	O
charged	O
species	O
into	O
cells	O
can	O
be	O
enhanced	O
by	O
noncovalently	O
associating	O
such	O
species	O
with	O
specifically	O
modified	O
forms	O
of	O
cyclodextrin	O
.	O

The	O
invention	O
modified	O
forms	O
of	O
cyclodextrin	O
form	O
well	O
defined	O
stoichiometric	O
complexes	O
with	O
anionic	O
charged	O
molecules	O
.	O

This	O
discovery	O
enables	O
one	O
to	O
produce	O
various	O
compositions	O
containing	O
anionic	O
charged	O
molecules	O
and	O
facilitates	O
methods	O
for	O
enhancing	O
the	O
cellular	O
uptake	O
of	O
double	O
-	O
stranded	O
or	O
hairpin	O
nucleic	O
acid	O
.	O

Substituted	O
2-amino	O
-	O
fused	O
heterocyclic	O
compounds	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
:	O
R1	O
,	O
R2	O
,	O
Z1	O
,	O
t	O
,	O
and	O
ring	O
A	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
treating	O
a	O
condition	O
that	O
is	O
mediated	O
by	O
the	O
modulation	O
of	O
JNK	B
,	O
such	O
as	O
diabetes	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
a	O
mammal	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
.	O

Indazoles	O
Used	O
To	O
Treat	O
Estrogen	B
Receptor	I
Beta	I
Mediated	O
Disorders	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
indazole	O
derivatives	O
having	O
pharmacological	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
estrogen	B
receptor	I
beta	I
mediated	O
diseases	O
.	O

Site	O
-	O
specific	O
chemical	O
modification	O
of	O
proteins	O
at	O
their	O
n	O
-	O
termini	O
,	O
enabling	O
the	O
formation	O
of	O
homogeneous	O
adducts	O
Site	O
-	O
specific	O
modifications	O
of	O
proteins	O
at	O
their	O
N	O
-	O
termini	O
are	O
provided	O
.	O

In	O
particular	O
,	O
a	O
chemical	O
modification	O
of	O
proteins	O
at	O
their	O
N	O
-	O
termini	O
via	O
a	O
transamination	O
reaction	O
to	O
form	O
homogeneous	O
adducts	O
such	O
as	O
,	O
the	O
corresponding	O
oxime	O
derivatives	O
is	O
provided	O
.	O

Methods	O
of	O
making	O
and	O
using	O
the	O
adducts	O
in	O
radio	O
-	O
labelling	O
,	O
molecular	O
imaging	O
applications	O
,	O
and	O
treatment	O
of	O
disorders	O
such	O
as	O
cancer	O
,	O
Crohn	O
's	O
disease	O
,	O
arthritis	O
,	O
atherothrombosis	O
and	O
plaque	O
rupture	O
are	O
also	O
provided	O
.	O

Early	O
intervention	O
of	O
viral	O
infection	O
with	O
immune	O
activators	O
Symptoms	O
of	O
viral	O
infection	O
are	O
mitigated	O
by	O
administering	O
to	O
a	O
subject	O
exposed	O
to	O
a	O
virus	O
a	O
protective	O
or	O
symptom	O
-	O
mitigating	O
amount	O
of	O
a	O
dsRNA	O
and	O
continuing	O
administration	O
until	O
the	O
subject	O
's	O
symptoms	O
have	O
improved	O
.	O

Antibiotic	O
synergism	O
The	O
present	O
invention	O
relates	O
to	O
antibiotic	O
synergism	O
of	O
pharmaceutical	O
compositions	O
comprising	O
a	O
defensin	O
and	O
a	O
beta	O
-	O
lactam	O
antibiotic	O
.	O

Directional	O
use	O
The	O
invention	O
is	O
directed	O
to	O
a	O
method	O
for	O
oral	O
administration	O
of	O
a	O
liquid	O
containing	O
an	O
active	O
substance	O
to	O
a	O
subject	O
for	O
improved	O
absorption	O
into	O
the	O
subject	O
's	O
bloodstream	O
includes	O
the	O
steps	O
of	O
providing	O
a	O
delivery	O
device	O
containing	O
the	O
liquid	O
and	O
having	O
a	O
mouthpiece	O
for	O
directing	O
the	O
liquid	O
in	O
a	O
defined	O
direction	O
during	O
delivery	O
;	O
directing	O
the	O
mouthpiece	O
toward	O
a	O
localized	O
area	O
of	O
the	O
subject	O
's	O
mouth	O
being	O
especially	O
suitable	O
for	O
increased	O
uptake	O
and	O
faster	O
onset	O
of	O
action	O
of	O
the	O
active	O
substance	O
relative	O
to	O
other	O
areas	O
of	O
and/or	O
the	O
whole	O
mouth	O
;	O
and	O
delivering	O
a	O
measured	O
amount	O
of	O
the	O
liquid	O
directly	O
to	O
the	O
localized	O
area	O
using	O
the	O
delivery	O
device	O
,	O
and	O
a	O
spray	O
device	O
for	O
administering	O
an	O
active	O
substance	O
to	O
the	O
oral	O
cavity	O
of	O
a	O
subject	O
that	O
includes	O
a	O
container	O
capable	O
of	O
holding	O
a	O
liquid	O
containing	O
an	O
active	O
substance	O
,	O
and	O
a	O
mouthpiece	O
being	O
constructed	O
to	O
dispense	O
the	O
liquid	O
containing	O
the	O
substance	O
in	O
a	O
defined	O
direction	O
and	O
directly	O
to	O
a	O
localized	O
area	O
of	O
a	O
subject	O
's	O
mouth	O
,	O
the	O
localized	O
area	O
being	O
the	O
oral	O
vestibule	O
.	O

Cyclopropane	O
amides	O
and	O
analogs	O
exhibiting	O
anti	O
-	O
cancer	O
and	O
anti	O
-	O
proliferative	O
activities	O
Compounds	O
of	O
the	O
present	O
invention	O
find	O
utility	O
in	O
the	O
treatment	O
of	O
mammalian	O
cancers	O
and	O
especially	O
human	O
cancers	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
malignant	O
melanomas	O
,	O
solid	O
tumors	O
,	O
glioblastomas	O
,	O
ovarian	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
prostate	O
cancer	O
,	O
lung	O
cancers	O
,	O
breast	O
cancers	O
,	O
kidney	O
cancers	O
,	O
hepatic	O
cancers	O
,	O
cervical	O
carcinomas	O
,	O
metastasis	O
of	O
primary	O
tumor	O
sites	O
,	O
myeloproliferative	O
diseases	O
,	O
chronic	O
myelogenous	O
leukemia	O
,	O
leukemias	O
,	O
papillary	O
thyroid	O
carcinoma	O
,	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
mesothelioma	O
,	O
hypereosinophilic	O
syndrome	O
,	O
gastrointestinal	O
stromal	O
tumors	O
,	O
colonic	O
cancers	O
,	O
ocular	O
diseases	O
characterized	O
by	O
hyperproliferation	O
leading	O
to	O
blindness	O
including	O
various	O
retinopathies	O
,	O
diabetic	O
retinopathy	O
,	O
rheumatoid	O
arthritis	O
,	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
mastocytosis	O
,	O
mast	O
cell	O
leukemia	O
,	O
and	O
diseases	O
caused	O
by	O
PDGFR	B
-	I
α	I
kinase	O
,	O
PDGFR	B
-	I
β	I
kinase	O
,	O
c	B
-	I
KIT	I
kinase	O
,	O
cFMS	B
kinase	O
,	O
c	B
-	I
MET	I
kinase	O
,	O
and	O
oncogenic	O
forms	O
,	O
aberrant	O
fusion	O
proteins	O
and	O
polymorphs	O
of	O
any	O
of	O
the	O
foregoing	O
kinases	O
.	O

Sustained	O
release	O
formulation	O
of	O
melatonin	O
The	O
present	O
invention	O
relates	O
to	O
low	O
-	O
dose	O
formulations	O
of	O
melatonin	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
,	O
which	O
provide	O
a	O
sustained	O
release	O
of	O
melatonin	O
so	O
as	O
to	O
rapidly	O
increase	O
plasma	O
levels	O
of	O
melatonin	O
,	O
maintain	O
a	O
relatively	O
high	O
level	O
(	O
which	O
mimics	O
the	O
endogenous	O
level	O
of	O
a	O
young	O
subject	O
)	O
for	O
approximately	O
5	O
-	O
6	O
hours	O
,	O
and	O
then	O
decrease	O
so	O
as	O
to	O
achieve	O
low	O
levels	O
by	O
early	O
morning	O
(	O
rapid	O
washout	O
)	O
,	O
thereby	O
avoiding	O
a	O
""""	O
hangover	O
effect	O
""""	O
.	O

The	O
sustained	O
release	O
formulations	O
of	O
the	O
invention	O
may	O
be	O
used	O
to	O
treat	O
a	O
variety	O
of	O
sleep	O
-	O
related	O
disorders	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
delayed	O
onset	O
and	O
maintenance	O
forms	O
of	O
insomnia	O
.	O

Iodo	O
-	O
Hexose	O
Compounds	O
Useful	O
to	O
Treat	O
Cancer	O
Methods	O
of	O
treating	O
glioblastoma	O
and	O
pancreatic	O
cancer	O
are	O
provided	O
by	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
iodo	O
-	O
hexose	O
compound	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

The	O
subject	O
disclosure	O
includes	O
methods	O
of	O
treating	O
glioblastoma	O
and	O
pancreatic	O
cancer	O
comprising	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
hexose	O
compound	O
including	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
mannose	O
,	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
glucose	O
,	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
galactose	O
,	O
and/or	O
2-deoxy-2-iodo	O
-	O
D	O
-	O
talose	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

Novel	O
polymorphous	O
form	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	O
-	O
n-	O
(	O
{	O
(	O
5s	O
)	O
-2-oxo-3	O
[	O
4-	O
(	O
3-oxo-4-morpholinyl	O
(	O
-phenyl	O
]	O
-1,3-oxazolidine-5-yl	O
}	O
-methyl	O
)	O
-2-thiophene	O
carboxamide	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
polymorphic	O
form	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	O
-	O
N-	O
(	O
{	O
(	O
5S	O
)	O
-2-oxo-3-	O
[	O
4-	O
(	O
3-oxo-4-morpholinyl	O
)	O
-phenyl	O
]	O
-1,3-oxazolidin-5-yl	O
}	O
-methyl	O
)	O
-2-thiophene	O
-	O
carboxamide	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
medicaments	O
comprising	O
these	O
forms	O
,	O
and	O
their	O
use	O
in	O
the	O
control	O
of	O
diseases	O
.	O

Assays	O
For	O
Detecting	O
Inhibitors	O
Of	O
Binding	O
Between	O
COX-2	B
And	O
PDZ	B
Proteins	I

The	O
invention	O
provides	O
an	O
assay	O
for	O
determining	O
whether	O
a	O
test	O
agent	O
is	O
a	O
COX	B
modulator	O
.	O

In	O
general	O
terms	O
,	O
the	O
assay	O
includes	O
:	O
determining	O
whether	O
a	O
test	O
agent	O
modulates	O
binding	O
of	O
a	O
PDZ	B
-	I
containing	I
polypeptide	I
to	O
a	O
COX	B
PL	I
-	I
containing	I
polypeptide	I
.	O

The	O
PDZ	B
-	I
containing	I
polypeptide	I
may	O
contain	O
the	O
PDZ	B
domain	I
of	O
PDZ	B
domain	I
of	O
MAGI1	B
,	O
TIP-1	B
,	O
MAST2	B
,	O
PSD95	B
,	O
or	O
SHANK	B
.	O

The	O
assays	O
may	O
be	O
done	O
in	O
a	O
cell	O
-	O
free	O
environment	O
or	O
in	O
a	O
cellular	O
environment	O
,	O
particularly	O
using	O
a	O
neuronal	O
cell	O
.	O

The	O
invention	O
finds	O
use	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
including	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
treating	O
cancer	O
,	O
pain	O
,	O
inflammation	O
and	O
neuronal	O
conditions	O
caused	O
by	O
acute	O
insult	O
,	O
e.g.	O
,	O
stroke	O
.	O

Methods	O
for	O
detecting	O
and	O
modulating	O
the	O
sensitivity	O
of	O
tumor	O
cells	O
to	O
anti	O
-	O
mitotic	O
agents	O
and	O
for	O
modulating	O
turmorgenicity	O
Provided	O
herein	O
is	O
a	O
method	O
of	O
screening	O
a	O
tumour	O
cell	O
for	O
resistance	O
to	O
a	O
tubulin	B
-	O
binding	O
agent	O
,	O
the	O
method	O
comprising	O
detecting	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	B
II	I
,	I
class	I
III	I
and	I
class	I
IVb	I
β	I
-	I
tubulin	I
by	O
the	O
tumour	O
cell	O
,	O
wherein	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	B
II	I
,	I
class	I
III	I
and	I
class	I
IVb	I
β	I
-	I
tubulin	I
indicates	O
that	O
the	O
tumour	O
cell	O
has	O
resistance	O
or	O
potential	O
resistance	O
to	O
the	O
tubulin	B
-	O
binding	O
agent	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
modulating	O
the	O
sensitivity	O
of	O
a	O
tumour	O
cell	O
.	O

Also	O
provided	O
is	O
a	O
method	O
of	O
modulating	O
the	O
tumorigenesis	O
of	O
a	O
tumour	O
cell	O
.	O

Extracellular	O
matrix	O
/	O
metastasis	O
modifier	O
genes	O
for	O
the	O
prevention	O
or	O
inhibition	O
of	O
metastasis	O
or	O
growth	O
of	O
tumor	O
and	O
for	O
characterization	O
of	O
tumor	O
Disclosed	O
are	O
methods	O
involving	O
the	O
administration	O
of	O
an	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
/	O
metastasis	O
modifier	O
gene	O
,	O
e.g.	O
,	O
Anakin	B
,	O
Necdin	B
,	O
CentaurinD3	B
(	O
CentD3	B
)	O
,	O
Csf1r	B
,	O
Brd4	B
,	O
Pi16	B
,	O
and	O
Luc7l	B
,	O
for	O
the	O
prevention	O
or	O
inhibition	O
of	O
metastasis	O
or	O
of	O
tumor	O
growth	O
.	O

Further	O
disclosed	O
are	O
methods	O
of	O
characterizing	O
a	O
tumor	O
or	O
cancer	O
in	O
a	O
subject	O
comprising	O
detecting	O
(	O
i	O
)	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
an	O
Anakin	O
gene	O
or	O
a	O
Brd4	B
gene	O
of	O
the	O
subject	O
,	O
(	O
ii	O
)	O
an	O
amino	O
acid	O
substitution	O
in	O
an	O
Anakin	O
protein	O
in	O
the	O
subject	O
,	O
or	O
(	O
iii	O
)	O
a	O
level	O
of	O
expression	O
of	O
an	O
Anakin	O
gene	O
or	O
a	O
Brd4	B
gene	O
in	O
the	O
subject	O
.	O

Methods	O
of	O
screening	O
a	O
compound	O
for	O
anti	O
-	O
cancer	O
activity	O
and	O
use	O
of	O
a	O
compound	O
with	O
anti	O
-	O
cancer	O
activity	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
to	O
treat	O
or	O
prevent	O
cancer	O
in	O
a	O
subject	O
are	O
also	O
disclosed	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
Sipa-1	B
in	O
a	O
subject	O
.	O

Composition	O
comprising	O
egg	O
white	O
-	O
chalcanthite	O
for	O
preventing	O
or	O
treating	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
an	O
egg	O
white	O
-	O
chalcanthite	O
component	O
for	O
preventing	O
or	O
treating	O
cancer	O
,	O
and	O
more	O
particularly	O
,	O
to	O
a	O
composition	O
for	O
preventing	O
or	O
treating	O
cancer	O
,	O
which	O
comprises	O
egg	O
white	O
-	O
chalcanthite	O
prepared	O
by	O
mixing	O
a	O
roasted	O
chalcanthite	O
with	O
egg	O
white	O
to	O
reduce	O
the	O
toxicity	O
of	O
the	O
chalcanthite	O
or	O
comprises	O
a	O
mixture	O
of	O
the	O
egg	O
white	O
-	O
chalcanthite	O
and	O
a	O
bamboo	O
salt	O
,	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
composition	O
comprising	O
the	O
egg	O
white	O
-	O
chalcanthite	O
exhibits	O
excellent	O
anti	O
-	O
cancer	O
activity	O
,	O
and	O
thus	O
is	O
usefully	O
applicable	O
to	O
pharmaceutical	O
preparations	O
for	O
preventing	O
or	O
treating	O
cancer	O
or	O
the	O
manufacture	O
of	O
health	O
functional	O
foods	O
.	O

Use	O
of	O
spiro	O
-	O
oxindole	O
compounds	O
as	O
therapeutic	O
agents	O
This	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
using	O
spiro	O
-	O
oxindole	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
k	O
,	O
j	O
,	O
Q	O
,	O
R1	O
,	O
R2a	O
,	O
R2b	O
,	O
R2c	O
,	O
R2d	O
,	O
R3a	O
,	O
R3b	O
,	O
R3c	O
,	O
and	O
R3d	O
are	O
as	O
defined	O
herein	O
,	O
as	O
a	O
stereoisomer	O
,	O
enantiomer	O
,	O
tautomer	O
thereof	O
or	O
mixtures	O
thereof	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
hypercholesterolemia	O
,	O
benign	O
prostatic	O
hyperplasia	O
,	O
pruritis	O
and	O
cancer	O
.	O

Treating	O
post	O
-	O
seizure	O
patients	O
Patients	O
are	O
subject	O
to	O
a	O
post	O
-	O
seizure	O
treatment	O
regime	O
to	O
separately	O
inhibitor	O
consecutive	O
targets	O
of	O
an	O
epileptogenic	O
cascade	O
comprising	O
neurotransmitter	B
receptor	I
signaling	O
,	O
kinase	B
/	O
phosphatase	B
activity	O
,	O
protein	O
translation	O
,	O
and	O
apoptosis	O
or	O
inflammation	O
.	O

Treatment	O
of	O
Statin	O
Side	O
Effects	O
Using	O
Uridine	O
Derivatives	O
The	O
invention	O
relates	O
generally	O
to	O
treatment	O
of	O
muscle	O
pain	O
and/or	O
fatigue	O
and	O
to	O
methods	O
of	O
treatment	O
of	O
side	O
effects	O
of	O
statin	O
therapy	O
which	O
involve	O
the	O
administration	O
of	O
uridine	O
,	O
biological	O
precursors	O
or	O
derivatives	O
or	O
uridine	O
or	O
salts	O
,	O
esters	O
,	O
tautomers	O
or	O
analogues	O
thereof	O
,	O
which	O
are	O
collectively	O
referred	O
to	O
as	O
uridine	O
related	O
compounds	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
compositions	O
,	O
uses	O
and	O
combination	O
packs	O
or	O
kits	O
related	O
to	O
the	O
treatment	O
method	O
.	O

Protein	O
Kinase	B
Inhibitors	O
and	O
Methods	O
for	O
Using	O
Thereof	O
The	O
invention	O
provides	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
protein	O
kinase	O
inhibitors	O
,	O
and	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat	O
,	O
ameliorate	O
or	O
prevent	O
a	O
condition	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	O
activity	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat	O
,	O
ameliorate	O
or	O
prevent	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
Alk	B
,	O
Abl	B
,	O
Aurora	B
-	I
A	I
,	O
B	B
-	I
Raf	I
,	O
C	B
-	I
Raf	I
,	O
Bcr	B
-	O
Abl	B
,	O
BRK	B
,	O
Blk	B
,	O
Bmx	B
,	O
BTK	B
,	O
C	B
-	I
Kit	I
,	O
CSK	B
,	O
C	B
-	I
Src	I
,	O
EphB1	B
,	O
EphB2	B
,	O
EphB4	B
,	O
FLT1	B
,	O
Fms	B
,	O
Flt3	B
,	O
Fyn	B
,	O
FRK3	B
,	O
JAK2	B
,	O
KDR	B
,	O
Lck	B
,	O
Lyn	B
,	O
PDGFRα	B
,	O
PDGFRβ	B
,	O
PKCα	B
,	O
SAPK2α	B
,	O
Src	B
,	O
SIK	B
,	O
Syk	B
,	O
Tie2	B
and	O
TrkB	B
kinases	O
.	O

Preservative	O
-	O
free	O
prostaglandin	O
-	O
based	O
ophthalmic	O
solution	O
The	O
present	O
invention	O
provides	O
an	O
ophthalmic	O
solution	O
without	O
an	O
antimicrobial	O
preservative	O
.	O

The	O
solution	O
includes	O
as	O
an	O
active	O
substance	O
at	O
least	O
one	O
prostaglandin	O
and	O
as	O
a	O
solubilizing	O
agent	O
,	O
a	O
surfactant	O
,	O
where	O
the	O
solubilizing	O
agent	O
is	O
polyoxyl-15-hydroxystearate	O
.	O

Methods	O
of	O
Preventing	O
the	O
Serotonin	O
Syndrome	O
and	O
Compositions	O
for	O
Use	O
Therefor	O
The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
and	O
the	O
use	O
thereof	O
for	O
preventing	O
or	O
minimizing	O
the	O
intensity	O
of	O
the	O
serotonin	O
syndrome	O
.	O

The	O
present	O
invention	O
is	O
directed	O
at	O
a	O
method	O
of	O
preventing	O
or	O
minimizing	O
the	O
intensity	O
of	O
the	O
serotonin	O
syndrome	O
in	O
humans	O
which	O
comprises	O
administering	O
proserotonergic	O
agents	O
and	O
serotonin	O
surge	O
protectors	O
,	O
wherein	O
said	O
concurrent	O
administration	O
reduces	O
or	O
prevents	O
serotonin	O
excess	O
,	O
which	O
is	O
the	O
cause	O
of	O
the	O
serotonin	O
syndrome	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
proserotonergic	O
agents	O
and	O
serotonin	O
surge	O
protectors	O
useful	O
for	O
carrying	O
out	O
the	O
method	O
of	O
the	O
present	O
invention	O
.	O

Small	O
molecules	O
to	O
induce	O
weight	O
loss	O
or	O
to	O
reduce	O
weight	O
gain	O
Embodiments	O
of	O
the	O
present	O
invention	O
include	O
the	O
use	O
of	O
heterocyclic	O
trialkyl	O
ammonium	O
-	O
containing	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
alkaline	B
phosphatase	I
or	O
other	O
weight	O
loss	O
-	O
inducing	O
drugs	O
or	O
methods	O
to	O
reduce	O
or	O
reverse	O
excess	O
weight	O
gain	O
and	O
obesity	O
as	O
well	O
as	O
reduce	O
the	O
risk	O
of	O
development	O
and	O
help	O
treatment	O
of	O
diseases	O
and	O
unhealthy	O
conditions	O
related	O
to	O
overweight	O
and	O
obesity	O
.	O

Immunostimulatory	O
activity	O
of	O
palindromic	O
immune	O
modulatory	O
oligonucleotides	O
(	O
imo	O
)	O
containing	O
different	O
lengths	O
of	O
palindromic	O
segments	O
The	O
invention	O
provides	O
a	O
palindromic	O
immune	O
modulatory	O
nucleic	O
acid	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
generating	O
,	O
enhancing	O
and	O
modifying	O
the	O
immune	O
response	O
caused	O
by	O
palindromic	O
immune	O
modulatory	O
compounds	O
used	O
for	O
immunotherapy	O
applications	O

Method	O
for	O
treating	O
onychoschizia	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
containing	O
a	O
combination	O
of	O
a	O
herb	O
from	O
the	O
genus	O
Equisetum	O
together	O
with	O
one	O
film	O
forming	O
agent	O
and	O
its	O
use	O
as	O
a	O
nail	O
topical	O
formulation	O
,	O
like	O
nail	O
varnish	O
,	O
cream	O
,	O
gel	O
,	O
lotion	O
or	O
foam	O
.	O

The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
the	O
use	O
of	O
a	O
water	O
soluble	O
film	O
forming	O
agent	O
as	O
an	O
additive	O
in	O
a	O
nail	O
topical	O
formulation	O
.	O

These	O
compositions	O
can	O
be	O
used	O
to	O
treat	O
specific	O
alterations	O
of	O
the	O
ungual	O
structure	O
,	O
with	O
onychoschizia	O
which	O
is	O
a	O
specific	O
alteration	O
of	O
the	O
ungual	O
structure	O
,	O
characterized	O
by	O
lamellar	O
splitting	O
of	O
the	O
nail	O
plate	O
.	O

Warming	O
vapor	O
pad	O
A	O
warming	O
vapor	O
pad	O
to	O
treat	O
respiratory	O
syncytial	O
virus	O
infections	O
in	O
babies	O
,	O
children	O
and	O
adults	O
includes	O
a	O
fabric	O
impregnated	O
with	O
a	O
topical	O
ointment	O
providing	O
medicated	O
vapors	O
to	O
relieve	O
a	O
user	O
's	O
cough	O
,	O
with	O
the	O
fabric	O
being	O
superimposed	O
on	O
an	O
elastic	O
thermal	O
wrap	O
for	O
application	O
as	O
a	O
single	O
layer	O
on	O
the	O
user	O
's	O
chest	O
.	O

Method	O
of	O
inhibiting	O
alveolar	O
bone	O
resorption	O
and	O
periodontal	O
membrane	O
loss	O
and	O
composition	O
for	O
internal	O
use	O
to	O
be	O
used	O
therein	O
Alveolar	O
bone	O
resorption	O
,	O
periodontal	O
membrane	O
loss	O
,	O
and	O
gingival	O
recession	O
can	O
be	O
inhibited	O
by	O
administering	O
500	O
mg	O
to	O
2000	O
mg	O
per	O
day	O
of	O
calcium	O
,	O
10	O
mg	O
to	O
40	O
mg	O
per	O
day	O
of	O
soy	O
isoflavone	O
aglycone	O
,	O
and	O
vitamin	O
D3	O
to	O
persons	O
having	O
a	O
tendency	O
for	O
decreased	O
bone	O
density	O
,	O
postmenopausal	O
women	O
,	O
and	O
periodontal	O
disease	O
patients	O
in	O
a	O
maintenance	O
phase	O
;	O
and	O
even	O
an	O
extended	O
period	O
of	O
administration	O
provides	O
a	O
high	O
degree	O
of	O
safety	O
.	O

Amide	O
Compounds	O
Useful	O
in	O
Therapy	O
A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
,	O
R1	O
and	O
R2	O
each	O
independently	O
represent	O
H	O
,	O
halogen	O
,	O
CF3	O
,	O
C1	O
-	O
3	O
alkyl	O
or	O
C1	O
-	O
3	O
alkoxy	O
;	O
R3	O
represents	O
C1	O
-	O
6	O
alkyl	O
,	O
C3	O
-	O
6	O
cycloalkyl	O
,	O
phenyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Ra	O
)	O
or	O
Het	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
OH	O
,	O
oxo	O
,	O
or	O
C1	O
-	O
4	O
alkyl	O
)	O
;	O
R4	O
represents	O
H	O
or	O
C1	O
-	O
3	O
alkyl	O
;	O
R5	O
represents	O
C1	O
-	O
6	O
alkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rb	O
)	O
,	O
C3	O
-	O
6	O
cycloalkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
oxo	O
or	O
OH	O
)	O
,	O
or	O
Het2	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rd	O
)	O
;	O
oxygen	O
atom	O
or	O
1	O
sulphur	O
atom	O
,	O
or	O
(	O
c	O
)	O
1	O
oxygen	O
atom	O
or	O
1	O
sulphur	O
atom	O
,	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
OH	O
,	O
oxo	O
or	O
C1	O
-	O
4	O
alkyl	O
)	O
;	O
and	O
R6	O
represents	O
C1	O
-	O
3	O
alkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rf	O
)	O
,	O
C3	O
-	O
5	O
cycloalkyl	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
halogen	O
)	O
,	O
CN	O
or	O
halogen	O
;	O
where	O
Rf	O
represents	O
halogen	O
or	O
phenyl	O
:	O
and	O
compositions	O
,	O
processes	O
for	O
the	O
preparation	O
,	O
and	O
uses	O
thereof	O
,	O
e.g.	O
in	O
the	O
treatment	O
of	O
endometriosis	O
or	O
uterine	O
fibroids	O

Substituted	O
Heteroarylpiperidine	O
Derivatives	O
As	O
Melanocortin-4	O
Receptor	O
Modulators	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
heteroarylpiperidine	O
derivatives	O
as	O
melanocortin-4	O
receptor	O
modulators	O
.	O

Depending	O
on	O
the	O
structure	O
and	O
the	O
stereochemistry	O
the	O
compounds	O
of	O
the	O
invention	O
are	O
either	O
selective	O
agonists	O
or	O
selective	O
antagonists	O
of	O
the	O
human	O
melanocortin-4	O
receptor	O
(	O
MC-4R	O
)	O
.	O

The	O
agonists	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
disorders	O
and	O
diseases	O
such	O
as	O
obesity	O
,	O
diabetes	O
and	O
sexual	O
dysfunction	O
,	O
whereas	O
the	O
antagonists	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
disorders	O
and	O
diseases	O
such	O
as	O
cancer	O
cachexia	O
,	O
muscle	O
wasting	O
,	O
anorexia	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
anxiety	O
and	O
depression	O
.	O

Generally	O
all	O
diseases	O
and	O
disorders	O
where	O
the	O
regulation	O
of	O
the	O
MC-4R	O
is	O
involved	O
can	O
be	O
treated	O
with	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Azole	O
derivatives	O
and	O
fused	O
bicyclic	O
azole	O
derivatives	O
as	O
therapeutic	O
agents	O
This	O
invention	O
provides	O
certain	O
compounds	O
,	O
methods	O
of	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
their	O
use	O
in	O
treating	O
human	O
or	O
animal	O
disorders	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
as	O
modulators	O
of	O
the	O
interaction	O
between	O
the	O
receptor	O
for	O
advanced	O
glycated	O
end	O
products	O
(	O
RAGE	O
)	O
and	O
its	O
ligands	O
,	O
such	O
as	O
advanced	O
glycated	O
end	O
products	O
(	O
AGEs	O
)	O
,	O
S100	O
/	O
calgranulin	O
/	O
EN	O
-	O
RAGE	O
,	O
β	O
-	O
amyloid	O
and	O
amphoterin	O
,	O
and	O
for	O
the	O
management	O
,	O
treatment	O
,	O
control	O
,	O
or	O
as	O
an	O
adjunct	O
treatment	O
for	O
diseases	O
in	O
humans	O
caused	O
by	O
RAGE	O
.	O

Such	O
diseases	O
or	O
disease	O
states	O
include	O
acute	O
and	O
chronic	O
inflammation	O
,	O
the	O
development	O
of	O
diabetic	O
late	O
complications	O
such	O
as	O
increased	O
vascular	O
permeability	O
,	O
nephrdpathy	O
,	O
atherosclerosis	O
,	O
and	O
retinopathy	O
,	O
the	O
development	O
of	O
Alzheimer	O
's	O
disease	O
,	O
erectile	O
dysfunction	O
,	O
and	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Method	O
of	O
treatment	O
This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
sulfonamide	O
substituted	O
diphenyl	O
urea	O
compound	O
to	O
treat	O
cystic	O
fibrosis	O
,	O
or	O
the	O
symptoms	O
associated	O
with	O
cystic	O
fibrosis	O
.	O

Methods	O
and	O
materials	O
for	O
genetic	O
analysis	O
of	O
tumors	O
This	O
invention	O
relates	O
generally	O
to	O
methods	O
and	O
materials	O
for	O
rapid	O
detection	O
of	O
mutations	O
for	O
tumor	O
genotyping	O
.	O

Indolo	O
[	O
3,2-c	O
]	O
quinoline	O
compounds	O
Disclosed	O
herein	O
are	O
indolo	O
[	O
3,2-c	O
]	O
quinoline	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R	O
and	O
m	O
are	O
given	O
the	O
definitions	O
as	O
set	O
forth	O
in	O
the	O
Specification	O
and	O
Claims	O
.	O

These	O
compounds	O
can	O
be	O
used	O
to	O
inhibit	O
both	O
growth	O
of	O
cancer	O
cells	O
and	O
activity	O
of	O
telomerase	B
.	O

Means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
based	O
on	O
hydrogenated	O
pyrido	O
(	O
4,3-b	O
)	O
indoles	O
(	O
variants	O
)	O
,	O
pharmacological	O
means	O
based	O
thereon	O
and	O
method	O
for	O
the	O
use	O
thereof	O
A	O
means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
based	O
on	O
hydrogenated	O
pyrido	O
(	O
4,3-b	O
)	O
indoles	O
(	O
variants	O
)	O
,	O
a	O
pharmacological	O
means	O
based	O
thereon	O
and	O
a	O
method	O
for	O
the	O
use	O
thereof	O
relate	O
to	O
the	O
use	O
of	O
chemical	O
compounds	O
in	O
the	O
field	O
of	O
medicine	O
and	O
may	O
be	O
used	O
to	O
extend	O
the	O
arsenal	O
of	O
means	O
which	O
can	O
be	O
utilized	O
for	O
substantial	O
enhancement	O
of	O
memory	O
and	O
activation	O
of	O
the	O
learning	O
process	O
,	O
for	O
the	O
treatment	O
of	O
impaired	O
cognitive	O
functions	O
and	O
memory	O
in	O
the	O
elderly	O
and	O
in	O
mild	O
cognitive	O
impairment	O
,	O
in	O
brain	O
trauma	O
,	O
in	O
chronic	O
cerebrovascular	O
insufficiency	O
,	O
in	O
hypoxic	O
encephalopathies	O
,	O
resulting	O
from	O
chronic	O
alcoholism	O
and	O
in	O
delayed	O
development	O
in	O
children	O
.	O

Said	O
task	O
is	O
resolved	O
by	O
the	O
use	O
of	O
hydrogenated	O
pyrido	O
(	O
[	O
4	O
,	O
3-b	O
]	O
)	O
indoles	O
of	O
formula	O
(	O
1	O
)	O
or	O
formula	O
(	O
2	O
)	O
as	O
means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
.	O

Lipophilic	O
drug	O
delivery	O
vehicle	O
and	O
methods	O
of	O
use	O
thereof	O
The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
delivery	O
of	O
a	O
bioactive	O
agent	O
to	O
an	O
individual	O
.	O

Delivery	O
vehicles	O
are	O
provided	O
that	O
include	O
a	O
bioactive	O
agent	O
in	O
disc	O
shaped	O
particles	O
that	O
include	O
one	O
or	O
more	O
lipid	O
binding	O
polypeptides	O
circumscribing	O
the	O
perimeter	O
of	O
a	O
lipid	O
bilayer	O
in	O
which	O
the	O
bioactive	O
agent	O
is	O
localized	O
.	O

Chimeric	O
lipid	O
binding	O
polypeptides	O
are	O
also	O
provided	O
and	O
may	O
be	O
used	O
to	O
add	O
additional	O
functional	O
properties	O
to	O
the	O
delivery	O
particles	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
cancer	O
and	O
modulating	O
signal	O
transduction	O
and	O
metabolism	O
pathways	O
This	O
invention	O
features	O
methods	O
and	O
compositions	O
for	O
treating	O
cancer	O
and	O
modulating	O
signal	O
transduction	O
and	O
metabolism	O
pathways	O
.	O

For	O
example	O
,	O
the	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
can	O
be	O
used	O
to	O
kill	O
or	O
inhibit	O
the	O
growth	O
or	O
spread	O
of	O
cancer	O
cells	O
.	O

The	O
invention	O
also	O
features	O
a	O
method	O
of	O
identifying	O
a	O
compound	O
that	O
modulates	O
a	O
signal	O
transduction	O
or	O
metabolic	O
pathway	O
.	O

Treatment	O
of	O
Cancer	O
and	O
Inflammatory	O
Disorder	O
Disclosed	O
are	O
extracts	O
,	O
compositions	O
,	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
inflammatory	O
disorders	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
preparing	O
extracts	O
or	O
compounds	O
for	O
treating	O
the	O
disorders	O
.	O

Pyrazinooxazepine	O
derivatives	O
Provided	O
is	O
a	O
compound	O
having	O
a	O
serotonin	O
5-HT2C	O
receptor	O
activating	O
action	O
.	O

A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I0	O
)	O
:	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
salt	O
thereof	O
.	O

Sphingosine-1-phosphate	B
(	I
s1p	I
)	I
receptor	I
compounds	O
The	O
invention	O
relates	O
to	O
compounds	O
,	O
in	O
particular	O
2-amino-3,4,5,-trisubstituted	O
thiophenes	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
the	O
uses	O
of	O
said	O
compounds	O
and	O
compositions	O
for	O
diseases	O
related	O
to	O
sphingosine-1-phosphate	B
(	I
S1P	I
)	I
receptors	I
,	O
predominantly	O
S1P3	B
receptors	I
.	O

The	O
diseases	O
include	O
cardiovascular	O
diseases	O
,	O
atherosclerosis	O
,	O
cancer	O
,	O
pulmonary	O
oedema	O
,	O
autoimmune	O
disorders	O
and	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
.	O

RNA	O
INTERFERENCE	O
MEDIATED	O
INHIBITION	O
OF	O
PLATELET	B
DERIVED	I
GROWTH	I
FACTOR	I
(	O
PDGF	B
)	O
AND	O
PLATELET	B
DERIVED	I
GROWTH	I
FACTOR	I
RECEPTOR	I
(	O
PDGFR	B
)	O
GENE	O
EXPRESSION	O
USING	O
SHORT	O
INTERFERING	O
NUCLEIC	O
ACID	O
(	O
siNA	O
)	O
This	O
invention	O
relates	O
to	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
useful	O
for	O
modulating	O
platelet	B
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
and/or	O
platelet	B
derived	I
growth	I
factor	I
receptor	I
(	O
PDGFr	B
)	O
gene	O
expression	O
using	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
molecules	O
.	O

This	O
invention	O
also	O
relates	O
to	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
useful	O
for	O
modulating	O
the	O
expression	O
and	O
activity	O
of	O
other	O
genes	O
involved	O
in	O
pathways	O
of	O
platelet	B
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
and/or	O
platelet	B
derived	I
growth	I
factor	I
receptor	I
(	O
PDGFr	B
)	O
gene	O
expression	O
and/or	O
activity	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
using	O
small	O
nucleic	O
acid	O
molecules	O
.	O

In	O
particular	O
,	O
the	O
instant	O
invention	O
features	O
small	O
nucleic	O
acid	O
molecules	O
,	O
such	O
as	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
,	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
,	O
micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
,	O
and	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
molecules	O
and	O
methods	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
platelet	B
derived	I
growth	I
factor	I
(	O
PDGF	B
)	O
and/or	O
platelet	B
derived	I
growth	I
factor	I
receptor	I
(	O
PDGFr	B
)	O
genes	O
,	O
such	O
as	O
PDGF	B
and/or	O
PDGFr	B
.	O

Rosemary	O
extracts	O
,	O
dietary	O
and	O
pharmaceutical	O
compostions	O
containing	O
them	O
and	O
their	O
uses	O
The	O
present	O
invention	O
refers	O
to	O
rosemary	O
extracts	O
for	O
use	O
as	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
connected	O
to	O
reduced	O
neurotransmission	O
,	O
as	O
well	O
as	O
to	O
dietary	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
rosemary	O
extracts	O
and	O
their	O
uses	O
.	O

Hyperhidrosis	O
treatment	O
Disclosed	O
is	O
a	O
medicinal	O
composition	O
and	O
method	O
of	O
use	O
conspiring	O
topiramate	O
for	O
treating	O
drug	O
-	O
induced	O
excessive	O
sweating	O
(	O
hyperhidrosis	O
)	O
.	O

As	O
a	O
further	O
embodiment	O
of	O
this	O
invention	O
,	O
topiramate	O
may	O
be	O
administered	O
along	O
with	O
another	O
medicament	O
that	O
causes	O
excessive	O
sweating	O
to	O
prevent	O
such	O
excessive	O
sweating	O
.	O

As	O
still	O
a	O
further	O
embodiment	O
of	O
this	O
invention	O
,	O
topiramate	O
may	O
be	O
administered	O
along	O
with	O
another	O
medicament	O
that	O
treats	O
excessive	O
sweating	O
,	O
such	O
that	O
the	O
synergy	O
of	O
the	O
drugs	O
effectively	O
treats	O
the	O
sweating	O
.	O

Method	O
of	O
increasing	O
metabolism	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
and/or	O
energy	O
expenditure	O
in	O
a	O
subject	O
,	O
e.g.	O
,	O
to	O
treat	O
or	O
prevent	O
obesity	O
and/or	O
a	O
related	O
condition	O
and/or	O
to	O
reduce	O
adiposity	O
,	O
the	O
method	O
comprising	O
increasing	O
the	O
level	O
and/or	O
activity	O
of	O
Hypoxia	B
Induced	I
Factor	I
1α	I
(	O
HIF-1α	B
)	O
in	O
a	O
cell	O
,	O
tissue	O
or	O
organ	O
of	O
the	O
subject	O
,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
in	O
a	O
subject	O
,	O
the	O
method	O
comprising	O
administering	O
an	O
iron	O
chelating	O
agent	O
to	O
the	O
subject	O
,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O

Method	O
for	O
controlling	O
glucose	O
uptake	O
and	O
insulin	B
sensitivity	O
The	O
invention	O
provides	O
methods	O
for	O
treating	O
diabetes	O
and	O
related	O
disorders	O
,	O
such	O
as	O
metabolic	O
syndromes	O
(	O
which	O
includes	O
insulin	B
resistance	O
)	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
osteopontin	B
(	O
OPN	B
)	O
,	O
which	O
includes	O
an	O
antibody	O
,	O
antibody	O
fragment	O
,	O
siRNA	O
,	O
and	O
aptamer	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
increasing	O
glucose	O
uptake	O
by	O
cells	O
in	O
a	O
subject	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
OPN	B
.	O

Prophylactic	O
or	O
therapeutic	O
agent	O
for	O
eye	O
disease	O
accompanied	O
by	O
optic	O
nerve	O
disorder	O
The	O
present	O
invention	O
provides	O
a	O
novel	O
pharmaceutical	O
use	O
of	O
2-phenyl-1,2-benzisoselenazol-3	O
(	O
2H	O
)	O
-one	O
or	O
a	O
salt	O
thereof	O
.	O

2-Phenyl-1,2-benzisoselenazol-3	O
(	O
2H	O
)	O
-one	O
or	O
a	O
salt	O
thereof	O
exhibits	O
an	O
excellent	O
suppressive	O
effect	O
on	O
retinal	O
ganglion	O
cell	O
death	O
in	O
a	O
pharmacological	O
test	O
using	O
rats	O
,	O
and	O
is	O
therefore	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
an	O
eye	O
disease	O
accompanied	O
by	O
optic	O
nerve	O
disorder	O
.	O

Quinoline	O
compounds	O
suitable	O
for	O
treating	O
disorders	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	O
5-ht6	B
receptor	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
quinoline	O
compounds	O
.	O

The	O
compounds	O
possess	O
valuable	O
therapeutic	O
properties	O
and	O
are	O
particularly	O
suitable	O
,	O
for	O
treating	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	O
5-HT6	B
receptor	O
.	O

wherein	O
R	O
is	O
a	O
moiety	O
of	O
the	O
formula	O
wherein	O
A	O
,	O
R1	O
to	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
specification	O
,	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
m	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
Ra	O
,	O
Rb	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	O
,	O
CN	O
,	O
C1-C4-alkyl	O
,	O
C1-C4-haloalkyl	O
,	O
C1-C4-alkoxy	O
,	O
C1-C4-haloalkoxy	O
,	O
C	O
(	O
O	O
)	O
Raa	O
,	O
C	O
(	O
O	O
)	O
NRccRbb	O
and	O
NRccRbb	O
;	O
X	O
is	O
CH2	O
,	O
C	O
(	O
O	O
)	O
,	O
S	O
,	O
S	O
(	O
O	O
)	O
or	O
S	O
(	O
O	O
)	O
2	O
;	O
which	O
is	O
located	O
in	O
the	O
3-	O
or	O
4-position	O
of	O
the	O
quinoline	O
ring	O
;	O
Ar	O
is	O
a	O
radical	O
Ar1	O
,	O
Ar2—Ar3	O
or	O
Ar2—O	O
—	O
Ar3	O
,	O
wherein	O
Ar1	O
,	O
Ar2	O
and	O
Ar3	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aryl	O
or	O
hetaryl	O
wherein	O
aryl	O
or	O
hetaryl	O
moieties	O
may	O
be	O
unsubstituted	O
or	O
may	O
carry	O
1	O
,	O
2	O
,	O
3	O
substituents	O
Rx	O
,	O
wherein	O
and	O
physiologically	O
tolerated	O
acid	O
addition	O
salts	O
and	O
the	O
N	O
-	O
oxides	O
thereof	O
.	O

Solubilized	O
thiazolopyridines	O
Provided	O
herein	O
are	O
novel	O
sirtuin	B
-	O
modulating	O
compounds	O
Structural	O
Formula	O
(	O
I	O
)	O
:	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

The	O
sirtuin	B
-	O
modulating	O
compounds	O
may	O
be	O
used	O
for	O
increasing	O
the	O
lifespan	O
of	O
a	O
cell	O
,	O
and	O
treating	O
and/or	O
preventing	O
a	O
wide	O
variety	O
of	O
diseases	O
and	O
disorders	O
including	O
,	O
for	O
example	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
aging	O
or	O
stress	O
,	O
diabetes	O
,	O
obesity	O
,	O
neurodegenerative	O
diseases	O
,	O
cardiovascular	O
disease	O
,	O
blood	O
clotting	O
disorders	O
,	O
inflammation	O
,	O
cancer	O
,	O
and/or	O
flushing	O
as	O
well	O
as	O
diseases	O
or	O
disorders	O
that	O
would	O
benefit	O
from	O
increased	O
mitochondrial	O
activity	O
.	O

Also	O
provided	O
are	O
compositions	O
comprising	O
a	O
sirtuin	B
-	O
modulating	O
compound	O
in	O
combination	O
with	O
another	O
therapeutic	O
agent	O
.	O

Formulations	O
and	O
Methods	O
of	O
Administration	O
of	O
Cephalotaxines	O
,	O
Including	O
Homoharringtonine	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
cephalotaxines	O
,	O
for	O
example	O
,	O
homoharringtonine	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
improvements	O
in	O
the	O
purity	O
,	O
manufacturing	O
process	O
,	O
formulation	O
and	O
administration	O
of	O
homoharringtonine	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
aberrant	O
cellular	O
diseases	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
and	O
compositions	O
for	O
antiparasitic	O
,	O
antifungal	O
,	O
antiviral	O
and	O
antibacterial	O
treatments	O
.	O

Tricyclic	O
compounds	O
for	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O
The	O
present	O
invention	O
provides	O
compounds	O
represented	O
by	O
formula	O
1	O
:	O
wherein	O
,	O
R1	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
,	O
R11	O
,	O
R12	O
,	O
R13	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
in	O
all	O
its	O
stereoisomeric	O
and	O
tautomeric	O
forms	O
and	O
mixtures	O
thereof	O
in	O
all	O
ratios	O
,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutically	O
acceptable	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
polymorphs	O
and	O
prodrugs	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
treatment	O
of	O
inflammatory	O
disorders	O
including	O
those	O
caused	O
by	O
elevated	O
levels	O
of	O
proinflammatory	O
cytokines	O
such	O
as	O
Tumor	B
Necrosis	I
Factor	I
(	O
TNF	B
-	I
α	I
and/or	O
interleukins	B
(	O
IL-1β	B
,	O
IL-6	B
,	O
IL-8	B
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
compounds	O
of	O
formula	O
1	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Methods	O
of	O
treating	O
pre	O
-	O
eclampsia	O
or	O
eclampsia	O
Disclosed	O
herein	O
are	O
methods	O
for	O
treating	O
pre	O
-	O
eclampsia	O
and	O
eclampsia	O
using	O
compounds	O
that	O
increase	O
VEGF	B
or	O
PlGF	B
levels	O
or	O
compounds	O
that	O
decrease	O
sFlt-1	B
levels	O
.	O

Compounds	O
that	O
inhibit	O
the	O
binding	O
of	O
VEGF	B
or	O
PlGF	B
to	O
sFlt1—are	B
also	O
disclosed	O
herein	O
for	O
the	O
treatment	O
of	O
pre	O
-	O
eclampsia	O
or	O
eclampsia	O
.	O

Pre	O
-	O
or	O
post	O
-	O
exposure	O
treatment	O
for	O
filovirus	O
or	O
arenavirus	O
infection	O
The	O
compositions	O
and	O
methods	O
of	O
the	O
invention	O
described	O
herein	O
provide	O
pre-	O
or	O
post	O
-	O
exposure	O
treatments	O
against	O
filovirus	O
or	O
arenavirus	O
infection	O
by	O
expressing	O
one	O
or	O
more	O
genes	O
(	O
e.g.	O
,	O
two	O
ore	O
more	O
genes	O
)	O
from	O
filoviruses	O
or	O
arenaviruses	O
in	O
a	O
delivery	O
vehicle	O
(	O
e.g.	O
,	O
a	O
recombinant	O
viral	O
vector	O
or	O
a	O
liposome	O
)	O
.	O

Formulation	O
with	O
reduced	O
hygroscopicity	O
The	O
invention	O
relates	O
to	O
formulations	O
of	O
hygroscopic	O
solids	O
with	O
a	O
lipophilic	O
coating	O
layer	O
,	O
and	O
a	O
method	O
of	O
production	O
thereof	O
.	O

Pharmaceutical	O
composition	O
,	O
methods	O
for	O
treating	O
and	O
uses	O
thereof	O
The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
claim	O
1	O
comprising	O
an	O
SGLT2	B
inhibitor	O
,	O
a	O
DPPIV	B
inhibitor	O
and	O
a	O
third	O
antidiabetic	O
agent	O
which	O
is	O
suitable	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
one	O
or	O
more	O
conditions	O
selected	O
from	O
type	O
1	O
diabetes	O
mellitus	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
impaired	O
glucose	O
tolerance	O
and	O
hyperglycemia	O
.	O

In	O
addition	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
preventing	O
or	O
treating	O
of	O
metabolic	O
disorders	O
and	O
related	O
conditions	O
.	O

Methods	O
of	O
treating	O
a	O
flaviviridae	O
family	O
viral	O
infection	O
and	O
compositions	O
for	O
treating	O
a	O
flaviviridae	O
family	O
viral	O
infection	O
Briefly	O
described	O
,	O
embodiments	O
of	O
this	O
disclosure	O
include	O
compositions	O
,	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
treating	O
a	O
host	O
infected	O
with	O
a	O
virus	O
from	O
the	O
Flaviviridae	O
family	O
of	O
viruses	O
,	O
methods	O
of	O
treating	O
HCV	O
replication	O
in	O
a	O
host	O
,	O
methods	O
of	O
inhibiting	O
the	O
binding	O
of	O
NS4B	B
polypeptide	O
to	O
the	O
3′UTR	B
of	I
HCV	I
negative	O
strand	O
RNA	O
in	O
a	O
host	O
,	O
methods	O
of	O
treating	O
liver	O
fibrosis	O
in	O
a	O
host	O
,	O
and	O
the	O
like	O
.	O

Chiral	O
Complexes	O
of	O
Ascorbic	O
Acid	O
with	O
Natural	O
Antioxidant	O
and	O
Anti	O
-	O
Inflammatory	O
Ketones	O
Including	O
Aloe	O
,	O
Citrus	O
,	O
Ginger	O
,	O
and	O
Mango	O
for	O
Skin	O
and	O
Hair	O
Care	O

This	O
invention	O
relates	O
to	O
certain	O
complexes	O
of	O
ascorbic	O
acid	O
and	O
its	O
derivatives	O
with	O
certain	O
natural	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
ketones	O
for	O
topical	O
or	O
oral	O
application	O
;	O
said	O
complexes	O
having	O
general	O
chemical	O
formula	O
(	O
I	O
)	O
,	O
its	O
isomers	O
,	O
and	O
salts	O
thereof	O
,	O
including	O
their	O
optically	O
active	O
or	O
racemic	O
forms	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
skin	O
condition	O
,	O
including	O
dark	O
skin	O
,	O
age	O
spots	O
,	O
acne	O
,	O
inflammation	O
,	O
loss	O
of	O
cellular	O
antioxidants	O
,	O
collagen	O
loss	O
with	O
aging	O
,	O
loss	O
of	O
skin	O
pliability	O
,	O
loss	O
of	O
skin	O
suppleness	O
,	O
skin	O
wrinkles	O
,	O
oxidation	O
,	O
damage	O
from	O
radiation	O
,	O
malfunction	O
of	O
matrix	B
metalloproteases	I
,	O
malfunction	O
of	O
tyrosinases	B
,	O
damage	O
from	O
free	O
radicals	O
,	O
photo	O
-	O
damage	O
,	O
nutritional	O
deficiency	O
,	O
and	O
combinations	O
thereof	O
;	O

Stable	O
Hyaluronan	O
/	O
Steroid	O
Formulation	O
A	O
pharmaceutical	O
composition	O
comprising	O
in	O
admixture	O
a	O
hyaluronic	O
acid	O
related	O
component	O
(	O
HARC	O
)	O
and	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
triamcinolone	O
hexacetonide	O
(	O
TAH	O
)	O
.	O

The	O
composition	O
is	O
stable	O
in	O
an	O
accelerated	O
shelf	O
life	O
test	O
in	O
which	O
the	O
composition	O
is	O
heated	O
to	O
80	O
°	O
C.	O
for	O
24	O
hours	O
.	O

Novel	O
phosphate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
production	O
method	O
therefor	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
central	O
nervous	O
system	O
disorders	O
containing	O
the	O
same	O
as	O
an	O
active	O
component	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
{	O
4-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
-1-	O
(	O
1-hydroxycyclohexyl	O
)	O
ethyl	O
]	O
phenoxy	O
}	O
phosphate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
production	O
method	O
therefor	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
central	O
nervous	O
system	O
disorders	O
which	O
contains	O
the	O
same	O
as	O
an	O
active	O
component	O
.	O

The	O
novel	O
{	O
4-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
-1-	O
(	O
1-hydroxycyclohexyl	O
)	O
ethyl	O
]	O
phenoxy	O
}	O
phosphate	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
according	O
to	O
the	O
present	O
invention	O
can	O
beneficially	O
be	O
used	O
to	O
prevent	O
and	O
treat	O
central	O
nervous	O
system	O
disorders	O
since	O
it	O
exhibits	O
an	O
equivalent	O
biological	O
and	O
pharmacological	O
activity	O
to	O
venlafaxine	O
and	O
salts	O
thereof	O
which	O
are	O
known	O
in	O
the	O
field	O
,	O
it	O
has	O
very	O
little	O
toxicity	O
,	O
and	O
,	O
in	O
particular	O
,	O
it	O
is	O
outstandingly	O
soluble	O
in	O
water	O
as	O
compared	O
with	O
prior	O
-	O
art	O
venlafaxine	O
derivatives	O
.	O

Compounds	O
and	O
compositions	O
useful	O
for	O
the	O
treatment	O
of	O
parasitic	O
diseases	O
The	O
invention	O
provides	O
a	O
class	O
of	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
malaria	O
.	O

2-Aryl	O
Glycinamide	O
Derivatives	O

The	O
disclosure	O
provides	O
compounds	O
of	O
Formula	O
I	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutical	O
compositions	O
,	O
and	O
their	O
uses	O
in	O
inhibiting	O
β	B
-	I
amyloid	I
peptide	I
(	O
β	B
-	I
AP	I
)	O
production	O
.	O

Xanthophyll	O
composition	O
containing	O
macular	O
pigments	O
and	O
a	O
process	O
for	O
its	O
preparation	O
A	O
xanthophyll	O
composition	O
that	O
contains	O
macular	O
pigments	O
including	O
trans	O
-	O
lutein	O
and	O
zeaxanthin	O
isomers	O
,	O
namely	O
,	O
(	O
R	O
,	O
R	O
)	O
-zeaxanthin	O
and	O
(	O
R	O
,	O
S	O
)	O
-zeaxanthin	O
,	O
derived	O
from	O
the	O
plant	O
extract	O
/	O
oleoresin	O
containing	O
xanthophylls	O
/	O
xanthophylls	O
esters	O
which	O
is	O
safe	O
for	O
human	O
consumption	O
and	O
useful	O
for	O
nutrition	O
and	O
health	O
care	O
.	O

The	O
composition	O
has	O
at	O
least	O
80	O
%	O
by	O
weight	O
that	O
is	O
total	O
xanthophylls	O
,	O
of	O
which	O
the	O
ratio	O
of	O
trans	O
-	O
lutein	O
and	O
zeaxanthin	O
isomers	O
being	O
in	O
the	O
range	O
of	O
about	O
4:1	O
to	O
about	O
6:1	O
and	O
the	O
ratio	O
of	O
the	O
isomers	O
of	O
zeaxanthin	O
being	O
in	O
the	O
range	O
of	O
about	O
80	O
to	O
20:20	O
to	O
80	O
.	O

Composition	O
for	O
the	O
treatment	O
of	O
hair	O
loss	O
and	O
baldness	O
A	O
synergistic	O
composition	O
,	O
or	O
the	O
use	O
of	O
that	O
composition	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
,	O
or	O
a	O
method	O
of	O
treatment	O
including	O
the	O
use	O
of	O
that	O
composition	O
,	O
for	O
the	O
treatment	O
of	O
hair	O
loss	O
and	O
baldness	O
,	O
for	O
combined	O
,	O
sequential	O
or	O
simultaneous	O
administration	O
,	O
in	O
any	O
form	O
,	O
via	O
any	O
biological	O
route	O
.	O

In	O
its	O
optimal	O
embodiment	O
the	O
composition	O
consists	O
,	O
in	O
the	O
form	O
of	O
a	O
lotion	O
:	O
1600	O
-	O
2400	O
IU	O
/	O
mL	O
Vitamin	O
A	O
Palmitate	O
,	O
0.64%-0.96	O
%	O
Thiamine	O
Hydrochloride	O
,	O
0.64%-0.96	O
%	O
Pyridoxine	O
Hydrochloride	O
,	O
4.8%-7.2	O
%	O
Niacinamide	O
,	O
2.85%-5.2	O
%	O
D	O
-	O
Panthenol	O
,	O
1.6%-2.4	O
%	O
L	O
-	O
Arginine	O
,	O
3.6%-4.4	O
%	O
Methyl	O
Sulphonyl	O
Methane	O
(	O
MSM	O
)	O
,	O
0.08%-0.12	O
%	O
Ginger	O
Oil	O
,	O
0.08%-0.12	O
%	O
Cinnamon	O
Oil	O
,	O
0.0996%-0.1494	O
%	O
Oleoresin	O
Capsicum	O
,	O
1.3%-1.95	O
%	O
Magnesium	O
,	O
2.4%-3.6	O
%	O
Zinc	O
,	O
0.192%-0.288	O
%	O
Manganese	O
,	O
2.6%-3.9	O
%	O
Urea	O
,	O
2.4%-3.6	O
%	O
Sodium	O
Glycerophosphate	O
,	O
4.8%-7.2	O
%	O
L	O
-	O
Lysine	O
HCl	O
,	O
plus	O
Preservatives	O
,	O
Co	O
-	O
solvent	O
(	O
Propylene	O
Glycol	O
)	O
,	O
Fragrances	O
,	O
Anti	O
-	O
Oxidant	O
,	O
Cooling	O
agent	O
(	O
Menthol	O
)	O
,	O
Emulsifier	O
,	O
and	O
Vehicle	O
(	O
Purified	O
water	O
)	O
.	O

Pharmaceutically	O
useful	O
heterocycle	O
-	O
substituted	O
lactams	O
The	O
invention	O
provides	O
compounds	O
that	O
inhibit	O
CK2	B
and/or	O
Pim	B
kinases	I
and	O
compositions	O
containing	O
such	O
compounds	O
.	O

These	O
compounds	O
and	O
compositions	O
are	O
useful	O
for	O
treating	O
proliferative	O
disorders	O
such	O
as	O
cancer	O
,	O
as	O
well	O
as	O
other	O
kinase	O
-	O
associated	O
conditions	O
including	O
inflammation	O
,	O
pain	O
,	O
infections	O
,	O
and	O
certain	O
immunological	O
disorders	O
.	O

Substituted	O
quinazolines	O
as	O
blood	O
platelet	O
lowering	O
agents	O
This	O
invention	O
relates	O
to	O
the	O
discovery	O
of	O
substituted	O
analogues	O
of	O
the	O
selective	O
platelet	O
lowering	O
agent	O
anagrelide	O
with	O
reduced	O
potential	O
for	O
cardiovascular	O
side	O
-	O
effects	O
which	O
should	O
lead	O
to	O
improved	O
patient	O
compliance	O
and	O
safety	O
in	O
the	O
treatment	O
of	O
myeloproliferative	O
diseases	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
certain	O
imidazoquinazoline	O
derivatives	O
which	O
have	O
the	O
general	O
formula	O
shown	O
below	O
wherein	O
the	O
substituents	O
have	O
the	O
meanings	O
defined	O
in	O
claim	O
(	O
I	O
)	O
:	O
and	O
which	O
have	O
utility	O
as	O
platelet	O
lowering	O
agents	O
in	O
humans	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
function	O
by	O
inhibiting	O
megakaryocytopoeisis	O
and	O
hence	O
the	O
formation	O
of	O
blood	O
platelets	O
.	O

Thiophenyl	O
Sulfonamides	O
for	O
the	O
Treatment	O
of	O
Alzheimer	O
's	O
Disease	O
There	O
is	O
provided	O
a	O
series	O
of	O
novel	O
α-	O
(	O
N	O
-	O
sulfonamido	O
)	O
acetamide	O
compounds	O
of	O
the	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
and	O
n	O
are	O
defined	O
herein	O
,	O
which	O
are	O
inhibitors	O
of	O
β	B
-	I
amyloid	I
peptide	I
(	O
β	B
-	I
AP	I
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
anti	O
-	O
amyloid	O
activity	O
.	O

Molecular	O
targets	O
and	O
compounds	O
,	O
and	O
methods	O
to	O
identify	O
the	O
same	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
capable	O
of	O
inhibiting	O
the	O
mutant	O
huntingtin	O
protein	O
,	O
inhibiting	O
or	O
reducing	O
polyglutamine	O
-	O
induced	O
protein	O
aggregation	O
,	O
and/or	O
altering	O
huntingtin	B
protein	O
conformation	O
,	O
which	O
inhibition	O
is	O
useful	O
in	O
the	O
prevention	O
,	O
amelioration	O
and/or	O
treatment	O
of	O
neurodegenerative	O
diseases	O
,	O
and	O
protein	O
aggregation	O
diseases	O
more	O
generally	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
Huntington	O
's	O
disease	O
.	O

The	O
invention	O
provides	O
polypeptide	O
and	O
nucleic	O
acid	O
TARGETs	O
and	O
siRNA	O
sequences	O
based	O
on	O
these	O

Prophylactic	O
and	O
therapeutic	O
treatment	O
of	O
neuro	O
-	O
degenerative	O
diseases	O
and	O
protein	O
aggregation	O
diseases	O
A	O
composition	O
and	O
method	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
related	O
amyloid	O
plaque	O
development	O
and	O
reduction	O
of	O
amyloid	O
plaque	O
,	O
amyloidosis	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
as	O
well	O
as	O
neuro	O
-	O
degenerative	O
diseases	O
and	O
protein	O
aggregation	O
diseases	O
,	O
includes	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
phytic	O
acid	O
(	O
inositol	O
hexakisphosphate	O
)	O
,	O
a	O
phytate	O
salt	O
,	O
an	O
isomer	O
or	O
hydrolysate	O
of	O
phytic	O
acid	O
or	O
a	O
phytate	O
salt	O
,	O
or	O
a	O
mixture	O
of	O
any	O
combination	O
thereof	O
,	O
being	O
administered	O
to	O
a	O
person	O
in	O
an	O
amount	O
from	O
about	O
0.5	O
grams	O
to	O
about	O
18.75	O
grams	O
per	O
day	O
,	O
with	O
or	O
without	O
a	O
dephosphorylating	O
enzyme	O
.	O

Composite	O
material	O
The	O
invention	O
relates	O
to	O
a	O
composite	O
material	O
,	O
a	O
precursor	O
for	O
forming	O
the	O
composite	O
material	O
and	O
a	O
method	O
of	O
forming	O
the	O
composite	O
material	O
from	O
the	O
precursor	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
composite	O
material	O
and	O
in	O
particular	O
to	O
its	O
use	O
as	O
an	O
antibacterial	O
or	O
antimicrobial	O
agent	O
.	O

Compositions	O
of	O
nanoparticles	O
and	O
methods	O
of	O
making	O
the	O
same	O
Disclosed	O
herein	O
are	O
compositions	O
of	O
nanoparticles	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
nanoparticles	O
are	O
Janus	O
particles	O
,	O
where	O
each	O
particle	O
includes	O
a	O
first	O
component	O
and	O
second	O
component	O
that	O
are	O
exposed	O
to	O
the	O
surface	O
of	O
the	O
particle	O
.	O

Also	O
,	O
disclosed	O
are	O
methods	O
and	O
systems	O
for	O
making	O
a	O
composition	O
of	O
nanoparticles	O
.	O

Finally	O
,	O
a	O
method	O
of	O
treating	O
a	O
mammal	O
by	O
administering	O
a	O
composition	O
of	O
nanoparticles	O
is	O
disclosed	O
.	O

Method	O
of	O
conjugating	O
therapeutic	O
compounds	O
to	O
cell	O
targeting	O
devices	O
via	O
metal	O
complexes	O
The	O
present	O
invention	O
relates	O
to	O
a	O
cell	O
-	O
targeting	O
complex	O
comprising	O
a	O
targeting	O
moiety	O
and	O
a	O
deliverable	O
compound	O
,	O
wherein	O
said	O
targeting	O
moiety	O
and	O
said	O
deliverable	O
compound	O
are	O
joined	O
by	O
means	O
of	O
a	O
(	O
transition	O
)	O
metal	O
ion	O
complex	O
having	O
at	O
least	O
a	O
first	O
reactive	O
moiety	O
for	O
forming	O
a	O
coordination	O
bond	O
with	O
a	O
reactive	O
site	O
of	O
said	O
targeting	O
moiety	O
and	O
having	O
at	O
least	O
a	O
second	O
reactive	O
moiety	O
for	O
forming	O
a	O
coordination	O
bond	O
with	O
a	O
reactive	O
site	O
of	O
said	O
deliverable	O
compound	O
,	O
and	O
wherein	O
said	O
deliverable	O
compound	O
is	O
a	O
therapeutic	O
compound	O
.	O

Inhibition	O
of	O
degradation	O
of	O
extracellular	O
matrix	O
This	O
application	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
the	O
degradation	O
of	O
an	O
extracellular	O
matrix	O
associated	O
with	O
islet	O
beta	O
cells	O
,	O
said	O
method	O
comprising	O
contacting	O
said	O
extracellular	O
matrix	O
with	O
an	O
effective	O
amount	O
of	O
a	O
heparanase	B
inhibitor	O
.	O

Novel	O
Lapachone	O
Compounds	O
And	O
Methods	O
of	O
Use	O

Thereof	O
The	O
present	O
invention	O
provides	O
novel	O
tricyclic	O
spiro	O
-	O
oxathiine	O
naphthoquinone	O
derivatives	O
,	O
a	O
synthetic	O
method	O
for	O
making	O
the	O
derivatives	O
,	O
and	O
the	O
use	O
of	O
the	O
derivatives	O
to	O
induce	O
cell	O
death	O
and/or	O
to	O
inhibit	O
proliferation	O
of	O
cancer	O
or	O
precancerous	O
cells	O
.	O

The	O
naphthoquinone	O
derivatives	O
of	O
the	O
present	O
invention	O
are	O
related	O
to	O
the	O
compound	O
known	O
as	O
β	O
-	O
lapachone	O
(	O
3,4-dihydro-2,2-dimethyl-2H	O
-	O
naphtho	O
(	O
1,2-b	O
)	O
pyran-5,6-dione	O
)	O
.	O

2-AMINO-9-	O
[	O
4-	O
(	O
4-METHOXY	O
-	O
PHENOXY	O
)	O
-PIPERIDIN-1-YL	O
]	O
-4-PHENYL	O
-	O
INDENO	O
[	O
1,2-D	O
]	O
PYRIMIDIN-5-ONE	O
AND	O
ITS	O
USE	O
AS	O
A	O
HIGHLY	O
SELECTIVE	O
ADENOSINE	B
A2a	I
RECEPTOR	I
ANTAGONIST	O
This	O
invention	O
relates	O
to	O
a	O
novel	O
arylindenopyrimidine	O
,	O
A	O
,	O
and	O
its	O
therapeutic	O
and	O
prophylactic	O
uses	O
.	O

Disorders	O
treated	O
and/or	O
prevented	O
include	O
Parkinson	O
's	O
Disease	O
.	O

Drug	O
Delivery	O
Platforms	O
Comprising	O
Silk	O
Fibroin	O
Hydrogels	O
and	O
Uses	O
Thereof	O

The	O
present	O
specification	O
provides	O
drug	O
delivery	O
platforms	O
useful	O
for	O
the	O
controlled	O
release	O
of	O
a	O
compound	O
over	O
time	O
in	O
an	O
individual	O
.	O

Methods	O
for	O
enhancing	O
muscle	O
performance	O
and	O
tone	O
This	O
disclosure	O
concerns	O
the	O
use	O
of	O
agonists	O
of	O
AMP	B
-	I
activated	I
protein	I
kinase	I
(	O
AMPK	B
)	O
for	O
improving	O
exercise	O
and	O
modifying	O
energy	O
metabolism	O
in	O
a	O
subject	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
a	O
combination	O
of	O
AMPK	B
and	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
(	I
PPAR	I
)	I
δ	I
agonists	O
for	O
improving	O
exercise	O
performance	O
in	O
a	O
subject	O
,	O
methods	O
for	O
identifying	O
substance	O
-	O
enhanced	O
exercise	O
performance	O
in	O
a	O
subject	O
,	O
and	O
methods	O
for	O
identifying	O
compounds	O
that	O
affect	O
the	O
interaction	O
of	O
PPARδ	B
with	O
exercise	O
-	O
induced	O
kinases	B
.	O

Use	O
Of	O
Tranilast	O
And	O
Derivatives	O
Thereof	O

For	O
The	O
Therapy	O
Of	O
Neurological	O
Conditions	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
tranilast	O
and	O
derivatives	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
and/or	O
preventing	O
a	O
neuronal	O
condition	O
where	O
there	O
is	O
a	O
need	O
of	O
neuroprotection	O
and	O
neuroregeneration	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
the	O
use	O
of	O
tranilast	O
and	O
derivatives	O
thereof	O
for	O
the	O
in	O
vitro	O
differentiation	O
of	O
neuronal	O
stem	O
cells	O
and	O
the	O
use	O
of	O
such	O
pre	O
-	O
treated	O
cells	O
for	O
stem	O
cell	O
therapy	O
von	O
neurological	O
conditions	O
.	O

Preparation	O
and	O
enantiomeric	O
separation	O
of	O
7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
]	O
nonane	O
and	O
novel	O
salt	O
forms	O
of	O
the	O
racemate	O
and	O
enantiomers	O
A	O
novel	O
scalable	O
synthesis	O
for	O
the	O
preparation	O
of	O
7-	O
(	O
3-pyridinyI	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
)	O
nonane	O
has	O
been	O
developed	O
,	O
and	O
7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
]	O
nonane	O
salts	O
have	O
been	O
formed	O
with	O
succinic	O
acid	O
and	O
oxalic	O
acid	O
.	O

Additionally	O
,	O
7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diaza	O
-	O
spiro	O
[	O
4.4	O
]	O
nonane	O
has	O
been	O
separated	O
into	O
its	O
stereoisomers	O
via	O
resolution	O
with	O
L	O
and	O
D	O
di	O
-	O
p	O
-	O
toluoyltartaric	O
acids	O
,	O
giving	O
(	O
R	O
)	O
-	O
and	O
(	O
S	O
)	O
-7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
]	O
nonane	O
of	O
high	O
enantiomeric	O
purity	O
.	O

Numerous	O
solid	O
salts	O
of	O
the	O
resulting	O
(	O
R	O
)	O
-	O
and	O
(	O
S	O
)	O
-7-	O
(	O
3-pyridinyl	O
)	O
-1,7-diazaspiro	O
[	O
4.4	O
}	O
nonane	O
have	O
been	O
prepared	O
.	O

Methods	O
for	O
the	O
preparation	O
of	O
the	O
racemic	O
and	O
enantiomeric	O
salts	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
salts	O
,	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

The	O
salts	O
can	O
be	O
administered	O
to	O
patients	O
susceptible	O
to	O
or	O
suffering	O
from	O
conditions	O
and	O
disorders	O
,	O
such	O
as	O
central	O
nervous	O
system	O
disorders	O
,	O
to	O
treat	O
and/or	O
prevent	O
such	O
disorders	O
.	O

PYRAZOLO	O
[	O
1,5-a	O
]	O
PYRIMIDINES	O
USEFUL	O
AS	O
JAK2	B
INHIBITORS	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
selective	O
inhibitors	O
of	O
JAK2	B
kinase	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
acceptable	O
compositions	O
comprising	O
said	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
,	O
conditions	O
or	O
disorders	O
.	O

The	O
invention	O
also	O
provides	O
processes	O
for	O
preparing	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Thienopyrimidine	O
compounds	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
A2B	O
receptor	O
antagonists	O
,	O
wherein	O
R1	O
is	O
optionally	O
substituted	O
aryl	O
or	O
an	O
optionally	O
substituted	O
5-	O
or	O
6-membered	O
heteroaryl	O
ring	O
;	O
R2	O
and	O
R3	O
are	O
independently	O
selected	O
from	O
hydrogen	O
,	O
C1-C6	O
alkyl	O
,	O
C3-C8	O
cycloalkyl	O
,	O
C3-C8	O
cycloalkyl-	O
(	O
C1-C6	O
)	O
-alkyl	O
,	O
aryl-	O
(	O
C1-C6	O
)	O
-alkyl	O
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
thereof	O
,	O
a	O
5-	O
or	O
6-membered	O
monocyclic	O
heterocyclic	O
group	O
optionally	O
linked	O
via	O
a	O
C1-C6	O
alkylene	O
chain	O
and	O
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
thereof	O
,	O
benzimidazol-2-yl	O
-	O
methyl	O
,	O
pyrid-3-yl	O
-	O
carbonyl	O
,	O
or	O
(	O
1-methyl	O
-	O
piperidin-4-yl	O
)	O
-carbonyl	O
-	O
methyl	O
;	O
or	O
R2	O
and	O
R3	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
5-	O
or	O
6-membered	O
ring	O
;	O
R4	O
is	O
C1-C3	O
alkyl	O
,	O
C2-C3	O
alkenyl	O
,	O
—N	O
(	O
—R5	O
)	O
—R6	O
,	O
or	O
optionally	O
substituted	O
heteroarylmethylamino	O
;	O
and	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
hydrogen	O
or	O
C1-C3	O
alkyl	O
;	O
or	O
R5	O
and	O
R6	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
4-	O
to	O
6-membered	O
saturated	O
ring	O
.	O

6	O
-	O
1h	O
-	O
imidazo	O
-	O
quinazoline	O
and	O
quinolines	O
derivatives	O
,	O
new	O
mao	B
inhibitors	O
and	O
imidazoline	O
receptor	O
ligands	O
The	O
present	O
invention	O
is	O
directed	O
to	O
6-	O
(	O
1H	O
-	O
imidazo-1-yl	O
)	O
-2-aryl	O
and	O
2-heteroaryl	O
quinazoline	O
and	O
quinolines	O
derivatives	O
,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
pharmaceutical	O
acceptable	O
salts	O
and	O
solvates	O
and	O
corresponding	O
pharmaceutical	O
compositions	O
,	O
that	O
acts	O
as	O
Monoamine	B
Oxidase	I
(	O
MAO	B
)	O
inhibitors	O
and	O
Imidazoline	B
Receptor	I
ligands	O
:	O
wherein	O
:	O
X	O
is	O
independently	O
selected	O
from	O
—CH	O
group	O
or	O
a	O
nitrogen	O
atom	O
(	O
—N	O
)	O
,	O
W	O
is	O
independently	O
selected	O
from	O
an	O
aryl	O
group	O
,	O
an	O
heteroaryl	O
group	O
,	O
or	O
a	O
benzocondensed	O
heteroaryl	O
group	O
such	O
as	O
1,3-benzodioxole	O
,	O
benzofuran	O
,	O
2,3-dihydrobenzofuran	O
,	O
benzothiophene	O
,	O
2,3-dihydrobenzothiophene	O
,	O
indole	O
,	O
2,3-dihydroindole	O
,	O
benzimidazole	O
,	O
benzoxazole	O
,	O
benzothiazole	O
,	O
2H-3,4-dihydrobenzopyran	O
,	O
[	O
1,4	O
]	O
-benzodioxine	O
,	O
2,3-dihydro-	O
[	O
1,4	O
]	O
-benzodioxine	O
(	O
1,4-benzodioxan	O
)	O
.	O

R1	O
is	O
independently	O
selected	O
from	O
hydrogen	O
(	O
—H	O
)	O
,	O
C1-C4	O
alkyl	O
,	O
hydroxymethyl	O
(	O
—CH2OH	O
)	O
,	O
aminomethyl	O
(	O
—CH2NH2	O
)	O
,	O
alkylaminomethyl	O
[	O
CH2NH	O
(	O
R2	O
)	O
]	O
,	O
or	O
di	O
-	O
alkylaminomethyl	O
[	O
CH2N	O
(	O
R2	O
)	O
2	O
]	O
,	O
trifluoromethyl	O
(	O
—CF3	O
)	O
.	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
elicited	O
a	O
pharmacological	O
profile	O
suitable	O
for	O
the	O
clinical	O
treatment	O
of	O
depression	O
and	O
related	O
disorders	O
,	O
Parkinson	O
disease	O
,	O
drug	O
abuse	O
,	O
and	O
morphine	O
tolerance	O
and	O
dependence	O
.	O

Multi	O
-	O
phase	O
contraceptive	O
preparation	O
based	O
on	O
a	O
natural	O
estrogen	O
The	O
multiphase	O
preparation	O
having	O
higher	O
contraceptive	O
safety	O
and	O
reduced	O
side	O
effects	O
is	O
based	O
on	O
a	O
combination	O
of	O
a	O
natural	O
oestrogen	O
with	O
dienogest	O
or	O
drospirenon	O
.	O

The	O
multiphase	O
prepration	O
is	O
characterized	O
by	O
a	O
first	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
dose	O
units	O
of	O
3	O
mg	O
of	O
oestradiol	O
valerate	O
,	O
a	O
second	O
phase	O
consisting	O
of	O
2	O
groups	O
of	O
daily	O
dose	O
units	O
,	O
wherein	O
a	O
first	O
group	O
is	O
formed	O
by	O
5	O
daily	O
dose	O
units	O
each	O
containing	O
a	O
combination	O
of	O
2	O
mg	O
of	O
oestradiol	O
valerate	O
and	O
at	O
least	O
two	O
or	O
three	O
times	O
an	O
ovulation	O
-	O
inhibitory	O
dose	O
of	O
dienogest	O
or	O
drospirenon	O
and	O
a	O
second	O
group	O
is	O
formed	O
by	O
17	O
daily	O
dose	O
units	O
each	O
containing	O
a	O
combination	O
of	O
2	O
mg	O
of	O
oestradiol	O
valerate	O
and	O
at	O
least	O
three	O
or	O
four	O
times	O
the	O
ovulation	O
-	O
inhibitory	O
dose	O
of	O
dienogest	O
or	O
drospirenon	O
,	O
a	O
third	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
units	O
of	O
1	O
mg	O
of	O
oestradiol	O
valerate	O
,	O
and	O
a	O
further	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
units	O
of	O
pharmaceutically	O
acceptable	O
placebo	O
.	O

Substituted	O
Carbamate	O
Derivatives	O
as	O
Modulators	O
of	O
Corticotropin	O
-	O
Releasing	O
Factor	O
Receptor	O
Activity	O

The	O
disclosure	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
including	O
their	O
salts	O
,	O
as	O
well	O
as	O
compositions	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O

The	O
compounds	O
are	O
CRF	B
receptor	I
antagonists	O
and	O
may	O
be	O
useful	O
for	O
treating	O
disorders	O
associated	O
with	O
abnormal	O
CRF	B
levels	O
or	O
aberrant	O
functioning	O
of	O
CRF	B
receptors	I
.	O

Viscous	O
Terpolymers	O
as	O
Drug	O
Delivery	O
Platform	O
Disclosed	O
are	O
terpolymer	O
compositions	O
of	O
lactide	O
,	O
glycolide	O
,	O
and	O
caprolactone	O
and	O
methods	O
of	O
making	O
such	O
polymers	O
with	O
an	O
initiator	O
.	O

Methods	O
of	O
using	O
the	O
terpolymers	O
as	O
a	O
drug	O
delivery	O
platform	O
are	O
also	O
disclosed	O
.	O

Platelet	O
adhesion	O
-	O
resistant	O
material	O
A	O
platelet	O
adhesion	O
-	O
resistant	O
material	O
is	O
provided	O
,	O
which	O
includes	O
polytriuret	O
-	O
urethane	O
consisting	O
essentially	O
of	O
repeating	O
structural	O
units	O
of	O
formulae	O
(	O
I	O
)	O
to	O
(	O
III	O
)	O
in	O
a	O
random	O
order	O
,	O
in	O
which	O
when	O
the	O
total	O
number	O
of	O
the	O
three	O
repeating	O
structural	O
units	O
in	O
the	O
polytriuret	O
-	O
urethane	O
is	O
100	O
,	O
the	O
number	O
of	O
the	O
repeating	O
structural	O
units	O
(	O
I	O
)	O
is	O
about	O
5	O
to	O
about	O
50	O
:	O
in	O
which	O
each	O
R	O
independently	O
represents	O
a	O
C2-C16	O
alkylene	O
group	O
,	O
a	O
C6-C30	O
aromatic	O
group	O
,	O
a	O
C6-C30	O
alicyclic	O
group	O
;	O
n	O
is	O
an	O
integer	O
of	O
2	O
to	O
16	O
;	O
and	O
R1	O
represents	O
—	O
(	O
OCmH2m	O
)	O
p	O
,	O
in	O
which	O
m	O
is	O
an	O
integer	O
of	O
2	O
to	O
5	O
,	O
and	O
p	O
is	O
an	O
integer	O
of	O
3	O
to	O
150	O
.	O

Mzb1	B
,	O
a	O
novel	O
b	O
cell	O
factor	O
,	O
and	O
uses	O
thereof	O
The	O
marginal	O
zone	O
(	O
MZ	O
)	O
and	O
B1	O
subsets	O
of	O
B	O
cells	O
,	O
which	O
differ	O
from	O
conventional	O
follicular	O
(	O
FO	O
)	O
B	O
cells	O
both	O
developmentally	O
and	O
functionally	O
,	O
are	O
involved	O
in	O
early	O
responses	O
to	O
infectious	O
pathogens	O
and	O
the	O
production	O
of	O
self	O
-	O
reactive	O
antibodies	O
.	O

A	O
novel	O
gene	O
,	O
mzb1	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
MZ	O
and	O
B1	O
B	O
cells	O
but	O
at	O
low	O
level	O
,	O
if	O
at	O
all	O
,	O
in	O
FOB	O
cells	O
.	O

MZB1	B
is	O
involved	O
in	O
the	O
regulation	O
of	O
proliferation	O
,	O
BCR	B
-	O
mediated	O
signal	O
transduction	O
,	O
and	O
antibody	O
production	O
in	O
B	O
cells	O
.	O

Inhibitors	O
,	O
activators	O
and	O
enhancers	O
of	O
MZB1	B
expression	O
or	O
activity	O
can	O
be	O
used	O
as	O
immune	O
modulators	O
for	O
research	O
and	O
therapeutic	O
purposes	O
.	O

Methods	O
and	O
Compositions	O
for	O
the	O
Treatment	O
of	O
Chronic	O
Renal	O
Hypertension	O
Methods	O
and	O
compositions	O
for	O
the	O
treating	O
chronic	O
renal	O
hypertension	O
in	O
a	O
subject	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
nitroxide	O
-	O
containing	O
composition	O
to	O
the	O
subject	O
,	O
particularly	O
4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl	O
(	O
Tempol	O
)	O
.	O

Methods	O
and	O
compositions	O
for	O
targeted	O
delivery	O
of	O
gene	O
therapeutic	O
vectors	O
Embodiments	O
of	O
the	O
present	O
invention	O
relate	O
to	O
methods	O
and	O
compositions	O
for	O
tissue-	O
specific	O
delivery	O
of	O
a	O
gene	O
therapeutic	O
,	O
transgenic	O
nucleic	O
acid	O
in	O
mammals	O
.	O

Methods	O
and	O
compositions	O
of	O
the	O
invention	O
include	O
the	O
steps	O
of	O
providing	O
a	O
nucleic	O
acid	O
comprising	O
a	O
transgene	O
flanked	O
by	O
two	O
terminal	O
repeats	O
and	O
,	O
within	O
the	O
same	O
or	O
on	O
a	O
separate	O
nucleic	O
acid	O
,	O
a	O
nucleotide	O
sequence	O
encoding	O
a	O
transposase	O
,	O
wherein	O
the	O
transgene	O
comprises	O
a	O
biotherapeutic	O
gene	O
,	O
contacting	O
the	O
nucleic	O
acid	O
with	O
perfluorocarbon	O
gas	O
-	O
filled	O
microbubbles	O
to	O
form	O
a	O
mixture	O
,	O
introducing	O
the	O
mixture	O
into	O
the	O
bloodstream	O
of	O
a	O
mammal	O
,	O
and	O
focusing	O
ultrasound	O
pulses	O
on	O
a	O
specific	O
tissue	O
of	O
said	O
mammal	O
,	O
wherein	O
said	O
pulses	O
disrupt	O
said	O
microbubbles	O
of	O
said	O
mixture	O
and	O
release	O
said	O
nucleic	O
acid	O
into	O
the	O
bloodstream	O
within	O
the	O
target	O
tissue	O
,	O
thereby	O
enabling	O
uptake	O
of	O
the	O
transgenic	O
nucleic	O
acid	O
into	O
the	O
cells	O
of	O
said	O
target	O
tissue	O
.	O

Use	O
of	O
extracellular	O
rna	O
to	O
measure	O
disease	O
Stable	O
,	O
extracellular	O
microRNAs	O
and	O
methods	O
for	O
isolating	O
and	O
identifying	O
such	O
microRNAs	O
from	O
a	O
body	O
fluid	O
are	O
provided	O
.	O

The	O
extracellular	O
microRNAs	O
isolated	O
from	O
a	O
bodily	O
fluid	O
of	O
a	O
subject	O
can	O
be	O
used	O
to	O
measure	O
disease	O
and	O
provide	O
sensitive	O
,	O
efficient	O
,	O
and	O
non	O
invasive	O
methods	O
for	O
the	O
detection	O
of	O
disease	O
,	O
including	O
cancer	O
.	O

The	O
extracellular	O
microRNAs	O
can	O
be	O
used	O
to	O
develop	O
new	O
therapeutics	O
for	O
the	O
treatment	O
of	O
disease	O
,	O
including	O
cancer	O
.	O

The	O
examples	O
illustrate	O
diagnosis	O
of	O
prostate	O
and	O
ovarian	O
cancer	O
and	O
differential	O
expression	O
of	O
miR-100	B
,	O
miR-135b	B
,	O
miR-141	B
,	O
miR-148a	B
,	O
miR-200a	B
,	O
miR-200c	B
,	O
miR-210	B
,	O
miR-222	B
,	O
miR-375	B
,	O
miR-425-Sp	B
and	O
miR-429	B
.	O

Device	O
and	O
methods	O
for	O
treatment	O
and	O
prevention	O
of	O
tendon	O
injuries	O
The	O
present	O
invention	O
relates	O
to	O
treatment	O
and	O
prevention	O
devices	O
and	O
regimens	O
for	O
tendon	O
injury	O
and	O
damage	O
.	O

The	O
invention	O
further	O
provides	O
compositions	O
comprising	O
therapeutic	O
agents	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
disorders	O
,	O
injuries	O
and	O
conditions	O
beneficially	O
treated	O
by	O
these	O
agents	O
,	O
particularly	O
those	O
relating	O
to	O
the	O
management	O
of	O
tendon	O
damage	O
.	O

Cd44	B
splice	O
variants	O
in	O
neurodegenerative	O
diseases	O
There	O
is	O
provided	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
,	O
which	O
includes	O
administration	O
of	O
a	O
composition	O
that	O
includes	O
a	O
reagent	O
capable	O
of	O
modulating	O
expression	O
of	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
encoded	O
by	O
a	O
nucleic	O
acid	O
,	O
wherein	O
the	O
nucleic	O
acid	O
is	O
selected	O
from	O
a	O
group	O
that	O
includes	O
a	O
contiguous	O
nucleotide	O
sequence	O
being	O
at	O
least	O
90	O
%	O
homologous	O
to	O
at	O
least	O
20	O
nucleotides	O
of	O
:	O
SEQ	O
ID	O
NO	O
:	O
1	O
,	O
SEQ	O
ID	O
NO	O
:	O
3	O
,	O
SEQ	O
ID	O
NO	O
:	O
5	O
,	O
SEQ	O
ID	O
NO	O
:	O
7	O
,	O
or	O
any	O
combination	O
thereof	O
.	O

There	O
is	O
further	O
provided	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
,	O
which	O
includes	O
administration	O
of	O
a	O
composition	O
that	O
includes	O
a	O
reagent	O
capable	O
of	O
modulating	O
expression	O
and/or	O
activity	O
of	O
a	O
polypeptide	O
,	O
wherein	O
the	O
sequence	O
of	O
the	O
polypeptide	O
is	O
selected	O
from	O
a	O
group	O
that	O
includes	O
a	O
contiguous	O
amino	O
acid	O
sequence	O
being	O
at	O
least	O
90	O
%	O
homologous	O
to	O
at	O
least	O
10	O
amino	O
acid	O
of	O
:	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
SEQ	O
ID	O
NO	O
:	O
4	O
,	O
SEQ	O
ID	O
NO	O
:	O
6	O
,	O
SEQ	O
ID	O
NO	O
:	O
8	O
,	O
or	O
any	O
combination	O
thereof	O
.	O

Rna	O
interference	O
for	O
the	O
treatment	O
of	O
gain	O
-	O
of	O
-	O
function	O
disorders	O
The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
of	O
an	O
effective	O
treatment	O
for	O
a	O
variety	O
of	O
gain	O
-	O
of	O
-	O
function	O
diseases	O
,	O
in	O
particular	O
,	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
.	O

The	O
present	O
invention	O
utilizes	O
RNA	O
Interference	O
technology	O
(	O
RNAi	O
)	O
against	O
polymorphic	O
regions	O
in	O
the	O
genes	O
encoding	O
various	O
gain	O
-	O
of	O
-	O
function	O
mutant	O
proteins	O
resulting	O
in	O
an	O
effective	O
treatment	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
disease	O
.	O

Compositions	O
comprising	O
cationic	O
microparticles	O
and	O
hcv	B
e1e2	I
dna	I
and	O
methods	O
of	O
use	O
thereof	O
Immunogenic	O
HCV	B
E1E2809	I
DNA	I
compositions	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
described	O
.	O

The	O
compositions	O
comprise	O
HCV	B
E1E2809	I
DNA	I
adsorbed	O
to	O
cationic	O
microparticles	O
,	O
such	O
as	O
poly	O
(	O
lactide	O
-	O
co	O
-	O
glycolide	O
)	O
(	O
PLG	O
)	O
microparticles	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
boronic	O
acid	O
compounds	O
Pharmaceutical	O
compositions	O
comprising	O
bortezomib	O
for	O
oral	O
or	O
parenteral	O
administration	O
.	O

Specific	O
aspects	O
relate	O
to	O
stable	O
,	O
sugar	O
free	O
pharmaceutical	O
compositions	O
of	O
bortezomib	O
,	O
including	O
its	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
,	O
in	O
the	O
form	O
of	O
ready	O
-	O
to	O
-	O
use	O
solutions	O
,	O
lyophilized	O
forms	O
,	O
or	O
physical	O
admixtures	O
,	O
and	O
the	O
preparation	O
thereof	O
.	O

Other	O
aspects	O
include	O
processes	O
for	O
preparing	O
compositions	O
and	O
methods	O
of	O
using	O
compositions	O
for	O
treating	O
various	O
types	O
of	O
cancers	O
in	O
mammals	O
.	O

minoxidil	O
composition	O
and	O
non	O
-	O
aerosol	O
,	O
non	O
-	O
spray	O
foam	O
method	O
of	O
delivery	O
therefor	O
A	O
foamable	O
composition	O
is	O
described	O
that	O
contains	O
one	O
or	O
more	O
of	O
:	O
minoxidil	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
an	O
aqueous	O
-	O
alcoholic	O
solvent	O
medium	O
which	O
enables	O
said	O
minoxidil	O
or	O
said	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
be	O
solubilized	O
,	O
a	O
surfactant	O
,	O
such	O
as	O
oleth-20	O
,	O
a	O
foam	O
stabilizer	O
,	O
such	O
as	O
lauryl	O
glucoside	O
,	O
and	O
a	O
sunscreen	O
.	O

The	O
foamable	O
minoxidil	O
composition	O
is	O
optionally	O
delivered	O
in	O
a	O
measured	O
dosage	O
as	O
a	O
foam	O
using	O
a	O
non	O
-	O
pressurized	O
container	O
,	O
where	O
the	O
foam	O
is	O
produced	O
within	O
the	O
container	O
without	O
use	O
of	O
a	O
propellant	O
.	O

Tricyclic	O
indole	O
derivatives	O
and	O
methods	O
of	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
Tricyclic	O
Indole	O
Derivatives	O
,	O
compositions	O
comprising	O
at	O
least	O
one	O
Tricyclic	O
Indole	O
Derivatives	O
,	O
and	O
methods	O
of	O
using	O
the	O
Tricyclic	O
Indole	O
Derivatives	O
for	O
treating	O
or	O
preventing	O
a	O
viral	O
infection	O
or	O
a	O
virus	O
-	O
related	O
disorder	O
in	O
a	O
patient	O
.	O

Dispersible	O
phospholipid	O
stabilized	O
microparticles	O
Rapidly	O
dispersing	O
solid	O
dry	O
therapeutic	O
dosage	O
form	O
comprised	O
of	O
a	O
water	O
insoluble	O
compound	O
existing	O
as	O
a	O
nanometer	O
or	O
micrometer	O
particulate	O
solid	O
which	O
is	O
surface	O
stabilized	O
by	O
the	O
presence	O
of	O
at	O
least	O
one	O
phospholipid	O
,	O
the	O
particulate	O
solid	O
being	O
dispersed	O
throughout	O
a	O
bulking	O
matrix	O
.	O

When	O
the	O
dosage	O
form	O
is	O
introduced	O
into	O
an	O
aqueous	O
environment	O
the	O
bulking	O
matrix	O
is	O
substantially	O
completely	O
dissolves	O
within	O
less	O
than	O
2	O
minutes	O
thereby	O
releasing	O
the	O
water	O
insoluble	O
particulate	O
solid	O
in	O
an	O
unaggregated	O
and/or	O
unagglomerated	O
state	O
.	O

The	O
matrix	O
is	O
composed	O
of	O
a	O
water	O
insoluble	O
substance	O
or	O
therapeutically	O
useful	O
water	O
insoluble	O
or	O
poorly	O
water	O
soluble	O
compound	O
,	O
a	O
phospholipid	O
and	O
optionally	O
also	O
at	O
least	O
one	O
non	O
-	O
ionic	O
,	O
anionic	O
,	O
cationic	O
,	O
or	O
amphipathic	O
surfactant	O
,	O
together	O
with	O
a	O
matrix	O
or	O
bulking	O
agent	O
and	O
if	O
needed	O
a	O
release	O
agent	O
.	O

The	O
volume	O
weighted	O
mean	O
particle	O
size	O
of	O
the	O
water	O
insoluble	O
particle	O
is	O
5	O
micrometers	O
or	O
less	O
.	O

Screening	O
Method	O
for	O
Identifying	O
Patients	O
at	O
Risk	O
of	O
Adverse	O
Hepatologic	O
Events	O

This	O
present	O
invention	O
provides	O
methods	O
and	O
kits	O
for	O
identifying	O
patients	O
at	O
risk	O
of	O
suffering	O
from	O
a	O
drug	O
induced	O
liver	O
injury	O
,	O
particularly	O
for	O
an	O
antioxidant	O
drug	O
,	O
or	O
for	O
identifying	O
patients	O
who	O
are	O
suffering	O
from	O
early	O
stages	O
of	O
a	O
liver	O
disorder	O
by	O
assessing	O
the	O
levels	O
of	O
apolipoprotein	O
in	O
a	O
sample	O
of	O
the	O
patient	O
and	O
comparing	O
that	O
to	O
a	O
reference	O
value	O
.	O

The	O
reference	O
value	O
is	O
predetermined	O
by	O
identifying	O
a	O
population	O
sample	O
and	O
determining	O
an	O
upper	O
limit	O
of	O
normal	O
value	O
.	O

This	O
value	O
is	O
then	O
used	O
as	O
a	O
reference	O
point	O
for	O
comparison	O
of	O
apolipoprotein	O
levels	O
from	O
patient	O
samples	O
.	O

In	O
one	O
embodiment	O
,	O
apolipoprotein	O
levels	O
are	O
combined	O
with	O
ATL	O
and/or	O
total	O
bilirubin	O
levels	O
for	O
predicting	O
liver	O
damage	O
,	O
hepatotoxicity	O
or	O
hepatic	O
events	O
after	O
drug	O
administration	O
.	O

Modified	O
chloroquines	O
with	O
single	O
ring	O
moiety	O
or	O
fused	O
ring	O
moiety	O
The	O
disclosure	O
provides	O
modified	O
chloroquine	O
compounds	O
having	O
single	O
ring	O
or	O
fused	O
ring	O
moieties	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
inhibit	O
or	O
treat	O
diseases	O
or	O
conditions	O
caused	O
by	O
chloroquine	O
-	O
resistant	O
(	O
CQR	O
)	O
and	O
chloroquine	O
-	O
sensitive	O
(	O
CqS	O
)	O
malaria	O
parasites	O
and	O
other	O
CQ	O
-	O
susceptible	O
microorganisms	O
,	O
and	O
processes	O
and	O
intermediates	O
useful	O
for	O
preparing	O
such	O
compounds	O
.	O

Method	O
and	O
Kit	O
for	O
Assessing	O
a	O
Patient	O
's	O
Genetic	O
Information	O
,	O
Lifestyle	O
and	O
Environment	O
Conditions	O
,	O
and	O
Providing	O
a	O
Tailored	O
Therapeutic	O
Regime	O
A	O
method	O
of	O
determining	O
a	O
personalised	O
therapeutic	O
regime	O
,	O
comprising	O
:	O
receiving	O
genetic	O
information	O
relating	O
to	O
a	O
patient	O
;	O
determining	O
genetic	O
criteria	O
relevant	O
to	O
a	O
personalised	O
therapeutic	O
regime	O
for	O
the	O
patient	O
using	O
the	O
genetic	O
information	O
;	O
receiving	O
personal	O
information	O
relating	O
to	O
the	O
patient	O
;	O
determining	O
personal	O
criteria	O
relevant	O
to	O
the	O
personalised	O
therapeutic	O
regime	O
using	O
the	O
personal	O
information	O
;	O
and	O
combining	O
the	O
genetic	O
criteria	O
and	O
the	O
personal	O
criteria	O
to	O
determine	O
the	O
personalised	O
therapeutic	O
regime	O
for	O
the	O
patient	O
.	O

Methods	O
for	O
enhancing	O
immune	O
response	O
This	O
disclosure	O
demonstrates	O
a	O
novel	O
therapy	O
immunological	O
approach	O
using	O
polyamine	O
-	O
based	O
therapy	O
(	O
PBT	O
)	O
for	O
relieving	O
tumor	O
-	O
induced	O
suppression	O
of	O
the	O
patient	O
's	O
immune	O
system	O
.	O

The	O
demonstration	O
of	O
the	O
pharmacological	O
release	O
from	O
the	O
naturally	O
occurring	O
polyamine	O
-	O
mediated	O
immune	O
suppression	O
offers	O
profound	O
impact	O
on	O
the	O
immunotherapy	O
of	O
cancer	O
together	O
with	O
a	O
variety	O
of	O
diseases	O
caused	O
by	O
the	O
disease	O
-	O
causing	O
vector	O
's	O
ability	O
to	O
evade	O
an	O
immune	O
reaction	O
.	O

This	O
therapeutic	O
approach	O
is	O
equally	O
applicable	O
to	O
disease	O
states	O
whereby	O
immune	O
system	O
suppression	O
by	O
polyamines	O
has	O
been	O
demonstrated	O
including	O
;	O
bacterial	O
infections	O
,	O
parasitic	O
infections	O
including	O
malaria	O
and	O
typanosomiasis	O
,	O
viral	O
infections	O
,	O
peptic	O
ulcers	O
and	O
gastric	O
cancer	O
due	O
to	O
H.	O
Pylori	O
infection	O
together	O
with	O
prevention	O
of	O
pregnancy	O
.	O

With	O
a	O
small	O
molecule	O
drug	O
,	O
used	O
in	O
combination	O
with	O
DFMO	O
,	O
the	O
pharmacological	O
manipulation	O
of	O
polyamine	O
levels	O
for	O
therapeutic	O
benefit	O
in	O
various	O
disease	O
states	O
is	O
possible	O
.	O

Micronutrient	O
Supplement	O
Dispensing	O
Package	O
Provided	O
herein	O
is	O
a	O
prenatal	O
and	O
postpartum	O
multivitamin	O
and	O
mineral	O
supplement	O
package	O
provided	O
in	O
the	O
form	O
of	O
a	O
plurality	O
of	O
solid	O
oral	O
dosage	O
units	O
individually	O
contained	O
in	O
blister	O
packs	O
wherein	O
a	O
portion	O
of	O
the	O
dosage	O
forms	O
are	O
iron	O
-	O
containing	O
while	O
at	O
least	O
half	O
of	O
the	O
dosage	O
units	O
are	O
essentially	O
iron	O
-	O
free	O
and	O
wherein	O
the	O
total	O
amount	O
of	O
iron	O
in	O
the	O
package	O
as	O
sold	O
to	O
purchasers	O
is	O
less	O
than	O
about	O
1300	O
mg	O
of	O
elemental	O
iron	O
.	O

Alkaloid	O
aminoester	O
derivatives	O
and	O
medicinal	O
composition	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
alkaloid	O
aminoester	O
compounds	O
which	O
act	O
as	O
muscarinic	B
receptor	I
antagonists	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
comprising	O
them	O
,	O
and	O
therapeutic	O
uses	O
thereof	O
.	O

Cardenolides	O
for	O
the	O
treatment	O
of	O
ocular	O
cancer	O
The	O
instant	O
invention	O
provides	O
methods	O
of	O
using	O
a	O
class	O
of	O
compounds	O
known	O
as	O
cardenolides	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
.	O

In	O
particular	O
,	O
the	O
instant	O
invention	O
provides	O
methods	O
of	O
treating	O
ocular	O
cancer	O
{	O
e.g.	O
,	O
retinoblastoma	O
)	O
using	O
intraarterial	O
infusion	O
to	O
administer	O
cardenolides	O
locally	O
to	O
the	O
eye	O
of	O
a	O
subject	O
with	O
an	O
ocular	O
cancer	O
.	O

Novel	O
Saponin	O
Compounds	O
,	O
Methods	O
of	O
Preparation	O
Thereof	O
,	O
Use	O
Thereof	O
and	O
Pharmaceutical	O
Compositions	O

This	O
invention	O
relates	O
to	O
novel	O
saponin	O
compounds	O
of	O
formula	O
II	O
wherein	O
MBz	O
denotes	O
p	O
-	O
methoxybenzoyl	O
,	O
and	O
R	O
is	O
selected	O
from	O
the	O
group	O
comprising	O
C6	O
-	O
10	O
aryl	O
,	O
C6	O
-	O
10	O
aryl	O
-	O
C1	O
-	O
4	O
alkyl-	O
,	O
C1	O
-	O
18	O
alkanoyl	O
,	O
C3	O
-	O
18	O
alkenyl	O
,	O
C6	O
-	O
10	O
aryl	O
-	O
C	O
(	O
O	O
)	O
—	O
,	O
C6	O
-	O
10	O
aryl	O
-	O
C1	O
-	O
4	O
alkyl	O
-	O
C	O
(	O
O	O
)	O
—	O
,	O
wherein	O
each	O
of	O
the	O
groups	O
can	O
optionally	O
be	O
substituted	O
.	O

These	O
compounds	O
possess	O
a	O
selective	O
cytostatic	O
activity	O
,	O
useful	O
,	O
e.g.	O
,	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
preparation	O
of	O
the	O
novel	O
compounds	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
these	O
compounds	O
.	O

(	O
2-aryloxyacetylamino	O
)	O
phenylpropionic	O
acid	O
derivatives	O
,	O
processes	O
for	O
preparation	O
thereof	O
and	O
use	O
thereof	O
as	O
medicaments	O
The	O
invention	O
relates	O
to	O
substituted	O
(	O
2-aryloxyacetylamino	O
)	O
phenylpropionic	O
acid	O
derivatives	O
,	O
and	O
to	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
and	O
A	O
are	O
each	O
defined	O
as	O
specified	O
,	O
and	O
the	O
physiologically	O
compatible	O
salts	O
thereof	O
.	O

The	O
compounds	O
are	O
suitable	O
,	O
for	O
example	O
,	O
for	O
treatment	O
of	O
diabetes	O
.	O

Succinate	O
salt	O
of	O
(	O
2r	O
)	O
-methyl-1-piperazine	O
The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
which	O
are	O
therapeutically	O
active	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
one	O
aspect	O
,	O
the	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
HA	O
is	O
a	O
pharmaceutically	O
acceptable	O
acid	O
and	O
R1-R4	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
,	O
halogen	O
,	O
C1-C6-alkyl	O
,	O
C1-C6-alkoxy	O
,	O
and	O
di	O
-	O
C1-C6-alkylamino	O
-	O
C2-C6-alkoxy	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compound	O
to	O
manufacture	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
serotonin	O
-	O
related	O
disorder	O
.	O

Oligomer	O
-	O
Diarylpiperazine	O
Conjugates	O
The	O
invention	O
relates	O
to	O
(	O
among	O
other	O
things	O
)	O
oligomer	O
-	O
diarylpiperazine	O
conjugates	O
and	O
related	O
compounds	O
.	O

A	O
conjugate	O
of	O
the	O
invention	O
,	O
when	O
administered	O
by	O
any	O
of	O
a	O
number	O
of	O
administration	O
routes	O
,	O
exhibits	O
advantages	O
over	O
previously	O
administered	O
un	O
-	O
conjugated	O
diarylpiperazine	O
compounds	O
.	O

Rna	O
antagonist	O
compounds	O
for	O
the	O
inhibition	O
of	O
expression	O
of	O
mitochondrial	B
glycerol-3	I
phosphate	I
acyltransferase	I
1	I
(	O
mtgpat1	B
)	O
The	O
present	O
invention	O
relates	O
to	O
oligomer	O
compounds	O
(	O
oligomers	O
)	O
,	O
which	O
target	O
mtGPAT1mRNA	B
in	O
a	O
cell	O
,	O
leading	O
to	O
reduced	O
expression	O
of	O
mtGPAT1	B
.	O

Reduction	O
of	O
mtGPAT1	B
expression	O
is	O
beneficial	O
for	O
the	O
treatment	O
of	O
certain	O
medical	O
disorders	O
,	O
such	O
as	O
overweight	O
,	O
obesity	O
,	O
fatty	O
liver	O
,	O
hepatosteatosis	O
,	O
non	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
non	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
,	O
insulin	B
resistance	O
,	O
and	O
non	O
insulin	B
dependent	O
diabetes	O
mellitus	O
(	O
NIDDM	O
)	O
.	O

Treatment	O
of	O
delta	B
-	I
like	I
1	I
homolog	I
(	O
dlk1	B
)	O
related	O
diseases	O
by	O
inhibition	O
of	O
natural	O
antisense	O
transcript	O
to	O
dlk1	B
The	O
present	O
invention	O
relates	O
to	O
antisense	O
oligonucleotides	O
that	O
modulate	O
the	O
expression	O
of	O
and/or	O
function	O
of	O
Delta	B
-	I
like	I
(	I
1	I
)	I
homolog	I
(	O
DLK1	B
)	O
,	O
in	O
particular	O
,	O
by	O
targeting	O
natural	O
antisense	O
polynucleotides	O
of	O
Delta	B
-	I
like	I
(	I
1	I
)	I
homolog	I
(	O
DLK1	B
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
identification	O
of	O
these	O
antisense	O
oligonucleotides	O
and	O
their	O
use	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
the	O
expression	O
of	O
(	O
DLK1	B
)	O
.	O

Methods	O
and	O
compounds	O
for	O
treatment	O
of	O
neurodegenerative	O
disorders	O
Methods	O
,	O
compounds	O
and	O
compositions	O
for	O
promoting	O
motor	O
neuron	O
survival	O
and	O
the	O
treatment	O
of	O
a	O
neurodegenerative	O
disorders	O
such	O
as	O
Spinal	O
Muscular	O
Atrophy	O
(	O
SMA	O
)	O
are	O
described	O
herein	O
.	O

Method	O
of	O
mitigating	O
adverse	O
drug	O
events	O
using	O
omega-3	O
fatty	O
acids	O
as	O
a	O
parenteral	O
therapeutic	O
drug	O
vehicle	O
A	O
method	O
of	O
parenterally	O
administering	O
a	O
composition	O
,	O
the	O
method	O
including	O
parenterally	O
administering	O
to	O
a	O
person	O
a	O
composition	O
including	O
at	O
least	O
one	O
omega-3	O
fatty	O
acid	O
and	O
at	O
least	O
one	O
drug	O
,	O
wherein	O
the	O
at	O
least	O
one	O
omega-3	O
fatty	O
acid	O
source	O
and	O
the	O
at	O
least	O
one	O
drug	O
are	O
administered	O
simultaneously	O
.	O

Crystalline	O
forms	O
of	O
oxymorphone	O
hydrochloride	O
The	O
present	O
invention	O
is	O
directed	O
to	O
crystalline	O
forms	O
of	O
oxymorphone	O
hydrochloride	O
.	O

Pectin	O
-	O
containing	O
jelly	O
formulation	O
There	O
is	O
disclosed	O
a	O
technique	O
for	O
imparting	O
an	O
appropriate	O
rupture	O
strength	O
and	O
high	O
drug	O
-	O
release	O
properties	O
to	O
a	O
jelly	O
formulation	O
comprising	O
pectin	O
.	O

The	O
jelly	O
formulation	O
of	O
the	O
present	O
invention	O
comprises	O
a	O
drug	O
,	O
pectin	O
,	O
and	O
divalent	O
metal	O
ion	O
,	O
and	O
further	O
comprises	O
a	O
component	O
selected	O
from	O
sucrose	O
,	O
maltitol	O
and	O
C3-C4	O
alditols	O
,	O
and	O
a	O
component	O
selected	O
from	O
C5-C6	O
alditols	O
in	O
combination	O
.	O

Pharmaceutical	O
depot	O
for	O
5-fluoro-2-	O
[	O
[	O
(	O
1s	O
)	O
-1-	O
(	O
5-fluoro-2-pyridyl	O
)	O
ethyl	O
]	O
amino	O
]	O
-6-	O
[	O
(	O
5-isopropoxy-1h	O
-	O
pyrazol-3-yl	O
)	O
amino	O
]	O
pyridine-3-carbonitrile	O
A	O
pharmaceutical	O
depot	O
comprising	O
(	O
i	O
)	O
5-fluoro-2-	O
[	O
[	O
(	O
1S	O
)	O
-1-	O
(	O
5-fluoro-2-pyridyl	O
)	O
ethyl	O
]	O
amino	O
]	O
-6-	O
[	O
(	O
5-isopropoxy-1H	O
-	O
pyrazol-3-yl	O
)	O
amino	O
]	O
pyridine-3-carbonitrile	O
,	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
,	O
as	O
a	O
pharmaceutical	O
agent	O
(	O
PA	O
)	O
and	O
(	O
ii	O
)	O
a	O
polymer	O
which	O
degrades	O
to	O
create	O
an	O
acidic	O
microclimate	O
,	O
wherein	O
the	O
PA	O
is	O
released	O
from	O
the	O
polymer	O
upon	O
polymer	O
degradation	O
.	O

Low	O
-	O
dose	O
,	O
non	O
-	O
irritating	O
nicotine	O
nasal	O
composition	O
to	O
reduce	O
the	O
desire	O
to	O
smoke	O
A	O
composition	O
for	O
administration	O
to	O
the	O
nasal	O
mucosa	O
of	O
a	O
subject	O
comprises	O
a	O
solution	O
of	O
nicotine	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
a	O
pharmaceutically	O
acceptable	O
solvent	O
.	O

The	O
composition	O
has	O
a	O
nicotine	O
concentration	O
less	O
than	O
0.08	O
mg	O
/	O
ml	O
.	O

The	O
composition	O
used	O
alone	O
assists	O
in	O
reduction	O
of	O
the	O
desire	O
of	O
a	O
subject	O
to	O
smoke	O
tobacco	O
.	O

It	O
also	O
reduces	O
the	O
nasal	O
symptoms	O
associated	O
with	O
administration	O
of	O
higher	O
concentrations	O
of	O
nicotine	O
to	O
the	O
nasal	O
mucosa	O
.	O

Inhibitor	O
for	O
elevation	O
of	O
gip	B
level	O
Provided	O
is	O
a	O
GIP	B
-	O
increase	O
inhibitor	O
,	O
which	O
is	O
customary	O
used	O
for	O
food	O
production	O
,	O
is	O
excellent	O
in	O
safety	O
,	O
and	O
is	O
useful	O
for	O
,	O
for	O
example	O
,	O
a	O
medicine	O
or	O
a	O
food	O
.	O

The	O
GIP	B
-	O
increase	O
inhibitor	O
contains	O
catechins	O
as	O
active	O
ingredient	O
.	O

Use	O
of	O
bipolar	O
trans	O
carotenoids	O
as	O
a	O
pretreatment	O
and	O
in	O
the	O
treatment	O
of	O
peripheral	O
vascular	O
disease	O
The	O
subject	O
application	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
peripheral	O
vascular	O
disease	O
(	O
PVD	O
)	O
as	O
well	O
as	O
ischemic	O
osteonecrosis	O
,	O
peritoneal	O
ischemia	O
,	O
chronic	O
ocular	O
disease	O
,	O
macular	O
degeneration	O
,	O
or	O
diabetic	O
retinopathy	O
,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
trans	O
carotenoid	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
carotenoids	O
as	O
pretreatments	O
for	O
mammals	O
at	O
risk	O
of	O
an	O
ischemic	O
event	O
.	O

Cdk	B
inhibitor	O
salts	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
form	O
(	O
s	O
)	O
of	O
water	O
-	O
soluble	O
salts	O
and	O
of	O
free	O
base	O
of	O
a	O
cdk	B
inhibitor	O
.	O

Such	O
crystal	O
salts	O
are	O
for	O
example	O
fumarate	O
,	O
L	O
-	O
malate	O
,	O
maleate	O
,	O
succinate	O
,	O
adipate	O
,	O
malonate	O
,	O
glycolate	O
,	O
phosphate	O
,	O
mesylate	O
,	O
L	O
-	O
lactate	O
,	O
hydrochloride	O
,	O
di	O
-	O
hydrochloride	O
,	O
tri	O
-	O
hydrochloride	O
.	O

Hydrates	O
and	O
polymorphs	O
of	O
such	O
new	O
salt	O
forms	O
,	O
a	O
process	O
for	O
their	O
preparation	O
,	O
their	O
utility	O
in	O
therapy	O
and	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
claimed	O
and	O
described	O
in	O
the	O
present	O
application	O
.	O

Substituted	O
spirocyclic	O
amines	O
useful	O
as	O
antidiabetic	O
compounds	O
Substituted	O
spirocyclic	O
amines	O
of	O
structural	O
formula	O
I	O
are	O
selective	O
antagonists	O
of	O
the	O
somatostatin	B
sub	I
-	I
type	I
receptor	I
5	I
(	O
SSTR5	B
)	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
,	O
control	O
or	O
prevention	O
of	O
disorders	O
responsive	O
to	O
antagonism	O
of	O
SSTR5	B
,	O
such	O
as	O
Type	O
2	O
diabetes	O
,	O
insulin	B
resistance	O
,	O
lipid	O
disorders	O
,	O
obesity	O
,	O
atherosclerosis	O
,	O
metabolic	O
syndrome	O
,	O
depression	O
,	O
and	O
anxiety	O
.	O

Tapentadol	O
for	O
treating	O
pain	O
due	O
to	O
osteoarthritis	O
The	O
use	O
of	O
tapentadol	O
for	O
treating	O
pain	O
due	O
to	O
osteoarthritis	O
.	O

Formulation	O
of	O
a	O
mixture	O
of	O
free	O
-	O
b	O
-	O
ring	O
flavonoids	O
and	O
flavans	O
for	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
cognitive	O
decline	O
and	O
age	O
-	O
related	O
memory	O
impairments	O
The	O
present	O
invention	O
provides	O
a	O
novel	O
method	O
for	O
preventing	O
and	O
treating	O
memory	O
and	O
cognitive	O
impairment	O
resulting	O
from	O
oxidative	O
stress	O
,	O
inflammation	O
and	O
the	O
process	O
of	O
aging	O
,	O
as	O
well	O
as	O
,	O
neurodegenerative	O
conditions	O
.	O

The	O
method	O
is	O
comprised	O
of	O
administering	O
a	O
composition	O
comprising	O
a	O
mixture	O
of	O
Free	O
-	O
B	O
-	O
Ring	O
flavonoids	O
and	O
flavans	O
synthesized	O
and/or	O
isolated	O
from	O
a	O
single	O
plant	O
or	O
multiple	O
plants	O
to	O
a	O
host	O
in	O
need	O
thereof	O
.	O

The	O
present	O
also	O
includes	O
a	O
novel	O
method	O
for	O
simultaneously	O
inhibiting	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
preventing	O
ROS	O
generation	O
and	O
augmenting	O
anti	O
-	O
oxidant	O
defenses	O
.	O

The	O
activity	O
of	O
this	O
composition	O
is	O
conducive	O
to	O
ultimately	O
preserving	O
cognitive	O
function	O
and	O
providing	O
a	O
level	O
of	O
neuroprotection	O
.	O

Optically	O
active	O
pyrazolylaminoquinazoline	O
,	O
and	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
thereof	O
Provided	O
herein	O
is	O
an	O
optically	O
active	O
pyrozolylaminoquinazaline	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

Also	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
JAK	B
-	O
mediated	O
condition	O
,	O
disorder	O
,	O
or	O
disease	O
.	O

Further	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
proliferative	O
disease	O
,	O
inflammatory	O
disease	O
,	O
or	O
renal	O
disease	O
.	O

Bace	O
2	O
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
N-1-Benzyl-2-hydroxy-3-	O
(	O
hetero	O
)	O
arylamino	O
-	O
propyl	O
)	O
-isophthalamides	O
of	O
formula	O
I	O
having	O
BACE2	O
inhibitory	O
activity	O
and	O
their	O
use	O
as	O
therapeutically	O
active	O
substances	O
,	O
their	O
manufacture	O
and	O
pharmaceutical	O
compositions	O
.	O

The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
therapeutic	O
and/or	O
prophylactic	O
treatment	O
of	O
e.g.	O
type	O
2	O
diabetes	O
.	O

Slow	O
-	O
degrading	O
polymers	O
for	O
undelayed	O
and	O
sustained	O
drug	O
delivery	O
The	O
invention	O
provides	O
polymers	O
and	O
methods	O
for	O
their	O
use	O
.	O

Certain	O
embodiments	O
of	O
the	O
invention	O
provide	O
slow	O
degrading	O
microspheres	O
for	O
undelayed	O
and	O
sustained	O
drug	O
delivery	O
.	O

Ipp	B
complex	O
as	O
marker	O
for	O
erlotinib	O
treatment	O
The	O
present	O
invention	O
provides	O
biomarkers	O
which	O
are	O
predictive	O
for	O
the	O
clinical	O
benefit	O
of	O
erlotinib	O
hydrochloride	O
treatment	O
in	O
cancer	O
patients	O
.	O

Methods	O
and	O
compositions	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
mapk	B
)	O
pathway	O
inhibitors	O
for	O
treating	O
pulmonary	O
fibrosis	O
Methods	O
and	O
compositions	O
of	O
inhibitors	O
of	O
MAPK	B
kinases	I
1	I
and	I
2	I
(	O
MEK1	B
and	O
MEK2	B
,	O
or	O
together	O
,	O
MEK1	B
/	I
2	I
)	O
,	O
such	O
as	O
ARRY142886	O
,	O
and	O
their	O
use	O
in	O
inhibiting	O
MEK1	B
/	I
2	I
kinase	B
activity	O
in	O
mammals	O
for	O
the	O
treatment	O
and/or	O
reversal	O
of	O
the	O
symptoms	O
of	O
pulmonary	O
fibrosis	O
.	O

MEK1	B
/	I
2	I
inhibitors	O
can	O
selectively	O
inhibit	O
the	O
MAPK	B
/	O
ERK	B
pathway	O
in	O
vivo	O
and	O
prevent	O
TGF	B
-	I
α	I
mediated	O
fibrosis	O
.	O

There	O
are	O
several	O
distinct	O
MAPK	B
pathways	O
that	O
are	O
important	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
development	O
,	O
inflammation	O
,	O
survival	O
,	O
and	O
migration	O
.	O

The	O
Ras	B
-	O
Raf	B
-	O
MEK	B
-	O
ERK	B
pathway	O
(	O
a	O
key	O
component	O
of	O
the	O
MAPK	B
pathway	O
)	O
via	O
inhibition	O
of	O
MEK1	B
/	I
2	I
is	O
an	O
attractive	O
strategy	O
for	O
therapeutic	O
intervention	O
in	O
idiopathic	O
pulmonary	O
fibrosis	O
,	O
because	O
inhibition	O
of	O
MEK1	B
/	I
2	I
has	O
the	O
potential	O
to	O
block	O
inappropriate	O
signal	O
transduction	O
leading	O
to	O
pulmonary	O
fibrosis	O
,	O
regardless	O
of	O
the	O
upstream	O
position	O
of	O
the	O
aberration	O
causing	O
it	O
.	O

Tricyclic	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
I	O
:	O
or	O
salt	O
thereof	O
,	O
which	O
are	O
modulators	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O

The	O
compounds	O
and	O
salts	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
glucocorticoid	B
receptor	I
activity	O
.	O

Imidazo	O
[	O
1,2	O
a	O
]	O
pyridine	O
6	O
carboxamide	O
derivatives	O
,	O
their	O
use	O
for	O
the	O
treatment	O
of	O
colon	O
cancer	O
and	O
their	O
method	O
of	O
manufacture	O
This	O
invention	O
relates	O
to	O
the	O
manufacture	O
of	O
novel	O
chemical	O
compounds	O
which	O
have	O
biological	O
activity	O
,	O
particularly	O
to	O
novel	O
chemical	O
compounds	O
that	O
are	O
cytotoxic	O
against	O
colon	O
cancer	O
cells	O
and	O
colon	O
cancer	O
cell	O
lines	O
.	O

The	O
manufacturing	O
of	O
said	O
chemical	O
compounds	O
displaying	O
anti	O
-	O
cancer	O
properties	O
employs	O
the	O
use	O
of	O
multi	O
-	O
component	O
chemical	O
reactions	O
.	O

The	O
object	O
of	O
this	O
invention	O
is	O
to	O
manufacture	O
and	O
isolate	O
analogues	O
of	O
imidazo	O
[	O
1,2-a	O
]	O
pyridine	O
,	O
namely	O
compounds	O
of	O
Formula	O
1	O
,	O
which	O
are	O
cytotoxic	O
against	O
colon	O
cancer	O
cells	O
,	O
while	O
concomitantly	O
being	O
relatively	O
inactive	O
against	O
white	O
blood	O
cells	O
.	O

wherein	O
,	O
R	O
is	O
bromo	O
,	O
methyl	O
,	O
phenyl	O
,	O
nitro	O
,	O
hydrogen	O
or	O
an	O
amide	O
functional	O
group	O
;	O
R1	O
is	O
benzyl	O
,	O
2,6-dimethylphenyl	O
or	O
cyclohexyl	O
;	O
and	O
R2	O
is	O
methoxy	O
,	O
benzyloxy	O
or	O
hydroxy	O
.	O

Aminotetrahydroindazoloacetic	O
Acids	O
The	O
invention	O
is	O
concerned	O
with	O
the	O
compounds	O
of	O
formula	O
I	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
,	O
wherein	O
Q	O
,	O
W	O
,	O
X	O
,	O
R1-R5	O
and	O
n	O
are	O
defined	O
in	O
the	O
detailed	O
description	O
and	O
claims	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
manufacturing	O
and	O
using	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
antagonists	O
at	O
the	O
CRTH2	B
receptor	O
and	O
may	O
be	O
useful	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
that	O
receptor	O
such	O
as	O
asthma	O
.	O

5-membered	O
heteroaryl	O
derivatives	O
used	O
as	O
sphingosine	O
1-	O
phosphate	O
receptor	O
agonists	O
5-membered	O
heteroaryl	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
or	O
salts	O
thereof	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
mediated	O
by	O
S1P1	O
receptors	O
are	O
disclosed	O
.	O

Ready	O
to	O
Use	O
Ketorolac	O
Formulations	O
Disclosed	O
in	O
certain	O
embodiments	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
parenteral	O
administration	O
comprising	O
:	O
an	O
aqueous	O
solution	O
comprising	O
ketorolac	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
an	O
amount	O
from	O
about	O
0.1	O
mg	O
/	O
mL	O
to	O
about	O
10	O
mg	O
/	O
mL	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
;	O
wherein	O
the	O
formulation	O
is	O
substantially	O
free	O
of	O
alcohol	O
.	O

Synergistic	O
treatment	O
of	O
cancer	O
using	O
immunomers	O
in	O
conjunction	O
with	O
chemotherapeutic	O
agents	O
The	O
invention	O
relates	O
to	O
the	O
therapeutic	O
use	O
of	O
immunostimulatory	O
oligonucleotides	O
and/or	O
immunomers	O
in	O
combination	O
with	O
chemotherapeutic	O
agents	O
to	O
provide	O
a	O
synergistic	O
therapeutic	O
effect	O
.	O

Gene	O
expression	O
levels	O
of	O
egfr	B
,	O
vegfr2	B
,	O
and	O
ercc1	B
associated	O
with	O
clinical	O
outcomes	O
of	O
chemotherapy	O
The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
identifying	O
a	O
cancer	O
patient	O
suitable	O
for	O
anti	O
-	O
VEGF	B
therapy	O
.	O

After	O
determining	O
if	O
a	O
patient	O
is	O
likely	O
to	O
be	O
successfully	O
treated	O
,	O
the	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
the	O
patients	O
.	O

Product	O
for	O
the	O
preparation	O
of	O
dermatological	O
,	O
cosmetic	O
or	O
cosmeceutical	O
compositions	O
intended	O
for	O
skin	O
treatment	O
The	O
present	O
invention	O
relates	O
to	O
a	O
product	O
obtained	O
from	O
gastropod	O
spawn	O
,	O
to	O
be	O
used	O
to	O
prepare	O
dermatological	O
,	O
cosmetic	O
or	O
cosmeceutical	O
compositions	O
designed	O
for	O
skin	O
care	O
;	O
said	O
product	O
has	O
the	O
capacity	O
to	O
activate	O
and	O
mobilise	O
skin	O
stem	O
cells	O
,	O
as	O
well	O
as	O
prevent	O
the	O
loss	O
thereof	O
that	O
takes	O
place	O
as	O
a	O
consequence	O
of	O
chronological	O
and	O
premature	O
ageing	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
process	O
followed	O
in	O
order	O
to	O
obtain	O
said	O
product	O
.	O

Effective	O
Antitumor	O
Treatments	O
ET-743	O
is	O
used	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
an	O
effective	O
treatment	O
of	O
a	O
tumour	O
by	O
combination	O
therapy	O
employing	O
ET-743	O
with	O
another	O
drug	O
.	O

Transdermal	O
delivery	O
of	O
beneficial	O
substances	O
effected	O
by	O
a	O
hostile	O
biophysical	O
environment	O
The	O
present	O
invention	O
generally	O
relates	O
to	O
the	O
transdermal	O
delivery	O
of	O
substances	O
In	O
one	O
aspect	O
,	O
various	O
methods	O
for	O
the	O
transdermal	O
delivery	O
of	O
beneficial	O
substances	O
are	O
disclosed	O
.	O

By	O
creating	O
a	O
hostile	O
biophysical	O
environment	O
,	O
beneficial	O
substances	O
may	O
be	O
delivered	O
,	O
according	O
to	O
certain	O
embodiments	O
,	O
through	O
the	O
stratum	O
corneum	O
of	O
the	O
skin	O
into	O
the	O
body	O
.	O

Beneficial	O
substances	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
pharmaceutical	O
agents	O
,	O
drugs	O
,	O
vitamins	O
,	O
co	O
-	O
factors	O
,	O
peptides	O
,	O
dietary	O
supplements	O
,	O
and	O
others	O
.	O

The	O
beneficial	O
effects	O
disclosed	O
include	O
,	O
for	O
instance	O
,	O
relief	O
of	O
pain	O
and	O
inflammation	O
,	O
prevention	O
and	O
healing	O
of	O
ulcers	O
of	O
the	O
skin	O
,	O
relief	O
of	O
headache	O
,	O
improved	O
sexual	O
function	O
and	O
enjoyment	O
,	O
growth	O
of	O
hair	O
on	O
the	O
scalp	O
,	O
improving	O
muscle	O
size	O
and/or	O
function	O
,	O
removing	O
body	O
fat	O
and/or	O
cellulite	O
,	O
treating	O
cancer	O
,	O
treating	O
viral	O
infections	O
and	O
others	O
.	O

A	O
hostile	O
biophysical	O
environment	O
may	O
also	O
be	O
used	O
in	O
conjunction	O
with	O
systems	O
and	O
methods	O
for	O
increasing	O
local	O
blood	O
flow	O
,	O
according	O
to	O
one	O
set	O
of	O
embodiments	O
.	O

Low	O
molecular	O
weight	O
cyclin	O
e	O
(	O
lmw	O
-	O
e	O
)	O
as	O
a	O
biomarker	O
for	O
personalization	O
of	O
cancer	O
therapies	O
Methods	O
are	O
disclosed	O
for	O
predicting	O
a	O
patient	O
response	O
to	O
anti	O
-	O
Her2	O
therapy	O
or	O
anti	O
-	O
aromatase	O
therapy	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
methods	O
involve	O
the	O
identification	O
of	O
low	O
molecular	O
weight	O
cyclin	O
E	O
(	O
LMW	O
-	O
E	O
)	O
in	O
cancers	O
,	O
such	O
as	O
breast	O
cancer	O
cells	O
,	O
as	O
a	O
predictive	O
and	O
prognostic	O
marker	O
.	O

In	O
further	O
embodiments	O
,	O
LMW	O
-	O
E	O
expression	O
by	O
a	O
cancerous	O
or	O
pre	O
-	O
cancerous	O
cell	O
may	O
be	O
used	O
to	O
predict	O
response	O
to	O
an	O
aromatase	O
inhibitor	O
and/or	O
CDK2	O
inhibitor	O
,	O
and	O
determination	O
of	O
LMW	O
-	O
E	O
expression	O
may	O
be	O
used	O
in	O
the	O
personalization	O
of	O
cancer	O
therapies	O
.	O

Compound	O
inhibiting	O
in	O
vivo	O
phosphorus	O
transport	O
and	O
medicine	O
containing	O
the	O
same	O
An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
compounds	O
that	O
can	O
effectively	O
suppress	O
the	O
concentration	O
of	O
phosphorus	O
in	O
serum	O
to	O
effectively	O
prevent	O
or	O
treat	O
diseases	O
induced	O
by	O
an	O
increase	O
in	O
concentration	O
of	O
phosphate	O
in	O
serum	O
.	O

The	O
compounds	O
according	O
to	O
the	O
present	O
invention	O
are	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
:	O
wherein	O
A	O
represents	O
an	O
optionally	O
substituted	O
five-	O
to	O
nine	O
-	O
membered	O
unsaturated	O
carbocyclic	O
moiety	O
or	O
a	O
five-	O
to	O
nine	O
-	O
membered	O
unsaturated	O
heterocyclic	O
moiety	O
,	O
and	O
represents	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
,	O
R5	O
represents	O
optionally	O
substituted	O
aryl	O
or	O
the	O
like	O
,	O
Z	O
represents	O
—N	O
═	O
CHR6R7	O
or	O
the	O
like	O
,	O
R6	O
and	O
R7	O
represent	O
H	O
,	O
optionally	O
substituted	O
alkyl	O
,	O
optionally	O
substituted	O
aryl	O
or	O
the	O
like	O
,	O
R101	O
and	O
R102	O
together	O
form	O
═	O
O	O
,	O
and	O
R103	O
and	O
R104	O
represent	O
H	O
,	O
or	O
R101	O
and	O
R104	O
together	O
from	O
a	O
bond	O
,	O
and	O
R102	O
and	O
R103	O
together	O
form	O
a	O
bond	O
.	O

Facially	O
Amphiphilic	O
Compounds	O
,	O
Compositions	O
,	O
And	O

Uses	O
Thereof	O

In	O
Treating	O
Cancer	O
The	O
present	O
invention	O
discloses	O
compositions	O
of	O
facially	O
amphiphilic	O
compounds	O
and	O
their	O
use	O
in	O
methods	O
for	O
treating	O
or	O
reducing	O
cancers	O
in	O
animals	O
,	O
such	O
as	O
humans	O
.	O

Quinolinone	O
PDE2	B
Inhibitors	O
The	O
present	O
invention	O
is	O
directed	O
to	O
quinolinone	O
compounds	O
which	O
are	O
useful	O
as	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
disorders	O
associated	O
with	O
phosphodiesterase	B
2	I
(	O
PDE2	B
)	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
treating	O
neurological	O
and	O
psychiatric	O
disorders	O
,	O
such	O
as	O
schizophrenia	O
,	O
psychosis	O
or	O
Huntington	O
's	O
disease	O
,	O
and	O
those	O
associated	O
with	O
striatal	O
hypofunction	O
or	O
basal	O
ganglia	O
dysfunction	O
.	O

Isogenic	O
human	O
cell	O
lines	O
comprising	O
mutated	O
cancer	O
alleles	O
and	O
process	O
using	O
the	O
cell	O
lines	O
Isogenic	O
human	O
cell	O
lines	O
comprising	O
at	O
least	O
one	O
mutated	O
cancer	O
allele	O
under	O
the	O
control	O
of	O
the	O
cell	O
line	O
endogenous	O
promoter	O
,	O
which	O
corresponds	O
to	O
the	O
wild	O
-	O
type	O
cancer	O
allele	O
promoter	O
are	O
disclosed	O
,	O
as	O
well	O
as	O
an	O
in	O
vitro	O
process	O
for	O
determining	O
sensitivity	O
/	O
resistance	O
of	O
a	O
patient	O
suffering	O
from	O
a	O
tumor	O
to	O
a	O
pharmacological	O
agent	O
comprising	O
the	O
following	O
steps	O
:	O
a	O
)	O
identifying	O
at	O
least	O
one	O
mutated	O
cancer	O
allele	O
in	O
a	O
tissue	O
affected	O
by	O
a	O
tumor	O
of	O
said	O
patient	O
;	O
b	O
)	O
providing	O
an	O
isogenic	O
human	O
cell	O
line	O
representative	O
of	O
the	O
tissue	O
,	O
wherein	O
the	O
cell	O
line	O
comprises	O
at	O
least	O
the	O
identified	O
mutated	O
cancer	O
allele	O
,	O
which	O
is	O
under	O
the	O
control	O
of	O
the	O
cell	O
line	O
endogenous	O
promoter	O
corresponding	O
to	O
the	O
wild	O
-	O
type	O
cancer	O
allele	O
promoter	O
;	O
c	O
)	O
putting	O
in	O
contact	O
said	O
cell	O
line	O
with	O
the	O
pharmacological	O
agent	O
;	O
d	O
)	O
determining	O
a	O
variation	O
of	O
proliferation	O
,	O
apoptosis	O
or	O
cytotoxicity	O
of	O
the	O
cell	O
line	O
in	O
presence	O
of	O
the	O
pharmacological	O
agent	O
;	O
wherein	O
the	O
variation	O
of	O
proliferation	O
,	O
apoptosis	O
car	O
cytotoxicity	O
indicative	O
of	O
the	O
sensitivity	O
/	O
resistance	O
of	O
the	O
patient	O
tumor	O
to	O
the	O
pharmacological	O
agent	O
.	O

PAR-1	B
Activation	O
by	O
Metalloproteinase-1	B
(	O
MMP-1	B
)	O
Matrix	B
metalloproteases	I
(	O
MMPs	B
)	O
play	O
many	O
important	O
roles	O
in	O
normal	O
and	O
pathological	O
remodeling	O
processes	O
including	O
atherothrombotic	O
disease	O
,	O
inflammation	O
,	O
angiogenesis	O
and	O
cancer	O
.	O

This	O
invention	O
relates	O
to	O
the	O
activation	O
of	O
protease	B
-	I
activated	I
receptor-1	I
(	O
PAR-1	B
)	O
by	O
endogenous	O
platelet	O
MMP-1	B
collagenase	B
on	O
the	O
surface	O
of	O
platelets	O
.	O

Exposure	O
of	O
platelets	O
to	O
fibrillar	O
collagen	O
converts	O
the	O
surface	O
-	O
bound	O
pro	B
-	I
MMP-1	I
zymogen	O
to	O
active	O
MMP-1	B
,	O
which	O
promotes	O
aggregation	O
through	O
PAR-1	B
,	O
MMP-1	B
is	O
shown	O
to	O
cleave	O
the	O
PAR-1	B
extracellular	I
domain	I
at	O
a	O
novel	O
site	O
,	O
which	O
then	O
strongly	O
activates	O
Rho	B
-	O
GTP	O
signaling	O
pathways	O
,	O
cell	O
shape	O
change	O
and	O
motility	O
,	O
and	O
MAPK	B
signaling	O
.	O

Blockade	O
of	O
MMP	B
-	O
PAR	B
1	I
suppresses	O
thrombogenesis	O
under	O
arterial	O
flow	O
conditions	O
and	O
inhibited	O
thrombosis	O
in	O
animals	O
.	O

These	O
studies	O
provide	O
a	O
link	O
between	O
matrix	O
-	O
dependent	O
activation	O
of	O
metalloproteases	B
and	O
platelet	O
-	O
G	B
protein	I
signaling	O
and	O
identify	O
MMP-1	B
/	O
PAR-1	B
as	O
a	O
new	O
target	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
arterial	O
thrombosis	O
and	O
other	O
thrombotic	O
diseases	O
.	O

Biomarkers	O
Related	O
to	O
Insulin	B
Resistance	O
and	O
Methods	O
using	O
the	O
Same	O
Biomarkers	O
relating	O
to	O
glucose	O
disposal	O
rate	O
,	O
insulin	B
resistance	O
,	O
and/or	O
insulin	B
resistance	O
-	O
related	O
disorders	O
are	O
provided	O
.	O

Methods	O
based	O
on	O
the	O
same	O
biomarkers	O
are	O
also	O
provided	O
.	O

Compositions	O
and	O
methods	O
for	O
modulating	O
d1-d2	B
dopamine	I
receptor	I
interaction	O
and	O
function	O
The	O
present	O
invention	O
provides	O
for	O
prevention	O
and/or	O
treatment	O
of	O
neurological	O
or	O
neuropsychiatric	O
disorders	O
involving	O
abnormal	O
D1-D2	B
dopamine	I
receptor	I
coupling	O
and/or	O
activation	O
.	O

Methods	O
and	O
agents	O
are	O
provided	O
for	O
modulating	O
dopamine	O
receptor	O
function	O
arising	O
from	O
D1-D2	B
coupling	O
and/or	O
activation	O
.	O

Agents	O
of	O
the	O
present	O
invention	O
include	O
fragments	O
of	O
D2	B
receptor	I
or	O
D1	B
receptor	I
that	O
can	O
disrupt	O
D1-D2	B
coupling	O
.	O

(	O
s	O
)	O
-n	O
-	O
methylnaltrexone	O

This	O
invention	O
relates	O
to	O
S	O
-	O
MNTX	O
,	O
methods	O
of	O
producing	O
S	O
-	O
MNTX	O
,	O
pharmaceutical	O
preparations	O
comprising	O
S	O
-	O
MNTX	O
and	O
methods	O
for	O
their	O
use	O
.	O

Small	O
Molecule	O
Antagonists	O
of	O
Phosphatidylinositol-3,4,5-Triphosphate	O
(	O
PIP3	O
)	O
and	O
Uses	O
Thereof	O
Disclosed	O
are	O
a	O
new	O
class	O
of	O
non	O
-	O
lipid	O
small	O
molecule	O
inhibitors	O
which	O
interfere	O
with	O
the	O
interaction	O
between	O
PIP3	O
and	O
pleckstrin	O
homology	O
domains	O
.	O

These	O
molecules	O
target	O
a	O
broad	O
range	O
of	O
PIP3-dependent	O
signaling	O
events	O
in	O
vitro	O
and	O
exert	O
significant	O
anti	O
-	O
tumor	O
activity	O
in	O
vivo	O
.	O

The	O
small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
can	O
be	O
used	O
alone	O
or	O
together	O
with	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
-related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
or	O
other	O
cancer	O
medicament	O
to	O
treat	O
cancer	O
.	O

Small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
act	O
synergistically	O
in	O
combination	O
with	O
TRAIL	O
in	O
treating	O
cancer	O
.	O

Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
cancer	O
are	O
provided	O
.	O

Topical	O
,	O
periocular	O
,	O
or	O
intraocular	O
use	O
of	O
tocotrienols	O
for	O
the	O
treatment	O
of	O
ophthalmic	O
diseases	O
A	O
method	O
for	O
preventing	O
,	O
reducing	O
,	O
ameliorating	O
or	O
treating	O
ophthalmic	O
disorders	O
associated	O
with	O
neurodegenerative	O
diseases	O
or	O
trauma	O
,	O
comprising	O
the	O
topical	O
,	O
periocular	O
,	O
or	O
intraocular	O
application	O
of	O
an	O
ophthalmic	O
formulation	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
ophthalmic	O
agents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alpha	O
-	O
tocotrienol	O
,	O
beta	O
-	O
tocotrienol	O
,	O
gamma	O
-	O
tocotrienol	O
,	O
delta	O
-	O
tocotrienol	O
,	O
or	O
esters	O
or	O
mixtures	O
thereof	O
is	O
disclosed	O
.	O

Use	O
of	O
tocotrienols	O
for	O
the	O
prevention	O
,	O
reduction	O
,	O
amelioration	O
or	O
treatment	O
of	O
ophthalmic	O
disorders	O
that	O
are	O
,	O
or	O
that	O
are	O
associated	O
with	O
,	O
mitochondrial	O
diseases	O
is	O
also	O
discussed	O
.	O

Topical	O
ophthalmic	O
formulations	O
comprising	O
tocotrienols	O
are	O
also	O
discussed	O
.	O

Method	O
and	O
Pharmaceutical	O
Composition	O
for	O
Use	O
in	O
the	O
Treatment	O
of	O
Neurodegenerative	O
Disorders	O
The	O
invention	O
relates	O
to	O
compounds	O
which	O
activate	O
the	O
BASIGIN	O
signaling	O
pathway	O
,	O
preferably	O
agonists	O
of	O
BASIGIN	O
,	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O

Microcapsules	O
containing	O
salts	O
for	O
food	O
products	O
A	O
composition	O
for	O
delivering	O
edible	O
salts	O
into	O
food	O
products	O
via	O
microcapsules	O
having	O
a	O
protein	O
-	O
polysaccharide	O
shell	O
matrix	O
and	O
an	O
edible	O
salt	O
-	O
containing	O
active	O
material	O
.	O

A	O
method	O
of	O
treating	O
osteoporosis	O
is	O
also	O
disclosed	O
.	O

Compositions	O
for	O
Inhibiting	O
Growth	O
of	O
Cancer	O
Stem	O
Cells	O

The	O
present	O
invention	O
is	O
a	O
biomarker	O
of	O
chemotherapeutic	O
drug	O
-	O
resistant	O
cancer	O
stem	O
cells	O
and	O
a	O
method	O
of	O
inhibiting	O
the	O
growth	O
of	O
drug	O
-	O
resistant	O
cancer	O
stem	O
cells	O
.	O

In	O
one	O
embodiment	O
the	O
cancer	O
stem	O
cells	O
are	O
testicular	O
cancer	O
germ	O
cells	O
.	O

In	O
another	O
embodiment	O
the	O
present	O
invention	O
is	O
a	O
method	O
of	O
overcoming	O
drug	O
resistance	O
in	O
cancer	O
treatment	O
where	O
the	O
combination	O
of	O
low	O
dose	O
decitabine	O
and	O
administration	O
of	O
a	O
chemotherapeutic	O
drug	O
to	O
which	O
cancer	O
cells	O
were	O
resistant	O
results	O
in	O
successful	O
cancer	O
treatment	O
.	O

Homeopathic	O
Formulations	O
For	O
Treatment	O
Of	O
Herpes	O
Virus	O
Symptoms	O
Compositions	O
and	O
methods	O
of	O
preparing	O
and	O
using	O
such	O
compositions	O
to	O
treat	O
the	O
symptoms	O
of	O
herpes	O
virus	O
.	O

Methods	O
for	O
treating	O
cancer	O
and	O
non	O
-	O
neoplastic	O
conditions	O
Compounds	O
that	O
selectively	O
inhibit	O
pathological	O
production	O
of	O
human	B
vascular	I
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O

Compounds	O
that	O
inhibit	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
reducing	O
VEGF	B
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
non	O
-	O
neoplastic	O
conditions	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O

Further	O
described	O
are	O
methods	O
of	O
inhibiting	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
viral	O
infections	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O

The	O
Compounds	O
may	O
be	O
administered	O
as	O
a	O
single	O
agent	O
therapy	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
additional	O
therapies	O
to	O
a	O
human	O
in	O
need	O
of	O
such	O
treatments	O
.	O

Tricyclic	O
and	O
Tetracyclic	O
Systems	O
with	O
Activity	O
on	O
the	O
Central	O
Nervous	O
and	O
Vascular	O
Systems	O

The	O
present	O
invention	O
relates	O
to	O
chemistry	O
and	O
pharmacy	O
and	O
,	O
in	O
particular	O
,	O
to	O
the	O
production	O
of	O
novel	O
molecular	O
entities	O
,	O
tricyclic	O
and	O
tetracyclic	O
derivatives	O
of	O
benzodiazepine	O
,	O
pyridodiazepine	O
and	O
pyrimidodiazepine	O
type	O
fused	O
with	O
1,4-dihydropyridine	O
derivatives	O
,	O
having	O
an	O
effect	O
on	O
the	O
central	O
-	O
nervous	O
and	O
vascular	O
systems	O
.	O

Derivatives	O
containing	O
a	O
dihydropyridine	O
ring	O
are	O
used	O
,	O
by	O
means	O
of	O
reactions	O
with	O
compounds	O
of	O
the	O
ortho	O
-	O
phenylenediamine	O
,	O
ortho	O
-	O
diaminopyridine	O
and	O
ortho	O
-	O
diaminopyrimidine	O
type	O
,	O
and	O
also	O
subsequent	O
conversions	O
to	O
some	O
thereof	O
,	O
to	O
obtain	O
tricyclic	O
and	O
tetracyclic	O
derivatives	O
of	O
general	O
formula	O
I	O
-	O
XII	O
that	O
contain	O
a	O
diazepine	O
or	O
diazepinone	O
nucleus	O
fused	O
to	O
a	O
1,4-dihydropyridine	O
nucleus	O
,	O
in	O
which	O
the	O
A	O
ring	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
benzene	O
,	O
pyridine	O
or	O
pyrimidine	O
ring	O
.	O

These	O
molecular	O
entities	O
exhibit	O
GABAergica	O
and	O
modulating	O
action	O
in	O
the	O
case	O
of	O
calcium	O
channels	O
which	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
cardiovascular	O
,	O
cerebrovascular	O
,	O
neurodegenerative	O
,	O
neuropsychiatric	O
and	O
neurological	O
disorders	O
.	O

Combination	O
therapy	O
using	O
a	O
beta	B
3	I
adrenergic	I
receptor	I
agonists	O
and	O
an	O
antimuscarinic	O
agent	O
Described	O
herein	O
is	O
an	O
improved	O
method	O
of	O
treating	O
overactive	O
bladder	O
,	O
wherein	O
the	O
method	O
comprises	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
beta	B
3	I
adrenergic	I
receptor	I
agonist	O
,	O
an	O
antimuscarinic	O
agent	O
,	O
and	O
an	O
optional	O
selective	O
M2	B
antagonist	O
.	O

Such	O
combination	O
therapy	O
provides	O
improved	O
efficacy	O
and/or	O
reduced	O
side	O
effects	O
.	O

Novel	O
Tetrahydroisoquinoline	O
Compounds	O
The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
having	O
an	O
excellent	O
DGAT	B
inhibitory	O
effect	O
and	O
feeding	O
suppressant	O
effect	O
.	O

The	O
present	O
invention	O
provides	O
trans-6-	O
[	O
3-	O
(	O
2,4-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2-chloro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2,3-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2,5-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
trans-6-	O
[	O
3-	O
(	O
2,6-difluoro	O
-	O
phenyl	O
)	O
-ureido	O
]	O
-3,4-dihydro-1H	O
-	O
isoquinoline-2-carboxylic	O
acid	O
4-carboxymethyl	O
-	O
cyclohexyl	O
ester	O
,	O
or	O
the	O
like	O
,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Selenium	O
Nanoparticles	O
with	O
Improvded	O
Biological	O
Effects	O
Novel	O
methods	O
for	O
biological	O
effective	O
,	O
stable	O
amorphous	O
and	O
monoclinic	O
selenium	O
nanoparticles	O
are	O
disclosed	O
.	O

They	O
are	O
prepared	O
by	O
reacting	O
selenium	O
source	O
with	O
a	O
reducing	O
agent	O
or	O
an	O
oxidative	O
agent	O
in	O
an	O
aqueous	O
media	O
at	O
a	O
temperature	O
between	O
0	O
-	O
100	O
°	O
C.	O
in	O
the	O
presence	O
of	O
selenium	O
binding	O
polymer	O
molecules	O
such	O
as	O
poly	O
/	O
oligopeptide	O
acids	O
or	O
peptone	O
or	O
nucleic	O
acids	O
or	O
poly	O
/	O
oligosaccharide	O
or	O
their	O
mixtures	O
.	O

Methods	O
of	O
treating	O
or	O
preventing	O
influenza	O
associated	O
illness	O
with	O
oxidative	O
reductive	O
potential	O
water	O
solutions	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
,	O
reducing	O
,	O
and/or	O
preventing	O
the	O
incidence	O
of	O
an	O
influenza	O
related	O
viral	O
infection	O
in	O
a	O
patient	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
oxidative	O
reductive	O
potential	O
(	O
ORP	O
)	O
water	O
solution	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
reducing	O
or	O
preventing	O
the	O
incidence	O
of	O
an	O
influenza	O
related	O
viral	O
infection	O
in	O
a	O
patient	O
associated	O
with	O
a	O
medical	O
device	O
comprising	O
contacting	O
the	O
medical	O
device	O
with	O
an	O
effective	O
amount	O
of	O
an	O
ORP	O
water	O
solution	O
.	O

Versatile	O
nanoparticulate	O
biomaterial	O
for	O
controlled	O
delivery	O
and/or	O
containment	O
of	O
therapeutic	O
and	O
diagnostic	O
material	O
The	O
invention	O
provides	O
compositions	O
for	O
controlled	O
delivery	O
and/or	O
containment	O
of	O
therapeutic	O
and/or	O
diagnostic	O
agents	O
comprising	O
the	O
agent	O
or	O
agents	O
encapsulated	O
by	O
a	O
matrix	O
containing	O
chitosan	O
,	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
and/or	O
polyvinyl	O
alcohol	O
(	O
PVA	O
)	O
,	O
and	O
tetra	O
-	O
methoxy	O
-	O
ortho	O
-	O
silicate	O
(	O
TMOS	O
)	O
or	O
tetra	O
-	O
ethoxy	O
-	O
ortho	O
-	O
silicate	O
(	O
TEOS	O
)	O
,	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
the	O
compositions	O
,	O
and	O
uses	O
of	O
the	O
compositions	O
for	O
therapy	O
and	O
imaging	O
.	O

Compositions	O
of	O
omega	O
fatty	O
acids	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
dental	O
caries	O
resulting	O
from	O
oral	O
infections	O
The	O
present	O
invention	O
discloses	O
compositions	O
of	O
omega	O
polyunsaturated	O
fatty	O
acids	O
for	O
controlling	O
and	O
preventing	O
dental	O
caries	O
resulting	O
from	O
oral	O
infections	O
.	O

The	O
compositions	O
of	O
fatty	O
acids	O
include	O
omega-3	O
fatty	O
acids	O
,	O
omega-6	O
fatty	O
acids	O
,	O
and	O
other	O
fatty	O
acids	O
,	O
for	O
their	O
synergistic	O
bioactivity	O
against	O
cariogenic	O
pathogens	O
.	O

The	O
application	O
of	O
this	O
composition	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
drugs	O
,	O
nutritional	O
supplements	O
,	O
food	O
and	O
daily	O
necessities	O
with	O
oral	O
health	O
care	O
and	O
therapeutic	O
effects	O
.	O

Proteostasis	O
regulators	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formulae	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
,	O
(	O
V	O
)	O
,	O
(	O
VI	O
)	O
,	O
(	O
VII	O
)	O
,	O
and	O
(	O
VIII	O
)	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
a	O
dysfunction	O
in	O
proteostasis	O
.	O

Molecular	O
Predictors	O
of	O
Therapeutic	O
Response	O
to	O
Specific	O
Anti	O
-	O
Cancer	O
Agents	O
Herein	O
is	O
described	O
the	O
use	O
of	O
a	O
collection	O
of	O
50	O
breast	O
cancer	O
cell	O
lines	O
to	O
match	O
responses	O
to	O
77	O
conventional	O
and	O
experimental	O
therapeutic	O
agents	O
with	O
transcriptional	O
,	O
proteomic	O
and	O
genomic	O
subtypes	O
found	O
in	O
primary	O
tumors	O
.	O

Almost	O
all	O
compounds	O
produced	O
strong	O
differential	O
responses	O
across	O
the	O
cell	O
lines	O
produced	O
responses	O
that	O
were	O
associated	O
with	O
transcriptional	O
and	O
proteomic	O
subtypes	O
and	O
produced	O
responses	O
that	O
were	O
associated	O
with	O
recurrent	O
genome	O
copy	O
number	O
abnormalities	O
.	O

These	O
associations	O
can	O
now	O
be	O
incorporated	O
into	O
clinical	O
trials	O
that	O
test	O
subtype	O
markers	O
and	O
clinical	O
responses	O
simultaneously	O
.	O

Method	O
of	O
regulating	O
the	O
expression	O
level	O
of	O
survival	B
of	I
motor	I
neuron	I
1	I
(	O
smn1	B
)	O
and	O
detecting	O
enzyme	O
activity	O
of	O
ubiquitin	B
carboxyl	I
-	I
terminal	I
hydrolase	I
l1	I
(	O
uchl1	B
)	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
regulating	O
the	O
expression	O
level	O
of	O
survival	B
of	I
motor	I
neuron	I
1	I
(	O
SMN1	B
)	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
ubiquitin	B
carboxyl	I
-	I
terminal	I
hydrolase	I
L1	I
(	O
UCHL1	B
)	O
regulator	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
detecting	O
enzyme	O
activity	O
of	O
ubiquitin	B
carboxyl	I
-	I
terminal	I
hydrolase	I
L1	I
(	O
UCHL1	B
)	O
in	O
human	O
fibroblasts	O
comprising	O
detecting	O
protein	O
expression	O
level	O
of	O
survival	B
of	I
motor	I
neuron	I
1	I
(	O
SMN1	B
)	O
.	O

Anti	O
-	O
miR-1	B
Therapy	O
for	O
Wound	O
Healing	O
Methods	O
for	O
modulating	O
gene	O
expression	O
in	O
a	O
skin	O
cell	O
by	O
administering	O
to	O
the	O
cell	O
an	O
amount	O
of	O
a	O
therapeutic	O
composition	O
in	O
an	O
amount	O
sufficient	O
to	O
modulate	O
the	O
expression	O
of	O
miR-1	B
,	O
and	O
therapeutic	O
compositions	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

Stable	O
rasagiline	O
composition	O
The	O
present	O
invention	O
provides	O
a	O
stable	O
composition	O
of	O
rasagiline	O
comprising	O
an	O
effective	O
dosage	O
of	O
rasagiline	O
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
and	O
an	O
antioxidant	O
used	O
as	O
a	O
stabilizer	O
.	O

The	O
dosage	O
forms	O
of	O
the	O
composition	O
are	O
pharmaceutically	O
common	O
transdermal	O
-	O
drug	O
delivery	O
dosage	O
form	O
and	O
mucoadhesive	O
delivery	O
dosage	O
form	O
,	O
such	O
as	O
patch	O
,	O
gel	O
,	O
ointment	O
,	O
cream	O
,	O
cataplasm	O
,	O
film	O
,	O
spray	O
and	O
solution	O
,	O
etc	O
.	O

The	O
composition	O
can	O
be	O
used	O
to	O
prevent	O
or	O
treat	O
mental	O
disorders	O
.	O

Inhibitions	O
of	O
glutaminase	O
c	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
reducing	O
the	O
production	O
of	O
glutamate	O
from	O
glutamine	O
by	O
glutaminase	O
C	O
in	O
a	O
cell	O
or	O
tissue	O
.	O

The	O
method	O
involves	O
inhibiting	O
glutaminase	O
C	O
activity	O
in	O
the	O
cell	O
or	O
tissue	O
under	O
conditions	O
effective	O
to	O
reduce	O
production	O
of	O
glutamate	O
from	O
glutamine	O
.	O

Compounds	O
for	O
carrying	O
out	O
this	O
method	O
are	O
also	O
disclosed	O
.	O

Novel	O
dental	O
appliances	O
and	O
methods	O
for	O
their	O
fabrication	O
The	O
invention	O
consists	O
of	O
a	O
rapidly	O
crosslinkable	O
,	O
two	O
-	O
component	O
silicone	O
elastomer	O
together	O
with	O
a	O
specially	O
designed	O
tray	O
that	O
serves	O
as	O
a	O
form	O
for	O
the	O
silicone	O
resin	O
and	O
forms	O
an	O
integral	O
portion	O
of	O
a	O
dental	O
appliance	O
.	O

Pegylated	O
polyplexes	O
containing	O
two	O
or	O
more	O
different	O
polymers	O
for	O
polynucleotide	O
delivery	O
The	O
present	O
invention	O
provides	O
polymers	O
,	O
compositions	O
thereof	O
,	O
and	O
polyplexes	O
comprising	O
said	O
polymers	O
.	O

In	O
particular	O
,	O
cationic	O
polymers	O
,	O
pegylated	O
versions	O
thereof	O
,	O
and	O
polynucleotide	O
containing	O
polyplexes	O
comprising	O
such	O
polymers	O
are	O
provided	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
of	O
using	O
said	O
polymers	O
and	O
polyplexes	O
.	O

Bioactive	O
Load	O
-	O
Bearing	O
Composites	O
Methods	O
of	O
preparing	O
bioactive	O
composites	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
molding	O
such	O
composites	O
.	O

Shaped	O
bodies	O
comprising	O
bioactive	O
composites	O
are	O
further	O
described	O
.	O

Method	O
of	O
treating	O
cancers	O
and	O
a	O
pharmaceutical	O
composition	O
that	O
may	O
be	O
used	O
in	O
practicing	O
said	O
method	O
The	O
method	O
of	O
treating	O
a	O
person	O
having	O
a	O
cancer	O
selected	O
from	O
carcinoma	O
,	O
sarcoma	O
or	O
hematopoietic	O
cancer	O
by	O
administering	O
(	O
a	O
)	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
anti	O
-	O
cancer	O
drug	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
EGFR	B
)	O
inhibitor	O
,	O
a	O
vascular	B
endothelial	I
growth	I
factor	I
receptor	I
(	O
VEGFR	B
)	O
inhibitor	O
and	O
a	O
Raf	B
kinase	O
inhibitor	O
and	O
(	O
b	O
)	O
an	O
effective	O
amount	O
of	O
5-	O
(	O
4-	O
(	O
6-	O
(	O
4-amino-3,5-dimethyl	O
-	O
phenoxy	O
)	O
-1-methyl-1H	O
-	O
benzimidazol-2-ylmethoxy	O
)	O
-benzyl	O
)	O
-thiazolidine-2,4-dione.dihydrochloride	O
provided	O
that	O
said	O
carcinoma	O
is	O
not	O
lung	O
cancer	O
when	O
an	O
EGFR	B
inhibitor	O
is	O
erlotinib	O
.	O

The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
that	O
may	O
be	O
used	O
in	O
practicing	O
said	O
method	O
.	O

Adamantane	O
analogs	O
Provided	O
are	O
compounds	O
that	O
are	O
capable	O
of	O
modulating	O
the	O
activity	O
of	O
the	O
influenza	O
A	O
virus	O
via	O
interaction	O
with	O
the	O
M2	B
transmembrane	I
protein	I
.	O

Also	O
provided	O
are	O
methods	O
for	O
treating	O
an	O
influenza	O
A	O
-	O
affected	O
disease	O
state	O
or	O
infection	O
comprising	O
administering	O
a	O
composition	O
comprising	O
one	O
or	O
more	O
compounds	O
that	O
have	O
been	O
identified	O
as	O
being	O
capable	O
of	O
interaction	O
with	O
the	O
M2	B
protein	I
.	O

Rapidly	O
disintegrating	O
tablet	O
in	O
oral	O
cavity	O
The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
suppressing	O
the	O
bitter	O
taste	O
of	O
a	O
drug	O
when	O
a	O
rapidly	O
disintegrating	O
tablet	O
in	O
an	O
oral	O
cavity	O
is	O
produced	O
.	O

When	O
a	O
rapidly	O
disintegrating	O
tablet	O
in	O
an	O
oral	O
cavity	O
is	O
produced	O
,	O
the	O
bitter	O
taste	O
of	O
a	O
drug	O
is	O
suppressed	O
by	O
utilizing	O
(	O
a	O
)	O
a	O
granule	O
which	O
contains	O
a	O
drug	O
having	O
a	O
bitter	O
taste	O
and	O
an	O
excipient	O
and	O
in	O
which	O
the	O
bitter	O
taste	O
has	O
not	O
been	O
suppressed	O
and	O
(	O
b	O
)	O
a	O
granule	O
containing	O
a	O
water	O
soluble	O
saccharide	O
.	O

Microgel	O
compositions	O
This	O
invention	O
relates	O
to	O
microgel	O
compositions	O
,	O
and	O
in	O
particular	O
,	O
to	O
gel	O
compositions	O
formed	O
by	O
binding	O
a	O
plurality	O
of	O
individual	O
microgel	O
particles	O
together	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
compositions	O
and	O
their	O
use	O
for	O
particular	O
applications	O
,	O
especially	O
medical	O
applications	O
such	O
as	O
the	O
repair	O
of	O
damaged	O
,	O
degenerated	O
or	O
inappropriately	O
formed	O
load	O
-	O
bearing	O
tissue	O
(	O
such	O
as	O
,	O
for	O
example	O
,	O
intervertebral	O
discs	O
)	O
.	O

Compositions	O
of	O
Apatite	O
and	O
Methods	O
of	O
Use	O
Compositions	O
of	O
apatite	O
derivative	O
crystals	O
are	O
disclosed	O
herein	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
these	O
compositions	O
to	O
treat	O
tooth	O
sensitivity	O
,	O
to	O
use	O
as	O
an	O
anticaries	O
treatment	O
,	O
to	O
use	O
as	O
a	O
restorative	O
material	O
,	O
to	O
use	O
as	O
a	O
tooth	O
surface	O
whitener	O
,	O
and	O
to	O
combat	O
or	O
lessen	O
the	O
side	O
effects	O
of	O
tooth	O
whitening	O
.	O

Inhibiting	O
hepatitis	O
c	O
viral	O
replication	O
with	O
sirna	O
combinations	O
Compositions	O
are	O
disclosed	O
of	O
combinations	O
of	O
small	O
interfering	O
RNAs	O
(	O
siRNA	O
)	O
that	O
can	O
inhibit	O
the	O
replication	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
in	O
liver	O
cells	O
,	O
along	O
with	O
methods	O
of	O
co	O
-	O
administering	O
the	O
siRNAs	O
to	O
subjects	O
.	O

Further	O
,	O
methods	O
are	O
disclosed	O
for	O
improving	O
the	O
delivery	O
of	O
nucleic	O
acids	O
to	O
the	O
liver	O
.	O

5-membered	O
heterocycle	O
derivatives	O
and	O
manufacturing	O
process	O
thereof	O
Disclosed	O
are	O
a	O
novel	O
5-membered	O
heterocycle	O
derivatives	O
of	O
Formula	O
I	O
,	O
a	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
thereof	O
and	O
a	O
pharmaceutical	O
use	O
thereof	O
.	O

The	O
5-membered	O
heterocycle	O
derivatives	O
of	O
Formula	O
I	O
,	O
a	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
thereof	O
and	O
compositions	O
containing	O
them	O
are	O
useful	O
for	O
treating	O
a	O
tumor	O
.	O

Novel	O
uses	O
of	O
adipic	O
acid	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
obesity	O
,	O
diabetes	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
or	O
insulin	B
resistance	O
syndrome	O
,	O
comprising	O
:	O
administering	O
to	O
a	O
mammalian	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
adipic	O
acid	O
.	O

The	O
present	O
composition	O
containing	O
adipic	O
acid	O
as	O
an	O
active	O
ingredient	O
is	O
very	O
effective	O
in	O
preventing	O
or	O
treating	O
obesity	O
,	O
diabetes	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
(	O
preferably	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
)	O
or	O
insulin	B
resistance	O
syndrome	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
useful	O
as	O
pharmaceuticals	O
compositions	O
or	O
functional	O
food	O
compositions	O
has	O
therapeutic	O
efficacies	O
for	O
obesity	O
,	O
dyslipidemia	O
or	O
fatty	O
liver	O
,	O
and	O
also	O
induces	O
significant	O
decrease	O
in	O
fasting	O
glucose	O
level	O
and	O
blood	O
insulin	B
level	O
to	O
improve	O
type	O
2	O
diabetes	O
,	O
insulin	B
resistance	O
and	O
related	O
metabolic	O
diseases	O
.	O

Cutaneous	O
composition	O
comprising	O
vitamin	O
d	O
analogue	O
and	O
a	O
mixture	O
of	O
solvent	O
and	O
surfactants	O
A	O
pharmaceutical	O
composition	O
comprising	O
a	O
vitamin	O
D	O
derivative	O
or	O
analogue	O
as	O
the	O
active	O
ingredient	O
dissolved	O
in	O
a	O
three	O
-	O
component	O
surfactant	O
-	O
solvent	O
mixture	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
dermal	O
disorders	O
or	O
conditions	O
.	O

Pharmaceutical	O
kit	O
for	O
treating	O
neuronal	O
damages	O
A	O
pharmaceutical	O
kit	O
for	O
treating	O
neuronal	O
damages	O
is	O
disclosed	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
comprises	O
:	O
a	O
first	O
pharmaceutical	O
composition	O
comprising	O
a	O
first	O
effective	O
amount	O
of	O
a	O
Mg2	O
+	O
-containing	O
compound	O
;	O
and	O
a	O
second	O
pharmaceutical	O
composition	O
comprising	O
a	O
second	O
effective	O
amount	O
of	O
a	O
COX-2	B
inhibitor	O
.	O

Nucleic	O
acid	O
molecules	O
encoding	O
bank1	B
splice	O
variants	O
The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
splice	O
variant	O
of	O
BANK1	B
,	O
the	O
use	O
of	O
SNPs	O
in	O
BANK1	B
for	O
diagnostics	O
and	O
the	O
use	O
of	O
antagonists	O
to	O
modulate	O
BANK1	B
and/or	O
the	O
BANK1	B
pathway	O
.	O

Hydrogel	O
materials	O
incorporating	O
eluting	O
ceragenin	O
compound	O
A	O
hydrogel	O
polymer	O
includes	O
a	O
ceragenin	O
compound	O
.	O

The	O
ceragenin	O
compound	O
has	O
a	O
hydrophobicity	O
/	O
hydrophilicity	O
that	O
produces	O
a	O
release	O
rate	O
in	O
a	O
range	O
of	O
0.1	O
-	O
100	O
μg	O
/	O
ml	O
for	O
at	O
least	O
3	O
days	O
.	O

Aqueous	O
Pharmaceutical	O
Formulation	O
of	O
Tapentadol	O
for	O
Oral	O
Administration	O
An	O
aqueous	O
pharmaceutical	O
composition	O
containing	O
tapentadol	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
thereof	O
and	O
being	O
adapted	O
for	O
oral	O
administration	O
.	O

The	O
composition	O
has	O
excellent	O
storage	O
stability	O
without	O
relying	O
on	O
the	O
presence	O
of	O
high	O
amounts	O
of	O
preservatives	O
.	O

Promyelocytic	B
leukemia	I
protein	I
as	O
a	O
redox	O
sensor	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
determining	O
the	O
redox	O
status	O
of	O
a	O
cell	O
or	O
tissue	O
comprising	O
a	O
step	O
consisting	O
of	O
determining	O
the	O
level	O
of	O
PML	B
nuclear	O
bodies	O
in	O
said	O
cell	O
or	O
tissue	O
.	O

Drug	O
-	O
delivery	O
endovascular	O
stent	O
and	O
method	O
of	O
forming	O
the	O
same	O
An	O
intravascular	O
stent	O
and	O
method	O
for	O
inhibiting	O
restenosis	O
,	O
following	O
vascular	O
injury	O
,	O
is	O
disclosed	O
.	O

The	O
stent	O
has	O
an	O
expandable	O
,	O
linked	O
-	O
filament	O
body	O
and	O
a	O
drug	O
-	O
release	O
coating	O
formed	O
on	O
the	O
stent	O
-	O
body	O
filaments	O
,	O
for	O
contacting	O
the	O
vessel	O
injury	O
site	O
when	O
the	O
stent	O
is	O
placed	O
in	O
-	O
situ	O
in	O
an	O
expanded	O
condition	O
.	O

The	O
coating	O
releases	O
,	O
for	O
a	O
period	O
of	O
at	O
least	O
4	O
weeks	O
,	O
a	O
restenosis	O
-	O
inhibiting	O
amount	O
of	O
a	O
monocyclic	O
triene	O
immunosuppressive	O
compound	O
having	O
an	O
alkyl	O
group	O
substituent	O
at	O
carbon	O
position	O
40	O
in	O
the	O
compound	O
.	O

The	O
stent	O
,	O
when	O
used	O
to	O
treat	O
a	O
vascular	O
injury	O
,	O
gives	O
good	O
protection	O
against	O
clinical	O
restenosis	O
,	O
even	O
when	O
the	O
extent	O
of	O
vascular	O
injury	O
involves	O
vessel	O
overstretching	O
by	O
more	O
than	O
30	O
%	O
diameter	O
.	O

Also	O
disclosed	O
is	O
a	O
stent	O
having	O
a	O
drug	O
-	O
release	O
coating	O
composed	O
of	O
(	O
i	O
)	O
10	O
and	O
60	O
weight	O
percent	O
poly	O
-	O
dl	O
-	O
Iactide	O
polymer	O
substrate	O
and	O
(	O
ii	O
)	O
40	O
-	O
90	O
weight	O
percent	O
of	O
an	O
anti	O
-	O
restenosis	O
compound	O
,	O
and	O
a	O
polymer	O
undercoat	O
having	O
a	O
thickness	O
of	O
between	O
1	O
-	O
5	O
microns	O
.	O

Compositions	O
and	O
Methods	O
for	O
Treating	O
Pain	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
pain	O
in	O
mammals	O
.	O

A	O
composition	O
of	O
the	O
invention	O
comprises	O
one	O
or	O
more	O
anti	O
-	O
inflammatory	O
agents	O
and	O
optionally	O
contains	O
one	O
or	O
more	O
anti	O
-	O
oxidants	O
and	O
immune	O
system	O
boosting	O
agents	O
.	O

Modified	O
release	O
dosage	O
form	O
comprising	O
desvenlafaxine	O
or	O
salts	O
thereof	O
The	O
present	O
invention	O
refers	O
to	O
a	O
modified	O
release	O
pharmaceutical	O
composition	O
comprising	O
desvenlafaxine	O
or	O
salts	O
thereof	O
,	O
a	O
release	O
rate	O
modifying	O
system	O
that	O
controls	O
the	O
release	O
of	O
active	O
agent	O
(	O
s	O
)	O
in	O
both	O
acidic	O
and	O
basic	O
environments	O
.	O

A	O
process	O
of	O
making	O
and	O
method	O
of	O
using	O
the	O
above	O
-	O
described	O
composition	O
is	O
also	O
disclosed	O
.	O

Substituted	O
Carbonyloxymethylphosphoramidate	O
Compounds	O
and	O
Pharmaceutical	O
Compositions	O
for	O
the	O
Treatment	O
of	O
Viral	O
Infections	O
Provided	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
liver	O
disorders	O
,	O
including	O
HCV	O
infections	O
.	O

In	O
certain	O
embodiments	O
,	O
compounds	O
and	O
compositions	O
of	O
nucleoside	O
derivatives	O
are	O
disclosed	O
,	O
which	O
can	O
be	O
administered	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
anti	O
-	O
viral	O
agents	O
.	O

COMPOUNDS	O
AS	O
RORyT	B
MODULATORS	O
AND	O
USES	O
THEREOF	O
Heterocyclic	O
compounds	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
are	O
disclosed	O
as	O
RORγt	B
modulators	O
that	O
have	O
a	O
formula	O
represented	O
by	O
the	O
following	O
:	O
and	O
wherein	O
n1	O
,	O
n2	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
as	O
described	O
herein	O
.	O

These	O
compounds	O
may	O
be	O
used	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non	O
-	O
limiting	O
example	O
,	O
inflammatory	O
conditions	O
,	O
autoimmune	O
disorders	O
,	O
cancer	O
,	O
and	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
.	O

Method	O
of	O
Achieving	O
Improved	O
Hair	O
Feel	O
A	O
method	O
of	O
achieving	O
improved	O
hair	O
feel	O
.	O

The	O
method	O
comprises	O
applying	O
to	O
hair	O
a	O
composition	O
comprising	O
:	O
(	O
a	O
)	O
a	O
specific	O
cationic	O
guar	O
polymer	O
;	O
(	O
b	O
)	O
a	O
specific	O
cationic	O
copolymer	O
;	O
(	O
c	O
)	O
an	O
anti	O
-	O
dandruff	O
active	O
;	O
(	O
d	O
)	O
a	O
cosmetically	O
acceptable	O
carrier	O
;	O
(	O
e	O
)	O
a	O
surfactant	O
;	O
wherein	O
the	O
weight	O
ratio	O
of	O
(	O
a	O
)	O
:	O
(	O
b	O
)	O
is	O
from	O
about	O
1000:1	O
to	O
about	O
3.5:1	O
;	O
and	O
wherein	O
the	O
sum	O
of	O
(	O
a	O
)	O
+	O
(	O
b	O
)	O
is	O
an	O
amount	O
of	O
from	O
about	O
0.0001	O
%	O
to	O
about	O
0.7	O
%	O
,	O
by	O
total	O
weight	O
of	O
the	O
composition	O
.	O

The	O
composition	O
forms	O
coacervate	O
particles	O
upon	O
dilution	O
of	O
the	O
composition	O
with	O
water	O
and	O
the	O
coacervate	O
particles	O
have	O
a	O
squeeze	O
flow	O
viscosity	O
of	O
from	O
about	O
1	O
cP	O
to	O
about	O
100	O
cP.	O
The	O
percentage	O
of	O
coacervate	O
particles	O
with	O
a	O
floc	O
size	O
of	O
greater	O
than	O
about	O
20	O
micron	O
is	O
from	O
about	O
1	O
%	O
to	O
about	O
60	O
%	O
and	O
the	O
on	O
-	O
scalp	O
deposition	O
of	O
the	O
anti	O
-	O
dandruff	O
active	O
is	O
at	O
least	O
about	O
1	O
microgram	O
/	O
cm2	O
.	O

Antimicrobial	O
carboline	O
compounds	O
The	O
invention	O
provides	O
compositions	O
comprising	O
carboline	O
compounds	O
for	O
treating	O
infections	O
such	O
as	O
viral	O
conjunctivitis	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
of	O
other	O
infections	O
,	O
including	O
ocular	O
infections	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
carboline	O
compounds	O
for	O
the	O
treatment	O
of	O
ocular	O
infections	O
such	O
as	O
viral	O
conjunctivitis	O
,	O
particularly	O
those	O
caused	O
by	O
adenovirus	O

Novel	O
iso	O
-	O
ergoline	O
derivatives	O
Provided	O
herein	O
are	O
novel	O
iso	O
-	O
ergoline	O
derivatives	O
and	O
compositions	O
thereof	O
.	O

In	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
treatment	O
,	O
prevention	O
,	O
or	O
amelioration	O
of	O
a	O
variety	O
of	O
medical	O
disorders	O
such	O
as	O
,	O
for	O
example	O
,	O
migraine	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
agonizing	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
5-HT1D	O
and/or	O
the	O
5-HT1Breceptor	O
,	O
without	O
agonizing	O
the	O
5-HT2B	O
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
antagonizing	O
or	O
inhibiting	O
activity	O
at	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
adrenergic	O
alpha2A	O
and/or	O
the	O
alpha2Breceptors	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

Administration	O
of	O
intravenous	O
ibuprofen	O
to	O
trauma	O
patients	O
A	O
method	O
for	O
treating	O
human	O
patients	O
who	O
require	O
hospitalization	O
for	O
a	O
trauma	O
injury	O
wherein	O
the	O
patients	O
are	O
intravenously	O
administered	O
a	O
first	O
dose	O
of	O
a	O
therapeutically	O
effective	O
dose	O
of	O
ibuprofen	O
intravenously	O
as	O
soon	O
as	O
possible	O
after	O
hospitalization	O
is	O
disclosed	O
.	O

The	O
patients	O
are	O
further	O
treated	O
with	O
intravenous	O
ibuprofen	O
at	O
suitable	O
dosing	O
intervals	O
to	O
the	O
human	O
patient	O
until	O
(	O
a	O
)	O
the	O
patient	O
no	O
longer	O
requires	O
intravenous	O
dosing	O
of	O
ibuprofen	O
.	O

Method	O
and	O
composition	O
for	O
ameliorating	O
the	O
effects	O
for	O
a	O
subject	O
exposed	O
to	O
radiation	O
or	O
other	O
sources	O
of	O
oxidative	O
stress	O
Radiation	O
-	O
oxidative	O
exposure	O
treatment	O
compositions	O
may	O
include	O
a	O
mixture	O
of	O
micronutrient	O
multivitamin	O
and	O
trace	O
elements	O
,	O
a	O
mixture	O
of	O
antioxidants	O
and	O
chemopreventative	O
agents	O
,	O
and	O
optionally	O
a	O
mixture	O
of	O
fatty	O
acids	O
.	O

Methods	O
of	O
treatment	O
of	O
a	O
subject	O
exposed	O
to	O
a	O
radiation	O
source	O
or	O
an	O
oxidative	O
stress	O
with	O
the	O
radiation	O
-	O
oxidative	O
exposure	O
treatment	O
composition	O
may	O
include	O
the	O
step	O
of	O
administering	O
to	O
the	O
subject	O
a	O
daily	O
dose	O
of	O
the	O
radiation	O
-	O
oxidative	O
exposure	O
treatment	O
composition	O
such	O
that	O
the	O
life	O
shortening	O
effects	O
induced	O
by	O
the	O
radiation	O
source	O
or	O
the	O
oxidative	O
stress	O
are	O
ameliorated	O
.	O

Nanoparticles	O
,	O
Compositions	O
Thereof	O
,	O
and	O
Methods	O
of	O
Use	O
,	O
and	O
Methods	O
of	O
Making	O
the	O
Same	O
The	O
disclosure	O
is	O
directed	O
to	O
a	O
nanoparticle	O
comprising	O
a	O
porous	O
framework	O
core	O
including	O
a	O
porous	O
framework	O
material	O
and	O
a	O
compound	O
,	O
and	O
a	O
lipid	O
layer	O
disposed	O
on	O
the	O
surface	O
of	O
the	O
porous	O
framework	O
core	O
.	O

Controlled	O
release	O
hydrocodone	O
A	O
solid	O
oral	O
controlled	O
-	O
release	O
dosage	O
form	O
of	O
hydrocodone	O
is	O
disclosed	O
,	O
the	O
dosage	O
form	O
comprising	O
an	O
analgesically	O
effective	O
amount	O
of	O
hydrocodone	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
controlled	O
release	O
material	O
.	O

Fullerene	O
derivative	O
and	O
composition	O
comprising	O
the	O
same	O
A	O
fullerene	O
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
[	O
wherein	O
,	O
A	O
is	O
a	O
residue	O
of	O
monosaccharides	O
or	O
disaccharides	O
,	O
and	O
Alk	O
is	O
a	O
lower	O
alkylene	O
group	O
,	O
the	O
group	O
represented	O
by	O
the	O
formula	O
(	O
X	O
)	O
:	O
is	O
a	O
fullerene	O
residual	O
skeleton	O
,	O
and	O
n	O
is	O
an	O
integral	O
number	O
of	O
1	O
or	O
2	O
]	O
or	O
its	O
salt	O
produces	O
a	O
formulation	O
usable	O
for	O
PDT	O
which	O
has	O
more	O
hydrophilicity	O
and	O
lipophilicity	O
,	O
is	O
expected	O
to	O
have	O
selectivity	O
to	O
tumor	O
cells	O
by	O
cell	O
recognition	O
,	O
shows	O
no	O
toxicity	O
to	O
the	O
cells	O
in	O
a	O
dark	O
place	O
and	O
has	O
a	O
cytocidal	O
effect	O
by	O
light	O
irradiation	O
.	O

Method	O
for	O
producing	O
a	O
tablet	O
made	O
of	O
isomaltulose	O
,	O
isomalt	O
or	O
isomalt	O
variants	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
producing	O
an	O
improved	O
compressed	O
product	O
,	O
wherein	O
agglomeration	O
of	O
the	O
ingredients	O
is	O
induced	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
compressed	O
product	O
produced	O
by	O
this	O
method	O
.	O

2-Ureido	O
-	O
thiazole	O
derivatives	O
,	O
process	O
for	O
their	O
preparation	O
,	O
and	O
their	O
use	O
as	O
antitumor	O
agents	O
Compounds	O
which	O
are	O
2-ureido-1,3-thiazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
is	O
a	O
halogen	O
atom	O
,	O
a	O
nitro	O
group	O
,	O
an	O
optionally	O
substituted	O
amino	O
group	O
or	O
it	O
is	O
a	O
group	O
optionally	O
further	O
substituted	O
,	O
selected	O
from	O
:	O
i	O
)	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
;	O
ii	O
)	O
C3-C6	O
cycloalkyl	O
;	O
iii	O
)	O
aryl	O
or	O
arylalkyl	O
with	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
within	O
the	O
straight	O
or	O
branched	O
alkyl	O
chain	O
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
group	O
selected	O
from	O
:	O
i	O
)	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
;	O
ii	O
)	O
3	O
to	O
6	O
membered	O
carbocycle	O
or	O
5	O
to	O
7	O
membered	O
heterocycle	O
ring	O
;	O
iii	O
)	O
aryl	O
or	O
arylcarbonyl	O
;	O
iv	O
)	O
arylalkyl	O
with	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
within	O
the	O
straight	O
or	O
branched	O
alkyl	O
chain	O
;	O
R2	O
is	O
hydrogen	O
,	O
a	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
or	O
C2-C4	O
alkenyl	O
or	O
alkynyl	O
group	O
;	O
or	O
,	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
so	O
which	O
they	O
are	O
bonded	O
,	O
R1	O
and	O
R2	O
form	O
a	O
substituted	O
or	O
unsubstituted	O
group	O
selected	O
from	O
:	O
i	O
)	O
an	O
optionally	O
benzocondensed	O
or	O
bridged	O
5	O
to	O
7	O
membered	O
heterocycle	O
;	O
or	O
ii	O
)	O
a	O
9	O
to	O
11	O
membered	O
spiro	O
-	O
heterocyclic	O
compound	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
are	O
useful	O
for	O
treating	O
cell	O
proliferative	O
disorders	O
associated	O
with	O
an	O
altered	O
cell	O
dependent	O
kinase	O
activity	O
.	O

Oxalipatinum	O
preparation	O
packaging	O
Flexible	O
impervious	O
bag	O
for	O
medical	O
use	O
containing	O
a	O
pharmaceutical	O
preparation	O
of	O
liquid	O
oxaliplatinum	O
said	O
flexible	O
bag	O
is	O
constructed	O
from	O
plastic	O
materials	O
,	O
with	O
the	O
proviso	O
that	O
any	O
portion	O
to	O
the	O
bag	O
in	O
direct	O
contact	O
with	O
said	O
pharmaceutical	O
preparation	O
of	O
liquid	O
oxaliplatinum	O
does	O
not	O
contain	O
polyvinylchloride	O
-	O
based	O
plastic	O
material	O
.	O

Useful	O
for	O
relieving	O
infertility	O
in	O
females	O
and	O
males	O
Certain	O
novel	O
sterol	O
derivatives	O
can	O
be	O
used	O
for	O
regulating	O
the	O
meiosis	O
in	O
oocytes	O
and	O
in	O
male	O
germ	O
cells	O
.	O

Viricides	O
;	O
human	O
immunodeficiency	O
virus	O
Compounds	O
of	O
the	O
formula	O
I	O
:	O
where	O
;	O
R1	O
is	O
O	O
,	O
S	O
;	O
R2	O
is	O
an	O
optionally	O
substituted	O
nitrogen	O
-	O
containing	O
heterocycle	O
,	O
wherein	O
the	O
nitrogen	O
is	O
located	O
at	O
the	O
2	O
position	O
relative	O
to	O
the	O
(	O
thio	O
)	O
urea	O
bond	O
;	O
R3	O
is	O
H	O
,	O
C1-C3	O
alkyl	O
,	O
R4-R7	O
are	O
independently	O
selected	O
from	O
H	O
,	O
C1-C6	O
alkyl	O
,	O
C2-C6	O
alkenyl	O
,	O
C2-C6	O
alkynyl	O
,	O
haloC1-C6	O
alkyl	O
,	O
C1-C6	O
alkanoyl	O
,	O
haloC1-C6	O
alkanoyl	O
,	O
C1-C6	O
alkoxy	O
,	O
haloC1-C6	O
alkoxy	O
,	O
C1-C6	O
alkyloxy	O
-	O
C1-C6	O
alkyl	O
,	O
haloC1-C6	O
alkyloxy	O
-	O
C1-C6	O
alkyl	O
hydroxy	O
-	O
C1-C6	O
alkyl	O
,	O
amino	O
-	O
C1-C6	O
alkyl	O
,	O
carboxy	O
-	O
C1-C6	O
alkyl	O
,	O
cyano	O
-	O
C1-C6	O
alkyl	O
,	O
amino	O
,	O
carboxy	O
,	O
carbamoyl	O
,	O
cyano	O
,	O
halo	O
,	O
hydroxy	O
,	O
keto	O
;	O
X	O
is	O
—	O
(	O
CH2	O
)	O
n−—D—	O
(	O
CH2	O
)	O
m—	O
;	O
D	O
is	O
—O—	O
,	O
—S—	O
;	O
n	O
and	O
m	O
are	O
independently	O
0	O
or	O
1	O
;	O
and	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
have	O
utility	O
as	O
inhibitors	O
of	O
HIV-1	B
reverse	I
transcriptase	I
,	O
particularly	O
drug	O
escape	O
mutants	O
.	O

Diazocine	O
derivatives	O
and	O
their	O
use	O
as	O
tryptase	B
inhibitors	O
Compounds	O
of	O
the	O
formula	O
I	O
,	O
in	O
which	O
B1	O
,	O
B2	O
,	O
R1	O
,	O
R2	O
,	O
R6	O
,	O
R7	O
,	O
K1	O
and	O
K2	O
are	O
as	O
defined	O
in	O
the	O
description	O
are	O
novel	O
effective	O
tryp	B
-	I
tase	I
inhibitors	O
.	O

Active	O
agent	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
anabasine	O
,	O
anatabine	O
,	O
nomicotine	O
,	O
Yerbamate	O
(	O
Ilex	O
paraguariensis	O
)	O
extract	O
,	O
and	O
a	O
liquid	O
extract	O
of	O
tobacco	O
;	O
especially	O
for	O
treating	O
psychological	O
disorders	O
The	O
present	O
invention	O
provides	O
a	O
group	O
of	O
tobacco	O
alkaloids	O
,	O
tobacco	O
extract	O
,	O
Yerbamaté	O
extract	O
,	O
and	O
an	O
extract	O
of	O
chewing	O
gum	O
and	O
lozenges	O
which	O
are	O
modulators	O
of	O
monoamine	O
oxidase	O
(	O
MAO	O
)	O
activity	O
(	O
i.e.	O
,	O
compounds	O
and	O
substances	O
which	O
inhibit	O
MAO	O
enzyme	O
and	O
prevent	O
its	O
biological	O
activity	O
)	O
.	O

The	O
MAO	O
inhibitors	O
of	O
the	O
present	O
invention	O
can	O
cause	O
an	O
increase	O
in	O
the	O
level	O
of	O
norepinephrine	O
,	O
dopamine	O
,	O
and	O
serotonin	O
in	O
the	O
brain	O
and	O
other	O
tissues	O
,	O
and	O
thus	O
can	O
cause	O
a	O
wide	O
variety	O
of	O
pharmacological	O
effects	O
mediated	O
by	O
their	O
effects	O
on	O
these	O
compounds	O
.	O

The	O
MAO	O
inhibitors	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
such	O
as	O
the	O
treatment	O
of	O
depression	O
,	O
disorders	O
of	O
attention	O
and	O
focus	O
,	O
mood	O
and	O
emotional	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
,	O
extrapyramidal	O
disorders	O
,	O
hypertension	O
,	O
substance	O
abuse	O
,	O
smoking	O
substitution	O
,	O
anti	O
-	O
depression	O
therapy	O
,	O
eating	O
disorders	O
,	O
withdrawal	O
syndromes	O
,	O
and	O
the	O
cessation	O
of	O
smoking	O
.	O

Phosphate	O
prodrugs	O
of	O
fluoroxindoles	O
The	O
present	O
invention	O
provides	O
novel	O
phosphate	O
derivatives	O
having	O

the	O
general	O
Formula	O
I	O
wherein	O
the	O
wavy	O
bond	O
(	O
)	O
represents	O
the	O
racemate	O
,	O
the	O
(	O
R	O
)	O
-enantiomer	O
or	O
the	O
(	O
S	O
)	O
-enantiomer	O
and	O
A	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
or	O
a	O
nontoxic	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
which	O
are	O
responsive	O
to	O
the	O
opening	O
of	O
potassium	O
channels	O
.	O

Fused	O
indazoles	O
and	O
indoles	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
glaucoma	O
Novel	O
fused	O
indazoles	O
and	O
indoles	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
the	O
lowering	O
and	O
controlling	O
of	O
normal	O
or	O
elevated	O
intraocular	O
pressure	O
as	O
well	O
as	O
a	O
method	O
for	O
the	O
treatment	O
of	O
glaucoma	O
using	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
.	O

Cosmetic	O
or	O
dermatological	O
composition	O
comprising	O
of	O
a	O
combination	O
of	O
an	O
elastase	B
inhibitor	O
of	O
the	O
N	O
-	O
acylaminoamide	O
family	O
and	O
at	O
least	O
one	O
antifungal	O
agent	O
or	O
at	O
least	O
one	O
antibacterial	O
agent	O
Cosmetic	O
or	O
dermatological	O
composition	O
characterized	O
in	O
that	O
it	O
comprises	O
a	O
combination	O
of	O
an	O
elastase	B
inhibitor	O
of	O
the	O
N	O
-	O
acylaminoamide	O
family	O
and	O
at	O
least	O
one	O
antifungal	O
agent	O
or	O
at	O
least	O
one	O
antibacterial	O
agent	O
.	O

useful	O
as	O
a	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
HER2	O
(	O
Human	O
epidermal	O
growth	O
factor	O
receptor-2	O
)	O
inhibitor	O
;	O
for	O
treating	O
cancer	O
This	O
invention	O
provides	O
a	O
heterocyclic	O
compound	O
having	O
potent	O
tyrosine	O
kinase	O
-	O
inhibiting	O
activity	O
represented	O
by	O
the	O
formula	O
:	O
wherein	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
3	O
;	O
n	O
is	O
an	O
integer	O
of	O
1	O
or	O
2	O
;	O
R1	O
is	O
a	O
halogen	O
atom	O
or	O
an	O
optionally	O
halogenated	O
C1	O
-	O
2	O
alkyl	O
group	O
;	O
each	O
of	O
R2	O
and	O
R3	O
is	O
,	O
same	O
or	O
different	O
,	O
a	O
hydrogen	O
atom	O
,	O
a	O
halogen	O
atom	O
,	O
a	O
lower	O
alkyl	O
group	O
or	O
a	O
lower	O
alkoxy	O
group	O
;	O
R4	O
is	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
wherein	O
p	O
is	O
an	O
integer	O
of	O
2	O
to	O
5	O
;	O
R5	O
is	O
a	O
C1	O
-	O
4	O
alkyl	O
group	O
substituted	O
by	O
alkoxycarbonyl	O
group	O
,	O
carbamoyl	O
group	O
,	O
carbamoyloxy	O
group	O
,	O
alkylsulfonyl	O
group	O
,	O
alkylsulfinyl	O
group	O
,	O
sulfamoyl	O
group	O
,	O
carbamoylamino	O
group	O
,	O
alkylsulfonylamino	O
group	O
,	O
acylamino	O
group	O
,	O
and	O
the	O
like	O
;	O
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
thereof	O
.	O

To	O
treat	O
and/or	O
prevent	O
hypertension	O
,	O
cardiac	O
hypertrophy	O
,	O
cardiac	O
insufficiency	O
,	O
coronary	O
heart	O
diseases	O
such	O
as	O
angina	O
pectoris	O
,	O
and	O
endothelial	O
dysfunction	O
or	O
endothelial	O
damage	O
as	O
a	O
consequence	O
of	O
atherosclerotic	O
processes	O
or	O
diabetes	O
The	O
invention	O
relates	O
to	O
p	O
-	O
thienylbenzylamides	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R	O
(	O
1	O
)	O
,	O
R	O
(	O
2	O
)	O
,	O
R	O
(	O
3	O
)	O
,	O
R	O
(	O
4	O
)	O
,	O
R	O
(	O
5	O
)	O
,	O
R	O
(	O
6	O
)	O
and	O
X	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
potent	O
agonists	O
of	O
angiotensin-	B
(	I
1	I
-	I
7	I
)	I
receptors	I
and	O
are	O
useful	O
as	O
pharmaceutically	O
active	O
compounds	O
to	O
treat	O
and/or	O
prevent	O
hypertension	O
;	O
cardiac	O
hypertrophy	O
;	O
cardiac	O
insufficiency	O
;	O
coronary	O
heart	O
diseases	O
,	O
such	O
as	O
angina	O
pectoris	O
;	O
and	O
endothelial	O
dysfunction	O
or	O
endothelial	O
damage	O
as	O
a	O
consequence	O
,	O
for	O
example	O
,	O
of	O
atherosclerotic	O
processes	O
or	O
in	O
association	O
with	O
diabetes	O
mellitus	O
.	O

Prodrug	O
of	O
an	O
estradiol	O
conjugated	O
to	O
a	O
glucuronide	O
sugar	O
;	O
6-oxo-2-methoxyestradiol	O
;	O
3-acetyl-6-oxo-2-methoxyestradiol	O
;	O
and	O
2-methoxyestradiol-6-hydrazone	O
;	O
angiogenesis	O
inhibitor	O
;	O
antiinflammatory	O
for	O
asthma	O
or	O
rheumatoid	O
arthritis	O
A	O
conjugated	O
prodrug	O
of	O
an	O
estradiol	O
compound	O
conjugated	O
to	O
a	O
biological	O
activity	O
modifying	O
agent	O
.	O

Formulation	O
for	O
controlled	O
release	O
of	O
drugs	O
by	O
combining	O
hyrophilic	O
and	O
hydrophobic	O
agents	O
Combinations	O
of	O
hydrophilic	O
and	O
hydrophobic	O
entities	O
in	O
a	O
biodegradable	O
sustained	O
release	O
implant	O
are	O
shown	O
to	O
modulate	O
each	O
other	O
's	O
rate	O
of	O
release	O
.	O

Formulations	O
of	O
a	O
therapeutically	O
active	O
agent	O
and	O
modulator	O
provide	O
controlled	O
,	O
sustained	O
release	O
for	O
an	O
extended	O
period	O
of	O
time	O
.	O

Nitrogen	O
compounds	O
such	O
as	O
1-	O
(	O
(	O
3-	O
Phenylimidazo	O
(	O
5,1-a	O
)	O
-isoquinolin-6-yl	O
)	O
carbonyl	O
)	O
piperidine	O
,	O
that	O
bind	O
preferentially	O
to	O
gamma	B
-	I
aminobutyric	I
acid	I
(	I
GABAA	I
)	I
receptors	I
;	O
prophylaxis	O
of	O
nervous	O
system	O
disorders	O
Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
:	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
W	O
,	O
Q	O
,	O
X	O
,	O
X1	O
,	O
Y	O
and	O
Z	O
are	O
as	O
defined	O
herein	O
.	O

These	O
compounds	O
bind	O
with	O
high	O
selectivity	O
and/or	O
high	O
affinity	O
to	O
the	O
benzodiazepine	O
site	O
of	O
GABAA	B
receptors	I
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
diseases	O
and	O
as	O
probes	O
for	O
the	O
localization	O
of	O
GABAA	B
receptors	I
in	O
tissue	O
samples	O
.	O

Also	O
disclosed	O
are	O
intermediates	O
useful	O
in	O
the	O
preparation	O
of	O
these	O
compounds	O
.	O

Orphan	B
opioid	I
receptor	I
(	O
orl-1	B
)	O
ligands	O
;	O
anxiety	O
,	O
depression	O
,	O
neuropathic	O
and	O
acute	O
pain	O
,	O
migraines	O
,	O
asthma	O
,	O
improved	O
cognition	O
The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
1,3,8-triazaspiro	O
[	O
4.5	O
]	O
decan-4-one	O
derivatives	O
of	O
the	O
general	O
formula	O
wherein	O
all	O
variables	O
are	O
as	O
defined	O
herein	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
mediated	O
by	O
the	O
ORL-1	B
G	B
-	I
protein	I
coupled	I
receptor	I
.	O

More	O
particularly	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
such	O
as	O
anxiety	O
,	O
depression	O
,	O
substance	O
abuse	O
,	O
neuropathic	O
pain	O
,	O
acute	O
pain	O
,	O
migraine	O
,	O
asthma	O
,	O
cough	O
and	O
for	O
improved	O
cognition	O
.	O

N	O
-	O
acylamino	O
benzyl	O
ether	O
derivatives	O
This	O
invention	O
relates	O
to	O
N	O
-	O
acylamino	O
aryl	O
derivatives	O
of	O
the	O
formula	O
where	O
R1	O
,	O
R21	O
,	O
R22	O
,	O
R23	O
,	O
R24	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
and	O
where	O
X	O
is	O
—CHRO	O
,	O
—OCHR—	O
,	O
—CH2S—	O
,	O
—SCH2—	O
,	O
—CH2CH2—	O
,	O
—CH	O
═	O
CH—	O
or	O
—C≡C—.	O
The	O
compounds	O
of	O
the	O
invention	O
are	O
selective	O
monoamine	O
oxidase	O
B	O
inhibitors	O
,	O
and	O
they	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
monoamine	O
oxidase	O
B	O
,	O
for	O
example	O
,	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
or	O
senile	O
dementia	O
.	O

N-	O
(	O
4-carbamimidoyl	O
-	O
phenyl	O
)	O
-glycine	O
derivatives	O
The	O
invention	O
is	O
concerned	O
with	O
novel	O
N-	O
(	O
4-carbamimidoyl	O
-	O
phenyl	O
)	O
-glycine	O
derivatives	O
of	O
the	O
formula	O
:	O
wherein	O
R1	O
,	O
E	O
,	O
X1	O
to	O
X4	O
and	O
G1	O
and	O
G2	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
the	O
claims	O
,	O
as	O
well	O
as	O
hydrates	O
or	O
solvates	O
and	O
physiologically	O
usable	O
salts	O
thereof	O
.	O

Compositions	O
and	O
methods	O
for	O
inducing	O
cell	O
death	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
inducing	O
cell	O
death	O
via	O
activation	O
of	O
the	O
caspase	B
,	O
SAPK	B
,	O
and	O
apoptotic	O
signaling	O
cascades	O
in	O
a	O
cell	O
comprising	O
administering	O
to	O
a	O
cell	O
a	O
composition	O
comprising	O
tempo	O
in	O
a	O
amount	O
sufficient	O
to	O
induce	O
death	O
of	O
said	O
cell	O
.	O

Use	O
of	O
the	O
(	O
1S,2R	O
)	O
enantiomer	O
of	O
milnacipran	O
for	O
the	O
preparation	O
of	O
a	O
drug	O
A	O
method	O
for	O
treating	O
or	O
preventing	O
a	O
disorder	O
or	O
a	O
condition	O
by	O
double	O
inhibition	O
of	O
serotonin	O
(	O
5-HT	O
)	O
and	O
noradrenaline	O
(	O
NA	O
)	O
reuptake	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
while	O
limiting	O
the	O
risks	O
of	O
cardiovascular	O
disturbances	O
and/or	O
organ	O
and/or	O
tissue	O
toxicity	O
,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
subject	O
a	O
mixture	O
of	O
enantiomers	O
of	O
milnacipran	O
enriched	O
in	O
the	O
(	O
1S,2R	O
)	O
enantiomer	O
of	O
milnacipran	O
and/or	O
of	O
at	O
least	O
one	O
of	O
its	O
metabolites	O
,	O
as	O
well	O
as	O
their	O
pharmaceutically	O
-	O
acceptable	O
salts	O
.	O

Antidepressants	O
and	O
their	O
analogues	O
as	O
long	O
-	O
acting	O
local	O
anesthetics	O
and	O
analgesics	O
Methods	O
and	O
compositions	O
of	O
antidepressants	O
and	O
analogs	O
thereof	O
for	O
inducing	O
local	O
long	O
-	O
lasting	O
anesthesia	O
and	O
analgesia	O
are	O
provided	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
useful	O
for	O
alleviating	O
acute	O
and	O
chronic	O
pain	O
,	O
particularly	O
useful	O
for	O
treating	O
a	O
localized	O
pain	O
.	O

Uses	O
of	O
galanin	O
GALR2	B
receptors	O
This	O
invention	O
provides	O
isolated	O
nucleic	O
acids	O
encoding	O
mammalian	B
galanin	I
receptors	I
,	O
isolated	O
galanin	B
receptor	I
proteins	O
,	O
vectors	O
comprising	O
isolated	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
cells	O
comprising	O
such	O
vectors	O
,	O
antibodies	O
directed	O
to	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
nucleic	O
acid	O
probes	O
useful	O
for	O
detecting	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
antisense	O
oligonucleotides	O
complementary	O
to	O
unique	O
sequences	O
of	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	B
galanin	I
receptor	I
,	O
nonhuman	O
transgenic	O
animals	O
which	O
express	O
DNA	O
encoding	O
a	O
normal	O
or	O
a	O
mutant	O
mammalian	B
galanin	I
receptor	I
,	O
as	O
well	O
as	O
methods	O
of	O
determining	O
binding	O
of	O
compounds	O
to	O
mammalian	B
galanin	I
receptors	I
.	O

Preparation	O
and	O
use	O
of	O
carbohydrate	O
-	O
based	O
bicyclic	O
ring	O
structures	O
with	O
antimicrobial	O
and	O
cytostatic	O
activity	O
Novel	O
carbohydrate	O
-	O
based	O
compounds	O
with	O
an	O
attached	O
ring	O
system	O
that	O
have	O
antimicrobial	O
or	O
cytostatic	O
activity	O
.	O

The	O
compounds	O
are	O
administered	O
to	O
humans	O
and	O
animals	O
for	O
the	O
treatment	O
or	O
amelioration	O
of	O
bacterial	O
,	O
fungal	O
,	O
viral	O
or	O
protozoal	O
infections	O
or	O
tumors	O
.	O

The	O
compounds	O
are	O
of	O
the	O
general	O
formula	O
:	O

Injection	O
made	O
from	O
Ixeris	O
Sonchifolia	O
Hance	O
for	O
treatment	O
of	O
cardio	O
-	O
cerebral	O
vascular	O
diseases	O
and	O
fundus	O
diseases	O
and	O
method	O
of	O
producing	O
thereof	O
The	O
invention	O
discloses	O
an	O
injection	O
made	O
from	O
Chinese	O
herb	O
Ixeris	O
Sonchifolia	O
Hance	O
for	O
treatment	O
of	O
cardio	O
-	O
cerebral	O
vascular	O
diseases	O
and	O
fundus	O
diseases	O
and	O
method	O
of	O
producing	O
thereof	O
.	O

The	O
injection	O
is	O
in	O
a	O
form	O
of	O
lyophilized	O
powder	O
in	O
which	O
the	O
rate	O
of	O
flavone	O
to	O
adenosine	O
is	O
5	O
mg:15	O
μg	O
or	O
5	O
mg:30	O
μg	O
.	O

The	O
flavone	O
and	O
adenosine	O
from	O
Ixeris	O
Sonchifolia	O
Hance	O
is	O
more	O
stable	O
in	O
the	O
lyophilized	O
powder	O
form	O
than	O
in	O
liquid	O
form	O
for	O
injection	O
so	O
that	O
it	O
is	O
easy	O
to	O
control	O
the	O
quality	O
of	O
the	O
product	O
so	O
as	O
to	O
make	O
the	O
medicament	O
safe	O
and	O
effective	O
.	O

It	O
has	O
benefit	O
in	O
store	O
.	O

Reducing	O
risk	O
of	O
thrombotic	O
cardiovascular	O
events	O
such	O
as	O
stroke	O
,	O
myocardial	O
ischemia	O
,	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
,	O
and	O
transient	O
ischemic	O
attack	O
;	O
side	O
effect	O
reduction	O
The	O
invention	O
encompasses	O
novel	O
compounds	O
of	O
Formula	O
I	O
,	O
which	O
are	O
nitric	O
oxide	O
-	O
releasing	O
prodrugs	O
of	O
diaryl-2-	O
(	O
5H	O
)	O
furanones	O
useful	O
in	O
the	O
treatment	O
of	O
cyclooxygenase-2	B
mediated	O
diseases	O
.	O

The	O
invention	O
also	O
encompasses	O
certain	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
cyclooxygenase-2	B
mediated	O
diseases	O
comprising	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
I.	O
The	O
above	O
compounds	O
may	O
be	O
used	O
as	O
a	O
combination	O
therapy	O
with	O
low	O
-	O
dose	O
aspirin	O
to	O
treat	O
chronic	O
cyclooxygenase-2	B
mediated	O
diseases	O
or	O
conditions	O
while	O
also	O
reducing	O
the	O
risk	O
of	O
thrombotic	O
cardiovascular	O
events	O
.	O

Composition	O
based	O
on	O
ethyl	O
ester	O
of	O
linoleic	O
acid	O
and	O
triethyl	O
ester	O
of	O
citric	O
acid	O
for	O
topical	O
use	O
in	O
the	O
treatment	O
of	O
seborrhea	O
and	O
acne	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
topical	O
use	O
for	O
treating	O
and	O
improving	O
the	O
aesthetic	O
conditions	O
of	O
the	O
skin	O
,	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
mixture	O
of	O
ethyllinoleate	O
and	O
triethylcitrate	O
.	O

This	O
composition	O
is	O
active	O
in	O
the	O
treatment	O
of	O
seborrhea	O
and	O
acne	O
.	O

Compounds	O
having	O
prolyl	B
oligopeptidase	I
inhibitory	O
activity	O
,	O
methods	O
for	O
their	O
preparation	O
and	O
their	O
use	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
symbol	O
aa	O
means	O
a	O
residue	O
of	O
an	O
α	O
-	O
amino	O
acid	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
a	O
method	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
their	O
use	O
as	O
prolyl	B
oligopeptide	I
inhibitors	O
,	O
for	O
example	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Use	O
of	O
ozone	O
for	O
the	O
treatment	O
of	O
gum	O
disease	O
A	O
method	O
of	O
treating	O
gum	O
disease	O
,	O
includes	O
directing	O
a	O
stream	O
of	O
oxidizing	O
gas	O
onto	O
a	O
diseased	O
gum	O
for	O
a	O
period	O
of	O
time	O
sufficient	O
to	O
kill	O
microorganisms	O
.	O

Melanin	B
-	I
concentrating	I
hormone	I
antagonist	O
A	O
melanin	B
-	I
concentrating	I
hormone	I
antagonist	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
:	O
wherein	O
R	O
is	O
hydrogen	O
atom	O
or	O
a	O
cyclic	O
group	O
which	O
may	O
be	O
substituted	O
;	O
X	O
is	O
a	O
bond	O
or	O
a	O
spacer	O
having	O
a	O
main	O
chain	O
of	O
1	O
to	O
10	O
atoms	O
;	O
Y	O
is	O
a	O
spacer	O
having	O
a	O
main	O
chain	O
of	O
1	O
to	O
6	O
atoms	O
;	O
ring	O
A	O
is	O
benzene	O
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
ring	O
B	O
is	O
a	O
5-	O
to	O
9-membered	O
nitrogen	O
-	O
containing	O
non	O
-	O
aromatic	O
heterocyclic	O
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
hydrogen	O
atom	O
,	O
a	O
hydrocarbon	O
group	O
which	O
may	O
be	O
substituted	O
or	O
a	O
heterocyclic	O
group	O
which	O
may	O
be	O
substituted	O
;	O
or	O
R1	O
and	O
R2	O
,	O
together	O
with	O
the	O
adjacent	O
nitrogen	O
atom	O
,	O
may	O
form	O
a	O
nitrogen	O
-	O
containing	O
heterocyclic	O
ring	O
which	O
may	O
be	O
substituted	O
;	O
or	O
R2	O
,	O
together	O
with	O
the	O
adjacent	O
nitrogen	O
atom	O
and	O
Y	O
,	O
may	O
form	O
a	O
nitrogen	O
-	O
containing	O
heterocyclic	O
ring	O
which	O
may	O
be	O
substituted	O
;	O
or	O
a	O
salt	O
thereof	O
is	O
useful	O
as	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
obesity	O
,	O
etc	O
.	O

A	O
polynucleotide	O
comprising	O
a	O
RNA	B
polymerase	I
promoter	I
,	O
able	O
encoding	O
a	O
siRNA	O
;	O
treating	O
cancer	O
and	O
genetic	O
disorders	O
;	O
genetic	O
engineering	O
,	O
inhibit	O
gene	O
expression	O
of	O
a	O
target	O
gene	O
The	O
present	O
invention	O
provides	O
a	O
polynucleotide	O
comprising	O
a	O
RNA	B
polymerase	I
III	I
promoter	I
,	O
a	O
region	O
encoding	O
a	O
siRNA	O
,	O
and	O
a	O
transcriptional	O
termination	O
element	O
comprising	O
five	O
consecutive	O
thymine	O
residues	O
.	O

The	O
invention	O
also	O
provides	O
for	O
vectors	O
,	O
cells	O
and	O
non	O
-	O
human	O
transgenic	O
animal	O
comprising	O
the	O
polynucleotides	O
of	O
the	O
invention	O
as	O
well	O
as	O
their	O
use	O
in	O
medicaments	O
for	O
various	O
conditions	O
.	O

Recombinant	O
sequence	O
,	O
its	O
preparation	O
and	O
use	O
An	O
isolated	O
,	O
purified	O
or	O
recombinant	O
nucleic	O
acid	O
sequence	O
is	O
disclosed	O
,	O
comprising	O
:	O
(	O
a	O
)	O
a	O
sequence	O
that	O
encodes	O
both	O
an	O
angiogenic	O
factor	O
antagonist	O
and	O
a	O
vascular	O
endothelial	O
structure	O
regulator	O
;	O
(	O
b	O
)	O
a	O
sequence	O
substantially	O
homologous	O
to	O
or	O
that	O
hybridizes	O
to	O
sequence	O
(	O
a	O
)	O
under	O
stringent	O
conditions	O
;	O
or	O
(	O
c	O
)	O
a	O
sequence	O
substantially	O
homologous	O
to	O
or	O
that	O
hybridizes	O
under	O
stringent	O
conditions	O
to	O
the	O
sequence	O
(	O
a	O
)	O
or	O
(	O
b	O
)	O
but	O
for	O
the	O
degeneracy	O
of	O
the	O
genetic	O
code	O
;	O
or	O
(	O
g	O
)	O
an	O
oligonucleotide	O
specific	O
for	O
any	O
of	O
the	O
sequences	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
or	O
(	O
c	O
)	O
.	O

Particular	O
oligonucleotides	O
(	O
d	O
)	O
are	O
those	O
encoding	O
the	O
vascular	O
endothelial	O
structure	O
regulator	O
.	O

Also	O
described	O
are	O
methods	O
for	O
preparing	O
the	O
recombinant	O
polynucleotide	O
,	O
proteins	O
encoded	O
by	O
such	O
polynucleotides	O
and	O
their	O
use	O
in	O
gene	O
or	O
protein	O
therapy	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
cancer	O
.	O

Benzofuran	O
inhibitors	O
of	O
factor	O
VIIa	O
Compounds	O
of	O
Formula	O
I	O
are	O
useful	O
for	O
inhibiting	O
serine	O
protease	O
enzymes	O
,	O
such	O
as	O
TF	O
/	O
factor	O
VIIa	O
,	O
factor	O
Xa	O
,	O
thrombin	O
and	O
kallikrein	O
and	O
have	O
improved	O
pharmacokinetic	O
properties	O
.	O

These	O
compounds	O
may	O
be	O
used	O
in	O
methods	O
of	O
preventing	O
and/or	O
treating	O
clotting	O
disorders	O
.	O

Infections	O
caused	O
by	O
Gram	O
positive	O
and/or	O
negative	O
pathogens	O
The	O
invention	O
relates	O
to	O
novel	O
tetrahydroisoquinoline	O
derivatives	O
of	O
general	O
formula	O
I	O
and	O
theirs	O
use	O
as	O
active	O
ingredients	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
.	O

The	O
invention	O
also	O
concerns	O
related	O
aspects	O
including	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
those	O
compounds	O
and	O
their	O
use	O
as	O
anti	O
-	O
infectives	O
,	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
claim	O
1	O
.	O

Method	O
for	O
use	O
of	O
IGF	B
-	I
binding	I
protein	I
for	O
selective	O
sensitization	O
of	O
target	O
cells	O
in	O
vivo	O
New	O
methods	O
for	O
the	O
treatment	O
of	O
human	O
disease	O
are	O
provided	O
.	O

IGFBP-3	B
is	O
administered	O
together	O
with	O
a	O
co	O
-	O
administered	O
agent	O
to	O
subjects	O
having	O
disease	O
,	O
thereby	O
alleviating	O
the	O
symptoms	O
of	O
the	O
disease	O
,	O
under	O
conditions	O
where	O
administration	O
of	O
IGFBP-3	B
alone	O
at	O
the	O
maximum	O
practicable	O
dose	O
has	O
no	O
measurable	O
beneficial	O
effect	O
on	O
the	O
disease	O
condition	O
.	O

Inhibiting	O
cyclin	B
-	I
dependent	I
kinase	I
complexes	I
including	O
cdk1	B
/	O
cyclin	B
B	I
,	O
cdk2	B
/	O
cyclin	B
E	I
and	O
cdk4	B
/	O
cyclin	B
D1	I
;	O
preventing	O
apoptosis	O
The	O
present	O
invention	O
is	O
directed	O
to	O
acyl	O
and	O
sulfonyl	O
derivatives	O
of	O
6,9-disubstituted	O
2-	O
(	O
trans-1,4	O
-diaminocyclohexyl	O
)	O
-purines	O
of	O
the	O
formula	O
where	O
Z	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
—S	O
(	O
O	O
)	O
2—	O
,	O
and	O
—C	O
(	O
O	O
)	O
—.	O

Methods	O
for	O
treating	O
or	O
preventing	O
an	O
inflammatory	O
or	O
metabolic	O
condition	O
or	O
inhibiting	O
JNK	B
This	O
invention	O
generally	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
responsive	O
to	O
JNK	B
inhibition	O
,	O
such	O
as	O
a	O
metabolic	O
condition	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
an	O
Anilinopyrimidine	O
Derivative	O
having	O
the	O
following	O
structure	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
through	O
R6	O
are	O
as	O
defined	O
herein	O
.	O

Inhibition	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
vertebrates	O
by	O
dietary	O
fibers	O
The	O
use	O
of	O
a	O
dietary	O
fiber	O
or	O
a	O
mixture	O
of	O
dietary	O
fibers	O
for	O
the	O
manufacture	O
of	O
a	O
composition	O
,	O
being	O
a	O
pharmaceutical	O
composition	O
or	O
a	O
functional	O
food	O
or	O
a	O
functional	O
feed	O
,	O
for	O
the	O
prevention	O
,	O
the	O
inhibition	O
and/or	O
the	O
treatment	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
in	O
vertebrates	O
caused	O
by	O
pathogenic	O
bacteria	O
is	O
disclosed	O
.	O

A	O
method	O
for	O
the	O
prevention	O
,	O
the	O
inhibition	O
and/or	O
the	O
treatment	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
in	O
vertebrates	O
caused	O
by	O
pathogenic	O
bacteria	O
,	O
comprising	O
administration	O
to	O
said	O
beings	O
,	O
orally	O
,	O
through	O
tube	O
feeding	O
or	O
rectally	O
,	O
a	O
composition	O
containing	O
an	O
effective	O
amount	O
of	O
a	O
dietary	O
fiber	O
or	O
mixture	O
of	O
dietary	O
fibers	O
is	O
also	O
disclosed	O
.	O

The	O
dietary	O
fiber	O
is	O
preferably	O
a	O
fructan	O
,	O
typically	O
inulin	O
and/or	O
oligofructose	O
,	O
most	O
preferably	O
chicory	O
inulin	O
with	O
an	O
average	O
degree	O
of	O
polymerization	O
(	O
DP	O
)	O
of	O
at	O
least	O
20	O
.	O

Diazepine	O
compounds	O
as	O
ligands	O
of	O
the	O
melanocortin	B
1	I
and/or	I
4	I
receptors	I
There	O
is	O
provided	O
novel	O
diazepines	O
that	O
function	O
as	O
agonists	O
at	O
the	O
melanocortin	B
4	I
receptor	I
and	O
as	O
agonists	O
at	O
the	O
melanocortin	B
1	I
receptor	I
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
methods	O
for	O
their	O
use	O
in	O
treatment	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

For	O
treatment	O
of	O
rheumatoid	O
arthritis	O
,	O
inflammatory	O
or	O
autoimmune	O
condition	O
,	O
viral	O
infection	O
,	O
cancer	O
;	O
4-	O
{	O
[	O
4-	O
(	O
4-chlorophenyl	O
)	O
pyrimidin-2-yl	O
]	O
amino	O
}	O
benzamide	O
Compounds	O
having	O
activity	O
as	O
inhibitors	O
of	O
IKK	B
are	O
disclosed	O
,	O
particularly	O
IKK-2	B
.	O

The	O
compounds	O
of	O
this	O
invention	O
are	O
anilinopyrimidine	O
derivatives	O
having	O
the	O
following	O
structure	O
:	O
wherein	O
R1	O
and	O
R6	O
are	O
as	O
defined	O
herein	O
.	O

Such	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
conditions	O
that	O
are	O
responsive	O
to	O
IKK	B
inhibition	O
.	O

Thus	O
,	O
methods	O
of	O
treating	O
such	O
conditions	O
are	O
also	O
disclosed	O
,	O
as	O
are	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
compounds	O
of	O
the	O
above	O
compounds	O
.	O

Adust	O
fatty	O
acid	O
oxidation	O
;	O
stimulant	O
of	O
carnitine	B
plamitoyl	I
treansferrase	I
This	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
inducing	O
weight	O
loss	O
and	O
maintaining	O
optimum	O
weight	O
comprising	O
administering	O
an	O
agent	O
that	O
stimulates	O
carnitine	B
palmitoyl	I
transferase-1	I
(	O
CPT-1	B
)	O
activity	O
to	O
the	O
patient	O
in	O
need	O
,	O
including	O
human	O
patients	O
.	O

These	O
methods	O
do	O
not	O
require	O
inhibition	O
of	O
fatty	O
acid	O
synthesis	O
.	O

In	O
particular	O
,	O
this	O
invention	O
provides	O
methods	O
for	O
development	O
of	O
therapeutics	O
that	O
selectively	O
enhance	O
fatty	O
acid	O
oxidation	O
,	O
increase	O
energy	O
production	O
,	O
and	O
reduce	O
adiposity	O
while	O
preserving	O
lean	O
mass	O
,	O
through	O
the	O
pharmacological	O
stimulation	O
of	O
CPT-1	B
activity	O
.	O

In	O
a	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
increase	O
fatty	O
acid	O
oxidation	O
.	O

In	O
another	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
antagonize	O
malonyl	O
CoA	O
inhibition	O
of	O
CPT-1	B
.	O

In	O
yet	O
another	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
increase	O
malonyl	O
CoA	O
level	O
.	O

Identifying	O
modulators	O
for	O
prevention	O
and	O
treatment	O
of	O
infection	O
,	O
blood	O
,	O
metabolic	O
,	O
cell	O
proliferative	O
and	O
respiratory	O
system	O
disorders	O
The	O
present	O
invention	O
provides	O
a	O
purified	O
polynucleotide	O
encoding	O
a	O
novel	O
polypeptide	O
,	O
designated	O
Fhm	O
,	O
which	O
belongs	O
to	O
the	O
TNF	B
gene	O
superfamily	O
;	O
to	O
purified	O
Fhm	O
polypeptide	O
molecules	O
;	O
to	O
antibodies	O
that	O
bind	O
Fhm	O
;	O
to	O
materials	O
comprising	O
such	O
molecules	O
;	O
and	O
to	O
methods	O
of	O
using	O
such	O
molecules	O
.	O

Use	O
of	O
phosphodiesterase	O
4	O
inhibitors	O
such	O
as	O
6,7-dimethoxy-1-	O
[	O
2-	O
(	O
1,3-dioxocyclohexan-2-yl	O
)	O
pyridin-4-yl	O
]	O
-2,3-bis	O
(	O
hydroxymethyl	O
)	O
naphthalene	O
to	O
treat	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
septic	O
shock	O
,	O
ulcerative	O
colitis	O
The	O
present	O
invention	O
provides	O
a	O
novel	O
a	O
condensed	O
polycyclic	O
compound	O
useful	O
as	O
a	O
phosphodiesterase	B
4	I
inhibitor	O
,	O
which	O
is	O
shown	O
by	O
the	O
formula	O
[	O
I	O
]	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
.	O

Heparin	O
prodrugs	O
and	O
drug	O
delivery	O
stents	O
formed	O
therefrom	O
A	O
prodrug	O
comprising	O
a	O
heparin	O
and	O
a	O
drug	O
is	O
provided	O
.	O

The	O
prodrug	O
can	O
be	O
used	O
to	O
form	O
a	O
coating	O
on	O
a	O
medical	O
device	O
.	O

The	O
prodrug	O
can	O
also	O
be	O
used	O
with	O
a	O
polymeric	O
material	O
to	O
form	O
a	O
coating	O
on	O
a	O
medical	O
device	O
.	O

The	O
polymeric	O
material	O
can	O
be	O
a	O
hydrophobic	O
polymer	O
,	O
a	O
hydrophilic	O
polymer	O
,	O
a	O
non	O
-	O
fouling	O
polymer	O
,	O
or	O
combinations	O
thereof	O
.	O

The	O
medical	O
device	O
can	O
be	O
implanted	O
in	O
a	O
human	O
being	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
such	O
as	O
atherosclerosis	O
,	O
thrombosis	O
,	O
restenosis	O
,	O
hemorrhage	O
,	O
vascular	O
dissection	O
or	O
perforation	O
,	O
vascular	O
aneurysm	O
,	O
vulnerable	O
plaque	O
,	O
chronic	O
total	O
occlusion	O
,	O
claudication	O
,	O
anastomotic	O
proliferation	O
for	O
vein	O
and	O
artificial	O
grafts	O
,	O
bile	O
duct	O
obstruction	O
,	O
ureter	O
obstruction	O
,	O
tumor	O
obstruction	O
,	O
or	O
combinations	O
thereof	O
.	O

administering	O
a	O
cholinesterase	B
inhibitor	O
(	O
a	O
dimethoxyindanone	O
derivative	O
)	O
to	O
treat	O
dementia	O
associated	O
with	O
or	O
caused	O
by	O
vascular	O
diseases	O
The	O
invention	O
describes	O
novel	O
methods	O
for	O
treating	O
and	O
preventing	O
dementia	O
caused	O
by	O
vascular	O
diseases	O
;	O
dementia	O
associated	O
with	O
Parkinson	O
's	O
disease	O
;	O
Lewy	O
Body	O
dementia	O
;	O
AIDS	O
dementia	O
;	O
mild	O
cognitive	O
impairments	O
;	O
age	O
-	O
associated	O
memory	O
impairments	O
;	O
cognitive	O
impairments	O
and/or	O
dementia	O
associated	O
with	O
neurologic	O
and/or	O
psychiatric	O
conditions	O
,	O
including	O
epilepsy	O
,	O
brain	O
tumors	O
,	O
brain	O
lesions	O
,	O
multiple	O
sclerosis	O
,	O
Down	O
's	O
syndrome	O
,	O
Rett	O
's	O
syndrome	O
,	O
progressive	O
supranuclear	O
palsy	O
,	O
frontal	O
lobe	O
syndrome	O
,	O
and	O
schizophrenia	O
and	O
related	O
psychiatric	O
disorders	O
;	O
cognitive	O
impairments	O
caused	O
by	O
traumatic	O
brain	O
injury	O
,	O
post	O
coronary	O
artery	O
by	O
-	O
pass	O
graft	O
surgery	O
,	O
electroconvulsive	O
shock	O
therapy	O
,	O
and	O
chemotherapy	O
,	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	B
inhibitor	O
compounds	O
described	O
herein	O
.	O

The	O
invention	O
also	O
describes	O
novel	O
methods	O
for	O
treating	O
and	O
preventing	O
delirium	O
,	O
Tourette	O
's	O
syndrome	O
,	O
myasthenia	O
gravis	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
autism	O
,	O
dyslexia	O
,	O
mania	O
,	O
depression	O
,	O
apathy	O
,	O
and	O
myopathy	O
associated	O
with	O
diabetes	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	B
inhibitor	O
compounds	O
described	O
herein	O
.	O

The	O
invention	O
also	O
describes	O
novel	O
methods	O
for	O
delaying	O
the	O
onset	O
of	O
Alzheimer	O
's	O
disease	O
,	O
for	O
enhancing	O
cognitive	O
functions	O
,	O
for	O
treating	O
and	O
preventing	O
sleep	O
apnea	O
,	O
for	O
alleviating	O
tobacco	O
withdrawal	O
syndrome	O
,	O
and	O
for	O
treating	O
the	O
dysfunctions	O
of	O
Huntington	O
's	O
Disease	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	B
inhibitor	O
compounds	O
described	O
herein	O
.	O

A	O
preferred	O
cholinesterase	B
inhibitor	O
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
invention	O
is	O
donepezil	O
hydrochloride	O
or	O
ARICEPT	O
®	O
.	O

For	O
therapy	O
of	O
oncoses	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
N	O
-	O
substituted	O
indole-3-glyoxylamides	O
of	O
the	O
general	O
formula	O
I	O
as	O
antitumor	O
agents	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
having	O
antitumor	O
action	O
,	O
characterized	O
in	O
that	O
it	O
contains	O
at	O
least	O
one	O
of	O
the	O
compounds	O
of	O
the	O
general	O
formula	O
1	O
,	O
if	O
appropriate	O
also	O
in	O
the	O
form	O
of	O
the	O
physiologically	O
tolerable	O
acid	O
addition	O
salts	O
or	O
N	O
-	O
oxides	O
.	O

Furthermore	O
,	O
the	O
invention	O
also	O
includes	O
antitumor	O
agents	O
comprising	O
as	O
active	O
compound	O
one	O
or	O
more	O
N	O
-	O
substituted	O
indole-3-glyoxylamides	O
according	O
to	O
the	O
general	O
formula	O
1	O
and	O
,	O
if	O
appropriate	O
,	O
their	O
physiologically	O
tolerable	O
acid	O
addition	O
salts	O
and	O
,	O
if	O
possible	O
,	O
N	O
-	O
oxides	O
and	O
a	O
pharmaceutically	O
utilizable	O
carrier	O
and/or	O
diluent	O
or	O
auxiliary	O
substance	O
in	O
the	O
form	O
of	O
tablets	O
,	O
coated	O
tablets	O
,	O
capsules	O
,	O
solutions	O
for	O
infusion	O
or	O
ampoules	O
,	O
suppositories	O
,	O
patches	O
,	O
powder	O
preparations	O
which	O
can	O
be	O
employed	O
by	O
inhalation	O
,	O
suspensions	O
,	O
creams	O
and	O
ointments	O
.	O

Epothilone	O
derivatives	O
and	O
their	O
synthesis	O
and	O
use	O
The	O
invention	O
relates	O
to	O
epothilone	O
analog	O
represented	O
by	O
the	O
formula	O
I	O
wherein	O
(	O
i	O
)	O
R2	O
is	O
absent	O
or	O
oxygen	O
;	O
""""	O
a	O
""""	O
can	O
be	O
either	O
a	O
single	O
or	O
double	O
bond	O
;	O
""""	O
b	O
""""	O
can	O
be	O
either	O
absent	O
or	O
a	O
single	O
bond	O
;	O
and	O
""""	O
c	O
""""	O
can	O
be	O
either	O
absent	O
or	O
a	O
single	O
bond	O
,	O
with	O
the	O
proviso	O
that	O
if	O
R2	O
is	O
oxygen	O
then	O
""""	O
b	O
""""	O
and	O
""""	O
c	O
""""	O
are	O
both	O
a	O
single	O
bond	O
and	O
""""	O
a	O
""""	O
is	O
a	O
single	O
bond	O
;	O
if	O
R2	O
is	O
absent	O
then	O
""""	O
b	O
""""	O
and	O
""""	O
c	O
""""	O
are	O
absent	O
and	O
""""	O
a	O
""""	O
is	O
a	O
double	O
bond	O
;	O
and	O
if	O
""""	O
a	O
""""	O
is	O
a	O
double	O
bond	O
,	O
then	O
R2	O
,	O
""""	O
b	O
""""	O
and	O
""""	O
c	O
""""	O
are	O
absent	O
;	O
R3	O
is	O
a	O
radical	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
;	O
lower	O
alkyl	O
;	O
—CH	O
═	O
CH2	O
;	O
—C≡CH	O
;	O
—CH2F	O
;	O
—CH2Cl	O
;	O
—CH2—OH	O
;	O
—CH2—O—	O
(	O
C1-C6-alkyl	O
)	O
;	O
and	O
—CH2—S—	O
(	O
C1-C6-alkyl	O
)	O
;	O
R4	O
and	O
R5	O
are	O
independently	O
selected	O
from	O
hydrogen	O
,	O
methyl	O
or	O
a	O
protecting	O
group	O
;	O
and	O
R1	O
is	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
salt	O
of	O
a	O
compound	O
of	O
the	O
formula	O
I	O
where	O
a	O
salt	O
-	O
forming	O
group	O
is	O
present	O
.	O

A	O
further	O
aspect	O
of	O
the	O
invention	O
is	O
related	O
to	O
the	O
synthesis	O
of	O
epothilone	O
E.	O
These	O
compounds	O
have	O
inter	O
alia	O
microtubuli	O
depolymerisation	O
inhibiting	O
activity	O
and	O
are	O
e.g.	O
useful	O
against	O
proliferative	O
diseases	O
.	O

Modulators	O
of	O
blood	O
glucose	O
levels	O
,	O
triglyceride	O
levels	O
,	O
insulin	B
levels	O
and	O
non	O
-	O
esterified	O
fatty	O
acid	O
(	O
NEFA	O
)	O
levels	O
;	O
hypoglycemia	O
Compounds	O
are	O
provided	O
which	O
have	O
the	O
structure	O
wherein	O
Q	O
is	O
C	O
or	O
N	O
,	O
A	O
is	O
O	O
or	O
S	O
,	O
Z	O
is	O
O	O
or	O
a	O
bond	O
,	O
X	O
is	O
CH	O
or	O
N	O
and	O
R1	O
,	O
R2	O
,	O
R2a	O
,	O
R2b	O
,	O
R2c	O
,	O
R3	O
,	O
Y	O
,	O
x	O
,	O
m	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
which	O
compounds	O
are	O
useful	O
as	O
antidiabetic	O
,	O
hypolipidemic	O
,	O
and	O
antiobesity	O
agents	O
.	O

Antidiabetic	O
agents	O
,	O
antilipemic	O
agents	O
,	O
dietetics	O
,	O
anticholesterol	O
agents	O
,	O
hypotensive	O
agents	O
,	O
cardiovascular	O
disorders	O
;	O
(	O
S	O
)	O
-Ethyl	O
2-methoxy-3-	O
[	O
4-	O
{	O
3-	O
(	O
4-methanesulfonyloxyphenyl	O
)	O
propylamino	O
}	O
phenyl	O
]	O
propionate	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
antidiabetic	O
,	O
hypolipidemic	O
,	O
antiobesity	O
and	O
hypocholesterolemic	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
their	O
analogs	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
polymorphs	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

Antiproliferative	O
agents	O
;	O
antiinflammatory	O
agents	O
;	O
anticancer	O
agents	O
;	O
diagnosis	O
,	O
therapy	O
The	O
present	O
invention	O
pertains	O
to	O
the	O
use	O
of	O
a	O
compounds	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
proliferative	O
condition	O
,	O
wherein	O
the	O
compounds	O
have	O
the	O
following	O
formula	O
:	O
wherein	O
:	O
each	O
of	O
RB2	O
,	O
RB3	O
,	O
RB4	O
,	O
and	O
RB5	O
is	O
independently	O
—H	O
,	O
—OH	O
,	O
or	O
—OMe	O
;	O
each	O
of	O
R1	O
and	O
R2	O
is	O
independently	O
:	O
—H	O
,	O
optionally	O
substituted	O
C1	O
-	O
4alkyl	O
,	O
or	O
optionally	O
substituted	O
C5	O
-	O
20aryl	O
;	O
RA3	O
is	O
—H	O
,	O
—OH	O
,	O
—OC	O
(	O
═	O
O	O
)	O
RE	O
,	O
—OS	O
(	O
═	O
O	O
)	O
2OH	O
,	O
or	O
—OP	O
(	O
═	O
O	O
)	O
(	O
OH	O
)	O
2	O
;	O
RE	O
is	O
:	O
—H	O
,	O
optionally	O
substituted	O
C1	O
-	O
6alkyl	O
,	O
optionally	O
substituted	O
C3	O
-	O
20	O
heterocyclyl	O
,	O
or	O
optionally	O
substituted	O
C5	O
-	O
20aryl	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
,	O
amide	O
,	O
ester	O
,	O
ether	O
,	O
chemically	O
protected	O
form	O
,	O
or	O
prodrug	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
for	O
both	O
diagnosis	O
and	O
treatment	O
of	O
,	O
for	O
example	O
,	O
proliferative	O
conditions	O
,	O
such	O
as	O
cancer	O
,	O
and	O
inflammatory	O
conditions	O
.	O

Induce	O
cell	O
differentiation	O
;	O
process	O
control	O
The	O
invention	O
features	O
methods	O
for	O
increasing	O
or	O
maintaining	O
the	O
number	O
of	O
functional	O
cells	O
of	O
a	O
predetermined	O
type	O
,	O
for	O
example	O
,	O
insulin	B
producing	O
cells	O
of	O
the	O
pancreas	O
,	O
blood	O
cells	O
,	O
spleen	O
cells	O
,	O
brain	O
cells	O
,	O
heart	O
cells	O
,	O
vascular	O
tissue	O
cells	O
,	O
cells	O
of	O
the	O
bile	O
duct	O
,	O
or	O
skin	O
cells	O
,	O
in	O
a	O
mammal	O
(	O
e.g.	O
,	O
a	O
human	O
patient	O
)	O
that	O
has	O
injured	O
or	O
damaged	O
cells	O
of	O
the	O
predetermined	O
type	O
.	O

Fluidized	O
bed	O
granulation	O
,	O
compression	O
to	O
form	O
tablets	O
A	O
process	O
for	O
the	O
preparation	O
of	O
an	O
orally	O
administrable	O
calcium	O
composition	O
comprising	O
the	O
steps	O
of	O
:	O
(	O
i	O
)	O
obtaining	O
a	O
physiologically	O
tolerable	O
particulate	O
calcium	O
compound	O
having	O
a	O
mean	O
particle	O
size	O
in	O
the	O
range	O
3	O
to	O
40	O
μm	O
,	O
having	O
a	O
crystalline	O
structure	O
and	O
having	O
a	O
surface	O
area	O
of	O
0.1	O
to	O
1.2	O
m2	O
/	O
g	O
;	O
(	O
ii	O
)	O
mixing	O
the	O
calcium	O
compound	O
with	O
a	O
water	O
-	O
soluble	O
diluent	O
and	O
an	O
aqueous	O
solution	O
of	O
a	O
water	O
soluble	O
binder	O
in	O
a	O
fluid	O
bed	O
granulation	O
apparatus	O
and	O
drying	O
the	O
resulting	O
mixture	O
to	O
produce	O
a	O
first	O
granulate	O
;	O
(	O
iii	O
)	O
optionally	O
mixing	O
the	O
first	O
granulate	O
with	O
one	O
or	O
more	O
further	O
components	O
to	O
produce	O
a	O
second	O
granulate	O
;	O
and	O
(	O
iv	O
)	O
optionally	O
compressing	O
the	O
first	O
or	O
second	O
granulate	O
to	O
form	O
tablets	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
the	O
eye	O
Methods	O
and	O
compositions	O
for	O
prophylaxis	O
and/or	O
treatment	O
of	O
diseases	O
of	O
the	O
eye	O
of	O
a	O
patient	O
resulting	O
angiogenesis	O
in	O
the	O
eye	O
using	O
antagonists	O
of	O
the	O
integrin	O
receptors	O
αv	O
β3	O
and/or	O
αv	O
β5	O
.	O

The	O
compositions	O
can	O
be	O
nanoparticles	O
and	O
are	O
administered	O
to	O
the	O
eye	O
by	O
injection	O
into	O
the	O
sclera	O
of	O
the	O
eye	O
.	O

4-Deoxy-3,4-	O
[	O
2-spiro-	O
[	O
1-	O
[	O
2-	O
(	O
2-methyl-5-nitro	O
-	O
imidazol-1-yl	O
)	O
ethyl	O
]	O
-piperidin-4-yl	O
]	O
]	O
-	O
(	O
1H	O
)	O
-imidazo-	O
(	O
2,5-dihydro	O
)	O
rifamycin	O
;	O
antibiotic	O
resistance	O
;	O
synergistic	O
effects	O
of	O
covalently	O
linking	O
antibacterial	O
pharmacophores	O
together	O
;	O
pharmacokinetics	O
;	O
aerobic	O
,	O
anaerobic	O
gram	O
-	O
positive	O
and	O
gram	O
-	O
negative	O
bacteria	O
Substituted	O
rifamycin	O
derivatives	O
in	O
which	O
a	O
nitroimidazole	O
,	O
nitrothiazole	O
or	O
nitrofuran	O
pharmacophore	O
is	O
covalently	O
bonded	O
to	O
a	O
rifamycin	O
,	O
methods	O
of	O
using	O
the	O
rifamycin	O
derivatives	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
rifamycin	O
derivatives	O
are	O
disclosed	O
.	O

Methods	O
of	O
synthesizing	O
these	O
substituted	O
rifamycin	O
derivatives	O
are	O
also	O
disclosed	O
.	O

The	O
rifamycin	O
derivatives	O
possess	O
antibacterial	O
activity	O
,	O
and	O
are	O
effective	O
against	O
a	O
number	O
of	O
human	O
and	O
veterinary	O
pathogens	O
in	O
the	O
treatment	O
of	O
bacterial	O
diseases	O
.	O

3-	O
(	O
(	O
1,2,5,6-tetrahydro-2-methyl-5,6-d	O
ioxo-1,2,4-triazine-3-yl	O
)	O
thio	O
)	O
methyl	O
)	O
-7-	O
[	O
[	O
[	O
[	O
[	O
(	O
1-methyl	O
ethyl	O
)	O
amino	O
]	O
[	O
(	O
1-methylethyl	O
)	O
imino	O
]	O
methyl	O
]	O
thio	O
]	O
acetyl	O
]	O
amino	O
]	O
-8-oxo-5-thia-1-aza	O
-	O
bicyclo	O
[	O
4.2.0	O
]	O
oct-2-ene-2-carboxylic	O
acid	O
;	O
bioavailibility	O
;	O
stability	O
;	O
pharmacokinetics	O
;	O
antibiotics	O
;	O
infections	O
Disclosed	O
herein	O
are	O
a	O
cephalosporin	O
compound	O
of	O
formula	O
I	O
,	O
wherein	O
R1	O
is	O
selected	O
from	O
the	O
following	O
groups	O
:	O
wherein	O
R2	O
is	O
selected	O
from	O
the	O
following	O
groups	O
:	O
the	O
preparation	O
and	O
uses	O
thereof	O
.	O

A	O
method	O
of	O
preparing	O
the	O
cephalosporin	O
compound	O
as	O
disclosed	O
herein	O
comprises	O
reacting	O
a	O
starting	O
cephalosporin	O
comprising	O
a	O
C7	O
amino	O
group	O
and	O
a	O
C3	O
thio	O
-	O
methyl	O
moiety	O
substituted	O
with	O
an	O
N	O
-	O
containing	O
heterocyclic	O
group	O
with	O
bromoacetyl	O
bromide	O
and	O
then	O
with	O
a	O
N	O
,	O
N′-bissubstituted	O
thiourea	O
.	O

Methods	O
of	O
treating	O
an	O
infectious	O
disease	O
are	O
also	O
disclosed	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
the	O
pharmaceutical	O
composition	O
disclosed	O
herein	O
.	O

1-Substituted-	O
[	O
1H	O
-	O
indene-6,1'-cyclopropane	O
]	O
-4-one	O
derivatives	O
:	O
solid	O
tumors	O
and	O
multi	O
-	O
drug	O
resistant	O
tumors	O
;	O
-cell	O
leukemia	O
,	O
B	O
-	O
cell	O
lymphoma	O
,	O
myeloma	O
,	O
T	O
-	O
cell	O
leukemia	O
,	O
T	O
-	O
cell	O
lymphoma	O
,	O
small	O
leukemia	O
,	O
and	O
small	O
cell	O
lymphoma	O
The	O
present	O
invention	O
provides	O
illudin	O
analogs	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
where	O
R1	O
is	O
(	O
CH2	O
)	O
n	O
—	O
X	O
—	O
Y	O
or	O
H	O
;	O
n	O
is	O
0	O
to	O
4	O
;	O
X	O
is	O
O	O
or	O
S	O
or	O
N	O
or	O
absent	O
;	O
and	O
Y	O
is	O
an	O
optionally	O
substituted	O
(	O
C1-C8	O
)	O
alkyl	O
,	O
(	O
C6-C10	O
)	O
aryl	O
,	O
(	O
C6-C10	O
)	O
aryl	O
(	O
C1-C4	O
)	O
alkyl	O
or	O
cyclo	O
(	O
C3-C6	O
)	O
alkyl	O
optionally	O
comprising	O
one	O
or	O
more	O
heteroatoms	O
;	O
a	O
monosaccharide	O
,	O
an	O
amino	O
acid	O
residue	O
,	O
or	O
H	O
when	O
n	O
is	O
2	O
-	O
4	O
;	O
R2	O
is	O
absent	O
;	O
or	O
R1	O
and	O
R2	O
together	O
comprise	O
a	O
5	O
-	O
7	O
membered	O
cyclic	O
ring	O
;	O
R3	O
is	O
(	O
C1-C4	O
)	O
alkyl	O
or	O
H	O
;	O
R4	O
is	O
H	O
,	O
SCH2CO2	O
(	O
C1-C4	O
)	O
alkyl	O
,	O
O—	O
(	O
C5-C12	O
)	O
aryl	O
or	O
—S—	O
(	O
C5-C12	O
)	O
aryl	O
;	O
R5	O
is	O
H	O
,	O
OH	O
or	O
absent	O
;	O
R6	O
is	O
(	O
C1-C4	O
)	O
alkyl	O
or	O
absent	O
;	O
R7	O
is	O
OH	O
or	O
OSi	O
(	O
(	O
C1-C4	O
)	O
alkyl	O
)	O
3	O
;	O
or	O
R6	O
and	O
R7	O
together	O
are	O
ethylenedioxy	O
;	O
R8	O
is	O
optionally	O
substituted	O
(	O
C1-C4	O
)	O
alkyl	O
;	O
and	O
the	O
bonds	O
represented	O
by	O
-----	O
are	O
individually	O
present	O
or	O
absent	O
.	O

The	O
invention	O
further	O
provides	O
dimers	O
comprising	O
analogs	O
of	O
formula	O
(	O
I	O
)	O
.	O

10-	O
(	O
o	O
-	O
Hydroxyphenyl	O
)	O
--3a,4,9,10-tetrahydro-2-alkyl-2,9,10a	O
-	O
triazacyclopenty	O
[	O
b	O
]	O
fluorene-1,3-diones	O
or	O
the	O
corresponding	O
2,10a	O
-	O
diaza-9	O
oxafluorenediones	O
or	O
1,10a	O
-	O
diaza-9-thiafluorenediones	O
;	O
antiproliferative	O
,	O
apoptosis	O
-	O
inducing	O
agents	O
;	O
treating	O
color	O
cancer	O
Compounds	O
of	O
the	O
formula	O
(	O
1	O
)	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
,	O
are	O
novel	O
effective	O
compounds	O
with	O
Eg5	B
inhibitory	O
,	O
anti	O
-	O
proliferative	O
and/or	O
apoptosis	O
inducing	O
activity	O
.	O

Fasudil	O
-	O
containing	O
preparation	O
and	O
method	O
of	O
improving	O
stability	O
thereof	O
Fasudil	O
-	O
containing	O
preparations	O
that	O
despite	O
the	O
us	O
of	O
a	O
container	O
excelling	O
in	O
the	O
visibility	O
of	O
contents	O
without	O
particularly	O
blocking	O
of	O
light	O
,	O
exhibit	O
high	O
stability	O
against	O
light	O
;	O
and	O
a	O
method	O
of	O
improving	O
the	O
stability	O
of	O
the	O
preparations	O
against	O
light	O
of	O
storing	O
the	O
same	O
.	O

By	O
regulating	O
the	O
pH	O
value	O
of	O
aqueous	O
solution	O
of	O
fasudil	O
charged	O
in	O
a	O
colorless	O
transparent	O
container	O
to	O
≦5.5	O
,	O
there	O
can	O
be	O
provided	O
fasudil	O
-	O
containing	O
preparations	O
excelling	O
in	O
stability	O
against	O
light	O
;	O
and	O
can	O
be	O
provided	O
a	O
method	O
of	O
improving	O
the	O
stability	O
of	O
the	O
aqueous	O
solution	O
of	O
fasudil	O
against	O
light	O
,	O
or	O
storing	O
the	O
same	O
.	O

Dengue	O
viruses	O
useful	O
for	O
vaccination	O
against	O
Flavivirus	O
;	O
Modified	O
Vaccinia	O
Virus	O
Ankara	O
(	O
MVA	O
)	O
;	O
stable	O
,	O
can	O
easily	O
be	O
produced	O
The	O
present	O
invention	O
relates	O
to	O
NS1	O
proteins	O
or	O
parts	O
thereof	O
of	O
Flaviviruses	O
,	O
in	O
particular	O
of	O
Dengue	O
viruses	O
useful	O
for	O
vaccination	O
against	O
said	O
Flavivirus	O
and	O
against	O
one	O
or	O
more	O
other	O
Flaviviruses	O
.	O

The	O
invention	O
further	O
concerns	O
the	O
NS1	O
protein	O
or	O
parts	O
thereof	O
of	O
one	O
Dengue	O
virus	O
serotype	O
,	O
in	O
particular	O
serotype	O
2	O
,	O
useful	O
for	O
vaccination	O
against	O
Dengue	O
viruses	O
from	O
all	O
serotypes	O
.	O

The	O
invention	O
further	O
concerns	O
DNA	O
comprising	O
an	O
expression	O
cassette	O
coding	O
for	O
a	O
Flavivirus	O
NS1	O
or	O
parts	O
thereof	O
,	O
vectors	O
comprising	O
said	O
DNA	O
and	O
vaccines	O
containing	O
or	O
expressing	O
a	O
Flavivirus	O
NS1	O
.	O

inhibition	O
of	O
heat	B
shock	I
protein	I
90	I
(	O
HSP90	B
)	O
comprising	O
administering	O
benzoyl	O
compounds	O
or	O
prodrugs	O
,	O
as	O
antitumor	O
agents	O
The	O
present	O
invention	O
provides	O
Hsp90	B
family	O
protein	O
inhibitors	O
comprising	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
benzoyl	O
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
wherein	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
10	O
;	O
R1	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkoxy	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkoxycarbonyl	O
,	O
CONR7R8	O
or	O
the	O
like	O
;	O
R2	O
represents	O
substituted	O
or	O
unsubstituted	O
aryl	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	O
heterocyclic	O
group	O
or	O
the	O
like	O
;	O
R3	O
and	O
R5	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
each	O
represent	O
a	O
hydrogen	O
atom	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkenyl	O
or	O
the	O
like	O
;	O
and	O
R4	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
each	O
represent	O
a	O
hydrogen	O
atom	O
,	O
halogen	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	O
,	O
substituted	O
or	O
unsubstituted	O
aryl	O
or	O
the	O
like	O
)	O
or	O
a	O
prodrug	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
said	O
benzoyl	O
compound	O
or	O
said	O
prodrug	O
.	O

Isomaltooligosaccharides	O
to	O
inhibit	O
avian	O
pathogenic	O
intestinal	O
bacteria	O
Isomaltooligosaccharides	O
(	O
IMOs	O
)	O
produced	O
by	O
Leuconostoc	O
mesenteroides	O
ATCC	O
13146	O
fermentation	O
with	O
a	O
sucrose	O
:	O
maltose	O
ratio	O
of	O
2:1	O
have	O
been	O
discovered	O
to	O
be	O
effective	O
prebiotics	O
in	O
mixed	O
cultures	O
of	O
microbial	O
populations	O
,	O
including	O
cultures	O
from	O
chicken	O
ceca	O
.	O

Surprisingly	O
in	O
mixed	O
microbial	O
cultures	O
this	O
IMO	O
composition	O
proved	O
as	O
effective	O
as	O
FOS	O
.	O

Thus	O
,	O
these	O
IMOs	O
can	O
be	O
used	O
as	O
effective	O
prebiotics	O
for	O
both	O
birds	O
and	O
mammals	O
.	O

Moreover	O
,	O
the	O
IMOs	O
were	O
discovered	O
to	O
be	O
effective	O
non	O
-	O
competitive	O
inhibitors	O
of	O
α	B
-	I
glucosidase	I
.	O

These	O
IMOs	O
also	O
will	O
be	O
useful	O
,	O
as	O
an	O
α	B
-	I
glucosidase	I
inhibitor	O
,	O
in	O
a	O
therapeutic	O
application	O
for	O
several	O
diseases	O
,	O
including	O
obesity	O
,	O
diabetes	O
mellitus	O
,	O
pre	O
-	O
diabetes	O
,	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
caries	O
,	O
cancer	O
,	O
viral	O
disease	O
such	O
as	O
hepatitis	O
B	O
and	O
C	O
,	O
HIV	O
,	O
and	O
AIDS	O
.	O

A	O
diet	O
with	O
5	O
-	O
20	O
%	O
IMOs	O
was	O
also	O
shown	O
to	O
reduce	O
the	O
abdominal	O
fat	O
tissue	O
in	O
mammals	O
.	O

Detecting	O
a	O
colorectal	O
cancer	O
and/or	O
gastric	O
cancer	O
,	O
detecting	O
selective	O
hybridization	O
of	O
nucleic	O
acid	O
,	O
therapeutic	O
treatment	O
of	O
a	O
cancer	O
,	O
a	O
kit	O
contains	O
oligonucleotide	O
A	O
method	O
of	O
identifying	O
epigenetically	O
silenced	O
genes	O
,	O
e.g.	O
,	O
methylation	O
silenced	O
genes	O
,	O
in	O
cancer	O
cells	O
is	O
provided	O
.	O

In	O
addition	O
,	O
methods	O
of	O
identifying	O
a	O
cancer	O
by	O
detecting	O
epigenetic	O
silencing	O
of	O
gene	O
expression	O
are	O
provided	O
,	O
as	O
are	O
methods	O
of	O
treating	O
a	O
subject	O
having	O
such	O
a	O
cancer	O
,	O
for	O
example	O
,	O
a	O
colorectal	O
cancer	O
and/or	O
gastric	O
cancer	O
.	O

Reagents	O
for	O
practicing	O
such	O
methods	O
also	O
are	O
provided	O
.	O

fewer	O
side	O
-	O
effects	O
by	O
showing	O
no	O
hormone	O
properties	O
;	O
enhancing	O
the	O
learning	O
and	O
memory	O
-	O
retention	O
,	O
treat	O
dementia	O
The	O
present	O
invention	O
relates	O
to	O
cinnamic	O
acid	O
dimers	O
,	O
their	O
preparation	O
and	O
the	O
use	O
thereof	O
for	O
treating	O
neurodegenerative	O
disease	O
,	O
which	O
have	O
excellent	O
effect	O
on	O
enhancing	O
the	O
learning	O
and	O
memory	O
-	O
retention	O
ability	O
in	O
vivo	O
and	O
have	O
fewer	O
side	O
-	O
effects	O
by	O
showing	O
no	O
hormone	O
properties	O
,	O
even	O
when	O
administered	O
for	O
a	O
long	O
period	O
of	O
time	O
,	O
and	O
thus	O
which	O
can	O
be	O
used	O
for	O
neurodegenerative	O
disease	O
including	O
dementia	O
.	O

Using	O
HIV	B
protease	I
inhibitors	O
(	O
indinavir	O
,	O
nelfinavir	O
,	O
ritonavir	O
,	O
or	O
saquinavir	O
)	O
alone	O
or	O
in	O
combination	O
with	O
chemotherapy	O
,	O
radiotherapy	O
,	O
or	O
surgery	O
Liposarcomas	O
are	O
treated	O
using	O
HIV	B
protease	I
inhibitors	O
,	O
particularly	O
nelfinavir	O
.	O

The	O
protease	O
inhibitors	O
may	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
traditional	O
cancer	O
treatments	O
,	O
such	O
as	O
chemotherapy	O
,	O
radiotherapy	O
,	O
or	O
surgery	O
.	O

combination	O
of	O
N-	O
(	O
1-methylpiperidin-4-yl	O
)	O
-N-	O
(	O
4-fluorophenylmethyl	O
)	O
-N'-	O
(	O
4-	O
(	O
2-methylpropyloxy	O
)	O
phenylmethyl	O
)	O
carbamide	O
andmonoamine	O
oxidase	B
inhibitor	O
(	O
MAO	B
-	O
I	O
)	O
selected	O
from	O
tranylcypromine	O
(	O
Parnate	O
)	O
,	O
phenelzine	O
(	O
Nardil	O
)	O
,	O
maprotiline	O
,	O
and	O
isocarboxazid	O
(	O
Marplan	O
)	O
;	O
anti	O
-	O
psychotic	O
agent	O
;	O
dosage	O
form	O
;	O
capsule	O
Disclosed	O
herein	O
are	O
pharmaceutical	O
compositions	O
comprising	O
an	O
inverse	O
serotonin	B
receptor	I
agonist	O
or	O
a	O
serotonin	B
receptor	I
antagonist	O
and	O
an	O
anti	O
-	O
psychotic	O
agent	O
.	O

Disclosed	O
herein	O
are	O
also	O
methods	O
of	O
treating	O
psychotic	O
disorders	O
using	O
the	O
disclosed	O
pharmaceutical	O
compositions	O
.	O

Substituted	O
5-phenyl-3,6-dihydro-2-oxo-6H-1,3,4-thiadiazines	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
m	O
,	O
Q	O
and	O
B	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
tyrosine	B
kinases	I
,	O
in	O
particular	O
Met	B
kinase	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
tumours	O
.	O

Antiproliferative	O
agents	O
;	O
gene	O
overexpression	O
This	O
invention	O
relates	O
to	O
vitamin	O
-	O
mitomycin	O
conjugates	O
,	O
to	O
a	O
method	O
of	O
using	O
the	O
conjugates	O
to	O
selectively	O
eliminate	O
a	O
population	O
of	O
pathogenic	O
cells	O
in	O
a	O
host	O
animal	O
harboring	O
the	O
pathogenic	O
cells	O
,	O
and	O
to	O
a	O
method	O
of	O
preparation	O
of	O
the	O
conjugates	O
.	O

The	O
conjugate	O
is	O
of	O
the	O
general	O
formula	O
B	O
-	O
L	O
-	O
X	O
wherein	O
the	O
group	O
B	O
is	O
a	O
vitamin	O
,	O
or	O
an	O
analog	O
or	O
a	O
derivative	O
thereof	O
,	O
that	O
binds	O
to	O
a	O
surface	O
accessible	O
vitamin	O
receptor	O
that	O
is	O
uniquely	O
expressed	O
,	O
overexpressed	O
,	O
or	O
preferentially	O
expressed	O
by	O
a	O
population	O
of	O
pathogenic	O
cells	O
,	O
wherein	O
the	O
group	O
L	O
comprises	O
a	O
cleavable	O
linker	O
,	O
and	O
wherein	O
the	O
group	O
X	O
comprises	O
a	O
mitomycin	O
compound	O
,	O
or	O
an	O
analog	O
or	O
a	O
derivative	O
thereof	O
.	O

An	O
additional	O
therapeutic	O
agent	O
,	O
such	O
as	O
a	O
chemotherapeutic	O
agent	O
,	O
can	O
be	O
administered	O
in	O
combination	O
with	O
the	O
conjugate	O
.	O

Such	O
as	O
6-benzenesulfonyl-4-piperazin-1-yl	O
-	O
quinoline	O
hydrochloride	O
;	O
for	O
treatment	O
of	O
central	O
nervous	O
system	O
and/or	O
5-	B
HT6	I
receptor	O
related	O
disorders	O
;	O
for	O
weight	O
gain	O
/	O
loss	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
P	O
is	O
sulfone	O
or	O
sulfonamide	O
;	O
and	O
A	O
,	O
B	O
,	O
W	O
,	O
X	O
,	O
Y	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
;	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
medical	O
conditions	O
relating	O
to	O
obesity	O
,	O
type	O
II	O
diabetes	O
,	O
and/or	O
CNS	O
disorders	O
,	O
to	O
achieve	O
reduction	O
of	O
body	O
weight	O
and	O
of	O
body	O
weight	O
gain	O
.	O

Gene	O
repair	O
involving	O
in	O
vivo	O
excision	O
of	O
targeting	O
DNA	O
Methods	O
of	O
modifying	O
,	O
repairing	O
,	O
attenuating	O
and	O
inactivating	O
a	O
gene	O
or	O
other	O
chromosomal	O
DNA	O
in	O
a	O
cell	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
or	O
prophylaxis	O
of	O
a	O
genetic	O
disease	O
in	O
an	O
individual	O
in	O
need	O
thereof	O
.	O

Sustained	O
release	O
portion	O
of	O
unit	O
dose	O
containing	O
guaifenesin	O
,	O
dextromethorphan	O
and	O
a	O
release	O
-	O
delaying	O
matrix	O
contains	O
a	O
hydrophilic	O
polymer	O
and	O
a	O
water	O
insoluble	O
polymer	O
,	O
immediate	O
release	O
portion	O
containing	O
guaifenesin	O
The	O
invention	O
relates	O
to	O
a	O
novel	O
pharmaceutical	O
modified	O
release	O
formulation	O
of	O
guaifenesin	O
and	O
dextromethorphan	O
.	O

The	O
formulation	O
may	O
comprise	O
a	O
hydrophilic	O
polymer	O
,	O
preferably	O
a	O
hydroxypropyl	O
methylcellulose	O
,	O
and	O
a	O
water	O
-	O
insoluble	O
polymer	O
,	O
preferably	O
an	O
acrylic	O
resin	O
,	O
in	O
a	O
ratio	O
range	O
of	O
about	O
one	O
-	O
to	O
-	O
one	O
(	O
1:1	O
)	O
to	O
about	O
nine	O
-	O
to	O
-	O
one	O
(	O
9:1	O
)	O
,	O
more	O
preferably	O
a	O
range	O
of	O
about	O
three	O
-	O
to	O
-	O
two	O
(	O
3:2	O
)	O
to	O
about	O
six	O
-	O
to	O
-	O
one	O
(	O
6:1	O
)	O
,	O
and	O
most	O
preferably	O
in	O
a	O
range	O
of	O
about	O
two	O
-	O
to	O
-	O
one	O
(	O
2:1	O
)	O
to	O
about	O
four	O
-	O
to	O
-	O
one	O
(	O
4:1	O
)	O
by	O
weight	O
.	O

This	O
formulation	O
capable	O
of	O
providing	O
therapeutically	O
effective	O
bioavailability	O
of	O
guaifenesin	O
for	O
at	O
least	O
twelve	O
hours	O
after	O
dosing	O
in	O
a	O
human	O
subject	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
modified	O
release	O
product	O
which	O
has	O
two	O
portions	O
:	O
a	O
first	O
portion	O
having	O
an	O
immediate	O
release	O
formulation	O
of	O
guaifenesin	O
and	O
a	O
second	O
portion	O
having	O
a	O
sustained	O
release	O
formulation	O
of	O
guaifenesin	O
,	O
wherein	O
one	O
or	O
both	O
portions	O
further	O
comprises	O
dextromethorphan	O
.	O

The	O
modified	O
release	O
product	O
has	O
a	O
maximum	O
guaifenesin	O
serum	O
concentration	O
equivalent	O
to	O
that	O
of	O
an	O
immediate	O
release	O
guaifenesin	O
tablet	O
,	O
and	O
is	O
capable	O
of	O
providing	O
therapeutically	O
effective	O
bioavailability	O
of	O
guaifenesin	O
for	O
at	O
least	O
twelve	O
hours	O
after	O
dosing	O
in	O
a	O
human	O
subject	O
.	O

Crystalline	O
forms	O
of	O
rapamycin	O
analogs	O
Provided	O
is	O
a	O
rapamycin	O
analog	O
composition	O
including	O
a	O
crystalline	O
form	O
of	O
a	O
rapamycin	O
analog	O
.	O

The	O
crystal	O
can	O
be	O
a	O
hydrate	O
.	O

dehydrate	O
,	O
solvate	O
,	O
or	O
desolvate	O
.	O

The	O
rampamycin	O
analog	O
can	O
have	O
a	O
structure	O
of	O
Formula	O
1	O
,	O
which	O
is	O
optionally	O
a	O
prodrug	O
,	O
salt	O
,	O
derivative	O
,	O
or	O
combination	O
thereof	O
:	O

Adenine	O
compound	O
A	O
novel	O
adenine	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
:	O
[	O
wherein	O
R1	O
is	O
substituted	O
or	O
unsubstituted	O
alkyl	O
,	O
etc	O
.	O
,	O
X	O
is	O
oxygen	O
,	O
etc	O
.	O
,	O
A1	O
is	O
4-	O
to	O
8-membered	O
substituted	O
or	O
unsubstituted	O
saturated	O
nitrogen	O
-	O
containing	O
heterocycle	O
containing	O
1	O
to	O
2	O
hetero	O
atom	O
(	O
s	O
)	O
selected	O
from	O
1	O
to	O
2	O
nitrogen	O
(	O
s	O
)	O
,	O
0	O
to	O
1	O
oxygen	O
and	O
0	O
to	O
1	O
sulfur	O
,	O
etc	O
.	O
,	O
A2	O
is	O
substituted	O
or	O
unsubstituted	O
6-	O
to	O
10-membered	O
aryl	O
,	O
etc	O
.	O
,	O
L1	O
and	O
L2	O
are	O
independently	O
a	O
straight	O
chain	O
or	O
branched	O
chain	O
alkylene	O
,	O
etc	O
.	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
which	O
is	O
useful	O
as	O
a	O
medicament	O
.	O

An	O
enzyme	O
in	O
the	O
tryptophan	O
degradation	O
pathway	O
,	O
used	O
to	O
treat	O
neurodegenerative	O
disorders	O
,	O
certain	O
cancers	O
,	O
drug	O
addiction	O
;	O
arylsulfonamides	O
such	O
as	O
3,4-dimethoxy	O
-	O
N-	O
[	O
5-	O
(	O
4-chlorophenyl	O
)	O
-1,2,4-thiadiazole-3-yl	O
]	O
benzenesulfonamide	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
below	O
and	O
their	O
tautomers	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
compositions	O
and	O
methods	O
of	O
uses	O
thereof	O
:	O

Administering	O
oligosaccharides	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
prebiotic	O
(	O
prebiotic	O
adjuvant	O
)	O
for	O
decreasing	O
inflammatory	O
process	O
by	O
improving	O
the	O
homeostasis	O
of	O
non	O
-	O
specific	O
immune	O
parameters	O
and	O
of	O
lymphocyte	O
subpopulations	O
.	O

It	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
prebiotic	O
formulation	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
or	O
a	O
food	O
or	O
petfood	O
composition	O
for	O
decreasing	O
inflammatory	O
process	O
and/or	O
abnormal	O
activation	O
of	O
non	O
-	O
specific	O
immune	O
parameters	O
,	O
such	O
as	O
phagocytes	O
.	O

Selective	O
proton	B
coupled	I
folate	I
transporter	I
and	O
folate	B
receptor	I
,	O
and	O
GARFTase	B
inhibitor	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
same	O
Fused	O
cyclic	O
pyrimidine	O
compounds	O
,	O
including	O
tautomers	O
thereof	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
prodrugs	O
,	O
solvates	O
and	O
hydrates	O
thereof	O
,	O
are	O
disclosed	O
having	O
the	O
general	O
Formula	O
I	O
:	O
These	O
compounds	O
are	O
useful	O
in	O
methods	O
for	O
treating	O
cancer	O
,	O
selectively	O
targeting	O
cancerous	O
cells	O
via	O
the	O
proton	B
coupled	I
folate	I
transporter	I
,	O
folate	B
receptor	I
alpha	I
,	O
and/or	O
folate	B
receptor	I
beta	I
pathways	O
,	O
inhibiting	O
GARFTase	B
in	O
cancerous	O
cells	O
,	O
and	O
selectively	O
targeting	O
activated	O
macrophages	O
in	O
a	O
patient	O
having	O
an	O
autoimmune	O
disease	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O

Method	O
for	O
restructuring	O
the	O
epidermis	O
using	O
a	O
polyol	O
-	O
glycoside	O
composition	O
A	O
method	O
for	O
restructuring	O
the	O
epidermis	O
with	O
a	O
composition	O
,	O
wherein	O
said	O
composition	O
includes	O
a	O
polyol	O
-	O
glycoside	O
and	O
said	O
polyol	O
-	O
glycoside	O
is	O
obtained	O
by	O
the	O
acetalization	O
of	O
a	O
polyol	O
with	O
a	O
reducing	O
sugar	O
.	O

Fused	O
amino	O
pyridine	O
as	O
HSP90	B
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
HSP90	B
inhibitors	O
containing	O
fused	O
amino	O
pyridine	O
core	O
that	O
are	O
useful	O
as	O
inhibitors	O
of	O
HSP90	B
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
HSP90	B
related	O
diseases	O
and	O
disorders	O
such	O
as	O
cancer	O
,	O
an	O
autoimmune	O
disease	O
,	O
or	O
a	O
neurodegenerative	O
disease	O
.	O

Compounds	O
and	O
compositions	O
for	O
treating	O
cancer	O
The	O
invention	O
relates	O
to	O
compounds	O
and	O
composition	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O
.	O

The	O
invention	O
also	O
covers	O
all	O
diseases	O
that	O
may	O
be	O
treated	O
by	O
selective	O
modulation	O
of	O
levels	O
of	O
reactive	O
oxygen	O
species	O
in	O
diseased	O
cells	O
versus	O
normal	O
cells	O
.	O

Methods	O
for	O
the	O
preparation	O
and	O
administration	O
of	O
such	O
compositions	O
are	O
also	O
disclosed	O
.	O

Characterization	O
of	O
GRP94-ligand	B
interactions	O
and	O
purification	O
,	O
screening	O
,	O
and	O
therapeutic	O
methods	O
relating	O
thereto	O
The	O
presently	O
disclosed	O
subject	O
matter	O
discloses	O
characterization	O
of	O
interactions	O
between	O
ligands	O
and	O
Hsp90	B
proteins	O
,	O
including	O
GRP94	B
,	O
wherein	O
ligand	O
binding	O
to	O
the	O
N	O
-	O
terminal	O
nucleotide	O
binding	O
domain	O
of	O
GRP94	B
elicits	O
a	O
conformational	O
change	O
that	O
converts	O
the	O
GRP94	B
from	O
an	O
inactive	O
to	O
an	O
active	O
conformation	O
,	O
and	O
wherein	O
the	O
chaperone	O
and	O
peptide	O
-	O
binding	O
activities	O
of	O
the	O
GRP94	B
are	O
markedly	O
stimulated	O
.	O

Also	O
disclosed	O
are	O
purification	O
,	O
screening	O
,	O
and	O
therapeutic	O
methods	O
pertaining	O
to	O
the	O
biological	O
activity	O
of	O
GRP94	B
,	O
and	O
in	O
some	O
instances	O
HSP90	O
,	O
based	O
upon	O
the	O
characterization	O
of	O
ligand	O
interactions	O
of	O
Hsp90	B
peptide	O
-	O
binding	O
proteins	O
,	O
including	O
GRP94	B
.	O

Wound	O
care	O
device	O
A	O
wound	O
care	O
device	O
for	O
local	O
treatment	O
of	O
pain	O
in	O
a	O
wound	O
,	O
said	O
device	O
comprising	O
an	O
active	O
pain	O
relieving	O
composition	O
,	O
the	O
device	O
being	O
constructed	O
in	O
such	O
a	O
manner	O
that	O
the	O
pain	O
killing	O
agent	O
is	O
released	O
to	O
the	O
wound	O
in	O
such	O
a	O
way	O
that	O
substantially	O
no	O
effective	O
systemic	O
plasma	O
concentration	O
of	O
the	O
pain	O
killing	O
agent	O
can	O
be	O
found	O
and	O
wherein	O
a	O
majority	O
of	O
said	O
pain	O
killing	O
agent	O
is	O
in	O
direct	O
contact	O
with	O
the	O
wound	O
.	O

Thieno-	O
and	O
furo	O
-	O
pyrimidine	O
modulators	O
of	O
the	O
histamine	B
H4	I
receptor	I
Thieno-	O
and	O
furo	O
-	O
pyrimidine	O
compounds	O
are	O
described	O
,	O
which	O
are	O
useful	O
as	O
H4	B
receptor	I
modulators	O
.	O

Such	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
modulation	O
of	O
histamine	B
H4	I
receptor	I
activity	O
and	O
for	O
the	O
treatment	O
of	O
disease	O
states	O
,	O
disorders	O
,	O
and	O
conditions	O
mediated	O
by	O
H4	B
receptor	I
activity	O
,	O
such	O
as	O
inflammation	O
.	O

Polysaccharides	O
with	O
antithrombotic	O
activity	O
,	O
including	O
a	O
covalent	O
bond	O
and	O
an	O
amino	O
chain	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
synthetic	O
polysaccharides	O
with	O
antithrombotic	O
activity	O
,	O
having	O
at	O
least	O
one	O
covalent	O
bond	O
with	O
an	O
amino	O
chain	O
,	O
and	O
to	O
the	O
preparation	O
method	O
thereof	O
and	O
to	O
the	O
therapeutic	O
use	O
thereof	O
.	O

Dietary	O
fiber	O
formulation	O
and	O
method	O
of	O
administration	O
The	O
invention	O
provides	O
dietary	O
fiber	O
formulation	O
and	O
related	O
methods	O
for	O
its	O
administration	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
invention	O
provides	O
a	O
dietary	O
fiber	O
formulation	O
comprising	O
:	O
partially	O
-	O
hydrolyzed	O
guar	O
gum	O
(	O
PHGG	O
)	O
;	O
and	O
fructooligosaccharides	O
(	O
FOS	O
)	O
,	O
wherein	O
the	O
dietary	O
fiber	O
formulation	O
exhibits	O
a	O
prebiotic	O
potential	O
greater	O
than	O
a	O
prebiotic	O
potential	O
of	O
PHGG	O
and	O
FOS	O
individually	O
.	O

Assay	O
for	O
identifying	O
a	O
modulator	O
of	O
HIF	B
hydroxylase	I
A	O
novel	O
class	O
of	O
hydroxylases	O
is	O
described	O
having	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
,	O
and	O
variants	O
and	O
fragments	O
thereof	O
having	O
HIF	O
hydroxylation	O
activity	O
.	O

The	O
polypeptides	O
of	O
the	O
invention	O
have	O
in	O
particular	O
prolyl	O
hydroxylase	O
activity	O
.	O

An	O
assay	O
method	O
monitors	O
the	O
interaction	O
of	O
the	O
HIF	B
hydroxylase	I
with	O
a	O
substrate	O
.	O

Modulators	O
of	O
HIF	B
hydroxylase	I
are	O
provided	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
increased	O
or	O
decreased	O
HIF	O
levels	O
or	O
activity	O
or	O
for	O
the	O
treatment	O
of	O
a	O
condition	O
where	O
it	O
is	O
desirable	O
to	O
modulate	O
HIF	O
levels	O
or	O
activity	O
.	O

Heteroaryl	O
substituted	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyridines	O
and	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyrimidines	O
as	O
Janus	B
kinase	I
inhibitors	O
The	O
present	O
invention	O
provides	O
heteroaryl	O
substituted	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyridines	O
and	O
heteroaryl	O
substituted	O
pyrrolo	O
[	O
2,3-b	O
]	O
pyrimidines	O
that	O
modulate	O
the	O
activity	O
of	O
Janus	B
kinases	I
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
activity	O
of	O
Janus	B
kinases	I
including	O
,	O
for	O
example	O
,	O
immune	O
-	O
related	O
diseases	O
,	O
skin	O
disorders	O
,	O
myeloid	O
proliferative	O
disorders	O
,	O
cancer	O
,	O
and	O
other	O
diseases	O
.	O

Composition	O
for	O
treating	O
mental	O
health	O
disorders	O
A	O
composition	O
of	O
three	O
compounds	O
each	O
selected	O
from	O
a	O
selective	O
re	O
-	O
uptake	O
inhibitor	O
of	O
serotonin	O
,	O
a	O
monoamine	O
oxidase	O
inhibitor	O
,	O
and	O
a	O
phosphodiesterase	O
inhibitor	O
,	O
such	O
that	O
all	O
three	O
compounds	O
are	O
different	O
and	O
are	O
naturally	O
occurring	O
.	O

Methods	O
for	O
recommending	O
neurophysiological	O
disorder	O
therapy	O
Neurophysiologic	O
information	O
such	O
as	O
quantitative	O
electroencephalography	O
(	O
QEEG	O
)	O
is	O
used	O
in	O
a	O
method	O
for	O
classifying	O
,	O
diagnosing	O
,	O
and	O
treating	O
physiologic	O
brain	O
imbalances	O
.	O

Neurophysiologic	O
information	O
is	O
also	O
used	O
to	O
guide	O
sample	O
selection	O
in	O
clinical	O
tests	O
for	O
psychopharmacologic	O
drug	O
candidates	O
.	O

Finally	O
,	O
neurophysiologic	O
information	O
is	O
used	O
for	O
remotely	O
assessing	O
and	O
treating	O
patients	O
with	O
physiologic	O
brain	O
imbalances	O
.	O

Desensitizing	O
drug	O
product	O
Desensitizing	O
drug	O
products	O
,	O
methods	O
of	O
making	O
desensitizing	O
drug	O
products	O
,	O
and	O
methods	O
of	O
using	O
desensitizing	O
drug	O
products	O
including	O
delivery	O
of	O
desensitizing	O
drug	O
products	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
desensitizing	O
drug	O
products	O
are	O
male	O
genital	O
desensitizers	O
that	O
comprise	O
one	O
or	O
anesthetic	O
agents	O
and	O
one	O
or	O
more	O
melting	O
point	O
depressing	O
agents	O
.	O

Remedy	O
for	O
overactive	O
bladder	O
comprising	O
acetic	O
acid	O
anilide	O
derivative	O
as	O
the	O
active	O
ingredient	O
(	O
R	O
)	O
-2-	O
(	O
2-aminothiazol-4-yl	O
)	O
-4′-	O
[	O
2-	O
[	O
(	O
2-hydroxy-2-phenylethyl	O
)	O
amino	O
]	O
ethyl	O
]	O
acetic	O
acid	O
anilide	O
or	O
its	O
salt	O
shows	O
a	O
potent	O
bladder	O
relaxation	O
effect	O
in	O
""""	O
isolated	O
rat	O
bladder	O
smooth	O
muscle	O
relaxation	O
test	O
""""	O
,	O
dose	O
-	O
dependently	O
lowers	O
the	O
contraction	O
frequency	O
of	O
rhythmic	O
bladder	O
contractions	O
in	O
""""	O
rat	O
rhythmic	O
bladder	O
contraction	O
measurement	O
test	O
""""	O
and	O
,	O
moreover	O
,	O
prolongs	O
the	O
urination	O
intervals	O
in	O
""""	O
urination	O
functions	O
measurement	O
test	O
on	O
cyclophosphamide	O
-	O
induced	O
overactive	O
bladder	O
model	O
rat	O
""""	O
.	O

Owing	O
to	O
these	O
effects	O
,	O
the	O
above	O
compound	O
is	O
useful	O
as	O
a	O
remedy	O
for	O
overactive	O
bladder	O
.	O

Hepatitis	O
C	O
inhibitor	O
tri	O
-	O
peptides	O
Racemates	O
,	O
diastereoisomers	O
and	O
optical	O
isomers	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
B	O
is	O
H	O
,	O
a	O
C6	O
or	O
C10	O
aryl	O
,	O
C7	O
-	O
16	O
aralkyl	O
;	O
Het	O
or	O
(	O
lower	O
alkyl	O
)	O
-Het	O
,	O
all	O
of	O
which	O
optionally	O
substituted	O
with	O
C1	O
-	O
6	O
alkyl	O
;	O
C1	O
-	O
6	O
alkoxy	O
;	O
C1	O
-	O
6	O
alkanoyl	O
;	O
hydroxy	O
;	O
hydroxyalkyl	O
;	O
halo	O
;	O
haloalkyl	O
;	O
nitro	O
;	O
cyano	O
;	O
cyanoalkyl	O
;	O
amino	O
optionally	O
substituted	O
with	O
C1	O
-	O
6	O
alkyl	O
;	O
amido	O
;	O
or	O
(	O
lower	O
alkyl	O
)	O
amide	O
;	O
or	O
B	O
is	O
an	O
acyl	O
derivative	O
of	O
formula	O
R4—C	O
(	O
O	O
)	O
—	O
;	O
a	O
carboxyl	O
of	O
formula	O
R4—O	O
—	O
C	O
(	O
O	O
)	O
—	O
;	O
an	O
amide	O
of	O
formula	O
R4—N	O
(	O
R5	O
)	O
—C	O
(	O
O	O
)	O
—	O
;	O
a	O
thioamide	O
of	O
formula	O
R4—N	O
(	O
R5	O
)	O
—C	O
(	O
S	O
)	O
—	O
;	O
or	O
a	O
sulfonyl	O
of	O
formula	O
R4—SO2	O
;	O
R5	O
is	O
H	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
and	O
Y	O
is	O
H	O
or	O
C1	O
-	O
6	O
alkyl	O
;	O
R3	O
is	O
C1	O
-	O
8	O
alkyl	O
,	O
C3	O
-	O
7	O
cycloalkyl	O
,	O
or	O
C4	O
-	O
10	O
alkylcycloalkyl	O
,	O
all	O
optionally	O
substituted	O
with	O
hydroxy	O
,	O
C1	O
-	O
6	O
alkoxy	O
,	O
C1	O
-	O
6	O
thioalkyl	O
,	O
amido	O
,	O
(	O
lower	O
alkyl	O
)	O
amido	O
,	O
C6	O
or	O
C10	O
aryl	O
,	O
or	O
C7	O
-	O
16	O
aralkyl	O
;	O
R2	O
is	O
CH2—R20	O
,	O
NH	O
—	O
R20	O
,	O
O	O
—	O
R20	O
or	O
S	O
—	O
R20	O
,	O
wherein	O
R20	O
is	O
a	O
saturated	O
or	O
unsaturated	O
C3	O
-	O
7	O
cycloalkyl	O
or	O
C4	O
-	O
10	O
(	O
alkylcycloalkyl	O
)	O
,	O
all	O
of	O
which	O
being	O
optionally	O
mono-	O
,	O
di-	O
or	O
tri	O
-	O
substituted	O
with	O
R21	O
,	O
or	O
R20	O
is	O
a	O
C6	O
or	O
C10	O
aryl	O
or	O
C7	O
-	O
14	O
aralkyl	O
optionally	O
substituted	O
,	O
or	O
R20	O
is	O
Het	O
or	O
(	O
lower	O
alkyl	O
)	O
-Het	O
,	O
both	O
optionally	O
substituted	O
,	O
Het	O
or	O
(	O
lower	O
alkyl	O
)	O
-Het	O
;	O
carboxyl	O
;	O
carboxy	O
(	O
lower	O
alkyl	O
)	O
;	O
C6	O
or	O
C10	O
aryl	O
,	O
C7	O
-	O
14	O
aralkyl	O
or	O
Het	O
,	O
said	O
aryl	O
,	O
aralkyl	O
or	O
Het	O
being	O
optionally	O
substituted	O
;	O
and	O
R1	O
is	O
H	O
;	O
C1	O
-	O
6	O
alkyl	O
,	O
C3	O
-	O
7	O
cycloalkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
,	O
or	O
C2	O
-	O
6	O
alkynyl	O
,	O
all	O
optionally	O
substituted	O
with	O
halogen	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
.	O

Use	O
of	O
medium	O
chain	O
triglycerides	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
alzheimer	O
's	O
disease	O
and	O
other	O
diseases	O
resulting	O
from	O
reduced	O
neuronal	O
metabolism	O
Methods	O
and	O
compositions	O
for	O
treating	O
or	O
preventing	O
,	O
the	O
occurrence	O
of	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
's	O
type	O
,	O
or	O
other	O
conditions	O
arising	O
from	O
reduced	O
neuronal	O
metabolism	O
and	O
leading	O
to	O
lessened	O
cognitive	O
function	O
are	O
described	O
.	O

In	O
a	O
preferred	O
embodiment	O
the	O
administration	O
of	O
triglicerides	O
or	O
fatty	O
acids	O
with	O
chain	O
lengths	O
between	O
5	O
and	O
12	O
,	O
to	O
said	O
patient	O
at	O
a	O
level	O
produce	O
an	O
improvement	O
in	O
cognitive	O
ability	O
.	O

C6-	O
and	O
c9-substituted	O
chromeno	O
[	O
4	O
,	O
3-c	O
]	O
isoxazoline	O
derivatives	O
and	O
their	O
use	O
as	O
anti	O
-	O
depressants	O
The	O
invention	O
concerns	O
substituted	O
tricyclic	O
isoxazoline	O
derivatives	O
,	O
more	O
in	O
particular	O
tricyclic	O
dihydrobenzopyranoisoxazoline	O
,	O
dihydroquinolinoisoxazoline	O
,	O
dihydronaphthalenoisoxazoline	O
and	O
dihydrobenzothiopyranoisoxazoline	O
derivatives	O
substituted	O
on	O
at	O
least	O
one	O
of	O
the	O
C6-	O
and	O
C9-positions	O
of	O
the	O
phenylpart	O
of	O
the	O
tricyclic	O
moiety	O
with	O
a	O
selected	O
radical	O
,	O
according	O
to	O
Formula	O
(	O
I	O
)	O
wherein	O
X	O
=	O
CH2	O
,	O
N	O
-	O
R7	O
,	O
S	O
or	O
O	O
,	O
R1	O
,	O
R2	O
,	O
R14	O
and	O
R15	O
are	O
certain	O
specific	O
substituents	O
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
R14	O
and	O
R15	O
is	O
not	O
hydrogen	O
,	O
Pir	O
is	O
preferably	O
an	O
optionally	O
substituted	O
piperidinyl	O
or	O
piperazinyl	O
radical	O
and	O
R3	O
represents	O
an	O
optionally	O
substituted	O
aromatic	O
homocyclic	O
or	O
heterocyclic	O
ring	O
system	O
including	O
a	O
partially	O
or	O
completely	O
hydrogenated	O
hydrocarbon	O
chain	O
of	O
maximum	O
6	O
atoms	O
long	O
with	O
which	O
the	O
ring	O
system	O
is	O
attached	O
to	O
the	O
Pir	O
radical	O
and	O
which	O
may	O
contain	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
the	O
group	O
of	O
O	O
,	O
N	O
and	O
S	O
;	O
a	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
as	O
a	O
medicine	O
,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
anxiety	O
,	O
movement	O
disorders	O
,	O
psychosis	O
,	O
Parkinson	O
's	O
disease	O
and	O
body	O
weight	O
disorders	O
..	O

The	O
compounds	O
according	O
to	O
the	O
invention	O
have	O
surprisingly	O
been	O
shown	O
to	O
have	O
a	O
serotonine	O
(	O
5-HT	O
)	O
reuptake	O
inhibitor	O
activity	O
in	O
combination	O
with	O
additional	O
α2-adrenoceptor	B
antagonist	O
activity	O
and	O
show	O
a	O
strong	O
anti	O
-	O
depressant	O
activity	O
without	O
being	O
sedative	O
.	O

The	O
invention	O
also	O
relates	O
to	O
novel	O
combination	O
of	O
isoxazoline	O
derivatives	O
according	O
to	O
the	O
invention	O
with	O
one	O
or	O
more	O
other	O
compounds	O
selected	O
from	O
the	O
group	O
of	O
antidepressants	O
,	O
anxiolytics	O
,	O
anti	O
-	O
psychotics	O
and	O
anti	O
-	O
Parkinson	O
's	O
disease	O
drugs	O
to	O
improve	O
efficacy	O
and/or	O
onset	O
of	O
action	O
.	O

PREPARATION	O
FOR	O
EXTERNAL	O
PERCUTANEOUS	O
ADMINISTRATION	O
CONTAINING	O
NON	O
-	O
STEROIDAL	O
ANTI	O
-	O
INFLAMMATORY	O
DRUG	O
AND	O
INTERLEUKIN-1α	B
PRODUCTION	O
INHIBITOR	O
A	O
preparation	O
for	O
external	O
percutaneous	O
administration	O
which	O
comprises	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
an	O
alkyl	O
gallate	O
,	O
and	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	O
group	O
.	O

Also	O
provided	O
is	O
an	O
interleukin-1α	B
production	O
inhibitor	O
which	O
comprises	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	O
group	O
and/or	O
an	O
alkyl	O
gallate	O
.	O

Tlr7	B
ligands	O
for	O
the	O
treatment	O
of	O
hepatitis	O
c	O
This	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
hepatitis	O
C	O
virus	O
infections	O
in	O
mammals	O
using	O
Toll	B
-	I
Like	I
Receptor	I
(	I
TLR	I
)	I
7	I
ligands	O
and	O
prodrugs	O
thereof	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
relates	O
to	O
methods	O
of	O
orally	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
prodrugs	O
of	O
TLR7	B
ligands	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
hepatitis	O
C	O
viral	O
infection	O
.	O

Oral	O
administration	O
of	O
these	O
TLR7	B
immunomodulating	O
ligands	O
and	O
prodrugs	O
thereof	O
to	O
a	O
mammal	O
provides	O
therapeutically	O
effective	O
amounts	O
and	O
reduced	O
undesirable	O
side	O
effects	O
.	O

Antimycotic	O
nail	O
polish	O
formulations	O
comprising	O
substituted	O
2-aminothiazoles	O
as	O
an	O
active	O
substance	O
The	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
(	O
A	O
)	O
a	O
pharmaceutically	O
effective	O
compound	O
from	O
the	O
compound	O
class	O
of	O
antimycotic	O
substituted	O
2-aminothiazoles	O
,	O
and	O
(	O
B	O
)	O
a	O
nail	O
polish	O
formulation	O
of	O
said	O
compound	O
.	O

The	O
invention	O
further	O
relates	O
to	O
antimycotic	O
nail	O
polish	O
formulations	O
for	O
treating	O
onychomycoses	O
and	O
other	O
diseases	O
of	O
the	O
fingernails	O
or	O
toenails	O
caused	O
by	O
fungal	O
infections	O
.	O

The	O
invention	O
particularly	O
relates	O
to	O
antimycotic	O
nail	O
polish	O
formulations	O
that	O
are	O
applied	O
to	O
nails	O
and	O
form	O
a	O
coating	O
from	O
which	O
the	O
antimycotic	O
agent	O
is	O
released	O
and	O
can	O
penetrate	O
into	O
the	O
nail	O
.	O

Said	O
method	O
allows	O
nails	O
of	O
humans	O
and	O
animals	O
to	O
be	O
treated	O
against	O
fungal	O
infections	O
or	O
fungal	O
infections	O
to	O
be	O
prevented	O
.	O

N	O
-	O
acylated-3-	O
(	O
benzoyl	O
)	O
-	O
pyrrolidines	O
as	O
11-beta	B
-	I
hsd1	I
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
.	O

The	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
variable	O
groups	O
are	O
defined	O
within	O
;	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
use	O
in	O
the	O
inhibition	O
of	O
11βHSD1	B
,	O
processes	O
for	O
making	O
them	O
,	O
certain	O
compounds	O
within	O
the	O
definition	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
described	O
.	O

Agent	O
or	O
method	O
for	O
treatment	O
for	O
severe	O
aphasia	O
in	O
chronic	O
-	O
stage	O
cerebrovascular	O
disorder	O
An	O
agent	O
or	O
method	O
for	O
treatments	O
for	O
severe	O
aphasia	O
in	O
chronic	O
-	O
stage	O
cerebrovascular	O
disorders	O
which	O
contains	O
or	O
employs	O
2-oxo-1-pyrrolidineacetamide	O
as	O
an	O
active	O
ingredient	O
.	O

Use	O
of	O
conjugated	O
linolenic	O
acids	O
for	O
reducing	O
body	O
fat	O
mass	O
The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
conjugated	O
linolenic	O
acids	O
selected	O
from	O
the	O
groups	O
consisting	O
of	O
Cl	O
8:3	O
(	O
9cis	O
,	O
11	O
trans	O
,	O
15	O
cis	O
)	O
octadecatrienoic	O
acid	O
,	O
C18:3	O
(	O
9cis,13trans,15cis	O
)	O
octadecatrienoic	O
acid	O
and	O
mixtures	O
thereof	O
in	O
the	O
reduction	O
of	O
body	O
fat	O
mass	O
and	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
obesity	O
.	O

These	O
conjugated	O
linolenic	O
acids	O
may	O
be	O
provided	O
in	O
the	O
form	O
of	O
a	O
food	O
supplement	O
or	O
as	O
a	O
component	O
of	O
a	O
prepared	O
food	O
product	O
.	O

Active	O
oxygen	O
eliminator	O
originating	O
in	O
natural	O
material	O
and	O
use	O
of	O
the	O
same	O
An	O
active	O
oxygen	O
eliminator	O
originating	O
in	O
a	O
natural	O
material	O
which	O
comprises	O
water	O
,	O
an	O
organic	O
solvent	O
,	O
an	O
emulsifier	O
and	O
,	O
as	O
the	O
main	O
active	O
ingredients	O
,	O
p	O
-	O
coumalic	O
acid	O
,	O
3,4-di	O
-	O
O	O
-	O
caffeoylquinic	O
acid	O
,	O
3,5-di	O
-	O
O	O
-	O
caffeoylquinic	O
acid	O
,	O
4-hydroxy-3-prenylcinnamic	O
acid	O
and	O
3,5,7-trihydroxy-4'-methoxyflavonol	O
;	O
and	O
a	O
food	O
and	O
a	O
cosmetic	O
containing	O
this	O
active	O
oxygen	O
eliminator	O
.	O

Extracts	O
of	O
scutellaria	O
for	O
the	O
treatment	O
of	O
sars	O
The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
having	O
antiviral	O
activity	O
against	O
Coronavirus	O
,	O
and	O
more	O
particularly	O
against	O
those	O
viruses	O
responsible	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
.	O

In	O
a	O
preferred	O
embodiment	O
it	O
comprises	O
a	O
total	O
standardised	O
extract	O
of	O
a	O
Scutellariae	O
spp	O
.	O

Remedy	O
for	O
urinary	O
disorder	O
It	O
is	O
intended	O
to	O
provide	O
a	O
remedy	O
for	O
urinary	O
disorder	O
.	O

Namely	O
,	O
a	O
remedy	O
for	O
urinary	O
disorder	O
containing	O
a	O
compound	O
which	O
suppresses	O
the	O
GIRK	B
channel	I
activated	O
current	O
while	O
showing	O
no	O
suppressive	O
effect	O
on	O
the	O
glycine	B
receptor	I
activated	O
current	O
or	O
NMDA	B
receptor	I
activated	O
current	O
.	O

Method	O
of	O
treating	O
sepsis	O
Compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
sepsis	O
in	O
an	O
animal	O
are	O
disclosed	O
.	O

The	O
method	O
comprises	O
administering	O
an	O
electrolyzed	O
saline	O
solution	O
to	O
the	O
animal	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
electrolyzed	O
saline	O
solution	O
comprises	O
ozone	O
and	O
at	O
least	O
one	O
active	O
chlorine	O
species	O
.	O

The	O
electrolyzed	O
saline	O
can	O
further	O
comprise	O
at	O
least	O
one	O
active	O
hydrogen	O
species	O
.	O

Composition	O
against	O
aids	O
virus	O
and	O
method	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
An	O
antiviral	O
composition	O
having	O
an	O
effect	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
which	O
comprises	O
,	O
as	O
the	O
active	O
ingredient	O
,	O
iodine	O
ion	O
or	O
a	O
compound	O
forming	O
iodine	O
ion	O
;	O
a	O
functional	O
food	O
containing	O
the	O
antiviral	O
composition	O
as	O
described	O
above	O
and	O
thus	O
having	O
an	O
antiviral	O
function	O
imparted	O
thereto	O
;	O
and	O
an	O
antiviral	O
drug	O
comprising	O
the	O
antiviral	O
composition	O
as	O
described	O
above	O
and	O
having	O
an	O
effect	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
.	O

Thus	O
,	O
it	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
antiviral	O
composition	O
and	O
so	O
on	O
having	O
a	O
function	O
of	O
selectively	O
inactivating	O
AIDS	O
virus	O
-	O
infected	O
cells	O
,	O
viral	O
cancer	O
cells	O
,	O
etc	O
.	O

Imine	O
derivative	O
and	O
amide	O
derivative	O
A	O
medicine	O
having	O
prostaglandin	O
D2	O
(	O
PGD2	O
)	O
production	O
inhibitory	O
activity	O
and	O
having	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
selected	O
from	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
A	O
-	O
Y	O
-	O
B	O
{	O
wherein	O
A	O
and	O
B	O
each	O
independently	O
represents	O
an	O
optionally	O
substituted	O
,	O
cyclic	O
hydrocarbon	O
or	O
heterocyclic	O
group	O
;	O
and	O
Y	O
represents	O
-CH	O
=	O
N-	O
,	O
-N	O
=	O
CH-	O
,	O
-CONH-	O
,	O
or	O
-NHCO-	O
,	O
provided	O
that	O
the	O
compounds	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I-1	O
)	O
[	O
wherein	O
X	O
represents	O
the	O
formula	O
-N	O
=	O
C	O
(	O
R5	O
)	O
-	O
(	O
wherein	O
the	O
left	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
benzene	O
ring	O
and	O
the	O
right	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
nitrogen	O
atom	O
)	O
or	O
the	O
formula	O
-NH	O
-	O
CH	O
(	O
R5	O
)	O
-	O
(	O
wherein	O
the	O
left	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
benzene	O
ring	O
and	O
the	O
right	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
nitrogen	O
atom	O
)	O
;	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
each	O
independently	O
represents	O
hydrogen	O
,	O
halogeno	O
,	O
or	O
optionally	O
substituted	O
C1	O
-	O
6	O
alkyl	O
or	O
hydroxy	O
;	O
R5	O
represents	O
an	O
optionally	O
substituted	O
C1	O
-	O
6	O
alkyl	O
or	O
C6	O
-	O
10	O
aryl	O
group	O
;	O
and	O
R	O
represents	O
optionally	O
substituted	O
amino	O
]	O
are	O
excluded	O
}	O
,	O
salts	O
,	O
hydrates	O
,	O
and	O
solvates	O
.	O

Macrolide	O
compositions	O
as	O
therapeutic	O
agent	O
The	O
present	O
invention	O
provides	O
compositions	O
including	O
a	O
macrolide	O
compound	O
that	O
inhibits	O
MHC	B
class	I
II	I
expression	O
.	O

The	O
compositions	O
of	O
the	O
invention	O
are	O
used	O
as	O
an	O
immunosuppressive	O
agent	O
in	O
the	O
treatment	O
prior	O
to	O
,	O
during	O
and/or	O
after	O
organ	O
or	O
tissue	O
transplantation	O
,	O
as	O
well	O
as	O
in	O
the	O
treatment	O
of	O
immune	O
-	O
related	O
disorders	O
.	O

Abnormal	O
cannabidiols	O
for	O
lowering	O
intraocular	O
pressure	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
Abnormal	O
Cannabidiols	O
as	O
potent	O
ocular	O
hypotensives	O
,	O
and	O
are	O
particular	O
suitable	O
for	O
the	O
management	O
of	O
glaucoma	O
.	O

In	O
particular	O
said	O
compounds	O
are	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
formula	O
(	O
II	O
)	O
or	O
formula	O
(	O
III	O
)	O
.	O

These	O
compounds	O
have	O
also	O
been	O
found	O
to	O
be	O
useful	O
in	O
providing	O
neuroprotective	O
effect	O
to	O
the	O
eye	O
.	O

Amino	O
-	O
tropane	O
derivatives	O
,	O
preparation	O
thereof	O
and	O
therapeutic	O
use	O
thereof	O
The	O
invention	O
concerns	O
amino	O
-	O
tropane	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
Ra	O
R	O
a	O
'	O
et	O
R5	O
represent	O
hydrogen	O
atoms	O
or	O
alkyl	O
groups	O
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
an	O
alkyl	O
,	O
cycloalkyl	O
,	O
heterocycloalkyl	O
or	O
aryl	O
group	O
;	O
R2	O
represents	O
a	O
group	O
of	O
formula	O
-	O
(	O
CH2	O
)	O
x-	O
(	O
CO	O
)	O
y	O
-	O
Y	O
or	O
-	O
(	O
CO	O
)	O
y-	O
(	O
CH2	O
)	O
x	O
-	O
Y	O
,	O
wherein	O
Y	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
hydroxy	O
,	O
alkyl	O
,	O
cycloalkyl	O
,	O
alkoxy	O
,	O
aryl	O
,	O
heteroaryl	O
group	O
or	O
NR11R12	O
;	O
R3	O
represents	O
1	O
to	O
3	O
groups	O
selected	O
among	O
halogen	O
atoms	O
and	O
alkyl	O
,	O
cycloalkyl	O
OR	O
,	O
-NRR	O
'	O
,	O
-CO	O
-	O
NRR	O
'	O
,	O
-NR	O
-	O
CO	O
-	O
R	O
'	O
,	O
-NR	O
-	O
CO	O
-	O
NRR	O
'	O
,	O
-NR	O
-	O
COOR	O
'	O
,	O
-NO2	O
,	O
-CN	O
and	O
-COOR	O
groups	O
;	O
R4	O
is	O
selected	O
among	O
a	O
group	O
of	O
formula	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
,	O
(	O
c	O
)	O
or	O
(	O
d	O
)	O
:	O
or	O
a	O
group	O
of	O
formula	O
-A	O
-	O
R18	O
,	O
-A	O
-	O
CH	O
=	O
N	O
-	O
R19	O
,	O
-A	O
-	O
N	O
(	O
R20	O
)	O
-A'-R19	O
,	O
-A	O
-	O
CO	O
-	O
N	O
(	O
R2O	O
)	O
-A'-R19	O
,	O
-A	O
-	O
CH	O
(	O
NH2	O
)	O
-R19	O
,	O
-A	O
-	O
N	O
(	O
R20	O
)	O
-COO	O
-	O
A	O
'	O
or	O
-	O
(	O
CH2	O
)	O
r	O
-	O
heteroaryl	O
.	O

The	O
invention	O
also	O
concerns	O
a	O
method	O
for	O
preparing	O
said	O
derivatives	O
and	O
the	O
therapeutic	O
use	O
thereof	O
.	O

Donepezyl	O
salts	O
The	O
invention	O
relates	O
to	O
crystalline	O
acid	O
addition	O
salts	O
of	O
donepezil	O
with	O
an	O
organic	O
acid	O
.	O

The	O
acid	O
addition	O
salts	O
have	O
a	O
lower	O
corrosivity	O
compared	O
to	O
the	O
previously	O
known	O
donepezil	O
hydrochloride	O
.	O

The	O
salts	O
can	O
be	O
used	O
for	O
the	O
production	O
of	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
dementia	O
.	O

Preparation	O
of	O
phenol	O
-	O
amide	O
compounds	O
with	O
antioxidant	O
properties	O
The	O
invention	O
relates	O
to	O
the	O
preparation	O
of	O
compounds	O
comprising	O
at	O
least	O
one	O
phenol	O
function	O
and	O
one	O
amide	O
function	O
derived	O
from	O
amino-2	O
alkanol-1	O
having	O
formula	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
,	O
which	O
have	O
antioxidant	O
and	O
antiradical	O
properties	O
and	O
which	O
are	O
soluble	O
in	O
lipid	O
media	O
.	O

The	O
inventive	O
compounds	O
can	O
be	O
used	O
as	O
cosmetic	O
or	O
pharmaceutical	O
preparations	O
for	O
the	O
prevention	O
of	O
biological	O
degradation	O
caused	O
by	O
free	O
radicals	O
.	O

Therapeutic	O
agent	O
for	O
parkinson	O
's	O
disease	O
A	O
medicine	O
for	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

It	O
comprises	O
a	O
combination	O
of	O
(	O
2R	O
)	O
-2-propyloctanoic	O
acid	O
,	O
a	O
salt	O
or	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
of	O
either	O
with	O
an	O
agent	O
for	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

The	O
medicine	O
is	O
highly	O
effective	O
in	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

In	O
particular	O
,	O
when	O
the	O
medicinal	O
composition	O
which	O
is	O
for	O
oral	O
administration	O
,	O
which	O
contains	O
(	O
2R	O
)	O
-2-propyloctanoic	O
acid	O
,	O
a	O
salt	O
or	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
of	O
either	O
as	O
an	O
active	O
ingredient	O
,	O
is	O
administered	O
in	O
combination	O
with	O
a	O
levodopa	O
preparation	O
,	O
levodopa	O
/	O
benserazide	O
preparation	O
,	O
levodopa	O
/	O
carbidopa	O
preparation	O
,	O
and/or	O
bromocriptine	O
mesilate	O
in	O
the	O
manner	O
and	O
dose	O
shown	O
in	O
the	O
description	O
,	O
then	O
effects	O
unobtainable	O
with	O
conventional	O
treatments	O
can	O
be	O
produced	O
,	O
such	O
as	O
a	O
dose	O
reduction	O
,	O
alleviation	O
of	O
side	O
effects	O
,	O
and	O
therapeutic	O
-	O
effect	O
enhancement	O
.	O

(	O
(	O
1h	O
-	O
indazol-3-yl	O
)	O
methyl	O
)	O
phenols	O
and	O
(	O
hydroxyphenyl	O
)	O
(	O
1h	O
-	O
indazol-3-yl	O
)	O
methanones	O
as	O
ligands	O
of	O
the	O
estrogen	B
receptor	I
This	O
invention	O
provides	O
anti	O
-	O
inflammatory	O
agents	O
of	O
formula	O
(	O
I	O
)	O
,	O
having	O
the	O
structure	O
:	O
formula	O
(	O
I	O
)	O
,	O
formula	O
(	O
II	O
)	O
,	O
wherein	O
A	O
and	O
R1-R10	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
N	O
-	O
oxide	O
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O

Nitrogen	O
-	O
containing	O
fused	O
ring	O
compound	O
and	O
use	O
thereof	O
An	O
URAT1	B
activity	O
inhibitor	O
which	O
contains	O
a	O
nitrogen	O
-	O
containing	O
fused	O
ring	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
[	O
1	O
]	O
:	O
[	O
1	O
]	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
.	O

This	O
URAT1	B
activity	O
inhibitor	O
is	O
useful	O
in	O
,	O
for	O
example	O
,	O
treating	O
pathological	O
conditions	O
in	O
which	O
uric	O
acid	O
participates	O
such	O
as	O
hyperuricemia	O
,	O
gouty	O
node	O
,	O
acute	O
gouty	O
arthritis	O
,	O
chronic	O
gouty	O
arthritis	O
,	O
gouty	O
kidney	O
,	O
urinary	O
calcus	O
,	O
renal	O
dysfunction	O
,	O
coronary	O
artery	O
disease	O
and	O
ischemic	O
heart	O
disease	O
.	O

Indole	O
derivatives	O
for	O
use	O
as	O
ppar	B
active	O
compounds	O
Compounds	O
are	O
described	O
that	O
are	O
active	O
on	O
at	O
least	O
one	O
of	O
PPARα	B
,	O
PPARδ	B
,	O
and	O
PPARϜ	B
,	O
which	O
are	O
useful	O
for	O
therapeutic	O
and/or	O
prophylactic	O
methods	O
involving	O
modulation	O
of	O
at	O
least	O
one	O
of	O
PPARα	B
,	O
PPARδ	B
,	O
and	O
PPARϜ.	B

Method	O
of	O
treating	O
dry	O
eye	O
disorders	O
using	O
13	O
(	O
s	O
)	O
-hode	O
and	O
its	O
analogs	O
The	O
topical	O
use	O
of	O
13	O
(	O
S	O
)	O
-HODE	O
and	O
analogs	O
are	O
disclosed	O
for	O
the	O
treatment	O
of	O
dry	O
eye	O
disorders	O
.	O

Therapeutic	O
compositions	O
for	O
intranasal	O
administration	O
of	O
ketorolac	O
Therapeutic	O
compositions	O
,	O
particularly	O
sprayable	O
aqueous	O
compositions	O
,	O
comprise	O
ketorolac	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
in	O
combination	O
with	O
a	O
local	O
anesthetic	O
,	O
such	O
as	O
lidocaine	O
hydrochloride	O
.	O

The	O
compositions	O
are	O
nasally	O
administered	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
to	O
treat	O
pain	O
or	O
inflammation	O
and	O
have	O
the	O
benefit	O
of	O
reduced	O
stinging	O
and	O
improved	O
efficacy	O
,	O
compared	O
to	O
known	O
nasally	O
administered	O
compositions	O
.	O

A	O
tetracycline	O
metal	O
complex	O
in	O
a	O
solid	O
dosage	O
form	O
The	O
present	O
invention	O
is	O
a	O
solid	O
dosage	O
form	O
of	O
a	O
metal	O
complex	O
of	O
tetracycline	O
of	O
Formula	O
(	O
I	O
)	O
for	O
pharmaceutical	O
administration	O
,	O
(	O
I	O
)	O
wherein	O
R1	O
=	O
Cl	O
,	O
N	O
(	O
CH3	O
)	O
2	O
,	O
or	O
H	O
;	O
R2	O
=	O
CH3	O
,	O
H	O
,	O
or	O
CH2=	O
;	O
R3	O
=	O
CH3	O
,	O
H	O
,	O
OH	O
,	O
or	O
absent	O
;	O
and	O
R4	O
=	O
OH	O
or	O
H	O
,	O
with	O
the	O
proviso	O
that	O
if	O
R2	O
is	O
CH3	O
and	O
R3	O
is	O
H	O
,	O
then	O
R4	O
is	O
not	O
OH	O
.	O

Bambuterol	O
and	O
integrin	B
inhibitor	O
combination	O
The	O
present	O
invention	O
provides	O
novel	O
solid	O
pharmaceutical	O
dosage	O
forms	O
for	O
oral	O
administration	O
comprising	O
a	O
therapeutically	O
active	O
amount	O
of	O
bambuterol	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
therapeutically	O
effective	O
amount	O
of	O
N-	O
(	O
2-chloro-6-methylbenzoyl	O
)	O
-4-	O
[	O
(	O
2,6-dichlorobenzoyl	O
)	O
amino	O
]	O
-L	O
-	O
phenylalanine-2-	O
(	O
diethylamino	O
)	O
ethyl	O
ester	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

These	O
novel	O
solid	O
pharmaceutical	O
dosage	O
forms	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
control	O
of	O
asthma	O
.	O

Human	O
monoclonal	O
antibody	O
specific	O
for	O
lipopolysaccharides	O
(	O
lps	O
)	O
of	O
the	O
pseudomonas	O
aeruginosa	O
iats	O
o11	O
serotype	O
The	O
present	O
invention	O
relates	O
to	O
a	O
human	O
monoclonal	O
antibody	O
specific	O
for	O
the	O
serotype	O
IATS	O
O11	O
of	O
P.	O
aeruginosa	O
,	O
a	O
hybridoma	O
producing	O
it	O
,	O
nucleic	O
acids	O
encoding	O
it	O
,	O
and	O
host	O
cells	O
transfected	O
therewith	O
.	O

Further	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
producing	O
said	O
monoclonal	O
antibody	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
antibody	O
or	O
at	O
least	O
one	O
nucleic	O
acid	O
encoding	O
said	O
antibody	O
.	O

Composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B
resistance	O
syndrome	O
It	O
is	O
intended	O
to	O
conveniently	O
and	O
efficiently	O
provide	O
a	O
specific	O
compound	O
originating	O
in	O
a	O
natural	O
material	O
and	O
a	O
composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B
resistance	O
syndrome	O
characterized	O
by	O
containing	O
the	O
above	O
compound	O
as	O
the	O
active	O
ingredient	O
.	O

Namely	O
,	O
a	O
composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	B
resistance	O
syndrome	O
which	O
contains	O
,	O
as	O
the	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
among	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
,	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
4	O
)	O
and	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
5	O
)	O
or	O
a	O
salt	O
or	O
an	O
ester	O
of	O
the	O
same	O
.	O

4-hydroxy	O
pentanamides	O
,	O
the	O
preparation	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
provides	O
4-hydroxy	O
pentanamides	O
having	O
the	O
following	O
formula	O
(	O
1	O
)	O
,	O
preparation	O
and	O
use	O
thereof	O
.	O

The	O
said	O
compounds	O
show	O
effective	O
activity	O
of	O
inhibiting	O
BACE	O
and	O
preclude	O
the	O
formation	O
of	O
Aβ	O
.	O

Thus	O
the	O
said	O
compounds	O
are	O
useful	O
in	O
the	O
manufacture	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
's	O
Disease	O
.	O

Use	O
of	O
deuterated	O
n-	O
[	O
2-	O
(	O
5-methoxy-1h	O
-	O
indol-3-yl	O
)	O
-ethyl	O
]	O
acetamides	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
medicaments	O
containing	O
said	O
compounds	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
deuterated	O
N-	O
[	O
2-	O
(	O
5-methoxy-1H	O
-	O
indol-3-yl	O
)	O
ethyl	O
]	O
acetamides	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
preventing	O
,	O
treating	O
,	O
or	O
controlling	O
a	O
disorder	O
,	O
disease	O
,	O
or	O
biological	O
function	O
that	O
is	O
related	O
to	O
a	O
relative	O
melatonin	O
deficiency	O
and/or	O
can	O
be	O
treated	O
or	O
influenced	O
by	O
administering	O
melatonin	O
provided	O
that	O
the	O
disease	O
or	O
disorder	O
is	O
not	O
a	O
disorder	O
in	O
the	O
framework	O
of	O
manic	O
depression	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
deuterated	O
N-	O
[	O
2-	O
(	O
5-methoxy-1H	O
-	O
indol-3-yl	O
)	O
ethyl	O
]	O
acetamides	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
producing	O
a	O
medicament	O
.	O

Also	O
disclosed	O
is	O
a	O
medicament	O
containing	O
deuterated	O
N-	O
[	O
2-	O
(	O
5-methoxy-1H	O
-	O
indol-3-yl	O
)	O
ethyl	O
]	O
acetamides	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

2-quinolone	O
compounds	O
as	O
inhibitors	O
of	O
phosphodiesterases	B
There	O
is	O
provided	O
according	O
to	O
the	O
invention	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
solvates	O
thereof	O
.	O

Novel	O
preventive	O
or	O
remedy	O
for	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
use	O
therefor	O
[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
Focusing	O
on	O
the	O
multidrug	O
therapy	O
,	O
a	O
medicine	O
is	O
designed	O
by	O
using	O
a	O
novel	O
phenylpropionic	O
acid	O
derivative	O
serving	O
as	O
a	O
PPARα	B
activator	O
(	O
for	O
example	O
,	O
(	O
S	O
)	O
-2-ethyl-3-	O
[	O
4-methoxy-3-	O
[	O
N-	O
[	O
[	O
4-	O
(	O
4-fluorophenoxy	O
)	O
phenyl	O
]	O
methyl	O
]	O
carbamoyl	O
]	O
phenyl	O
]	O
propionic	O
acid	O
(	O
KRP-101	O
)	O
)	O
together	O
with	O
a	O
statin	O
drug	O
serving	O
as	O
an	O
antihyperlipidemic	O
or	O
blending	O
them	O
to	O
synergistically	O
or	O
additionally	O
enhance	O
the	O
lipid	O
-	O
lowering	O
effect	O
,	O
thereby	O
providing	O
a	O
novel	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O

Substituted	O
oxindol	O
derivatives	O
,	O
drugs	O
containing	O
said	O
derivatives	O
and	O
the	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
novel	O
oxindol	O
derivative	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
substituents	O
R1	O
,	O
R2	O
,	O
A	O
,	O
B	O
and	O
Y	O
are	O
such	O
as	O
defined	O
in	O
a	O
claim	O
1	O
.	O

Drugs	O
containing	O
said	O
derivatives	O
and	O
the	O
use	O
thereof	O
for	O
preventing	O
and/or	O
treating	O
vassopress	O
-	O
and	O
/	O
or	O
oxytocin	O
-	O
dependent	O
-	O
diseases	O
are	O
also	O
disclosed	O
.	O

Antineoplastic	O
preparation	O
The	O
inventive	O
antineoplastic	O
preparation	O
is	O
based	O
on	O
a	O
gluconic	O
acid	O
and	O
exhibits	O
an	O
apoptotic	O
and	O
anti	O
-	O
proliferative	O
effect	O
preserving	O
healthy	O
cells	O
.	O

In	O
the	O
first	O
variant	O
,	O
said	O
preparation	O
is	O
embodied	O
in	O
the	O
form	O
of	O
at	O
least	O
one	O
type	O
of	O
gluconate	O
,	O
wherein	O
a	O
salt	O
-	O
forming	O
agent	O
is	O
selected	O
from	O
a	O
group	O
comprising	O
magnesium	O
,	O
sodium	O
,	O
potassium	O
,	O
η	O
-	O
aminobutyric	O
acid	O
,	O
ethylenediamine	O
or	O
the	O
mixture	O
thereof	O
.	O

In	O
the	O
second	O
variant	O
,	O
the	O
perpetration	O
is	O
embodied	O
in	O
the	O
form	O
of	O
a	O
co	O
-	O
ordination	O
compound	O
which	O
is	O
based	O
on	O
a	O
magnesium	O
gluconate	O
in	O
which	O
ligands	O
are	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
a	O
η	O
-	O
aminobutyric	O
acid	O
,	O
3-hydroxy	O
-	O
η	O
-	O
aminobutyric	O
acid	O
,	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
and	O
an	O
ethylene	O
glycol	O
tetraacetic	O
acid	O
.	O

In	O
the	O
third	O
variant	O
,	O
the	O
composition	O
is	O
embodied	O
in	O
the	O
form	O
of	O
a	O
binary	O
salt	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
a	O
magnesium	O
butyrate	O
-	O
gluconate	O
,	O
magnesium	O
oxybutyrate	O
-	O
gluconate	O
,	O
magnesium	O
glucarate	O
-	O
gluconate	O
,	O
calcium	O
butyrate	O
-	O
gluconate	O
,	O
butyrate	O
-	O
gluconate	O
oxybutyrate	O
-	O
gluconate	O
,	O
calcium	O
glucarate	O
-	O
gluconate	O
and	O
the	O
combination	O
thereof	O
.	O

Perkinson	O
disease	O
-	O
related	O
gene	O
grk5	B
and	O
use	O
thereof	O
As	O
a	O
result	O
of	O
a	O
large	O
scale	O
SNP	O
analysis	O
on	O
a	O
group	O
of	O
Perkinson	O
disease	O
patients	O
and	O
a	O
control	O
group	O
of	O
normal	O
persons	O
,	O
it	O
has	O
succeeded	O
in	O
the	O
identification	O
of	O
a	O
gene	O
involved	O
in	O
Perkinson	O
disease	O
(	O
GRK5	B
)	O
.	O

It	O
is	O
now	O
found	O
that	O
the	O
increase	O
in	O
the	O
expression	O
of	O
the	O
GRK5	B
gene	O
induces	O
the	O
enhancement	O
of	O
the	O
phosphorylation	O
of	O
α	B
-	I
synuclein	I
,	O
which	O
in	O
turn	O
induces	O
the	O
enhancement	O
of	O
the	O
formation	O
of	O
a	O
soluble	O
α	B
-	I
synuclein	I
oligomer	O
,	O
leading	O
to	O
the	O
development	O
of	O
Perkinson	O
disease	O
.	O

It	O
becomes	O
possible	O
to	O
diagnose	O
Perkinson	O
disease	O
and	O
screen	O
a	O
therapeutic	O
agent	O
for	O
Perkinson	O
disease	O
by	O
using	O
the	O
expression	O
of	O
the	O
GRK5	B
gene	O
.	O

Pharmaceutical	O
compositions	O
of	O
antiretrovirals	O
The	O
present	O
invention	O
relates	O
to	O
the	O
stable	O
pharmaceutical	O
dosage	O
forms	O
of	O
combination	O
of	O
antiretroviral	O
agents	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
stable	O
pharmaceutical	O
dosage	O
forms	O
of	O
Lamivudine	O
,	O
Zidovudine	O
and	O
Nevirapine	O
,	O
prepared	O
by	O
granulation	O
technology	O
.	O

Heterocyclic	O
n	O
-	O
oxides	O
as	O
hypoxic	O
selective	O
protein	B
kinase	I
inhibitors	O
The	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
N	O
-	O
oxides	O
which	O
are	O
useful	O
as	O
hypoxic	O
selective	O
cytotoxic	O
agents	O
that	O
mediate	O
and/or	O
inhibit	O
cell	O
proliferation	O
,	O
for	O
example	O
,	O
through	O
the	O
activity	O
of	O
protein	B
kinases	I
.	O

The	O
invention	O
is	O
further	O
related	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
compositions	O
,	O
and	O
to	O
methods	O
of	O
treating	O
cancer	O
as	O
well	O
as	O
other	O
disease	O
states	O
associated	O
with	O
unwanted	O
ahgiogenesis	O
and/or	O
cellular	O
proliferation	O
by	O
administering	O
effective	O
amounts	O
of	O
such	O
compounds	O
.	O

Method	O
for	O
treatment	O
of	O
uterine	O
fibroid	O
tumors	O
Various	O
injectable	O
or	O
insertable	O
uterine	O
fibroid	O
treatment	O
formulations	O
are	O
provided	O
,	O
which	O
comprise	O
a	O
uterine	O
fibroid	O
treatment	O
agent	O
in	O
an	O
amount	O
effective	O
to	O
cause	O
shrinkage	O
or	O
elimination	O
of	O
uterine	O
fibroids	O
.	O

The	O
injectable	O
or	O
insertable	O
formulations	O
are	O
typically	O
solids	O
,	O
semi	O
-	O
solids	O
or	O
high	O
-	O
viscosity	O
fluids	O
.	O

Other	O
aspects	O
of	O
the	O
invention	O
are	O
directed	O
to	O
systems	O
and	O
methods	O
for	O
treatment	O
of	O
uterine	O
fibroids	O
.	O

Substituted	O
benzo	O
(	O
d	O
)	O
isoxazol-3-yl	O
amine	O
compounds	O
as	O
analgesics	O
Disclosed	O
are	O
substituted	O
benzo	O
[	O
d	O
]	O
isoxazol-3-yl	O
amine	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
pain	O
while	O
being	O
provided	O
with	O
an	O
excellent	O
affinity	O
to	O
the	O
KCNQ2	B
/	I
3	I
K+	I
channel	I
and	O
thus	O
being	O
suitable	O
for	O
the	O
treatment	O
of	O
disorders	O
or	O
diseases	O
that	O
are	O
transmitted	O
at	O
least	O
in	O
part	O
through	O
KCNQ2	B
/	I
3	I
K+	I
channels	I
.	O

Compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
their	O
use	O
in	O
treating	O
metabolic	O
disorders	O
The	O
present	O
invention	O
provides	O
compounds	O
useful	O
,	O
for	O
example	O
,	O
for	O
modulating	O
insulin	B
levels	O
in	O
a	O
subject	O
,	O
having	O
the	O
general	O
formula	O
I	O
:	O
wherein	O
Q	O
is	O
an	O
optionally	O
substituted	O
phenyl	O
;	O
L	O
is	O
a	O
bond	O
or	O
O	O
;	O
P	O
is	O
a	O
benzene	O
or	O
an	O
optionally	O
substituted	O
thiazole	O
ring	O
;	O
and	O
R1	O
has	O
the	O
values	O
provided	O
herein	O
.	O

The	O
present	O
invention	O
also	O
provides	O
compositions	O
,	O
uses	O
,	O
and	O
methods	O
for	O
use	O
of	O
the	O
compounds	O
,	O
for	O
instance	O
,	O
for	O
treatment	O
of	O
type	O
II	O
diabetes	O
.	O

Combinations	O
of	O
erbb2	B
inhibitors	O
with	O
other	O
therapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
cancer	O
This	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
cancer	O
with	O
a	O
combination	O
of	O
an	O
additional	O
therapeutic	O
agent	O
in	O
mammals	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
kit	O
useful	O
in	O
the	O
treatment	O
of	O
abnormal	O
cell	O
growth	O
in	O
mammals	O
,	O
especially	O
humans	O
.	O

Sulindac	O
derivatives	O
for	O
treatment	O
of	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
non	O
steroidal	O
anti	O
-	O
inflammatory	O
compounds	O
(	O
NSAIDs	O
)	O
derivatives	O
of	O
sulindac	O
,	O
for	O
the	O
treatment	O
/	O
prevention	O
,	O
alone	O
or	O
in	O
combination	O
,	O
of	O
cancer	O
.	O

Heterocyclic	O
containing	O
amines	O
as	O
kinase	O
b	O
inhibitors	O
The	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
solvate	O
,	O
tautomer	O
or	O
N	O
-	O
oxide	O
thereof	O
;	O
for	O
use	O
as	O
a	O
PKB	O
kinase	O
inhibitor	O
or	O
PKA	O
kinase	O
inhibitor	O
.	O

In	O
formula	O
(	O
I	O
)	O
,	O
A	O
is	O
a	O
saturated	O
hydrocarbon	O
linker	O
group	O
;	O
E	O
is	O
a	O
monocyclic	O
or	O
bicyclic	O
carbocyclic	O
or	O
heterocyclic	O
group	O
;	O
HET	O
is	O
a	O
monocyclic	O
heterocyclic	O
group	O
;	O
R1	O
is	O
an	O
aryl	O
or	O
heteroaryl	O
group	O
;	O
n	O
is	O
0	O
to	O
4	O
;	O
and	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
,	O
provided	O
that	O
HET	O
is	O
other	O
than	O
an	O
unsubstituted	O
or	O
substituted	O
pyrazole-4-yl	O
group	O
.	O

Fluorescent	O
sulfonamide	O
derivatives	O
having	O
carbonic	B
anhydrase	I
inhibiting	O
activity	O
and	O
their	O
use	O
as	O
theapeutic	O
and	O
diagnostic	O
agents	O
The	O
present	O
invention	O
discloses	O
sulfonamide	O
CA	B
IX	I
-	O
selective	O
inhibitors	O
,	O
which	O
selectively	O
bind	O
to	O
the	O
enzyme	O
under	O
hypoxic	O
conditions	O
and	O
are	O
able	O
to	O
reverse	O
the	O
tumor	O
acidification	O
mediated	O
by	O
the	O
enzyme	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
anticancer	O
therapies	O
based	O
on	O
tumor	O
-	O
associated	O
CA	B
isozyme	I
inhibition	O
as	O
well	O
as	O
for	O
hypoxic	O
tumor	O
imaging	O
.	O

The	O
inhibitors	O
contain	O
a	O
fluorescent	O
moiety	O
,	O
preferably	O
fluorescein	O
.	O

Tablet	O
containing	O
poorly	O
soluble	O
active	O
ingredient	O
Disclosed	O
is	O
a	O
tablet	O
containing	O
about	O
3	O
-	O
50	O
%	O
by	O
weight	O
(	O
w	O
/	O
w	O
)	O
of	O
a	O
poorly	O
soluble	O
active	O
ingredient	O
relative	O
to	O
the	O
total	O
tablet	O
weight	O
,	O
magnesium	O
stearate	O
and	O
a	O
hydroxypropylcellulose	O
having	O
a	O
viscosity	O
of	O
about	O
1	O
-	O
4	O
mPa·s	O
.	O

This	O
tablet	O
is	O
suppressed	O
in	O
dissolution	O
variation	O
between	O
lots	O
.	O

Pharmaceutical	O
compositions	O
containing	O
clopidogrel	O
bisulfate	O
Provided	O
is	O
a	O
pharmaceutical	O
composition	O
including	O
clopidogrel	O
bisulfate	O
and	O
a	O
pregelatinized	O
starch	O
.	O

The	O
pharmaceutical	O
composition	O
in	O
which	O
the	O
stability	O
of	O
clopido	O
grel	O
bisulfate	O
is	O
significantly	O
enhanced	O
can	O
be	O
obtained	O
by	O
mixing	O
clopidogrel	O
bisulfate	O
w	O
ith	O
the	O
pregelatinized	O
starch	O
.	O

Compounds	O
and	O
their	O
salts	O
specific	O
to	O
the	O
ppar	B
receptors	O
and	O
the	O
egf	B
receptors	I
and	O
their	O
use	O
in	O
the	O
medical	O
field	O
Therefore	O
the	O
present	O
invention	O
relates	O
specifically	O
to	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
and	O
R2	O
,	O
which	O
may	O
be	O
identical	O
or	O
different	O
,	O
are	O
selected	O
from	O
the	O
group	O
comprising	O
H	O
,	O
-CnH2n-1	O
,	O
a	O
linear	O
or	O
branched	O
alkyl	O
group	O
having	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
,	O
or	O
together	O
form	O
an	O
aromatic	O
or	O
aliphatic	O
ring	O
with	O
5	O
or	O
6	O
atoms	O
;	O
R3	O
is	O
selected	O
from	O
-CO	O
-	O
CH3	O
,	O
-NHOH	O
,	O
-OH	O
,	O
-OR6	O
in	O
which	O
R6	O
is	O
a	O
linear	O
or	O
branched	O
alkyl	O
group	O
having	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
;	O
R4	O
is	O
selected	O
from	O
H	O
,	O
a	O
linear	O
or	O
branched	O
alkyl	O
group	O
having	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
,	O
phenyl	O
,	O
benzyl	O
,	O
-CF3	O
or	O
-CF2CF3	O
,	O
vinyl	O
or	O
allyl	O
;	O
R5	O
,	O
R7	O
,	O
R8	O
are	O
hydrogen	O
atoms	O
;	O
or	O
R3	O
and	O
R4	O
,	O
R4	O
and	O
R5	O
,	O
or	O
R7	O
and	O
R8	O
together	O
form	O
a	O
ring	O
,	O
fused	O
to	O
the	O
benzene	O
,	O
aromatic	O
or	O
aliphatic	O
ring	O
with	O
5	O
or	O
6	O
atoms	O
comprising	O
from	O
1	O
to	O
2	O
heteroatoms	O
selected	O
independently	O
from	O
the	O
group	O
comprising	O
N	O
,	O
O.	O
and	O
use	O
thereof	O
in	O
the	O
medical	O
field	O
.	O

Simon	O
potato	O
extract	O
,	O
glycosphingolipid	O
derived	O
from	O
simon	O
potato	O
,	O
and	O
process	O
for	O
production	O
of	O
the	O
extract	O
or	O
glycosphingolipid	O
[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
process	O
for	O
producing	O
a	O
glycolipid	O
-	O
containing	O
Simon	O
potato	O
extract	O
or	O
a	O
glycosphingolipid	O
from	O
a	O
Simon	O
potato	O
for	O
the	O
purpose	O
of	O
providing	O
an	O
alternative	O
to	O
a	O
livestock	O
brain	O
ganglioside	O
which	O
is	O
free	O
from	O
the	O
risk	O
of	O
BSE	O
or	O
the	O
like	O
,	O
is	O
safe	O
to	O
a	O
human	O
body	O
and	O
can	O
be	O
ingested	O
on	O
a	O
daily	O
basis	O
,	O
and	O
to	O
provide	O
a	O
nerve	O
cell	O
activator	O
comprising	O
a	O
glycolipid	O
or	O
glycosphingolipid	O
derived	O
from	O
a	O
Simon	O
potato	O
and	O
a	O
health	O
food	O
prepared	O
by	O
using	O
the	O
glycolipid	O
or	O
glycosphingolipid	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O

A	O
Simon	O
potato	O
extract	O
can	O
be	O
produced	O
by	O
immersing	O
a	O
Simon	O
potato	O
in	O
a	O
polar	O
solvent	O
to	O
extract	O
a	O
glycolipid	O
or	O
glycosphingolipid	O
into	O
the	O
polar	O
solvent	O
and	O
then	O
concentrating	O
the	O
resulting	O
immersion	O
fluid	O
.	O

The	O
nerve	O
cell	O
activation	O
effect	O
of	O
the	O
glycolipid	O
or	O
glycosphingolipid	O
is	O
confirmed	O
using	O
an	O
established	O
neuroblast	O
.	O

Hepatitis	B
c	I
serine	I
protease	I
inhibitors	O
and	O
uses	O
therefor	O
The	O
present	O
invention	O
provides	O
novel	O
compounds	O
which	O
mimic	O
peptides	O
with	O
a	O
C	O
-	O
terminal	O
penultimate	O
proline	O
,	O
such	O
compounds	O
being	O
useful	O
as	O
protease	B
inhibitors	O
,	O
particularly	O
as	O
inhibitors	O
of	O
serine	B
proteases	I
,	O
and	O
more	O
particularly	O
as	O
inhibitors	O
of	O
the	O
NS3	B
serine	I
protease	I
from	O
hepatitis	O
C.	O
The	O
compounds	O
find	O
utility	O
as	O
antiviral	O
agents	O
directed	O
at	O
hepatitis	O
C.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
employing	O
such	O
inhibitors	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
,	O
to	O
treat	O
hepatitis	O
C	O
infection	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
.	O

Vaginal	O
treatment	O
composition	O
A	O
vaginal	O
treatment	O
composition	O
that	O
rapidly	O
forms	O
a	O
gel	O
when	O
placed	O
into	O
contact	O
with	O
monovalent	O
or	O
polyvalent	O
cations	O
,	O
such	O
as	O
sodium	O
(	O
Na+	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
cations	O
naturally	O
found	O
in	O
vaginal	O
mucosa	O
,	O
is	O
provided	O
.	O

The	O
gel	O
may	O
form	O
in	O
less	O
than	O
about	O
1	O
hour	O
,	O
in	O
some	O
embodiments	O
less	O
than	O
about	O
1	O
minute	O
,	O
and	O
in	O
some	O
embodiments	O
,	O
less	O
than	O
about	O
30	O
seconds	O
.	O

Among	O
other	O
things	O
,	O
such	O
rapid	O
gelation	O
reduces	O
the	O
likelihood	O
of	O
leakage	O
during	O
use	O
.	O

In	O
addition	O
,	O
because	O
the	O
gel	O
may	O
form	O
intravaginally	O
,	O
it	O
is	O
more	O
likely	O
to	O
retain	O
its	O
structure	O
and	O
shape	O
over	O
an	O
extended	O
period	O
of	O
time	O
.	O

In	O
this	O
manner	O
,	O
the	O
gel	O
may	O
provide	O
the	O
prolonged	O
release	O
of	O
a	O
therapeutic	O
agent	O
that	O
inhibits	O
and/or	O
treats	O
vaginal	O
infection	O
.	O

For	O
instance	O
,	O
the	O
gel	O
may	O
remain	O
within	O
the	O
vagina	O
for	O
about	O
2	O
to	O
about	O
48	O
hours	O
to	O
provide	O
the	O
desired	O
effect	O
.	O

Chromane	O
substituted	O
2-alkyl	O
imidazopyridine	O
derivatives	O
and	O
use	O
thereof	O
as	O
acid	O
pump	O
antagonists	O
This	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
:	O
A	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
each	O
as	O
described	O
herein	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
method	O
and	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
acid	O
pump	O
antagonistic	O
activity	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
as	O
gastrointestinal	O
disease	O
,	O
gastroesophageal	O
disease	O
,	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
,	O
peptic	O
ulcer	O
,	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
NSAID	O
-	O
induced	O
ulcers	O
,	O
gastritis	O
,	O
infection	O
of	O
Helicobacter	O
pylori	O
,	O
dyspepsia	O
,	O
functional	O
dyspepsia	O
,	O
Zollinger	O
-	O
Ellison	O
syndrome	O
,	O
non	O
-	O
erosive	O
reflux	O
disease	O
(	O
NERD	O
)	O
,	O
visceral	O
pain	O
,	O
heartburn	O
,	O
nausea	O
,	O
esophagitis	O
,	O
dysphagia	O
,	O
hypersalivation	O
,	O
airway	O
disorders	O
or	O
asthma	O
.	O

Sunscreen	O
and	O
cosmetic	O
compositions	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
skin	O
cancers	O
There	O
are	O
provided	O
sunscreen	O
and	O
cosmetics	O
compositions	O
containing	O
non	O
-	O
steroidal	O
anti-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
in	O
the	O
form	O
of	O
metal	O
complexes	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
cancers	O
of	O
the	O
skin	O
.	O

The	O
ligand	O
(	O
s	O
)	O
of	O
the	O
complex	O
typically	O
independently	O
comprise	O
a	O
carboxylate	O
,	O
or	O
a	O
derivative	O
of	O
a	O
carboxylate	O
,	O
having	O
anti	O
-	O
inflammatory	O
activity	O
.	O

Carboxylate	O
derivatives	O
having	O
anti	O
-	O
inflammatory	O
activity	O
that	O
may	O
be	O
used	O
include	O
hydroxamates	O
,	O
hydroximates	O
,	O
amides	O
and	O
esters	O
.	O

Copper	O
and	O
zinc	O
metal	O
complexes	O
including	O
the	O
NSAIDs	O
indomethacin	O
and	O
acematacin	O
are	O
particularly	O
preferred	O
.	O

7-	O
[	O
2-	O
[	O
4-	O
(	O
6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL	O
)	O
-1-PIPERAZINYL	O
]	O
ETHYL	O
]	O
-2-	O
(	O
1-PROPYNYL	O
)	O
-7H	O
-	O
PYRAZOLO-	O
[	O
4,3-e	O
]	O
-	O
[	O
1,2,4	O
]	O
-TRIAZOLO-	O
[	O
1,5-c	O
]	O
-PYRIMIDIN-5	O

AMINE	O
The	O
compound	O
having	O
the	O
structural	O
formula	O
I	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
is	O
disclosed	O
,	O
as	O
well	O
as	O
its	O
use	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
diseases	O
,	O
in	O
particular	O
Parkinson	O
's	O
disease	O
,	O
Extra	O
Pyramidal	O
Syndrome	O
,	O
restless	O
legs	O
syndrome	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
pharmaceutical	O
compositions	O
comprising	O
it	O
,	O
and	O
combinations	O
with	O
other	O
agents	O
.	O

Thienopyridine-2-carboxamide	O
derivative	O
Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

(	O
In	O
the	O
formula	O
,	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1-C6	O
alkyl	O
group	O
,	O
and	O
R2	O
represents	O
a	O
substituted	O
cyclic	O
amino	O
.	O
)	O

PYRIDOPYRIMIDINONE	O
INHIBITORS	O
OF	O
PI3Kα	B
The	O
invention	O
is	O
directed	O
to	O
Compounds	O
of	O
Formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
as	O
well	O
as	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O

The	O
oral	O
agent	O
for	O
improving	O
and	O
protecting	O
the	O
function	O
of	O
joint	O
comprising	O
hyaluronic	O
acid	O
-	O
phospholipid	O
complexes	O
An	O
oral	O
formulation	O
compring	O
hyaluronid	O
acid-	O
phospholipid	O
complexes	O
as	O
active	O
ingredient	O
and	O
the	O
application	O
of	O
hyaluronic	O
acid-	O
phosphlipid	O
complexes	O
in	O
preparation	O
of	O
the	O
product	O
for	O
improving	O
and	O
protecting	O
the	O
function	O
of	O
joint	O
.	O

Pqs	O
and	O
its	O
conjugates	O
as	O
adjuvants	O
and	O
their	O
uses	O
in	O
pharmaceutical	O
compositions	O
The	O
present	O
invention	O
relates	O
to	O
new	O
adjuvants	O
and	O
the	O
uses	O
in	O
pharmaceutical	O
compositions	O
,	O
like	O
in	O
vaccines	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
new	O
compounds	O
useful	O
as	O
adjuvants	O
and/or	O
immunomodulators	O
for	O
prophylactic	O
and/or	O
therapeutic	O
vaccination	O
in	O
the	O
treatment	O
of	O
infectious	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
tumours	O
,	O
allergies	O
as	O
well	O
as	O
for	O
the	O
control	O
of	O
fertility	O
in	O
human	O
or	O
animal	O
populations	O
.	O

The	O
compounds	O
are	O
particularly	O
useful	O
not	O
only	O
as	O
systemic	O
,	O
but	O
preferably	O
as	O
mucosal	O
adjuvants	O
.	O

In	O
addition	O
,	O
the	O
invention	O
relates	O
to	O
its	O
uses	O
as	O
active	O
ingredients	O
in	O
pharmaceutical	O
compositions	O
.	O

Macrolones	O
A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
having	O
antimicrobial	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
medicine	O
.	O

N4-phenyl	O
-	O
quinaz0line-4	O
-amine	O
derivatives	O
and	O
related	O
compounds	O
as	O
erbb	B
type	I
i	I
receptor	I
tyrosine	I
kinase	I
inhibitors	O
for	O
the	O
treatment	O
of	O
hyperproliferative	O
diseases	O
This	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
B	O
,	O
G	O
,	O
A	O
,	O
E	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
which	O
are	O
useful	O
as	O
type	B
I	I
receptor	I
tyrosine	I
kinase	I
inhibitors	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
in	O
mammals	O
.	O

Novel	O
proline	O
-	O
derivative	O
based	O
cosmetological	O
and/or	O
dermatological	O
compositions	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
the	O
necessities	O
of	O
life	O
,	O
and	O
more	O
particularly	O
to	O
the	O
field	O
of	O
cosmetology	O
and	O
dermatology	O
.	O

It	O
relates	O
more	O
particularly	O
to	O
novel	O
cosmetological	O
and/or	O
dermatological	O
compositions	O
which	O
bring	O
about	O
a	O
very	O
significant	O
increase	O
in	O
the	O
deposition	O
of	O
collagen	B
type	I
(	I
III	I
)	I
in	O
the	O
extracellular	O
matrix	O
,	O
characterized	O
in	O
that	O
they	O
contain	O
,	O
as	O
active	O
ingredient	O
,	O
a	O
combination	O
of	O
a	O
4-hydroxyproline	O
fatty	O
acid	O
amido	O
ester	O
,	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R1	O
and	O
R'1	O
are	O
identical	O
or	O
different	O
aliphatic	O
chains	O
containing	O
from	O
10	O
to	O
24	O
carbon	O
atoms	O
that	O
are	O
in	O
a	O
straight	O
line	O
or	O
branched	O
,	O
and	O
of	O
an	O
extract	O
of	O
the	O
epicarp	O
of	O
the	O
Opuntia	O
ficus	O
-	O
indica	O
(	O
Barbary	O
fig	O
)	O
fruit	O
in	O
an	O
inert	O
,	O
nontoxic	O
excipient	O
or	O
carrier	O
suitable	O
for	O
topical	O
use	O
.	O

Use	O
in	O
the	O
form	O
of	O
a	O
fatty	O
cream	O
or	O
gel	O
for	O
the	O
increased	O
production	O
of	O
collagen	B
,	O
without	O
amplifying	O
that	O
of	O
procollagen	B
(	I
III	I
)	I
or	O
of	O
enzymes	O
of	O
the	O
metalloproteinase	B
family	O
.	O

A	O
g	B
protein	I
-	I
coupled	I
receptor	I
antagonist	O
and	O
its	O
use	O
for	O
preventing	O
and	O
treating	O
alzheimer	O
's	O
disease	O
A	O
method	O
of	O
screening	O
reagents	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
's	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O

The	O
method	O
comprises	O
:	O
(	O
a	O
)	O
stimulating	O
a	O
receptor	O
and	O
identifying	O
its	O
degree	O
of	O
internalization	O
,	O
wherein	O
the	O
receptor	O
is	O
a	O
G	B
protein	I
-	I
coupled	I
receptor	I
combining	O
with	O
PS1	B
;	O
(	O
b	O
)	O
stimulating	O
the	O
receptor	O
as	O
step	O
(	O
a	O
)	O
in	O
the	O
presence	O
of	O
a	O
reagent	O
,	O
and	O
identifying	O
its	O
degree	O
of	O
internalization	O
again	O
;	O
(	O
c	O
)	O
comparing	O
the	O
difference	O
between	O
the	O
internalizing	O
degrees	O
of	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
;	O
(	O
d	O
)	O
repeating	O
steps	O
(	O
a	O
)	O
-	O
(	O
c	O
)	O
if	O
the	O
difference	O
is	O
less	O
than	O
the	O
least	O
value	O
.	O

And	O
use	O
of	O
the	O
receptor	O
antagonist	O
for	O
preparing	O
a	O
drug	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
's	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O

The	O
receptor	O
antagonist	O
can	O
be	O
used	O
to	O
inhibit	O
the	O
internalization	O
of	O
the	O
G	B
protein	I
-	I
coupled	I
receptor	I
combing	O
with	O
PS1	B
.	O

Mutilin	O
derivatives	O
and	O
their	O
use	O
as	O
pharmaceutical	O
14	O
-	O
0-	O
[	O
(	O
(	O
(	O
C1.6	O
)	O
Alkoxy-	O
(	O
C1.6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
(	O
C1	O
-	O
6	O
)	O
Mono-	O
or	O
dialkylamino-	O
(	O
C1.6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Hydroxy-	O
(	O
C1	O
-	O
6	O
)	O
-alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Formyl-	O
(	O
C0.5	O
)	O
-alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Guanidino	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Ureido	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alky	O
)	O
-phenylsulfany	O
]	O
-acety	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
Thioureido	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
,	O
14-O-	O
[	O
(	O
(	O
lsothioureido	O
-	O
imino-	O
(	O
C1	O
-	O
6	O
)	O
alkyl	O
)	O
-phenylsulfanyl	O
)	O
-acetyl	O
]	O
-mutilins	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

Sulfonamide	O
derivatives	O
,	O
preparation	O
thereof	O
and	O
therapeutic	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
sulphonamide	O
derivatives	O
corresponding	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
Ar1	O
represents	O
an	O
aryl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclyl	O
group	O
;	O
T	O
represents	O
a	O
-	O
(	O
CH2	O
)	O
n-	O
or	O
a	O
group	O
(	O
II	O
)	O
,	O
Ar2	O
represents	O
an	O
aryl	O
as	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclyl	O
group	O
;	O
Ar3	O
represents	O
an	O
aryl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
else	O
an	O
optionally	O
substituted	O
heterocyclyl	O
,	O
R1	O
represents	O
a	O
group	O
of	O
formula	O
(	O
A	O
)	O
or	O
(	O
B	O
)	O
:	O
(	O
A	O
)	O
(	O
B	O
)	O
in	O
the	O
form	O
of	O
a	O
base	O
,	O
an	O
addition	O
salt	O
with	O
an	O
acid	O
,	O
a	O
hydrate	O
or	O
a	O
solvate	O
,	O
in	O
the	O
form	O
of	O
enantiomers	O
,	O
diastereoisomers	O
,	O
rotamers	O
or	O
atropoisomers	O
,	O
or	O
mixtures	O
thereof	O
.	O

It	O
also	O
relates	O
to	O
the	O
process	O
for	O
the	O
preparation	O
and	O
also	O
the	O
therapeutic	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

Topical	O
preparation	O
composition	O
containing	O
a	O
thiourea	O
derivative	O
for	O
preventing	O
or	O
treating	O
pruritic	O
or	O
irritant	O
skin	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
topical	O
composition	O
comprising	O
a	O
thiourea	O
derivative	O
,	O
which	O
is	O
a	O
vanilloid	O
receptor	O
antagonist	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
a	O
pharmaceutical	O
use	O
of	O
the	O
same	O
.	O

The	O
topical	O
composition	O
according	O
to	O
the	O
present	O
invention	O
is	O
excellent	O
in	O
skin	O
permeation	O
and	O
stability	O
and	O
effective	O
in	O
treatment	O
of	O
pruritic	O
or	O
irritant	O
skin	O
diseases	O
.	O

Compositions	O
and	O
methods	O
for	O
effecting	O
controlled	O
posterior	O
vitreous	O
detachment	O
A	O
composition	O
comprises	O
plasmin	O
or	O
an	O
enzymatically	O
equivalent	O
derivative	O
thereof	O
and	O
at	O
least	O
an	O
anti	O
-	O
inflammatory	O
medicament	O
,	O
such	O
as	O
triamcinolone	O
acetonide	O
.	O

The	O
composition	O
can	O
be	O
used	O
to	O
effect	O
or	O
induce	O
a	O
controlled	O
posterior	O
vitreous	O
detachment	O
(	O
'	O
PVD	O
'	O
)	O
to	O
prevent	O
,	O
treat	O
,	O
or	O
ameliorate	O
a	O
potential	O
complication	O
of	O
a	O
pathological	O
ocular	O
condition	O
.	O

Such	O
a	O
composition	O
can	O
be	O
administered	O
intravitreally	O
.	O

Hair	O
grower	O
The	O
invention	O
provides	O
a	O
hair	O
grower	O
having	O
a	O
hair	O
-	O
glowing	O
effect	O
and	O
useful	O
application	O
forms	O
of	O
the	O
hair	O
grower	O
.	O

The	O
invention	O
relates	O
to	O
a	O
hair	O
grower	O
containing	O
as	O
the	O
active	O
ingredient	O
a	O
lithospermic	O
acid	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
;	O
and	O
oral	O
preparations	O
,	O
external	O
preparations	O
,	O
and	O
foods	O
,	O
containing	O
the	O
hair	O
grower	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
are	O
each	O
hydrogen	O
or	O
optionally	O
substituted	O
C1	O
-	O
4	O
alkyl	O
;	O
and	O
R3	O
is	O
hydrogen	O
,	O
optionally	O
substituted	O
C1	O
-	O
4	O
alkyl	O
,	O
or	O
a	O
group	O
represented	O
by	O
the	O
general	O
formula	O
(	O
II	O
)	O
.	O

Diphenylurea	O
derivatives	O
and	O
their	O
use	O
as	O
chloride	B
channel	I
blockers	O
or	O
bkca	B
channel	I
modulators	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
diphenylurea	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
chloride	O
channel	O
blockers	O
or	O
BKCa	B
channel	I
modulators	O
.	O

In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Thiazolyldihydroindazoles	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
thiazolyldihydroindazoles	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
where	O
the	O
R1	O
,	O
R2	O
and	O
R3	O
radicals	O
are	O
each	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
description	O
,	O
to	O
their	O
tautomers	O
,	O
racemates	O
,	O
enantiomers	O
,	O
diastereomers	O
and	O
mixtures	O
thereof	O
,	O
and	O
where	O
appropriate	O
to	O
their	O
pharmacologically	O
safe	O
acid	O
addition	O
salts	O
,	O
solvates	O
and	O
hydrates	O
,	O
and	O
to	O
processes	O
for	O
preparing	O
these	O
thiazolyldihydroindazoles	O
and	O
to	O
their	O
use	O
as	O
medicaments	O
.	O

Heterocyclic	O
gaba	B
alpha	I
subtype	I
selective	I
receptor	I
modulators	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
or	O
prodrugs	O
thereof	O
,	O
wherein	O
Y	O
,	O
Ar	O
,	O
R1	O
and	O
R2	O
are	O
defined	O
herein	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
their	O
use	O
and	O
methods	O
of	O
preparing	O
the	O
compounds	O
.	O

1,4:3,6-dianhydromannitol	O
derivatives	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
,	O
amongst	O
other	O
things	O
,	O
to	O
the	O
use	O
of	O
1,4:3,6-dianhydromannitol	O
derivatives	O
of	O
formulae	O
(	O
Ia	O
)	O
-	O
(	O
I	O
d	O
)	O
as	O
therapeutic	O
agents	O
.	O

3-tetrazolyl	O
indazoles	O
,	O
3-tetrazolyl	O
pyrazolopyridines	O
,	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
novel	O
3-tetrazolyl	O
indazole	O
derivatives	O
and	O
3-tetrazolyl	O
pyrazolo	O
[	O
3,4-b	O
]	O
-pyridine	O
derivatives	O
,	O
methods	O
for	O
producing	O
the	O
same	O
,	O
the	O
exclusive	O
or	O
combined	O
use	O
thereof	O
for	O
treating	O
and/or	O
preventing	O
diseases	O
,	O
and	O
the	O
use	O
thereof	O
for	O
producing	O
medicaments	O
utilized	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
,	O
particularly	O
cardiovascular	O
diseases	O
.	O

Isatin	O
and	O
its	O
derivatives	O
for	O
use	O
as	O
a	O
medicament	O
The	O
present	O
invention	O
relates	O
to	O
2,3-dioxoindole	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
for	O
use	O
as	O
a	O
medicament	O
,	O
and	O
particularly	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
fever	O
,	O
inflammation	O
or	O
pain	O
,	O
wherein	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
;	O
R1	O
is	O
hydrogen	O
,	O
or	O
(	O
C1-C10	O
)	O
linear	O
or	O
branched	O
alkyl	O
or	O
hydroxyalkyl	O
group	O
or	O
acyl	O
group	O
containing	O
(	O
C1-C10	O
)	O
linear	O
or	O
branched	O
alkyl	O
group	O
,	O
R2-R5	O
are	O
independently	O
hydrogen	O
,	O
halogen	O
,	O
amino	O
group	O
,	O
nitro	O
group	O
,	O
optionally	O
halogen	O
substituted	O
(	O
C1-C10	O
)	O
alkyl	O
group	O
,	O
(	O
C1-C10	O
)	O
alkoxy	O
group	O
or	O
hydroxyl	O
group	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
fever	O
,	O
inflammation	O
or	O
pain	O
,	O
wherein	O
a	O
medicament	O
incorporating	O
a	O
pharmacologically	O
effective	O
dose	O
of	O
the	O
above	O
described	O
active	O
ingredient	O
is	O
administered	O
to	O
patients	O
in	O
need	O
of	O
such	O
treatment	O
.	O

Antiperiodontitis	O
agents	O
,	O
and	O
drinks	O
,	O
foods	O
or	O
oral	O
hygiene	O
products	O
containing	O
the	O
agents	O
The	O
invention	O
provides	O
antiperiodontitis	O
agents	O
which	O
originate	O
in	O
plant	O
components	O
free	O
from	O
the	O
anxiety	O
about	O
safety	O
and	O
have	O
no	O
peculiar	O
spice	O
-	O
like	O
aroma	O
or	O
taste	O
and	O
which	O
have	O
high	O
antibacterial	O
effects	O
on	O
bacteria	O
causative	O
of	O
periodontal	O
diseases	O
and	O
can	O
prevent	O
or	O
cure	O
periodontal	O
diseases	O
;	O
and	O
drinks	O
,	O
foods	O
,	O
or	O
oral	O
hygiene	O
products	O
,	O
containing	O
the	O
agents	O
.	O

Antiperiodontitis	O
agents	O
,	O
characterized	O
by	O
containing	O
one	O
or	O
more	O
isothiocyanate	O
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ω	O
-	O
alkenyl	O
isothiocyanate	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
1	O
]	O
,	O
ω	O
-	O
alkylthioalkyl	O
isothiocyanate	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
2	O
]	O
,	O
and	O
ω	O
-	O
phenylalkyl	O
isothiocyanate	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
3	O
]	O
and	O
mint	O
essential	O
oil	O
or	O
a	O
mint	O
essential	O
oil	O
component	O
;	O
and	O
drinks	O
,	O
foods	O
,	O
or	O
oral	O
hygiene	O
products	O
,	O
containing	O
the	O
agents	O
:	O
General	O
formula	O
[	O
1	O
]	O
:	O
CH2	O
=	O
CH-	O
(	O
CH2	O
)	O
m	O
-	O
NCS	O
(	O
wherein	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
)	O
General	O
formula	O
[	O
2	O
]	O
:	O
R	O
-	O
S-	O
(	O
CH2	O
)	O
n	O
-	O
NCS	O
(	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
and	O
R	O
is	O
straight-	O
or	O
branched	O
-	O
chain	O
alkyl	O
of	O
1	O
to	O
4	O
carbon	O
atoms	O
)	O
,	O
and	O
General	O
formula	O
[	O
3	O
]	O
:	O
Ph-	O
(	O
CH2	O
)	O
p	O
-	O
NCS	O
(	O
wherein	O
Ph	O
is	O
phenyl	O
and	O
p	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
)	O
.	O

Compounds	O
for	O
use	O
as	O
a	O
medicament	O
A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
for	O
use	O
as	O
a	O
medicament	O
.	O

A	O
pharmaceutical	O
composition	O
the	O
compound	O
.	O

Use	O
of	O
the	O
compound	O
for	O
preparing	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
selected	O
from	O
hyperproliferative	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
and	O
heart	O
diseases	O
.	O

Methods	O
and	O
compositions	O
for	O
modulating	O
hepsin	O
activation	O
of	O
urokinase	B
-	I
type	I
plasminogen	I
activator	I
The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
modulating	O
hepsin	O
activity	O
and	O
the	O
uPA	B
/	O
plasmin	O
pathway	O
,	O
in	O
particular	O
by	O
regulating	O
pro	O
-	O
uPA	B
activation	O
by	O
hepsin	O
.	O

4,6-dl-	O
and	O
2,4,6-trisubstituted	O
quinazoline	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
useful	O
for	O
treating	O
viral	O
infections	O
This	O
invention	O
provides	O
the	O
treatment	O
of	O
viral	O
infections	O
with	O
a	O
4,6-	O
disubstituted	O
or	O
2,4,6-trisubstituted	O
quinazoline	O
derivative	O
represented	O
by	O
the	O
structural	O
formula	O
[	O
(	O
I	O
)	O
]	O
wherein	O
:	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	O
,	O
NR'R	O
'	O
and	O
C1	O
-	O
7	O
alkyl	O
;	O
-	O
A	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
bond	O
,	O
O	O
,	O
S	O
(	O
O	O
)	O
n	O
,	O
C1	O
-	O
7	O
alkylene	O
,	O
C2	O
-	O
7	O
alkenylene	O
and	O
C2	O
-	O
7	O
alkynylene	O
;	O
R4	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
C1	O
-	O
7	O
alkyl	O
,	O
C2	O
-	O
7	O
alkenyl	O
,	O
C3	O
-	O
10	O
cycloalkyl	O
,	O
C3	O
-	O
10	O
cycloalkenyl	O
,	O
aryl	O
,	O
heterocyclic	O
,	O
arylalkyl	O
,	O
heterocyclic	O
-	O
substituted	O
alkyl	O
and	O
cycloalkyl	O
-	O
alkyl	O
;	O
-	O
Y	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
single	O
bond	O
,	O
C1	O
-	O
7	O
alkylene	O
,	O
C2	O
-	O
7	O
alkenylene	O
,	O
and	O
C2	O
-	O
7	O
alkynylene	O
;	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
and	O
R6	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	O
,	O
heteroaryl	O
and	O
aryl	O
;	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
,	O
a	O
stereoisomer	O
,	O
a	O
mono-	O
or	O
a	O
di	O
-	O
Λ	O
/	O
-oxide	O
,	O
a	O
solvate	O
or	O
a	O
pro	O
-	O
drug	O
thereof	O
.	O

4,6-dl-	O
and	O
2,4,6-trisubstituted	O
quinazoline	O
derivatives	O
useful	O
for	O
treating	O
viral	O
infections	O
This	O
invention	O
provides	O
quinazoline	O
derivatives	O
represented	O
by	O
the	O
structural	O
formula	O
:	O
(	O
I	O
)	O
;	O
wherein	O
:	O
R2	O
is	O
hydrogen	O
,	O
NR'R	O
'	O
,	O
C1	O
-	O
7	O
alkyl	O
,	O
arylC1	O
-	O
7	O
alkyl	O
or	O
C3	O
-	O
10	O
cycloalkyl	O
;	O
R4	O
is	O
amino	O
,	O
C1	O
-	O
7	O
alkyl	O
,	O
C2	O
-	O
7	O
alkenyl	O
,	O
C3	O
-	O
10	O
cycloalkyl	O
,	O
C3	O
-	O
10	O
cycloalkenyl	O
,	O
aryl	O
,	O
heterocyclic	O
,	O
arylalkyl	O
,	O
heterocyclic	O
-	O
substituted	O
C1	O
-	O
7	O
alkyl	O
or	O
C3	O
-	O
10	O
cycloalkyl	O
-	O
C1	O
-	O
7	O
alkyl	O
;	O
R5	O
is	O
hydrogen	O
or	O
C1	O
-	O
7	O
alkyl	O
,	O
or	O
R5	O
and	O
R4	O
together	O
with	O
the	O
nitrogen	O
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
heterocyclic	O
ring	O
;	O
Y	O
is	O
a	O
single	O
bond	O
,	O
C1	O
-	O
7alkylene	O
,	O
C2	O
-	O
7	O
alkenylene	O
or	O
C2	O
-	O
7	O
alkynylene	O
;	O
R6	O
is	O
halogen	O
,	O
heteroaryl	O
or	O
aryl	O
;	O
R	O
'	O
and	O
R	O
'	O
are	O
each	O
independently	O
hydrogen	O
,	O
C1	O
-	O
7	O
alkyl	O
-	O
carbonyl	O
or	O
C1	O
-	O
7	O
alkyl	O
;	O
provided	O
that	O
R4	O
is	O
not	O
phenyl	O
substituted	O
with	O
morpholino	O
when	O
R2	O
is	O
H	O
and	O
R5	O
is	O
H	O
,	O
and	O
provided	O
that	O
when	O
NR4R5	O
is	O
piperazinyl	O
,	O
said	O
NR4R5	O
is	O
either	O
non	O
-	O
substituted	O
or	O
substituted	O
with	O
methyl	O
or	O
acetyl	O
;	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
,	O
a	O
stereoisomer	O
,	O
a	O
mono-	O
or	O
a	O
di	O
-	O
N	O
-	O
oxide	O
,	O
a	O
solvate	O
or	O
a	O
pro	O
-	O
drug	O
thereof	O
,	O
for	O
the	O
treatment	O
of	O
viral	O
infections	O
.	O

Drug	O
combinations	O
for	O
treating	O
airway	O
diseases	O
The	O
invention	O
relates	O
to	O
novel	O
drug	O
combinations	O
,	O
comprising	O
,	O
in	O
addition	O
to	O
one	O
or	O
more	O
,	O
preferably	O
one	O
,	O
compound	O
of	O
general	O
formula	O
(	O
1	O
)	O
,	O
where	O
the	O
groups	O
R1	O
,	O
R2	O
and	O
R3	O
can	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
description	O
,	O
at	O
least	O
one	O
further	O
active	O
ingredient	O
2	O
,	O
a	O
method	O
for	O
production	O
and	O
use	O
thereof	O
as	O
a	O
drug	O
.	O

Remedy	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
The	O
invention	O
relates	O
to	O
an	O
inhibitor	O
of	O
pulmonary	O
emphysematous	O
lesions	O
containing	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
having	O
an	O
action	O
of	O
promoting	O
the	O
degradation	O
of	O
CSPG	O
,	O
an	O
action	O
of	O
inhibiting	O
the	O
synthesis	O
of	O
CSPG	O
,	O
or	O
an	O
action	O
of	O
inhibiting	O
the	O
sulfation	O
of	O
CSPG	O
,	O
for	O
example	O
,	O
chondroitinase	B
ABC	O
,	O
a	O
C6ST	O
antisense	O
agent	O
,	O
a	O
GalNAc	O
antisense	O
agent	O
or	O
the	O
like	O
,	O
an	O
inhibitor	O
of	O
emphysematous	O
lesions	O
suitable	O
for	O
treating	O
or	O
preventing	O
COPD	O
,	O
a	O
therapeutic	O
or	O
preventive	O
agent	O
for	O
COPD	O
,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
emphysematous	O
lesions	O
and	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
COPD	O
.	O

Morpholine	O
d3	B
dopamine	I
antagonists	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
to	O
intermediates	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
medicinal	O
use	O
as	O
modulators	O
of	O
the	O
dopamine	B
D3	I
receptor	I
,	O
particularly	O
as	O
psychotherapeutic	O
agents	O
.	O

2-alkyl-6-	O
(	O
pyrazolopyridin-4-yl	O
)	O
pyridazinone	O
derivative	O
,	O
addition	O
salt	O
thereof	O
,	O
and	O
pde	B
inhibitor	O
comprising	O
the	O
derivative	O
or	O
the	O
salt	O
as	O
active	O
ingredient	O
[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
2-alkyl-6-	O
(	O
pyrazolopyridin-	O
4-yl	O
)	O
pyridazinone	O
derivative	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
having	O
a	O
phosphodiesterase	B
-	O
inhibiting	O
activity	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
A	O
2-alkyl-6-	O
(	O
pyrazolopyridin-4-yl	O
)	O
pyridazinone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
(	O
a	O
specific	O
example	O
:	O
6-	O
(	O
7-methoxy-2-	O
trifluoromethylpyrazolo	O
[	O
1,5-a	O
]	O
pyridin-4-yl	O
)	O
-5-methyl-2-	O
[	O
3-	O
[	O
4-	O
(	O
4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-	O
yl	O
)	O
phenoxy	O
]	O
propyl	O
]	O
-4,5-dihydro-2H-	O
pyridazin-3-one	O
)	O
.	O

Indazole	O
derivatives	O
as	O
modulators	O
of	O
interleukin-	O
1	O
receptor	O
-	O
associated	O
kinase	O
The	O
present	O
invention	O
relates	O
to	O
modulators	O
of	O
IRAK	B
kinases	O
of	O
formula	O
(	O
I	O
)	O
and	O
provides	O
compositions	O
comprising	O
such	O
modulators	O
,	O
as	O
well	O
as	O
methods	O
therewith	O
for	O
treating	O
IRAK-	B
mediated	O
or	O
IRAK	B
-associated	O
conditions	O
or	O
diseases	O
.	O

Therapeutical	O
formulation	O
comprising	O
a	O
thiazolidinedione	O
and	O
a	O
nitric	O
oxide	O
scavenger	O
.	O

A	O
therapeutic	O
formulation	O
comprising	O
of	O
Thiazolidinediones	O
as	O
active	O
agents	O
namely	O
,	O
Pioglitazone	O
and	O
Rosiglitazone	O
,	O
characterized	O
in	O
that	O
said	O
Thiazolidinediones	O
are	O
combined	O
or	O
complexated	O
with	O
NO	O
Scavenger	O
to	O
prevent	O
Diabetic	O
Complications	O
arising	O
out	O
of	O
Nitrosative	O
stress	O
.	O

Treatment	O
of	O
fibrosis	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
fibrosis	O
.	O

In	O
one	O
aspect	O
the	O
invention	O
provides	O
the	O
use	O
of	O
an	O
agent	O
capable	O
of	O
increasing	O
the	O
number	O
of	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
available	O
to	O
and/or	O
engraftment	O
at	O
a	O
site	O
of	O
fibrosis	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
conjunction	O
with	O
an	O
anti-	O
fibrotic	O
agent	O
for	O
the	O
treatment	O
of	O
fibrosis	O
.	O

The	O
anti	O
-	O
fibrotic	O
agent	O
can	O
be	O
supplied	O
to	O
the	O
subject	O
before	O
,	O
at	O
the	O
same	O
time	O
,	O
or	O
after	O
the	O
agent	O
capable	O
of	O
increasing	O
the	O
number	O
of	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
available	O
to	O
and/or	O
engraftment	O
at	O
a	O
site	O
of	O
fibrosis	O
.	O

The	O
fibrosis	O
may	O
be	O
idiopathic	O
pulmonary	O
fibrosis	O
.	O

The	O
anti	O
-	O
fibrotic	O
agent	O
can	O
be	O
a	O
modulator	O
of	O
RhoA	O
,	O
RhoA	O
GTPases	O
,	O
TGF	O
-	O
βl	O
or	O
CTGF	O
,	O
or	O
any	O
other	O
member	O
of	O
the	O
RhoA	O
signalling	O
pathway	O
;	O
or	O
can	O
modulate	O
the	O
effect	O
of	O
suppressor	O
of	O
cytokine	O
signalling	O
1	O
(	O
SOCS	O
1	O
)	O
,	O
suppressor	O
of	O
cytokine	O
signalling	O
3	O
(	O
SOCS	O
3	O
)	O
or	O
TLR9	O
;	O
or	O
can	O
be	O
a	O
statin	O
compound	O
or	O
derivative	O
thereof	O
.	O

Enantiomerically	O
pure	O
phosphoindoles	O
as	O
hiv	O
inhibitors	O
3-phosphoindole	O
compounds	O
substantially	O
in	O
the	O
form	O
of	O
a	O
single	O
enantiomer	O
useful	O
for	O
the	O
treatment	O
of	O
Flaviviridae	O
virus	O
infections	O
,	O
and	O
particularly	O
for	O
HLV	O
infections	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
3-phosphoindole	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
antiviral	O
agents	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
and	O
methods	O
of	O
manufacturing	O
a	O
medicament	O
incorporating	O
these	O
compounds	O
.	O

The	O
3-phosphoindole	O
compounds	O
are	O
of	O
the	O
formula	O
(	O
A	O
)	O
or	O
(	O
B	O
)	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
hydrates	O
,	O
or	O
esters	O
thereof	O
.	O

In	O
the	O
formulae	O
X	O
is	O
hydrogen	O
;	O
aryl	O
or	O
heterocyclyl	O
;	O
C2	O
-	O
6	O
alkenyl	O
,	O
C2	O
-	O
6	O
alkynyl	O
or	O
alkyl	O
;	O
Y	O
is	O
hydrogen	O
,	O
-R	O
,	O
-O	O
-	O
R	O
,	O
-NH	O
-	O
R	O
,	O
or	O
-NRR	O
;	O
Z	O
is	O
-OR	O
,	O
-NHR	O
,	O
-NRR	O
,	O
carboxamido	O
,	O
arnido	O
,	O
carboxyl	O
,	O
carbonyl	O
,	O
or	O
an	O
amino	O
acid	O
residue	O
;	O
R1	O
is	O
hydrogen	O
,	O
acyl	O
,	O
-S	O
(	O
O	O
)	O
n	O
-	O
R	O
,	O
carboxyl	O
,	O
carbonyl	O
,	O
or	O
an	O
amino	O
acid	O
residue	O
;	O
each	O
R4	O
'	O
,	O
R5	O
'	O
,	O
R6	O
'	O
and	O
R7	O
'	O
is	O
independently	O
hydrogen	O
,	O
C2	O
-	O
6	O
alkenyl	O
,	O
C2	O
-	O
6	O
alkynyl	O
,	O
aryl	O
,	O
heterocyclyl	O
,	O
halogen	O
,	O
-CN	O
,	O
-CF3	O
,	O
-OR	O
,	O
-NHR	O
,	O
-NRR	O
,	O
or	O
-NO2	O
;	O
n	O
is	O
0	O
,	O
1	O
,	O
or	O
2	O
;	O
and	O
each	O
R	O
is	O
independently	O
hydrogen	O
,	O
alkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
,	O
C2	O
-	O
6	O
alkynyl	O
,	O
aryl	O
,	O
or	O
heterocyclyl	O
.	O

Crystalline	O
carbapenem	O
compounds	O
The	O
invention	O
provides	O
crystalline	O
substances	O
each	O
consisting	O
of	O
the	O
carbapenem	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
.	O

The	O
crystalline	O
substances	O
are	O
excellent	O
in	O
handleability	O
and	O
storage	O
stability	O
.	O

Further	O
,	O
the	O
invention	O
also	O
provides	O
solid	O
compositions	O
each	O
containing	O
both	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
an	O
alkali	O
metal	O
halide	O
.	O

The	O
crystalline	O
substances	O
and	O
the	O
solid	O
compositions	O
exhibit	O
excellent	O
antimicrobial	O
activity	O
.	O

5-	O
[	O
(	O
2r	O
)	O
-	O
[	O
2-	O
[	O
2-	O
[	O
2-	O
(	O
2,2,2-trifluoroethoxy	O
)	O
phenoxy	O
]	O
ethyl	O
]	O
amino	O
]	O
propyl	O
]	O
-2-methoxybenzenesulfonamide	O
5-	O
[	O
(	O
2R	O
)	O
-	O
[	O
2-	O
[	O
2-	O
[	O
2-	O
(	O
2,2,2-trifluoroethoxy	O
)	O
phenoxy	O
]	O
ethyl	O
]	O
amino	O
]	O
propyl	O
]	O
-2-methoxybenzenesulfonamide	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
the	O
synthesis	O
method	O
thereof	O
.	O

The	O
compound	O
has	O
strong	O
antagonism	O
toward	O
α1-adrenoceptor	B
and	O
has	O
high	O
selectivity	O
toward	O
smooth	O
muscle	O
of	O
urethra	O
.	O

Thienyl	O
-	O
containing	O
glycopyranosyl	O
derivatives	O
as	O
antidiabetics	O
The	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
described	O
herein	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
prodrug	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
.	O

Aminothiazole	O
macrocycles	O
,	O
their	O
use	O
as	O
antibacterial	O
compounds	O
and	O
processes	O
for	O
their	O
production	O
This	O
invention	O
relates	O
to	O
a	O
novel	O
antibiotic	O
compounds	O
,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
to	O
methods	O
for	O
obtaining	O
such	O
compounds	O
.	O

Use	O
of	O
glucopyranosyloxy-	O
pyrazoles	O
for	O
preventing	O
and	O
treating	O
neurodegenerative	O
disorders	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
glucopyranosyloxy	O
-	O
pyrazole	O
as	O
defined	O
in	O
claim	O
1	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
,	O
preventing	O
or	O
slowing	O
,	O
delaying	O
or	O
reversing	O
progression	O
of	O
one	O
or	O
more	O
neurodegenerative	O
disorders	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

Agent	O
for	O
activating	O
or	O
improving	O
neuronal	O
cell	O
or	O
brain	O
function	O
Disclosed	O
are	O
:	O
an	O
agent	O
for	O
activating	O
,	O
improving	O
or	O
protecting	O
a	O
neuronal	O
cell	O
;	O
an	O
agent	O
for	O
activating	O
,	O
improving	O
or	O
protecting	O
the	O
brain	O
function	O
;	O
and	O
a	O
prophylactic	O
,	O
ameliorating	O
or	O
therapeutic	O
agent	O
for	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
each	O
of	O
which	O
comprises	O
reduced	O
coenzyme	O
A	O
as	O
an	O
active	O
ingredient	O
.	O

Specifically	O
disclosed	O
are	O
:	O
a	O
prophylactic	O
,	O
ameliorating	O
or	O
therapeutic	O
agent	O
for	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
which	O
has	O
less	O
adverse	O
side	O
effects	O
and	O
is	O
highly	O
safe	O
;	O
and	O
a	O
method	O
for	O
treating	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
which	O
is	O
characterized	O
by	O
administering	O
the	O
agent	O
.	O

Methods	O
for	O
the	O
treatment	O
of	O
senile	O
dementia	O
of	O
the	O
alzheimer	O
's	O
type	O
The	O
present	O
invention	O
relates	O
to	O
the	O
diagnosis	O
,	O
risk	O
assessment	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
Senile	O
Dementia	O
of	O
the	O
Alzheimer	O
's	O
Type	O
(	O
SDAT	O
)	O
.	O

More	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
the	O
measurement	O
of	O
ethanolamine	O
phospholipids	O
in	O
human	O
serum	O
.	O

Subsets	O
of	O
these	O
molecules	O
are	O
significantly	O
altered	O
in	O
subjects	O
with	O
pathologically	O
confirmed	O
deposits	O
of	O
β	O
-	O
amyloid	O
versus	O
subjects	O
without	O
β	O
-	O
amyloid	O
deposits	O
and	O
in	O
subjects	O
with	O
a	O
clinical	O
manifestation	O
of	O
dementia	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SDAT	O
versus	O
non	O
-	O
demented	O
controls	O
.	O

Further	O
,	O
the	O
invention	O
relates	O
to	O
the	O
diagnosis	O
of	O
various	O
stages	O
of	O
SDAT	O
,	O
the	O
early	O
detection	O
and	O
prevention	O
of	O
SDAT	O
symptoms	O
,	O
the	O
treatment	O
of	O
SDAT	O
,	O
the	O
differential	O
diagnosis	O
of	O
non	O
-	O
SDAT	O
dementia	O
,	O
and	O
the	O
identification	O
of	O
molecular	O
targets	O
for	O
which	O
chemical	O
or	O
biological	O
treatments	O
can	O
be	O
designed	O
for	O
the	O
therapeutic	O
intervention	O
of	O
SDAT	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
using	O
a	O
molecular	O
diagnostic	O
assay	O
to	O
direct	O
and	O
select	O
the	O
appropriate	O
therapeutic	O
intervention	O
for	O
subjects	O
suffering	O
from	O
dementia	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
small	O
molecules	O
or	O
metabolites	O
that	O
are	O
found	O
to	O
have	O
significantly	O
different	O
abundances	O
between	O
persons	O
with	O
a	O
clinical	O
manifestation	O
of	O
SDAT	O
and	O
normal	O
,	O
non	O
-	O
demented	O
patients	O
.	O

6-benzyl-2,3,4,7-tetrahydro	O
-	O
indolo	O
[	O
2	O
,	O
3-c	O
]	O
quinoline	O
compounds	O
useful	O
as	O
pde5	B
inhibitors	O
The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R8	O
and	O
R11	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
,	O
the	O
salts	O
thereof	O
,	O
the	O
N	O
-	O
oxides	O
of	O
the	O
compounds	O
and	O
the	O
salts	O
thereof	O
,	O
and	O
the	O
stereoisomers	O
of	O
the	O
compounds	O
,	O
the	O
salts	O
,	O
the	O
N	O
-	O
oxides	O
of	O
the	O
compounds	O
and	O
the	O
N	O
-	O
oxides	O
of	O
the	O
salts	O
thereof	O
are	O
effective	O
inhibitors	O
of	O
the	O
type	B
5	I
phosphodiesterase	I
.	O

Compositions	O
comprising	O
mkc-733	O
(	O
pumosetrag	O
)	O
useful	O
for	O
treating	O
irritable	O
bowel	O
syndrome	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
irritable	O
bowel	O
syndrome	O
with	O
constipation	O
(	O
IBS	O
-	O
c	O
)	O
or	O
irritable	O
bowel	O
syndrome	O
with	O
alternating	O
constipation	O
and	O
diarrhea	O
(	O
IBS	O
-	O
a	O
)	O
in	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
.	O

The	O
method	O
comprises	O
administering	O
to	O
said	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
thieno	O
[	O
3,2-b	O
]	O
pyridine	O
compound	O
of	O
Structural	O
Formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
N	O
-	O
oxide	O
derivative	O
thereof	O
.	O

Method	O
for	O
the	O
treatment	O
of	O
amyloidoses	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
treatment	O
of	O
an	O
amyloidosis	O
such	O
as	O
Alzheimer	O
's	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
characterized	O
in	O
that	O
it	O
comprises	O
administering	O
an	O
agonist	O
of	O
the	O
P	O
/	O
Q	O
type	O
voltage	B
-	I
gated	I
presynaptic	I
calcium	I
channel	I
to	O
said	O
subject	O
.	O

Derivatives	O
of	O
benzoxadiazole	O
suitable	O
for	O
the	O
treatment	O
of	O
cell	O
proliferative	O
diseases	O
This	O
invention	O
describes	O
compounds	O
and	O
pharmaceutical	O
compositions	O
useful	O
as	O
ubiquitin	B
agent	O
inhibitors	O
,	O
particularly	O
ubiquitin	B
ligase	I
inhibitors	O
.	O

The	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
are	O
useful	O
as	O
inhibitors	O
of	O
the	O
biochemical	O
pathways	O
of	O
organisms	O
in	O
which	O
ubiquitination	O
is	O
involved	O
,	O
such	O
as	O
signal	O
transduction	O
pathways	O
.	O

The	O
invention	O
also	O
comprises	O
the	O
use	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
for	O
the	O
treatment	O
of	O
conditions	O
that	O
require	O
inhibition	O
of	O
ubiquitination	O
.	O

Furthermore	O
,	O
the	O
invention	O
comprises	O
methods	O
of	O
inhibiting	O
ubiquitination	O
in	O
a	O
cell	O
comprising	O
contacting	O
a	O
cell	O
in	O
which	O
inhibition	O
of	O
ubiquitination	O
is	O
desired	O
with	O
a	O
compound	O
or	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
invention	O
.	O

Particularly	O
,	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
are	O
useful	O
to	O
inhibit	O
the	O
ubiquitin	O
ligase	O
activity	O
of	O
TRAF6	B
.	O

Compounds	O
to	O
promote	O
regeneration	O
of	O
bone	O
marrow	O
Embodiments	O
of	O
the	O
present	O
invention	O
include	O
the	O
use	O
of	O
heterocyclic	O
trialkyl	O
ammonium	O
-	O
containing	O
compounds	O
to	O
promote	O
regeneration	O
of	O
bone	O
marrow	O
from	O
endogenous	O
or	O
exogenous	O
stem	O
/	O
progenitor	O
cells	O
and	O
to	O
normalize	O
blood	O
cell	O
and	O
platelet	O
counts	O
.	O

Substituted	O
piperidines	O
for	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O
The	O
present	O
invention	O
relates	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
are	O
believed	O
to	O
possess	O
antibacterial	O
activity	O
.	O

Compositions	O
containing	O
phosphatidylserine	O
in	O
treating	O
diabetes	O
associated	O
conditions	O
Provided	O
is	O
a	O
pharmaceutical	O
and	O
nutraceutical	O
composition	O
for	O
oral	O
delivery	O
which	O
contains	O
at	O
least	O
60	O
wt%	O
of	O
glycerophospholipids	O
(	O
GPLs	O
)	O
,	O
in	O
which	O
the	O
ratio	O
of	O
esterified	O
to	O
free	O
phosphatidic	O
acid	O
is	O
between	O
6	O
and	O
7	O
,	O
and	O
wherein	O
phosphatidylserine	O
constitutes	O
more	O
than	O
50	O
wt%	O
of	O
the	O
phosphatidic	O
esters	O
.	O

The	O
composition	O
mitigates	O
diabetes	O
-	O
like	O
conditions	O
and	O
boosts	O
mental	O
and	O
bodily	O
vigor	O
.	O

Sirna	O
against	O
thymidylate	B
synthase	I
and	O
uses	O
thereof	O
in	O
cancer	O
treatment	O
regimens	O
Small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
that	O
target	O
a	O
mammalian	B
thymidylate	I
synthase	I
gene	O
(	O
TS	B
)	O
,	O
and	O
which	O
are	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
their	O
target	O
gene	O
,	O
are	O
provided	O
The	O
siRNA	O
molecules	O
are	O
also	O
capable	O
of	O
sensitizing	O
cells	O
to	O
the	O
effects	O
of	O
other	O
anti	O
-	O
cancer	O
agents	O
,	O
particularly	O
chemotherapeutic	O
agents	O
that	O
target	O
TS	O
Methods	O
of	O
treating	O
cancer	O
using	O
the	O
TS	B
siRNA	O
in	O
combination	O
with	O
another	O
anti	O
-	O
cancer	O
agent	O
are	O
also	O
provided	O
Methods	O
of	O
enhancing	O
the	O
effect	O
of	O
a	O
TS	B
siRNA	O
on	O
cancer	O
cell	O
proliferation	O
by	O
combining	O
the	O
TS	B
siRNA	O
with	O
a	O
siRNA	O
targeting	O
a	O
cell	O
survival	O
gene	O
such	O
as	O
Bcl-2	B
are	O
further	O
provided	O
.	O

5-aminopyrazol-3-yl-3h	O
-	O
imidazo	O
[	O
4,5-b	O
]	O
pyridine	O
derivatives	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
,	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
provide	O
a	O
treatment	O
for	O
myeloproliferative	O
disorders	O
and	O
cancer	O
.	O

External	O
preparation	O
for	O
skin	O
and	O
external	O
preparation	O
for	O
lips	O
Disclosed	O
are	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
improving	O
wrinkles	O
and	O
sagging	O
,	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
moisture	O
retention	O
,	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
promoting	O
wound	O
healing	O
and	O
an	O
external	O
preparation	O
for	O
lips	O
,	O
each	O
of	O
which	O
contains	O
raspberry	O
ketone	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
respiratory	O
disease	O
Disclosed	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
involving	O
disturbances	O
in	O
glutathione	O
(	O
GSH	O
)	O
metabolism	O
and	O
oxidative	O
stress	O
,	O
especially	O
respiratory	O
diseases	O
or	O
disorders	O
,	O
and	O
most	O
especially	O
asthma	O
.	O

In	O
particular	O
embodiments	O
,	O
methods	O
are	O
disclosed	O
for	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
or	O
disorders	O
,	O
involving	O
the	O
step	O
of	O
administering	O
an	O
agent	O
that	O
inhibits	O
gamma	B
glutamyl	I
transpeptidase	I
(	O
GGT	B
)	O
activity	O
in	O
lung	O
and	O
airway	O
lining	O
fluid	O
.	O

Phosphate	O
-	O
modified	O
oligonucleotide	O
analogs	O
with	O
immunostimulatory	O
activity	O
The	O
invention	O
relates	O
to	O
oligonucleotides	O
including	O
at	O
least	O
one	O
backbone	O
modification	O
and	O
a	O
pyrimidine	O
-	O
purine	O
dinucleotide	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Compositions	O
and	O
methods	O
for	O
making	O
therapies	O
delivered	O
by	O
viral	O
vectors	O
reversible	O
for	O
safety	O
or	O
allele	O
-	O
specificity	O
The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
methods	O
and	O
kits	O
for	O
regulation	O
of	O
gene	O
therapies	O
,	O
including	O
,	O
without	O
limitation	O
,	O
reversible	O
gene	O
therapies	O
and	O
allele-	O
specific	O
therapies	O
.	O

Triazolyl	O
aminopyrimidine	O
compounds	O
The	O
present	O
invention	O
provides	O
triazolyl	O
aminopyrimidine	O
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

Potassium	B
ion	I
channel	I
modulators	O
and	O
uses	O
thereof	O
Compounds	O
of	O
general	O
formula	O
(	O
1	O
)	O
and	O
pharmacologically	O
acceptable	O
salts	O
and	O
pro	O
-	O
drugs	O
thereof	O
:	O
wherein	O
A	O
and	O
B	O
are	O
CH2	O
or	O
CH2CH2	O
,	O
R1	O
is	O
hydrogen	O
,	O
alkyl	O
,	O
cycloalkyl	O
,	O
aryl	O
,	O
aralkyl	O
or	O
heteroaralkyl	O
,	O
D	O
,	O
E	O
and	O
G	O
are	O
CR2	O
or	O
nitrogen	O
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
D	O
,	O
E	O
and	O
G	O
is	O
nitrogen	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
hydrogen	O
,	O
alkyl	O
,	O
halogen	O
,	O
haloalkyl	O
,	O
alkoxy	O
,	O
alkoxycarbonyl	O
,	O
carboxyl	O
,	O
hydroxyl	O
or	O
cyano	O
,	O
X	O
is	O
R5SO2	O
,	O
R5R7NCO	O
,	O
R5R7NSO2or	O
R5SO2NR7CO	O
,	O
Y	O
is	O
R6CO	O
,	O
R6SO2	O
,	O
R6R7NCO	O
,	O
R6R7NSO2	O
,	O
R6SO2NR7CO	O
or	O
CO2R8	O
,	O
R5	O
and	O
R6	O
are	O
hydrogen	O
,	O
alkyl	O
,	O
aryl	O
,	O
aralkyl	O
,	O
heteroaryl	O
or	O
heteroaralkyl	O
,	O
R7	O
is	O
hydrogen	O
,	O
alkyl	O
,	O
aryl	O
or	O
aralkyl	O
,	O
and	O
R8	O
is	O
alkyl	O
,	O
aryl	O
,	O
aralkyl	O
,	O
alkoxyalkyl	O
,	O
heteroaryl	O
or	O
heteroarylalkyl	O
,	O
are	O
of	O
use	O
inthe	O
prophylaxis	O
or	O
treatment	O
of	O
diseases	O
and	O
conditions	O
in	O
which	O
Kv1.x	B
channels	I
are	O
involved	O
,	O
such	O
as	O
lower	O
urinary	O
tract	O
disorders	O
,	O
cardiovascular	O
diseases	O
,	O
inflammatory	O
and	O
immunological	O
diseases	O
and	O
pain	O
.	O

Pyrazolone	O
derivative	O
and	O
pde	B
inhibitor	O
containing	O
the	O
same	O
as	O
active	O
ingredient	O
Disclosed	O
is	O
a	O
novel	O
pyrazolone	O
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
below	O
,	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
product	O
having	O
phosphodiesterase	B
inhibitory	O
activity	O
.	O

(	O
1	O
)	O
R1	O
,	O
R2	O
:	O
C1	O
-	O
6	O
alkyl	O
R3	O
,	O
R4	O
:	O
H	O
,	O
X	O
,	O
C1	O
-	O
6	O
alkoxy	O
Z	O
:	O
O	O
,	O
S	O
A	O
:	O
AA	O
,	O
BB	O
(	O
R5	O
:	O
H	O
,	O
C1	O
-	O
6	O
alkyl	O
;	O
R6	O
,	O
R7	O
:	O
C1	O
-	O
6	O
alkyl	O
)	O

Quinazoline	O
derivatives	O
as	O
pi3	O
kinase	O
inhibitors	O
Invented	O
is	O
a	O
method	O
of	O
inhibiting	O
the	O
activity	O
/	O
function	O
of	O
P13	O
kinases	O
using	O
quinazoline	O
derivatives	O
.	O

Also	O
invented	O
is	O
a	O
method	O
of	O
treating	O
one	O
or	O
more	O
disease	O
states	O
selected	O
from	O
:	O
autoimmune	O
disorders	O
,	O
inflammatory	O
diseases	O
,	O
cardiovascular	O
diseases	O
,	O
neurodegenerative	O
diseases	O
,	O
allergy	O
,	O
asthma	O
,	O
pancreatitis	O
,	O
multiorgan	O
failure	O
,	O
kidney	O
diseases	O
,	O
platelet	O
aggregation	O
,	O
cancer	O
,	O
sperm	O
motility	O
,	O
transplantation	O
rejection	O
,	O
graft	O
rejection	O
and	O
lung	O
injuries	O
by	O
the	O
administration	O
of	O
quinazoline	O
derivatives	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
and	O
methods	O
of	O
using	O
same	O
The	O
present	O
invention	O
provides	O
novel	O
methods	O
of	O
making	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
for	O
use	O
as	O
an	O
alkalinity	O
increasing	O
agent	O
and/or	O
antioxidant	O
.	O

The	O
present	O
invention	O
further	O
provides	O
novel	O
compositions	O
and	O
methods	O
which	O
can	O
be	O
used	O
to	O
provide	O
relief	O
from	O
disorders	O
related	O
to	O
or	O
complicated	O
by	O
acidosis	O
or	O
excessive	O
free	O
radical	O
or	O
other	O
reactive	O
oxygen	O
species	O
production	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
gout	O
,	O
Lesch	O
-	O
Nyhan	O
syndrome	O
,	O
hemochromatosis	O
,	O
Alzheimer	O
's	O
,	O
amyotropic	O
lateral	O
sclerosis	O
,	O
arthritis	O
,	O
atherosclerosis	O
,	O
cancer	O
,	O
cataracts	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
diabetes	O
,	O
cellulitis	O
,	O
coronary	O
artery	O
disease	O
,	O
heart	O
failure	O
,	O
hypertension	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
macular	O
degeneration	O
,	O
multiple	O
sclerosis	O
,	O
Parkinson	O
's	O
,	O
Reynaud	O
's	O
phenomenon	O
,	O
reperfusion	O
injury	O
,	O
pancreatic	O
impairment	O
,	O
skin	O
infections	O
,	O
Hepatitis	O
C	O
,	O
methicillin-	O
resistant	O
Staphylococcus	O
aureus	O
and	O
infection	O
.	O

The	O
compositions	O
and	O
methods	O
of	O
the	O
present	O
invention	O
additionally	O
supply	O
relief	O
from	O
microbial	O
infections	O
including	O
fungal	O
infections	O
as	O
well	O
as	O
prevent	O
secondary	O
infections	O
.	O

Additional	O
compositions	O
and	O
methods	O
are	O
provided	O
which	O
employ	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
in	O
combination	O
with	O
a	O
second	O
alkalinity	O
increasing	O
agent	O
and/or	O
antioxidant	O
,	O
or	O
other	O
therapeutic	O
agent	O
to	O
yield	O
a	O
more	O
effective	O
treatment	O
tool	O
against	O
acidosis	O
and/or	O
excessive	O
ROS	O
production	O
including	O
free	O
radical	O
production	O
useful	O
to	O
prevent	O
or	O
reduce	O
acidosis	O
and/or	O
excessive	O
ROS	O
production	O
or	O
related	O
symptoms	O
or	O
conditions	O
associated	O
with	O
acidosis	O
and/or	O
excessive	O
free	O
radical	O
production	O
in	O
mammalian	O
subjects	O
.	O

Flavonoid	O
ppar	B
agonists	O
The	O
present	O
invention	O
relates	O
to	O
PPAR	B
agonists	O
,	O
and	O
their	O
use	O
in	O
therapy	O
including	O
the	O
treatment	O
of	O
disease	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
flavonoid	O
compounds	O
which	O
are	O
PPAR	B
-	I
gamma	I
agonists	O
and/or	O
PPAR	B
alpha	I
/	I
gamma	I
dual	O
agonists	O
.	O

2,4	O
diaminopyrimid'lnes	O
for	O
the	O
treatment	O
of	O
myeloproliferative	O
disorders	O
and	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
salts	O
,	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
use	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
.	O

These	O
compounds	O
provide	O
a	O
treatment	O
for	O
myeloproliferative	O
disorders	O
and	O
cancer	O
.	O

Therapeutic	O
agent	O
for	O
cancer	O
with	O
resistance	O
to	O
protease	B
inhibitor	O
A	O
therapeutic	O
agent	O
for	O
cancers	O
having	O
resistance	O
to	O
protease	B
inhibitors	O
which	O
contains	O
,	O
as	O
a	O
heat	B
shock	I
protein	I
90	I
(	O
Hsp90	B
)	O
family	O
protein	O
inhibitor	O
,	O
either	O
a	O
benzoyl	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1	O
-	O
5	O
;	O
R1	O
represents	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
CONR7R8	O
(	O
wherein	O
R7	O
and	O
R8	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen	O
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
etc	O
.	O
)	O
,	O
etc	O
.	O
;	O
R2	O
represents	O
(	O
un	O
)	O
substituted	O
aryl	O
,	O
etc	O
.	O
;	O
R3	O
and	O
R5	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen	O
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
etc	O
.	O
;	O
R4	O
represents	O
hydrogen	O
,	O
etc	O
.	O
;	O
and	O
R6	O
represents	O
hydrogen	O
,	O
halogeno	O
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	O
,	O
etc	O
.	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O

Anti	O
-	O
bacterial	O
agents	O
The	O
invention	O
relates	O
to	O
novel	O
acylphloroglucinols	O
which	O
have	O
strong	O
growth	O
inhibitory	O
effects	O
on	O
multi	O
-	O
drug	O
resistant	O
strains	O
of	O
bacteria	O
,	O
particularly	O
MRSA	O
.	O

Typically	O
the	O
compounds	O
have	O
a	O
terpene	O
substituent	O
,	O
or	O
a	O
terpene-	O
derived	O
substituent	O
.	O

Methods	O
of	O
isolating	O
the	O
compounds	O
from	O
natural	O
sources	O
,	O
and	O
synthetic	O
methods	O
for	O
forming	O
the	O
compounds	O
are	O
also	O
provided	O
.	O

Combination	O
059	O

This	O
invention	O
relates	O
to	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
MEK	B
inhibitor	O
and	O
a	O
mTOR	B
-	O
selective	O
inhibitor	O
,	O
and	O
to	O
methods	O
for	O
the	O
production	O
of	O
an	O
anti	O
-	O
cancer	O
effect	O
in	O
a	O
patient	O
,	O
which	O
is	O
accordingly	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
patient	O
.	O

More	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
;	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
MEK	B
inhibitor	O
and	O
a	O
mTOR	B
-	O
selective	O
inhibitor	O
;	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
kit	O
of	O
parts	O
comprising	O
a	O
MEK	B
inhibitor	O
and	O
a	O
mTOR	B
-	O
selective	O
inhibitor	O
;	O
use	O
of	O
the	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
in	O
the	O
treatment	O
of	O
cancer	O
;	O
a	O
method	O
of	O
treating	O
cancer	O
comprising	O
administering	O
the	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
to	O
a	O
patient	O
.	O

The	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
and	O
methods	O
of	O
the	O
invention	O
are	O
also	O
useful	O
in	O
the	O
treatment	O
of	O
other	O
diseases	O
associated	O
with	O
the	O
activity	O
of	O
MEK	B
,	O
and/or	O
mTOR	B
.	O

Modulators	O
of	O
the	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
egfr	B
)	O
pathway	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
substance	O
abuse	O
The	O
present	O
invention	O
provides	O
methods	O
of	O
using	O
modulators	O
of	O
the	O
epidermal	B
growth	I
factor	I
receptor	I
(	O
EGFR	B
)	O
pathway	O
for	O
treatment	O
or	O
prevention	O
of	O
substance	O
abuse	O
such	O
as	O
alcohol	O
abuse	O
.	O

The	O
modulators	O
include	O
small	O
molecule	O
inhibitors	O
such	O
as	O
Erlotinib	O
(	O
TARCEVA	O
®	O
,	O
N-	O
(	O
3-ethynylphenyl	O
)	O
-6,7-bis	O
(	O
2-methoxyethoxy	O
)	O
-4-	O
quinazolineamine	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	O
or	O
prodrug	O
thereof	O
and	O
Gefitinib	O
[	O
IRES	O
S	O
A	O
®	O
,	O
N-	O
(	O
3	O
-chloro-4-fluoro	O
-	O
phenyl	O
)	O
-7-methoxy-6-	O
(	O
3	O
-morpholin-4-	O
ylpropoxy	O
)	O
quinazolin-4-amine	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	O
or	O
prodrug	O
thereof	O
and	O
various	O
macromolecular	O
inhibitors	O
of	O
the	O
EGFR	B
pathway	O
such	O
as	O
siRNAs	O
and	O
antibodies	O
that	O
target	O
genes	O
or	O
proteins	O
in	O
the	O
EGFR	B
/	O
ERK	B
pathway	O
such	O
as	O
one	O
of	O
the	O
EGFR	B
/	O
ErbB	B
protein	O
or	O
a	O
homolog	O
thereof	O
.	O

Inhibition	O
of	O
11	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
for	O
ocular	O
neuroprotection	O
A	O
composition	O
comprises	O
a	O
material	O
capable	O
of	O
controlling	O
a	O
level	O
of	O
cortisol	O
in	O
an	O
ocular	O
environment	O
for	O
effecting	O
ocular	O
neuroprotection	O
in	O
subjects	O
in	O
risk	O
of	O
developing	O
or	O
worsening	O
an	O
ocular	O
neurodegenerative	O
condition	O
.	O

Such	O
a	O
composition	O
is	O
injected	O
into	O
or	O
implanted	O
in	O
the	O
subject	O
's	O
posterior	O
segment	O
to	O
provide	O
such	O
neuroprotection	O
.	O

Carboxamidξ	O
compounds	O
and	O
their	O
use	O
as	O
chemokine	B
receptor	I
agonists	O
Chemokine	B
receptor	I
antagonists	O
,	O
in	O
particular	O
,	O
compounds	O
of	O
Formula	O
(	O
I-	O
A	O
)	O
that	O
act	O
as	O
antagonists	O
of	O
the	O
chemokine	B
CCR2	B
receptor	O
,	O
including	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O
to	O
treat	O
or	O
prevent	O
diseases	O
associated	O
with	O
monocyte	O
accumulation	O
,	O
lymphocyte	O
accumulation	O
or	O
leukocyte	O
accumulation	O
are	O
described	O
herein	O
.	O

Trail	B
variants	O
for	O
treating	O
cancer	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
TRAIL	B
protein	O
to	O
treat	O
various	O
cancers	O
in	O
mammals	O
.	O

The	O
invention	O
provides	O
a	O
variant	O
TRAIL	B
protein	O
,	O
which	O
has	O
superior	O
selectivity	O
for	O
the	O
death	B
receptor	I
5	I
,	O
for	O
treating	O
a	O
mammal	O
diagnosed	O
with	O
cancer	O
.	O

Cucurbitane	O
triterpenoid	O
saponins	O
,	O
pharmaceutical	O
composition	O
thereof	O
,	O
preparation	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
field	O
and	O
discloses	O
cucurbitane	O
triterpenoid	O
saponins	O
extracted	O
from	O
Momordica	O
charantia	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
and	O
their	O
preparation	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
use	O
of	O
such	O
compounds	O
in	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
obesity	O
and	O
hyperlipaemia	O
.	O

The	O
saponins	O
disclosed	O
in	O
the	O
invention	O
are	O
represented	O
by	O
formula	O
I.	O

Preparations	O
with	O
rosehip	O
extracts	O
,	O
and	O
method	O
of	O
producing	O
rosehip	O
extracts	O
Composition	O
comprising	O
an	O
anti	O
-	O
inflammatory	O
plant	O
extract	O
from	O
rosehips	O
together	O
with	O
a	O
cartilage	O
-	O
protective	O
substance	O
,	O
and	O
a	O
method	O
of	O
producing	O
the	O
rosehip	O
extract	O
.	O

A2b	O
adenosine	O
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
cancer	O
Disclosed	O
are	O
methods	O
for	O
treating	O
asthma	O
,	O
inflammatory	O
gastrointestinal	O
tract	O
disorders	O
,	O
cancer	O
,	O
cardiovascular	O
diseases	O
,	O
neurological	O
disorders	O
,	O
and	O
diseases	O
related	O
to	O
undesirable	O
angiogenesis	O
using	O
A2B	O
adenosine	O
receptor	O
antagonists	O
having	O
the	O
structure	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
.	O

Aryl	O
-	O
substituted	O
imidazolidine-2,4-diones	O
,	O
method	O
for	O
the	O
production	O
thereof	O
,	O
medicaments	O
containing	O
said	O
compounds	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
groups	O
R	O
and	O
R	O
'	O
A	O
,	O
D	O
,	O
E	O
,	O
G	O
,	O
L	O
,	O
p	O
and	O
Rl	O
to	O
R1O	O
have	O
the	O
stated	O
meanings	O
and	O
to	O
their	O
physiologically	O
compatible	O
salts	O
.	O

Said	O
compounds	O
are	O
suitable	O
,	O
for	O
example	O
,	O
as	O
anti	O
-	O
obesity	O
drugs	O
.	O

Imidazopyridine	O
compounds	O
The	O
present	O
invention	O
provides	O
imidazopyridines	O
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
compounds	O
show	O
inhibitory	O
activity	O
against	O
protein	O
kinase	B
,	O
especially	O
VEGFR2	B
,	O
FLT3	B
,	O
and	O
C	B
-	I
KIT	I
receptors	O
and	O
so	O
on	O
,	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicament	O
for	O
treating	O
diseases	O
associated	O
with	O
abnormal	O
high	O
level	O
of	O
kinase	B
activity	O
,	O
such	O
as	O
cancer	O
.	O

Processes	O
for	O
the	O
preparation	O
of	O
bosentan	O
and	O
related	O
compounds	O
Provided	O
herein	O
are	O
novel	O
,	O
commercially	O
viable	O
and	O
industrially	O
advantageous	O
processes	O
for	O
the	O
preparation	O
of	O
substantially	O
pure	O
ethylene	O
glycol	O
sulfonamide	O
compounds	O
such	O
as	O
bosentan	O
.	O

Pyrido	O
[	O
3	O
,	O
4-b	O
]	O
indoles	O
and	O
methods	O
of	O
use	O
This	O
disclosure	O
relates	O
to	O
new	O
heterocyclic	O
compounds	O
that	O
may	O
be	O
used	O
to	O
modulate	O
a	O
histamine	O
receptor	O
in	O
an	O
individual	O
.	O

Pyrido	O
[	O
3,4-b	O
]	O
indoles	O
are	O
described	O
,	O
as	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
including	O
the	O
treatment	O
of	O
a	O
cognitive	O
disorder	O
,	O
psychotic	O
disorder	O
,	O
neurotransmitter	O
-	O
mediated	O
disorder	O
and/or	O
a	O
neuronal	O
disorder	O
.	O

2-aryl-	O
and	O
2-heteroarylthiazolyl	O
compounds	O
,	O
methods	O
for	O
their	O
preparation	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
discloses	O
fused	O
bicyclic	O
2-aryl-	O
or	O
2-heteroarylthiazolyl	O
compounds	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
,	O
which	O
are	O
useful	O
for	O
inhibiting	O
the	O
growth	O
of	O
cancerous	O
cells	O
,	O
inhibiting	O
human	O
breast	O
carcinoma	O
tumor	O
growth	O
in	O
particular	O
and	O
to	O
treat	O
diseases	O
or	O
disorders	O
associated	O
with	O
securin	O
,	O
including	O
elevated	O
securin	O
levels	O
.	O

Gem	O
-	O
disubstituted	O
and	O
spirocyclic	O
amino	O
pyridines	O
/	O
pyrimidines	O
as	O
cell	O
cycle	O
inhibitors	O
Compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
are	O
provided	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
CDK4-mediated	B
disorders	O
,	O
such	O
as	O
cancer	O
.	O

The	O
subject	O
compounds	O
are	O
gem	O
-	O
disubstituted	O
or	O
spirocyclic	O
pyridine	O
,	O
pyrimidine	O
and	O
triazine	O
derivatives	O
.	O

Therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
Disclosed	O
are	O
:	O
a	O
therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
R1	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	O
]	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
arterial	O
occlusive	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
IA	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
arterial	O
occlusive	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
IA	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
and	O
others	O
.	O

Indole-	O
3	O
-glyoxylamide	O
derivatives	O
for	O
use	O
as	O
calcium	O
ion	O
channel	O
modulators	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
of	O
use	O
in	O
treating	O
a	O
range	O
of	O
conditions	O
,	O
including	O
pain	O
.	O

Method	O
of	O
treating	O
anxious	O
major	O
depressive	O
disorder	O
The	O
invention	O
is	O
directed	O
to	O
using	O
4-	O
{	O
(	O
3-aminophenyl	O
)	O
[	O
4-	O
(	O
4-fluorobenzyl	O
)	O
piperazin-1-yl	O
]	O
methyl	O
}	O
-N	O
,	O
N	O
-	O
diethylbenzamide	O
,	O
or	O
enantiomer	O
thereof	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and/or	O
mixture	O
thereof	O
to	O
treat	O
anxious	O
major	O
depressive	O
disorder	O
(	O
AMDD	O
)	O
.	O

Cancer	O
drug	O
target	O
and	O
methods	O
of	O
diagnosis	O
and	O
therapy	O
A	O
single	O
nucleotide	O
G	O
>	O
A	O
polymorphism	O
at	O
position	O
-126	O
in	O
the	O
promoter	O
of	O
the	O
human	B
myeloid	I
cell	I
leukemia-1	I
gene	I
is	O
associated	O
with	O
a	O
reduced	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O

The	O
G>;A	O
polymorphism	O
is	O
in	O
an	O
ELK4	B
transcription	O
factor	O
binding	O
site	O
,	O
which	O
results	O
in	O
reduced	O
myeloid	B
cell	I
leukemia-1	I
gene	I
expression	O
.	O

Elevated	O
levels	O
of	O
ELK4	B
and	O
Mcl-1	B
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
an	O
increased	O
predisposition	O
to	O
cancer	O
and	O
an	O
decreased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
agents	O
.	O

Reduced	O
levels	O
of	O
ELK4	B
and	O
Mcl-1	B
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
less	O
of	O
a	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O

Methods	O
of	O
cancer	O
diagnosis	O
and/or	O
therapy	O
which	O
target	O
ELK4	B
and/or	O
Mcl-1	B
protein	O
and/or	O
nucleic	O
acids	O
are	O
particularly	O
applicable	O
to	O
cancers	O
such	O
as	O
glioma	O
,	O
colon	O
cancer	O
,	O
lung	O
cancer	O
,	O
thyroid	O
cancer	O
,	O
kidney	O
cancer	O
and/or	O
melanoma	O
.	O

Such	O
methods	O
and	O
compositions	O
may	O
sensitize	O
or	O
improve	O
responsiveness	O
of	O
cancer	O
cells	O
to	O
pro	O
-	O
apoptotic	O
agents	O
.	O

Benzo	O
[	O
1	O
,	O
4	O
]	O
diazepines	O
substituted	O
at	O
the	O
1-position	O
by	O
a	O
ring	O
,	O
for	O
use	O
as	O
antidepressants	O
It	O
is	O
intended	O
to	O
provide	O
a	O
benzodiazepine	O
compound	O
useful	O
in	O
the	O
production	O
of	O
an	O
antidepressant	O
drug	O
that	O
has	O
a	O
wider	O
therapeutic	O
spectrum	O
and	O
can	O
exert	O
sufficient	O
therapeutic	O
effects	O
in	O
a	O
short	O
period	O
.	O

The	O
benzodiazepine	O
compound	O
of	O
the	O
present	O
invention	O
is	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
and	O
R7	O
respectively	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
and	O
R6	O
represents	O
a	O
substituted	O
phenyl	O
group	O
or	O
the	O
like	O
.	O

4	O
,	O
6-diphenylpyrid-2	O
-	O
0nes	O
against	O
cancer	O
A	O
compound	O
for	O
use	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders	O
,	O
such	O
as	O
cancer	O
,	O
having	O
the	O
following	O
formula	O
:	O
z	O
wherein	O
:	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
independently	O
H	O
or	O
lower	O
alkyl	O
;	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
,	O
provided	O
that	O
at	O
least	O
one	O
is	O
-O	O
-	O
lower	O
alkyl	O
;	O
or	O
at	O
least	O
one	O
pair	O
of	O
R4	O
to	O
R8	O
,	O
the	O
members	O
of	O
which	O
pair	O
are	O
adjacent	O
to	O
one	O
another	O
on	O
the	O
ring	O
,	O
are	O
conjoined	O
to	O
form-0-	O
(	O
CR14R15	O
)	O
n	O
-	O
O-	O
,	O
where	O
n	O
is	O
1	O
or	O
2	O
and	O
R14	O
and	O
R15	O
are	O
independently	O
H	O
or	O
lower	O
alkyl	O
,	O
and	O
the	O
remainder	O
of	O
R4	O
to	O
R8	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
;	O
and	O
R9	O
,	O
R10	O
,	O
R11	O
,	O
R12	O
and	O
R13	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
,	O
provided	O
that	O
at	O
least	O
one	O
is	O
-O	O
-	O
lower	O
alkyl	O
;	O
or	O
at	O
least	O
one	O
pair	O
of	O
R9	O
to	O
R13	O
,	O
the	O
members	O
of	O
which	O
pair	O
are	O
adjacent	O
to	O
one	O
another	O
on	O
the	O
ring	O
,	O
are	O
conjoined	O
to	O
form	O
-	O
O-	O
(	O
CR16R17	O
)	O
m	O
-	O
O-	O
,	O
where	O
m	O
is	O
1	O
or	O
2	O
and	O
R16	O
and	O
R17	O
are	O
independently	O
H	O
or	O
lower	O
alkyl	O
,	O
and	O
the	O
remainder	O
of	O
R9	O
to	O
R13	O
are	O
independently	O
H	O
,	O
halo	O
,	O
lower	O
alkyl	O
or	O
-O	O
-	O
lower	O
alkyl	O
.	O

Novel	O
pde	B
inhibitors	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
processes	O
for	O
their	O
preparation	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
phosphodiesterase	B
inhibitors	O
(	O
PDEs	B
)	O
,	O
in	O
particular	O
phosphodiesterase	B
type	I
4	I
inhibitors	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

These	O
novel	O
PDEs	B
are	O
useful	O
in	O
treating	O
allergic	O
and	O
inflammatory	O
diseases	O
(	O
such	O
as	O
asthma	O
,	O
COPD	O
,	O
allergic	O
rhinitis	O
,	O
allergic	O
conjunctivitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
chronic	O
bronchitis	O
,	O
nephritis	O
,	O
rheumatoid	O
spondylitis	O
,	O
osteoarthritis	O
,	O
atopic	O
dermatitis	O
,	O
eosinophilic	O
granuloma	O
,	O
psoriasis	O
,	O
rheumatoid	O
septic	O
shock	O
,	O
ulcerative	O
colitis	O
,	O
multiple	O
sclerosis	O
,	O
chronic	O
inflammation	O
,	O
Crohn	O
's	O
syndrome	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
)	O
and	O
for	O
inhibiting	O
the	O
production	O
of	O
Tumor	B
Necrosis	I
Factor	I
(	O
TNF	B
-	I
α	I
)	O
.	O

Combination	O
product	O
of	O
receptor	B
tyrosine	I
kinase	I
inhibitor	O
and	O
fatty	B
acid	I
synthase	I
inhibitor	O
for	O
treating	O
cancer	O
A	O
pharmaceutical	O
combination	O
product	O
is	O
disclosed	O
that	O
comprises	O
a	O
receptor	B
tyrosine	I
kinase	I
inhibitor	O
and	O
a	O
fatty	B
acid	I
synthase	I
inhibitor	O
,	O
and	O
to	O
the	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
cancer	O
.	O

5h	O
-	O
pyrr0l0	O
[	O
2,3-b	O
]	O
pyrazine	O
derivatives	O
for	O
kinase	O
modulation	O
,	O
and	O
indications	O
therefor	O
Compounds	O
active	O
on	O
Fms	B
and/or	O
Kit	B
protein	I
kinases	I
are	O
described	O
,	O
as	O
well	O
as	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
and	O
conditions	O
associated	O
with	O
aberrant	O
activity	O
of	O
Fms	B
and/or	O
Kit	B
protein	I
kinases	I
.	O

Thiosemicarbazone	O
compounds	O
and	O
use	O
thereof	O
A	O
method	O
of	O
treating	O
a	O
proliferative	O
disease	O
in	O
a	O
vertebrate	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
vertebrate	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
of	O
formula	O
(	O
I	O
)	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
selected	O
from	O
H	O
,	O
C1	O
-	O
6	O
alkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
and	O
phenyl	O
;	O
R2	O
is	O
selected	O
from	O
H	O
,	O
C1	O
-	O
6	O
alkyl	O
,	O
C2	O
-	O
6	O
alkenyl	O
and	O
phenyl	O
;	O
wherein	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
,	O
or	O
a	O
salt	O
,	O
hydrate	O
,	O
or	O
iron	O
complex	O
thereof	O
,	O
or	O
a	O
pharmaceutical	O
composition	O
comprising	O
said	O
compound	O
,	O
salt	O
,	O
hydrate	O
or	O
iron	O
complex	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
diluent	O
or	O
excipient	O
.	O

Deuterated	O
ibudilast	O
This	O
invention	O
relates	O
to	O
novel	O
compounds	O
that	O
are	O
2-alkyl-3-acylpyrazolo	O
[	O
l,5-	O
a	O
]	O
pyridines	O
,	O
their	O
derivatives	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
2-alkyl-3-acylpyrazolo	O
[	O
l,5-a	O
]	O
pyridine	O
compounds	O
that	O
are	O
derivatives	O
of	O
ibudilast	O
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibitor	O
,	O
a	O
leukotriene	O
CysLTl	O
(	O
LTD4	O
)	O
antagonist	O
,	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
,	O
and/or	O
a	O
glial	O
cell	O
activation	O
suppressant	O
,	O
such	O
as	O
ibudilast	O
.	O

Tricyclic	O
heterocycle	O
derivatives	O
as	O
histamine	B
h3	I
antagonists	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
Tricyclic	O
Heterocylce	O
Derivatives	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
Tricyclic	O
Heterocycle	O
Derivatives	O
and	O
the	O
use	O
of	O
these	O
compounds	O
for	O
treating	O
or	O
preventing	O
allergy	O
,	O
an	O
allergy	O
-	O
induced	O
airway	O
response	O
,	O
congestion	O
,	O
a	O
cardiovascular	O
disease	O
,	O
an	O
inflammatory	O
disease	O
,	O
a	O
gastrointestinal	O
disorder	O
,	O
a	O
neurological	O
disorder	O
,	O
a	O
metabolic	O
disorder	O
,	O
obesity	O
or	O
an	O
obesity	O
-	O
related	O
disorder	O
,	O
diabetes	O
,	O
a	O
diabetic	O
complication	O
,	O
impaired	O
glucose	O
tolerance	O
or	O
impaired	O
fasting	O
glucose	O
.	O

R1	O
is	O
formula	O
(	O
Ia	O
)	O
,	O
(	O
Ib	O
)	O
or	O
(	O
Ic	O
)	O
;	O
R2	O
is	O
alkvl	O
,	O
alkenyl	O
,	O
alkynyl	O
,	O
aryl	O
,	O
heteroaryl	O
,	O
cycloalkyl	O
or	O
heterocycloalkyl	O
.	O

any	O
of	O
which	O
can	O
be	O
optionally	O
substituted	O
with	O
R11	O
;	O
M1	O
is	O
-CH-	O
.	O

-C	O
(	O
halo	O
)	O
-	O
or	O
-N-	O
;	O
Y	O
is	O
-C	O
(	O
O	O
)	O
-	O
,	O
-S-	O
.	O
-S	O
(	O
O	O
)	O
-	O
,	O
-S	O
(	O
O	O
)	O
2-	O
,	O
-CH2-	O
or	O
-O-	O
,	O
such	O
that	O
Y	O
is	O
not	O
-O-	O
when	O
an	O
adjacent	O
atom	O
is	O
N.	O

Polyglutamine	O
aggregation	O
inhibitor	O
Disclosed	O
is	O
a	O
polyglutamine	O
aggregation	O
inhibitor	O
including	O
a	O
chemical	O
compound	O
represented	O
by	O
any	O
of	O
the	O
following	O
general	O
formulae	O
(	O
1	O
)	O
-	O
(	O
13	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

(	O
1	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
2	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y-	O
]	O
n	O
-	O
R4	O
;	O
(	O
3	O
)	O
R3-	O
[	O
-B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
4	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-	O
]	O
n	O
-	O
R4	O
;	O
(	O
5	O
)	O
R3-	O
[	O
-B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
6	O
)	O
R3-X	O
-	O
B	O
(	O
ZR1	O
)	O
-T	O
[	O
B	O
(	O
ZR2	O
)	O
-W	O
-	O
R4	O
]	O
2	O
;	O
(	O
7	O
)	O
R3-B	O
(	O
OH	O
)	O
2	O
;	O
(	O
8)	O
R3-B	O
(	O
ZR1	O
)	O
-X	O
-	O
B	O
(	O
ZR2	O
)	O
-R4	O
;	O
(	O
9	O
)	O
R3-B	O
(	O
R1	O
)	O
-O	O
-	O
B	O
(	O
R2	O
)	O
-R4	O
;	O
(	O
10	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-	O
]	O
n	O
-	O
R4	O
;	O
(	O
11	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W	O
-	O
Q-	O
]	O
n	O
-	O
R4	O
;	O
(	O
12	O
)	O
R3-	O
[	O
-P	O
-	O
X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
and	O
(	O
13	O
)	O
[	O
R3-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
]	O
2B	O
(	O
ZR2	O
)	O
(	O
wherein	O
the	O
symbols	O
in	O
each	O
formula	O
carry	O
the	O
same	O
definitions	O
as	O
those	O
used	O
in	O
the	O
Specification	O
)	O
.	O

Pyridine	O
derivatives	O
as	O
vegfr-2	B
receptor	O
and	O
protein	B
tyrosine	I
kinase	I
inhibitors	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
W	O
,	O
D	O
,	O
E	O
,	O
G	O
,	O
J	O
,	O
L	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
Y	O
are	O
as	O
defined	O
herein	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
,	O
or	O
solvates	O
thereof	O
,	O
for	O
use	O
-alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds-	O
in	O
therapy	O
,	O
for	O
treating	O
diseases	O
associated	O
with	O
deregulated	O
angiogenesis	O
,	O
such	O
as	O
cancer	O
and	O
skin	O
and	O
eye	O
diseases	O
.	O

Hybrid	O
tripyrrole	O
-	O
octaarginine	O
compounds	O
and	O
their	O
use	O
as	O
medicament	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
microbial	O
illnesses	O
Hybrid	O
tripyrrole	O
-	O
octaarginine	O
compounds	O
.	O

Hybrids	O
formed	O
of	O
a	O
tripyrrole	O
group	O
linked	O
to	O
a	O
polyarginine	O
peptide	O
which	O
permit	O
efficient	O
cellular	O
internalisation	O
and	O
promotes	O
greater	O
affinity	O
for	O
DNA	O
.	O

The	O
method	O
of	O
obtainment	O
and	O
uses	O
thereof	O
.	O

Methods	O
for	O
increasing	O
neurogenesis	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compounds	O
useful	O
for	O
increasing	O
neurogenesis	O
.	O

Methods	O
and	O
compounds	O
for	O
increasing	O
dopaminergic	O
differentiation	O
are	O
also	O
provided	O
.	O

Methods	O
for	O
treating	O
neurological	O
disorders	O
by	O
increasing	O
neurogenesis	O
are	O
also	O
provided	O
.	O

Macrocyclics	O
pyrimidines	O
as	O
aurora	B
kinase	I
inhibitors	O
Macrocyclic	O
derivative	O
compounds	O
that	O
inhibit	O
protein	B
kinase	I
enzymes	O
are	O
disclosed	O
along	O
with	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
for	O
synthesizing	O
the	O
same	O
.	O

Such	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
resulting	O
from	O
unregulated	O
and/or	O
disturbed	O
kinase	B
activity	O
such	O
as	O
cancers	O
,	O
psoriasis	O
,	O
viral	O
and	O
bacterial	O
infections	O
,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O

Antibacterial	O
and/or	O
anti	O
-	O
acne	O
formulations	O
containing	O
salicylic	O
acid	O
or	O
a	O
derivative	O
thereof	O
Antibacterial	O
and/or	O
anti	O
-	O
acne	O
formulation	O
containing	O
(	O
a	O
)	O
salicylic	O
acid	O
or	O
a	O
derivative	O
thereof	O
and	O
(	O
b	O
)	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
derivative	O
thereof	O
:	O
formula	O
(	O
I	O
)	O
wherein	O
each	O
of	O
R1	O
and	O
R2	O
is	O
independently	O
selected	O
from	O
methyl	O
and	O
ethyl	O
and	O
R3	O
is	O
hydrogen	O
.	O

The	O
formulation	O
is	O
particularly	O
active	O
against	O
propionibacteria	O
,	O
and	O
may	O
therefore	O
be	O
used	O
to	O
treat	O
acne	O
.	O

Naringenin	O
complexes	O
and	O
methods	O
of	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
hepatitis	O
C	O
,	O
dyslipidemia	O
,	O
insulin	B
resistance	O
,	O
and	O
inflammation	O
,	O
with	O
flavonoid-	O
sugar	O
complexes	O
.	O

Akr1c3	B
as	O
a	O
biomarker	O
,	O
methods	O
of	O
selecting	O
and	O
treating	O
patients	O
based	O
upon	O
an	O
akr1c3	B
profile	O
and	O
compounds	O
for	O
use	O
therein	O
The	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
enzyme	O
AKR1C3	B
is	O
capable	O
of	O
exhibiting	O
nitroreductase	B
activity	O
and	O
activating	O
nitroaromatic	O
prodrugs	O
to	O
release	O
the	O
cytotoxic	O
effector	O
.	O

AKR1C3-activated	B
nitroaromatic	O
prodrugs	O
include	O
dinitrobenzamide	O
mustards	O
such	O
as	O
2-	O
(	O
(	O
2-bromoethyl	O
)	O
-2-	O
{	O
[	O
(	O
2-hydroxyethyl	O
)	O
amino	O
]	O
carbonyl	O
}	O
-4,6-dinitroanilino	O
)	O
ethyl	O
methanesulfonate	O
(	O
PR-104A	O
)	O
,	O
and	O
the	O
corresponding	O
pre	O
-	O
prodrug	O
2-	O
[	O
(	O
2-	O
(	O
bromoethyl	O
)	O
-2,4-dinitro-6-	O
[	O
[	O
[	O
2-	O
(	O
phosphonooxy	O
)	O
ethyl	O
]	O
amino	O
]	O
carbonyl	O
]	O
anilino	O
]	O
ethyl	O
methanesulfonate	O
(	O
PR-104	O
)	O
.	O

The	O
invention	O
provides	O
methods	O
and	O
procedures	O
to	O
determine	O
drug	O
sensitivity	O
in	O
patients	O
to	O
allow	O
the	O
identification	O
of	O
individualized	O
patient	O
profiles	O
which	O
will	O
aid	O
in	O
treating	O
diseases	O
and	O
disorders	O
,	O
such	O
as	O
cancer	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treatment	O
which	O
are	O
based	O
upon	O
such	O
biomarker	O
-	O
related	O
profiles	O
,	O
as	O
well	O
as	O
compounds	O
suitable	O
for	O
use	O
in	O
such	O
methods	O
and	O
compositions	O
comprising	O
""""	O
such	O
compounds	O
.	O

Fused	O
heteroaryl	O
diamide	O
compounds	O
useful	O
as	O
mmp-13	B
inhibitors	O
Disclosed	O
are	O
compounds	O
and	O
compositions	O
of	O
the	O
formula	O
I	O
as	O
described	O
herein	O
which	O
are	O
inhibitors	O
of	O
MMP-13	B
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
and	O
making	O
compounds	O
of	O
the	O
formula	O
I.	O

Pyrimidine	O
derivative	O
and	O
pyridine	O
derivative	O
both	O
having	O
pi3k	B
inhibitory	O
activity	O
A	O
pyrimidine	O
derivative	O
or	O
a	O
pyridine	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
pyrimidine	O
derivative	O
or	O
the	O
pyridine	O
derivative	O
,	O
which	O
can	O
inhibit	O
the	O
activity	O
of	O
PI3	B
K	I
to	O
control	O
many	O
biological	O
processes	O
including	O
growth	O
,	O
differentiation	O
,	O
survival	O
,	O
proliferation	O
,	O
migration	O
and	O
metabolism	O
of	O
cells	O
and	O
is	O
therefore	O
useful	O
for	O
the	O
prevention	O
/	O
treatment	O
of	O
diseases	O
including	O
inflammatory	O
diseases	O
,	O
arteriosclerosis	O
,	O
vascular	O
/	O
cardiovascular	O
diseases	O
,	O
cancer	O
/	O
tumors	O
,	O
immune	O
diseases	O
,	O
cell	O
proliferative	O
diseases	O
and	O
infectious	O
diseases	O
.	O

Use	O
of	O
sabcomeline	O
for	O
the	O
treatment	O
of	O
add	O
or	O
adhd	O
The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
attention	O
deficit	O
disorder	O
(	O
ADD	O
)	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
to	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
associated	O
with	O
ADD	O
or	O
ADHD	O
,	O
and	O
to	O
sabcomeline	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
compositions	O
comprising	O
sabcomeline	O
for	O
use	O
in	O
said	O
treatments	O
.	O

Oxidized	O
cardiolipin	O
as	O
a	O
novel	O
pro	O
-	O
inflammatory	O
factor	O
Low	O
levels	O
of	O
antibodies	O
reactive	O
with	O
oxidised	O
Cardiolipin	O
(	O
oxCL	O
)	O
in	O
mammals	O
are	O
related	O
to	O
an	O
increased	O
risk	O
of	O
developing	O
cardivacular	O
diseases	O
,	O
auto	O
-	O
immune	O
diseases	O
or	O
inflammatory	O
conditions	O
.	O

High	O
levels	O
can	O
have	O
a	O
protective	O
function	O
and	O
in	O
general	O
there	O
is	O
a	O
negative	O
association	O
between	O
manifestations	O
of	O
these	O
conditions	O
and	O
antibodies	O
against	O
oxCL	O
.	O

Thus	O
,	O
based	O
on	O
their	O
relations	O
methods	O
of	O
monitoring	O
,	O
determining	O
and	O
diagnosing	O
as	O
well	O
as	O
methods	O
of	O
immunisation	O
and	O
therapy	O
of	O
these	O
diseases	O
and	O
conditions	O
are	O
provided	O
.	O

1,3-heterocycles	O
condensed	O
with	O
monoterpene	O
skeleton	O
,	O
their	O
use	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
The	O
invention	O
relates	O
to	O
chiral	O
compounds	O
with	O
monoterpene	O
skeleton	O
of	O
general	O
formula	O
(	O
I	O
)	O
-	O
where	O
in	O
the	O
formula	O
X	O
stands	O
for	O
O	O
or	O
H2	O
;	O
W	O
stands	O
for	O
O	O
,	O
S	O
,	O
N	O
-	O
R2	O
or	O
Ph	O
-	O
R3	O
;	O
Y	O
stands	O
for	O
O	O
or	O
N	O
-	O
R4	O
;	O
R1	O
stands	O
for	O
H	O
,	O
C1	O
-	O
4Alk	O
or	O
(	O
C2	O
)	O
1	O
-	O
4-Ph	O
;	O
R2	O
stands	O
for	O
C1	O
-	O
4Alk	O
or	O
Ph	O
-	O
R3	O
;	O
R3	O
stands	O
for	O
H	O
,	O
C1	O
-	O
4Alk	O
,	O
C1	O
-	O
4Alk	O
-	O
O	O
or	O
Hlg	O
;	O
R4	O
stands	O
for	O
H	O
or	O
Ph	O
;	O
and	O
one	O
of	O
the	O
signs	O
---	O
means	O
the	O
presence	O
of	O
a	O
double	O
bond	O
and	O
the	O
other	O
means	O
the	O
absense	O
of	O
a	O
double	O
bond	O
,	O
with	O
the	O
proviso	O
that	O
only	O
one	O
of	O
W	O
and	O
Y	O
may	O
simultaneously	O
stand	O
for	O
oxygen	O
-	O
as	O
well	O
as	O
to	O
their	O
prodrugs	O
and	O
salts	O
formed	O
with	O
pharmaceutically	O
acceptable	O
acids	O
.	O

Furthermore	O
,	O
the	O
invention	O
relates	O
to	O
cytostatic	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
usual	O
inert	O
pharmaceutical	O
carriers	O
and/or	O
auxiliary	O
agents	O
,	O
to	O
the	O
use	O
of	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
for	O
preparing	O
cytostatic	O
pharmaceutical	O
compositions	O
as	O
well	O
as	O
to	O
the	O
treatment	O
and/or	O
curing	O
of	O
cancerous	O
illnesses	O
.	O

Pyrrolotriazines	O
as	O
alk	B
and	O
jak2	B
inhibitors	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
form	O
thereof	O
,	O
wherein	O
Q1	O
,	O
Q2	O
,	O
Q3	O
,	O
and	O
Q4	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compound	O
of	O
formula	O
(	O
I	O
)	O
has	O
ALK	B
and/or	O
JAK2	B
inhibitory	O
activity	O
,	O
and	O
may	O
be	O
used	O
to	O
treat	O
proliferative	O
disorders	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
rosuvastatin	O
salts	O
The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
process	O
for	O
the	O
preparation	O
of	O
rosuvastatin	O
[	O
7-	O
[	O
4-	O
(	O
4-Fluorophenyl	O
)	O
-6-isopropyl-2-	O
(	O
methanesulphonyl	O
-	O
methyl	O
-	O
amino	O
)	O
-pyrimidin-5-yl	O
]	O
-	O
(	O
3R,51S	O
)	O
-	O
dihydroxy	O
-	O
hept-6-enoic	O
acid	O
]	O
of	O
the	O
formula	O
(	O
I	O
)	O
salts	O
formed	O
with	O
bivalent	O
cations	O
,	O
preferably	O
with	O
calcium	O
or	O
zinc	O
ions	O
,	O
characterized	O
in	O
that	O
rosuvastatin	O
tert	O
.-	O
butylammonium	O
salt	O
is	O
reacted	O
with	O
the	O
appropriate	O
bivalent	O
cation	O
,	O
preferably	O
with	O
calcium	O
or	O
zinc	O
ions	O
in	O
a	O
mixture	O
of	O
a	O
water	O
immiscible	O
or	O
slightly	O
miscible	O
organic	O
solvent	O
and	O
water	O
and	O
the	O
formed	O
salt	O
is	O
isolated	O
.	O

Novel	O
metabolic	O
disease	O
therapy	O
The	O
invention	O
relates	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
abnormalities	O
characterized	O
by	O
abnormal	O
glucose	O
metabolism	O
,	O
including	O
diabetes	O
mellitus	O
and	O
new	O
onset	O
diabetes	O
mellitus	O
through	O
the	O
use	O
of	O
fibroblast	B
activation	I
protein	I
(	O
FAP	B
)	O
selective	O
inhibitors	O
.	O

Bumetanide	O
,	O
furosemide	O
,	O
piretanide	O
,	O
azosemide	O
,	O
and	O
torsemide	O
analogs	O
,	O
compositions	O
and	O
methods	O
of	O
use	O
The	O
present	O
invention	O
provides	O
bumetanide	O
,	O
furosemide	O
,	O
piretanide	O
,	O
azosemide	O
,	O
and	O
torsemide	O
analogs	O
and	O
compositions	O
comprising	O
such	O
analogs	O
.	O

The	O
present	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
containing	O
these	O
bumetanide	O
,	O
furosemide	O
,	O
piretanide	O
,	O
azosemide	O
,	O
and	O
torsemide	O
analogs	O
and	O
methods	O
for	O
their	O
use	O
.	O

All	O
of	O
these	O
analogs	O
are	O
particularly	O
useful	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
conditions	O
that	O
involve	O
the	O
Na+K+Cl-	B
co	I
-	I
transporter	I
or	O
GABAA	B
receptor	I
including	O
but	O
not	O
limited	O
to	O
addictive	O
disorders	O
,	O
Alzheimer	O
's	O
Disease	O
,	O
anxiety	O
disorders	O
,	O
ascites	O
,	O
autism	O
,	O
bipolar	O
disorder	O
,	O
cancer	O
,	O
depression	O
,	O
endothelial	O
corneal	O
dystrophy	O
,	O
edema	O
,	O
epilepsy	O
,	O
glaucoma	O
,	O
Huntington	O
's	O
Disease	O
,	O
insomnia	O
,	O
ischemia	O
,	O
migraine	O
,	O
migraine	O
with	O
aura	O
,	O
neuropathic	O
pain	O
,	O
nociceptive	O
neuralgia	O
,	O
nociceptive	O
pain	O
,	O
ocular	O
diseases	O
,	O
pain	O
,	O
Parkinson	O
's	O
disease	O
,	O
personality	O
disorders	O
,	O
postherpetic	O
neuralgia	O
,	O
psychosis	O
,	O
schizophrenia	O
,	O
seizure	O
disorders	O
,	O
tinnitus	O
,	O
and	O
withdrawal	O
syndromes	O
.	O

C-7	O
isoxazolinyl	O
quinolone	O
/	O
naphthyridine	O
derivatives	O
useful	O
as	O
antibacterial	O
agents	O
The	O
present	O
invention	O
relates	O
to	O
C-7	O
isoxazolyl	O
quinoline	O
/	O
naphthyridine	O
derivatives	O
useful	O
as	O
antimicrobial	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
derivatives	O
and	O
the	O
use	O
of	O
said	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
as	O
antimicrobial	O
agents	O
against	O
pathogenic	O
microorganisms	O
,	O
particularly	O
against	O
resistant	O
microbes	O
.	O

Method	O
for	O
facilitating	O
extinction	O
training	O
using	O
d	O
-	O
cycloserine	O
Methods	O
are	O
disclosed	O
for	O
improving	O
treatment	O
of	O
various	O
medical	O
conditions	O
via	O
administration	O
of	O
D	O
-	O
cycloserine	O
to	O
facilitate	O
learning	O
.	O

Specifically	O
,	O
by	O
administering	O
D-	O
cycloserine	O
to	O
a	O
patient	O
at	O
a	O
time	O
that	O
is	O
both	O
subsequent	O
to	O
extinction	O
training	O
during	O
the	O
day	O
and	O
within	O
two	O
hours	O
prior	O
to	O
the	O
patient	O
's	O
initial	O
nightly	O
sleep	O
period	O
following	O
the	O
extinction	O
training	O
,	O
the	O
known	O
ability	O
of	O
D	O
-	O
cycloserine	O
to	O
facilitate	O
extinction	O
learning	O
can	O
be	O
enhanced	O
.	O

Therapeutic	O
uses	O
of	O
mastic	O
gum	O
fractions	O
The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
formulations	O
comprising	O
polymeric	O
myrcene	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compositions	O
comprising	O
an	O
isolated	O
fraction	O
of	O
polymeric	O
myrcene	O
in	O
a	O
hydrophobic	O
carrier	O
and	O
formulations	O
which	O
maintain	O
the	O
biological	O
activity	O
of	O
the	O
active	O
polymer	O
.	O

2-indolyl	O
imidazo	O
[	O
4,5-d	O
]	O
phenanthroline	O
derivatives	O
and	O
their	O
use	O
to	O
inhibit	O
angiogenesis	O
2-Indolyl	O
imidazo	O
[	O
4,5-d	O
]	O
phenanthroline	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
that	O
are	O
capable	O
of	O
inhibiting	O
angiogenesis	O
are	O
provided	O
Methods	O
of	O
inhibiting	O
angiogenesis	O
using	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
methods	O
and	O
uses	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
in	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
associated	O
diseases	O
and	O
disorders	O
such	O
as	O
cancer	O
,	O
age-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
,	O
diabetic	O
retinopathy	O
and	O
retinal	O
vein	O
occlusion	O
are	O
also	O
provided	O
.	O

2	O
,	O
5-disubstituted	O
tetrazole	O
derivatives	O
and	O
their	O
use	O
as	O
nicotinic	B
acetylcholine	I
receptor	I
modulators	O
This	O
invention	O
relates	O
to	O
novel	O
tetrazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
found	O
to	O
be	O
modulators	O
of	O
the	O
nicotinic	B
acetylcholine	I
receptors	I
.	O

Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction	O
,	O
endocrine	O
diseases	O
or	O
disorders	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-	O
degeneration	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation	O
,	O
pain	O
,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O

A	O
novel	O
medical	O
use	O
of	O
kynurenic	O
acid	O
,	O
its	O
precursors	O
and	O
derivatives	O
The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
kynurenic	O
acid	O
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
hydroxy	O
,	O
NHR2	O
,	O
NR2R2	O
or	O
C1	O
-	O
10	O
straight	O
or	O
branched	O
alkoxy	O
or	O
glyceryl	O
group	O
;	O
R2	O
is	O
hydrogen	O
atom	O
or	O
C1	O
-	O
10	O
straight	O
or	O
branched	O
alkyl	O
group	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
hydrogen	O
atom	O
,	O
halogen	O
atom	O
,	O
C1	O
-	O
10	O
alkyl	O
,	O
C2	O
-	O
10	O
alkenyl	O
or	O
alkynyl	O
group	O
optionally	O
substituted	O
with	O
a	O
halogen	O
atom	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
or	O
amide	O
thereof	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and/or	O
vacuolization	O
and/or	O
destruction	O
of	O
pancreatic	O
tissue	O
and/or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	O
α	O
-	O
amylase	O
.	O

Prefereably	O
,	O
in	O
the	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
R1	O
is	O
a	O
hydroxy	O
,	O
NH2	O
,	O
NH-	O
(	O
C1	O
-	O
5	O
straight	O
or	O
branched	O
alkyl	O
)	O
or	O
C1	O
-	O
5	O
straight	O
or	O
branched-	O
alkoxy	O
or	O
glyceryl	O
group	O
;	O
R2	O
is	O
a	O
hydrogen	O
atom	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
a	O
hydrogen	O
atom	O
,	O
halogen	O
atom	O
or	O
CF3	O
group	O
.	O

In	O
the	O
most	O
preferred	O
embodiment	O
,	O
the	O
invention	O
concerns	O
the	O
use	O
of	O
kynurenic	O
acid	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and/or	O
vacuolization	O
and/or	O
destruction	O
of	O
pancreatic	O
tissue	O
and/or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	B
α	I
-	I
amylase	I
.	O

Benzoxazoles	O
for	O
the	O
treatment	O
of	O
duchenne	O
muscular	O
dystrophy	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
X	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
conditions	O
such	O
as	O
Duchenne	O
muscular	O
dystrophy	O
,	O
Becker	O
muscular	O
dystrophy	O
,	O
and	O
cachexia	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
1-	O
[	O
[	O
[	O
3-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
ethyl	O
]	O
-1h	O
-	O
indol-5-yl	O
]	O
methyl	O
]	O
sulfonyl	O
]	O
pyrrolidine	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
A	O
process	O
for	O
preparation	O
of	O
1-	O
[	O
[	O
[	O
3-	O
[	O
2-	O
(	O
dimethylamino	O
)	O
ethyl	O
]	O
-1H	O
-	O
indol-5-yl	O
]	O
methyl	O
]	O
sulfonyl	O
]	O
pyrrolidine	O
of	O
Formula	O
(	O
1	O
)	O
,	O
which	O
is	O
commonly	O
known	O
as	O
Almotriptan	O
,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
is	O
provided	O
.	O

The	O
required	O
purity	O
of	O
almotriptan	O
malate	O
free	O
of	O
impurities	O
is	O
attained	O
in	O
three	O
different	O
ways	O
,	O
including	O
by	O
preparing	O
the	O
acid	O
addition	O
salts	O
of	O
amino	O
indole	O
compound	O
,	O
by	O
proceeding	O
through	O
the	O
almotriptan	O
succinate	O
and	O
by	O
specific	O
purification	O
of	O
almotriptan	O
malate	O
from	O
a	O
suitable	O
solvent	O
.	O

Tumor	O
-	O
specific	O
promoter	O
and	O
use	O
thereof	O
As	O
a	O
tumor	O
-	O
specific	O
promoter	O
,	O
a	O
polynucleotide	O
is	O
used	O
which	O
comprises	O
the	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:1	O
or	O
a	O
nucleotide	O
sequence	O
capable	O
of	O
hybridizing	O
to	O
a	O
nucleotide	O
sequence	O
complementary	O
to	O
the	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:1	O
under	O
stringent	O
conditions	O
and	O
which	O
has	O
a	O
tumor	O
-	O
specific	O
promoter	O
activity	O
.	O

Stable	O
pharmaceutical	O
compositions	O
with	O
high	O
bioavailability	O
The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
a	O
strontium	O
compound	O
alone	O
or	O
in	O
combination	O
with	O
vitamin	O
D	O
which	O
is	O
used	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
abnormal	O
bone	O
resorption	O
and/or	O
effective	O
as	O
a	O
supplement	O
.	O

Preparation	O
for	O
external	O
use	O
Provided	O
is	O
a	O
new	O
external	O
preparation	O
of	O
a	O
tertiary	O
amine	O
compound	O
that	O
exhibits	O
a	O
CXCR4-antagonizing	O
action	O
,	O
said	O
preparation	O
being	O
a	O
nonaqueous	O
preparation	O
containing	O
a	O
tertiary	O
amine	O
compound	O
indicated	O
by	O
general	O
formula	O
(	O
1	O
)	O
,	O
in	O
solution	O
in	O
a	O
fatty	O
acid	O
ionic	O
liquid	O
.	O

(	O
1	O
)	O
(	O
In	O
general	O
formula	O
(	O
1	O
)	O
,	O
R1	O
through	O
R6	O
each	O
independently	O
represent	O
either	O
a	O
hydrogen	O
atom	O
or	O
a	O
C1–4	O
lower	O
alkyl	O
group	O
;	O
n	O
1	O
through	O
n	O
3	O
are	O
integers	O
from	O
1	O
to	O
4	O
,	O
inclusive	O
;	O
A1	O
and	O
A2	O
represent	O
substituted	O
or	O
unsubstituted	O
heteroaromatic	O
ring	O
groups	O
;	O
W	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
phenylene	O
group	O
;	O
X	O
represents	O
an	O
N-	O
(	O
carboxymethyl	O
)	O
methylene	O
group	O
;	O
and	O
D	O
represents	O
a	O
C1–5	O
lower	O
alkylene	O
group	O
substituted	O
with	O
a	O
secondary	O
amino	O
group	O
having	O
a	O
C1–4	O
lower	O
alkyl	O
group	O
.	O
)	O

Fused	O
pyrrolopyridine	O
derivative	O
Disclosed	O
is	O
a	O
fused	O
pyrrolopyridine	O
derivative	O
which	O
is	O
useful	O
as	O
an	O
active	O
ingredient	O
for	O
a	O
pharmaceutical	O
composition	O
,	O
in	O
particular	O
a	O
pharmaceutical	O
composition	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O

The	O
inventors	O
have	O
intensively	O
studied	O
on	O
compounds	O
having	O
JAK	B
inhibitory	O
activity	O
,	O
and	O
found	O
that	O
the	O
compound	O
of	O
the	O
present	O
invention	O
,	O
namely	O
a	O
fused	O
pyrrolopyridine	O
derivative	O
has	O
excellent	O
JAK	B
inhibitory	O
activity	O
and	O
is	O
thus	O
useful	O
as	O
an	O
agent	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O

Treatment	O
of	O
non	O
-	O
localized	O
inflammation	O
with	O
pan	O
-	O
hdac	B
inhibitors	O
Described	O
herein	O
are	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
non	O
-	O
localized	O
inflammatory	O
condition	O
(	O
or	O
any	O
symptoms	O
associated	O
with	O
such	O
inflammation	O
)	O
,	O
including	O
systemic	O
inflammation	O
,	O
and	O
inflammatory	O
conditions	O
affecting	O
the	O
large	O
portions	O
of	O
or	O
the	O
whole	O
body	O
,	O
or	O
sepsis	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan	O
-	O
HDAC	B
inhibitor	O
.	O

Also	O
described	O
herein	O
are	O
methods	O
for	O
decreasing	O
iNOS	B
and	O
cytokine	B
expression	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan	O
-	O
HDAC	B
inhibitor	O
.	O

Sulfonamide	O
compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O
Compounds	O
are	O
provided	O
according	O
to	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
W	O
,	O
X	O
,	O
Z	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
ml	O
are	O
as	O
defined	O
herein	O
.	O

Provided	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non-	O
limiting	O
example	O
,	O
pain	O
,	O
inflammation	O
,	O
cognitive	O
disorders	O
,	O
anxiety	O
,	O
depression	O
,	O
and	O
others	O
.	O

Provided	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
also	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non-	O
limiting	O
example	O
immune	O
-	O
mediated	O
disorders	O
and	O
autoimmune	O
diseases	O
,	O
including	O
multiple	O
sclerosis	O
,	O
type-1	O
diabetes	O
mellitus	O
,	O
type-2	O
diabetes	O
mellitus	O
,	O
rheumatoid	O
arthritis	O
,	O
psoriasis	O
,	O
contact	O
dermatitis	O
,	O
obesity	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
graft	O
-	O
versus	O
host	O
disease	O
,	O
transplant	O
rejection	O
,	O
and	O
others	O
.	O

Anti	O
-	O
hyperglycemic	O
and/or	O
anti	O
-	O
hyperlipidemic	O
agent	O
comprising	O
material	O
containing	O
avian	O
skin	O
-	O
derived	O
sphingomyelin	O
as	O
active	O
ingredient	O
Disclosed	O
is	O
a	O
sphingomyelin	O
-	O
containing	O
material	O
which	O
can	O
be	O
produced	O
in	O
a	O
large	O
quantity	O
at	O
low	O
cost	O
.	O

Also	O
disclosed	O
is	O
an	O
useful	O
use	O
application	O
of	O
a	O
sphingomyelin	O
-	O
containing	O
material	O
.	O

Specifically	O
disclosed	O
is	O
an	O
anti	O
-	O
hyperglycemic	O
and/or	O
anti	O
-	O
hyperlipidemic	O
agent	O
comprising	O
a	O
material	O
containing	O
a	O
sphingomyelin	O
derived	O
from	O
an	O
avain	O
skin	O
as	O
an	O
active	O
ingredient	O
.	O

SUBSTITUTED	O
IMIDAZO	O
[	O
1,5-a	O
]	O
QUINOXALINES	O
AS	O
INHIBITORS	O
OF	O
PHOSPHODIESTERASE	B
10	I
The	O
invention	O
relates	O
to	O
imidazo	O
[	O
1,5-a	O
]	O
quinoxaline	O
derivatives	O
which	O
are	O
inhibitors	O
of	O
phosphodiesterase	B
10	I
(	O
PDE10	B
)	O
useful	O
in	O
treating	O
central	O
nervous	O
system	O
diseases	O
such	O
as	O
psychosis	O
and	O
also	O
in	O
treating	O
,	O
for	O
example	O
,	O
obesity	O
,	O
type	O
2	O
diabetes	O
,	O
metabolic	O
syndrome	O
,	O
glucose	O
intolerance	O
,	O
and	O
pain	O
.	O

A	O
novel	O
4-methylbenzenesulphonate	O
salt	O
and	O
a	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
salt	O
The	O
invention	O
provides	O
a	O
4-methylbenzenesulphonate	O
salt	O
of	O
the	O
muscarinic	O
antagonist	O
(	O
R	O
)	O
-	O
1-	O
(	O
4-fluorophenethyl	O
)	O
-3-	O
(	O
(	O
S	O
)	O
-2-phenyl-2-	O
(	O
piperidin-1	O
-yl	O
)	O
propanoyloxy	O
)	O
-1-	O
azoniabicyclo	O
[	O
2.2.2	O
]	O
octane	O
and	O
its	O
use	O
in	O
therapy	O
,	O
as	O
well	O
as	O
a	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
salt	O
and	O
its	O
use	O
in	O
therapy	O
.	O

Liquiritigenin	O
derivatives	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O
Liquiritigenin	O
derivatives	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

More	O
specifically	O
,	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
isomers	O
,	O
racemates	O
,	O
enantiomers	O
,	O
diastereomers	O
,	O
enantiomer	O
enrichments	O
,	O
solvates	O
,	O
prodrugs	O
,	O
and	O
esters	O
thereof	O
are	O
disclosed	O
,	O
in	O
which	O
n	O
is	O
0	O
or	O
1	O
,	O
R1	O
is	O
C3	O
-	O
8	O
cycloalkyl	O
and	O
R2	O
is	O
H.	O
The	O
preparation	O
methods	O
for	O
the	O
compounds	O
of	O
formula	O
I	O
,	O

the	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
and	O
the	O
uses	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
treating	O
and/or	O
preventing	O
cerebral	O
ischemic	O
diseases	O
,	O
neurodegenerative	O
diseases	O
and	O
inflammatory	O
diseases	O
are	O
also	O
disclosed	O
.	O

Conjugates	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
-	O
chlorine	O
derivatives	O
,	O
photosensitizer	O
containing	O
same	O
and	O
composition	O
for	O
treating	O
cancer	O
containing	O
same	O
The	O
present	O
invention	O
relates	O
to	O
conjugates	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
-	O
chlorine	O
derivatives	O
,	O
photosensitizer	O
containing	O
the	O
same	O
and	O
composition	O
for	O
treating	O
cancer	O
containing	O
the	O
same	O
.	O

The	O
conjugates	O
,	O
photosensitizer	O
and	O
composition	O
suppress	O
cancer	O
cell	O
proliferation	O
and	O
enables	O
photodynamic	O
therapy	O
at	O
the	O
same	O
time	O
by	O
conjugating	O
chlorine	O
derivatives	O
with	O
photodynamic	O
activity	O
and	O
an	O
anticancer	O
chemotherapeutic	O
agent	O
with	O
activity	O
of	O
suppressing	O
cell	O
proliferation	O
,	O
as	O
well	O
as	O
being	O
useful	O
in	O
cancer	O
therapy	O
by	O
reducing	O
the	O
toxicity	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
and	O
avoiding	O
chemotherapeutic	O
agent	O
-	O
resistance	O
.	O

Luteinising	O
hormone	O
releasing	O
hormone	O
antagonist	O
with	O
hydantoin	O
structure	O
A	O
decapeptide	O
derivative	O
of	O
formula	O
(	O
I	O
)	O
possessing	O
hydantoin	O
structure	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
said	O
decapeptide	O
derivative	O
and	O
applications	O
thereof	O
in	O
preparing	O
medications	O
are	O
provided	O
.	O

The	O
decapeptide	O
derivative	O
is	O
a	O
luteinising	O
hormone	O
releasing	O
hormone	O
(	O
LHRH	O
)	O
antagonist	O
,	O
having	O
LHRH	O
receptor	O
antagonist	O
activity	O
and	O
inhibiting	O
pituitary	O
gonadotropin	O
secretion	O
and	O
steroid	O
hormone	O
secretion	O
of	O
sexual	O
glands	O
.	O

Formula	O
(	O
I	O
)	O
,	O
R	O
-	O
Xaa3-Ser	O
-	O
Xaa5-	O
Xaa6-	O
Xaa7-	O
Xaa8-Pro	O
-	O
D	O
-	O
Ala	O
-	O
B	O

CREATINE	O
β	O
-	O
ALANINATE	O
:	O
A	O
NOVEL	O
SALT	O
FOR	O
INCREASING	O
ATHLETIC	O
PERFORMANCE	O
Disclosed	O
are	O
creatine	O
β	O
-	O
alaninate	O
,	O
compositions	O
and	O
formulations	O
containing	O
same	O
,	O
and	O
methods	O
of	O
use	O
therefor	O
.	O

Aromatic	O
fused	O
heterocyclic	O
derivative	O
and	O
pharmaceutical	O
composition	O
containing	O
same	O
Disclosed	O
is	O
a	O
compound	O
having	O
an	O
activity	O
of	O
modulating	O
a	O
histamine	B
-	I
H4	I
receptor	I
.	O

Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
Ra	O
and	O
Rb	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
,	O
or	O
the	O
like	O
;	O
X	O
represents	O
-O-	O
or	O
-S	O
(	O
O	O
)	O
p-	O
;	O
p	O
represents	O
an	O
integer	O
of	O
0	O
to	O
2	O
;	O
Y	O
represents	O
=	O
O	O
or	O
=	O
S	O
;	O
R1	O
represents	O
a	O
halogen	O
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
,	O
or	O
the	O
like	O
;	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
4	O
;	O
and	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	O
group	O
,	O
or	O
the	O
like	O
]	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
.	O

Inhibitors	O
of	O
kshv	B
vil6	I
and	O
human	B
il6	I
The	O
invention	O
features	O
compositions	O
comprising	O
microRNAs	O
that	O
are	O
capable	O
of	O
repressing	O
vIL6	B
or	O
hIL6	B
,	O
and	O
related	O
methods	O
of	O
using	O
the	O
microRNAs	O
for	O
treating	O
Kaposi	O
's	O
sarcoma-	O
associated	O
herpes	O
virus	O
(	O
KSHV	O
)	O
infections	O
or	O
diseases	O
caused	O
by	O
KSHV	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
bi-1356	O
and	O
metformin	O
The	O
present	O
invention	O
relates	O
to	O
therapeutic	O
uses	O
of	O
pharmaceutical	O
compositions	O
or	O
combinations	O
of	O
a	O
DPP-4	O
inhibitor	O
with	O
metformin	O
.	O

Use	O
of	O
flubendazole	O
and	O
vinca	O
alkaloids	O
for	O
treatment	O
of	O
hematological	O
diseases	O
Provided	O
are	O
methods	O
for	O
treating	O
a	O
hematological	O
malignancy	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
flubendazole	O
alone	O
or	O
in	O
combination	O
with	O
a	O
vinca	O
alkaloid	O
.	O

Also	O
provided	O
are	O
compositions	O
and	O
kits	O
comprising	O
an	O
effective	O
amount	O
of	O
flubendazole	O
and/or	O
a	O
vinca	O
alkaloid	O
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
disclosure	O
.	O

Process	O
for	O
preparation	O
of	O
propargylated	O
aminoindans	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
A	O
process	O
for	O
preparation	O
of	O
propargylated	O
aminoindans	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
comprises	O
:	O
a	O
)	O
reacting	O
an	O
indanone	O
derivative	O
or	O
a	O
salt	O
thereof	O
with	O
propargyl	O
amine	O
or	O
a	O
salt	O
thereof	O
in	O
the	O
presence	O
of	O
a	O
Lewis	O
acid	O
;	O
b	O
)	O
subjecting	O
the	O
resultant	O
reaction	O
mixture	O
to	O
reduction	O
.	O

Thiadiazolidinedioxide	O
p2x7	B
receptor	I
antagonists	O
The	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
wherein	O
:	O
R1	O
is	O
C1	O
-	O
3alkyl	O
or	O
C1fluoroalkyl	O
-	O
CH2	O
;	O
R2	O
is	O
hydrogen	O
,	O
C1	O
-	O
4alkyl	O
,	O
C1fluoroalkyl	O
-	O
CH2-	O
,	O
C3	O
-	O
6cycloalkyl	O
,	O
C3	O
-	O
6cycloalkyl	O
-	O
methyl-	O
,	O
optionally	O
substituted	O
benzyl	O
,	O
or	O
optionally	O
substituted	O
heteroaryl-	O
(	O
CH2	O
)	O
n-	O
,	O
wherein	O
n	O
is	O
0	O
or	O
1	O
,	O
wherein	O
in	O
R2	O
the	O
benzyl	O
is	O
optionally	O
substituted	O
on	O
the	O
ring	O
with	O
one	O
or	O
two	O
substituents	O
independently	O
being	O
methyl	O
,	O
methoxy	O
,	O
fluorine	O
or	O
chlorine	O
,	O
and	O
wherein	O
in	O
R2	O
the	O
heteroaryl-	O
(	O
CH2	O
)	O
n-	O
optionally	O
substituted	O
on	O
the	O
heteroaryl	O
ring	O
with	O
one	O
or	O
two	O
substituents	O
independently	O
being	O
C1	O
-	O
3alkyl	O
,	O
CF3	O
,	O
methoxy	O
,	O
a	O
halogen	O
atom	O
,	O
or	O
cyano	O
;	O
and	O
wherein	O
:	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
independently	O
are	O
hydrogen	O
,	O
a	O
halogen	O
atom	O
,	O
C1	O
-	O
4alkyl	O
,	O
trifluoromethyl	O
,	O
or	O
cyano	O
,	O
such	O
that	O
one	O
or	O
both	O
of	O
R3	O
and	O
R7	O
is	O
or	O
are	O
a	O
group	O
other	O
than	O
hydrogen	O
.	O

Anti	O
-	O
inflammatory	O
extract	O
The	O
present	O
invention	O
provides	O
anti	O
-	O
inflammatory	O
extracts	O
derived	O
from	O
plants	O
of	O
the	O
Dodonaeoideae	O
subfamily	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
an	O
anti	O
-	O
inflammatory	O
extracts	O
.	O

Other	O
aspects	O
of	O
the	O
present	O
invention	O
also	O
relate	O
to	O
pharmaceutical	O
compositions	O
comprising	O
anti	O
-	O
inflammatory	O
extracts	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
inflammation	O
in	O
a	O
subject	O
.	O

Novel	O
antithrombotic	O
agents	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
methods	O
for	O
their	O
preparation	O
,	O
use	O
of	O
these	O
compounds	O
in	O
medicine	O
and	O
the	O
intermediates	O
involved	O
in	O
their	O
preparation	O
.	O

Novel	O
inositol	O
phosphate	O
derivatives	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1,R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
,	O
X	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O

Preferred	O
compounds	O
are	O
inositol	O
phosphate	O
derivatives	O
wherein	O
R1	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	O
and	O
at	O
least	O
one	O
of	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
is	O
PO3	O
2-	O
Alternative	O
compounds	O
are	O
inositol	O
phosphate	O
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
a	O
fiuorophore	O
moiety	O
The	O
compounds	O
are	O
useful	O
alone	O
or	O
in	O
combination	O
with	O
known	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
diseases	O
,	O
especially	O
cancer	O
.	O

Use	O
of	O
alpha	O
2	O
adrenergic	O
receptor	O
agonists	O
for	O
treating	O
or	O
preventing	O
psoriasis	O
Methods	O
and	O
kits	O
for	O
treating	O
or	O
preventing	O
psoriasis	O
or	O
a	O
symptom	O
associated	O
with	O
psoriasis	O
in	O
a	O
subject	O
are	O
described	O
.	O

The	O
methods	O
involve	O
topical	O
applications	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
α2	O
adrenergic	O
receptor	O
agonist	O
,	O
such	O
as	O
brimonidine	O
.	O

Compositions	O
containing	O
salmeterol	O
,	O
fluticasone	O
and	O
cromoglicic	O
acid	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cromoglicic	O
acid	O
and/or	O
nedocromil	O
salts	O
in	O
pharmaceutically	O
effective	O
amounts	O
in	O
a	O
pharmaceutical	O
composition	O
containing	O
salmeterol	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
a	O
β2-agonisti	O
combined	O
with	O
fluticasone	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
a	O
corticosteroid	O
for	O
the	O
treatment	O
of	O
the	O
respiratory	O
diseases	O
.	O

Compounds	O
which	O
effecttively	O
remove	O
tumor	O
or	O
cancer	O
cell	O
Compounds	O
which	O
effectively	O
remove	O
tumor	O
or	O
cancer	O
cell	O
and	O
their	O
use	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
tumor	O
or	O
cancer	O
by	O
making	O
immune	O
system	O
find	O
tumor	O
or	O
cancer	O
cell	O
are	O
provided	O
.	O

In	O
detail	O
,	O
by	O
immune	O
identifier	O
of	O
tumor	O
or	O
cancer	O
cell	O
the	O
immune	O
system	O
of	O
organism	O
can	O
find	O
and	O
remove	O
them	O
in	O
time	O
.	O

The	O
substances	O
used	O
for	O
immune	O
identifier	O
are	O
organic	O
molecules	O
(	O
including	O
organometallic	O
compounds	O
)	O
which	O
are	O
adhered	O
to	O
on	O
the	O
surface	O
of	O
the	O
cell	O
.	O

These	O
organic	O
molecules	O
are	O
linked	O
with	O
sugar	O
molecule	O
.	O

Docosahexaenoic	O
acid	O
ethyl	O
esters	O
and/or	O
its	O
derivatives	O
for	O
prevention	O
and/or	O
treatment	O
of	O
age	O
-	O
related	O
macular	O
degeneration	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
DHA	O
ethyl	O
esters	O
with	O
over	O
80	O
%	O
by	O
weight	O
purity	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
age	O
related	O
macular	O
degeneration	O
,	O
that	O
uses	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARƴ	O
)	O
as	O
target	O
.	O

Controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
containing	O
quetiapine	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O
The	O
present	O
invention	O
discloses	O
a	O
controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
and	O
preparation	O
method	O
as	O
well	O
as	O
the	O
use	O
thereof	O
.	O

Said	O
preparation	O
contains	O
quetiapine	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
5	O
-	O
50	O
%	O
of	O
polyoxyethylene	O
in	O
amount	O
of	O
total	O
weight	O
of	O
said	O
controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
,	O
and	O
remaining	O
amount	O
of	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Method	O
of	O
accelerating	O
corneal	O
wound	O
healing	O
The	O
topical	O
ophthalmic	O
use	O
of	O
5,6,7-trihydroxyheptanoic	O
acid	O
and	O
analogs	O
for	O
the	O
acceleration	O
of	O
corneal	O
wound	O
healing	O
in	O
humans	O
,	O
is	O
disclosed	O
.	O

Pharmaceutical	O
compositions	O
containing	O
berberine	O
for	O
treatment	O
or	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
associated	O
with	O
anti	O
-	O
psychotic	O
drugs	O
The	O
compositions	O
and	O
methods	O
disclosed	O
herein	O
are	O
of	O
use	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
.	O

In	O
particular	O
,	O
the	O
compositions	O
and	O
methods	O
include	O
treatment	O
of	O
weight	O
gain	O
and	O
obesity	O
with	O
berberine	O
and/or	O
berberine	O
analogs	O
alone	O
or	O
in	O
combination	O
thereof	O
to	O
cause	O
a	O
reduction	O
in	O
an	O
individual	O
's	O
weight	O
or	O
prevent	O
weight	O
gain	O
or	O
obesity	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
weight	O
gain	O
and	O
obesity	O
are	O
associated	O
with	O
administration	O
of	O
anti	O
-	O
psychotic	O
drugs	O
.	O

In	O
an	O
alternative	O
embodiment	O
,	O
the	O
compositions	O
and	O
methods	O
provide	O
berberine	O
or	O
berberine	O
analogs	O
alone	O
or	O
for	O
coadministration	O
with	O
an	O
anti	O
-	O
psychotic	O
agent	O
.	O

In	O
an	O
additional	O
embodiment	O
,	O
the	O
compositions	O
and	O
methods	O
further	O
include	O
a	O
natural	O
product	O
.	O

The	O
usefulness	O
of	O
the	O
present	O
invention	O
is	O
that	O
berberine	O
and	O
berberine	O
analogs	O
do	O
not	O
have	O
synergistic	O
effects	O
with	O
other	O
drugs	O
and	O
administration	O
results	O
in	O
few	O
side	O
effects	O
.	O

Such	O
characteristics	O
of	O
berberine	O
or	O
berberine	O
analogs	O
are	O
a	O
great	O
improvement	O
able	O
to	O
support	O
the	O
widespread	O
use	O
of	O
the	O
compositions	O
and	O
methods	O
of	O
the	O
present	O
invention	O
as	O
therapeutics	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
.	O

Macrolide	O
inhibitors	O
of	O
mtor	B
The	O
present	O
invention	O
relates	O
to	O
new	O
macrolide	O
inhibitors	O
of	O
mTOR	B
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
(	O
Formula	O
I	O
)	O
.	O

Perifosine	O
and	O
capecitabine	O
as	O
a	O
combined	O
treatment	O
for	O
cancer	O
Treatment	O
regimens	O
comprising	O
co	O
-	O
treatment	O
of	O
cancer	O
with	O
perifosine	O
and	O
capecitabine	O
are	O
disclosed	O
herein	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
unit	O
dosage	O
forms	O
thereof	O
formulated	O
to	O
be	O
suitable	O
for	O
use	O
in	O
said	O
treatment	O
regimens	O
.	O

Heterocyclic	O
compounds	O
and	O
their	O
use	O
as	O
pi3k	B
inhibitors	O
Substituted	O
bicyclic	O
heteroaryls	O
and	O
compositions	O
containing	O
them	O
,	O
for	O
the	O
treatment	O
of	O
general	O
inflammation	O
,	O
arthritis	O
,	O
rheumatic	O
diseases	O
,	O
osteoarthritis	O
,	O
inflammatory	O
bowel	O
disorders	O
,	O
inflammatory	O
eye	O
disorders	O
,	O
inflammatory	O
or	O
unstable	O
bladder	O
disorders	O
,	O
psoriasis	O
,	O
skin	O
complaints	O
with	O
inflammatory	O
components	O
,	O
chronic	O
inflammatory	O
conditions	O
,	O
including	O
but	O
not	O
restricted	O
to	O
autoimmune	O
diseases	O
such	O
as	O
systemic	O
lupus	O
erythematosis	O
(	O
SLE	O
)	O
,	O
myestenia	O
gravis	O
,	O
rheumatoid	O
arthritis	O
,	O
acute	O
disseminated	O
encephalomyelitis	O
,	O
idiopathic	O
thrombocytopenic	O
purpura	O
,	O
multiples	O
sclerosis	O
,	O
Sjoegren	O
's	O
syndrome	O
and	O
autoimmune	O
hemolytic	O
anemia	O
,	O
allergic	O
conditions	O
including	O
all	O
forms	O
of	O
hypersensitivity	O
,	O
The	O
present	O
invention	O
also	O
enables	O
methods	O
for	O
treating	O
cancers	O
that	O
are	O
mediated	O
,	O
dependent	O
on	O
or	O
associated	O
with	O
p110	B
activity	O
,	O
including	O
but	O
not	O
restricted	O
to	O
leukemias	O
,	O
such	O
as	O
Acute	O
Myeloid	O
leukaemia	O
(	O
AML	O
)	O
Myelo	O
-	O
dysplastic	O
syndrome	O
(	O
MDS	O
)	O
myelo	O
-	O
proliferative	O
diseases	O
(	O
MPD	O
)	O
Chronic	O
Myeloid	O
Leukemia	O
(	O
CML	O
)	O
T	O
-	O
cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
T	O
-	O
ALL	O
)	O
B	O
-	O
cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
B	O
-	O
ALL	O
)	O
Non	O
Hodgkins	O
Lymphoma	O
(	O
NHL	O
)	O
B	O
-	O
cell	O
lymphoma	O
and	O
solid	O
tumors	O
,	O
such	O
as	O
breast	O
cancer	O
.	O

Fully	O
openable	O
multifunction	O
drawer	O
for	O
household	O
appliances	O
The	O
present	O
invention	O
describes	O
a	O
washing	O
machine	O
(	O
1	O
)	O
comprising	O
an	O
external	O
chassis	O
(	O
11	O
)	O
,	O
on	O
the	O
front	O
panel	O
(	O
12	O
)	O
of	O
which	O
are	O
accessible	O
at	O
least	O
one	O
aperture	O
(	O
13	O
)	O
,	O
equipped	O
with	O
a	O
door	O
(	O
14	O
)	O
,	O
for	O
the	O
loading	O
and/or	O
unloading	O
of	O
garments	O
into	O
or	O
from	O
the	O
rotary	O
drum	O
inside	O
said	O
chassis	O
(	O
11	O
)	O
,	O
a	O
soap	O
dispenser	O
(	O
2	O
)	O
of	O
washing	O
agents	O
assembled	O
on	O
the	O
slidable	O
drawer	O
support	O
structure	O
(	O
21	O
)	O
able	O
to	O
additionally	O
contain	O
,	O
adjacent	O
to	O
compartments	O
(	O
22	O
;	O
221	O
,	O
222	O
,	O
223	O
,	O
224	O
)	O
,	O
one	O
or	O
more	O
receptacles	O
(	O
23	O
)	O
,	O
able	O
to	O
contain	O
and	O
house	O
various	O
types	O
of	O
useful	O
objects	O
and	O
accessories	O
,	O
and	O
a	O
control	O
panel	O
(	O
26	O
;	O
261	O
,	O
262	O
)	O
.	O

Microsomal	O
prostaglandin	B
e	I
syntase-1	I
inhibitors	O
This	O
invention	O
relates	O
to	O
piperidine	O
derivatives	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
medicine	O
.	O

Aromatic	O
butan-2-ol	O
compounds	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O
Provided	O
are	O
compounds	O
shown	O
by	O
formula	O
I	O
,	O
optical	O
isomers	O
,	O
racemes	O
,	O
diastereoisomers	O
,	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
wherein	O
each	O
substituent	O
has	O
the	O
meaning	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Also	O
provided	O
are	O
their	O
preparation	O
methods	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
uses	O
of	O
said	O
compounds	O
for	O
preparation	O
of	O
drugs	O
useful	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
or	O
disorders	O
caused	O
by	O
the	O
infection	O
of	O
mycobacterium	O
tuberculosis	O
.	O

Cycloamino	O
derivatives	O
as	O
gpr119	B
agonists	O
Therapeutic	O
compounds	O
are	O
disclosed	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
that	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
,	O
including	O
type	O
II	O
diabetes	O
.	O

The	O
compounds	O
have	O
activity	O
as	O
agonists	O
of	O
GPR119	B
.	O

Compounds	O
having	O
the	O
stereochemistry	O
of	O
formula	O
(	O
la	O
)	O
may	O
also	O
demonstrate	O
DPP	B
-	I
IV	I
inhibitory	O
activity	O
.	O

SUBSTITUTED	O
THIAZOLIDINEDIONE	O
INDAZOLES	O
,	O
INDOLES	O
AND	O
BENZOTRIAZOLES	O
AS	O
ESTROGEN	O
-	O
RELATED	O
RECEPTOR	O
-	O
α	O
MODULATORS	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
methods	O
for	O
preparing	O
these	O
compounds	O
,	O
compositions	O
,	O
intermediates	O
and	O
derivatives	O
thereof	O
and	O
for	O
treating	O
a	O
condition	O
including	O
but	O
not	O
limited	O
to	O
ankylosing	O
spondylitis	O
,	O
artherosclerosis	O
,	O
arthritis	O
(	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
infectious	O
arthritis	O
,	O
childhood	O
arthritis	O
,	O
psoriatic	O
arthritis	O
,	O
reactive	O
arthritis	O
)	O
,	O
bone	O
-	O
related	O
diseases	O
(	O
including	O
those	O
related	O
to	O
bone	O
formation	O
)	O
,	O
breast	O
cancer	O
(	O
including	O
those	O
unresponsive	O
to	O
anti	O
-	O
estrogen	O
therapy	O
)	O
,	O
cardiovascular	O
disorders	O
,	O
cartilage	O
-	O
related	O
disease	O
(	O
such	O
as	O
cartilage	O
injury	O
/	O
loss	O
,	O
cartilage	O
degeneration	O
,	O
and	O
those	O
related	O
to	O
cartilage	O
formation	O
)	O
,	O
chondrodysplasia	O
,	O
chondrosarcoma	O
,	O
chronic	O
back	O
injury	O
,	O
chronic	O
bronchitis	O
,	O
chronic	O
inflammatory	O
airway	O
disease	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
diabetes	O
,	O
disorders	O
of	O
energy	O
homeostasis	O
,	O
gout	O
,	O
pseudogout	O
,	O
lipid	O
disorders	O
,	O
metabolic	O
syndrome	O
,	O
multiple	O
myeloma	O
,	O
obesity	O
,	O
osteoarthritis	O
,	O
osteogenesis	O
imperfecta	O
,	O
osteolytic	O
bone	O
metastasis	O
,	O
osteomalacia	O
,	O
osteoporosis	O
,	O
Paget	O
's	O
disease	O
,	O
periodontal	O
disease	O
,	O
polymyalgia	O
rheumatica	O
,	O
Reiter	O
's	O
syndrome	O
,	O
repetitive	O
stress	O
injury	O
,	O
hyperglycemia	O
,	O
elevated	O
blood	O
glucose	O
level	O
,	O
and	O
insulin	O
resistance	O
.	O

Xenon	O
-	O
based	O
inhalable	O
drug	O
for	O
preventing	O
addiction	O
relapses	O
in	O
humans	O
The	O
invention	O
relates	O
to	O
a	O
gas	O
composition	O
containing	O
xenon	O
gas	O
for	O
use	O
in	O
preventing	O
the	O
relapse	O
of	O
a	O
patient	O
who	O
has	O
been	O
weaned	O
from	O
at	O
least	O
one	O
psychotropic	O
product	O
which	O
resulted	O
in	O
said	O
patient	O
becoming	O
habituated	O
,	O
the	O
xenon	O
being	O
administered	O
to	O
the	O
patient	O
by	O
inhalation	O
.	O

The	O
composition	O
of	O
the	O
invention	O
contains	O
an	O
effective	O
volume	O
proportion	O
of	O
xenon	O
,	O
in	O
particular	O
from	O
5	O
to	O
70	O
%	O
by	O
volume	O
of	O
xenon	O
.	O

DRAWING	O
:	O
FIG	O
.	O

5	O
:	O
Nombres	O
de	O
pression	O
sur	O
le	O
levier	O
/	O
session	O
Number	O
of	O
presses	O
on	O
the	O
lever	O
/	O
session	O
Levier	O
respectif	O
inactif	O
Respective	O
inactive	O
lever	O
rechute	O
relapse	O

A	O
role	O
for	O
somatostatin	O
to	O
modulate	O
initiation	O
of	O
follicular	O
growth	O
in	O
the	O
human	O
ovary	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
and/or	O
preventing	O
gynecological	O
diseases	O
,	O
by	O
modulating	O
a	O
receptor	O
which	O
is	O
specifically	O
and	O
highly	O
expressed	O
in	O
granulosa	O
cells	O
and	O
oocytes	O
of	O
primates	O
.	O

6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	O
-	O
based	O
composition	O
and	O
method	O
for	O
the	O
production	O
thereof	O
The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
industry	O
,	O
and	O
specifically	O
to	O
a	O
composition	O
based	O
on	O
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	O
(	O
ubinone	O
,	O
ubiquinone	O
,	O
coenzyme	O
Q10	O
)	O
in	O
liquid	O
form	O
,	O
which	O
can	O
be	O
used	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
various	O
illnesses	O
,	O
for	O
restoring	O
fitness	O
for	O
work	O
,	O
and	O
also	O
as	O
a	O
food	O
additive	O
.	O

In	O
addition	O
to	O
the	O
active	O
substance	O
,	O
the	O
composition	O
comprises	O
a	O
nonionic	O
surface	O
-	O
active	O
substance	O
,	O
an	O
antioxidant	O
,	O
a	O
preservative	O
,	O
a	O
fat	O
-	O
soluble	O
emulsion	O
stabilizer	O
,	O
water	O
-	O
soluble	O
cellulose	O
derivatives	O
,	O
a	O
water	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
water	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
high	O
bioaccessibility	O
and	O
an	O
extended	O
storage	O
life	O
.	O

The	O
method	O
for	O
producing	O
the	O
composition	O
consists	O
in	O
that	O
the	O
nonionic	O
surface	O
-	O
active	O
substance	O
and	O
the	O
antioxidant	O
are	O
mixed	O
and	O
heated	O
to	O
40	O
-	O
120	O
°	O
C	O
,	O
the	O
fat	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	O
are	O
dissolved	O
in	O
the	O
solution	O
produced	O
,	O
the	O
resultant	O
mixture	O
is	O
cooled	O
to	O
30	O
-	O
60	O
°	O
С	O
and	O
poured	O
under	O
intensive	O
stirring	O
into	O
a	O
mixed	O
solution	O
,	O
preheated	O
to	O
30	O
-	O
100	O
°	O
С	O
,	O
of	O
the	O
water	O
-	O
soluble	O
cellulose	O
derivatives	O
,	O
water	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
preservative	O
in	O
water	O
.	O

6-	O
(	O
sulfonylaryl	O
)	O
pyrido	O
[	O
2,3-d	O
]	O
pyrimidin-7	O
(	O
8h	O
)	O
-ones	O
for	O
the	O
treatment	O
of	O
cns	O
disorders	O
Provided	O
herein	O
are	O
PAK	B
inhibitors	O
and	O
methods	O
of	O
utilizing	O
PAK	B
inhibitors	O
for	O
the	O
treatment	O
of	O
CNS	O
disorders	O
such	O
as	O
neuropsychiatric	O
disoders	O
.	O

Anti	O
-	O
wssv	O
and/or	O
tsv	O
nucleic	O
acid	O
drug	O
An	O
anti	O
-	O
WSSV	O
and/or	O
TSV	O
nucleic	O
acid	O
drug	O
,	O
the	O
active	O
ingredients	O
of	O
which	O
are	O
five	O
nucleic	O
acids	O
whose	O
nucleotide	O
sequences	O
are	O
respectively	O
sequence	O
1	O
,	O
sequence	O
2	O
,	O
sequence	O
3	O
,	O
sequence	O
4	O
and	O
sequence	O
5	O
in	O
the	O
sequence	O
list	O
.	O

Amids	O
substituted	O
indazole	O
derivativees	O
as	O
ploy	B
(	I
adp	I
-	I
ribose	I
)	I
polymerase	I
inhibitors	O
Amide	O
substituted	O
indazoles	O
and	O
benzotriazoles	O
as	O
inhibitors	O
of	O
the	O
enzyme	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
(	O
PARP	B
)	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
mono	O
-	O
therapies	O
in	O
tumors	O
with	O
specific	O
defects	O
in	O
DNA	O
-	O
repair	O
pathways	O
,	O
as	O
enhancers	O
of	O
certain	O
DNA	O
-	O
damaging	O
agents	O
such	O
as	O
anticancer	O
agents	O
and	O
radiotherapy	O
,	O
for	O
reducing	O
cell	O
necrosis	O
(	O
in	O
stroke	O
and	O
myocardial	O
infarction	O
)	O
,	O
regulating	O
inflammation	O
and	O
tissue	O
injury	O
,	O
treating	O
retroviral	O
infections	O
,	O
and	O
protecting	O
against	O
the	O
toxicity	O
of	O
chemotherapy	O
.	O

Nitrogenated	O
aromatic	O
heterocyclic	O
ring	O
derivative	O
A	O
nitrogenated	O
aromatic	O
heterocyclic	O
ring	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
R1	O
and	O
R2	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
W	O
represents	O
CR3	O
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
;	O
R9	O
represents	O
a	O
pyrazolyl	O
group	O
which	O
may	O
have	O
a	O
substituent	O
,	O
or	O
the	O
like	O
;	O
and	O
R12	O
and	O
R13	O
independently	O
represent	O
a	O
hydrogen	O
atom	O
or	O
the	O
like	O
]	O
(	O
wherein	O
N-	O
[	O
2-chloro-4-	O
(	O
6,7-dimethoxy-4-	O
quinolyloxy	O
)	O
phenyl	O
]	O
-N'-	O
(	O
5-methyl-3-isooxazolyl	O
)	O
urea	O
is	O
excluded	O
from	O
the	O
derivative	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
FGFR	B
inhibitor	O
or	O
the	O
like	O
which	O
comprises	O
the	O
derivative	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
as	O
an	O
active	O
ingredient	O
.	O

Polydeoxyribonucleotides	O
(	O
pdrns	O
)	O
for	O
use	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
and	O
polydeoxyribonucleotide	O
-	O
based	O
compositions	O
for	O
the	O
aforesaid	O
use	O
The	O
use	O
of	O
polydeoxyribonucleotides	O
(	O
PDRNs	O
)	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
conditions	O
is	O
described	O
.	O

Compositions	O
comprising	O
the	O
synergistic	O
combination	O
of	O
polydeoxyribonucleotides	O
and	O
one	O
methyl	O
amide	O
,	O
such	O
as	O
carnitine	O
,	O
are	O
also	O
described	O
,	O
which	O
are	O
particularly	O
effective	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
conditions	O
.	O

The	O
compositions	O
of	O
the	O
invention	O
may	O
include	O
further	O
optional	O
active	O
ingredients	O
,	O
such	O
as	O
a	O
calcium	O
salt	O
,	O
vitamins	O
of	O
the	O
D	O
or	O
B	O
groups	O
,	O
a	O
sodium	O
salt	O
and	O
a	O
potassium	O
salt	O
,	O
preferably	O
used	O
in	O
combination	O
.	O

Novel	O
polymorph	O
of	O
bis	O
[	O
(	O
e	O
)	O
-7-	O
[	O
4-	O
(	O
4-fluorophenyl	O
)	O
-6-iso	O
-	O
propyl-2-	O
[	O
methyl	O
(	O
methylsulfonyl	O
)	O
amino	O
]	O
pyrimidin-5-yl	O
]	O
(	O
3r,5s	O
)	O
-3,5-dihydroxyhept-6-enoic	O
acid	O
]	O
calcium	O
salt	O
Disclosed	O
are	O
novel	O
polymorphic	O
forms	O
of	O
bis	O
[	O
(	O
E	O
)	O
-7-	O
[	O
4-	O
(	O
4-fluorophenyl	O
)	O
-6-iso	O
-	O
propyl-2-	O
[	O
methyl	O
(	O
methylsulfonyl	O
)	O
amino	O
]	O
pyrimidin-5-yl	O
]	O
(	O
3R,5S	O
)	O
-3,5-dihydroxyhept-6-enoic	O
acid	O
]	O
calcium	O
.	O

Composition	O
suppressing	O
matrix	B
-	I
metalloproteinase	I
activity	O
The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
composition	O
that	O
has	O
the	O
effect	O
of	O
suppressing	O
matrix	B
-	I
metalloproteinase	I
activity	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
pertains	O
to	O
a	O
composition	O
which	O
suppresses	O
matrix	B
-	I
metalloproteinase	I
activity	O
and	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
glucose	O
-	O
metabolism	O
inhibitor	O
.	O

Novel	O
antibiotically	O
active	O
compound	O
and	O
an	O
antibiotic	O
composition	O
comprising	O
the	O
compound	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
antibiotically	O
active	O
compound	O
and	O
to	O
an	O
antibiotic	O
composition	O
comprising	O
the	O
compound	O
,	O
and	O
more	O
specifically	O
relates	O
to	O
a	O
compound	O
that	O
inhibits	O
microorganism	O
protein	O
synthesis	O
and	O
to	O
a	O
use	O
for	O
the	O
compound	O
.	O

Atorbastatin	O
-	O
containing	O
medicinal	O
tablet	O
Provided	O
is	O
a	O
medicinal	O
tablet	O
,	O
particularly	O
an	O
orally	O
disintegrating	O
tablet	O
,	O
in	O
which	O
unpleasant	O
taste	O
of	O
atorbastatin	O
in	O
the	O
oral	O
cavity	O
is	O
reduced	O
(	O
drug	O
compliance	O
)	O
,	O
and	O
which	O
can	O
be	O
dispersed	O
or	O
eluted	O
rapidly	O
in	O
the	O
digestive	O
tract	O
.	O

This	O
medicinal	O
tablet	O
comprises	O
atorbastatin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
glycyrrhetinic	O
acid	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Isoxazol-3	O
(	O
2h	O
)	O
-one	O
analogs	O
as	O
plasminogen	B
inhibitors	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
fibrinolysis	O
related	O
diseases	O
A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
hydrogen	O
;	O
R2	O
is	O
C1-C10	O
alkyl	O
,	O
which	O
C1-C10	O
alkyl	O
comprises	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
heteroatoms	O
,	O
selected	O
from	O
O	O
and	O
N	O
,	O
or	O
0	O
,	O
1	O
or	O
2	O
acid	O
,	O
ester	O
or	O
amide	O
functionalities	O
,	O
and	O
said	O
C1-C10	O
alkyl	O
is	O
substituted	O
by	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
CH3	O
,	O
halogen	O
or	O
CF3	O
,	O
or	O
-XR20	O
,	O
wherein	O
X	O
is	O
a	O
bond	O
or	O
_	O
-CH2-	O
,	O
and	O
R20	O
is	O
a	O
4	O
to	O
10	O
membered	O
,	O
monocyclic	O
or	O
bicyclic	O
heterocyclic	O
aromatic	O
or	O
non	O
-	O
aromatic	O
ring	O
containing	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
heteroatoms	O
selected	O
from	O
O	O
and	O
N	O
,	O
and	O
R20	O
is	O
substituted	O
by	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
CH3	O
,	O
halogen	O
or	O
CF3	O
,	O
pharmaceutical	O
compositions	O
,	O
medical	O
uses	O
and	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
disease	O
or	O
condition	O
in	O
which	O
modulation	O
of	O
fibrinolysisis	O
is	O
beneficial	O
.	O

Phosphatidylcholine	O
in	O
the	O
treatment	O
ophosphatidylcholinef	O
tumours	O
The	O
present	O
invention	O
regards	O
the	O
use	O
of	O
phosphatidylcholine	O
in	O
the	O
treatment	O
of	O
tumoral	O
pathologies	O
.	O

In	O
particular	O
,	O
the	O
phosphatidylcholine	O
according	O
to	O
the	O
present	O
invention	O
is	O
polyunsaturated	O
phosphatidylcholine	O
.	O

The	O
phosphatidylcholine	O
suitable	O
for	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
extraction	O
from	O
egg	O
-	O
yolk	O
or	O
from	O
soybean	O
seeds	O
.	O

The	O
tumoral	O
pathologies	O
that	O
can	O
be	O
treated	O
according	O
to	O
the	O
invention	O
are	O
in	O
particular	O
hepatoma	O
and	O
mammary	O
tumour	O
.	O

Novel	O
esters	O
of	O
(	O
acyloxymethyl	O
)	O
acrylamide	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
,	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
the	O
thioredoxin	O
-	O
thioredoxin	B
reductase	I
system	O
The	O
subject	O
of	O
the	O
present	O
invention	O
are	O
novel	O
esters	O
of	O
(	O
acyloxymethyl	O
)	O
acrylamide	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
production	O
of	O
drugs	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
oncogenic	O
diseases	O
and	O
diseases	O
connected	O
with	O
increased	O
cell	O
proliferation	O
.	O

Agent	O
for	O
inducing	O
endogenous	O
interferon	O
The	O
invention	O
relates	O
to	O
medicine	O
and	O
can	O
be	O
used	O
for	O
treating	O
a	O
range	O
of	O
diseases	O
in	O
the	O
treatment	O
of	O
which	O
interferon	O
is	O
used	O
.	O

The	O
agent	O
for	O
inducing	O
endogenous	O
interferon	O
is	O
comprised	O
of	O
the	O
compound	O
6-	O
(	O
3-methoxycarbonyl	O
phenyl	O
)	O
amino-2,4	O
(	O
1Н	O
,	O
ЗН	O
)	O
-pyrimidinedione	O
C12H11N3О4	O
of	O
general	O
formula	O
:	O
(	O
I	O
)	O
.	O

The	O
preparation	O
exhibits	O
greater	O
activity	O
both	O
when	O
injected	O
and	O
when	O
administered	O
orally	O
.	O

Intraesophageal	O
administration	O
of	O
targeted	O
nitroxide	O
agents	O
for	O
protection	O
against	O
ionizing	O
irradiation	O
-	O
induced	O
esophagatis	O
Provided	O
herein	O
are	O
compositions	O
and	O
related	O
methods	O
useful	O
for	O
prevention	O
or	O
mitigation	O
of	O
ionizing	O
radiation	O
-	O
induced	O
esophagitis	O
.	O

The	O
compositions	O
comprise	O
compounds	O
comprising	O
a	O
nitroxide	O
-	O
containing	O
group	O
attached	O
to	O
a	O
mitochondria	O
-	O
targeting	O
group	O
.	O

The	O
compounds	O
can	O
be	O
cross	O
-	O
linked	O
into	O
dimers	O
without	O
loss	O
of	O
activity	O
.	O

The	O
method	O
comprises	O
delivering	O
a	O
compound	O
,	O
as	O
described	O
herein	O
,	O
to	O
a	O
patient	O
in	O
an	O
amount	O
and	O
dosage	O
regimen	O
effective	O
to	O
prevent	O
or	O
mitigate	O
esophageal	O
damage	O
caused	O
by	O
radiation	O
.	O

Therapeutic	O
compositions	O
comprising	O
rilpivirine	O
hcl	O
and	O
tenofovir	O
disoproxil	O
fumarate	O
The	O
invention	O
provides	O
multilayer	O
tablets	O
that	O
contain	O
rilpivirine	O
hydrochloride	O
,	O
emtricitabine	O
,	O
and	O
tenofivir	O
disoproxil	O
fumarate	O
.	O

The	O
tablets	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV	O
.	O

Composition	O
and	O
use	O
of	O
a	O
fermented	O
olive	O
leaf	O
product	O
for	O
the	O
treatment	O
of	O
nail	O
and	O
skin	O
infections	O
.	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
the	O
treatment	O
of	O
nail	O
infections	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
olive	O
leaf	O
product	O
,	O
and	O
oleuropein	O
and	O
derivatives	O
thereof	O
,	O
for	O
the	O
preparation	O
of	O
a	O
product	O
for	O
the	O
treatment	O
of	O
infections	O
,	O
in	O
particular	O
nail	O
infections	O
,	O
more	O
in	O
particular	O
bacterial	O
and/or	O
fungal	O
nail	O
infections	O
.	O

The	O
compositions	O
according	O
to	O
the	O
invention	O
are	O
based	O
on	O
natural	O
products	O
and	O
have	O
a	O
lower	O
chance	O
to	O
induce	O
allergies	O
in	O
users	O
than	O
conventional	O
products	O
.	O

Antifungal	O
composition	O
including	O
polycyclic	O
peptide	O
compound	O
and	O
method	O
for	O
producing	O
same	O
The	O
present	O
invention	O
provides	O
an	O
antifungal	O
composition	O
including	O
as	O
an	O
active	O
ingredient	O
a	O
AN1542	O
strain	O
(	O
accession	O
number	O
:	O
KCTC	O
12113BP	O
)	O
in	O
a	O
Streptomyces	O
sp.	O
having	O
antifungal	O
activity	O
,	O
an	O
antifungal	O
composition	O
including	O
a	O
compound	O
represented	O
by	O
Formula	O
1	O
or	O
Formula	O
2	O
or	O
a	O
strain	O
producing	O
same	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
.	O

The	O
compound	O
or	O
the	O
strain	O
of	O
the	O
present	O
invention	O
exhibits	O
strong	O
antifungal	O
activity	O
to	O
pathogenic	O
microorganisms	O
and	O
antibiotics	O
-	O
tolerant	O
bacteria	O
,	O
and	O
in	O
particular	O
,	O
can	O
be	O
useful	O
in	O
treating	O
contagious	O
diseases	O
due	O
to	O
super	O
bacteria	O
by	O
exhibiting	O
strong	O
antifungal	O
activity	O
to	O
MRSA	O
,	O
QRSA	O
,	O
VRSA	O
,	O
and	O
VRE	O
.	O

Pyrazole	O
derivatives	O
as	O
erk	B
inhibitors	O
This	O
invention	O
describes	O
substituted	O
pyrazole	O
derivatives	O
of	O
Formula	O
I	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O

These	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
or	O
diseases	O
in	O
which	O
modification	O
of	O
the	O
activity	O
of	O
ERK	B
would	O
have	O
a	O
positive	O
therapeutic	O
outcome	O
,	O
for	O
instance	O
various	O
cancers	O
,	O
psoriasis	O
and	O
actinic	O
keratosis	O
.	O

Therapeutic	O
eye	O
drop	O
comprising	O
doxycycline	O
and	O
a	O
stabilizer	O
The	O
present	O
invention	O
provides	O
stable	O
aqueous	O
doxycycline	O
aqueous	O
solutions	O
suitable	O
for	O
pharmaceutical	O
,	O
especially	O
ophthalmic	O
,	O
use	O
.	O

The	O
doxycycline	O
aqueous	O
solutions	O
have	O
a	O
pH	O
ranging	O
from	O
4.5	O
-	O
8	O
,	O
and	O
contain	O
an	O
antioxidant	O
and	O
a	O
stabilizer	O
such	O
as	O
caffeine	O
,	O
creatine	O
or	O
mixtures	O
thereof	O
.	O

The	O
solutions	O
have	O
improved	O
lifetimes	O
and	O
can	O
be	O
used	O
topically	O
.	O

Dextrin	O
inclusion	O
complex	O
,	O
preparation	O
method	O
thereof	O
and	O
pharmaceutical	O
formulation	O
comprising	O
said	O
inclusion	O
complex	O
A	O
dextrin	O
inclusion	O
complex	O
of	O
total	O
ginsenoside	O
and	O
total	O
flavone	O
of	O
epimedium	O
and	O
the	O
preparation	O
method	O
thereof	O
are	O
disclosed	O
.	O

A	O
pharmaceutical	O
formulation	O
comprising	O
the	O
dextrin	O
inclusion	O
complex	O
and	O
the	O
use	O
of	O
the	O
dextrin	O
inclusion	O
complex	O
in	O
preparing	O
a	O
pharmaceutical	O
formulation	O
are	O
also	O
disclosed	O
.	O

Fucoidan	O
for	O
thrombolysis	O
,	O
derived	O
from	O
seaweed	O
To	O
study	O
different	O
types	O
of	O
thrombolytic	O
agents	O
,	O
both	O
thrombolysis	O
and	O
stimulation	O
of	O
fucoidan	O
were	O
studied	O
in	O
a	O
mouse	O
model	O
of	O
ferric	O
chloride	O
-	O
induced	O
arterial	O
thrombosis	O
and	O
were	O
compared	O
with	O
those	O
of	O
a	O
heparin	O
and	O
tissue	B
plasminogen	I
activator	I
(	O
t	B
-	I
PA	I
)	O
.	O

Thrombosis	O
was	O
induced	O
by	O
applying	O
a	O
filter	O
paper	O
saturated	O
with	O
5	O
%	O
FeCl3	O
to	O
the	O
left	O
carotid	O
artery	O
.	O

20	O
minutes	O
after	O
complete	O
occlusion	O
,	O
several	O
test	O
preparations	O
including	O
a	O
fucoidan	O
source	O
from	O
Undaria	O
pinnatifida	O
sporophylls	O
were	O
intravenously	O
injected	O
to	O
each	O
mouse	O
group	O
by	O
various	O
dosages	O
of	O
10	O
-	O
200	O
mg	O
/	O
kg-1	O
.	O

To	O
study	O
the	O
stimulation	O
effect	O
of	O
fucoidan	O
with	O
respect	O
to	O
t	B
-	I
PA	I
,	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t	B
-	I
PA	I
was	O
injected	O
by	O
a	O
dose	O
of	O
1	O
-	O
10	O
mg	O
/	O
kg	O
.	O

Then	O
,	O
the	O
time	O
to	O
reperfusion	O
was	O
measured	O
.	O

As	O
a	O
result	O
,	O
an	O
occluded	O
aorta	O
was	O
dose	O
-	O
dependently	O
reperfused	O
,	O
and	O
the	O
reperfusion	O
was	O
observed	O
at	O
37.5±12.4	O
minutes	O
after	O
the	O
administration	O
of	O
100	O
mg	O
/	O
kg-1	O
of	O
unfractionated	O
fucoidan	O
.	O

The	O
time	O
to	O
reperfusion	O
was	O
retarded	O
to	O
55.0±8.0	O
minutes	O
when	O
a	O
large	O
amount	O
of	O
fucoidan	O
such	O
as	O
1	O
g	O
/	O
kg-1	O
was	O
administered	O
to	O
a	O
mouse	O
provided	O
with	O
low	O
molecular	O
weight	O
fucoidan	O
(	O
LMWF	O
)	O
.	O

Reperfusion	O
occurred	O
at	O
16.67	O
minutes	O
after	O
administration	O
in	O
a	O
mouse	O
of	O
a	O
control	O
group	O
provided	O
with	O
20	O
mg	O
/	O
kg-1	O
of	O
t	B
-	I
PA	I
.	O

On	O
the	O
contrary	O
,	O
reperfusion	O
was	O
not	O
observed	O
in	O
an	O
occluded	O
mouse	O
provided	O
with	O
heparin	O
(	O
p<0.01	O
)	O
.	O

The	O
occluded	O
artery	O
was	O
recovered	O
without	O
reperfusion	O
at	O
17.2	O
minutes	O
after	O
injection	O
if	O
the	O
least	O
amount	O
of	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t	B
-	I
PA	I
was	O
provided	O
.	O

All	O
the	O
data	O
show	O
that	O
fucoidan	O
can	O
serve	O
as	O
both	O
a	O
thrombolytic	O
agent	O
and	O
a	O
stimulant	O
with	O
respect	O
to	O
thrombolysis	O
activation	O
of	O
t	B
-	I
PA	I
in	O
a	O
thrombosis	O
model	O
,	O
differently	O
from	O
heparin	O
.	O

Treatment	O
of	O
severe	O
persitent	O
asthma	O
with	O
masitinib	O
The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
severe	O
persistent	O
asthma	O
,	O
and	O
in	O
particular	O
severe	O
persistent	O
corticosteroid	O
-	O
dependent	O
or	O
corticosteroid	O
-	O
resistant	O
asthma	O
,	O
comprising	O
administration	O
a	O
tyrosine	O
kinase	O
inhibitor	O
or	O
a	O
mast	O
cell	O
inhibitor	O
,	O
especially	O
masitinib	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Anti	O
-	O
angiogenic	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
same	O
,	O
and	O
use	O
thereof	O
The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
A	O
)	O
having	O
an	O
anti	O
-	O
angiogenic	O
and/or	O
anti	O
-	O
tumoral	O
activity	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
same	O
,	O
and	O
to	O
the	O
use	O
thereof	O
for	O
treating	O
cancer	O
.	O

(	O
substituted	O
)	O
N-	O
(	O
CH2	O
)	O
m	O
-	O
A	O
-	O
Rc	O
where	O
A	O
is	O
a	O
bond	O
,	O
Het-	O
(	O
CH2	O
)	O
1	O
-	O
6	O
or	O
NH-	O
(	O
CH2	O
)	O
1	O
-	O
6	O
and	O
Rc	O
is	O
O	O
-	O
substituted	O
or	O
N	O
-	O
substituted	O
.	O

4-aminoalcoholquinoline	O
derivatives	O
,	O
enantioselective	O
synthesis	O
methods	O
and	O
the	O
use	O
thereof	O
The	O
present	O
invention	O
is	O
intended	O
to	O
provide	O
new	O
antimalarial	O
compounds	O
with	O
a	O
strong	O
antimalarial	O
activity	O
as	O
well	O
as	O
antibacterial	O
activity	O
with	O
few	O
neurological	O
side	O
effects	O
and	O
a	O
new	O
enantioselective	O
pathway	O
to	O
mefloquine	O
amino	O
-	O
analogs	O
allowing	O
the	O
access	O
of	O
such	O
compounds	O
.	O

The	O
present	O
invention	O
relates	O
to	O
new	O
4	O
-aminoalcohol	O
quinoline	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
the	O
synthesis	O
methods	O
and	O
the	O
uses	O
of	O
such	O
derivatives	O
.	O

In	O
which	O
Y	O
is	O
one	O
selected	O
from	O
formulae	O
(	O
II	O
)	O
to	O
(	O
III	O
)	O
.	O

In	O
which	O
Z	O
is	O
selected	O
from	O
formulae	O
(	O
IV	O
)	O
to	O
(	O
VI	O
)	O
,	O
and	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O

Cell	O
therapy	O
composition	O
for	O
preventing	O
or	O
treating	O
immune	O
disease	O
comprising	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
t	O
-	O
cells	O
as	O
active	O
ingredient	O
The	O
present	O
invention	O
relates	O
to	O
a	O
cell	O
therapy	O
composition	O
for	O
preventing	O
or	O
treating	O
immune	O
disease	O
comprising	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
T	O
-	O
cells	O
as	O
an	O
active	O
ingredient	O
.	O

By	O
infusing	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
T	O
-	O
cells	O
,	O
which	O
are	O
the	O
cellular	O
therapeutic	O
agent	O
of	O
the	O
present	O
invention	O
,	O
into	O
bone	O
marrow	O
transplant	O
animals	O
,	O
rejection	O
to	O
the	O
host	O
is	O
suppressed	O
after	O
the	O
engraftment	O
of	O
transplanted	O
bone	O
-	O
marrow	O
to	O
thus	O
obtain	O
the	O
effect	O
of	O
reducing	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
and	O
immune	O
disease	O
.	O

Moreover	O
,	O
the	O
effect	O
of	O
such	O
GVHD	O
reduction	O
is	O
much	O
greater	O
than	O
the	O
one	O
obtained	O
when	O
only	O
mesenchymal	O
stem	O
cells	O
are	O
infused	O
.	O

Accordingly	O
,	O
the	O
cell	O
therapy	O
composition	O
of	O
the	O
present	O
invention	O
having	O
the	O
above	O
-	O
mentioned	O
effects	O
can	O
be	O
useful	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
immune	O
disease	O
.	O

Compositions	O
for	O
ameliorating	O
systemic	O
inflammation	O
and	O
methods	O
for	O
making	O
and	O
using	O
them	O
In	O
alternative	O
embodiments	O
the	O
invention	O
provides	O
compositions	O
,	O
e.g.	O
,	O
pharmaceutical	O
compositions	O
and	O
preparations	O
,	O
formulations	O
,	O
kits	O
and	O
other	O
products	O
of	O
manufacture	O
,	O
e.g.	O
,	O
exemplary	O
drug	O
combinations	O
packaged	O
together	O
or	O
separately	O
in	O
blister	O
packs	O
,	O
lidded	O
blisters	O
or	O
blister	O
cards	O
,	O
or	O
wrapped	O
in	O
paper	O
,	O
plastic	O
or	O
cellophane	O
wrappers	O
(	O
e.g.	O
,	O
a	O
shrink	O
wrap	O
)	O
,	O
comprising	O
a	O
combination	O
regimen	O
of	O
at	O
least	O
two	O
active	O
ingredients	O
designed	O
to	O
diminish	O
systemic	O
inflammation	O
by	O
targeting	O
(	O
inhibiting	O
)	O
two	O
different	O
,	O
but	O
convergent	O
,	O
signaling	O
pathways	O
,	O
i.e.	O
,	O
the	O
sympathetic	O
nervous	O
system	O
and	O
the	O
lipid-	O
derived	O
autacoid	O
system	O
;	O
and	O
methods	O
for	O
making	O
and	O
using	O
these	O
compositions	O
.	O

In	O
alternative	O
embodiments	O
,	O
the	O
compositions	O
of	O
the	O
invention	O
(	O
e.g.	O
,	O
the	O
combination	O
of	O
drugs	O
)	O
are	O
used	O
to	O
ameliorate	O
,	O
diminish	O
,	O
treat	O
,	O
block	O
or	O
prevent	O
an	O
inflammatory	O
response	O
secondary	O
to	O
an	O
infection	O
,	O
e.g.	O
,	O
a	O
viral	O
infection	O
and/or	O
a	O
reactivation	O
.	O

Use	O
of	O
poly	O
(	O
4-styrene	O
sulfonic	O
acid	O
-	O
copoly	O
-	O
maleic	O
acid	O
)	O
sodium	O
salt	O
and	O
pharmaceutical	O
composition	O
thereof	O
Use	O
of	O
poly	O
(	O
4-styrene	O
sulfonic	O
acid	O
-	O
copoly	O
-	O
maleic	O
acid	O
)	O
sodium	O
salt	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
inhibiting	O
infection	O
of	O
HIV-1	O
and	O
pharmaceutical	O
composition	O
thereof	O
.	O

Said	O
pharmaceutical	O
composition	O
comprises	O
poly	O
(	O
4-styrene	O
sulfonic	O
acid	O
-	O
copoly	O
-	O
maleic	O
acid	O
)	O
sodium	O
salt	O
as	O
active	O
ingredient	O
and	O
conventional	O
pharmaceutical	O
carrier	O
.	O

A	O
COMPOUND	O
FOR	O
INHIBITING	O
HUMAN	B
11-β	I
-	I
HYDROXY	I
STEROID	I
DEHYDROGENASE	I
TYPE	I
1	I
,	O
AND	O
A	O
PHARMACEUTICAL	O
COMPOSITION	O
COMPRISING	O
THE	O
SAME	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
,	O
or	O
a	O
stereoisomer	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
(	O
11β	B
-	I
HSD1	I
)	O
comprising	O
the	O
same	O
.	O

The	O
invention	O
provides	O
a	O
compound	O
,	O
which	O
has	O
excellent	O
activity	O
and	O
solubility	O
and	O
is	O
more	O
efficiently	O
formulated	O
and	O
delivered	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta	B
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
1	I
comprising	O
the	O
same	O
.	O

Method	O
for	O
treatment	O
of	O
xeroderma	O
pigmentosum	O
This	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
xeroderma	O
pigmentosum	O
and	O
related	O
symptoms	O
in	O
patients	O
by	O
administering	O
a	O
MC1R	O
before	O
or	O
after	O
exposing	O
them	O
to	O
visible	O
light	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
or	O
prophylaxis	O
of	O
neurogenic	O
diseases	O
The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
product	O
which	O
has	O
a	O
sufficient	O
curative	O
effect	O
on	O
multiple	O
sclerosis	O
and	O
has	O
excellent	O
autoimmune	O
inhibitory	O
activity	O
,	O
while	O
being	O
reduced	O
in	O
the	O
side	O
effects	O
which	O
steroidal	O
agents	O
and	O
interferon	O
β	O
have	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
multiple	O
sclerosis	O
,	O
which	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
4-	O
(	O
2-aminopyridin-4-yl	O
)	O
-3-	O
(	O
4-fluorophenyl	O
)	O
-1-	O
(	O
1,4,5,6-tetrahydro-6-oxopyridazin-3-yl	O
)	O
-1H	O
-	O
pyrazole	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Novel	O
cephalosporin	O
derivative	O
and	O
medical	O
composition	O
containing	O
same	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
cephalosporin	O
derivative	O
indicated	O
in	O
chemical	O
formula	O
1	O
of	O
the	O
description	O
.	O

In	O
the	O
chemical	O
formula	O
1	O
,	O
X	O
,	O
Y	O
,	O
L	O
,	O
R1	O
,	O
R2	O
are	O
identical	O
as	O
defined	O
in	O
the	O
detailed	O
explanation	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
an	O
antibiotic	O
medical	O
composition	O
containing	O
the	O
novel	O
cephalosporin	O
derivative	O
of	O
the	O
chemical	O
formula	O
1	O
,	O
a	O
prodrug	O
thereof	O
,	O
a	O
hydrate	O
thereof	O
,	O
a	O
solvate	O
thereof	O
,	O
an	O
isomer	O
thereof	O
,	O
and	O
a	O
pharmaceutically	O
permitted	O
salt	O
thereof	O
,	O
as	O
active	O
ingredients	O
.	O

The	O
novel	O
cephalosporin	O
derivative	O
of	O
the	O
chemical	O
formula	O
1	O
,	O
the	O
prodrug	O
thereof	O
,	O
the	O
hydrate	O
thereof	O
,	O
the	O
solvate	O
thereof	O
,	O
the	O
isomer	O
thereof	O
,	O
and	O
the	O
pharmaceutically	O
permitted	O
salt	O
thereof	O
have	O
a	O
wide	O
antibacterial	O
spectrum	O
for	O
resistant	O
bacteria	O
,	O
have	O
low	O
toxicity	O
,	O
and	O
in	O
particular	O
,	O
show	O
strong	O
antibacterial	O
effect	O
on	O
gram	O
negative	O
bacteria	O
,	O
and	O
is	O
thus	O
useful	O
as	O
an	O
antibiotic	O
.	O

Methods	O
for	O
treating	O
heartburn	O
and/or	O
preventing	O
gastric	O
bleeding	O
or	O
hemorrhage	O
in	O
patients	O
receiving	O
clopidogrel	O
therapy	O
The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
heartburn	O
in	O
a	O
patient	O
receiving	O
clopidogrel	O
therapy	O
.	O

In	O
another	O
aspect	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
preventing	O
gastric	O
bleeding	O
or	O
hemorrhage	O
in	O
patients	O
receiving	O
clopidogrel	O
therapy	O
.	O

Solid	O
forms	O
of	O
antiretroviral	O
compounds	O
and	O
anti	O
-	O
oxidative	O
acids	O
,	O
processes	O
for	O
preparation	O
and	O
pharmaceutical	O
compositions	O
thereof	O
Disclosed	O
are	O
solid	O
forms	O
of	O
antiretroviral	O
compounds	O
and	O
anti	O
-	O
oxidative	O
acids	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

Pharmaceutical	O
compositions	O
using	O
the	O
solid	O
forms	O
are	O
also	O
disclosed	O
.	O

Acadesine	O
derivatives	O
,	O
products	O
and	O
compositions	O
including	O
same	O
,	O
therapeutic	O
uses	O
thereof	O
,	O
and	O
methods	O
for	O
synthesizing	O
same	O
The	O
invention	O
relates	O
to	O
acadesine	O
derivatives	O
as	O
a	O
drug	O
,	O
as	O
well	O
as	O
to	O
said	O
derivatives	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
particularly	O
for	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
product	O
containing	O
said	O
derivatives	O
and	O
at	O
least	O
one	O
second	O
active	O
ingredient	O
as	O
a	O
combination	O
product	O
to	O
be	O
simultaneously	O
or	O
separately	O
administered	O
,	O
or	O
administered	O
over	O
time	O
,	O
in	O
the	O
treatment	O
of	O
cancer	O
,	O
as	O
well	O
as	O
to	O
a	O
pharmaceutical	O
composition	O
including	O
said	O
derivatives	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Finally	O
,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
in	O
vitro	O
inhibition	O
of	O
the	O
proliferation	O
of	O
cells	O
,	O
including	O
contacting	O
a	O
cell	O
with	O
said	O
derivatives	O
in	O
vitro	O
,	O
and	O
to	O
methods	O
for	O
synthesizing	O
said	O
derivatives	O
.	O

2α	O
-	O
METHYL	O
AND	O
2β	O
-	O
METHYL	O
ANALOGS	O
OF	O
19,26-DINOR-1α	O
,	O
25-DIHYDROXYVITAMIN	O
D3	O
AND	O
THEIR	O
USES	O

This	O
invention	O
discloses	O
2α	O
-	O
methyl	O
and	O
2β	O
-	O
methyl	O
analogs	O
of	O
19,26-dinor-1α,25-dihydroxyvitamin	O
D3	O
and	O
pharmaceutical	O
uses	O
therefor	O
.	O

These	O
compounds	O
exhibit	O
in	O
vitro	O
biological	O
activities	O
evidencing	O
use	O
as	O
an	O
anti	O
-	O
cancer	O
agent	O
and	O
for	O
the	O
treatment	O
of	O
skin	O
diseases	O
such	O
as	O
psoriasis	O
as	O
well	O
as	O
skin	O
conditions	O
such	O
as	O
wrinkles	O
,	O
slack	O
skin	O
,	O
dry	O
skin	O
and	O
insufficient	O
sebum	O
secretion	O
.	O

These	O
compounds	O
have	O
little	O
,	O
if	O
any	O
,	O
in	O
vivo	O
calcemic	O
activity	O
and	O
therefore	O
may	O
be	O
used	O
to	O
treat	O
autoimmune	O
disorders	O
in	O
humans	O
as	O
well	O
as	O
secondary	O
hyperparathyroidism	O
and	O
renal	O
osteodystrophy	O
.	O

Anti	O
-	O
wrinkle	O
agent	O
,	O
matrix	B
metalloproteinase	I
(	O
mmp	B
)	O
inhibitor	O
and/or	O
laminin	O
5	O
production	O
promoter	O
,	O
each	O
comprising	O
1-piperidine	O
propionate	O
The	O
purpose	O
of	O
the	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
and	O
effective	O
anti	O
-	O
wrinkle	O
agent	O
.	O

The	O
invention	O
relates	O
to	O
a	O
matrix	B
metalloproteinase	I
(	O
MMP	B
)	O
inhibitor	O
and/or	O
laminin	O
5	O
production	O
promoter	O
,	O
as	O
well	O
as	O
an	O
anti	O
-	O
wrinkle	O
agent	O
,	O
each	O
of	O
which	O
comprises	O
1-piperidine	O
propionate	O
and/or	O
a	O
salt	O
thereof	O
.	O

Condensed	O
2	O
-	O
carbamoylpyridazinones	O
as	O
potassium	B
channel	I
modulators	O
Disclosed	O
herein	O
are	O
KCNQ	B
potassium	B
channels	I
modulators	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
ring	O
G1	O
,	O
R1	O
,	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Compositions	O
comprising	O
such	O
compounds	O
;	O
and	O
methods	O
for	O
treating	O
conditions	O
and	O
disorders	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
also	O
described	O
.	O

Erk	B
inhibitors	O
for	O
use	O
in	O
treating	O
spinal	O
muscular	O
atrophy	O
The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
spinal	O
muscular	O
atrophy	O
and	O
other	O
related	O
neuromuscular	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
said	O
method	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
ERK	B
inhibitor	O
,	O
such	O
as	O
Selumetinib	O
to	O
said	O
subject	O
.	O

Skin	O
treatment	O
method	O
River	O
rocks	O
are	O
used	O
in	O
a	O
therapy	O
regime	O
whereby	O
the	O
river	O
rocks	O
are	O
used	O
to	O
absorb	O
excess	O
oils	O
from	O
the	O
skin	O
of	O
a	O
user	O
.	O

In	O
one	O
method	O
,	O
river	O
rocks	O
arc	O
collected	O
from	O
a	O
source	O
(	O
e.g	O
..	O
river	O
or	O
supplier	O
)	O
,	O
sorted	O
for	O
size	O
and	O
color	O
,	O
engraved	O
with	O
logo	O
or	O
other	O
content	O
,	O
packaged	O
and	O
shipped	O
to	O
customers	O
or	O
retailers	O
with	O
instructions	O
on	O
use	O
.	O

Use	O
comprises	O
placement	O
of	O
the	O
river	O
rocks	O
on	O
oily	O
portions	O
of	O
the	O
user	O
's	O
skin	O
for	O
an	O
appropriate	O
time	O
period	O
allowing	O
the	O
river	O
rock	O
to	O
absorb	O
the	O
excess	O
oils	O
.	O

The	O
river	O
rocks	O
are	O
reusable	O
after	O
being	O
washed	O
with	O
mild	O
soap	O
and	O
water	O
.	O

Thiocarbamate	O
and	O
sulfonamide	O
hydroxamate	O
inhibitors	O
of	O
insulin	B
-	I
degrading	I
enzyme	I
This	O
disclosure	O
relates	O
to	O
pharmaceutical	O
compositions	O
useful	O
for	O
inhibiting	O
insulin	B
-	I
degrading	I
enzyme	I
(	O
IDE	B
)	O
and	O
methods	O
of	O
treating	O
disorders	O
involving	O
the	O
same	O
or	O
peptide	O
substrates	O
of	O
the	O
same	O
.	O

For	O
example	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
treating	O
diabetes	O
,	O
promotion	O
of	O
wound	O
healing	O
,	O
and	O
improvement	O
of	O
memory	O
.	O

Pharmaceutical	O
composition	O
comprising	O
a	O
trpa1	B
antagonist	O
and	O
a	O
leukotriene	O
receptor	O
antagonist	O
The	O
present	O
patent	O
application	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
transient	B
receptor	I
potential	I
ankyrin-1	I
receptor	I
(	O
""""	O
TRPA1	B
""""	O
)	O
antagonist	O
and	O
a	O
leukotriene	O
receptor	O
antagonist	O
.	O

Antifungal	O
composition	O
comprising	O
cis	O
-	O
cyclo	O
(	O
l	O
-	O
phe	O
-	O
l	O
-	O
pro	O
)	O
having	O
genus	O
ganoderma	O
fungus	O
-	O
specific	O
antifungal	O
activity	O
The	O
present	O
invention	O
provides	O
an	O
antifungal	O
composition	O
comprising	O
cis	O
-	O
cyclo	O
(	O
L	O
-	O
Phe	O
-	O
L	O
-	O
Pro	O
)	O
as	O
an	O
active	O
ingredient	O
and	O
having	O
Genus	O
Ganoderma	O
fungus	O
-	O
specific	O
antifungal	O
activity	O
,	O
an	O
insecticide	O
composition	O
,	O
and	O
a	O
method	O
for	O
producing	O
an	O
antifungal	O
agent	O
for	O
Genus	O
Ganoderma	O
fungi	O
.	O

The	O
present	O
invention	O
exhibits	O
superior	O
antifungal	O
activity	O
to	O
the	O
Genus	O
Ganoderma	O
fungi	O
(	O
especially	O
,	O
to	O
Ganoderma	O
boninense	O
fungi	O
)	O
and	O
thus	O
can	O
be	O
applied	O
to	O
various	O
industrial	O
fields	O
requiring	O
removal	O
and	O
prevention	O
of	O
Genus	O
Ganoderma	O
fungi	O
,	O
and	O
is	O
economically	O
advantageous	O
in	O
terms	O
of	O
usage	O
due	O
to	O
the	O
antifungal	O
activity	O
even	O
with	O
a	O
small	O
amount	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
provides	O
basic	O
material	O
as	O
a	O
biological	O
agent	O
regarding	O
cis	O
-	O
cyclo	O
(	O
L	O
-	O
Phe	O
-	O
L	O
-	O
Pro	O
)	O
to	O
the	O
insecticide	O
industry	O
which	O
uses	O
biological	O
agents	O
.	O

Tricyclic	O
heterocyclic	O
compounds	O
as	O
kinase	B
inhibitors	O
There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
X	O
,	O
R3	O
and	O
R4	O
have	O
meanings	O
given	O
in	O
the	O
description	O
(	O
and	O
which	O
compounds	O
are	O
optionally	O
substituted	O
as	O
indicated	O
in	O
the	O
description	O
)	O
,	O
and	O
pharmaceutically	O
-	O
acceptable	O
esters	O
,	O
amides	O
,	O
solvates	O
or	O
salts	O
thereof	O
,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
a	O
protein	O
or	O
lipid	O
kinase	O
(	O
e.g.	O
a	O
PIM	B
family	I
kinase	O
,	O
such	O
as	O
PIM-1	B
,	O
PIM-2	B
and/or	O
PIM-3	B
)	O
is	O
desired	O
and/or	O
required	O
,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
cancer	O
or	O
a	O
proliferative	O
disease	O
.	O

There	O
is	O
also	O
provided	O
combinations	O
comprising	O
the	O
compounds	O
of	O
formula	O
I.	O

Tricyclic	O
inhibitors	O
of	O
kinases	B
useful	O
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
,	O
B	O
,	O
and	O
n	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
present	O
invention	O
relates	O
also	O
to	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	B
such	O
as	O
wee-1	O
and	O
methods	O
of	O
treating	O
diseases	O
such	O
as	O
cancer	O
.	O

Spirocyclic	O
molecules	O
as	O
protein	B
kinase	I
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
spirocyclic	O
compounds	O
of	O
formula	O
I	O
,	O
namely	O
spirocyclic	O
(	O
1H	O
-	O
pyrazol-4-yl	O
)	O
-3-	O
(	O
1-	O
(	O
2,6-dichloro-3-	O
fiuorophenyl	O
)	O
ethoxy	O
)	O
pyridin-2-amines	O
having	O
protein	B
kinase	I
inhibitory	O
activity	O
,	O
and	O
methods	O
of	O
synthesizing	O
and	O
using	O
such	O
compounds	O
.	O

Preferred	O
compounds	O
are	O
c	B
-	I
Met	I
and/or	O
ALK	B
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
abnormal	O
cell	O
growth	O
,	O
such	O
as	O
cancers	O
.	O

Composition	O
containing	O
5-hydroxyindole	O
compounds	O
or	O
sponge	O
scalarispongia	O
sp.	O
extracts	O
as	O
active	O
ingredients	O
for	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
5-hydroxyindole	O
compounds	O
or	O
sponge	O
Scalarispongia	O
sp.	O
extracts	O
as	O
active	O
ingredients	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
,	O
and	O
more	O
specifically	O
,	O
the	O
novel	O
compound	O
or	O
the	O
Scalarispongia	O
sp.	O
extract	O
and	O
more	O
specifically	O
,	O
the	O
novel	O
compound	O
or	O
the	O
Scalarispongia	O
sp.	O
extract	O
of	O
the	O
present	O
invention	O
exhibits	O
growth	O
inhibitory	O
activities	O
against	O
various	O
cancer	O
cell	O
lines	O
and	O
is	O
thus	O
useful	O
as	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
.	O

Pyridazine	O
derivatives	O
as	O
eaat2	B
activators	O
Pyridazine	O
derivatives	O
that	O
activate	O
the	O
excitatory	B
amino	I
acid	I
transporter	I
2	I
(	O
EAAT2	B
)	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
disorders	O
,	O
and	O
conditions	O
associated	O
with	O
glutamate	O
excitotoxicity	O
.	O

Novel	O
urea	O
derivatives	O
as	O
tec	O
kinase	O
inhibitors	O
and	O
uses	O
thereof	O
Provided	O
are	O
urea	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
Tec	O
kinase	O
inhibitors	O
,	O
in	O
particular	O
ITK	O
(	O
interleukin-2	O
inducible	O
tyrosine	O
kinase	O
)	O
inhibitors	O
.	O

Also	O
provided	O
herein	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein	O
,	O
intermediates	O
used	O
in	O
their	O
synthesis	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
conditions	O
and/or	O
disorders	O
mediated	O
by	O
ITK	O
.	O

Methods	O
of	O
treating	O
amyloidoses	O
with	O
vitamin	O
b12	O
and	O
test	O
for	O
detecting	O
amyloid	B
-	I
beta	I
peptides	O
Embodiments	O
of	O
the	O
invention	O
include	O
methods	O
of	O
using	O
vitamin	O
B12	O
to	O
influence	O
amyloid	B
-	I
beta	I
peptide	O
aggregation	O
.	O

A	O
preferred	O
method	O
comprises	O
contacting	O
at	O
least	O
one	O
amyloid	B
-	I
beta	I
peptide	O
oligomer	O
formed	O
from	O
a	O
plurality	O
of	O
amyloid	B
-	I
beta	I
peptide	O
monomers	O
with	O
an	O
effective	O
amount	O
of	O
vitamin	O
B12	O
,	O
the	O
effective	O
amount	O
being	O
sufficient	O
to	O
stimulate	O
dissociation	O
of	O
the	O
amyloid	B
-	I
beta	I
peptide	O
monomers	O
from	O
the	O
amyloid	B
-	I
beta	I
peptide	O
oligomer	O
or	O
fibril	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
Alzheimer	O
's	O
disease	O
and	O
diagnostic	O
tests	O
for	O
detecting	O
the	O
presence	O
of	O
amyloid	B
-	I
beta	I
peptides	O
.	O

Nkp30	B
receptor	O
targeted	O
therapeutics	O
The	O
invention	O
is	O
directed	O
to	O
T	O
cells	O
and	O
other	O
cells	O
that	O
express	O
chimeric	O
NKp30	B
receptors	O
(	O
""""	O
chimeric	O
NKp30	O
T	O
cells	O
""""	O
)	O
,	O
methods	O
of	O
making	O
and	O
using	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
and	O
methods	O
of	O
using	O
these	O
chimeric	O
NKp30	O
T	O
cells	O
to	O
address	O
diseases	O
and	O
disorders	O
.	O

In	O
one	O
aspect	O
,	O
the	O
disclosure	O
broadly	O
relates	O
to	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
isolated	O
populations	O
thereof	O
,	O
and	O
compositions	O
comprising	O
the	O
same	O
.	O

In	O
another	O
aspect	O
,	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
are	O
further	O
designed	O
to	O
express	O
a	O
functional	O
non	O
-	O
TCR	O
receptor	O
.	O

The	O
disclosure	O
also	O
pertains	O
to	O
methods	O
of	O
making	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
and	O
methods	O
of	O
reducing	O
or	O
ameliorating	O
,	O
or	O
preventing	O
or	O
treating	O
,	O
diseases	O
and	O
disorders	O
using	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
populations	O
thereof	O
,	O
or	O
compositions	O
comprising	O
the	O
same	O
.	O

Combination	O
use	O
of	O
vitamin	O
d	O
and	O
hmg	B
coa	I
reductase	I
inhibitor	O
for	O
treating	O
osteoporosis	O
The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
osteoporosis	O
by	O
co-	O
administration	O
of	O
a	O
vitamin	O
D	O
and	O
a	O
3-hydroxy-3-methyl	B
-	I
glutaryl	I
-	I
Co	I
A	I
reductase	I
(	O
HMG	B
Co	I
A	I
reductase	I
)	O
inhibitor	O
.	O

Also	O
provided	O
are	O
compositions	O
and	O
kits	O
useful	O
for	O
treating	O
osteoporosis	O
comprising	O
a	O
vitamin	O
D	O
and	O
an	O
HMG	B
Co	I
A	I
reductase	I
inhibitor	O
.	O

Retinal	O
cyclodextrin	O
acetals	O
and	O
hemiacetals	O
for	O
clarifying	O
skin	O
complexion	O
The	O
present	O
invention	O
discloses	O
certain	O
polyene	O
cyclodextrin	O
acetals	O
and	O
hemiacetals	O
that	O
are	O
effective	O
in	O
providing	O
skin	O
clarification	O
,	O
which	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
acne	O
,	O
and	O
skin	O
disfigurements	O
and	O
skin	O
darkening	O
resulting	O
from	O
acne	O
;	O
skin	O
darkening	O
from	O
cancer	O
,	O
diabetes	O
,	O
radiation	O
treatments	O
,	O
chemotherapy	O
,	O
and	O
sun	O
-	O
burn	O
;	O
mitochondrial	O
and	O
DNA	O
dysfunction	O
;	O
age	O
spots	O
;	O
loss	O
of	O
cellular	O
antioxidants	O
;	O
skin	O
changes	O
associated	O
with	O
aging	O
including	O
collagen	O
loss	O
,	O
loss	O
of	O
skin	O
pliability	O
,	O
loss	O
of	O
skin	O
suppleness	O
,	O
skin	O
wrinkles	O
and	O
fine	O
lines	O
,	O
oxidation	O
,	O
damage	O
from	O
radiation	O
,	O
damage	O
from	O
free	O
radicals	O
,	O
and	O
damage	O
from	O
UV	O
;	O
dry	O
skin	O
;	O
xerosis	O
;	O
ichthyosis	O
;	O
dandruff	O
;	O
brownish	O
spots	O
;	O
keratoses	O
;	O
melasma	O
;	O
lentigines	O
;	O
liver	O
spots	O
;	O
skin	O
pigmentation	O
including	O
pigmented	O
spots	O
,	O
dark	O
circles	O
under	O
the	O
eyes	O
,	O
darkened	O
skin	O
,	O
and	O
blemishes	O
;	O
oily	O
skin	O
;	O
warts	O
;	O
eczema	O
;	O
pruritic	O
skin	O
;	O
psoriasis	O
;	O
inflammatory	O
dermatoses	O
;	O
topical	O
inflammation	O
;	O
disturbed	O
keratinization	O
;	O
scalp	O
dryness	O
,	O
and	O
combinations	O
thereof	O
.	O

Benzoic	O
acid	O
derivatives	O
as	O
eif4e	B
inhibitors	O
Disclosed	O
are	O
compounds	O
with	O
the	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
and	O
R2	O
are	O
as	O
disclosed	O
herein	O
,	O
which	O
are	O
eIF4E	B
inhibitors	O
useful	O
in	O
the	O
treatment	O
of	O
cancers	O
.	O

Also	O
disclosed	O
are	O
compositions	O
comprising	O
the	O
compounds	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
cancer	O
using	O
the	O
compounds	O
.	O

Amide	O
compounds	O
,	O
compositions	O
and	O
applications	O
thereof	O
The	O
present	O
disclosure	O
relates	O
to	O
substituted	O
amide	O
compounds	O
that	O
are	O
inhibitors	O
of	O
Fatty	B
Acid	I
Amide	I
Hydrolase	I
(	O
FAAH	B
)	O
,	O
their	O
stereoisomers	O
,	O
tautomers	O
,	O
prodrugs	O
,	O
polymorphs	O
,	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
,	O
prophylaxis	O
,	O
management	O
,	O
or	O
adjunct	O
treatment	O
of	O
all	O
medical	O
conditions	O
related	O
to	O
inhibition	O
of	O
Fatty	B
Acid	I
Amide	I
Hydrolase	I
(	O
FAAH	B
)	O
,	O
such	O
as	O
pain	O
including	O
acute	O
and	O
post	O
operative	O
pain	O
,	O
chronic	O
pain	O
,	O
cancer	O
pain	O
,	O
cancer	O
chemotherapy	O
induced	O
pain	O
,	O
neuropathic	O
pain	O
,	O
nociceptive	O
pain	O
,	O
inflammatory	O
pain	O
,	O
back	O
pain	O
,	O
pain	O
due	O
to	O
disease	O
of	O
various	O
origin	O
such	O
as	O
:	O
diabetic	O
neuropathy	O
,	O
neurotropic	O
viral	O
disease	O
including	O
human	O
immunodeficient	O
virus	O
(	O
HIV	O
)	O
,	O
herpes	O
zoster	O
such	O
as	O
post	O
herpetic	O
neuralgia	O
;	O
polyneuropathy	O
,	O
neurotoxicity	O
,	O
mechanical	O
nerve	O
injury	O
,	O
carpal	O
tunnel	O
syndrome	O
,	O
immunologic	O
mechanisms	O
like	O
multiple	O
sclerosis	O
;	O
sleep	O
disorders	O
,	O
anxiety	O
and	O
depression	O
disorders	O
,	O
inflammatory	O
disorders	O
,	O
weight	O
and	O
eating	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
,	O
addiction	O
,	O
spasticity	O
,	O
hypertension	O
or	O
other	O
disorders	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
the	O
process	O
of	O
preparation	O
of	O
the	O
amide	O
compounds	O
.	O

Formula	O
(	O
1	O
)	O
.	O

The	O
present	O
disclosure	O
also	O
relates	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
compounds	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Methods	O
of	O
treating	O
fatty	O
liver	O
disease	O
with	O
helminth	O
-	O
derived	O
glycan	O
-	O
containing	O
compounds	O
The	O
present	O
invention	O
provides	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
(	O
e.g.	O
,	O
a	O
compound	O
comprising	O
a	O
Lewisx	O
antigen	O
(	O
e.g.	O
,	O
LNFPIII	O
)	O
,	O
a	O
non	O
-	O
Lewisx	O
antigen	O
(	O
e.g.	O
,	O
LNnT	O
,	O
LDN	O
,	O
and	O
LDN	O
derivatives	O
)	O
,	O
or	O
a	O
mixture	O
of	O
Lewisx	O
and	O
non	O
-	O
Lewisx	O
antigens	O
(	O
e.g.	O
,	O
SEA	O
)	O
)	O
,	O
useful	O
as	O
a	O
therapeutic	O
compound	O
for	O
treating	O
or	O
preventing	O
diseases	O
associated	O
with	O
fat	O
accumulation	O
in	O
the	O
liver	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
the	O
development	O
of	O
a	O
fatty	O
liver	O
disease	O
in	O
a	O
subject	O
that	O
has	O
the	O
disease	O
or	O
is	O
at	O
risk	O
of	O
developing	O
the	O
disease	O
,	O
and	O
inhibiting	O
lipogenesis	O
in	O
hepatocytes	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
regulating	O
the	O
Erk	O
-	O
c	O
-	O
fos	O
/	O
AP-1-FXRα	O
signalling	O
pathway	O
by	O
administering	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
to	O
a	O
subject	O
with	O
a	O
fatty	O
liver	O
disease	O
,	O
or	O
contacting	O
a	O
hepatocyte	O
with	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
.	O

Novel	O
chalcone	O
derivative	O
and	O
anticancer	O
composition	O
comprising	O
same	O
as	O
active	O
ingredient	O
The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
chalcone	O
derivative	O
and	O
to	O
an	O
anticancer	O
composition	O
comprising	O
same	O
as	O
an	O
active	O
ingredient	O
.	O

Liquid	O
composition	O
of	O
anti	O
-	O
hepatitis	O
b	O
virus	O
Disclosed	O
is	O
an	O
oral	O
liquid	O
for	O
treating	O
a	O
hepatitis	O
B	O
virus	O
infection	O
,	O
and	O
composed	O
of	O
entecavir	O
,	O
sodium	O
diacetate	O
and	O
water	O
.	O

The	O
content	O
of	O
entecavir	O
is	O
0.001	O
-	O
0.2mg	O
/	O
ml	O
,	O
and	O
the	O
content	O
of	O
sodium	O
diacetate	O
is	O
0.1	O
-	O
10mg	O
/	O
ml	O
.	O

Use	O
of	O
a	O
chemical	O
compound	O
derived	O
from	O
a	O
1,2,3,5-tetrasubstituted	O
pyrole	O
in	O
the	O
preparation	O
of	O
a	O
drug	O
for	O
use	O
in	O
treating	O
inflammatory	O
diseases	O
involving	O
processes	O
of	O
cellular	O
apoptosis	O
The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
derived	O
from	O
1,2,3,5-tetrasubstituted	O
pyroles	O
in	O
conjunction	O
with	O
pharmaceutically	O
acceptable	O
excipients	O
in	O
the	O
production	O
of	O
a	O
drug	O
that	O
can	O
be	O
used	O
to	O
treat	O
inflammatory	O
diseases	O
involving	O
processes	O
of	O
cellular	O
apoptosis	O
,	O
preferably	O
diseases	O
arising	O
through	O
sepsis	O
caused	O
by	O
Gram‑negative	O
bacteria	O
.	O

Said	O
diseases	O
include	O
acute	O
sepsis‑induced	O
pulmonary	O
diseases	O
,	O
acute	O
sepsis‑induced	O
respiratory	O
distress	O
syndrome	O
,	O
endotoxic	O
or	O
endotoxemic	O
shock	O
,	O
septic	O
peritonitis	O
or	O
trauma	O
.	O

The	O
invention	O
also	O
comprises	O
the	O
pharmaceutical	O
composition	O
for	O
treating	O
said	O
diseases	O
.	O

A	O
new	O
diaza	O
-	O
benzofluoranthene	O
derivative	O
as	O
drug	O
The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
16-tetrazolyl	O
-	O
eburnamenine	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and/or	O
hydrates	O
and/or	O
solvates	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
hydrates	O
or	O
solvates	O
thereof	O
as	O
active	O
ingredient	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
synthesis	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
the	O
chemical	O
and	O
pharmaceutical	O
manufacture	O
of	O
medicaments	O
containing	O
these	O
compounds	O
,	O
as	O
well	O
as	O
the	O
methods	O
of	O
treatment	O
of	O
mammals	O
-	O
including	O
human	O
-	O
with	O
these	O
compounds	O
.	O

There	O
is	O
still	O
further	O
provided	O
methods	O
for	O
the	O
treatment	O
of	O
neurological	O
,	O
neurodegenerative	O
and	O
psychiatric	O
diseases	O
or	O
conditions	O
as	O
well	O
as	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
human	O
,	O
in	O
need	O
of	O
such	O
treatment	O
and/or	O
prophylaxis	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
alone	O
or	O
together	O
with	O
at	O
least	O
one	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and/or	O
diluent	O
.	O

Hydroxymethylfurfural	O
derivative	O
A	O
hydroxymethylfurfural	O
derivative	O
represented	O
by	O
general	O
formula	O
(	O
A	O
)	O
.	O

In	O
the	O
formula	O
,	O
R	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
HOOCCH2COCO-	O
,	O
(	O
III	O
)	O
HOOCCH2CH2COCO-	O
,	O
and	O
(	O
IV	O
)	O
a	O
hydrogen	O
atom	O
.	O

Garcinia	O
buchananii	O
baker	O
compounds	O
,	O
compositions	O
and	O
related	O
methods	O
Embodiments	O
of	O
the	O
present	O
disclosure	O
related	O
to	O
compounds	O
and	O
compositions	O
derived	O
from	O
G.	O
buchananii	O
baker	O
and	O
methods	O
thereof	O
.	O

Formulations	O
of	O
(	O
+	O
)	O
-2-	O
[	O
1-	O
(	O
3-ethoxy-4-methoxy	O
-	O
phenyl	O
)	O
-2-methanesulfonyl	O
-	O
ethyl	O
]	O
-4-acetyl	O
aminoisoindoline-1,3-dione	O
Pharmaceutical	O
compositions	O
and	O
single	O
unit	O
dosage	O
forms	O
of	O
(	O
+	O
)	O
-2-	O
[	O
l-	O
(	O
3-ethox	O
4-mcthoxy	O
-	O
phcnyl	O
)	O
-2-mcthancsulfonyl	O
-	O
cthyl	O
]	O
-4-acctylaminoisoindolinc	O
-	O
l,3-dionc	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
stereoisomer	O
,	O
prodrug	O
,	O
salt	O
,	O
solvate	O
,	O
hydrate	O
,	O
or	O
clathrate	O
5	O
thereof	O
,	O
are	O
provided	O
herein	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
,	O
managing	O
,	O
or	O
preventing	O
various	O
diseases	O
or	O
disorders	O
.	O

The	O
compound	O
is	O
known	O
as	O
Apremilast	O
and	O
has	O
the	O
following	O
structural	O
formula	O
:	O

Formulation	O
and	O
method	O
for	O
treatment	O
of	O
pain	O
and/or	O
inflammation	O
associated	O
with	O
a	O
skin	O
condition	O
Topical	O
formulations	O
comprising	O
an	O
effective	O
amount	O
of	O
menthol	O
in	O
combination	O
with	O
an	O
acidifier	O
,	O
wherein	O
the	O
topical	O
formulation	O
has	O
a	O
pH	O
of	O
about	O
1	O
to	O
3	O
,	O
and	O
methods	O
comprising	O
administration	O
of	O
the	O
same	O
,	O
and	O
use	O
of	O
the	O
topical	O
formulations	O
to	O
treat	O
pain	O
and/or	O
inflammation	O
associated	O
with	O
a	O
skin	O
condition	O
are	O
described	O
.	O

For	O
example	O
,	O
the	O
topical	O
formulation	O
relieves	O
pain	O
,	O
redness	O
,	O
swelling	O
,	O
reduces	O
rash	O
and/or	O
itching	O
relating	O
to	O
skin	O
conditions	O
,	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
any	O
kind	O
of	O
envenomation	O
from	O
stings	O
and/or	O
bites	O
from	O
animals	O
,	O
insects	O
and	O
plants	O
in	O
addition	O
to	O
contact	O
dermatitis	O
,	O
burns	O
,	O
urticaria	O
,	O
rash	O
and	O
other	O
forms	O
of	O
dermatitis	O
.	O

Treatment	O
of	O
pain	O
and/or	O
inflammation	O
including	O
activation	O
and/or	O
stimulation	O
and/or	O
blocking	O
and/or	O
reducing	O
the	O
activity	O
of	O
one	O
or	O
more	O
pain	O
receptors	O
to	O
thereby	O
treat	O
the	O
pain	O
and/or	O
inflammation	O
is	O
described	O
.	O

Chinese	O
herbal	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
foot	O
A	O
Chinese	O
herbal	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
foot	O
,	O
consisting	O
of	O
the	O
following	O
raw	O
material	O
medicines	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
30	O
parts	O
of	O
scorpion	O
,	O
1	O
-	O
30	O
parts	O
of	O
lithargite	O
,	O
1	O
-	O
30	O
parts	O
of	O
centipede	O
,	O
1	O
-	O
20	O
parts	O
of	O
borneol	O
,	O
1	O
-	O
20	O
parts	O
of	O
cirsium	O
japonicum	O
,	O
1	O
-	O
20	O
parts	O
of	O
pangolin	O
,	O
1	O
-	O
20	O
parts	O
of	O
castor	O
beans	O
,	O
1	O
-	O
20	O
parts	O
of	O
garden	O
burnet	O
,	O
and	O
1	O
-	O
20	O
parts	O
of	O
safflower	O
.	O

The	O
composition	O
has	O
the	O
effects	O
of	O
clearing	O
heat	O
and	O
detoxicating	O
,	O
eliminating	O
necrotic	O
tissue	O
and	O
promoting	O
granulation	O
,	O
stimulating	O
blood	O
circulation	O
and	O
removing	O
blood	O
stasis	O
,	O
warming	O
and	O
activating	O
arteries	O
and	O
veins	O
,	O
and	O
reducing	O
swelling	O
and	O
stopping	O
pain	O
,	O
and	O
is	O
used	O
to	O
treat	O
nerve	O
patho	O
-	O
type	O
,	O
artery	O
ischemia	O
-	O
type	O
and	O
mixed	O
-	O
type	O
diabetic	O
foot	O
with	O
the	O
symptoms	O
of	O
foot	O
muscular	O
atrophy	O
,	O
deformity	O
,	O
skin	O
infection	O
,	O
purulence	O
,	O
rhagades	O
and	O
ulcers	O
,	O
and	O
toe	O
tip	O
ulcers	O
and	O
gangrene	O
.	O

Effervescent	O
pharmaceutical	O
formulations	O
comprising	O
pregabalin	O
and	O
vitamin	O
b12	O
The	O
present	O
invention	O
relates	O
to	O
an	O
effervescent	O
pharmaceutical	O
formulation	O
comprising	O
a	O
combination	O
of	O
pregabalin	O
and	O
vitamin	O
B12	O
and	O
use	O
of	O
this	O
formulation	O
in	O
the	O
treatment	O
of	O
epilepsy	O
,	O
central	O
nervous	O
system	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
;	O
Huntington	O
's	O
disease	O
;	O
tardive	O
dyskinesia	O
;	O
spasticity	O
;	O
cerebral	O
ischemia	O
;	O
postherpetic	O
neuralgia	O
;	O
social	O
phobia	O
;	O
fibromyalgia	O
and	O
spinal	O
cord	O
injury	O
induced	O
chronic	O
pains	O
;	O
neuropathic	O
pains	O
associated	O
with	O
diabetic	O
peripheral	O
neuropathy	O
and	O
common	O
anxiety	O
disorder	O
and	O
in	O
treatment	O
and/or	O
prevention	O
of	O
anemia	O
diseases	O
such	O
as	O
macrocytic	O
anemia	O
,	O
megaloblastic	O
anemia	O
and	O
pernicious	O
anemia	O
.	O

Fatty	O
acids	O
as	O
anti	O
-	O
inflammatory	O
agents	O
A	O
class	O
of	O
enzymatically	O
generated	O
electrophilic	O
fatty	O
acid	O
derivatives	O
(	O
EFADs	O
)	O
,	O
or	O
their	O
enzymatically	O
generated	O
metabolites	O
.	O

The	O
EFAD	O
's	O
and	O
their	O
metabolites	O
have	O
beneficial	O
effects	O
human	O
health	O
.	O

According	O
to	O
the	O
inventors	O
the	O
inventive	O
keto	O
fatty	O
acids	O
or	O
their	O
enzymatically	O
generated	O
metabolites	O
,	O
can	O
inhibit	O
inflammation	O
by	O
giving	O
rise	O
to	O
adaptive	O
signaling	O
molecules	O
in	O
vivo	O
.	O

Ionophore	O
antibiotic	O
suspension	O
An	O
alcohol	O
based	O
suspension	O
formulation	O
including	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
ionophore	O
antibiotic	O
in	O
an	O
organic	O
liquid	O
phase	O
including	O
at	O
least	O
one	O
polyol	O
and	O
benzyl	O
alcohol	O
and	O
at	O
least	O
one	O
or	O
more	O
of	O
at	O
least	O
one	O
anionic	O
and/or	O
non	O
-	O
ionic	O
surfactant	O
;	O
at	O
least	O
one	O
stabilising	O
agent	O
or	O
water	O
in	O
an	O
amount	O
of	O
less	O
than	O
or	O
equal	O
to	O
15	O
%	O
v	O
/	O
v	O
of	O
the	O
total	O
formulation	O
.	O

Methods	O
of	O
manufacture	O
of	O
the	O
formulation	O
are	O
also	O
described	O
along	O
with	O
methods	O
of	O
use	O
for	O
selected	O
treatments	O
.	O

Bicyclic	O
heterocyclic	O
derivatives	O
as	O
mnk1	B
and	O
mnk2	B
modulators	O
and	O
uses	O
thereof	O
The	O
present	O
invention	O
relates	O
to	O
certain	O
compounds	O
(	O
e.g.	O
,	O
imidazopyrazine	O
,	O
imidazopyridine	O
,	O
imidazopyridazine	O
and	O
imidazpyrimidine	O
compounds	O
)	O
that	O
act	O
as	O
inhibitors	O
of	O
the	O
MAP	B
kinase	I
interacting	O
kinases	O
MNK2a	B
,	O
MNK2b	B
,	O
MNK1a	B
,	O
and	O
MNK1b	B
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
(	O
e.g.	O
,	O
proliferative	O
diseases	O
(	O
e.g.	O
,	O
cancer	O
)	O
,	O
inflammatory	O
diseases	O
,	O
Alzheimer	O
's	O
disease	O
)	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
these	O
diseases	O
.	O

Treatment	O
method	O
for	O
steroid	O
responsive	O
dermatoses	O
Invented	O
is	O
a	O
method	O
of	O
treating	O
steroid	O
responsive	O
dermatoses	O
in	O
a	O
mammal	O
,	O
including	O
a	O
human	O
,	O
in	O
need	O
thereof	O
which	O
comprises	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
N-	O
{	O
(	O
1S	O
)	O
-2-Amino-1-	O
[	O
(	O
3-fluorophenyl	O
)	O
methyl	O
]	O
ethyl	O
}	O
-5-chloro-4-	O
(	O
4-chloro-1-methyl-1H	O
-	O
pyrazol-5-yl	O
)	O
-2-thiophenecarboxamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
the	O
compound	O
N-	O
{	O
(	O
1S	O
)	O
-2-amino-1-	O
[	O
(	O
3,4-difluorophenyl	O
)	O
methyl	O
]	O
ethyl	O
}	O
-5-chloro-4-	O
(	O
4-chloro-1-methyl-1H	O
-	O
pyrazol-5-yl	O
)	O
-2-	O
furancarboxamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
to	O
such	O
mammal	O
.	O

Pyrrolopyridinone	O
derivatives	O
as	O
ttx	O
-	O
s	O
blockers	O
The	O
present	O
invention	O
relates	O
to	O
pyrrolopyridinone	O
derivatives	O
which	O
have	O
blocking	O
activities	O
of	O
voltage	B
gated	I
sodium	I
channels	I
as	O
the	O
TTX	B
-	I
S	I
channels	I
,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
and	O
diseases	O
in	O
which	O
voltage	B
gated	I
sodium	I
channels	I
are	O
involved	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
voltage	B
gated	I
sodium	I
channels	I
are	O
involved	O
.	O

Cul4b	B
as	O
predictive	O
biomarker	O
for	O
cancer	O
treatment	O
The	O
current	O
disclosure	O
describes	O
materials	O
and	O
methods	O
for	O
identifying	O
subjects	O
that	O
would	O
benefit	O
from	O
treatment	O
with	O
a	O
DNA	B
topoisomerase	I
1	I
inhibitor	O
,	O
based	O
on	O
the	O
levels	O
of	O
cullin	B
4B	I
gene	O
,	O
RNA	O
and	O
protein	O
levels	O
in	O
the	O
subject	O
.	O

The	O
disclosure	O
identifies	O
CUL4B	B
as	O
a	O
predictive	O
biomarker	O
for	O
cancer	O
diagnosis	O
and	O
the	O
subsequent	O
treatment	O
with	O
directed	O
therapeutic	O
agents	O
.	O

The	O
current	O
disclosure	O
also	O
identifies	O
novel	O
therapeutic	O
agents	O
that	O
modulate	O
the	O
level	O
of	O
CUL4B	B
expression	O
,	O
and	O
sensitize	O
a	O
subject	O
to	O
treatment	O
with	O
a	O
second	O
therapeutic	O
agent	O
.	O

Prophylactic	O
agent	O
and/or	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
The	O
problem	O
to	O
be	O
solved	O
by	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
excellent	O
prophylactic	O
agent	O
and/or	O
an	O
excellent	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
.	O

The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
agent	O
and/or	O
a	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
,	O
which	O
comprises	O
an	O
effective	O
amount	O
of	O
4-piperidyldiphenylpropoxyacetate	O
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
carrier	O
.	O

Compositions	O
and	O
methods	O
for	O
modulating	O
hemoglobin	B
gene	O
family	O
expression	O
Aspects	O
of	O
the	O
invention	O
provide	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B
genes	O
(	O
HBB	B
,	O
HBD	B
,	O
HBEl	B
,	O
HBG1	B
or	O
HBG2	B
)	O
.	O

Further	O
aspects	O
provide	O
compositions	O
and	O
kits	O
comprising	O
single	O
stranded	O
oligonucleotides	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B
genes	O
.	O

Methods	O
for	O
modulating	O
expression	O
of	O
hemoglobin	B
genes	O
using	O
the	O
single	O
stranded	O
oligonucleotides	O
are	O
also	O
provided	O
.	O

Further	O
aspects	O
of	O
the	O
invention	O
provide	O
methods	O
for	O
selecting	O
a	O
candidate	O
oligonucleotide	O
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	B
genes	O
.	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
peridontitis	O
and	O
rheumatoid	O
arthritis	O
Disclosed	O
are	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
.	O

The	O
pharmaceutical	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
useful	O
for	O
the	O
treatment	O
of	O
periodontitis	O
and	O
rheumatoid	O
arthritis	O
may	O
be	O
formulated	O
for	O
oral	O
,	O
buccal	O
,	O
rectal	O
,	O
topical	O
,	O
transdermal	O
,	O
transmucosal	O
,	O
intravenous	O
,	O
parenteral	O
administration	O
,	O
syrup	O
or	O
injection	O
.	O

Polyoxopregnane	O
compounds	O
and	O
use	O
thereof	O
Disclosed	O
are	O
polyoxopregnane	O
compounds	O
and	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
manufacture	O
of	O
medicaments	O
reversing	O
or	O
inhibiting	O
mutidrug	O
resistance	O
of	O
tumor	O
cells	O
.	O

Composition	O
for	O
restricting	O
apoptosis	O
,	O
including	O
mirna	O
of	O
epstein	O
-	O
barr	O
virus	O
,	O
or	O
promoting	O
cell	O
proliferation	O
The	O
present	O
invention	O
relates	O
to	O
uses	O
for	O
:	O
restricting	O
apoptosis	O
of	O
miRNA	O
of	O
Epstein	O
-	O
Barr	O
virus	O
,	O
especially	O
miR	B
-	I
BART3	I
-	I
5p	I
,	O
miR	B
-	I
BART3	I
-	I
3p	I
,	O
miR	B
-	I
BART21	I
-	I
5p	I
,	O
miR	B
-	I
BART21	I
-	I
3p	I
,	O
miR	B
-	I
BART18	I
-	I
5p	I
,	O
miR	B
-	I
BART18	I
-	I
3p	I
,	O
miR	B
-	I
BART7	I
-	I
5p	I
,	O
miR	B
-	I
BART7	I
-	I
3p	I
,	O
miR	B
-	I
BART8	I
-	I
5p	I
,	O
miR	B
-	I
BART8	I
-	I
3p	I
,	O
miR	B
-	I
BART9	I
-	I
5p	I
,	O
miR	B
-	I
BART22	I
-	I
5p	I
,	O
miR	B
-	I
BART22	I
-	I
3p	I
,	O
miR	B
-	I
BART19	I
-	I
5p	I
,	O
miR	B
-	I
BART19	I
-	I
3p	I
,	O
miR	B
-	I
BART13	I
-	I
5p	I
,	O
miR	B
-	I
BART13	I
-	I
3p	I
,	O
miR	B
-	I
BART14	I
-	I
5p	I
,	O
miR	B
-	I
BART2	I
-	I
3p	I
,	O
miR	B
-	I
BART1	I
-	I
3p	I
,	O
miR	B
-	I
BART9	I
-	I
3p	I
,	O
miR	B
-	I
BART10	I
-	I
5p	I
,	O
miR	B
-	I
BART10	I
-	I
3p	I
,	O
miR	B
-	I
BART14	I
-	I
3p	I
and	O
their	O
mimics	O
;	O
and	O
promoting	O
cell	O
proliferation	O
.	O

Novel	O
therapeutics	O
for	O
brain	O
cancer	O
Provided	O
herein	O
are	O
novel	O
compositions	O
and	O
methods	O
to	O
inhibit	O
Olig2	B
activity	O
.	O

The	O
Olig2	B
inhibitors	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
useful	O
,	O
inter	O
alia	O
,	O
for	O
treating	O
cancer	O
.	O

In	O
particular	O
the	O
Olig2	B
inhibitors	O
may	O
be	O
used	O
to	O
treat	O
glioblastoma	O
.	O

Further	O
,	O
provided	O
are	O
peptide	O
compositions	O
capable	O
of	O
inhibiting	O
Olig	B
2	I
.	O

Neuroendocrine	O
tumor	O
treatment	O
A	O
method	O
for	O
treating	O
a	O
neuroendocrine	O
tumor	O
,	O
particularly	O
pancreatic	O
neuroendocrine	O
tumor	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
therapeutic	O
agent	O
,	O
wherein	O
said	O
neuroendocrine	O
tumor	O
is	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	B
inhibitor	O
;	O
uses	O
of	O
said	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
neuroendocrine	O
tumor	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	B
inhibitor	O
;	O
uses	O
of	O
said	O
compound	O
for	O
treating	O
said	O
disease	O
;	O
and	O
related	O
pharmaceutical	O
compositions	O
and	O
pharmaceutical	O
package	O
thereof	O
.	O

Method	O
for	O
obtaining	O
high	O
concentrations	O
of	O
the	O
chemical	O
constituent	O
trans	O
-	O
pinocarvyl	O
acetate	O
by	O
hydrodistillation	O
of	O
the	O
aerial	O
parts	O
of	O
microlicia	O
graveolens	O
and	O
obtaining	O
nano	O
-	O
emulsified	O
formulations	O
The	O
method	O
which	O
is	O
the	O
subject	O
matter	O
of	O
the	O
present	O
invention	O
provides	O
a	O
quantitative	O
and	O
qualitative	O
production	O
method	O
for	O
the	O
chemical	O
compound	O
known	O
as	O
trans	O
-	O
pinocarvyl	O
acetate	O
.	O

This	O
compound	O
has	O
relevant	O
applications	O
in	O
the	O
chemical	O
and	O
cosmetic	O
industries	O
for	O
producing	O
perfumes	O
and	O
fragrances	O
.	O

The	O
method	O
which	O
is	O
the	O
subject	O
matter	O
of	O
the	O
present	O
invention	O
also	O
provides	O
nanoemulsions	O
containing	O
essential	O
oil	O
of	O
Microlicia	O
graveolens	O
,	O
thus	O
making	O
its	O
use	O
possible	O
.	O

Novel	O
fatty	O
acid	O
-	O
salicylate	O
conjugates	O
with	O
enhanced	O
therapeutic	O
properties	O
The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
cancer	O
with	O
an	O
inventive	O
composition	O
.	O
'	O

The	O
invention	O
relates	O
to	O
the	O
fields	O
of	O
biomedicine	O
,	O
pharmacology	O
,	O
and	O
molecular	O
biology	O
.	O

Novel	O
heteroaryl	O
and	O
heterocycle	O
compounds	O
,	O
composition	O
and	O
methods	O
thereof	O
Disclosed	O
are	O
novel	O
heteroaryl	O
and	O
heterocycle	O
compounds	O
of	O
formula	O
I-1	O
,	O
I-2	O
or	O
I-3	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
,	O
uses	O
and	O
methods	O
thereof	O
for	O
inhibiting	O
the	O
activity	O
of	O
PI3	B
K	I
and	O
for	O
treating	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
cancer	O
.	O

Benzisoxazole	O
modulators	O
of	O
neurogenesis	O
The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
Ar1	O
/	O
Ar2	O
are	O
phenyl	O
or	O
a	O
5	O
or	O
6-membered	O
heteroaryl	O
;	O
R1	O
/	O
R2	O
is	O
hydrogen	O
,	O
halogen	O
,	O
lower	O
alkyl	O
,	O
CF3	O
or	O
lower	O
alkoxy	O
;	O
n	O
,	O
m	O
are	O
1	O
or	O
2	O
;	O
or	O
to	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
,	O
to	O
a	O
racemic	O
mixture	O
or	O
to	O
its	O
corresponding	O
enantiomer	O
and/or	O
optical	O
isomers	O
thereof	O
,	O
with	O
the	O
exception	O
of	O
the	O
compound	O
2,1-benzisoxazole,3-	O
(	O
4-chlorophenyl	O
)	O
-5-	O
(	O
1-phenyl-1H	O
-	O
pyrazol-5-yl	O
)	O
-	O
.	O

The	O
compounds	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
,	O
obsessive	O
-	O
compulsive	O
personality	O
disorder	O
,	O
major	O
depression	O
,	O
bipolar	O
disorders	O
,	O
anxiety	O
disorders	O
,	O
normal	O
aging	O
,	O
epilepsy	O
,	O
retinal	O
degeneration	O
,	O
traumatic	O
brain	O
injury	O
,	O
spinal	O
cord	O
injury	O
,	O
post	O
-	O
traumatic	O
stress	O
disorder	O
,	O
panic	O
disorder	O
,	O
Parkinson	O
's	O
disease	O
,	O
dementia	O
,	O
Alzheimer	O
's	O
disease	O
,	O
mild	O
cognitive	O
impairment	O
,	O
chemotherapy	O
-	O
induced	O
cognitive	O
dysfunction	O
,	O
Down	O
syndrome	O
,	O
autism	O
spectrum	O
disorders	O
,	O
hearing	O
loss	O
,	O
tinnitus	O
,	O
spinocerebellar	O
ataxia	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
multiple	O
sclerosis	O
,	O
Huntington	O
's	O
disease	O
,	O
stroke	O
,	O
radiation	O
therapy	O
,	O
chronic	O
stress	O
,	O
abuse	O
of	O
neuro	O
-	O
active	O
drugs	O
,	O
such	O
as	O
alcohol	O
,	O
opiates	O
,	O
methamphetamine	O
,	O
phencyclidine	O
and	O
cocaine	O
.	O

Substituted	O
naphthyridinedione	O
derivatives	O
as	O
hiv	B
integrase	I
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
Substituted	O
Naphthyridinedione	O
Derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
compositions	O
comprising	O
at	O
least	O
one	O
Substituted	O
Naphthyridinedione	O
Derivative	O
,	O
and	O
methods	O
of	O
using	O
the	O
Substituted	O
Naphthyridinedione	O
Derivatives	O
for	O
treating	O
or	O
preventing	O
HIV	O
infection	O
in	O
a	O
subject	O
.	O

Piperazinotrizole	O
compound	O
,	O
preparation	O
method	O
therefor	O
,	O
and	O
use	O
thereof	O
in	O
drug	O
preparation	O
Provided	O
is	O
a	O
piperazinotrizole	O
compound	O
represented	O
by	O
general	O
formula	O
I	O
or	O
an	O
isomer	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
,	O
prodrug	O
or	O
hydrate	O
thereof	O
.	O

Also	O
provided	O
are	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
,	O
a	O
drug	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
a	O
use	O
thereof	O
as	O
a	O
high	O
-	O
selectivity	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase-1	O
(	O
PARP1	B
)	O
inhibitor	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
PARP	B
-	O
related	O
diseases	O
.	O

Orl-1	B
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
anxiety	O
The	O
use	O
of	O
ORL-1	B
receptor	O
antagonists	O
of	O
the	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
is	O
described	O
.	O

(	O
aza-	O
)	O
isoquinolinone	O
derivatives	O
Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
X	O
,	O
Y	O
and	O
n	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
Tankyrase	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
cancer	O
,	O
cardiovascular	O
diseases	O
,	O
central	O
nervous	O
system	O
injury	O
and	O
different	O
forms	O
of	O
inflammation	O
.	O

Buffer	O
substance	O
for	O
the	O
treatment	O
of	O
wounds	O
The	O
invention	O
relates	O
to	O
buffer	O
substances	O
for	O
the	O
phase	O
-	O
appropriate	O
treatment	O
of	O
wounds	O
,	O
said	O
treatment	O
comprising	O
the	O
suppression	O
of	O
fibrin	B
formation	O
and/or	O
fibrin	B
cross	O
-	O
linking	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
wound	O
dressing	O
product	O
containing	O
said	O
buffer	O
substances	O
to	O
suppress	O
fibrin	B
formation	O
and/or	O
fibrin	B
cross	O
-	O
linking	O
.	O

Therapeutic	O
and	O
diagnostic	O
mirna	O
regulator	O
in	O
kidney	O
disease	O
The	O
present	O
invention	O
discloses	O
a	O
method	O
of	O
diagnosing	O
glomerular	O
kidney	O
disease	O
or	O
the	O
risk	O
of	O
glomerular	O
kidney	O
disease	O
comprising	O
determining	O
the	O
expression	O
level	O
of	O
miRNA	O
miR-193a	O
,	O
wherein	O
said	O
glomerular	O
kidney	O
disease	O
or	O
risk	O
thereof	O
is	O
detected	O
if	O
miR-193a	O
expression	O
levels	O
are	O
increased	O
as	O
compared	O
to	O
a	O
healthy	O
control	O
,	O
method	O
of	O
prophylactically	O
treating	O
a	O
glomerular	O
kidney	O
disease	O
or	O
of	O
reducing	O
the	O
risk	O
of	O
glomerular	O
kidney	O
disease	O
progression	O
in	O
a	O
patient	O
comprising	O
inhibiting	O
miR-193a	O
in	O
a	O
podocyte	O
cell	O
in	O
said	O
patient	O
and	O
suitable	O
means	O
for	O
said	O
methods	O
.	O

Preventive	O
products	O
against	O
pathogenic	O
germs	O
,	O
and	O
method	O
for	O
use	O
thereof	O
The	O
subject	O
of	O
the	O
invention	O
is	O
a	O
group	O
of	O
preventive	O
products	O
to	O
be	O
used	O
against	O
pathogenic	O
germs	O
,	O
and	O
the	O
method	O
for	O
using	O
these	O
products	O
,	O
each	O
product	O
is	O
being	O
a	O
special	O
combined	O
additive	O
for	O
preventive	O
purposes	O
,	O
which	O
could	O
be	O
used	O
as	O
additive	O
or	O
supplementary	O
material	O
in	O
animal	O
feed	O
to	O
produce	O
products	O
primarily	O
for	O
preventing	O
and	O
treating	O
bacterial	O
infection	O
of	O
poultry	O
,	O
which	O
selectively	O
inhibit	O
the	O
propagation	O
of	O
pathogenic	O
germs	O
that	O
generate	O
endo	O
and	O
exo	O
toxins	O
.	O

The	O
product	O
according	O
to	O
the	O
invention	O
suitable	O
primarily	O
for	O
preventing	O
and	O
treating	O
bacterial	O
contamination	O
of	O
poultry	O
.	O

It	O
is	O
charactrised	O
by	O
that	O
,	O
the	O
product	O
is	O
prepared	O
by	O
homogenizing	O
or	O
blending	O
methylglyoxal	O
or	O
its	O
diacetate	O
,	O
i.e.	O
methylglyoxal	O
diacetate	O
with	O
some	O
organic	O
acids	O
and/or	O
in	O
combination	O
with	O
Na	O
salts	O
of	O
organic	O
acids	O
.	O

During	O
the	O
method	O
according	O
to	O
the	O
invention	O
the	O
product	O
is	O
added	O
to	O
the	O
drinking	O
water	O
of	O
the	O
animals	O
and/or	O
mixed	O
in	O
the	O
feed	O
,	O
and	O
in	O
this	O
way	O
it	O
is	O
administered	O
to	O
the	O
animals	O
,	O
and/or	O
used	O
for	O
disinfecting	O
the	O
bedding	O
materials	O
.	O

1,6-	O
diazabicyclo	O
[	O
3,2,1	O
]	O
octan-	O
7-	O
one	O
derivatives	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O
Compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
their	O
preparation	O
and	O
use	O
in	O
preventing	O
or	O
treating	O
bacterial	O
infections	O
are	O
disclosed	O
.	O

Quinazolinone	O
compounds	O
and	O
derivatives	O
thereof	O
Compounds	O
of	O
Formula	O

I	O
are	O
useful	O
inhibitors	O
of	O
tankyrase	O
.	O

Compounds	O
of	O
Formula	O
I	O
have	O
the	O
following	O
structure	O
:	O
where	O
the	O
definitions	O
of	O
the	O
variables	O
are	O
provided	O
herein	O
.	O

Nootropic	O
compositions	O
for	O
improving	O
memory	O
performance	O
The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
improving	O
memory	O
and	O
related	O
functions	O
as	O
alertness	O
,	O
attention	O
,	O
concentration	O
,	O
learning	O
,	O
and	O
language	O
processing	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compositions	O
comprising	O
at	O
least	O
two	O
drugs	O
selected	O
from	O
cinacalcet	O
,	O
baclofen	O
,	O
acamprosate	O
,	O
mexiletine	O
,	O
sulfisoxazole	O
and	O
torasemide	O
useful	O
to	O
enhance	O
memory	O
and	O
related	O
functions	O
in	O
healthy	O
subjects	O
or	O
subjects	O
suffering	O
from	O
conditions	O
or	O
disorders	O
having	O
a	O
negative	O
impact	O
on	O
their	O
memory	O
.	O

Crystal	O
having	O
crystal	O
habits	O
and	O
pharmaceutical	O
composition	O
obtained	O
by	O
processing	O
the	O
crystal	O
An	O
object	O
is	O
to	O
provide	O
means	O
for	O
improving	O
the	O
solubility	O
of	O
luliconazole	O
.	O

Disclosed	O
is	O
a	O
crystal	O
of	O
luliconazole	O
wherein	O
the	O
crystal	O
has	O
such	O
a	O
crystal	O
habit	O
that	O
(	O
021	O
)	O
plane	O
is	O
a	O
specific	O
crystal	O
growth	O
plane	O
.	O

""""	O
novel	O
cross	O
-	O
linkers	O
for	O
hydrogels	O
,	O
hydrogels	O
including	O
these	O
cross	O
-	O
linkers	O
and	O
applications	O
thereof	O
""""	O
The	O
present	O
invention	O
relates	O
to	O
novel	O
cross	O
-	O
linkers	O
for	O
hydrogels	O
,	O
in	O
particular	O
for	O
hyaluronan	O
hydrogels	O
,	O
corresponding	O
hydrogels	O
including	O
said	O
cross	O
-	O
linkers	O
and	O
various	O
applications	O
thereof	O
.	O

The	O
cross	O
linker	O
of	O
the	O
invention	O
is	O
a	O
bi-	O
or	O
multifunctional	O
cross	O
-	O
linker	O
comprising	O
or	O
consisting	O
of	O
an	O
aromatic	O
or	O
heteroaromatic	O
ring	O
system	O
with	O
3	O
-	O
6	O
C	O
atoms	O
which	O
is	O
coupled	O
via	O
functional	O
groups	O
on	O
at	O
least	O
2	O
ring	O
positions	O
with	O
at	O
least	O
2	O
terminal	O
groups	O
capable	O
to	O
form	O
a	O
covalent	O
bond	O
with	O
thiol	O
or	O
amino	O
groups	O
,	O
in	O
particular	O
with	O
thiol	O
groups	O
in	O
a	O
thiol	O
-	O
en	O
reaction	O
.	O

The	O
cross	O
-	O
linker	O
may	O
be	O
charged	O
or	O
uncharged	O
.	O

In	O
a	O
specific	O
embodiment	O
,	O
the	O
terminal	O
groups	O
are	O
coupled	O
to	O
carboxy	O
groups	O
of	O
the	O
aromatic	O
or	O
heteroaromatic	O
ring	O
system	O
via	O
an	O
ester	O
or	O
amide	O
bond	O
.	O

More	O
specifically	O
,	O
the	O
cross	O
-	O
linker	O
of	O
the	O
invention	O
is	O
a	O
derivative	O
of	O
pyridine-3	O
,	O
5-dicarboxylic	O
acid	O
or	O
a	O
corresponding	O
pyridinium	O
salt	O
thereof	O
wherein	O
2	O
terminal	O
groups	O
are	O
coupled	O
to	O
the	O
carboxy	O
groups	O
of	O
the	O
pyridine	O
or	O
pyridinium	O
core	O
via	O
an	O
ester	O
or	O
amide	O
bond	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
cross	O
-	O
linker	O
is	O
N3,N5-bis	O
(	O
2-acrylamidoethyl	O
)	O
pyridine-3	O
,	O
5-dicarboxamide	O
or	O
a	O
3,5-bis	O
(	O
(	O
2-acrylamidoethyl	O
)	O
carbamoyl	O
)	O
-1-methylpyridin	O
-	O
l	O
-	O
ium	O
-	O
halogenide	O
.	O

Dihydroferulic	O
acid	O
and/or	O
dihydrocaffeic	O
acid	O
for	O
use	O
in	O
the	O
treatment	O
of	O
metabolic	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
I	O
for	O
use	O
as	O
a	O
medicament	O
,	O
wherein	O
R1	O
is	O
methyl	O
or	O
hydrogen	O
,	O
and	O
wherein	O
R2	O
is	O
methyl	O
or	O
hydrogen	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
food	O
ingredients	O
and	O
food	O
products	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
I.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
producing	O
compounds	O
of	O
the	O
formula	O
I.	O

Na	O
-	O
acyl	O
derivatives	O
of	O
aminoacyl-2-cyanopyrrolidine	O
-	O
inhibitors	O
of	O
prolyl	B
endopeptidase	I
and	O
dipeptidyl	B
peptidase	I
-	I
iv	I
,	O
having	O
hypoglycemic	O
,	O
antihypoxic	O
,	O
neuroprotective	O
action	O
and	O
action	O
of	O
cognitive	O
function	O
improvement	O
The	O
subject	O
of	O
the	O
present	O
invention	O
is	O
nα	O
-	O
acyl	O
derivatives	O
of	O
aminoacyl-2-cyanopyrrolidine	O
-	O
inhibitors	O
of	O
prolyl	O
endopeptidase	B
and	O
dipeptidyl	O
peptidase	B
-	I
iv	I
,	I
having	O
hypoglycemic	O
,	O
antihypoxic	O
,	O
neuroprotective	O
action	O
and	O
action	O
of	O
cognitive	O
function	O
improvement	O
.	O

Phenyl	O
1,2-isoxazolyl	O
or	O
phenyl	O
1,2-pyrazole	O
compound	O
and	O
application	O
thereof	O
Disclosed	O
is	O
an	O
application	O
of	O
a	O
phenyl	O
1,2-isoxazolyl	O
or	O
1,2-pyrazole	O
compound	O
of	O
the	O
following	O
structure	O
formula	O
(	O
I	O
)	O
.	O

It	O
is	O
proved	O
through	O
a	O
biological	O
activity	O
test	O
,	O
the	O
compound	O
has	O
an	O
obvious	O
activity	O
of	O
inhibiting	O
the	O
heat	B
shock	I
protein	I
90	I
.	O

Therefore	O
,	O
the	O
phenyl	O
1,2-isoxazolyl	O
or	O
1,2-pyrazole	O
compound	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
as	O
an	O
inhibitor	O
of	O
the	O
heat	B
shock	I
protein	I
90	I
for	O
curing	O
cancers	O
.	O

Combination	O
of	O
a	O
6-oxo-1,6-dihydro	O
-	O
pyridazine	O
derivative	O
having	O
anti	O
-	O
cancer	O
activity	O
with	O
a	O
mek	O
inhibitor	O
A	O
pharmaceutical	O
composition	O
comprising	O
:	O
3-	O
(	O
1-	O
{	O
3-	O
[	O
5-	O
(	O
1-methyl	O
-	O
piperidin-4-ylmethoxy	O
)	O
-pyrimidin-2-yl	O
]	O
-benzyl	O
}	O
-6-oxo-1,6-dihydro	O
-	O
pyridazin-3-yl	O
)	O
-	O
benzonitrile	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and/or	O
solvate	O
thereof	O
and	O
N-	O
(	O
(	O
S	O
)	O
-2,3-dihydroxy	O
-	O
propyl	O
)	O
-3-	O
(	O
2-fluoro-4-iodo	O
-	O
phenylamino	O
)	O
-isonicotinamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and/or	O
solvate	O
thereof	O
.	O

5-fluoro	O
-	O
n-	O
(	O
pyridin-2-yl	O
)	O
pyridin-2-amine	O
derivatives	O
containing	O
a	O
sulfone	O
group	O
The	O
present	O
invention	O
relates	O
to	O
5-fluoro	O
-	O
N-	O
(	O
pyridin-2-yl	O
)	O
pyridin-2-amine	O
derivatives	O
containing	O
a	O
sulfone	O
group	O
of	O
general	O
formula	O
(	O
I	O
)	O
as	O
described	O
and	O
defined	O
herein	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
,	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
disorders	O
,	O
in	O
particular	O
of	O
hyper	O
-	O
proliferative	O
disorders	O
and/or	O
virally	O
induced	O
infectious	O
diseases	O
and/or	O
of	O
cardiovascular	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
intermediate	O
compounds	O
useful	O
in	O
the	O
preparation	O
of	O
said	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
.	O

Anthocyanidin	O
complex	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
The	O
subject	O
matter	O
of	O
the	O
invention	O
is	O
a	O
complex	O
of	O
delphinidin	O
and	O
a	O
sulfoalkyl	O
ether	O
ß	O
-	O
cyclodextrin	O
for	O
use	O
as	O
a	O
medicinal	O
drug	O
,	O
in	O
particular	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
.	O

Inhibitors	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
7	I
(	O
cdk7	B
)	O
The	O
present	O
invention	O
provides	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
hydrates	O
,	O
polymorphs	O
,	O
co	O
-	O
crystals	O
,	O
tautomers	O
,	O
stereoisomers	O
,	O
isotopically	O
labeled	O
derivatives	O
,	O
prodrugs	O
,	O
and	O
compositions	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
and	O
kits	O
involving	O
the	O
inventive	O
compounds	O
or	O
compositions	O
for	O
treating	O
or	O
preventing	O
proliferative	O
diseases	O
(	O
e.g.	O
,	O
cancers	O
(	O
e.g.	O
,	O
leukemia	O
,	O
lymphoma	O
,	O
melanoma	O
,	O
multiple	O
myeloma	O
,	O
breast	O
cancer	O
,	O
Ewing	O
's	O
sarcoma	O
,	O
osteosarcoma	O
,	O
brain	O
cancer	O
,	O
neuroblastoma	O
,	O
lung	O
cancer	O
)	O
,	O
benign	O
neoplasms	O
,	O
angiogenesis	O
,	O
inflammatory	O
diseases	O
,	O
autoinflammatory	O
diseases	O
,	O
and	O
autoimmune	O
diseases	O
)	O
in	O
a	O
subject	O
.	O

Treatment	O
of	O
a	O
subject	O
with	O
a	O
proliferative	O
disease	O
using	O
a	O
compound	O
or	O
composition	O
of	O
the	O
invention	O
may	O
inhibit	O
the	O
aberrant	O
activity	O
of	O
a	O
kinase	B
,	O
such	O
as	O
cyclin	B
-	I
dependent	I
kinase	I
(	O
CDK	B
)	O
(	O
e.g.	O
,	O
cyclin	B
-	I
dependent	I
kinase	I
7	I
(	O
CDK7	B
)	O
)	O
,	O
and	O
therefore	O
,	O
induce	O
cellular	O
apoptosis	O
and/or	O
inhibit	O
transcription	O
in	O
the	O
subject	O
.	O

Substituted	O
pyrimidinyl	O
and	O
pyridinyl	O
-	O
pyrrolopyridinones	O
,	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
kinase	O
inhibitors	O
The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrimidinyl-	O
and	O
pyridinylpyrrolopyridinone	O
compounds	O
which	O
modulate	O
the	O
activity	O
of	O
protein	O
kinases	O
and	O
are	O
therefore	O
useful	O
in	O
treating	O
diseases	O
caused	O
by	O
dysregulated	O
protein	O
kinase	O
activity	O
,	O
in	O
particular	O
RET	O
family	O
kinases	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
preparing	O
these	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
treating	O
diseases	O
utilizing	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
.	O

Compositions	O
,	O
uses	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
dental	O
caries	O
The	O
present	O
invention	O
provides	O
compositions	O
,	O
uses	O
and	O
methods	O
thereof	O
,	O
for	O
inhibiting	O
the	O
growth	O
of	O
caries	O
-	O
causing	O
bacteria	O
.	O

The	O
composition	O
comprises	O
xylitol	O
,	O
sodium	O
citrate	O
,	O
sodium	O
bicarbonate	O
,	O
anionic	O
polymers	O
and	O
acceptable	O
carrier	O
materials	O
.	O

The	O
compositions	O
can	O
tend	O
to	O
be	O
used	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
caused	O
by	O
caries	O
-	O
causing	O
bacteria	O
The	O
compositions	O
can	O
further	O
tend	O
to	O
be	O
used	O
in	O
patients	O
such	O
as	O
children	O
,	O
adolescents	O
or	O
patients	O
suffering	O
from	O
a	O
heightened	O
susceptibility	O
to	O
toxic	O
substances	O
.	O

Use	O
of	O
pkc412	O
in	O
the	O
reactivation	O
of	O
latent	O
hiv-1	O
HIV-1	O
latency	O
is	O
a	O
major	O
obstacle	O
in	O
HIV-1	O
eradication	O
.	O

Although	O
current	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
efficiently	O
decreased	O
the	O
viral	O
load	O
in	O
patients	O
,	O
latently	O
infected	O
cells	O
are	O
permanent	O
reservoirs	O
and	O
inevitably	O
lead	O
to	O
viral	O
rebound	O
upon	O
discontinuation	O
of	O
HAART	O
.	O

Therefore	O
,	O
extensive	O
efforts	O
are	O
being	O
directed	O
toward	O
the	O
reactivation	O
of	O
latent	O
HIV	O
reservoirs	O
with	O
the	O
hope	O
that	O
latently	O
infected	O
cells	O
will	O
be	O
eliminated	O
by	O
the	O
host	O
immune	O
system	O
and/or	O
virus	O
-	O
mediated	O
cell	O
lysis	O
.	O

We	O
are	O
currently	O
working	O
on	O
developing	O
strategies	O
to	O
reactivate	O
the	O
latent	O
viral	O
reservoir	O
in	O
order	O
to	O
eliminate	O
them	O
.	O

Through	O
high	O
-	O
throughput	O
screening	O
,	O
an	O
anti-	O
cancer	O
molecule	O
PKC412	O
that	O
is	O
able	O
to	O
reactivate	O
HIV-1	O
expression	O
from	O
a	O
HIV-1	O
latently	O
infected	O
ACH2	O
cell	O
line	O
and	O
latently	O
infected	O
CD4	O
+	O
T	O
cells	O
has	O
been	O
identified	O
.	O

Medical	O
patch	O
[	O
Problem	O
]	O
To	O
provide	O
a	O
medical	O
patch	O
with	O
an	O
adhesive	O
layer	O
formed	O
thereon	O
,	O
said	O
medical	O
patch	O
containing	O
a	O
large	O
amount	O
of	O
a	O
drug	O
and	O
a	O
dissolution	O
auxiliary	O
,	O
being	O
flexible	O
without	O
losing	O
shape	O
and	O
leaving	O
behind	O
adhesive	O
residue	O
,	O
and	O
exhibiting	O
excellent	O
drug	O
release	O
from	O
the	O
adhesive	O
layer	O
.	O

[	O
Solution	O
]	O
A	O
medical	O
patch	O
comprising	O
:	O
a	O
drug	O
having	O
a	O
secondary	O
or	O
tertiary	O
amine	O
structure	O
in	O
the	O
molecules	O
thereof	O
;	O
a	O
liquid	O
auxiliary	O
for	O
the	O
drug	O
;	O
and	O
a	O
resin	O
composition	O
formed	O
by	O
cross	O
-	O
linking	O
a	O
copolymerized	O
acrylic	O
resin	O
with	O
an	O
isocyanate	O
group	O
-	O
containing	O
cross	O
-	O
linking	O
agent	O
that	O
has	O
been	O
blocked	O
,	O
said	O
copolymerized	O
acrylic	O
resin	O
having	O
a	O
(	O
meth	O
)	O
acrylate	O
monomer	O
as	O
a	O
main	O
monomer	O
component	O
and	O
having	O
a	O
functional	O
group	O
capable	O
of	O
reacting	O
with	O
the	O
aforementioned	O
isocyanate	O
group	O
-	O
containing	O
cross	O
-	O
linking	O
agent	O
to	O
thereby	O
form	O
a	O
cross	O
-	O
linked	O
structure	O
.	O

The	O
solubility	O
of	O
the	O
drug	O
in	O
a	O
phosphate	O
buffer	O
solution	O
(	O
pH6.4	O
)	O
is	O
at	O
least	O
0.5wt%	O
.	O

Inhibitor	B
of	I
apoptosis	I
protein	I
(	O
iap	B
)	O
antagonists	O
Provided	O
herein	O
are	O
compounds	O
that	O
modulate	O
the	O
activity	O
of	O
inhibitor	B
of	I
apoptosis	I
proteins	I
(	O
IAPs	B
)	O
,	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
comprising	O
the	O
compounds	O
.	O

Prevention	O
or	O
treatment	O
agent	O
for	O
hepatic	O
fibrosis	O
In	O
the	O
present	O
invention	O
,	O
a	O
CBP	B
/	O
β	B
-	I
catenin	I
inhibitor	O
exhibits	O
a	O
superior	O
defibrinating	O
effect	O
with	O
respect	O
to	O
Cre	O
/	O
loxP	O
/	O
HCV	O
-	O
MxCre	O
transgenic	O
mice	O
,	O
which	O
are	O
an	O
experimental	O
animal	O
model	O
for	O
hepatic	O
fibrosis	O
,	O
and	O
is	O
useful	O
as	O
a	O
prevention	O
or	O
treatment	O
drug	O
for	O
hepatic	O
fibrosis	O
.	O

Prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
Provided	O
is	O
a	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
,	O
which	O
comprises	O
a	O
novel	O
component	O
capable	O
of	O
preventing	O
the	O
deterioration	O
of	O
a	O
tear	O
fluid	O
secretion	O
ability	O
and	O
also	O
capable	O
of	O
inhibiting	O
the	O
generation	O
of	O
active	O
oxygen	O
in	O
tear	O
gland	O
tissues	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
contains	O
a	O
maqui	O
berry	O
extract	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
may	O
contain	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
delphinidin	O
glycoside	O
that	O
is	O
extracted	O
from	O
maqui	O
berry	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
may	O
contain	O
at	O
least	O
one	O
component	O
selected	O
from	O
delphinidin-3-sambubioside-5-glucoside	O
,	O
delphinidin-3,5-diglucoside	O
,	O
delphinidin-3-sambubioside	O
and	O
delphinidin-3-glucoside	O
,	O
desirably	O
delphinidin-3,5-diglucoside	O
,	O
as	O
an	O
active	O
ingredient	O
.	O

Pyrazolyl	O
-	O
based	O
carboxamides	O
i	O
as	O
crac	B
channel	I
inhibitors	O
The	O
Invention	O
relates	O
to	O
pyrazolyl	O
-	O
based	O
carboxamide	O
compounds	O
of	O
formula	O
(	O
l	O
)	O
useful	O
as	O
ICRAC	B
inhibitors	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
to	O
these	O
compounds	O
for	O
the	O
use	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
and/or	O
disorders	O
,	O
in	O
particular	O
inflammatory	O
diseases	O
and/or	O
inflammatory	O
disorders	O
.	O

Pyrrolotriazine	O
derivatives	O
as	O
pi3k	O
inhibitors	O
New	O
pyrrolotriazine	O
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
Phosphoinositide	O
3-Kinases	O
(	O
PI3Ks	O
)	O

Compositions	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
This	O
invention	O
provides	O
compounds	O
,	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
,	O
comprising	O
the	O
timely	O
administration	O
of	O
a	O
provided	O
compound	O
,	O
which	O
has	O
a	O
structure	O
related	O
to	O
an	O
endogenously	O
formed	O
lipid	O
mediator	O
.	O

One	O
embodiment	O
of	O
the	O
present	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
selected	O
from	O
a	O
group	O
having	O
the	O
general	O
formula	O
A.	O

Substituted	O
2-aza	O
-	O
bicyclo	O
[	O
2.2.1	O
]	O
heptane-3-carboxylic	O
acid	O
(	O
cyano	O
-	O
methyl	O
)	O
-amides	O
inhibitors	O
of	O
cathepsin	O
c	O
This	O
invention	O
relates	O
to	O
2-Aza	O
-	O
bicyclo	O
[	O
2.2.1	O
]	O
heptane-3-carboxylic	O
acid	O
(	O
cyano	O
-	O
methyl	O
)	O
-amides	O
of	O
formula	O
(	O
1	O
)	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
Cathepsin	O
C	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
methods	O
of	O
using	O
the	O
same	O
as	O
agents	O
for	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
connected	O
with	O
dipeptidyl	O
peptidase	O
I	O
activity	O
,	O
e.g.	O
respiratory	O
diseases	O
.	O

Pyrazole	O
-	O
amide	O
compound	O
and	O
medicinal	O
uses	O
therefor	O
Provided	O
is	O
a	O
compound	O
as	O
represented	O
by	O
formula	O
[	O
I	O
]	O
[	O
in	O
which	O
n	O
indicates	O
1	O
or	O
2	O
]	O
,	O
formula	O
[	O
II	O
]	O
or	O
[	O
IIh	O
]	O
,	O
or	O
formula	O
[	O
III	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Also	O
provided	O
are	O
medicinal	O
uses	O
for	O
the	O
compound	O
or	O
the	O
salt	O
thereof	O
.	O

Methods	O
of	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
ischemic	O
events	O
Methods	O
of	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
,	O
comprising	O
administering	O
to	O
the	O
patient	O
a	O
pharmaceutical	O
composition	O
comprising	O
cangrelor	O
.	O

The	O
method	O
may	O
further	O
comprise	O
administering	O
an	O
additional	O
therapeutic	O
agent	O
to	O
the	O
patient	O
,	O
the	O
additional	O
therapeutic	O
agent	O
comprising	O
a	O
P2Yi2	O
inhibitor	O
.	O

Pharmaceutical	O
compositions	O
useful	O
for	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
PCI	O
.	O

The	O
pharmaceutical	O
compositions	O
comprise	O
cangrelor	O
.	O

Methods	O
of	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
PCI	O
,	O
comprising	O
admixing	O
cangrelor	O
with	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

An	O
ischemic	O
event	O
may	O
include	O
stent	O
thrombosis	O
,	O
myocardial	O
infarction	O
,	O
ischemia	O
-	O
driven	O
revascularization	O
,	O
and	O
mortality	O
.	O

Compositions	O
for	O
use	O
in	O
treating	O
heavy	O
menstrual	O
bleeding	O
and	O
uterine	O
fibroids	O
The	O
present	O
invention	O
relates	O
to	O
the	O
method	O
of	O
treating	O
heavy	O
menstrual	O
bleeding	O
in	O
a	O
subject	O
with	O
or	O
without	O
uterine	O
fibroids	O
and	O
in	O
need	O
of	O
treatment	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
4-	O
(	O
(	O
R	O
)	O
-2-	O
[	O
5-	O
(	O
2-fluoro-3-methoxy	O
-	O
phenyl	O
)	O
-3-	O
(	O
2-fluoro-6-trifluoromethyl	O
-	O
benzyl	O
)	O
-4-	O
methyl-2,6-dioxo-3,6-dihydro-2H	O
-	O
pyrimidin	O
-	O
l	O
-	O
yl	O
]	O
-l	O
-	O
phenyl	O
-	O
ethylamino	O
)	O
-butyric	O
acid	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
combination	O
with	O
estrogens	O
and	O
progestogens	O
.	O

3-heteroaryl	O
substituted	O
indazoles	O
Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
inhibitors	O
of	O
Bub1	B
kinase	I
,	O
processes	O
for	O
their	O
production	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
and	O
a	O
treatment	O
method	O
therefor	O
.	O

A	O
pharmaceutical	O
composition	O
containing	O
siRNA	O
inhibiting	O
the	O
expression	O
of	O
a	O
CD98	B
heavy	O
chain	O
was	O
found	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

As	O
a	O
result	O
,	O
a	O
novel	O
treatment	O
method	O
can	O
be	O
provided	O
that	O
uses	O
the	O
siRNA	O
for	O
inflammatory	O
bowel	O
disease	O
for	O
which	O
there	O
has	O
conventionally	O
been	O
no	O
appropriate	O
treatment	O
method	O
.	O

Therapeutic	O
agent	O
for	O
neurodegenerative	O
diseases	O
The	O
present	O
invention	O
relates	O
to	O
a	O
therapeutic	O
agent	O
for	O
neurodegenerative	O
diseases	O
,	O
which	O
contains	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
.	O

(	O
In	O
the	O
formula	O
,	O
Ar1	O
represents	O
an	O
aromatic	O
group	O
;	O
X	O
represents	O
a	O
single	O
bond	O
or	O
a	O
linking	O
group	O
;	O
R1	O
represents	O
a	O
hydrogen	O
atom	O
,	O
an	O
aromatic	O
group	O
or	O
an	O
aralkyl	O
group	O
;	O
Y	O
represents	O
CH	O
(	O
R2	O
)	O
(	O
wherein	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
carbamoyl	O
group	O
,	O
an	O
acyl	O
group	O
or	O
an	O
alkyl	O
group	O
)	O
;	O
Z	O
represents	O
a	O
carbonyl	O
group	O
or	O
CH	O
(	O
R3	O
)	O
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	O
atom	O
,	O
an	O
aromatic	O
group	O
or	O
an	O
aralkyl	O
group	O
)	O
;	O
and	O
Y	O
and	O
Z	O
may	O
combine	O
together	O
and	O
represent	O
C	O
(	O
R2	O
)	O
=C	O
(	O
R4	O
)	O
(	O
wherein	O
R2	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
carbamoyl	O
group	O
,	O
an	O
acyl	O
group	O
or	O
an	O
alkyl	O
group	O
,	O
and	O
R4	O
represents	O
a	O
hydrogen	O
atom	O
,	O
a	O
hydroxyl	O
group	O
,	O
an	O
aromatic	O
group	O
or	O
an	O
aralkyl	O
group	O
)	O
.	O
)	O

Instantaneous	O
intestinal	O
regulator	O
The	O
present	O
invention	O
provides	O
an	O
instantaneous	O
intestinal	O
regulator	O
,	O
which	O
:	O
contains	O
a	O
Propionibacteriaceae	O
culture	O
,	O
DHNA	O
or	O
an	O
analog	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
manifests	O
intestine	O
-	O
regulating	O
effects	O
within	O
one	O
day	O
after	O
being	O
taken	O
;	O
and	O
manifests	O
more	O
pronounced	O
intestine	O
-	O
regulating	O
effects	O
within	O
two	O
days	O
after	O
being	O
taken	O
.	O

The	O
present	O
invention	O
also	O
provides	O
an	O
instantaneous	O
intestinal	O
regulator	O
,	O
which	O
contains	O
a	O
Propionibacteriaceae	O
culture	O
,	O
DHNA	O
or	O
an	O
analog	O
thereof	O
as	O
an	O
active	O
ingredient	O
and	O
maintains	O
the	O
intestine	O
-	O
regulating	O
effects	O
for	O
two	O
weeks	O
after	O
being	O
taken	O
.	O

